{"html": "<!DOCTYPE html><html><body><h1>Anthropometic and life style data of subjects.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Parameter</bold></td><td align=\"center\"><bold>Ascending Colon</bold></td><td align=\"center\"><bold>Descending Colon</bold></td><td align=\"center\"><bold>Sigmoid Colon</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>n</bold></td><td align=\"center\">10</td><td align=\"center\">7</td><td align=\"center\">24</td></tr><tr><td align=\"left\"><bold>Age</bold></td><td align=\"center\">52 &#177; 9</td><td align=\"center\">54 &#177; 15</td><td align=\"center\">55 &#177; 9</td></tr><tr><td align=\"left\"><bold>Sex : Female/male</bold></td><td align=\"center\">5/5</td><td align=\"center\">1/6</td><td align=\"center\">8/16</td></tr><tr><td align=\"left\"><bold>BMI</bold></td><td align=\"center\">26.5 &#177; 5.7</td><td align=\"center\">27.8 &#177; 4.9</td><td align=\"center\">25.4 &#177; 4.0</td></tr><tr><td align=\"left\" colspan=\"4\"><bold>Cigarette use</bold></td></tr><tr><td align=\"left\"><bold>Yes/No</bold></td><td align=\"center\">3/7</td><td align=\"center\">3/4</td><td align=\"center\">4/20</td></tr><tr><td align=\"left\"><bold>(number/d)</bold></td><td align=\"center\">2.8 &#177; 6.2</td><td align=\"center\">8.3 &#177; 9.8</td><td align=\"center\">1.5 &#177; 4.6</td></tr><tr><td align=\"left\" colspan=\"4\"><bold>Alcohol consumption</bold></td></tr><tr><td align=\"left\"><bold>Yes/No</bold></td><td align=\"center\">3/7</td><td align=\"center\">2/5</td><td align=\"center\">12/12</td></tr><tr><td align=\"left\"><bold>(g/d)</bold></td><td align=\"center\">9.4 &#177; 14.6</td><td align=\"center\">8.2 &#177; 7.8</td><td align=\"center\">9.8 &#177; 12.6</td></tr></tbody></table></body></html>", "text": "Pmid= 1291361:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Primers used for RT-PCR analysis</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Sense primer location</bold></td><td align=\"left\"><bold>Antisense primer location</bold></td><td align=\"center\"><bold>PCR product (bp)</bold></td><td align=\"left\"><bold>Reference</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Histone 3.3</bold></td><td align=\"left\">GCGTGCTAGCTGGATGTCTT</td><td align=\"left\">CCACTGAACTTCTGATTCGC</td><td align=\"center\">150</td><td align=\"left\">[18]</td></tr><tr><td align=\"left\"><bold>CYP2C8-19</bold></td><td align=\"left\">GCTAAAGTCCAGGAAGAGATTGA</td><td align=\"left\">TCCTGCTGAGAAAGGCATGAAGT</td><td align=\"center\">332</td><td align=\"left\">[19]</td></tr><tr><td align=\"left\"><bold>CYP2E1</bold></td><td align=\"left\">AGCACAACTCTGAGATATGG</td><td align=\"left\">ATAGTCACTGTACTTGAACT</td><td align=\"center\">365</td><td align=\"left\">[19]</td></tr><tr><td align=\"left\"><bold>CYP3A4</bold></td><td align=\"left\">CCAAGCTATGCTCTTCACCG</td><td align=\"left\">TCAGGCTCCACTTACGGTGC</td><td align=\"center\">324</td><td align=\"left\">[20]</td></tr><tr><td align=\"left\"><bold>CYP3A5</bold></td><td align=\"left\">TGTCCAGCAGAAACTGCAAA</td><td align=\"left\">TTGAAGAAGTCCTTGCGTGTC</td><td align=\"center\">472</td><td align=\"left\">[20]</td></tr></tbody></table></body></html>", "text": "Pmid= 1291361:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline characteristics of the patients (N = 1660)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Characteristic</bold></td><td align=\"center\"><bold>n (% of total)*</bold></td></tr></thead><tbody><tr><td align=\"left\" colspan=\"2\">Gender</td></tr><tr><td align=\"left\">&#8195;Male</td><td align=\"center\">1183 (71.3%)</td></tr><tr><td align=\"left\">&#8195;Female</td><td align=\"center\">430 (25.9%)</td></tr><tr><td align=\"left\">&#8195;Not specified</td><td align=\"center\">47 (2.8%)</td></tr><tr><td align=\"left\" colspan=\"2\">Ethnicity</td></tr><tr><td align=\"left\">&#8195;White</td><td align=\"center\">1116 (67.2%)</td></tr><tr><td align=\"left\">&#8195;Mestizo</td><td align=\"center\">300 (18.1%)</td></tr><tr><td align=\"left\">&#8195;Black</td><td align=\"center\">154 (9.3%)</td></tr><tr><td align=\"left\">&#8195;Chinese</td><td align=\"center\">8 (0.5%)</td></tr><tr><td align=\"left\">&#8195;Not specified</td><td align=\"center\">82 (4.9%)</td></tr><tr><td align=\"left\">Age (yr) total (183 not specified)</td><td align=\"center\">61.6 &#177; 13.0</td></tr><tr><td align=\"left\">Onset-infusion time (hours)</td><td align=\"center\">4.9 &#177; 3.7</td></tr><tr><td align=\"left\" colspan=\"2\">Previous SK</td></tr><tr><td align=\"left\">&#8195;&lt; 1 year</td><td align=\"center\">5 (0.3%)</td></tr><tr><td align=\"left\">&#8195;&gt; 1 year</td><td align=\"center\">9 (0.5%)</td></tr><tr><td align=\"left\" colspan=\"2\">Concomitant therapy</td></tr><tr><td align=\"left\">&#8195;Aspirin</td><td align=\"center\">1341 (80.8%)</td></tr><tr><td align=\"left\">&#8195;Beta-blockers</td><td align=\"center\">943 (56.8%)</td></tr><tr><td align=\"left\">&#8195;Nitrosorbide</td><td align=\"center\">258 (15.5%)</td></tr><tr><td align=\"left\">&#8195;Lidocaine</td><td align=\"center\">66 (3.9%)</td></tr><tr><td align=\"left\">&#8195;Pentaerythritol tetranitrate</td><td align=\"center\">45 (2.7%)</td></tr><tr><td align=\"left\">&#8195;Others</td><td align=\"center\">641 (38.6%)</td></tr></tbody></table></body></html>", "text": "Pmid= 1291362:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Suspected adverse reactions to streptokinase</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>ADR</bold></td><td align=\"center\"><bold>n</bold></td><td align=\"center\"><bold>%*</bold></td></tr></thead><tbody><tr><td align=\"left\">Hypotension</td><td align=\"center\">285</td><td align=\"center\">36.0</td></tr><tr><td align=\"left\">Arrhythmias</td><td align=\"center\">281</td><td align=\"center\">35.5</td></tr><tr><td align=\"left\">Chills</td><td align=\"center\">212</td><td align=\"center\">26.8</td></tr><tr><td align=\"left\">Tremors</td><td align=\"center\">197</td><td align=\"center\">24.9</td></tr><tr><td align=\"left\">Vomiting</td><td align=\"center\">187</td><td align=\"center\">23.6</td></tr><tr><td align=\"left\">Nauseas</td><td align=\"center\">103</td><td align=\"center\">13.0</td></tr><tr><td align=\"left\">Allergy</td><td align=\"center\">47</td><td align=\"center\">5.9</td></tr><tr><td align=\"left\">Bleeding</td><td align=\"center\">43</td><td align=\"center\">5.4</td></tr><tr><td align=\"left\">Fever</td><td align=\"center\">41</td><td align=\"center\">5.2</td></tr><tr><td align=\"left\">Lumbar pain</td><td align=\"center\">10</td><td align=\"center\">1.3</td></tr><tr><td align=\"left\">Sweating</td><td align=\"center\">9</td><td align=\"center\">1.1</td></tr><tr><td align=\"left\">Muscular cramp</td><td align=\"center\">5</td><td align=\"center\">0.6</td></tr><tr><td align=\"left\">Others</td><td align=\"center\">76</td><td align=\"center\">9.6</td></tr></tbody></table></body></html>", "text": "Pmid= 1291362:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Causes of death</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Cause</bold></td><td align=\"center\"><bold>n</bold></td><td align=\"center\"><bold>% of total deaths</bold></td></tr></thead><tbody><tr><td align=\"left\" colspan=\"3\"><bold>Cardiac causes</bold></td></tr><tr><td align=\"left\">&#8195;&#8195;Pump failure</td><td align=\"center\">32</td><td align=\"center\">44.4</td></tr><tr><td align=\"left\">&#8195;&#8195;Arrhythmias</td><td align=\"center\">15</td><td align=\"center\">20.8</td></tr><tr><td align=\"left\">&#8195;&#8195;Wall rupture</td><td align=\"center\">10</td><td align=\"center\">13.9</td></tr><tr><td align=\"left\" colspan=\"3\"><bold>Non cardiac causes</bold></td></tr><tr><td align=\"left\">&#8195;&#8195;Hemorrhagic stroke</td><td align=\"center\">3</td><td align=\"center\">4.2</td></tr><tr><td align=\"left\">&#8195;&#8195;Pulmonary embolism</td><td align=\"center\">1</td><td align=\"center\">1.4</td></tr><tr><td align=\"left\">&#8195;&#8195;Hypoxic encephalopathy</td><td align=\"center\">1</td><td align=\"center\">1.4</td></tr><tr><td align=\"left\">&#8195;&#8195;Sepsis</td><td align=\"center\">1</td><td align=\"center\">1.4</td></tr><tr><td align=\"left\"><bold>Unknown</bold></td><td align=\"center\">9</td><td align=\"center\">12.5</td></tr><tr><td align=\"left\"><bold>Total</bold></td><td align=\"center\">72</td><td align=\"center\">100</td></tr></tbody></table></body></html>", "text": "Pmid= 1291362:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Standard human population PBPK organ parameters (not varied).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Organ</bold></td><td align=\"center\"><bold>Weight (Kg)</bold></td><td align=\"center\"><bold>ECF water(L)</bold></td><td align=\"center\"><bold>Flow (L/min)</bold></td><td align=\"center\"><bold>ACE Tiss/Plasma</bold></td><td align=\"center\"><bold>Ramiprialat Ps (min<sup>-1</sup>)</bold></td><td align=\"center\"><bold>Ramiprilat fu_cell</bold></td><td align=\"center\"><bold>Ramipril Ps (min<sup>-1</sup>)</bold></td><td align=\"center\"><bold>Ramipril fu_cell</bold></td></tr></thead><tbody><tr><td align=\"center\"><bold>Blood</bold></td><td align=\"center\">5.5</td><td align=\"center\">2.68345</td><td/><td align=\"center\">0.52</td><td align=\"center\">0</td><td align=\"center\">----</td><td/><td/></tr><tr><td align=\"center\"><bold>liver</bold></td><td align=\"center\">1.8</td><td align=\"center\">0.2898</td><td align=\"center\">0.45</td><td align=\"center\">1.37</td><td align=\"center\">Adjustable</td><td align=\"center\">1</td><td align=\"center\">infinite</td><td align=\"center\">0.1</td></tr><tr><td align=\"center\"><bold>portal </bold></td><td align=\"center\">1.5</td><td align=\"center\">0.351</td><td align=\"center\">1.125</td><td align=\"center\">2.0</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>muscle</bold></td><td align=\"center\">26</td><td align=\"center\">3.042</td><td align=\"center\">0.585</td><td align=\"center\">1.0</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>kidney</bold></td><td align=\"center\">0.31</td><td align=\"center\">0.04092</td><td align=\"center\">1.24</td><td align=\"center\">5.62</td><td align=\"center\">Adjustable</td><td align=\"center\">10</td><td align=\"center\">infinite</td><td align=\"center\">0.01</td></tr><tr><td align=\"center\"><bold>brain</bold></td><td align=\"center\">1.4</td><td align=\"center\">0</td><td align=\"center\">0.784</td><td align=\"center\">0.8</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>heart</bold></td><td align=\"center\">0.33</td><td align=\"center\">0.066</td><td align=\"center\">0.264</td><td align=\"center\">1.7</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>lung</bold></td><td align=\"center\">0.536</td><td align=\"center\">0.08576</td><td align=\"center\">5.6184</td><td align=\"center\">34</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>skin</bold></td><td align=\"center\">2.6</td><td align=\"center\">1.092</td><td align=\"center\">0.26</td><td align=\"center\">3.51</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>tendon</bold></td><td align=\"center\">3</td><td align=\"center\">2.55</td><td align=\"center\">0.03</td><td align=\"center\">7.23</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>other</bold></td><td align=\"center\">5.524</td><td align=\"center\">3.75632</td><td align=\"center\">0.1104</td><td align=\"center\">5.79</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>bone</bold></td><td align=\"center\">4</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0</td><td align=\"center\">0.5</td></tr><tr><td align=\"center\"><bold>adipose</bold></td><td align=\"center\">17.5</td><td align=\"center\">3.5</td><td align=\"center\">0.7385</td><td align=\"center\">6.81</td><td align=\"center\">0</td><td align=\"center\">----</td><td align=\"center\">0.05</td><td align=\"center\">0.5</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"center\"><bold>Total</bold></td><td align=\"center\">70</td><td align=\"center\">17.4572</td><td align=\"center\">5.5877</td><td/><td/><td/><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 1373666:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Intestinal absorption parameters for oral ramipril: 1) the major ramipril absorption component (gamma function, A, a, and T); 2) a slow, long ramipril component (A</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Subject</td><td align=\"center\" colspan=\"3\">Ramipril- Major component</td><td align=\"center\">Slow absorp. Amount A<sub>slow </sub>(nmole)</td><td align=\"center\">Ramprilat Amount A<sub>R </sub>(nmole)</td><td align=\"center\">Total Absorption (nmole)</td></tr><tr><td/><td colspan=\"3\"><hr/></td><td/><td/><td/></tr><tr><td/><td align=\"center\">Amount (A) (nmole)</td><td align=\"center\">Time const. (T) (min)</td><td align=\"center\">Gamma (a)</td><td/><td/><td/></tr></thead><tbody><tr><td align=\"center\">1</td><td align=\"center\">2500</td><td align=\"center\">90</td><td align=\"center\">3</td><td align=\"center\">787</td><td align=\"center\">200</td><td align=\"center\">3487</td></tr><tr><td align=\"center\">3</td><td align=\"center\">1200</td><td align=\"center\">53</td><td align=\"center\">9</td><td align=\"center\">367</td><td align=\"center\">60</td><td align=\"center\">1627</td></tr><tr><td align=\"center\">4</td><td align=\"center\">1600</td><td align=\"center\">45</td><td align=\"center\">8</td><td align=\"center\">432</td><td align=\"center\">30</td><td align=\"center\">2062</td></tr><tr><td align=\"center\">5</td><td align=\"center\">1400</td><td align=\"center\">48</td><td align=\"center\">3.2</td><td align=\"center\">0</td><td align=\"center\">100</td><td align=\"center\">1500</td></tr><tr><td align=\"center\">6</td><td align=\"center\">1800</td><td align=\"center\">35</td><td align=\"center\">3</td><td align=\"center\">0</td><td align=\"center\">100</td><td align=\"center\">1900</td></tr><tr><td align=\"center\">7</td><td align=\"center\">800</td><td align=\"center\">25</td><td align=\"center\">3</td><td align=\"center\">320</td><td align=\"center\">41</td><td align=\"center\">1161</td></tr><tr><td align=\"center\">8</td><td align=\"center\">2100</td><td align=\"center\">70</td><td align=\"center\">2</td><td align=\"center\">756</td><td align=\"center\">200</td><td align=\"center\">3056</td></tr><tr><td align=\"center\">9</td><td align=\"center\">2200</td><td align=\"center\">65</td><td align=\"center\">6</td><td align=\"center\">0</td><td align=\"center\">100</td><td align=\"center\">2300</td></tr><tr><td align=\"center\">10</td><td align=\"center\">1800</td><td align=\"center\">60</td><td align=\"center\">5.5</td><td align=\"center\">0</td><td align=\"center\">100</td><td align=\"center\">1900</td></tr><tr><td align=\"center\">11</td><td align=\"center\">1100</td><td align=\"center\">35</td><td align=\"center\">3</td><td align=\"center\">346</td><td align=\"center\">100</td><td align=\"center\">1546</td></tr><tr><td align=\"center\">12</td><td align=\"center\">2700</td><td align=\"center\">80</td><td align=\"center\">4</td><td align=\"center\">0</td><td align=\"center\">400</td><td align=\"center\">3100</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">Ave (SD)</td><td align=\"center\">1745 (597)</td><td align=\"center\">55.1 (20.1)</td><td align=\"center\">4.4 (2.3)</td><td align=\"center\">273 (301)</td><td align=\"center\">130 (105)</td><td align=\"center\">2149 (755)</td></tr></tbody></table></body></html>", "text": "Pmid= 1373666:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Ramiprilat Adjustable PBPK Parameters: Intrinsic renal clearance, ACE plasma concentration, and liver and kidney cell membrane permeability coefficient. The \"average weighted residual error\" of the PBPK model for the IV ramiprilat input is listed in the last column.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Subject</td><td align=\"center\">Renal Clear. Cl<sub>u </sub>(l/min)</td><td align=\"center\">ACE<sub>plasma </sub>(nM)</td><td align=\"center\" colspan=\"2\">Membrane Permeability (Ps min<sup>-1</sup>)</td><td align=\"center\">IV Ramiprilat Ave. Error</td></tr><tr><td/><td/><td/><td colspan=\"2\"><hr/></td><td/></tr><tr><td/><td/><td/><td align=\"center\">Liver</td><td align=\"center\">Kidney</td><td/></tr></thead><tbody><tr><td align=\"center\">1</td><td align=\"center\">0.55</td><td align=\"center\">1.5</td><td align=\"center\">0.015</td><td align=\"center\">0.0003</td><td align=\"center\">0.11</td></tr><tr><td align=\"center\">3</td><td align=\"center\">0.4</td><td align=\"center\">2.35</td><td align=\"center\">0.007</td><td align=\"center\">0.0015</td><td align=\"center\">0.10</td></tr><tr><td align=\"center\">4</td><td align=\"center\">0.4</td><td align=\"center\">1.65</td><td align=\"center\">0.018</td><td align=\"center\">0.001</td><td align=\"center\">0.17</td></tr><tr><td align=\"center\">5</td><td align=\"center\">0.55</td><td align=\"center\">1.13</td><td align=\"center\">0.01</td><td align=\"center\">0.0006</td><td align=\"center\">0.16</td></tr><tr><td align=\"center\">6</td><td align=\"center\">0.4</td><td align=\"center\">1.25</td><td align=\"center\">0.015</td><td align=\"center\">0.002</td><td align=\"center\">0.27</td></tr><tr><td align=\"center\">7</td><td align=\"center\">0.7</td><td align=\"center\">2.25</td><td align=\"center\">0.01</td><td align=\"center\">0.0006</td><td align=\"center\">0.18</td></tr><tr><td align=\"center\">8</td><td align=\"center\">0.4</td><td align=\"center\">2.9</td><td align=\"center\">0.01</td><td align=\"center\">0.0006</td><td align=\"center\">0.11</td></tr><tr><td align=\"center\">9</td><td align=\"center\">0.37</td><td align=\"center\">1.75</td><td align=\"center\">0.008</td><td align=\"center\">0.0003</td><td align=\"center\">0.32</td></tr><tr><td align=\"center\">10</td><td align=\"center\">0.45</td><td align=\"center\">1.45</td><td align=\"center\">0.015</td><td align=\"center\">0.002</td><td align=\"center\">0.13</td></tr><tr><td align=\"center\">11</td><td align=\"center\">0.45</td><td align=\"center\">1.4</td><td align=\"center\">0.01</td><td align=\"center\">0.0003</td><td align=\"center\">0.30</td></tr><tr><td align=\"center\">12</td><td align=\"center\">0.4</td><td align=\"center\">2.25</td><td align=\"center\">0.006</td><td align=\"center\">0.0003</td><td align=\"center\">0.14</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Ave (SD)</td><td align=\"center\">0.46 (0.10)</td><td align=\"center\">1.81 (0.55)</td><td align=\"center\">0.011 (0.0039)</td><td align=\"center\">0.00086 (0.00067)</td><td align=\"center\">0.18 (0.08)</td></tr></tbody></table></body></html>", "text": "Pmid= 1373666:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Ramipril adjustable PBPK parameters: 1) intrinsic liver clearance (Cl</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Subject</td><td align=\"center\">Cl<sub>int_L </sub>(l/min)</td><td align=\"center\">Cl<sub>int_K </sub>(l/min)</td><td align=\"center\">Fraction to ramiprilat</td><td align=\"center\">IV Ramipril Ave. Error</td><td align=\"center\">Oral Ramipril Ave. Error</td></tr></thead><tbody><tr><td align=\"center\">1</td><td align=\"center\">4.8</td><td align=\"center\">1.2</td><td align=\"center\">0.1</td><td align=\"center\">0.2</td><td align=\"center\">0.23</td></tr><tr><td align=\"center\">3</td><td align=\"center\">1</td><td align=\"center\">1.5</td><td align=\"center\">0.32</td><td align=\"center\">0.17</td><td align=\"center\">0.25</td></tr><tr><td align=\"center\">4</td><td align=\"center\">3.6</td><td align=\"center\">0.9</td><td align=\"center\">0.4</td><td align=\"center\">0.23</td><td align=\"center\">0.27</td></tr><tr><td align=\"center\">5</td><td align=\"center\">2</td><td align=\"center\">2</td><td align=\"center\">0.0</td><td align=\"center\">0.17</td><td align=\"center\">Poor fit</td></tr><tr><td align=\"center\">6</td><td align=\"center\">3</td><td align=\"center\">1</td><td align=\"center\">0.25</td><td align=\"center\">0.23</td><td align=\"center\">0.28</td></tr><tr><td align=\"center\">7</td><td align=\"center\">4</td><td align=\"center\">1</td><td align=\"center\">0.2</td><td align=\"center\">0.14</td><td align=\"center\">0.14</td></tr><tr><td align=\"center\">8</td><td align=\"center\">5.5</td><td align=\"center\">0</td><td align=\"center\">0.4</td><td align=\"center\">0.13</td><td align=\"center\">0.22</td></tr><tr><td align=\"center\">9</td><td align=\"center\">3.48</td><td align=\"center\">0.52</td><td align=\"center\">0.2</td><td align=\"center\">0.12</td><td align=\"center\">0.38</td></tr><tr><td align=\"center\">10</td><td align=\"center\">3.5</td><td align=\"center\">1.5</td><td align=\"center\">0.4</td><td align=\"center\">0.30</td><td align=\"center\">0.34</td></tr><tr><td align=\"center\">11</td><td align=\"center\">2.8</td><td align=\"center\">1.2</td><td align=\"center\">0.3</td><td align=\"center\">0.23</td><td align=\"center\">0.14</td></tr><tr><td align=\"center\">12</td><td align=\"center\">6.16</td><td align=\"center\">0.84</td><td align=\"center\">0.2</td><td align=\"center\">0.13</td><td align=\"center\">0.2</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Ave (SD)</td><td align=\"center\">3.62 (1.5)</td><td align=\"center\">1.06 (0.53)</td><td align=\"center\">0.25 (0.13)</td><td align=\"center\">0.19 (0.057)</td><td align=\"center\">0.24 (0.077)</td></tr></tbody></table></body></html>", "text": "Pmid= 1373666:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Solid Phase Extraction</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\"><bold>Paclitaxel</bold></td><td align=\"center\" colspan=\"2\"><bold>Docetaxel</bold></td></tr></thead><tbody><tr><td align=\"center\"><bold>Author</bold></td><td align=\"center\"><bold>Willey [12]</bold></td><td align=\"center\"><bold>Andersen et al</bold></td><td align=\"center\"><bold>Rosing [24]</bold></td><td align=\"center\"><bold>Andersen et al</bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\"><bold>Columns</bold></td><td align=\"center\">1 ml CN-(?) 100 mg<sup>#</sup></td><td align=\"center\">LRC CN-U 100 mg</td><td align=\"center\">CN-E 100 mg</td><td align=\"center\">LRC CN-E 100 mg</td></tr><tr><td align=\"center\"><bold>Cond 1</bold></td><td align=\"center\">2 ml MeOH</td><td align=\"center\">10 ml MeOH</td><td align=\"center\">1 ml 0.1% TEA in MeCN</td><td align=\"center\">10 ml MeOH</td></tr><tr><td align=\"center\"><bold>Cond 2</bold></td><td align=\"center\">2 ml AmAc<sup>##</sup></td><td align=\"center\">5 ml AmAc</td><td align=\"center\">2 ml MeOH</td><td align=\"center\">2 ml AmAc</td></tr><tr><td align=\"center\"><bold>Cond 3</bold></td><td align=\"center\">None</td><td align=\"center\">None</td><td align=\"center\">2 ml AmAc</td><td align=\"center\">None</td></tr><tr><td align=\"center\"><bold>Load</bold></td><td align=\"center\">1 ml 50% plasma*</td><td align=\"center\">Up to 8 ml 50% plasma*</td><td align=\"center\">1.1 ml undiluted plasma</td><td align=\"center\">2 ml undiluted plasma</td></tr><tr><td align=\"center\"><bold>Wash 1</bold></td><td align=\"center\">2 ml AmAc</td><td align=\"center\">10 ml AmAc</td><td align=\"center\">2 ml AmAc</td><td align=\"center\">2 ml AmAc</td></tr><tr><td align=\"center\"><bold>Wash 2</bold></td><td align=\"center\">2 ml AmAc/20% MeOH</td><td align=\"center\">1 ml AmAc/20% MeOH</td><td align=\"center\">1 ml water/20% MeOH</td><td align=\"center\">1 ml AmAc/20% MeOH</td></tr><tr><td align=\"center\"><bold>Wash 3</bold></td><td align=\"center\">1 ml hexane</td><td align=\"center\">5 ml hexane</td><td align=\"center\">None</td><td align=\"center\">2 ml hexane</td></tr><tr><td align=\"center\"><bold>Elution</bold></td><td align=\"center\">2&#215; 1 ml 0.1% TEA in MeCN</td><td align=\"center\">2&#215; 250 &#956;l ethyl acetate</td><td align=\"center\">1&#215; 500 &#956;l 0.1% TEA in MeCN</td><td align=\"center\">2&#215; 250 &#956;l ethyl acetate</td></tr><tr><td align=\"center\"><bold>Evap</bold></td><td align=\"center\">Nitrogen gas blowdown</td><td align=\"center\">Vacuum centrifuge</td><td align=\"center\">Nitrogen gas blowdown</td><td align=\"center\">Vacuum centrifuge</td></tr><tr><td align=\"center\"><bold>Injection volume</bold></td><td align=\"center\">100 &#956;l (of 200 &#956;l) in MeOH/MeCN/AmAc</td><td align=\"center\">90 &#956;l (of 100 &#956;l) in 40% MeCN</td><td align=\"center\">50 &#956;l (of 100 &#956;l) in MeOH/MeCN/water</td><td align=\"center\">90 &#956;l (of 100 &#956;l) in 40% MeCN</td></tr></tbody></table></body></html>", "text": "Pmid= 1382254:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Intra- and inter-assay accuracy and precision (CV%) for paclitaxel and docetaxel determinations in plasma.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\">Concentration [nM]</td><td align=\"center\" colspan=\"3\">Intra-assay variability</td><td align=\"center\" colspan=\"3\">Inter-assay variability</td></tr><tr><td/><td/><td colspan=\"3\"><hr/></td><td colspan=\"3\"><hr/></td></tr><tr><td/><td/><td align=\"center\">n</td><td align=\"center\">Accuracy (%)</td><td align=\"center\">CV (%)</td><td align=\"center\">n</td><td align=\"center\">Accuracy (%)</td><td align=\"center\">CV (%)</td></tr></thead><tbody><tr><td align=\"center\">Paclitaxel</td><td align=\"center\">1000</td><td align=\"center\">3</td><td align=\"center\">89</td><td align=\"center\">2</td><td align=\"center\">5</td><td align=\"center\">100</td><td align=\"center\">2</td></tr><tr><td/><td align=\"center\">100</td><td align=\"center\">3</td><td align=\"center\">103</td><td align=\"center\">6</td><td align=\"center\">5</td><td align=\"center\">103</td><td align=\"center\">3</td></tr><tr><td/><td align=\"center\">10</td><td align=\"center\">3</td><td align=\"center\">111</td><td align=\"center\">2</td><td align=\"center\">5</td><td align=\"center\">104</td><td align=\"center\">9</td></tr><tr><td/><td align=\"center\">1.2</td><td align=\"center\">3</td><td align=\"center\">104</td><td align=\"center\">8</td><td align=\"center\">5</td><td align=\"center\">108</td><td align=\"center\">14</td></tr><tr><td/><td align=\"center\">0.7</td><td align=\"center\">3</td><td align=\"center\">105</td><td align=\"center\">20</td><td/><td align=\"center\">ND</td><td/></tr><tr><td align=\"center\">Docetaxel</td><td align=\"center\">750</td><td align=\"center\">3</td><td align=\"center\">100</td><td align=\"center\">1</td><td align=\"center\">5</td><td align=\"center\">101</td><td align=\"center\">3</td></tr><tr><td/><td align=\"center\">50</td><td align=\"center\">3</td><td align=\"center\">97</td><td align=\"center\">1</td><td align=\"center\">5</td><td align=\"center\">94</td><td align=\"center\">6</td></tr><tr><td/><td align=\"center\">5</td><td align=\"center\">3</td><td align=\"center\">99</td><td align=\"center\">4</td><td align=\"center\">5</td><td align=\"center\">100</td><td align=\"center\">5</td></tr><tr><td/><td align=\"center\">2</td><td align=\"center\">5</td><td align=\"center\">93</td><td align=\"center\">4</td><td/><td align=\"center\">ND</td><td/></tr><tr><td/><td align=\"center\">1</td><td align=\"center\">5</td><td align=\"center\">96</td><td align=\"center\">12</td><td/><td align=\"center\">ND</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 1382254:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Detectable plasma concentrations of compounds that revealed a mean degree of phase II conjugation of less than 100 %: catechin (n = 5), caffeic acid (n = 3), U2 (n = 5) and U7 (n = 3) in samples of volunteers after repeated intake of 200 mg Pycnogenol once daily for five days.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\">Total plasma concentration</td><td align=\"center\">Free plasma concentration</td><td align=\"center\">% conjugated</td></tr></thead><tbody><tr><td align=\"center\">Catechin [ng/ml]</td><td align=\"center\">48.6 &#177; 16.7</td><td align=\"center\">21.0 &#177; 13.1</td><td align=\"center\">56.5 &#177; 27.9</td></tr><tr><td align=\"center\">Caffeic acid [ng/ml]</td><td align=\"center\">2.42 &#177; 1.39</td><td align=\"center\">0.56 &#177; 0.02</td><td align=\"center\">69.4 &#177; 11.8</td></tr><tr><td align=\"center\">U2 [peak ratio]</td><td align=\"center\">0.0537 &#177; 0.0132</td><td align=\"center\">0.0105 &#177; 0.0084</td><td align=\"center\">77.1 &#177; 21.3</td></tr><tr><td align=\"center\">U7 [peak ratio]</td><td align=\"center\">0.0101 &#177; 0.0007</td><td align=\"center\">0.0057 &#177; 0.0020</td><td align=\"center\">45.0 &#177; 18.5</td></tr></tbody></table></body></html>", "text": "Pmid= 1559639:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Calculated pharmacokinetic parameters of components or metabolites after intake of a single dose of 300 mg Pycnogenol.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Compound</td><td align=\"center\">n</td><td align=\"center\">AUC<sub> [0-t] </sub>[ng/mL &#215; h]</td><td align=\"center\">AUC<sub> [t-8] </sub>[ng/mL &#215; h]</td><td align=\"center\">c<sub>max </sub>[ng/mL]</td><td align=\"center\">t<sub>max </sub>[h]</td><td align=\"center\">term t&#189; [h]</td></tr></thead><tbody><tr><td align=\"center\">Caffeic acid</td><td align=\"center\">9</td><td align=\"center\">75.66 &#177; 33.53</td><td align=\"center\">82.78 &#177; 36.47</td><td align=\"center\">16.67 &#177; 13.29</td><td align=\"center\">3.7 &#177; 2.4</td><td align=\"center\">4.42 &#177; 2.47</td></tr><tr><td align=\"center\">Catechin</td><td align=\"center\">9</td><td/><td/><td align=\"center\">107.22 &#177; 55.49</td><td align=\"center\">3.2 &#177; 1.7</td><td/></tr><tr><td align=\"center\">Taxifolin</td><td align=\"center\">6</td><td align=\"center\">231.11 &#177; 85.98</td><td align=\"center\">399.14 &#177; 98.95</td><td align=\"center\">33.34 &#177; 12.54</td><td align=\"center\">8.2 &#177; 2.5</td><td align=\"center\">8.89 &#177; 2.81</td></tr><tr><td align=\"center\">Ferulic acid</td><td align=\"center\">7</td><td align=\"center\">99.05 &#177; 28.09</td><td align=\"center\">141.19 &#177; 73.90</td><td align=\"center\">14.78 &#177; 5.89</td><td align=\"center\">1.2 &#177; 1.1</td><td align=\"center\">6.87 &#177; 3.83</td></tr><tr><td align=\"center\">M1</td><td align=\"center\">8</td><td/><td/><td align=\"center\">4.11 &#177; 2.08</td><td align=\"center\">10.0 &#177; 1.9</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 1559639:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Voriconazole (VOR) and sulphobutylether beta cyclodextrin sodium (SBECD) plasma levels in patients with intravenous voriconazole therapy and renal failure</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">patient no.</td><td align=\"left\">day of VOR therapy</td><td align=\"left\">dose of intravenous VOR</td><td align=\"left\">dose of SBECD</td><td align=\"left\">dialysis information</td><td align=\"left\">VOR (&#956;g/ml)</td><td align=\"left\">SBECD (&#956;g/ml)</td></tr></thead><tbody><tr><td align=\"left\">1</td><td align=\"left\">2</td><td align=\"left\">2 &#215; 400 mg</td><td align=\"left\">2 &#215; 6400 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">0.9</td><td align=\"left\">98.3</td></tr><tr><td align=\"left\">1</td><td align=\"left\">2</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">1.1</td><td align=\"left\">145</td></tr><tr><td align=\"left\">1</td><td align=\"left\">3</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">0.2</td><td align=\"left\">93.3</td></tr><tr><td align=\"left\">1</td><td align=\"left\">4</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">&lt; 0.2</td><td align=\"left\">121</td></tr><tr><td align=\"left\">1</td><td align=\"left\">7</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">0.4</td><td align=\"left\">78.9</td></tr><tr><td align=\"left\">1</td><td align=\"left\">8</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">0.5</td><td align=\"left\">86.4</td></tr><tr><td align=\"left\">1</td><td align=\"left\">9</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">0.4</td><td align=\"left\">59.6</td></tr><tr><td align=\"left\">1</td><td align=\"left\">9</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">&lt; 0.2</td><td align=\"left\">31.4</td></tr><tr><td align=\"left\">1</td><td align=\"left\">10</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">0.3</td><td align=\"left\">71.6</td></tr><tr><td align=\"left\">1</td><td align=\"left\">12</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">no dialysis</td><td align=\"left\">&lt; 0.2</td><td align=\"left\">15.6</td></tr><tr><td align=\"left\">1</td><td align=\"left\">13</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">no dialysis</td><td align=\"left\">&lt; 0.2</td><td align=\"left\">16.4</td></tr><tr><td align=\"left\">1</td><td align=\"left\">16</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">no dialysis</td><td align=\"left\">&lt; 0.2</td><td align=\"left\">18.4</td></tr><tr><td align=\"left\">2</td><td align=\"left\">10</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">0.4</td><td align=\"left\">523</td></tr><tr><td align=\"left\">2</td><td align=\"left\">11</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">0.3</td><td align=\"left\">400</td></tr><tr><td align=\"left\">2</td><td align=\"left\">12</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">no dialysis</td><td align=\"left\">0.3</td><td align=\"left\">348</td></tr><tr><td align=\"left\">2</td><td align=\"left\">13</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">no dialysis</td><td align=\"left\">0.7</td><td align=\"left\">508</td></tr><tr><td align=\"left\">3</td><td align=\"left\">4</td><td align=\"left\">2 &#215; 400 mg</td><td align=\"left\">2 &#215; 6400 mg</td><td align=\"left\">no dialysis</td><td align=\"left\">3.8</td><td align=\"left\">110</td></tr><tr><td align=\"left\">3</td><td align=\"left\">8</td><td align=\"left\">2 &#215; 400 mg</td><td align=\"left\">2 &#215; 6400 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">5.1</td><td align=\"left\">314</td></tr><tr><td align=\"left\">3</td><td align=\"left\">10</td><td align=\"left\">2 &#215; 400 mg</td><td align=\"left\">2 &#215; 6400 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">3.2</td><td align=\"left\">409</td></tr><tr><td align=\"left\">3</td><td align=\"left\">11</td><td align=\"left\">2 &#215; 400 mg</td><td align=\"left\">2 &#215; 6400 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">2.6</td><td align=\"left\">200</td></tr><tr><td align=\"left\">4</td><td align=\"left\">1</td><td align=\"left\">2 &#215; 400 mg</td><td align=\"left\">2 &#215; 6400 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">1.4</td><td align=\"left\">344</td></tr><tr><td align=\"left\">4</td><td align=\"left\">5</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">0.3</td><td align=\"left\">271</td></tr><tr><td align=\"left\">4</td><td align=\"left\">7</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">0.3</td><td align=\"left\">451</td></tr><tr><td align=\"left\">4</td><td align=\"left\">8</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">0.3</td><td align=\"left\">483</td></tr><tr><td align=\"left\">4</td><td align=\"left\">9</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">no dialysis</td><td align=\"left\">0.9</td><td align=\"left\">456</td></tr><tr><td align=\"left\">4</td><td align=\"left\">12</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">1.1</td><td align=\"left\">505</td></tr><tr><td align=\"left\">4</td><td align=\"left\">13</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">before dialysis</td><td align=\"left\">1.3</td><td align=\"left\">581</td></tr><tr><td align=\"left\">4</td><td align=\"left\">13</td><td align=\"left\">2 &#215; 200 mg</td><td align=\"left\">2 &#215; 3200 mg</td><td align=\"left\">after dialysis</td><td align=\"left\">0.9</td><td align=\"left\">563</td></tr></tbody></table></body></html>", "text": "Pmid= 1592308:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Liver function tests in patients with renal failure at start and end of intravenous voriconazole therapy</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\">ASAT (IU/l)<sup><italic>a</italic></sup></td><td align=\"center\" colspan=\"2\">&#947;-GT (IU/l)<sup><italic>b</italic></sup></td><td align=\"center\" colspan=\"2\">Total bilirubin (mg/dl)<sup><italic>c</italic></sup></td></tr></thead><tbody><tr><td/><td align=\"center\">start</td><td align=\"center\">end</td><td align=\"center\">start</td><td align=\"center\">end</td><td align=\"center\">start</td><td align=\"center\">end</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">patient no. 1</td><td align=\"center\">104</td><td align=\"center\">24</td><td align=\"center\">119</td><td align=\"center\">264</td><td align=\"center\">2.32</td><td align=\"center\">1.39</td></tr><tr><td align=\"left\">patient no. 2</td><td align=\"center\">100</td><td align=\"center\">26</td><td align=\"center\">93</td><td align=\"center\">71</td><td align=\"center\">0.83</td><td align=\"center\">0.32</td></tr><tr><td align=\"left\">patient no. 3</td><td align=\"center\">54</td><td align=\"center\">25</td><td align=\"center\">288</td><td align=\"center\">443</td><td align=\"center\">4.93</td><td align=\"center\">7.27</td></tr><tr><td align=\"left\">patient no. 4</td><td align=\"center\">30</td><td align=\"center\">22</td><td align=\"center\">238</td><td align=\"center\">216</td><td align=\"center\">3.29</td><td align=\"center\">1.34</td></tr></tbody></table></body></html>", "text": "Pmid= 1592308:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Comparison of BDI and HADS scores</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Before treatment</bold></td><td align=\"left\"><bold>After treatment</bold></td><td align=\"left\"><bold>Sig.</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>BDI</bold></td><td align=\"left\">12.11 (&#177; 7.50)</td><td align=\"left\">12.80 (&#177; 7.64)</td><td align=\"left\">&lt; 0.001</td></tr><tr><td align=\"left\"><bold>HADS-D</bold></td><td align=\"left\">4.04 (&#177; 2.52)</td><td align=\"left\">4.61 (&#177; 3.19)</td><td align=\"left\">0.005</td></tr><tr><td align=\"left\"><bold>HADS-A</bold></td><td align=\"left\">6.24 (&#177; 3.17)</td><td align=\"left\">6.60 (&#177; 3.06)</td><td align=\"left\">0.061</td></tr></tbody></table></body></html>", "text": "Pmid= 1622749:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Individuals in different depression categories measured by BDI and HADS-A</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Depression categories</bold></td><td align=\"left\"><bold>N</bold></td><td align=\"left\"><bold>Percent</bold></td><td align=\"left\"><bold>Mean (&#177; SD)</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Normal</bold></td><td align=\"left\">60</td><td align=\"left\">46.9</td><td align=\"left\">6.47 (&#177; 2.14)</td></tr><tr><td align=\"left\"><bold>Minimal depressive</bold></td><td align=\"left\">40</td><td align=\"left\">31.3</td><td align=\"left\">12.20 (&#177; 1.70)</td></tr><tr><td align=\"left\"><bold>symptoms</bold></td><td align=\"left\">23</td><td align=\"left\">18.0</td><td align=\"left\">22.26 (&#177; 4.25)</td></tr><tr><td align=\"left\"><bold>Mild depression</bold></td><td align=\"left\">5</td><td align=\"left\">3.9</td><td align=\"left\">32.60 (&#177; 0.55)</td></tr><tr><td align=\"left\"><bold>Moderate depression</bold></td><td align=\"left\">0</td><td align=\"left\">0</td><td/></tr><tr><td align=\"left\"><bold>Severe depression</bold></td><td align=\"left\">0</td><td align=\"left\">0</td><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Anxiety categories</bold></td><td align=\"left\"><bold>N</bold></td><td align=\"left\"><bold>Percent</bold></td><td align=\"left\"><bold>Mean (&#177; SD)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Normal</bold></td><td align=\"left\">78</td><td align=\"left\">60.9</td><td align=\"left\">3.99 (&#177; 2.14)</td></tr><tr><td align=\"left\"><bold>Mild anxiety</bold></td><td align=\"left\">37</td><td align=\"left\">28.9</td><td align=\"left\">8.95 (&#177; 0.78)</td></tr><tr><td align=\"left\"><bold>Moderate anxiety</bold></td><td align=\"left\">13</td><td align=\"left\">10.2</td><td align=\"left\">12.08 (&#177; 0.95)</td></tr><tr><td align=\"left\"><bold>Sever anxiety</bold></td><td align=\"left\">0</td><td align=\"left\">0</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 1622749:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Scores compared between two groups of libido loss positive and negative patients</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Sig.</bold></td></tr></thead><tbody><tr><td align=\"left\">BDI Before treatment</td><td align=\"left\">0.73</td></tr><tr><td align=\"left\">HADS-D Before treatment</td><td align=\"left\">0.61</td></tr><tr><td align=\"left\">HADS-A Before treatment</td><td align=\"left\">0.42</td></tr><tr><td align=\"left\">BDI After treatment</td><td align=\"left\">0.94</td></tr><tr><td align=\"left\">HADS-D After treatment</td><td align=\"left\">0.45</td></tr><tr><td align=\"left\">HADS-A After treatment</td><td align=\"left\">0.30</td></tr></tbody></table></body></html>", "text": "Pmid= 1622749:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Data on PMs and EMs in Gujratis and Marwadis</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td/><td align=\"center\"><bold>Gujratis n = 122</bold></td><td align=\"center\"><bold>Marwadis n = 42</bold></td><td align=\"center\"><bold>Total N = 164</bold></td></tr></thead><tbody><tr><td align=\"center\"><bold>Males n = 109</bold></td><td align=\"center\"><bold>PM n = 12</bold></td><td align=\"center\">10 (12.98%)</td><td align=\"center\">2 (06.25%)</td><td align=\"center\">12 (11.00%)</td></tr><tr><td/><td align=\"center\"><bold>EM n = 97</bold></td><td align=\"center\">67 (87.02%)</td><td align=\"center\">30 (93.75%)</td><td align=\"center\">97 (89%)</td></tr><tr><td/><td align=\"center\"><bold>total</bold></td><td align=\"center\">77</td><td align=\"center\">32</td><td align=\"center\">109</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\"><bold>Females n = 55</bold></td><td align=\"center\"><bold>PM n = 5</bold></td><td align=\"center\">4 (08.88%)</td><td align=\"center\">1 (10.00%)</td><td align=\"center\">5 (09.09%)</td></tr><tr><td/><td align=\"center\"><bold>EM n = 50</bold></td><td align=\"center\">41 (91.12%)</td><td align=\"center\">9 (90.00%)</td><td align=\"center\">50 (91.91%)</td></tr><tr><td/><td align=\"center\"><bold>total</bold></td><td align=\"center\">45</td><td align=\"center\">10</td><td align=\"center\">55</td></tr></tbody></table></body></html>", "text": "Pmid= 1630702:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Model human adipose blood flow heterogeneity.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Solute</bold></td><td align=\"left\"><bold>Ref</bold></td><td align=\"left\"><bold>Ave F l/kg/min</bold></td><td align=\"left\"><bold>F<sub>1 </sub>l/kg/min</bold></td><td align=\"left\"><bold>V<sub>1 </sub>fract</bold></td><td align=\"left\"><bold>F<sub>2 </sub>l/kg/min</bold></td><td align=\"left\"><bold>V<sub>2 </sub>fract</bold></td><td align=\"left\"><bold>F<sub>3 </sub>l/kg/min</bold></td><td align=\"left\"><bold>V<sub>2 </sub>fract</bold></td><td align=\"left\"><bold>Time</bold></td><td align=\"left\"><bold>Method</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Volatile Anesthetics</bold></td><td align=\"left\">This ms.</td><td align=\"left\">0.044</td><td align=\"left\">0.0739</td><td align=\"left\">0.5</td><td align=\"left\">0.0141</td><td align=\"left\">0.5</td><td/><td/><td align=\"left\">6 days</td><td align=\"left\">PBPK N = 2</td></tr><tr><td/><td/><td align=\"left\">0.044</td><td align=\"left\">0.095</td><td align=\"left\">0.33</td><td align=\"left\">0.031</td><td align=\"left\">0.33</td><td align=\"left\">0.0059</td><td align=\"left\">0.33</td><td align=\"left\">6 days</td><td align=\"left\">PBPK N = 3</td></tr><tr><td/><td align=\"left\">[38]</td><td align=\"left\">0.071</td><td align=\"left\">0.213</td><td align=\"left\">.26</td><td align=\"left\">0.022</td><td align=\"left\">0.74</td><td/><td/><td align=\"left\">5 days</td><td align=\"left\">PBPK N = 2</td></tr><tr><td/><td/><td align=\"left\">0.05</td><td align=\"left\">0.097</td><td align=\"left\">.41</td><td align=\"left\">0.019</td><td align=\"left\">0.59</td><td/><td/><td/><td/></tr><tr><td/><td align=\"left\">[4, 5]</td><td align=\"left\">0.06&#8211;0.071</td><td align=\"left\">.11&#8211;.15</td><td align=\"left\">&#8776; 0.5</td><td align=\"left\">0.021&#8211;0.024</td><td align=\"left\">&#8776; 0.5</td><td/><td/><td align=\"left\">6 days</td><td align=\"left\">Compartmental</td></tr><tr><td align=\"left\"><bold>Propofol</bold></td><td align=\"left\">[14]</td><td align=\"left\">0.042</td><td align=\"left\">0.042</td><td align=\"left\">1.0</td><td/><td/><td/><td/><td align=\"left\">600 min</td><td align=\"left\">PBPK N = 1</td></tr><tr><td align=\"left\"><bold>Toluene</bold></td><td align=\"left\">[55]</td><td align=\"left\">0.032</td><td align=\"left\">0.032</td><td align=\"left\">1.0</td><td/><td/><td/><td/><td align=\"left\">4 days</td><td align=\"left\">PBPK N = 1</td></tr><tr><td align=\"left\"><bold>Toluene</bold></td><td align=\"left\">[53]</td><td align=\"left\">0.024</td><td align=\"left\">0.042</td><td align=\"left\">0.4</td><td align=\"left\">0.013</td><td align=\"left\">0.5</td><td align=\"left\">0.0</td><td align=\"left\">0.1</td><td align=\"left\">20 hr</td><td align=\"left\">PBPK N = 2</td></tr><tr><td align=\"left\"><bold>Styrene</bold></td><td align=\"left\">[54]</td><td align=\"left\">0.028</td><td align=\"left\">0.052</td><td align=\"left\">0.4</td><td align=\"left\">0.014</td><td align=\"left\">0.5</td><td align=\"left\">0.0</td><td align=\"left\">0.1</td><td align=\"left\">20 hr</td><td align=\"left\">PBPK N = 2</td></tr></tbody></table></body></html>", "text": "Pmid= 1797001:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Volatile anesthetic partition coefficients at 37C.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Solute</bold></td><td align=\"left\"><bold>Blood/air</bold></td><td align=\"left\"><bold>Water/air</bold></td><td align=\"left\"><bold>Oil/air</bold></td><td align=\"left\"><bold>Adipose/Blood</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Isoflurane</bold></td><td align=\"left\">1.33 [56]</td><td align=\"left\">.544 [57]</td><td align=\"left\">88.2 [57]</td><td align=\"left\">53.2</td></tr><tr><td align=\"left\"><bold>Sevoflurane</bold></td><td align=\"left\">0.62 [58]</td><td align=\"left\">.37 [59]</td><td align=\"left\">47 [59]</td><td align=\"left\">60.8</td></tr><tr><td align=\"left\"><bold>Desflurane</bold></td><td align=\"left\">0.52 [58]</td><td align=\"left\">.225 [57]</td><td align=\"left\">17.9 [57]</td><td align=\"left\">27.7</td></tr></tbody></table></body></html>", "text": "Pmid= 1797001:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Physiological tissue model parameters</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Tissue</bold></td><td align=\"right\"><bold>Weight Kg</bold></td><td align=\"right\"><bold>Perfusion l/Kg/min</bold></td><td align=\"right\"><bold>Flow l/min</bold></td><td align=\"right\"><bold>Fat Fraction</bold></td><td align=\"right\"><bold>Total Fat Kg</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Blood</bold></td><td align=\"right\">5.6</td><td/><td/><td align=\"right\">0.0075</td><td align=\"right\">0.042</td></tr><tr><td align=\"left\"><bold>Liver</bold></td><td align=\"right\">1.83</td><td align=\"right\">0.25</td><td align=\"right\">0.4575</td><td align=\"right\">0.02</td><td align=\"right\">0.0366</td></tr><tr><td align=\"left\"><bold>Portal</bold></td><td align=\"right\">1.525</td><td align=\"right\">0.75</td><td align=\"right\">1.14375</td><td align=\"right\">0.016</td><td align=\"right\">0.0244</td></tr><tr><td align=\"left\"><bold>Muscle</bold></td><td align=\"right\">26.43</td><td align=\"right\">0.0225</td><td align=\"right\">0.594675</td><td align=\"right\">0.0136</td><td align=\"right\">0.359448</td></tr><tr><td align=\"left\"><bold>Kidney</bold></td><td align=\"right\">0.3152</td><td align=\"right\">4</td><td align=\"right\">1.2608</td><td align=\"right\">0.0136</td><td align=\"right\">0.004287</td></tr><tr><td align=\"left\"><bold>Brain</bold></td><td align=\"right\">1.423</td><td align=\"right\">0.56</td><td align=\"right\">0.79688</td><td align=\"right\">0.0176</td><td align=\"right\">0.025045</td></tr><tr><td align=\"left\"><bold>Heart</bold></td><td align=\"right\">0.3355</td><td align=\"right\">0.8</td><td align=\"right\">0.2684</td><td align=\"right\">0.0136</td><td align=\"right\">0.004563</td></tr><tr><td align=\"left\"><bold>Lung</bold></td><td align=\"right\">0.5449</td><td align=\"right\">0</td><td align=\"right\">0</td><td align=\"right\">0.0136</td><td align=\"right\">0.007411</td></tr><tr><td align=\"left\"><bold>Skin</bold></td><td align=\"right\">2.643</td><td align=\"right\">0.1</td><td align=\"right\">0.2643</td><td align=\"right\">0.0136</td><td align=\"right\">0.035945</td></tr><tr><td align=\"left\"><bold>Tendon</bold></td><td align=\"right\">3.05</td><td align=\"right\">0.01</td><td align=\"right\">0.0305</td><td align=\"right\">0.0136</td><td align=\"right\">0.04148</td></tr><tr><td align=\"left\"><bold>Other</bold></td><td align=\"right\">5.616</td><td align=\"right\">0.02</td><td align=\"right\">0.11232</td><td align=\"right\">0.0136</td><td align=\"right\">0.076378</td></tr><tr><td align=\"left\"><bold>Bone</bold></td><td align=\"right\">4.0617</td><td align=\"right\">0</td><td align=\"right\">0</td><td align=\"right\">0</td><td align=\"right\">0</td></tr><tr><td align=\"left\"><bold>Adipose 1</bold></td><td align=\"right\">5.5419</td><td align=\"right\">0.095</td><td align=\"right\">0.5264805</td><td align=\"right\">0.8</td><td align=\"right\">4.43352</td></tr><tr><td align=\"left\"><bold>Adipose 2</bold></td><td align=\"right\">5.5419</td><td align=\"right\">0.031</td><td align=\"right\">0.1717989</td><td align=\"right\">0.8</td><td align=\"right\">4.43352</td></tr><tr><td align=\"left\"><bold>Adipose 3</bold></td><td align=\"right\">5.5419</td><td align=\"right\">0.0059</td><td align=\"right\">0.0326972</td><td align=\"right\">0.8</td><td align=\"right\">4.43352</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td align=\"right\">70</td><td/><td align=\"right\">5.6601016</td><td/><td align=\"right\">14</td></tr></tbody></table></body></html>", "text": "Pmid= 1797001:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Cannabinoid partition coefficients</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Solute</bold></td><td align=\"left\"><bold>Oil/Water</bold></td><td align=\"left\"><bold>Blood/water</bold></td><td align=\"left\"><bold>Adipose/Blood</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Cannabinol</bold></td><td align=\"left\">257,000</td><td align=\"left\">1928</td><td align=\"left\">106.6</td></tr><tr><td align=\"left\"><bold>Cannibidiol</bold></td><td align=\"left\">24,000</td><td align=\"left\">181</td><td align=\"left\">106.1</td></tr></tbody></table></body></html>", "text": "Pmid= 1797001:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Weighted residual error (WRE), weighted residual sum of squares (WRSS) and Akaike number for each solute, adipose model and time period</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Solute</bold></td><td align=\"center\"><bold>Time period</bold></td><td align=\"center\"><bold>Data (# pts)</bold></td><td align=\"center\" colspan=\"3\"><bold>N = 1</bold></td><td align=\"center\" colspan=\"3\"><bold>N = 2</bold></td><td align=\"center\" colspan=\"3\"><bold>N = 3</bold></td></tr><tr><td/><td/><td/><td align=\"right\"><bold>WRE</bold></td><td align=\"right\"><bold>WRSS</bold></td><td align=\"right\"><bold>Akaike</bold></td><td align=\"right\"><bold>WRE</bold></td><td align=\"right\"><bold>WRSS</bold></td><td align=\"right\"><bold>Akaike</bold></td><td align=\"right\"><bold>WRE</bold></td><td align=\"right\"><bold>WRSS</bold></td><td align=\"right\"><bold>Akaike</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Isoflurane_S</bold></td><td align=\"center\">1</td><td align=\"center\">45</td><td align=\"right\">0.062</td><td align=\"right\">0.329</td><td align=\"right\">-50.0264</td><td align=\"right\">0.0572</td><td align=\"right\">0.285</td><td align=\"right\">-54.487</td><td align=\"right\">0.0575</td><td align=\"right\">0.284</td><td align=\"right\">-52.6451</td></tr><tr><td/><td align=\"center\">2</td><td align=\"center\">5</td><td align=\"right\">0.41</td><td align=\"right\">1.004</td><td align=\"right\">0.01996</td><td align=\"right\">0.0224</td><td align=\"right\">0.329</td><td align=\"right\">-3.55849</td><td align=\"right\">0.169</td><td align=\"right\">0.182</td><td align=\"right\">-4.51874</td></tr><tr><td/><td align=\"center\">3</td><td align=\"center\">10</td><td align=\"right\">0.44</td><td align=\"right\">3.94</td><td align=\"right\">13.71181</td><td align=\"right\">0.12</td><td align=\"right\">0.24</td><td align=\"right\">-12.2712</td><td align=\"right\">0.125</td><td align=\"right\">0.226</td><td align=\"right\">-10.8722</td></tr><tr><td align=\"left\"><bold>Isoflurane_D</bold></td><td align=\"center\">1</td><td align=\"center\">45</td><td align=\"right\">0.047</td><td align=\"right\">0.186</td><td align=\"right\">-75.6904</td><td align=\"right\">0.0385</td><td align=\"right\">0.116</td><td align=\"right\">-94.9374</td><td align=\"right\">0.0375</td><td align=\"right\">0.11</td><td align=\"right\">-95.3274</td></tr><tr><td/><td align=\"center\">2</td><td align=\"center\">6</td><td align=\"right\">0.37</td><td align=\"right\">1.044</td><td align=\"right\">0.258357</td><td align=\"right\">0.189</td><td align=\"right\">0.285</td><td align=\"right\">-5.5316</td><td align=\"right\">0.131</td><td align=\"right\">0.14</td><td align=\"right\">-7.79668</td></tr><tr><td/><td align=\"center\">3</td><td align=\"center\">9</td><td align=\"right\">0.32</td><td align=\"right\">1.096</td><td align=\"right\">0.825005</td><td align=\"right\">0.127</td><td align=\"right\">0.248</td><td align=\"right\">-10.5489</td><td align=\"right\">0.119</td><td align=\"right\">0.16</td><td align=\"right\">-12.4932</td></tr><tr><td align=\"left\"><bold>Sevoflurane</bold></td><td align=\"center\">1</td><td align=\"center\">45</td><td align=\"right\">0.0729</td><td align=\"right\">0.386</td><td align=\"right\">-42.8363</td><td align=\"right\">0.0664</td><td align=\"right\">0.332</td><td align=\"right\">-47.6179</td><td align=\"right\">0.0648</td><td align=\"right\">0.32</td><td align=\"right\">-47.2745</td></tr><tr><td/><td align=\"center\">2</td><td align=\"center\">5</td><td align=\"right\">0.39</td><td align=\"right\">0.955</td><td align=\"right\">-0.23022</td><td align=\"right\">0.242</td><td align=\"right\">0.364</td><td align=\"right\">-3.05301</td><td align=\"right\">0.192</td><td align=\"right\">0.225</td><td align=\"right\">-3.45827</td></tr><tr><td/><td align=\"center\">3</td><td align=\"center\">10</td><td align=\"right\">0.36</td><td align=\"right\">1.657</td><td align=\"right\">5.050087</td><td align=\"right\">0.215</td><td align=\"right\">0.573</td><td align=\"right\">-3.5687</td><td align=\"right\">0.103</td><td align=\"right\">0.171</td><td align=\"right\">-13.6609</td></tr><tr><td align=\"left\"><bold>Desflurane</bold></td><td align=\"center\">1</td><td align=\"center\">45</td><td align=\"right\">0.0869</td><td align=\"right\">0.866</td><td align=\"right\">-6.47417</td><td align=\"right\">0.0586</td><td align=\"right\">0.32</td><td align=\"right\">-49.2745</td><td align=\"right\">0.0477</td><td align=\"right\">0.195</td><td align=\"right\">-69.564</td></tr><tr><td/><td align=\"center\">2</td><td align=\"center\">6</td><td align=\"right\">0.323</td><td align=\"right\">0.768</td><td align=\"right\">-1.58379</td><td align=\"right\">0.167</td><td align=\"right\">0.204</td><td align=\"right\">-7.53781</td><td align=\"right\">0.119</td><td align=\"right\">0.114</td><td align=\"right\">-9.02934</td></tr><tr><td/><td align=\"center\">3</td><td align=\"center\">9</td><td align=\"right\">5.08</td><td align=\"right\">1416</td><td align=\"right\">65.30032</td><td align=\"right\">0.196</td><td align=\"right\">0.641</td><td align=\"right\">-2.00253</td><td align=\"right\">0.139</td><td align=\"right\">0.338</td><td align=\"right\">-5.76238</td></tr></tbody></table></body></html>", "text": "Pmid= 1797001:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Characteristic</bold></td><td align=\"center\"><bold>All Participants (<italic>n </italic>= 32)</bold></td></tr></thead><tbody><tr><td align=\"left\">Sex, <italic>n </italic>(%)</td><td/></tr><tr><td align=\"left\">&#8195;Male</td><td align=\"center\">20 (62.5)</td></tr><tr><td align=\"left\">&#8195;Female</td><td align=\"center\">12 (37.5)</td></tr><tr><td align=\"left\">Race, <italic>n </italic>(%)</td><td/></tr><tr><td align=\"left\">&#8195;Caucasian</td><td align=\"center\">26 (81.3)</td></tr><tr><td align=\"left\">&#8195;Asian</td><td align=\"center\">3 (9.4)</td></tr><tr><td align=\"left\">&#8195;Black</td><td align=\"center\">1 (3.1)</td></tr><tr><td align=\"left\">&#8195;Hispanic</td><td align=\"center\">1 (3.1)</td></tr><tr><td align=\"left\">&#8195;American Indian</td><td align=\"center\">1 (3.1)</td></tr><tr><td align=\"left\">Age (years)</td><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">33</td></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">20&#8211;50</td></tr><tr><td align=\"left\">Height (cm)</td><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">175</td></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">163&#8211;191</td></tr><tr><td align=\"left\">Weight (kg)</td><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">76.4</td></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">61.4&#8211;96.4</td></tr></tbody></table></body></html>", "text": "Pmid= 1808051:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Untransformed pharmacokinetic parameters after administration of OROS</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Parameter</bold></td><td align=\"center\"><bold>8 mg</bold></td><td align=\"center\"><bold>16 mg</bold></td><td align=\"center\"><bold>32 mg</bold></td><td align=\"center\"><bold>64 mg</bold></td></tr></thead><tbody><tr><td align=\"left\">C<sub>max </sub>(ng/mL)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">0.929</td><td align=\"center\">1.69</td><td align=\"center\">3.25</td><td align=\"center\">6.61</td></tr><tr><td align=\"left\">&#8195;SD</td><td align=\"center\">1.01</td><td align=\"center\">0.78</td><td align=\"center\">1.37</td><td align=\"center\">1.75</td></tr><tr><td align=\"left\">T<sub>max </sub>(hour)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Median</td><td align=\"center\">12.0</td><td align=\"center\">16.0</td><td align=\"center\">16.0</td><td align=\"center\">16.0</td></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">4.0&#8211;30.0</td><td align=\"center\">6.0&#8211;30.0</td><td align=\"center\">4.0&#8211;24.0</td><td align=\"center\">6.0&#8211;30.0</td></tr><tr><td align=\"left\">AUC<sub>0&#8211;48 </sub>(ng&#183;hr/mL)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">18.1</td><td align=\"center\">36.5</td><td align=\"center\">72.2</td><td align=\"center\">156</td></tr><tr><td align=\"left\">&#8195;SD</td><td align=\"center\">5.8</td><td align=\"center\">11.3</td><td align=\"center\">24.3</td><td align=\"center\">30.6</td></tr><tr><td align=\"left\">AUC<sub>0&#8211;&#8734; </sub>(ng&#183;hr/mL)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">19.5</td><td align=\"center\">40.8</td><td align=\"center\">80.3</td><td align=\"center\">178.7</td></tr><tr><td align=\"left\">&#8195;SD</td><td align=\"center\">5.9</td><td align=\"center\">13.7</td><td align=\"center\">29.6</td><td align=\"center\">35.2</td></tr><tr><td align=\"left\">t<sub>1/2 </sub>(hour)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">10.6</td><td align=\"center\">10.3</td><td align=\"center\">11.0</td><td align=\"center\">10.9</td></tr><tr><td align=\"left\">&#8195;SD</td><td align=\"center\">4.3</td><td align=\"center\">2.4</td><td align=\"center\">3.2</td><td align=\"center\">3.8</td></tr></tbody></table></body></html>", "text": "Pmid= 1808051:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Mean (SD) of the dose-normalized pharmacokinetic parameters after administration of OROS</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Parameter</bold></td><td align=\"center\"><bold>8 mg</bold></td><td align=\"center\"><bold>16 mg</bold></td><td align=\"center\"><bold>32 mg</bold></td><td align=\"center\"><bold>64 mg</bold></td></tr></thead><tbody><tr><td align=\"left\">C<sub>max</sub>, ng/mL/mg</td><td align=\"center\">0.116 (0.127)</td><td align=\"center\">0.106 (0.049)</td><td align=\"center\">0.102 (0.043)</td><td align=\"center\">0.103 (0.027)</td></tr><tr><td align=\"left\">AUC<sub>0&#8211;48</sub>, ng&#183;hr/mL/mg</td><td align=\"center\">2.26 (0.72)</td><td align=\"center\">2.28 (0.71)</td><td align=\"center\">2.26 (0.76)</td><td align=\"center\">2.44 (0.48)</td></tr><tr><td align=\"left\">AUC<sub>0&#8211;&#8734;</sub>, ng&#183;hr/mL/mg</td><td align=\"center\">2.44 (0.74)</td><td align=\"center\">2.55 (0.86)</td><td align=\"center\">2.51 (0.93)</td><td align=\"center\">2.79 (0.55)</td></tr></tbody></table></body></html>", "text": "Pmid= 1808051:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Adverse events occurring in 10% of subjects in any treatment group</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Event, <italic>n </italic>(%)</bold></td><td align=\"center\"><bold>8 mg (<italic>n </italic>= 31)</bold></td><td align=\"center\"><bold>16 mg (<italic>n </italic>= 31)</bold></td><td align=\"center\"><bold>32 mg (<italic>n </italic>= 31)</bold></td><td align=\"center\"><bold>64 mg (<italic>n </italic>= 32)</bold></td></tr></thead><tbody><tr><td align=\"left\">Asthenia</td><td align=\"center\">2 (6)</td><td align=\"center\">5 (16)</td><td align=\"center\">3 (10)</td><td align=\"center\">5 (16)</td></tr><tr><td align=\"left\">Nausea</td><td align=\"center\">4 (13)</td><td align=\"center\">5 (16)</td><td align=\"center\">3 (10)</td><td align=\"center\">3 (9)</td></tr><tr><td align=\"left\">Headache</td><td align=\"center\">2 (6)</td><td align=\"center\">3 (10)</td><td align=\"center\">5 (16)</td><td align=\"center\">3 (9)</td></tr><tr><td align=\"left\">Chest pain</td><td align=\"center\">0 (0)</td><td align=\"center\">0 (0)</td><td align=\"center\">3 (10)</td><td align=\"center\">2 (6)</td></tr></tbody></table></body></html>", "text": "Pmid= 1808051:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Characteristic</bold></td><td align=\"center\"><bold>All Participants (<italic>n </italic>= 30)</bold></td></tr></thead><tbody><tr><td align=\"left\">Sex, <italic>n </italic>(%)</td><td/></tr><tr><td align=\"left\">&#8195;Male</td><td align=\"center\">21 (70)</td></tr><tr><td align=\"left\">&#8195;Female</td><td align=\"center\">9 (30)</td></tr><tr><td align=\"left\">Race, <italic>n </italic>(%)</td><td/></tr><tr><td align=\"left\">&#8195;Caucasian</td><td align=\"center\">27 (90)</td></tr><tr><td align=\"left\">&#8195;Black</td><td align=\"center\">2 (7)</td></tr><tr><td align=\"left\">&#8195;Hispanic</td><td align=\"center\">1 (3)</td></tr><tr><td align=\"left\">Age (years)</td><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">33.1</td></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">19&#8211;49</td></tr><tr><td align=\"left\">Height (cm)</td><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">176</td></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">163&#8211;191</td></tr><tr><td align=\"left\">Weight (kg)</td><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">77.2</td></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">64.5&#8211;94.5</td></tr></tbody></table></body></html>", "text": "Pmid= 1810515:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic parameters for hydromorphone after administration of OROS</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Parameter</bold></td><td align=\"center\"><bold>Treatment Regimen A (fasting; <italic>n </italic>= 25)</bold></td><td align=\"center\"><bold>Treatment Regimen B (fed; <italic>n </italic>= 27)</bold></td><td align=\"center\"><bold>Treatment Regimen C (fasting with naltrexone block; <italic>n </italic>= 26)</bold></td></tr></thead><tbody><tr><td align=\"left\">C<sub>max </sub>(ng/mL)</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">1.107</td><td align=\"center\">1.352</td><td align=\"center\">1.635</td></tr><tr><td align=\"left\">&#8195;SD</td><td align=\"center\">0.2058</td><td align=\"center\">0.3633</td><td align=\"center\">0.5708</td></tr><tr><td align=\"left\">T<sub>max </sub>(h)</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Median</td><td align=\"center\">16.0</td><td align=\"center\">12.0</td><td align=\"center\">12.0</td></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">6.0&#8211;36.0</td><td align=\"center\">6.0&#8211;20.0</td><td align=\"center\">6.0&#8211;24.0</td></tr><tr><td align=\"left\">t<sub>1/2 </sub>(h)</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">14.7</td><td align=\"center\">12.5</td><td align=\"center\">10.1</td></tr><tr><td align=\"left\">&#8195;SD</td><td align=\"center\">6.07</td><td align=\"center\">5.22</td><td align=\"center\">3.95</td></tr><tr><td align=\"left\">AUC<sub>0-t </sub>(ng&#183; h/mL)</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">31.12</td><td align=\"center\">30.20</td><td align=\"center\">33.97</td></tr><tr><td align=\"left\">&#8195;SD</td><td align=\"center\">7.063</td><td align=\"center\">8.738</td><td align=\"center\">9.007</td></tr><tr><td align=\"left\">AUC<sub>0-&#8734;</sub>(ng&#183;h/mL)</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean</td><td align=\"center\">38.84</td><td align=\"center\">36.09</td><td align=\"center\">37.24</td></tr><tr><td align=\"left\">&#8195;SD</td><td align=\"center\">9.566</td><td align=\"center\">10.04</td><td align=\"center\">9.921</td></tr></tbody></table></body></html>", "text": "Pmid= 1810515:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Adverse events [</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Event</bold></td><td align=\"center\"><bold>Treatment Regimen A (fasting; <italic>n </italic>= 28)</bold></td><td align=\"center\"><bold>Treatment Regimen B (fed; <italic>n </italic>= 29)</bold></td><td align=\"center\"><bold>Treatment Regimen C (fasting with naltrexone block; <italic>n </italic>= 27)</bold></td></tr></thead><tbody><tr><td align=\"left\">Nausea</td><td align=\"center\">6 (21.4)</td><td align=\"center\">9 (31.0)</td><td align=\"center\">7 (25.9)</td></tr><tr><td align=\"left\">Asthenia</td><td align=\"center\">6 (21.4)</td><td align=\"center\">8 (27.6)</td><td align=\"center\">7 (25.9)</td></tr><tr><td align=\"left\">Dizziness</td><td align=\"center\">8 (28.6)</td><td align=\"center\">5 (17.2)</td><td align=\"center\">3 (11.1)</td></tr><tr><td align=\"left\">Pruritus</td><td align=\"center\">2 (7.1)</td><td align=\"center\">4 (13.8)</td><td align=\"center\">9 (33.3)</td></tr><tr><td align=\"left\">Headache</td><td align=\"center\">6 (21.4)</td><td align=\"center\">3 (10.3)</td><td align=\"center\">4 (14.8)</td></tr><tr><td align=\"left\">Vomiting</td><td align=\"center\">2 (7.1)</td><td align=\"center\">3 (10.3)</td><td align=\"center\">5 (18.5)</td></tr></tbody></table></body></html>", "text": "Pmid= 1810515:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Risk ratios for myocardial infarction among hypertensive patients treated with non-atenolol versus atenolol -blockers</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">Number of studies</td><td align=\"left\">Mean Risk ratio</td><td align=\"left\">Median risk ratio</td><td align=\"left\" colspan=\"2\">Credibility interval</td><td align=\"left\">Probability of risk ratio &#8804; 0.90</td></tr><tr><td/><td/><td/><td/><td align=\"left\">2.5 &#8211; 97.5 %</td><td align=\"left\">5 &#8211; 95 %</td><td/></tr></thead><tbody><tr><td align=\"left\">Studies that only included comparison with non-&#946;-blockers</td><td align=\"left\">8</td><td align=\"left\">0.836</td><td align=\"left\">0.828</td><td align=\"left\">0.633 &#8211; 1.078</td><td align=\"left\">0.664 &#8211; 1.031</td><td align=\"left\">0.836</td></tr><tr><td align=\"left\">Studies that only included comparison with placebo</td><td align=\"left\">6</td><td align=\"left\">0.918</td><td align=\"left\">0.906</td><td align=\"left\">0.711 &#8211; 1.172</td><td align=\"left\">0.734 &#8211; 1.125</td><td align=\"left\">0.475</td></tr><tr><td align=\"left\">All studies included</td><td align=\"left\">14</td><td align=\"left\">0.868</td><td align=\"left\">0.867</td><td align=\"left\">0.727 &#8211; 1.023</td><td align=\"left\">0.750 &#8211; 0.992</td><td align=\"left\">0.689</td></tr><tr><td align=\"left\">All studies except MRC Old atenolol versus other antihypertensive drugs</td><td align=\"left\">13</td><td align=\"left\">0.882</td><td align=\"left\">0.883</td><td align=\"left\">0.742 &#8211; 1.039</td><td align=\"left\">0.758 &#8211; 1.016</td><td align=\"left\">0.616</td></tr></tbody></table></body></html>", "text": "Pmid= 1876203:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Group demographics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">Methadone<break/> (<italic>n </italic>= 16)</td><td align=\"left\">Buprenorphine/Naloxone<break/> (<italic>n </italic>= 17)</td><td align=\"left\">Control<break/> (<italic>n </italic>= 17)</td><td align=\"left\">Group comparison<break/><italic>p</italic>-values</td></tr></thead><tbody><tr><td align=\"left\">Age, years (<italic>M, SD</italic>)</td><td align=\"left\">30.8 (8.8)</td><td align=\"left\">28.1 (6.3)</td><td align=\"left\">31.1 (11.2)</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">Sex: females/males</td><td align=\"left\">9/7</td><td align=\"left\">7/10</td><td align=\"left\">9/8</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">Verbal intelligence <sup>a </sup>(<italic>M, SD</italic>)</td><td align=\"left\">98.4 (8.7)</td><td align=\"left\">102.4 (8.4)</td><td align=\"left\">105.4 (9.8)</td><td align=\"left\">C &gt; M*</td></tr><tr><td align=\"left\">Education, years (M, SD)</td><td align=\"left\">10.4 (2.0)</td><td align=\"left\">11.1 (2.2)</td><td align=\"left\">13,0 (1.7)</td><td align=\"left\">C &gt; M**<break/> C &gt; BN**</td></tr><tr><td align=\"left\">Dependencies</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Opioid</td><td align=\"left\">100%</td><td align=\"left\">100%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">&#8195;Alcohol</td><td align=\"left\">0%</td><td align=\"left\">6%</td><td/><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">&#8195;Amphetamine</td><td align=\"left\">0%</td><td align=\"left\">11%</td><td/><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">&#8195;Benzodiazepines</td><td align=\"left\">100%</td><td align=\"left\">89%</td><td/><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">&#8195;Cannabis</td><td align=\"left\">6%</td><td align=\"left\">11%</td><td/><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">Main opioid of abuse used within last month (%)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Buprenorphine</td><td align=\"left\">75%</td><td align=\"left\">100%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">&#8195;Heroin</td><td align=\"left\">13%</td><td align=\"left\">0%</td><td/><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">&#8195;Methadone</td><td align=\"left\">13%</td><td align=\"left\">0%</td><td/><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">Other substances of abuse used within last month (%)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Alcohol (heavy use)<sup>c</sup></td><td align=\"left\">6%</td><td align=\"left\">17%</td><td align=\"left\">6%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">&#8195;Amphetamine</td><td align=\"left\">19%</td><td align=\"left\">29%</td><td align=\"left\">0%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">&#8195;Benzodiazepine<sup>d</sup></td><td align=\"left\">94%</td><td align=\"left\">94%</td><td align=\"left\">0%</td><td align=\"left\">M &amp; BN &gt; C**</td></tr><tr><td align=\"left\">&#8195;Cannabis</td><td align=\"left\">38%</td><td align=\"left\">24%</td><td align=\"left\">0%</td><td align=\"left\">M &gt; C*</td></tr><tr><td align=\"left\">&#8195;Nicotine (daily use)</td><td align=\"left\">100%</td><td align=\"left\">100%</td><td align=\"left\">35%</td><td align=\"left\">M &amp; BN &gt; C**</td></tr><tr><td align=\"left\">Duration of opioid substitution treatment in the day of testing, days (M, SD)</td><td align=\"left\">14.3 (7.4)</td><td align=\"left\">11.0 (8.1)</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">Duration of opioid abuse, years (M, SD)</td><td align=\"left\">12.1 (7.7)</td><td align=\"left\">10.0 (3.5)</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr><tr><td align=\"left\">Duration of any substance abuse, years (M, SD)</td><td align=\"left\">16.9 (8.7)</td><td align=\"left\">15.7 (5.0)</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup><italic>b</italic></sup></td></tr></tbody></table></body></html>", "text": "Pmid= 1914339:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Comedications among OST patients within the last 24 h before testing</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Medications used within 24 hours of test</td><td align=\"left\">Methadone-treated patients<break/> (<italic>n </italic>= 16)</td><td/><td align=\"left\">Buprenorphine/Naloxone- treated patients<break/> (<italic>n </italic>= 17)</td><td/></tr></thead><tbody><tr><td/><td align=\"left\">Proportion of patients</td><td align=\"left\">Dose, range</td><td align=\"left\">Proportion of patients</td><td align=\"left\">Dose, range</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Antidepressives (any)</td><td align=\"left\">44 %</td><td/><td align=\"left\">35\\'%</td><td/></tr><tr><td align=\"left\">&#8195;Essitalopram</td><td align=\"left\">6%</td><td align=\"left\">5 mg</td><td/><td/></tr><tr><td align=\"left\">&#8195;Citalopram</td><td align=\"left\">6 %</td><td align=\"left\">20 mg</td><td/><td/></tr><tr><td align=\"left\">&#8195;Doxepine</td><td/><td/><td align=\"left\">12%</td><td align=\"left\">75 &#8211; 100 mg</td></tr><tr><td align=\"left\">&#8195;Fluoxetine</td><td align=\"left\">13%</td><td align=\"left\">20 &#8211; 30 mg</td><td/><td/></tr><tr><td align=\"left\">&#8195;Mirtazapine</td><td align=\"left\">13%</td><td align=\"left\">15 mg</td><td/><td/></tr><tr><td align=\"left\">&#8195;Paroxetine</td><td/><td/><td align=\"left\">6%</td><td align=\"left\">50 mg</td></tr><tr><td align=\"left\">&#8195;Sertraline</td><td align=\"left\">6%</td><td align=\"left\">50 mg</td><td align=\"left\">12%</td><td align=\"left\">50 mg</td></tr><tr><td align=\"left\">&#8195;Venlaflaxine</td><td/><td/><td align=\"left\">12%</td><td align=\"left\">75 mg</td></tr><tr><td align=\"left\">Anxiolytics, sedatives and hypnotics:</td><td/><td/><td/><td/></tr><tr><td align=\"left\">Benzodiazepines (any)</td><td align=\"left\">81 %</td><td/><td align=\"left\">76%</td><td/></tr><tr><td align=\"left\">&#8195;Diazepam</td><td align=\"left\">38%</td><td align=\"left\">5&#8211;20 mg</td><td align=\"left\">29%</td><td align=\"left\">15 -40 mg</td></tr><tr><td align=\"left\">&#8195;Oxazepam</td><td align=\"left\">44%</td><td align=\"left\">45 &#8211; 120 mg</td><td align=\"left\">47%</td><td align=\"left\">30 &#8211; 90 mg</td></tr><tr><td align=\"left\">&#8195;Nitratzepam*</td><td align=\"left\">6%</td><td align=\"left\">20 mg</td><td/><td/></tr><tr><td align=\"left\">&#8195;Tematzepam *</td><td align=\"left\">19%</td><td align=\"left\">20 mg</td><td align=\"left\">12%</td><td align=\"left\">20 mg</td></tr><tr><td align=\"left\">Non-benzodiazepine hypnotics (any)</td><td align=\"left\">25%</td><td/><td align=\"left\">35%</td><td/></tr><tr><td align=\"left\">&#8195;Zolpidem *</td><td align=\"left\">6%</td><td align=\"left\">10 mg</td><td align=\"left\">6%</td><td align=\"left\">15 mg</td></tr><tr><td align=\"left\">&#8195;Zopiclone *</td><td align=\"left\">19%</td><td align=\"left\">7.5 &#8211; 15 mg</td><td align=\"left\">24%</td><td align=\"left\">7.5 &#8211; 15 mg</td></tr><tr><td align=\"left\">Neuroleptics &#8224; (any)</td><td align=\"left\">25%</td><td/><td align=\"left\">18%</td><td/></tr><tr><td align=\"left\">&#8195;Chlorpromazine</td><td/><td/><td align=\"left\">6%</td><td align=\"left\">50 mg</td></tr><tr><td align=\"left\">&#8195;Flupenthixole</td><td align=\"left\">6%</td><td align=\"left\">0.5 mg</td><td/><td/></tr><tr><td align=\"left\">&#8195;Levomepromazine</td><td align=\"left\">6%</td><td align=\"left\">150 mg</td><td align=\"left\">6%</td><td align=\"left\">100 mg</td></tr><tr><td align=\"left\">&#8195;Quetiapine</td><td align=\"left\">13%</td><td align=\"left\">50&#8211;100 mg</td><td align=\"left\">6%</td><td align=\"left\">300 mg</td></tr><tr><td align=\"left\">Opioid withdrawal symptom or pain relievers (any)</td><td align=\"left\">69 %</td><td/><td align=\"left\">53%</td><td/></tr><tr><td align=\"left\">&#8195;Hydroxyzine</td><td align=\"left\">38%</td><td align=\"left\">25&#8211;200 mg</td><td align=\"left\">24%</td><td align=\"left\">75 &#8211; 300 mg</td></tr><tr><td align=\"left\">&#8195;Ibuprofeine</td><td align=\"left\">13%</td><td align=\"left\">600&#8211; 2400 mg</td><td align=\"left\">6%</td><td align=\"left\">400 mg</td></tr><tr><td align=\"left\">&#8195;Lofexidine</td><td align=\"left\">6%</td><td align=\"left\">0.2mg</td><td align=\"left\">18%</td><td align=\"left\">0.2 &#8211; 0.6 mg</td></tr><tr><td align=\"left\">&#8195;Metoclopramide</td><td align=\"left\">6%</td><td align=\"left\">10 mg</td><td align=\"left\"/><td/></tr><tr><td align=\"left\">&#8195;Naproxen</td><td align=\"left\">6%</td><td align=\"left\">500 mg</td><td>6%</td><td align=\"left\">500 mg</td></tr><tr><td align=\"left\">&#8195;Propranol</td><td align=\"left\">6%</td><td align=\"left\">20 mg</td><td align=\"left\"/><td/></tr><tr><td align=\"left\">&#8195;Valproate</td><td align=\"left\">13%</td><td align=\"left\">500 &#8211; 1000 mg</td><td align=\"left\">24%</td><td align=\"left\">500 &#8211; 1000 mg</td></tr><tr><td align=\"left\">None medication</td><td align=\"left\">13%</td><td/><td align=\"left\">12%</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 1914339:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Groups comparisons of cognitive measures using ANOVA</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Domain Test</bold></td><td align=\"left\"><bold>Methadone (<italic>n </italic>= 16)</bold></td><td align=\"left\"><bold>Buprenorphine/Naloxone(<italic>n </italic>= 17)</bold></td><td align=\"left\"><bold>Control(<italic>n </italic>= 17)</bold></td><td align=\"left\"><bold>Statistical comparisons between groups showing better performance first</bold></td><td align=\"left\"><bold>Effect size (Cohen\\'s d)</bold></td></tr></thead><tbody><tr><td/><td align=\"left\"><bold>Mean &#177; SD</bold></td><td align=\"left\"><bold>Mean &#177; SD</bold></td><td align=\"left\"><bold>Mean &#177; SD</bold></td><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Attention</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;TAP Tonic Alertness, simple reaction time</td><td align=\"left\">257.6 &#177; 32.1</td><td align=\"left\">228.0 &#177; 13.0</td><td align=\"left\">244.4 &#177; 30.0</td><td align=\"left\">BN &lt; M **</td><td align=\"left\">1.11</td></tr><tr><td align=\"left\">&#8195;TAP Phasic Alertness, reaction time after warning signal</td><td align=\"left\">245.6 &#177; 30.4</td><td align=\"left\">227.4 &#177; 17.0</td><td align=\"left\">230.3 &#177; 31.7</td><td/><td/></tr><tr><td align=\"left\">&#8195;TAP Go/NoGo, reaction time</td><td align=\"left\">528.3 &#177; 82.0</td><td align=\"left\">496.9 &#177; 65.3<sup>a</sup></td><td align=\"left\">465.5 &#177; 39.5</td><td align=\"left\">C &lt; M*</td><td align=\"left\">0.88</td></tr><tr><td align=\"left\">&#8195;TAP Go/NoGo, errors</td><td align=\"left\">0.6 &#177; 0.7</td><td align=\"left\">1.2 &#177; 1.4<sup>a</sup></td><td align=\"left\">0.5 &#177; 0.6</td><td/><td/></tr><tr><td align=\"left\">Working memory</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;WMS-III LNS</td><td align=\"left\">8.8 &#177; 2.6<sup>b</sup></td><td align=\"left\">8.7 &#177; 1.7</td><td align=\"left\">11.8 &#177; 3.1</td><td align=\"left\">C &gt; M**<break/>C &gt; BN**</td><td align=\"left\">1.02<break/>1.21</td></tr><tr><td align=\"left\">&#8195;PASAT</td><td align=\"left\">34.9 &#177; 10.6<sup>b</sup></td><td align=\"left\">31.3 &#177; 10.8</td><td align=\"left\">47.8 &#177; 9.3</td><td align=\"left\">C &gt; M**<break/>C &gt; BN***</td><td align=\"left\">1.27<break/>1.60</td></tr><tr><td align=\"left\">Memory</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;MPD, first trial</td><td align=\"left\">10.1 &#177; 3.0</td><td align=\"left\">10.6 &#177; 2.4</td><td align=\"left\">13.0 &#177; 1.4</td><td align=\"left\">C &gt; M**<break/>C &gt; BN*</td><td align=\"left\">1.22<break/>1.19</td></tr><tr><td align=\"left\">&#8195;MPD, sum of two last trials</td><td align=\"left\">14.6 &#177; 1.0</td><td align=\"left\">14.8 &#177; 0.4</td><td align=\"left\">14.9 &#177; 0.2</td><td/><td/></tr><tr><td align=\"left\">&#8195;MPD, delayed recall</td><td align=\"left\">13.9 &#177; 1.0</td><td align=\"left\">14.2 &#177; 1.0</td><td align=\"left\">14.8 &#177; 0.4</td><td align=\"left\">C &gt; M**<break/>C &gt; BN*</td><td/></tr><tr><td align=\"left\">&#8195;WMS-III logical memory, immediate recall</td><td align=\"left\">12.5 &#177; 2.9</td><td align=\"left\">14.3 &#177; 3.6</td><td align=\"left\">16.3 &#177; 3.4</td><td align=\"left\">C &gt; M**</td><td align=\"left\">1.17</td></tr><tr><td align=\"left\">&#8195;WMS-III logical memory, delayed recall</td><td align=\"left\">11.1 &#177; 4.3</td><td align=\"left\">13.4 &#177; 3.3</td><td align=\"left\">14.5 &#177; 4.1</td><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 1914339:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Patient characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Characteristics</td><td align=\"center\">Patients</td></tr></thead><tbody><tr><td align=\"left\">Entered</td><td align=\"center\">8</td></tr><tr><td align=\"left\">Karnofsky performance score</td><td align=\"center\">90&#8211;100%</td></tr><tr><td align=\"left\">Age (years)</td><td/></tr><tr><td align=\"left\">&#8195;Median (range)</td><td align=\"center\">65.5 years (range 53 &#8211; 73 y)</td></tr><tr><td align=\"left\">Stage (primary diagnosis)</td><td/></tr><tr><td align=\"left\">&#8195;I</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;II</td><td align=\"center\">6 (75%)</td></tr><tr><td align=\"left\">&#8195;III</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;IV</td><td align=\"center\">1 (12.5%)</td></tr><tr><td align=\"left\">&#8195;Not available</td><td align=\"center\">1 (12.5%)</td></tr><tr><td align=\"left\">Ductal/Lobular</td><td align=\"center\">7/0</td></tr><tr><td align=\"left\">&#8195;Not available</td><td align=\"center\">1 (12.5%)</td></tr><tr><td align=\"left\">Grading</td><td/></tr><tr><td align=\"left\">&#8195;1</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;2</td><td align=\"center\">2 (25%)</td></tr><tr><td align=\"left\">&#8195;3</td><td align=\"center\">5 (62.5%)</td></tr><tr><td align=\"left\">&#8195;Not available</td><td align=\"center\">1 (12.5%)</td></tr><tr><td align=\"left\">Estrogens receptor/progesteron receptor positive</td><td align=\"center\">7/6</td></tr><tr><td align=\"left\">Her2 Status positive/negative (IHC/FISH*)</td><td align=\"center\">0/8</td></tr><tr><td align=\"left\">Adjuvant chemotherapy</td><td align=\"center\">3 (37.5%)</td></tr><tr><td align=\"left\">Adjuvant endocrine therapy</td><td align=\"center\">3 (37.5%)</td></tr><tr><td align=\"left\">Palliative endocrine therapy</td><td align=\"center\">4 (50%)</td></tr><tr><td align=\"left\">Prior anthracycline exposure</td><td align=\"center\">5 (62.5%)</td></tr><tr><td align=\"left\">Prior capecitabine exposure</td><td align=\"center\">2 (25%)</td></tr><tr><td align=\"left\">Time to recurrence</td><td/></tr><tr><td align=\"left\">&#8195;Median (range)</td><td align=\"center\">87 months (13 &#8211; 148 m)</td></tr><tr><td align=\"left\">Treatment line</td><td/></tr><tr><td align=\"left\">&#8195;First line</td><td align=\"center\">4 (50%)</td></tr><tr><td align=\"left\">&#8195;Second line</td><td align=\"center\">2 (25%)</td></tr><tr><td align=\"left\">&#8195;&gt;/= Third line</td><td align=\"center\">2 (25%)</td></tr><tr><td align=\"left\">Metastatic sites</td><td/></tr><tr><td align=\"left\">&#8195;Median (range)</td><td align=\"center\">2 (range 1 &#8211; 4)</td></tr><tr><td align=\"left\">&#8195;bones/soft tissue only</td><td align=\"center\">3 (37.5%)</td></tr><tr><td align=\"left\">&#8195;visceral only</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;both</td><td align=\"center\">5 (62.5%)</td></tr><tr><td align=\"left\">Localisation</td><td/></tr><tr><td align=\"left\">&#8195;Lung</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Liver</td><td align=\"center\">3</td></tr><tr><td align=\"left\">&#8195;Bones</td><td align=\"center\">5</td></tr><tr><td align=\"left\">&#8195;Lymph nodes</td><td align=\"center\">6</td></tr><tr><td align=\"left\">&#8195;Soft tissue</td><td align=\"center\">2</td></tr><tr><td align=\"left\">&#8195;Brain</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Skin</td><td align=\"center\">1</td></tr><tr><td align=\"left\">More than one metastatic site</td><td align=\"center\">7 (87.5%)</td></tr></tbody></table></body></html>", "text": "Pmid= 1939983:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Results</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Week</td><td align=\"left\">Measurement</td><td align=\"center\" colspan=\"2\">Results (TP ng/ml) (mean +/- SD; 95% CI; outliers)</td></tr></thead><tbody><tr><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">299.24 &#177; 35.09; 95% CI 199.09 &#8211; 258.58;</td><td align=\"left\">283.42; 169.49</td></tr><tr><td/><td align=\"left\">2</td><td align=\"left\">182.97 &#177; 56.18; 95% CI 136.00 &#8211; 229.93;</td><td align=\"left\">240.39; 93.80</td></tr><tr><td/><td align=\"left\">3</td><td align=\"left\">246.77 &#177; 70.14; 95% CI 188.13 &#8211; 305.41;</td><td align=\"left\">350.41; 173.99</td></tr><tr><td/><td align=\"left\">4</td><td align=\"left\">155.20 &#177; 72.11; 95% CI 94.92 &#8211; 215.49;</td><td align=\"left\">242.42; 49.57</td></tr><tr><td/><td align=\"left\">5</td><td align=\"left\">170.66 &#177; 47.63; 95% CI 130.84 &#8211; 210.47;</td><td align=\"left\">232.71; 115.57</td></tr><tr><td/><td align=\"left\">6</td><td align=\"left\">187.55 &#177; 67.24; 95% CI 131.33 &#8211; 243.76;</td><td align=\"left\">295.48; 79.59</td></tr><tr><td/><td align=\"left\">7</td><td align=\"left\">200.79 &#177; 105.45; 95% CI 112.64 &#8211; 288.95;</td><td align=\"left\">369.96; 17.24</td></tr><tr><td/><td align=\"left\">8</td><td align=\"left\">196.36 &#177; 139.83; 95% CI 79.46 &#8211; 313.27;</td><td align=\"left\">431.39; 4.74</td></tr><tr><td align=\"left\">6</td><td align=\"left\">1</td><td align=\"left\">233.98 &#177; 52.29; 95% CI 190.26 &#8211; 277.70;</td><td align=\"left\">297.52; 125.95</td></tr><tr><td/><td align=\"left\">2</td><td align=\"left\">177.54 &#177; 76.06; 95% CI 113.95 &#8211; 241.13;</td><td align=\"left\">258.41; 50.44</td></tr><tr><td/><td align=\"left\">3</td><td align=\"left\">179.14 &#177; 76.68; 95% CI 115.03 &#8211; 243.24;</td><td align=\"left\">273.87; 43.42</td></tr><tr><td/><td align=\"left\">4</td><td align=\"left\">110.93 &#177; 66.80; 95% CI 55.08 &#8211; 166.77;</td><td align=\"left\">187.07; 20.76</td></tr><tr><td/><td align=\"left\">5</td><td align=\"left\">183.81 &#177; 52.89; 95% CI 139.59 &#8211; 228.02;</td><td align=\"left\">228.32; 60.86</td></tr><tr><td/><td align=\"left\">6</td><td align=\"left\">185.02 &#177; 70.87; 95% CI 125.77 &#8211; 244.27;</td><td align=\"left\">251.34; 43.74</td></tr><tr><td/><td align=\"left\">7</td><td align=\"left\">232.50 &#177; 126.58; 95% CI 126.67 &#8211; 338.32;</td><td align=\"left\">371.45; 6.62</td></tr><tr><td/><td align=\"left\">8</td><td align=\"left\">215.03 &#177; 90.78; 95% CI 139.13 &#8211; 290.92;</td><td align=\"left\">297.99; 7.56</td></tr></tbody></table></body></html>", "text": "Pmid= 1939983:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Allelic and genotypic frequencies of</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold><italic>CYP2C19 </italic>Alleles</bold></td><td align=\"center\"><bold>Number of alleles</bold></td><td align=\"center\"><bold>Frequency (%) (95% CI)</bold></td></tr></thead><tbody><tr><td align=\"center\"><bold><italic>*1</italic></bold></td><td align=\"center\">345</td><td align=\"center\">91.3 (88.5&#8211;94.1)</td></tr><tr><td align=\"center\"><bold><italic>*2</italic></bold></td><td align=\"center\">33</td><td align=\"center\">8.7 (5.9&#8211;11.5)</td></tr><tr><td align=\"center\"><bold><italic>*3</italic></bold></td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"center\"><bold><italic>*4</italic></bold></td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"center\"><bold><italic>*5</italic></bold></td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"center\"><bold><italic>*6</italic></bold></td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"center\"><bold><italic>*8</italic></bold></td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"center\"><bold><italic>CYP2C19 </italic>genotypes</bold></td><td align=\"center\"><bold>Number of subjects</bold></td><td align=\"center\"><bold>Frequency (%) (95% CI)</bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"center\"><bold><italic>*1/*1</italic></bold></td><td align=\"center\">158</td><td align=\"center\">83.6 (78.3&#8211;88.9)</td></tr><tr><td align=\"center\"><bold><italic>*1/*2</italic></bold></td><td align=\"center\">29</td><td align=\"center\">15.3 (10.2&#8211;20.4)</td></tr><tr><td align=\"center\"><bold><italic>*2/*2</italic></bold></td><td align=\"center\">2</td><td align=\"center\">1.1 (0.4&#8211;3)</td></tr></tbody></table></body></html>", "text": "Pmid= 1950696:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Correlation between CYP2C19 genotype and MR in Colombian Mestizo individuals (n = 44). MR: Metabolic ratio, n: number of subjects, SD standard deviation.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>GENOTYPE</bold></td><td align=\"center\"><bold><italic>n</italic></bold></td><td align=\"center\"><bold>MR (mean &#177; SD)</bold></td><td align=\"center\"><bold><italic>P</italic></bold></td></tr></thead><tbody><tr><td align=\"center\"><italic>*1/*</italic>1</td><td align=\"center\">39</td><td align=\"center\">-0.01 &#177; 0.15</td><td/></tr><tr><td align=\"center\"><italic>*1/*2</italic></td><td align=\"center\">3</td><td align=\"center\">0.23 &#177; 0.15</td><td/></tr><tr><td align=\"center\"><italic>*2/*2</italic></td><td align=\"center\">2</td><td align=\"center\">0.99 &#177; 0.35</td><td align=\"center\">&lt;0.01</td></tr></tbody></table></body></html>", "text": "Pmid= 1950696:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Table depicting drugs and nature of adverse events seen during the study</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Drug Class/Drug</td><td align=\"left\"><bold>NO. (%) OF ADRS</bold></td><td align=\"left\">Individual drugs</td><td align=\"left\">Adverse Event</td></tr></thead><tbody><tr><td align=\"left\">Anti tubercular agents (AKT)</td><td align=\"left\">52</td><td align=\"left\">HRZ (35), AKT (7), Rifampin (4), Ethambutol (2), Pyrazinamide (2) Streptomycin (1), Isoniazid(1),</td><td align=\"left\">Thrombocytopenia, Hepatitis, Hepatic encephalopathy, Retro bulbar neuritis, Cholestatic jaundice, Erythema multiforme, Vestibular toxicity, Gastritis, Abdominal/Respiratory/Flu like syndrome, Hypersensitivity reaction, Psychosis, Peripheral neuropathy, dysglycemia</td></tr><tr><td align=\"left\">Antiepileptics</td><td align=\"left\">36</td><td align=\"left\">Phenytoin(24), Valproate (5), Phenobarbiturate(4) carbamazepine (3)</td><td align=\"left\">Erythema multiforme, Symptomatic toxic carbamazepine/phenytoin/valproate levels with cerebellar signs</td></tr><tr><td align=\"left\">Antimalarials</td><td align=\"left\">30</td><td align=\"left\">Chloroquine (29), Sulfadoxine-pyrimethamine (1)</td><td align=\"left\">Gastritis, Giddiness, Erthyema multiforme, Psychosis, Hypersensitivity reactions, Hypotension</td></tr><tr><td align=\"left\">Anticoagulants</td><td align=\"left\">25</td><td align=\"left\">Warfarin (24), Heparin (1)</td><td align=\"left\">GI bleeding, haematuria, high INR, Intracranial bleed</td></tr><tr><td align=\"left\">Oral hypoglycemic agents (OHA)</td><td align=\"left\">16</td><td align=\"left\">Glibenclamide (10), Glyburide (6)</td><td align=\"left\">Hypoglycemia, seizures,</td></tr><tr><td align=\"left\">NSAIDS</td><td align=\"left\">14</td><td align=\"left\">Paracetamol (6), Aspirin (3), Ibuprofen (1), Etoricoxib (1), Nimesulide (2), Diclofenac (1)</td><td align=\"left\">Hypersensitivity reaction, Gastritis, mucosal damage, Hematuria, (Etoricoxib) potentiates OHA induced Hypoglycemia, ARF on CRF, Thrombocytopenia</td></tr><tr><td align=\"left\">Antihypertensives</td><td align=\"left\">10</td><td align=\"left\">Atenolol (4), ACE inhibitors (2), Losartan (2), Clonidine (1), Isosorbide dinitrate (1)</td><td align=\"left\">Hypotension, Hypersensitivity reaction, AV block, Bradycardia, Hyperkalemia, Missed dose of clonidine leading to rebound hypertension, dry mouth</td></tr><tr><td align=\"left\">Cytotoxic drugs</td><td align=\"left\">9</td><td align=\"left\">Methotrexate (3), 5-Fluorouracil (2), Cisplatin (1), Etoposide (1), Paclitaxel (1), Chemo (1)</td><td align=\"left\">Bone marrow suppression (with opportunistic infection), Nephrotoxicity, Liver damage, GI mucositis, Anorexia, Myelodysplastic syndrome, Alopecia, Hyperuricemia, Abdominal pain, Neutropenia</td></tr><tr><td align=\"left\">Steroids</td><td align=\"left\">9</td><td align=\"left\">Prednisolone (7), Betamethasone (2)</td><td align=\"left\">Gastritis, Hypertension, Hyperglycemia, Mania, Fragile skin, Facial puffiness, Osteoporosis, Opportunistic infections</td></tr><tr><td align=\"left\">Insulin</td><td align=\"left\">8</td><td align=\"left\">Humulin70/30 (8)</td><td align=\"left\">Hypoglycemia, Erythema/swelling/stinging at injection site</td></tr><tr><td align=\"left\">Digoxin</td><td align=\"left\">8</td><td align=\"left\">--</td><td align=\"left\">Symptomatic toxic digoxin levels</td></tr><tr><td align=\"left\">Fluoroquinolones</td><td align=\"left\">8</td><td align=\"left\">Ciprofloxacin(4), Ofloxacin (2) Gatifloxacin (2)</td><td align=\"left\">Complex partial seizures, Peripheral neuropathy, Dystonia, Hypersensitivity reaction, tendinitis, dysguesia</td></tr><tr><td align=\"left\">B lactam antibiotics</td><td align=\"left\">8</td><td align=\"left\">Amoxicillin(3), Ampicillin(2), Cefadroxil (1), Ceftriaxone (1), Ceftazidime (1)</td><td align=\"left\">Hypersensitivity reaction, Fixed drug eruptions, Diarrhea, muscle spasm, Generalized tonic-clonic seizure</td></tr><tr><td align=\"left\">Antiretrovirals</td><td align=\"left\">4</td><td align=\"left\">Efavirenz (2), Stavudine (1), Zidovudine (1)</td><td align=\"left\">Metabolic acidosis, Drowsiness, hypokalemia, Peripheral neuropathy</td></tr><tr><td align=\"left\">Benzodiazepines</td><td align=\"left\">4</td><td align=\"left\">Chlordiazepoxide (2), Diazepam (2)</td><td align=\"left\">Increased appetite and weight gain, Drowsiness, Ataxia, Amnesia, Vertigo</td></tr><tr><td align=\"left\">Bronchodilators</td><td align=\"left\">4</td><td align=\"left\">Salbutamol (3), Theophylline (1)</td><td align=\"left\">Tremors</td></tr><tr><td align=\"left\">Haematinics</td><td align=\"left\">3</td><td align=\"left\">Ferrous fumarate(2) Ferrous sulfate (1)</td><td align=\"left\">Epigastric pain, Heart burn, Vomiting, Metallic taste in mouth</td></tr><tr><td align=\"left\">Fibrinolytics</td><td align=\"left\">2</td><td align=\"left\">Urokinase (2)</td><td align=\"left\">Hypotension, AV block</td></tr><tr><td align=\"left\">Miscellaneous</td><td align=\"left\">15</td><td align=\"left\">Metronidazole (1) Nicotinic acid (1) Fluconazole (1) Ethamsylate (1) Amitriptyline (1) Cotrimoxazole (1) Oxybutinin HCl (1) Dextropropoxy- phene (1) Urograffin (1) Amikacin (1) Benzthiazide (1) Amiodarone (1) Levodopa (1) Alendronate (1) Clozapine (1)</td><td align=\"left\">Gastritis Facial flush, Hypersensitivity reaction (4) Thrombocytopenia, dry mouth Perioral tingling numbness, Carpopedal spasm, Cochlear toxicity Muscle Cramps, Paresthesias raised liver functions Peak dose dyskinesias Esophagitis, constipation, seizure</td></tr></tbody></table></body></html>", "text": "Pmid= 1963321:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>ICD-10 codes (Y40Y59) for drugs, medicaments and biological substances causing adverse effects in therapeutic use</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>ICD-10</bold></td><td align=\"left\"><bold>External cause mortality/morbidity by:</bold></td></tr></thead><tbody><tr><td align=\"left\">Y40</td><td align=\"left\"><bold>Systemic antibiotics</bold>: Penicillins, cefalosporins and other beta-lactam antibiotics, chloramphenicol, macrolides, tetracyclines, aminoglycosides, rifamycins, antifungals, others</td></tr><tr><td align=\"left\">Y41</td><td align=\"left\"><bold>Other systemic anti-infectives and antiparasitics</bold>: Sulphonamides, other anti-mycobacterial, anti-malarials, anti-protozoal, anti-helminthics, anti-virals</td></tr><tr><td align=\"left\">Y42</td><td align=\"left\"><bold>Hormones and substitutes</bold>: Glucocorticoids, thyroid hormones, anti-thyroids, insulin, oral hypoglycaemics, oral contraceptives, oestrogen and progestogen, anti-gonadotrophins, anti-oestrogens, anti-progestogens, androgens</td></tr><tr><td align=\"left\">Y43</td><td align=\"left\"><bold>Systemic agents</bold>: Anti-allergic and anti-emetic drugs, anti-neoplastic and immunosuppressive drugs, acidifying/alkalising agents</td></tr><tr><td align=\"left\">Y44</td><td align=\"left\"><bold>Agents affecting blood constituents</bold>: Iron preparations, anti-megaloblastic-anaemia preparations, anticoagulants, anticoagulant antagonists, antithrombotic drugs, thrombolytic drugs, blood products, plasma substitutes</td></tr><tr><td align=\"left\">Y45</td><td align=\"left\"><bold>Analgesics, anti-pyretics and anti-inflammatory drugs</bold>: Opioids and related analgesics, salicylates, propionic acid derivatives, nonsteroidal anti-inflammatory drugs, antirheumatics, 4-aminophenol derivatives</td></tr><tr><td align=\"left\">Y46</td><td align=\"left\"><bold>Anti-epileptics and anti-parkinsonism drugs</bold>: Succinimides, oxazolidinediones, hydantoin derivatives, deoxybarbiturates, iminostilbenes, valproic acid, anti-parkinsonism drugs, anti-spasticity drugs</td></tr><tr><td align=\"left\">Y47</td><td align=\"left\"><bold>Sedatives, hypnotics and anti-anxiety drugs</bold>: Barbiturates, benzodiazepines, cloral derivatives, paraldehyde, bromine compounds, sedative, hypnotic and antianxiety drug, unspecified</td></tr><tr><td align=\"left\">Y48</td><td align=\"left\"><bold>Anaesthetics and therapeutic gases</bold>: Inhaled/parenteral anaesthetics, local anaesthetics, therapeutic gases</td></tr><tr><td align=\"left\">Y49</td><td align=\"left\"><bold>Psychotropic drugs</bold>: Tricyclic and tetracyclic antidepressants, monoamine-oxidase-inhibitor, phenothiazine antipsychotics and neuroleptics, butyrophenone and thioxanthene neuroleptics, other antidepressants, antipsychotics and neuroleptics</td></tr><tr><td align=\"left\">Y50</td><td align=\"left\"><bold>Central nervous system stimulants</bold>: Analeptics, opioid receptor antagonists, methylxanthines, other central nervous system stimulants</td></tr><tr><td align=\"left\">Y51</td><td align=\"left\"><bold>Drugs primarily affecting the autonomic nervous system</bold>: Anticholinesterase agents, cholinergics, ganglionic blocking drugs, anticholinergics, antimuscarinics, spasmolytics, alpha-adrenoreceptor agonists/antagonists, beta-adrenoreceptor agonists/antagonists, centrally acting and adrenergic-neuron-blocking agents</td></tr><tr><td align=\"left\">Y52</td><td align=\"left\"><bold>Agents affecting the cardiovascular system</bold>: Cardiac-stimulant glycosides, calcium-channel blockers, other anti-dysrhythmic drugs, other coronary vasodilators, angiotensin-converting-enzyme inhibitors, other anti-hypertensives, anti-hyperlipidaemic and anti-arteriosclerotic drugs, peripheral vasodilators, anti-varicose drugs</td></tr><tr><td align=\"left\">Y53</td><td align=\"left\"><bold>Agents affecting the gastrointestinal system</bold>: Antacids, anti-gastric-secretion drugs, laxatives, anti-diarrhoeal, emetics</td></tr><tr><td align=\"left\">Y54</td><td align=\"left\"><bold>Agents affecting water-balance and mineral and uric acid metabolism</bold>: Mineralocorticoids, mineralocorticoid antagonists, carbonic-anhydrase inhibitors, benzothiadiazine derivatives, other diuretics, electrolytic, caloric and water-balance agents, agents affecting calcification, agents affecting uric acid metabolism</td></tr><tr><td align=\"left\">Y55</td><td align=\"left\"><bold>Agents acting on smooth and skeletal muscles and the respiratory system</bold>: Oxytocic drugs, skeletal muscle relaxants, anti-tussives, expectorants, anti-common-cold drugs, anti-asthmatics</td></tr><tr><td align=\"left\">Y56</td><td align=\"left\"><bold>Topical agents primarily affecting skin and mucous membrane</bold>: Local anti-fungal, anti-infective, anti-inflammatory drugs, anti-pruritics, local detergents, emollients, keratolytics, ophthalmological drugs, otorhinolaryngological drugs, dental drugs</td></tr><tr><td align=\"left\">Y57</td><td align=\"left\"><bold>Other and unspecified drugs</bold>: Appetite depressants, lipotropic drugs, antidotes and chelating agents, alcohol deterrents, x-ray contrast media, vitamins</td></tr><tr><td align=\"left\">Y58</td><td align=\"left\"><bold>Bacterial vaccines</bold></td></tr><tr><td align=\"left\">Y59</td><td align=\"left\"><bold>Other vaccines</bold>: Viral/rickettsial/protozoal vaccines, immunoglobulin</td></tr></tbody></table></body></html>", "text": "Pmid= 2093926:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Total number of Hospital Episode Statsitics for which there was a primary diagnosis or 'external cause' of ADR 19982005</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\"><bold>1998&#8211;9</bold></td><td align=\"center\"><bold>1999&#8211;00</bold></td><td align=\"center\"><bold>2000&#8211;1</bold></td><td align=\"center\"><bold>2001&#8211;2</bold></td><td align=\"center\"><bold>2002&#8211;3</bold></td><td align=\"center\"><bold>2003&#8211;4</bold></td><td align=\"center\"><bold>2004&#8211;5</bold></td><td align=\"center\"><bold>% Change 1998&#8211;2005</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Total No. of Episodes</bold></td><td align=\"center\">11,983,893</td><td align=\"center\">12,167,574</td><td align=\"center\">12,674,277</td><td align=\"center\">12,357,360</td><td align=\"center\">12,757,656</td><td align=\"center\">13,174,480</td><td align=\"center\">13,706,765</td><td align=\"center\">14.4</td></tr><tr><td align=\"left\"><bold>No. with \\'drug induced\\' codes</bold></td><td align=\"center\">10506</td><td align=\"center\">10105</td><td align=\"center\">9823</td><td align=\"center\">9442</td><td align=\"center\">9246</td><td align=\"center\">9453</td><td align=\"center\">10396</td><td align=\"center\">-1.0</td></tr><tr><td align=\"left\"><bold>No. with external cause codes</bold></td><td align=\"center\">42,555</td><td align=\"center\">47,385</td><td align=\"center\">50,113</td><td align=\"center\">52,160</td><td align=\"center\">56,943</td><td align=\"center\">62,618</td><td align=\"center\">66,296</td><td align=\"center\">55.8</td></tr><tr><td align=\"left\"><bold>Total Adverse Drug Reactions</bold></td><td align=\"center\">53,061</td><td align=\"center\">57,490</td><td align=\"center\">59,936</td><td align=\"center\">61,602</td><td align=\"center\">66,189</td><td align=\"center\">72,071</td><td align=\"center\">76,692</td><td align=\"center\">44.5</td></tr></tbody></table></body></html>", "text": "Pmid= 2093926:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Annual number of Hospital Episode Statistics finished consultant episodes with a primary diagnosis for an ADR (ICD-10 code)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>ICD-10</bold></td><td/><td align=\"center\"><bold>1998&#8211;9</bold></td><td align=\"center\"><bold>1999&#8211;00</bold></td><td align=\"center\"><bold>2000&#8211;1</bold></td><td align=\"center\"><bold>2001&#8211;2</bold></td><td align=\"center\"><bold>2002&#8211;3</bold></td><td align=\"center\"><bold>2003&#8211;4</bold></td><td align=\"center\"><bold>2004&#8211;5</bold></td><td align=\"center\"><bold>% Change 1998&#8211;2005</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>D59.0/2</bold></td><td align=\"left\"><bold>Drug induced haemolytic anaemia</bold></td><td align=\"center\">15</td><td align=\"center\">30</td><td align=\"center\">28</td><td align=\"center\">37</td><td align=\"center\">34</td><td align=\"center\">36</td><td align=\"center\">154</td><td align=\"center\">926.7</td></tr><tr><td align=\"left\"><bold>D61.1</bold></td><td align=\"left\"><bold>Drug induced aplastic anaemia</bold></td><td align=\"center\">101</td><td align=\"center\">116</td><td align=\"center\">114</td><td align=\"center\">186</td><td align=\"center\">182</td><td align=\"center\">162</td><td align=\"center\">241</td><td align=\"center\">138.6</td></tr><tr><td align=\"left\"><bold>E03.2</bold></td><td align=\"left\"><bold>Hypothyroidism due to medicaments</bold></td><td align=\"center\">23</td><td align=\"center\">23</td><td align=\"center\">12</td><td align=\"center\">12</td><td align=\"center\">19</td><td align=\"center\">13</td><td align=\"center\">26</td><td align=\"center\">13.0</td></tr><tr><td align=\"left\"><bold>E27.3</bold></td><td align=\"left\"><bold>Drug induced adrenocortical failure</bold></td><td align=\"center\">24</td><td align=\"center\">22</td><td align=\"center\">24</td><td align=\"center\">38</td><td align=\"center\">39</td><td align=\"center\">53</td><td align=\"center\">59</td><td align=\"center\">145.8</td></tr><tr><td align=\"left\"><bold>F11</bold></td><td align=\"left\"><bold>Mental disorders due to opioids</bold></td><td align=\"center\">4360</td><td align=\"center\">4287</td><td align=\"center\">4398</td><td align=\"center\">4187</td><td align=\"center\">3916</td><td align=\"center\">3690</td><td align=\"center\">3746</td><td align=\"center\">-14.1</td></tr><tr><td align=\"left\"><bold>F13</bold></td><td align=\"left\"><bold>Mental disorders due to sedatives/hypnotics</bold></td><td align=\"center\">223</td><td align=\"center\">247</td><td align=\"center\">247</td><td align=\"center\">239</td><td align=\"center\">232</td><td align=\"center\">206</td><td align=\"center\">189</td><td align=\"center\">-15.2</td></tr><tr><td align=\"left\"><bold>F19</bold></td><td align=\"left\"><bold>Mental disorders due to multiple psychoactive drugs</bold></td><td align=\"center\">3513</td><td align=\"center\">3137</td><td align=\"center\">2725</td><td align=\"center\">2643</td><td align=\"center\">2601</td><td align=\"center\">2690</td><td align=\"center\">2775</td><td align=\"center\">-21.0</td></tr><tr><td align=\"left\"><bold>G21.0</bold></td><td align=\"left\"><bold>Malignant neuroleptic syndrome</bold></td><td align=\"center\">101</td><td align=\"center\">106</td><td align=\"center\">121</td><td align=\"center\">108</td><td align=\"center\">102</td><td align=\"center\">93</td><td align=\"center\">128</td><td align=\"center\">26.7</td></tr><tr><td align=\"left\"><bold>G21.1</bold></td><td align=\"left\"><bold>Drug induced Parkinsonism</bold></td><td align=\"center\">145</td><td align=\"center\">115</td><td align=\"center\">124</td><td align=\"center\">133</td><td align=\"center\">112</td><td align=\"center\">108</td><td align=\"center\">149</td><td align=\"center\">2.8</td></tr><tr><td align=\"left\"><bold>G24.0</bold></td><td align=\"left\"><bold>Drug induced dystonia</bold></td><td align=\"center\">149</td><td align=\"center\">130</td><td align=\"center\">145</td><td align=\"center\">130</td><td align=\"center\">115</td><td align=\"center\">152</td><td align=\"center\">109</td><td align=\"center\">-26.8</td></tr><tr><td align=\"left\"><bold>G25.1/4/6</bold></td><td align=\"left\"><bold>Drug induced extrapyramidal syndrome/chorea/tics</bold></td><td align=\"center\">136</td><td align=\"center\">146</td><td align=\"center\">110</td><td align=\"center\">125</td><td align=\"center\">44</td><td align=\"center\">51</td><td align=\"center\">48</td><td align=\"center\">-64.7</td></tr><tr><td align=\"left\"><bold>G72.0</bold></td><td align=\"left\"><bold>Drug induced myopathy</bold></td><td align=\"center\">47</td><td align=\"center\">53</td><td align=\"center\">51</td><td align=\"center\">51</td><td align=\"center\">57</td><td align=\"center\">39</td><td align=\"center\">55</td><td align=\"center\">17.0</td></tr><tr><td align=\"left\"><bold>H91.0</bold></td><td align=\"left\"><bold>Ototoxic hearing loss</bold></td><td align=\"center\">2</td><td align=\"center\">5</td><td align=\"center\">3</td><td align=\"center\">3</td><td align=\"center\">2</td><td align=\"center\">U/C<sup>1</sup></td><td align=\"center\">U/C</td><td align=\"center\">U/C</td></tr><tr><td align=\"left\"><bold>I42.7</bold></td><td align=\"left\"><bold>Drug induced cardiomyopathy</bold></td><td align=\"center\">25</td><td align=\"center\">25</td><td align=\"center\">53</td><td align=\"center\">38</td><td align=\"center\">67</td><td align=\"center\">77</td><td align=\"center\">61</td><td align=\"center\">144.0</td></tr><tr><td align=\"left\"><bold>J70.2/3/4</bold></td><td align=\"left\"><bold>Drug induced interstitial lung disorders</bold></td><td align=\"center\">54</td><td align=\"center\">45</td><td align=\"center\">43</td><td align=\"center\">43</td><td align=\"center\">86</td><td align=\"center\">71</td><td align=\"center\">94</td><td align=\"center\">74.1</td></tr><tr><td align=\"left\"><bold>K71</bold></td><td align=\"left\"><bold>Drug induced liver disease</bold></td><td align=\"center\">406</td><td align=\"center\">318</td><td align=\"center\">372</td><td align=\"center\">351</td><td align=\"center\">459</td><td align=\"center\">437</td><td align=\"center\">448</td><td align=\"center\">10.3</td></tr><tr><td align=\"left\"><bold>L56.0/1</bold></td><td align=\"left\"><bold>Drug induced phototoxicity</bold></td><td align=\"center\">4</td><td align=\"center\">5</td><td align=\"center\">2</td><td align=\"center\">4</td><td align=\"center\">1</td><td align=\"center\">3</td><td align=\"center\">5</td><td align=\"center\">25.0</td></tr><tr><td align=\"left\"><bold>M10.2</bold></td><td align=\"left\"><bold>Drug induced gout</bold></td><td align=\"center\">30</td><td align=\"center\">27</td><td align=\"center\">13</td><td align=\"center\">24</td><td align=\"center\">22</td><td align=\"center\">22</td><td align=\"center\">34</td><td align=\"center\">13.3</td></tr><tr><td align=\"left\"><bold>M32.0</bold></td><td align=\"left\"><bold>Drug induced systemic lupus erythematosus</bold></td><td align=\"center\">17</td><td align=\"center\">20</td><td align=\"center\">12</td><td align=\"center\">13</td><td align=\"center\">14</td><td align=\"center\">10</td><td align=\"center\">26</td><td align=\"center\">52.9</td></tr><tr><td align=\"left\"><bold>M34.2</bold></td><td align=\"left\"><bold>Drug induced systemic sclerosis</bold></td><td align=\"center\">3</td><td align=\"center\">3</td><td align=\"center\">4</td><td align=\"center\">3</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td></tr><tr><td align=\"left\"><bold>N14</bold></td><td align=\"left\"><bold>Drug induced nephropathy</bold></td><td align=\"center\">60</td><td align=\"center\">69</td><td align=\"center\">92</td><td align=\"center\">85</td><td align=\"center\">100</td><td align=\"center\">318</td><td align=\"center\">414</td><td align=\"center\">590.0</td></tr><tr><td align=\"left\"><bold>T88.3</bold></td><td align=\"left\"><bold>Malignant hyperthermia due to anaesthesia</bold></td><td align=\"center\">6</td><td align=\"center\">4</td><td align=\"center\">10</td><td align=\"center\">3</td><td align=\"center\">3</td><td align=\"center\">5</td><td align=\"center\">4</td><td align=\"center\">-33.3</td></tr><tr><td align=\"left\"><bold>T88.6</bold></td><td align=\"left\"><bold>Drug induced anaphylaxis</bold></td><td align=\"center\">366</td><td align=\"center\">435</td><td align=\"center\">399</td><td align=\"center\">384</td><td align=\"center\">375</td><td align=\"center\">469</td><td align=\"center\">563</td><td align=\"center\">53.8</td></tr><tr><td align=\"left\"><bold>T88.7</bold></td><td align=\"left\"><bold>Unspecified adverse drug effect</bold></td><td align=\"center\">696</td><td align=\"center\">737</td><td align=\"center\">721</td><td align=\"center\">602</td><td align=\"center\">664</td><td align=\"center\">748</td><td align=\"center\">1068</td><td align=\"center\">53.4</td></tr><tr><td colspan=\"10\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td/><td align=\"center\"><bold>10506</bold></td><td align=\"center\"><bold>10105</bold></td><td align=\"center\"><bold>9823</bold></td><td align=\"center\"><bold>9442</bold></td><td align=\"center\"><bold>9246</bold></td><td align=\"center\"><bold>9453</bold></td><td align=\"center\"><bold>10396</bold></td><td align=\"center\"><bold>-1.0</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2093926:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Annual number of HES finished consultant episodes with an 'external code' for an adverse drug reaction</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>ICD-10</bold></td><td/><td align=\"right\"><bold>1998&#8211;9</bold></td><td align=\"right\"><bold>1999&#8211;00</bold></td><td align=\"right\"><bold>2000&#8211;1</bold></td><td align=\"right\"><bold>2001&#8211;2</bold></td><td align=\"right\"><bold>2002&#8211;3</bold></td><td align=\"right\"><bold>2003&#8211;4</bold></td><td align=\"right\"><bold>2004&#8211;5</bold></td><td align=\"center\"><bold>% Change 1998&#8211;2005</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Y40</bold></td><td align=\"left\"><bold>Systemic antibiotics</bold></td><td align=\"right\">4,206</td><td align=\"right\">4,212</td><td align=\"right\">4,533</td><td align=\"right\">4,341</td><td align=\"right\">4,697</td><td align=\"right\">5,624</td><td align=\"right\">6,449</td><td align=\"center\">53.3</td></tr><tr><td align=\"left\"><bold>Y41</bold></td><td align=\"left\"><bold>Other systemic anti-infectives/anti-parasitics</bold></td><td align=\"right\">829</td><td align=\"right\">816</td><td align=\"right\">1,017</td><td align=\"right\">945</td><td align=\"right\">1,195</td><td align=\"right\">1,134</td><td align=\"right\">1,453</td><td align=\"center\">75.3</td></tr><tr><td align=\"left\"><bold>Y42</bold></td><td align=\"left\"><bold>Hormones (including synthetic, antagonists)</bold></td><td align=\"right\">4,547</td><td align=\"right\">5,088</td><td align=\"right\">4,934</td><td align=\"right\">5,113</td><td align=\"right\">5,803</td><td align=\"right\">5,461</td><td align=\"right\">5,319</td><td align=\"center\">17</td></tr><tr><td align=\"left\"><bold>Y43</bold></td><td align=\"left\"><bold>Primarily systemic agents</bold></td><td align=\"right\">7,501</td><td align=\"right\">8,271</td><td align=\"right\">9,078</td><td align=\"right\">9,877</td><td align=\"right\">10,766</td><td align=\"right\">11,226</td><td align=\"right\">12,054</td><td align=\"center\">60.7</td></tr><tr><td align=\"left\"><bold>Y44</bold></td><td align=\"left\"><bold>Agents primarily affecting blood constituents</bold></td><td align=\"right\">4,062</td><td align=\"right\">4,483</td><td align=\"right\">4,723</td><td align=\"right\">4,797</td><td align=\"right\">5,230</td><td align=\"right\">5,995</td><td align=\"right\">4,272</td><td align=\"center\">5.2</td></tr><tr><td align=\"left\"><bold>Y45</bold></td><td align=\"left\"><bold>Analgesics/antipyretics/anti-inflammatory</bold></td><td align=\"right\">5,951</td><td align=\"right\">6,726</td><td align=\"right\">6,787</td><td align=\"right\">6,819</td><td align=\"right\">7,540</td><td align=\"right\">8,079</td><td align=\"right\">9,004</td><td align=\"center\">51.3</td></tr><tr><td align=\"left\"><bold>Y46</bold></td><td align=\"left\"><bold>Antiepileptics/antiParkinsonism drugs</bold></td><td align=\"right\">1,230</td><td align=\"right\">1,267</td><td align=\"right\">1,224</td><td align=\"right\">1,340</td><td align=\"right\">1,401</td><td align=\"right\">1,501</td><td align=\"right\">1,628</td><td align=\"center\">32.4</td></tr><tr><td align=\"left\"><bold>Y47</bold></td><td align=\"left\"><bold>Sedatives, hypnotics, anti-anxiety drugs</bold></td><td align=\"right\">370</td><td align=\"right\">400</td><td align=\"right\">450</td><td align=\"right\">430</td><td align=\"right\">480</td><td align=\"right\">586</td><td align=\"right\">560</td><td align=\"center\">51.4</td></tr><tr><td align=\"left\"><bold>Y48</bold></td><td align=\"left\"><bold>Anaesthetics, therapeutic gases</bold></td><td align=\"right\">414</td><td align=\"right\">538</td><td align=\"right\">502</td><td align=\"right\">440</td><td align=\"right\">505</td><td align=\"right\">521</td><td align=\"right\">531</td><td align=\"center\">28.3</td></tr><tr><td align=\"left\"><bold>Y49</bold></td><td align=\"left\"><bold>Psychotropic drugs</bold></td><td align=\"right\">1,653</td><td align=\"right\">1,678</td><td align=\"right\">2,008</td><td align=\"right\">1,992</td><td align=\"right\">1,953</td><td align=\"right\">2,364</td><td align=\"right\">2,544</td><td align=\"center\">53.9</td></tr><tr><td align=\"left\"><bold>Y50</bold></td><td align=\"left\"><bold>Central nervous system stimulants</bold></td><td align=\"right\">46</td><td align=\"right\">67</td><td align=\"right\">75</td><td align=\"right\">76</td><td align=\"right\">69</td><td align=\"right\">71</td><td align=\"right\">93</td><td align=\"center\">102.2</td></tr><tr><td align=\"left\"><bold>Y51</bold></td><td align=\"left\"><bold>Drugs affecting autonomic nervous system</bold></td><td align=\"right\">1,702</td><td align=\"right\">2,056</td><td align=\"right\">2,277</td><td align=\"right\">2,470</td><td align=\"right\">2,686</td><td align=\"right\">3,239</td><td align=\"right\">3,532</td><td align=\"center\">107.5</td></tr><tr><td align=\"left\"><bold>Y52</bold></td><td align=\"left\"><bold>Agents primarily affecting cardiovascular system</bold></td><td align=\"right\">4,044</td><td align=\"right\">4,752</td><td align=\"right\">5,376</td><td align=\"right\">5,667</td><td align=\"right\">6,234</td><td align=\"right\">6,836</td><td align=\"right\">7,768</td><td align=\"center\">92.1</td></tr><tr><td align=\"left\"><bold>Y53</bold></td><td align=\"left\"><bold>Agents primarily affecting gastrointestinal system</bold></td><td align=\"right\">398</td><td align=\"right\">410</td><td align=\"right\">486</td><td align=\"right\">416</td><td align=\"right\">461</td><td align=\"right\">579</td><td align=\"right\">656</td><td align=\"center\">64.8</td></tr><tr><td align=\"left\"><bold>Y54</bold></td><td align=\"left\"><bold>Agents affecting water/mineral balance/uric acid</bold></td><td align=\"right\">2,136</td><td align=\"right\">2,617</td><td align=\"right\">2,945</td><td align=\"right\">3,526</td><td align=\"right\">4,151</td><td align=\"right\">5,118</td><td align=\"right\">5,638</td><td align=\"center\">164</td></tr><tr><td align=\"left\"><bold>Y55</bold></td><td align=\"left\"><bold>Agents affecting muscle/respiratory system</bold></td><td align=\"right\">312</td><td align=\"right\">299</td><td align=\"right\">342</td><td align=\"right\">321</td><td align=\"right\">323</td><td align=\"right\">430</td><td align=\"right\">422</td><td align=\"center\">35.3</td></tr><tr><td align=\"left\"><bold>Y56</bold></td><td align=\"left\"><bold>Topical agents affecting skin/ENT, dental</bold></td><td align=\"right\">1,138</td><td align=\"right\">1,236</td><td align=\"right\">983</td><td align=\"right\">1,202</td><td align=\"right\">1,065</td><td align=\"right\">1,079</td><td align=\"right\">1,224</td><td align=\"center\">7.6</td></tr><tr><td align=\"left\"><bold>Y57</bold></td><td align=\"left\"><bold>Other and unspecified medicaments</bold></td><td align=\"right\">1,524</td><td align=\"right\">1,715</td><td align=\"right\">1,780</td><td align=\"right\">1,907</td><td align=\"right\">1,906</td><td align=\"right\">2,014</td><td align=\"right\">2,398</td><td align=\"center\">57.3</td></tr><tr><td align=\"left\"><bold>Y58</bold></td><td align=\"left\"><bold>Bacterial vaccines</bold></td><td align=\"right\">226</td><td align=\"right\">347</td><td align=\"right\">255</td><td align=\"right\">182</td><td align=\"right\">197</td><td align=\"right\">356</td><td align=\"right\">281</td><td align=\"center\">24.3</td></tr><tr><td align=\"left\"><bold>Y59</bold></td><td align=\"left\"><bold>Other vaccines/biologicals</bold></td><td align=\"right\">266</td><td align=\"right\">407</td><td align=\"right\">338</td><td align=\"right\">299</td><td align=\"right\">281</td><td align=\"right\">405</td><td align=\"right\">470</td><td align=\"center\">76.7</td></tr><tr><td colspan=\"10\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td/><td align=\"right\">42,555</td><td align=\"right\">47,385</td><td align=\"right\">50,113</td><td align=\"right\">52,160</td><td align=\"right\">56,943</td><td align=\"right\">62,618</td><td align=\"right\">66,296</td><td align=\"center\"><bold>55.8</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2093926:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Number of HES finished consultant episodes with a primary diagnosis of an ADR in 2004/05: mean age of admissions, age & gender distribution of episodes and total bed days</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>ICD-10</bold></td><td/><td align=\"center\"><bold>Male %</bold></td><td align=\"center\"><bold>Mean age</bold></td><td align=\"center\"><bold>Age 0&#8211;14 (%)</bold></td><td align=\"center\"><bold>Age 15&#8211;59 (%)</bold></td><td align=\"center\"><bold>Age 60&#8211;74 (%)</bold></td><td align=\"center\"><bold>Age 75+ (%)</bold></td><td align=\"center\"><bold>Total Bed days</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>D59.0/2</bold></td><td align=\"left\"><bold>Drug induced haemolytic anaemia</bold></td><td align=\"center\">49</td><td align=\"center\">63</td><td align=\"center\">0 (0.0)</td><td align=\"center\">52 (0.5)</td><td align=\"center\">75 (0.8)</td><td align=\"center\">27 (0.3)</td><td align=\"center\">160</td></tr><tr><td align=\"left\"><bold>D61.1</bold></td><td align=\"left\"><bold>Drug induced aplastic anaemia</bold></td><td align=\"center\">49</td><td align=\"center\">64</td><td align=\"center\">2 (0.0)</td><td align=\"center\">89 (0.9)</td><td align=\"center\">74 (0.7)</td><td align=\"center\">73 (0.7)</td><td align=\"center\">604</td></tr><tr><td align=\"left\"><bold>E03.2</bold></td><td align=\"left\"><bold>Hypothyroidism due to medicaments</bold></td><td align=\"center\">42</td><td align=\"center\">72</td><td align=\"center\">0 (0.0)</td><td align=\"center\">6 (0.1)</td><td align=\"center\">3 (0.0)</td><td align=\"center\">17 (0.2)</td><td align=\"center\">191</td></tr><tr><td align=\"left\"><bold>E27.3</bold></td><td align=\"left\"><bold>Drug induced adrenocortical failure</bold></td><td align=\"center\">41</td><td align=\"center\">48</td><td align=\"center\">11 (0.1)</td><td align=\"center\">22 (0.2)</td><td align=\"center\">12 (0.1)</td><td align=\"center\">14 (0.1)</td><td align=\"center\">584</td></tr><tr><td align=\"left\"><bold>F11</bold></td><td align=\"left\"><bold>Mental disorders due to opioids</bold></td><td align=\"center\">66</td><td align=\"center\">32</td><td align=\"center\">14 (0.1)</td><td align=\"center\">3681 (36.9)</td><td align=\"center\">33 (0.3)</td><td align=\"center\">14 (0.1)</td><td align=\"center\">47390</td></tr><tr><td align=\"left\"><bold>F13</bold></td><td align=\"left\"><bold>Mental disorders due to sedatives/hypnotics</bold></td><td align=\"center\">54</td><td align=\"center\">47</td><td align=\"center\">6 (0.1)</td><td align=\"center\">123 (1.2)</td><td align=\"center\">33 (0.3)</td><td align=\"center\">27 (0.3)</td><td align=\"center\">4922</td></tr><tr><td align=\"left\"><bold>F19</bold></td><td align=\"left\"><bold>Mental disorders due to multiple psychoactive drugs</bold></td><td align=\"center\">75</td><td align=\"center\">31</td><td align=\"center\">14 (0.1)</td><td align=\"center\">2734 (27.4)</td><td align=\"center\">17 (0.2)</td><td align=\"center\">10 (0.1)</td><td align=\"center\">64152</td></tr><tr><td align=\"left\"><bold>G21.0</bold></td><td align=\"left\"><bold>Malignant neuroleptic syndrome</bold></td><td align=\"center\">67</td><td align=\"center\">50</td><td align=\"center\">0 (0.0)</td><td align=\"center\">88 (0.9)</td><td align=\"center\">28 (0.3)</td><td align=\"center\">12 (0.1)</td><td align=\"center\">2,315</td></tr><tr><td align=\"left\"><bold>G21.1</bold></td><td align=\"left\"><bold>Drug induced Parkinsonism</bold></td><td align=\"center\">43</td><td align=\"center\">77</td><td align=\"center\">1 0.0)</td><td align=\"center\">11 (0.1)</td><td align=\"center\">44 (0.4)</td><td align=\"center\">93 (0.9)</td><td align=\"center\">1,964</td></tr><tr><td align=\"left\"><bold>G24.0</bold></td><td align=\"left\"><bold>Drug induced dystonia</bold></td><td align=\"center\">47</td><td align=\"center\">43</td><td align=\"center\">10 (0.1)</td><td align=\"center\">65 (0.7)</td><td align=\"center\">16 (0.2)</td><td align=\"center\">18 (0.2)</td><td align=\"center\">550</td></tr><tr><td align=\"left\"><bold>G25.1/4/6</bold></td><td align=\"left\"><bold>Drug induced extrapyramidal syndrome/chorea/tics</bold></td><td align=\"center\">40</td><td align=\"center\">64</td><td align=\"center\">2 (0.0)</td><td align=\"center\">15 (0.2)</td><td align=\"center\">18 (0.2)</td><td align=\"center\">13 (0.1)</td><td align=\"center\">407</td></tr><tr><td align=\"left\"><bold>G72.0</bold></td><td align=\"left\"><bold>Drug induced myopathy</bold></td><td align=\"center\">51</td><td align=\"center\">65</td><td align=\"center\">1 (0.0)</td><td align=\"center\">12 (0.1)</td><td align=\"center\">20 (0.2)</td><td align=\"center\">22 (0.2)</td><td align=\"center\">517</td></tr><tr><td align=\"left\"><bold>H91.0</bold></td><td align=\"left\"><bold>Ototoxic hearing loss</bold></td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td></tr><tr><td align=\"left\"><bold>I42.7</bold></td><td align=\"left\"><bold>Drug induced cardiomyopathy</bold></td><td align=\"center\">48</td><td align=\"center\">43</td><td align=\"center\">7 (0.1)</td><td align=\"center\">42 (0.4)</td><td align=\"center\">7 (0.1)</td><td align=\"center\">5 (0.1)</td><td align=\"center\">376</td></tr><tr><td align=\"left\"><bold>J70.2/3/4</bold></td><td align=\"left\"><bold>Drug induced interstitial lung disorders</bold></td><td align=\"center\">49</td><td align=\"center\">64</td><td align=\"center\">3 (0.0)</td><td align=\"center\">24 (0.2)</td><td align=\"center\">40 (0.4)</td><td align=\"center\">27 (0.3)</td><td align=\"center\">858</td></tr><tr><td align=\"left\"><bold>K71</bold></td><td align=\"left\"><bold>Drug induced liver disease</bold></td><td align=\"center\">43</td><td align=\"center\">47</td><td align=\"center\">12 (0.1)</td><td align=\"center\">315 (3.2)</td><td align=\"center\">50 (0.5)</td><td align=\"center\">71 (0.7)</td><td align=\"center\">3408</td></tr><tr><td align=\"left\"><bold>L56.0/1</bold></td><td align=\"left\"><bold>Drug induced phototoxicity</bold></td><td align=\"center\">0</td><td align=\"center\">47</td><td align=\"center\">1 (0.0)</td><td align=\"center\">2 (0.0)</td><td align=\"center\">2 (0.0)</td><td align=\"center\">0 (0.0)</td><td align=\"center\">17</td></tr><tr><td align=\"left\"><bold>M10.2</bold></td><td align=\"left\"><bold>Drug induced gout</bold></td><td align=\"center\">53</td><td align=\"center\">75</td><td align=\"center\">0 (0.0)</td><td align=\"center\">4 (0.0)</td><td align=\"center\">9 (0.1)</td><td align=\"center\">21 (0.2)</td><td align=\"center\">237</td></tr><tr><td align=\"left\"><bold>M32.0</bold></td><td align=\"left\"><bold>Drug induced systemic lupus erythematosus</bold></td><td align=\"center\">27</td><td align=\"center\">43</td><td align=\"center\">0 (0.0)</td><td align=\"center\">19 (0.2)</td><td align=\"center\">2 (0.0)</td><td align=\"center\">5 (0.1)</td><td align=\"center\">69</td></tr><tr><td align=\"left\"><bold>M34.2</bold></td><td align=\"left\"><bold>Drug induced systemic sclerosis</bold></td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td><td align=\"center\">U/C</td></tr><tr><td align=\"left\"><bold>N14</bold></td><td align=\"left\"><bold>Drug induced nephropathy</bold></td><td align=\"center\">2</td><td align=\"center\">58</td><td align=\"center\">0 (0.0)</td><td align=\"center\">3 (0.0)</td><td align=\"center\">5 (0.1)</td><td align=\"center\">3 (0.0)</td><td align=\"center\">111</td></tr><tr><td align=\"left\"><bold>T88.3</bold></td><td align=\"left\"><bold>Malignant hyperthermia due to anaesthesia</bold></td><td align=\"center\">75</td><td align=\"center\">20</td><td align=\"center\">2 (0.0)</td><td align=\"center\">2 (0.0)</td><td align=\"center\">0 (0.0)</td><td align=\"center\">0 (0.0)</td><td align=\"center\">8</td></tr><tr><td align=\"left\"><bold>T88.6</bold></td><td align=\"left\"><bold>Drug induced anaphylaxis</bold></td><td align=\"center\">37</td><td align=\"center\">52</td><td align=\"center\">19 (0.2)</td><td align=\"center\">326 (3.3)</td><td align=\"center\">130 (1.3)</td><td align=\"center\">87 (0.9)</td><td align=\"center\">883</td></tr><tr><td align=\"left\"><bold>T88.7</bold></td><td align=\"left\"><bold>Unspecified adverse drug effect</bold></td><td align=\"center\">33</td><td align=\"center\">50</td><td align=\"center\">80 (0.8)</td><td align=\"center\">565 (5.7)</td><td align=\"center\">203 (2.0)</td><td align=\"center\">217 (2.2)</td><td align=\"center\">2,471</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td/><td align=\"center\">33</td><td align=\"center\">40</td><td align=\"center\">185 (1.9)</td><td align=\"center\">8200 (82.1)</td><td align=\"center\">821 (8.2)</td><td align=\"center\">776 (7.8)</td><td align=\"center\">132194</td></tr></tbody></table></body></html>", "text": "Pmid= 2093926:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Number of HES finished consultant episodes with an external ICD10 cause for an adverse drug reaction in 2004/05: mean age of admissions, age & gender distribution of episodes and total bed days</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>ICD-10</bold></td><td/><td align=\"center\"><bold>Male %</bold></td><td align=\"center\"><bold>Mean age</bold></td><td align=\"center\"><bold>Age 0&#8211;14 (%)</bold></td><td align=\"center\"><bold>Age 15&#8211;59 (%)</bold></td><td align=\"center\"><bold>Age 60&#8211;74 (%)</bold></td><td align=\"center\"><bold>Age 75+ (%)</bold></td><td align=\"center\"><bold>Total bed days</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Y40</bold></td><td align=\"left\"><bold>Antibiotics</bold></td><td align=\"center\">40</td><td align=\"center\">57</td><td align=\"center\">467 (0.7)</td><td align=\"center\">2468 (3.7)</td><td align=\"center\">1433 (2.2)</td><td align=\"center\">2064 (3.1)</td><td align=\"center\">48,868</td></tr><tr><td align=\"left\"><bold>Y41</bold></td><td align=\"left\"><bold>Other anti-infectives</bold></td><td align=\"center\">39</td><td align=\"center\">55</td><td align=\"center\">48 (0.1)</td><td align=\"center\">776 (1.2)</td><td align=\"center\">245 (0.4)</td><td align=\"center\">362 (0.5)</td><td align=\"center\">9,280</td></tr><tr><td align=\"left\"><bold>Y42</bold></td><td align=\"left\"><bold>Hormones</bold></td><td align=\"center\">37</td><td align=\"center\">61</td><td align=\"center\">173 (0.3)</td><td align=\"center\">2051 (3.1)</td><td align=\"center\">1571 (2.4)</td><td align=\"center\">1513 (2.3)</td><td align=\"center\">31,323</td></tr><tr><td align=\"left\"><bold>Y43</bold></td><td align=\"left\"><bold>Systemic agents</bold></td><td align=\"center\">46</td><td align=\"center\">52</td><td align=\"center\">1475 (2.2)</td><td align=\"center\">5123 (7.7)</td><td align=\"center\">4107 (6.2)</td><td align=\"center\">1323 (2.0)</td><td align=\"center\">83,049</td></tr><tr><td align=\"left\"><bold>Y44</bold></td><td align=\"left\"><bold>Blood constituents</bold></td><td align=\"center\">47</td><td align=\"center\">70</td><td align=\"center\">37 (0.1)</td><td align=\"center\">830 (1.3)</td><td align=\"center\">1331 (2.0)</td><td align=\"center\">2072 (3.1)</td><td align=\"center\">31,919</td></tr><tr><td align=\"left\"><bold>Y45</bold></td><td align=\"left\"><bold>Analgesics, antipyretics, anti-inflammatory</bold></td><td align=\"center\">44</td><td align=\"center\">66</td><td align=\"center\">101 (0.2)</td><td align=\"center\">2756 (4.2)</td><td align=\"center\">2392 (3.6)</td><td align=\"center\">3746 (5.7)</td><td align=\"center\">50,118</td></tr><tr><td align=\"left\"><bold>Y46</bold></td><td align=\"left\"><bold>Antiepileptics, antiparkinsonism</bold></td><td align=\"center\">51</td><td align=\"center\">59</td><td align=\"center\">69 (0.1)</td><td align=\"center\">641 (1.0)</td><td align=\"center\">434 (0.7)</td><td align=\"center\">484 (0.7)</td><td align=\"center\">15,002</td></tr><tr><td align=\"left\"><bold>Y47</bold></td><td align=\"left\"><bold>Sedatives, hypnotics, anti-anxiety</bold></td><td align=\"center\">43</td><td align=\"center\">56</td><td align=\"center\">54 (0.1)</td><td align=\"center\">210 (0.3)</td><td align=\"center\">104 (0.2)</td><td align=\"center\">190 (0.3)</td><td align=\"center\">4,782</td></tr><tr><td align=\"left\"><bold>Y48</bold></td><td align=\"left\"><bold>Anaesthetics, therapeutic gases</bold></td><td align=\"center\">47</td><td align=\"center\">50</td><td align=\"center\">32 (0.0)</td><td align=\"center\">275 (0.4)</td><td align=\"center\">145 (0.2)</td><td align=\"center\">78 (0.1)</td><td align=\"center\">2,263</td></tr><tr><td align=\"left\"><bold>Y49</bold></td><td align=\"left\"><bold>Psychotropic drugs</bold></td><td align=\"center\">39</td><td align=\"center\">65</td><td align=\"center\">33 (0.0)</td><td align=\"center\">822 (1.2)</td><td align=\"center\">610 (0.9)</td><td align=\"center\">1076 (1.6)</td><td align=\"center\">25,733</td></tr><tr><td align=\"left\"><bold>Y50</bold></td><td align=\"left\"><bold>Central nervous system stimulants</bold></td><td align=\"center\">46</td><td align=\"center\">51</td><td align=\"center\">6 (0.0)</td><td align=\"center\">47 (0.1)</td><td align=\"center\">17 (0.0)</td><td align=\"center\">23 (0.0)</td><td align=\"center\">404</td></tr><tr><td align=\"left\"><bold>Y51</bold></td><td align=\"left\"><bold>Autonomic nervous system</bold></td><td align=\"center\">49</td><td align=\"center\">73</td><td align=\"center\">16 (0.0)</td><td align=\"center\">473 (0.7)</td><td align=\"center\">1037 (1.6)</td><td align=\"center\">2006 (3.0)</td><td align=\"center\">16,886</td></tr><tr><td align=\"left\"><bold>Y52</bold></td><td align=\"left\"><bold>Cardiovascular system</bold></td><td align=\"center\">47</td><td align=\"center\">75</td><td align=\"center\">15 (0.0)</td><td align=\"center\">870 (1.3)</td><td align=\"center\">2210 (3.3)</td><td align=\"center\">4669 (7.1)</td><td align=\"center\">48,189</td></tr><tr><td align=\"left\"><bold>Y53</bold></td><td align=\"left\"><bold>Gastrointestinal system</bold></td><td align=\"center\">39</td><td align=\"center\">62</td><td align=\"center\">30 (0.0)</td><td align=\"center\">222 (0.3)</td><td align=\"center\">163 (0.2)</td><td align=\"center\">239 (0.4)</td><td align=\"center\">3,597</td></tr><tr><td align=\"left\"><bold>Y54</bold></td><td align=\"left\"><bold>Water-balance, mineral and uric acid</bold></td><td align=\"center\">33</td><td align=\"center\">77</td><td align=\"center\">13 (0.0)</td><td align=\"center\">411 (0.6)</td><td align=\"center\">1360 (2.1)</td><td align=\"center\">3848 (5.8)</td><td align=\"center\">42,568</td></tr><tr><td align=\"left\"><bold>Y55</bold></td><td align=\"left\"><bold>Smooth/skeletal muscle, respiratory system</bold></td><td align=\"center\">39</td><td align=\"center\">56</td><td align=\"center\">24 (0.0)</td><td align=\"center\">182 (0.3)</td><td align=\"center\">105 (0.2)</td><td align=\"center\">111 (0.2)</td><td align=\"center\">2,232</td></tr><tr><td align=\"left\"><bold>Y56</bold></td><td align=\"left\"><bold>Topical agents</bold></td><td align=\"center\">42</td><td align=\"center\">58</td><td align=\"center\">68 (0.1)</td><td align=\"center\">459 (0.7)</td><td align=\"center\">344 (0.5)</td><td align=\"center\">351 (0.5)</td><td align=\"center\">5,779</td></tr><tr><td align=\"left\"><bold>Y57</bold></td><td align=\"left\"><bold>Other unspecified drugs</bold></td><td align=\"center\">43</td><td align=\"center\">60</td><td align=\"center\">87 (0.1)</td><td align=\"center\">894 (1.4)</td><td align=\"center\">649 (1.0)</td><td align=\"center\">760 (1.1)</td><td align=\"center\">15,835</td></tr><tr><td align=\"left\"><bold>Y58</bold></td><td align=\"left\"><bold>Bacterial vaccines</bold></td><td align=\"center\">52</td><td align=\"center\">10</td><td align=\"center\">243 (0.4)</td><td align=\"center\">15 (0.0)</td><td align=\"center\">14 (0.0)</td><td align=\"center\">9 (0.0)</td><td align=\"center\">296</td></tr><tr><td align=\"left\"><bold>Y59</bold></td><td align=\"left\"><bold>Other vaccines, biological substance</bold></td><td align=\"center\">51</td><td align=\"center\">28</td><td align=\"center\">211 (0.3)</td><td align=\"center\">162 (0.2)</td><td align=\"center\">57 (0.1)</td><td align=\"center\">40 (0.1)</td><td align=\"center\">1,562</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td/><td align=\"center\"><bold>43</bold></td><td align=\"center\"><bold>63</bold></td><td align=\"center\"><bold>3202 (4.8)</bold></td><td align=\"center\"><bold>19687 (29.7)</bold></td><td align=\"center\"><bold>18328 (27.7)</bold></td><td align=\"center\"><bold>24964 (37.7)</bold></td><td align=\"center\"><bold>439,685</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\"><bold>Combined Primary Diagnosis and External Cause</bold></td><td align=\"center\"><bold>42</bold></td><td align=\"center\"><bold>60</bold></td><td align=\"center\"><bold>3387 (4.4)</bold></td><td align=\"center\"><bold>27887 (36.6)</bold></td><td align=\"center\"><bold>19149 (25.1)</bold></td><td align=\"center\"><bold>25740 (33.8)</bold></td><td align=\"center\"><bold>571,879</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2093926:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of baseline subject demographic data</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Mean</bold></td><td align=\"left\"><bold>SD</bold></td><td align=\"left\"><bold>Range</bold></td><td align=\"left\"><bold>n</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Age (years)</bold></td><td align=\"left\">35.40</td><td align=\"left\">8.31</td><td align=\"left\">22.0; 49.0</td><td align=\"left\">38</td></tr><tr><td align=\"left\"><bold>Height (m)</bold></td><td align=\"left\">177.80</td><td align=\"left\">6.15</td><td align=\"left\">160.0; 188.0</td><td align=\"left\">38</td></tr><tr><td align=\"left\"><bold>Weight (kg)</bold></td><td align=\"left\">80.67</td><td align=\"left\">7.49</td><td align=\"left\">66.5; 97.5</td><td align=\"left\">38</td></tr><tr><td align=\"left\"><bold>BMI (kg/m<sup>2</sup>)</bold></td><td align=\"left\">25.50</td><td align=\"left\">1.82</td><td align=\"left\">22.2; 29.8</td><td align=\"left\">38</td></tr></tbody></table></body></html>", "text": "Pmid= 2093927:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Mean (CV%) pharmacokinetic parameters after subcutaneous administration of 2.92 mg r-hGH/subject by cool.click 2 or needle injection</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>cool.click&#8482; 2 (test) mean (CV%)</bold></td><td align=\"left\"><bold>Needle and syringe (reference) mean (CV%)</bold></td><td align=\"left\"><bold>Ratio (test/ref)</bold></td><td align=\"left\"><bold>90% CI for ratio</bold></td><td align=\"left\"><bold>Falls within 80&#8211;125% range?</bold></td><td align=\"left\"><bold>p-value</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>AUC<sub>0-last </sub>(hours&#183;ng/mL)</bold></td><td align=\"left\">125.1 (30)</td><td align=\"left\">119.3 (27)</td><td align=\"left\">104.8</td><td align=\"left\">98.1, 112.0</td><td align=\"left\">Yes</td><td/></tr><tr><td align=\"left\"><bold>AUC<sub>0-inf </sub>(hours&#183;ng/mL)</bold></td><td align=\"left\">135.5 (27)</td><td align=\"left\">131.1 (24)</td><td align=\"left\">103.4</td><td align=\"left\">97.1, 110.0</td><td align=\"left\">Yes</td><td/></tr><tr><td align=\"left\"><bold>C<sub>max </sub>(ng/mL)</bold></td><td align=\"left\">20.0 (43)</td><td align=\"left\">18.0 (37)</td><td align=\"left\">110.8</td><td align=\"left\">103.7, 118.3</td><td align=\"left\">Yes</td><td/></tr><tr><td align=\"left\"><bold>t<sub>max </sub>(hours)*</bold></td><td align=\"left\">3.0 (2&#8211;6)</td><td align=\"left\">4.5 (2&#8211;6)</td><td/><td/><td/><td align=\"left\">0.002</td></tr><tr><td align=\"left\"><bold>t<sub>1/2 </sub>(hours)</bold></td><td align=\"left\">2.17 (42)</td><td align=\"left\">2.26 (37)</td><td/><td/><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 2093927:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Ethic committee approvals</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Study</bold></td><td align=\"center\"><bold>Ethical Committee</bold></td></tr></thead><tbody><tr><td align=\"left\">- single-dose, comparing 1 and 2 mg lozenges with 2 mg gum<break/>- multiple-dose, comparing 1 mg lozenge with 2 mg gum</td><td align=\"center\">CCPPRB de Franche-Comt&#233;, France</td></tr><tr><td align=\"left\">- multiple-dose, comparing 1 and 2 mg lozenges with 4 mg gum</td><td align=\"center\">CCPPRB of the H&#244;tel-Dieu Hospital (Lyon &#8211; France)</td></tr><tr><td align=\"left\">- safety assessment of 1 mg lozenge after swallowing</td><td align=\"center\">CREC Regipharm (Brussels &#8211; Belgium)</td></tr><tr><td align=\"left\">- French efficacy trial</td><td align=\"center\">CCPPRB of the Piti&#233;-Salp&#234;tri&#232;re Hospital (Paris &#8211; France)</td></tr><tr><td align=\"left\">- US efficacy trial</td><td align=\"center\">IRB at Research Testing Laboratories, Inc. (Great Neck, NY, USA)</td></tr></tbody></table></body></html>", "text": "Pmid= 2194660:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>PK parameters of nicotine in plasma after intake of a single dose of lozenge or gum (mean  SD; n = 9)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Formulation\\\\PK parameter</bold></td><td align=\"center\" colspan=\"2\"><bold>Nicotinell<sup>&#174; </sup></bold><break/><bold>lozenge</bold></td><td align=\"center\"><bold>Nicorette<sup>&#174; </sup></bold><break/><bold>gum</bold></td></tr><tr><td/><td colspan=\"2\"><hr/></td><td colspan=\"1\"><hr/></td></tr><tr><td/><td align=\"center\"><bold>1 mg</bold></td><td align=\"center\"><bold>2 mg</bold></td><td align=\"center\"><bold>2 mg</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Amount of nicotine released after 30 min (mg) </bold><break/>[% of minimal content]</td><td align=\"center\">0.67 &#177; 0.14 <break/>[67%]</td><td align=\"center\">1.39 &#177; 0.28 <break/>[67%]</td><td align=\"center\">0.81 &#177; 0.25 <break/>[42%]</td></tr><tr><td align=\"left\"><bold>observed C<sub>max </sub>(ng/ml) </bold><break/>[adjusted]<sup>&#8224;&#8225;</sup></td><td align=\"center\">2.3 &#177; 0.8 <break/>[3.5 &#177; 1.1]<sup>&#8224;</sup></td><td align=\"center\">4.8 &#177; 1.4<break/> [7.0 &#177; 1.7]</td><td align=\"center\">2.9 &#177; 1.2</td></tr><tr><td align=\"left\"><bold>t<sub>max </sub>(h) </bold><break/>[median (range)]</td><td align=\"center\">1.1 &#177; 0.7 <break/>[0.8 (0.8&#8211;3.0)]</td><td align=\"center\">0.8 &#177; 0.2 <break/>[0.8 (0.6&#8211;1.1)]</td><td align=\"center\">0.8 &#177; 0.1<break/> [0.8 (0.5&#8211;1.0)]</td></tr><tr><td align=\"left\"><bold>t<sub>1/2 </sub>(h)</bold></td><td align=\"center\">2.7 &#177; 0.7</td><td align=\"center\">2.8 &#177; 0.7</td><td align=\"center\">2.5 &#177; 1.0</td></tr><tr><td align=\"left\"><bold>AUC<sub>0-t </sub>(h&#183;ng/ml)</bold></td><td align=\"center\">8.3 &#177; 2.5</td><td align=\"center\">15.8 &#177; 4.1</td><td align=\"center\">10.6 &#177; 4.4</td></tr><tr><td align=\"left\"><bold>observed AUC<sub>0&#8211;&#8734;</sub>(h&#183;ng/ml) </bold><break/>[adjusted]<sup>&#8224;&#8225;</sup></td><td align=\"center\">10.7 &#177; 3.1 <break/>[16.5 &#177; 4.6]</td><td align=\"center\">20.0 &#177; 5.9 <break/>[30.1 &#177; 9.7]</td><td align=\"center\">13.8 &#177; 5.6</td></tr></tbody></table></body></html>", "text": "Pmid= 2194660:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>PK parameters of nicotine in plasma at steady state after 12 hourly doses</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Formulation\\\\PK parameter</bold></td><td align=\"center\"><bold>Nicotinell<sup>&#174; </sup>lozenge</bold></td><td align=\"center\"><bold>Nicorette<sup>&#174; </sup>gum</bold></td><td align=\"center\"><bold>90% CI </bold>(lozenge/gum)<sup>#</sup></td></tr><tr><td/><td colspan=\"2\"><hr/></td><td/></tr><tr><td/><td align=\"center\"><bold>1 mg</bold></td><td align=\"center\"><bold>2 mg<sup>&#8225;</sup></bold></td><td/></tr></thead><tbody><tr><td align=\"left\"><bold>C<sub>max </sub>(ng/ml)</bold></td><td align=\"center\">10.6 &#177; 2.9</td><td align=\"center\">11.4 &#177; 3.8</td><td align=\"center\">0.86&#8211;1.04</td></tr><tr><td align=\"left\"><bold>C<sub>min </sub>(ng/ml)</bold></td><td align=\"center\">8.1 &#177; 2.4</td><td align=\"center\">9.3 &#177; 3.4</td><td align=\"center\">ND</td></tr><tr><td align=\"left\"><bold>t<sub>max </sub>(h) </bold>[range]</td><td align=\"center\">0.54 &#177; 0.21 [0.00&#8211;0.77]</td><td align=\"center\">0.47 &#177; 0.19 [0.20&#8211;0.95]</td><td align=\"center\">ND</td></tr><tr><td align=\"left\"><bold>t<sub>1/2 </sub>(h)</bold></td><td align=\"center\">3.6 &#177; 1.2</td><td align=\"center\">3.2 &#177; 0.9</td><td align=\"center\">ND</td></tr><tr><td align=\"left\"><bold>AUC<sub>11&#8211;12 </sub>(h&#183;ng/ml)</bold></td><td align=\"center\">9.2 &#177; 2.6</td><td align=\"center\">10.2 &#177; 3.4</td><td align=\"center\">0.84&#8211;1.01</td></tr></tbody></table></body></html>", "text": "Pmid= 2194660:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Steady state</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Formulation\\\\PK parameter</bold></td><td align=\"center\" colspan=\"2\"><bold>Nicotinell<sup>&#174; </sup>lozenge 1 mg</bold></td><td align=\"center\"><bold>Nicotinell<sup>&#174; </sup>lozenge</bold></td><td align=\"center\"><bold>90% CI </bold>(2 mg/1 mg)<sup>#</sup></td></tr><tr><td/><td colspan=\"3\"><hr/></td><td/></tr><tr><td/><td align=\"center\"><bold>observed</bold></td><td align=\"center\"><bold>adj. to 2 mg<sup>&#8225;</sup></bold></td><td align=\"center\"><bold>2 mg</bold></td><td/></tr></thead><tbody><tr><td align=\"left\"><bold>C<sub>max </sub>(ng/ml)</bold></td><td align=\"center\">11.0 &#177; 4.9</td><td align=\"center\">22.0 &#177; 9.8</td><td align=\"center\">22.5 &#177; 7.0</td><td align=\"center\">0.97&#8211;1.19 (F = 1.07)</td></tr><tr><td align=\"left\"><bold>t<sub>max </sub>(h) </bold>Median [range]</td><td align=\"center\">0.5 [0.25&#8211;1.00]</td><td align=\"center\">-</td><td align=\"center\">0.5 [0.25&#8211;1.02]</td><td align=\"center\">NS (Friedman ANOVA)</td></tr><tr><td align=\"left\"><bold>AUC<sub>11&#8211;12 </sub>(h&#183;ng/ml)</bold></td><td align=\"center\">9.7 &#177; 3.9</td><td align=\"center\">19.3 &#177; 7.8</td><td align=\"center\">20.2 &#177; 6.8</td><td align=\"center\">0.98&#8211;1.20 (F = 1.08)</td></tr></tbody></table></body></html>", "text": "Pmid= 2194660:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>PK parameters of nicotine in plasma at steady state after 12 hourly doses</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Formulation\\\\PK parameter</bold></td><td align=\"center\"><bold>Nicotinell<sup>&#174; </sup>lozenge</bold></td><td align=\"center\"><bold>Nicorette<sup>&#174; </sup>gum</bold></td><td align=\"center\"><bold>90% CI </bold>(lozenge/gum)<sup>&#8225;</sup></td></tr><tr><td/><td colspan=\"2\"><hr/></td><td/></tr><tr><td/><td align=\"center\"><bold>2 mg</bold></td><td align=\"center\"><bold>4 mg</bold></td><td/></tr></thead><tbody><tr><td align=\"left\"><bold>C<sub>max </sub>(ng/ml)</bold></td><td align=\"center\">22.5 &#177; 7.0</td><td align=\"center\">30.5 &#177; 12.8</td><td align=\"center\">0.69&#8211;0.89 (F = 0.78)</td></tr><tr><td align=\"left\"><bold>t<sub>max </sub>(h) </bold>Median [range]</td><td align=\"center\">0.5 [0.25&#8211;1.02]</td><td align=\"center\">0.5 [0.25&#8211;1.00]</td><td align=\"center\">NS (Friedman ANOVA)</td></tr><tr><td align=\"left\"><bold>AUC<sub>11&#8211;12 </sub>(h&#183;ng/ml)</bold></td><td align=\"center\">20.2 &#177; 6.8</td><td align=\"center\">27.5 &#177; 11.4</td><td align=\"center\">0.68&#8211;0.88 (F = 0.77)</td></tr></tbody></table></body></html>", "text": "Pmid= 2194660:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>PK parameters of nicotine in plasma after swallowing without sucking of increasing numbers of 1 mg lozenge (mean  SD; n = 8 per group)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Group\\\\PK parameter</bold></td><td align=\"center\"><bold>A</bold></td><td align=\"center\"><bold>B</bold></td><td align=\"center\"><bold>C</bold></td></tr><tr><td/><td colspan=\"3\"><hr/></td></tr><tr><td/><td align=\"center\"><bold>3 lozenges</bold></td><td align=\"center\"><bold>6 lozenges</bold></td><td align=\"center\"><bold>12 lozenges</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>C<sub>max </sub>(ng/ml)</bold></td><td align=\"center\">8.2 &#177; 7.6</td><td align=\"center\">16.9 &#177; 11.8</td><td align=\"center\">20.5 &#177; 8.8</td></tr><tr><td align=\"left\"><bold>t<sub>max </sub>(h)</bold></td><td align=\"center\">2.7 &#177; 2.8</td><td align=\"center\">2.8 &#177; 2.0</td><td align=\"center\">2.2 &#177; 1.4</td></tr><tr><td align=\"left\"><bold>AUC<sub>10 min-12 h </sub>(h.ng/ml)</bold></td><td align=\"center\">37.0 &#177; 27.2</td><td align=\"center\">84.9 &#177; 48.9</td><td align=\"center\">103.1 &#177; 58.6</td></tr></tbody></table></body></html>", "text": "Pmid= 2194660:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Primary and secondary efficacy criteria: complete or partial abstinence during the 28 days preceding the 6-week visit (adopted from [17])</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Group\\\\Statistical results</bold></td><td align=\"center\"><bold>Nicotinell<sup>&#174; </sup></bold><break/><bold>lozenge 1 mg</bold></td><td align=\"center\" colspan=\"\"><bold>Placebo</bold></td></tr><tr><td/><td colspan=\"2\"><hr/></td></tr><tr><td/><td align=\"center\"><bold>(n = 211)</bold></td><td align=\"center\" colspan=\"\"><bold>(n = 222)</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Complete abstinence (%)</bold></td><td align=\"center\">48 (23%)</td><td align=\"center\" colspan=\"\">32 (14%)</td></tr><tr><td align=\"left\"><bold>OR </bold>[95% CI]</td><td align=\"center\" colspan=\"2\"><bold>1.72 [1.05&#8211;2.80]</bold></td></tr><tr><td align=\"left\"><bold>Statistical significance</bold></td><td align=\"center\" colspan=\"2\"><bold>p = 0.03</bold></td></tr><tr><td align=\"left\"><bold>Complete or partial abstinence (%)</bold></td><td align=\"center\">68 (32%)</td><td align=\"center\">39 (18%)</td></tr><tr><td align=\"left\"><bold>OR </bold>[95% CI]</td><td align=\"center\" colspan=\"2\"><bold>2.18 </bold>[1.40&#8211;3.41]</td></tr><tr><td align=\"left\"><bold>Statistical significance</bold></td><td align=\"center\" colspan=\"2\"><bold>p = 0.001</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2194660:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Complete abstinence from week 2 at each visit</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\" colspan=\"2\"><bold>Time since treatment started</bold></td><td align=\"center\" colspan=\"2\"><bold>6 weeks</bold></td><td align=\"center\" colspan=\"2\"><bold>12 weeks</bold></td><td align=\"center\" colspan=\"2\"><bold>26 weeks</bold></td></tr></thead><tbody><tr><td align=\"left\" colspan=\"2\"><bold>French study (FTDN 4 to7)</bold></td><td align=\"center\" colspan=\"6\">Placebo n = 222, Nicotinell Lozenge 1 mg n = 211</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\"><bold>Completely abstinent</bold></td><td align=\"right\">active</td><td align=\"center\">48</td><td align=\"center\"><bold>22.7%</bold></td><td align=\"center\">28</td><td align=\"center\"><bold>13.3%</bold></td><td align=\"center\">25</td><td align=\"center\"><bold>11.8%</bold></td></tr><tr><td align=\"left\"><bold>N (%)</bold></td><td align=\"right\">placebo</td><td align=\"center\">32</td><td align=\"center\"><bold>14.4%</bold></td><td align=\"center\">20</td><td align=\"center\"><bold>9.0%</bold></td><td align=\"center\">18</td><td align=\"center\"><bold>8.1%</bold></td></tr><tr><td align=\"left\"><bold>OR </bold>[95% CI]</td><td/><td align=\"center\" colspan=\"2\"><bold>1.72 </bold>[1.05&#8211;2.80]</td><td align=\"center\" colspan=\"2\"><bold>1.47 </bold>[0.82&#8211;2.65]</td><td align=\"center\" colspan=\"2\"><bold>1.48 </bold>[0.78&#8211;2.79]</td></tr><tr><td align=\"left\"><bold>Statistical significance</bold></td><td/><td align=\"center\" colspan=\"2\"><bold>p = 0.03</bold></td><td align=\"center\" colspan=\"2\"><bold>p = 0.199</bold></td><td align=\"center\" colspan=\"2\"><bold>p = 0.227</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\"><bold>USA study (FTND &#8805; 6)</bold></td><td/><td align=\"center\" colspan=\"6\">Placebo n = 230, Nicotinell Lozenge 1 mg n = 230</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\"><bold>Completely abstinent</bold></td><td align=\"right\">active</td><td align=\"center\">19</td><td align=\"center\"><bold>8.3%</bold></td><td align=\"center\">11</td><td align=\"center\"><bold>4.8%</bold></td><td align=\"center\">8</td><td align=\"center\"><bold>3.5%</bold></td></tr><tr><td align=\"left\"><bold>N (%)</bold></td><td align=\"right\">placebo</td><td align=\"center\">7</td><td align=\"center\"><bold>3.0%</bold></td><td align=\"center\">3</td><td align=\"center\"><bold>1.3%</bold></td><td align=\"center\">2</td><td align=\"center\"><bold>0.9%</bold></td></tr><tr><td align=\"left\"><bold>OR </bold>[95% CI]</td><td/><td align=\"center\" colspan=\"2\"><bold>2.87 </bold>[1.18&#8211;6.97]</td><td align=\"center\" colspan=\"2\"><bold>3.80 </bold>[1.05&#8211;13.80]</td><td align=\"center\" colspan=\"2\"><bold>4.11 </bold>[0.83&#8211;19.55]</td></tr><tr><td align=\"left\"><bold>Statistical significance</bold></td><td/><td align=\"center\" colspan=\"2\"><bold>p = 0.02</bold></td><td align=\"center\" colspan=\"2\"><bold>p = 0.03</bold></td><td align=\"center\" colspan=\"2\"><bold>p = 0.06</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2194660:Table= Table 8"}
{"html": "<!DOCTYPE html><html><body><h1>Percentage rizatriptan of prescribed and sold triptans before (May  July 2004) and after (May  July 2005) the intervention and absolute change in percentage rizatriptan (after minus before).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">Percentage rizatriptan before the intervention</td><td align=\"left\">Percentage rizatriptan after the intervention</td><td align=\"left\">Absolute change</td><td align=\"left\">Relative change</td><td align=\"left\">P-value</td></tr></thead><tbody><tr><td align=\"left\">Control</td><td align=\"left\">6 (2 &#8211; 13)</td><td align=\"left\">7 (2 &#8211; 11)</td><td align=\"left\">0 (-7 - 5)</td><td align=\"left\">-29 (-69 &#8211; 83)</td><td align=\"left\">-</td></tr><tr><td align=\"left\">Attachment I</td><td align=\"left\">3 (1 &#8211; 10)</td><td align=\"left\">8 (3 &#8211; 14)</td><td align=\"left\">3 (-2 &#8211; 8)</td><td align=\"left\">42 (-51 &#8211; 222)</td><td align=\"left\">0.071</td></tr><tr><td align=\"left\">Attachment II</td><td align=\"left\">7 (1 &#8211; 13)</td><td align=\"left\">8 (2 &#8211; 17)</td><td align=\"left\">1 (-4 &#8211; 6)</td><td align=\"left\">-1 (-59 &#8211; 70)</td><td align=\"left\">0.052</td></tr><tr><td align=\"left\">Attachment I + II</td><td align=\"left\">5 (1 &#8211; 12)</td><td align=\"left\">8 (3 &#8211; 16)</td><td align=\"left\">2 (-3 &#8211; 7)</td><td align=\"left\">20 (-54 &#8211; 140)</td><td align=\"left\">0.031</td></tr></tbody></table></body></html>", "text": "Pmid= 2203966:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>50% Inhibitory concentrations IC50 (nM) of ZL</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>3D7</bold></td><td align=\"left\"><bold>HB3</bold></td><td align=\"left\"><bold>W2</bold></td><td align=\"left\"><bold>Dd2</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>ZL<sub>3</sub>B</bold></td><td align=\"left\">40 &#177; 12</td><td align=\"left\">45 &#177; 5.8</td><td align=\"left\">34 &#177; 3.9</td><td align=\"left\">40 &#177; 11.1</td></tr><tr><td align=\"left\"><bold>Bortezomib</bold></td><td align=\"left\">31 &#177; 1.8</td><td align=\"left\">31 &#177; 2.7</td><td align=\"left\">43 &#177; 4</td><td align=\"left\">37 &#177; 5.1</td></tr><tr><td align=\"left\"><bold>Chloroquine</bold></td><td align=\"left\">6 &#177; 0.2</td><td align=\"left\">8 &#177; 1.4</td><td align=\"left\">90 &#177; 3.7</td><td align=\"left\">300 &#177; 21</td></tr><tr><td align=\"left\"><bold>Pyrimethamine</bold></td><td align=\"left\">5 &#177; 1.1</td><td align=\"left\">500 &#177; 45</td><td align=\"left\">1500 &#177; 5.8</td><td align=\"left\">2500 &#177; 97</td></tr></tbody></table></body></html>", "text": "Pmid= 2213633:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Mean prescribed daily dose (PDD) in milligrams of the different statins in three Norwegian counties</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Statin substance (C10AA)</td><td align=\"center\">DDD<sup>2</sup></td><td align=\"center\">High-c county (Hedmark) mg</td><td align=\"center\">Average-c county (Oppland) mg</td><td align=\"center\">Low-c county (Troms) mg</td></tr></thead><tbody><tr><td align=\"left\">Simvastatin (C10AA01)</td><td align=\"center\">15</td><td align=\"center\">25.9</td><td align=\"center\">24.0</td><td align=\"center\">22.5</td></tr><tr><td align=\"left\">Lovastatin (C10AA02)</td><td align=\"center\">30</td><td align=\"center\">31.8</td><td align=\"center\">30.3</td><td align=\"center\">28.2</td></tr><tr><td align=\"left\">Pravastatin (C10AA03)</td><td align=\"center\">20</td><td align=\"center\">32.1</td><td align=\"center\">32.1</td><td align=\"center\">32.3</td></tr><tr><td align=\"left\">Fluvastatin (C10AA04)</td><td align=\"center\">40</td><td align=\"center\">60.9</td><td align=\"center\">58.7</td><td align=\"center\">57.3</td></tr><tr><td align=\"left\">Atorvastatin (C10AA05)</td><td align=\"center\">10</td><td align=\"center\">21.9</td><td align=\"center\">19.8</td><td align=\"center\">18.0</td></tr></tbody></table></body></html>", "text": "Pmid= 2234392:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>ICSRs in children (<15 years old) and adults (15 years old) during 2005.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td/><td align=\"center\" colspan=\"4\"><bold>Children</bold></td><td align=\"center\" colspan=\"4\"><bold>Adults</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>ATC code</bold></td><td align=\"left\"><bold>Name of group</bold></td><td align=\"center\"><bold>ICSR (n)</bold></td><td align=\"center\"><bold>Serious ADR (n)</bold></td><td align=\"center\"><bold>Million DDD (n)</bold></td><td align=\"center\"><bold>ICSR per million DDD (95% CI)</bold></td><td align=\"center\"><bold>ICSR (n)</bold></td><td align=\"center\"><bold>Serious ADR (n)</bold></td><td align=\"center\"><bold>Million DDD (n)</bold></td><td align=\"center\"><bold>ICSR per million DDD (95% CI)</bold></td></tr><tr><td colspan=\"10\"><hr/></td></tr><tr><td align=\"left\">R03DC</td><td align=\"left\">Leukotriene receptor antagonists</td><td align=\"center\">16</td><td align=\"center\">0</td><td align=\"center\">0.7</td><td align=\"center\">24 (13.6 &#8211; 38.6)</td><td align=\"center\">7</td><td align=\"center\">0</td><td align=\"center\">5.2</td><td align=\"center\">1.4 (0.5 &#8211; 2.8)</td></tr><tr><td align=\"left\">N06BA</td><td align=\"left\">Centrally acting sympathomimetics</td><td align=\"center\">12</td><td align=\"center\">0</td><td align=\"center\">1.5</td><td align=\"center\">7.8 (4.0 &#8211; 13.6)</td><td align=\"center\">15</td><td align=\"center\">2</td><td align=\"center\">2.6</td><td align=\"center\">5.7 (3.2 &#8211; 9.5)</td></tr><tr><td align=\"left\">H02AB</td><td align=\"left\">Glucocorticoids</td><td align=\"center\">3</td><td align=\"center\">0</td><td align=\"center\">0.7</td><td align=\"center\">4.5 (0.9 &#8211; 13.0)</td><td align=\"center\">31</td><td align=\"center\">21</td><td align=\"center\">32</td><td align=\"center\">1.0 (0.7 &#8211; 1.4)</td></tr><tr><td align=\"left\">H01BA</td><td align=\"left\">Vasopressin and analogues</td><td align=\"center\">3</td><td align=\"center\">0</td><td align=\"center\">1.1</td><td align=\"center\">2.8 (0.6 &#8211; 8.2)</td><td align=\"center\">5</td><td align=\"center\">2</td><td align=\"center\">1.3</td><td align=\"center\">3.9 (1.3 &#8211; 9.2)</td></tr><tr><td align=\"left\">N03AX</td><td align=\"left\">Other antiepileptics</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0.4</td><td align=\"center\">2.4 (0.1 &#8211; 13.1)</td><td align=\"center\">58</td><td align=\"center\">19</td><td align=\"center\">9.7</td><td align=\"center\">6.0 (4.5 &#8211; 7.7)</td></tr><tr><td align=\"left\">R03CC</td><td align=\"left\">Selective beta-2-adrenoreceptor agonists</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0.4</td><td align=\"center\">2.3 (0.1 &#8211; 12.6)</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">1.4</td><td align=\"center\">0.7 (0.02&#8211;3.9)</td></tr><tr><td align=\"left\">J01CA</td><td align=\"left\">Penicillins with extended spectrum</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0.5</td><td align=\"center\">2.1 (0.1 &#8211; 11.5)</td><td align=\"center\">12</td><td align=\"center\">3</td><td align=\"center\">3.9</td><td align=\"center\">3.1 (1.6 &#8211; 5.4)</td></tr><tr><td align=\"left\">R05FA</td><td align=\"left\">Opium derivatives and expectorants</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">0.5</td><td align=\"center\">2.0 (0.1 &#8211; 11.4)</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">11</td><td align=\"center\">0.1 (0.002 &#8211; 0.5)</td></tr><tr><td align=\"left\">J01CE</td><td align=\"left\">Beta-lactamase sensitive penicillins</td><td align=\"center\">3</td><td align=\"center\">0</td><td align=\"center\">1.6</td><td align=\"center\">1.8 (0.4 &#8211; 5.3)</td><td align=\"center\">14</td><td align=\"center\">5</td><td align=\"center\">11</td><td align=\"center\">1.3 (0.7 &#8211; 2.1)</td></tr><tr><td align=\"left\">A10AE</td><td align=\"left\">Insulins and analogues. long-acting</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0.7</td><td align=\"center\">1.5 (0.04&#8211;8.5)</td><td align=\"center\">7</td><td align=\"center\">2</td><td align=\"center\">11</td><td align=\"center\">0.6 (0.3 &#8211; 1.3)</td></tr><tr><td align=\"left\">R06AX</td><td align=\"left\">Other antihistamines for systemic use</td><td align=\"center\">5</td><td align=\"center\">1</td><td align=\"center\">3.4</td><td align=\"center\">1.5 (0.5 &#8211; 3.5)</td><td align=\"center\">14</td><td align=\"center\">3</td><td align=\"center\">31</td><td align=\"center\">0.5 (0.3 &#8211; 0.8)</td></tr><tr><td align=\"left\">H01AC</td><td align=\"left\">Somatropin and somatropin agonists</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0.8</td><td align=\"center\">1.3 (0.03&#8211;7.1)</td><td align=\"center\">2</td><td align=\"center\">0</td><td align=\"center\">0.8</td><td align=\"center\">2.6 (0.3 &#8211; 9.5)</td></tr><tr><td align=\"left\">R03BA</td><td align=\"left\">Glucocorticoids, inhalants</td><td align=\"center\">4</td><td align=\"center\">0</td><td align=\"center\">3.6</td><td align=\"center\">1.1 (0.3 &#8211; 2.8)</td><td align=\"center\">5</td><td align=\"center\">0</td><td align=\"center\">37</td><td align=\"center\">0.1 (0.04 &#8211; 0.3)</td></tr><tr><td align=\"left\">R03AK</td><td align=\"left\">Adrenergics and other drugs for obstructive airway diseases</td><td align=\"center\">2</td><td align=\"center\">0</td><td align=\"center\">2.0</td><td align=\"center\">1.0 (0.1 &#8211; 3.7)</td><td align=\"center\">10</td><td align=\"center\">1</td><td align=\"center\">33</td><td align=\"center\">0.3 (0.1 &#8211; 0.6)</td></tr><tr><td align=\"left\">R05CB</td><td align=\"left\">Mucolytics</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">1.2</td><td align=\"center\">0.8 (0.02&#8211;4.5)</td><td align=\"center\">3</td><td align=\"center\">1</td><td align=\"center\">28</td><td align=\"center\">0.1 (0.02 &#8211; 0.3)</td></tr><tr><td align=\"left\">R06AE</td><td align=\"left\">Piperazine derivatives</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">1.5</td><td align=\"center\">0.7 (0.02&#8211;3.8)</td><td align=\"center\">3</td><td align=\"center\">1</td><td align=\"center\">19</td><td align=\"center\">0.2 (0.03 &#8211; 0.5)</td></tr><tr><td align=\"left\">R03AC</td><td align=\"left\">Selective beta-2-adrenoreceptor agonists</td><td align=\"center\">2</td><td align=\"center\">1</td><td align=\"center\">4.4</td><td align=\"center\">0.5 (0.1 &#8211; 1.7)</td><td align=\"center\">5</td><td align=\"center\">0</td><td align=\"center\">49</td><td align=\"center\">0.1 (0.03 &#8211; 0.2)</td></tr><tr><td align=\"left\">D07AA</td><td align=\"left\">Corticosteroids. weak (group I)</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">4.9</td><td align=\"center\">0.2 (0.01 &#8211; 1.1)</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">6.3</td><td align=\"center\">0.0 (-0.6)<sup>1</sup></td></tr><tr><td align=\"left\">D02AX</td><td align=\"left\">Other emollients and protectives</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">53</td><td align=\"center\">0.02 (0.001 &#8211; 0.1)</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">149</td><td align=\"center\">0 (-0.02)<sup>1</sup></td></tr></tbody></table></body></html>", "text": "Pmid= 2279106:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Description of ICSRs for children in the ATC code R03DC. All ICSRs concerned the substance montelukast.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Age (years)</bold></td><td align=\"center\"><bold>Dose (mg/day)</bold></td><td align=\"center\"><bold>Treatment duration (when known)</bold></td><td align=\"left\"><bold>ADR</bold></td><td align=\"center\"><bold>SPC (Yes/No)</bold></td></tr></thead><tbody><tr><td align=\"center\">4</td><td align=\"center\">4</td><td align=\"center\">-</td><td align=\"left\">Night mares</td><td align=\"center\">Yes</td></tr><tr><td align=\"center\">3</td><td align=\"center\">4</td><td align=\"center\">-</td><td align=\"left\">Sleep disorders</td><td align=\"center\">Yes</td></tr><tr><td align=\"center\">3</td><td align=\"center\">4</td><td align=\"center\">-</td><td align=\"left\">Cranial nerve lesion</td><td align=\"center\">No</td></tr><tr><td align=\"center\">4</td><td align=\"center\">4</td><td align=\"center\">2 years</td><td align=\"left\">Haemorrhage</td><td align=\"center\">Yes</td></tr><tr><td/><td/><td/><td align=\"left\">Pruritus</td><td align=\"center\">Yes</td></tr><tr><td/><td/><td/><td align=\"left\">Abdominal pain</td><td align=\"center\">Yes</td></tr><tr><td/><td/><td/><td align=\"left\">Rectal pain</td><td align=\"center\">No</td></tr><tr><td align=\"center\">2</td><td align=\"center\">4</td><td align=\"center\">-</td><td align=\"left\">Fever</td><td align=\"center\">No</td></tr><tr><td/><td/><td/><td align=\"left\">Fatigue</td><td align=\"center\">Yes</td></tr><tr><td/><td/><td/><td align=\"left\">Rash</td><td align=\"center\">No</td></tr><tr><td align=\"center\">1</td><td align=\"center\">4</td><td align=\"center\">4 days</td><td align=\"left\">Anxiety</td><td align=\"center\">No</td></tr><tr><td align=\"center\">3</td><td align=\"center\">4</td><td align=\"center\">-</td><td align=\"left\">Night mares</td><td align=\"center\">Yes</td></tr><tr><td/><td/><td/><td align=\"left\">Aggressiveness</td><td align=\"center\">Yes</td></tr><tr><td align=\"center\">2</td><td align=\"center\">4</td><td align=\"center\">4 days</td><td align=\"left\">Aggressiveness</td><td align=\"center\">Yes</td></tr><tr><td align=\"center\">3</td><td align=\"center\">4</td><td align=\"center\">continuing</td><td align=\"left\">Night mares</td><td align=\"center\">Yes</td></tr><tr><td align=\"center\">3</td><td align=\"center\">4</td><td align=\"center\">2 doses</td><td align=\"left\">Asthma aggravated</td><td align=\"center\">No</td></tr><tr><td align=\"center\">2</td><td align=\"center\">4</td><td align=\"center\">11 days</td><td align=\"left\">Rash</td><td align=\"center\">No</td></tr><tr><td/><td/><td/><td align=\"left\">Pruritus</td><td align=\"center\">Yes</td></tr><tr><td/><td/><td/><td align=\"left\">Sleep disorder</td><td align=\"center\">Yes</td></tr><tr><td/><td/><td/><td align=\"left\">Night mares</td><td align=\"center\">Yes</td></tr><tr><td align=\"center\">1</td><td align=\"center\">4</td><td align=\"center\">2 weeks</td><td align=\"left\">Anxiety</td><td align=\"center\">No</td></tr><tr><td/><td/><td/><td align=\"left\">Sleep disorder</td><td align=\"center\">Yes</td></tr><tr><td align=\"center\">6</td><td align=\"center\">5</td><td align=\"center\">8 weeks</td><td align=\"left\">Xerophthalmia</td><td align=\"center\">No</td></tr><tr><td align=\"center\">5</td><td align=\"center\">4</td><td align=\"center\">3 weeks</td><td align=\"left\">Appetite increased</td><td align=\"center\">No</td></tr><tr><td align=\"center\">8</td><td align=\"center\">5 (on demand)</td><td align=\"center\">5 weeks</td><td align=\"left\">Leucopenia</td><td align=\"center\">No</td></tr><tr><td/><td/><td/><td align=\"left\">Red blood cell disorder</td><td align=\"center\">No</td></tr><tr><td align=\"center\">14</td><td align=\"center\">10</td><td align=\"center\">2 years</td><td align=\"left\">Arthralgia</td><td align=\"center\">Yes</td></tr><tr><td/><td/><td/><td align=\"left\">Myalgia</td><td align=\"center\">Yes</td></tr></tbody></table></body></html>", "text": "Pmid= 2279106:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Frequency of adverse effects (AE) during inhalation sedation observed for trainee and expert practitioners for each type of patient.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td/><td align=\"center\" colspan=\"2\"><bold>Anxious adult or child</bold></td><td align=\"center\" colspan=\"2\"><bold>Preschool children</bold></td><td align=\"center\" colspan=\"2\"><bold>Intellectual disability</bold></td><td align=\"center\" colspan=\"2\"><bold>Stressful act</bold></td><td align=\"center\" colspan=\"2\"><bold>Total</bold></td></tr><tr><td/><td/><td colspan=\"2\"><hr/></td><td colspan=\"2\"><hr/></td><td colspan=\"2\"><hr/></td><td colspan=\"2\"><hr/></td><td colspan=\"2\"><hr/></td></tr><tr><td align=\"center\">Type of adverse effect</td><td align=\"center\">Practitioners</td><td align=\"center\"><italic>Sessions (n)</italic></td><td align=\"center\"><italic>AE (%)</italic></td><td align=\"center\"><italic>Sessions (n)</italic></td><td align=\"center\"><italic>AE (%)</italic></td><td align=\"center\"><italic>Sessions (n)</italic></td><td align=\"center\"><italic>AE (%)</italic></td><td align=\"center\"><italic>Sessions (n)</italic></td><td align=\"center\"><italic>AE (%)</italic></td><td align=\"center\"><italic>Sessions (n)</italic></td><td align=\"center\"><italic>AE (%)</italic></td></tr></thead><tbody><tr><td align=\"center\"><bold>Respiratory</bold></td><td align=\"center\">Trainee</td><td align=\"center\">291</td><td align=\"center\">0</td><td align=\"center\">143</td><td align=\"center\">0</td><td align=\"center\">262</td><td align=\"center\"><bold>8**</bold></td><td align=\"center\">87</td><td align=\"center\">0</td><td align=\"center\">783</td><td align=\"center\"><bold>3*</bold></td></tr><tr><td/><td align=\"center\">Expert</td><td align=\"center\">139</td><td align=\"center\">0</td><td align=\"center\">30</td><td align=\"center\">0</td><td align=\"center\">202</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">372</td><td align=\"center\">0</td></tr><tr><td align=\"center\"><bold>Digestive</bold></td><td align=\"center\">Trainee</td><td align=\"center\">292</td><td align=\"center\">4</td><td align=\"center\">143</td><td align=\"center\">1</td><td align=\"center\">261</td><td align=\"center\"><bold>9**</bold></td><td align=\"center\">87</td><td align=\"center\">2</td><td align=\"center\">783</td><td align=\"center\">5</td></tr><tr><td/><td align=\"center\">Expert</td><td align=\"center\">139</td><td align=\"center\">5</td><td align=\"center\">30</td><td align=\"center\">0</td><td align=\"center\">202</td><td align=\"center\">2</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">372</td><td align=\"center\">3</td></tr><tr><td align=\"center\"><bold>Neurological</bold></td><td align=\"center\">Trainee</td><td align=\"center\">292</td><td align=\"center\">1</td><td align=\"center\">141</td><td align=\"center\">0</td><td align=\"center\">259</td><td align=\"center\">0</td><td align=\"center\">87</td><td align=\"center\">0</td><td align=\"center\">781</td><td align=\"center\">0</td></tr><tr><td/><td align=\"center\">Expert</td><td align=\"center\">139</td><td align=\"center\">1</td><td align=\"center\">30</td><td align=\"center\">0</td><td align=\"center\">203</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">373</td><td align=\"center\">0</td></tr><tr><td align=\"center\"><bold>Behavioural</bold></td><td align=\"center\">Trainee</td><td align=\"center\">292</td><td align=\"center\">1</td><td align=\"center\">142</td><td align=\"center\">3</td><td align=\"center\">266</td><td align=\"center\"><bold>12**</bold></td><td align=\"center\">87</td><td align=\"center\">6</td><td align=\"center\">787</td><td align=\"center\"><bold>6*</bold></td></tr><tr><td/><td align=\"center\">Expert</td><td align=\"center\">139</td><td align=\"center\">1</td><td align=\"center\">30</td><td align=\"center\">7</td><td align=\"center\">202</td><td align=\"center\">2</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">372</td><td align=\"center\">2</td></tr><tr><td align=\"center\"><bold>Vaso-vagal</bold></td><td align=\"center\">Trainee</td><td align=\"center\">292</td><td align=\"center\">1</td><td align=\"center\">143</td><td align=\"center\">1</td><td align=\"center\">263</td><td align=\"center\"><bold>10**</bold></td><td align=\"center\">87</td><td align=\"center\">2</td><td align=\"center\">785</td><td align=\"center\"><bold>4**</bold></td></tr><tr><td/><td align=\"center\">Expert</td><td align=\"center\">139</td><td align=\"center\">1</td><td align=\"center\">30</td><td align=\"center\">0</td><td align=\"center\">202</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">372</td><td align=\"center\">1</td></tr><tr><td align=\"center\"><bold>Others</bold></td><td align=\"center\">Trainee</td><td align=\"center\">291</td><td align=\"center\">1</td><td align=\"center\">143</td><td align=\"center\">0</td><td align=\"center\">254</td><td align=\"center\"><bold>7**</bold></td><td align=\"center\">87</td><td align=\"center\">3</td><td align=\"center\">775</td><td align=\"center\">3</td></tr><tr><td/><td align=\"center\">Expert</td><td align=\"center\">139</td><td align=\"center\">2</td><td align=\"center\">31</td><td align=\"center\">6</td><td align=\"center\">199</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">370</td><td align=\"center\">2</td></tr></tbody></table></body></html>", "text": "Pmid= 2438323:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Peak Changes in Physiological Variables in Response to Inhaled l-Methamphetamine, IV phenylephrine and IV l-methamphetamine.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Measure</td><td align=\"center\">16 Inhalations</td><td align=\"center\">32 Inhalations</td><td align=\"center\">64 Inhalations</td><td align=\"center\">PE<sub>1</sub></td><td align=\"center\">PE<sub>2</sub></td><td align=\"center\">IV l-Meth</td><td align=\"center\">Overall P-Value</td></tr></thead><tbody><tr><td align=\"center\">Systolic Blood Pressure (mmHg)</td><td align=\"center\">11.8 (16.2)<sup>&#8225;&#167;||</sup>**</td><td align=\"center\">12.3 (20.5)<sup>&#8225;&#167;||</sup>**</td><td align=\"center\">- 1.2 (16.0)</td><td align=\"center\">0.9 (10.1)</td><td align=\"center\">1.4 (9.8)</td><td align=\"center\">2.9 (9.3)</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Diastolic Blood Pressure (mmHg)</td><td align=\"center\">8.7 (8.9)<sup>||</sup>**</td><td align=\"center\">6.6 (9.9)<sup>||</sup></td><td align=\"center\">9.0 (12.4)<sup>||</sup>**</td><td align=\"center\">1.9 (8.3)</td><td align=\"center\">-2 (10.2)</td><td align=\"center\">7.4 (12.5)<sup>||</sup></td><td align=\"center\">0.04</td></tr><tr><td align=\"center\">Heart Rate (beats/min)</td><td align=\"center\">1.3 (12.3)</td><td align=\"center\">4.2 (19.2)</td><td align=\"center\">2.3 (14.3)</td><td align=\"center\">2.8 (9.7)</td><td align=\"center\">-4.2 (7.9)</td><td align=\"center\">- 0.33 (8.4)</td><td align=\"center\">0.62</td></tr><tr><td align=\"center\">Respiratory Rate (breaths/min)</td><td align=\"center\">0.17 (4.3)</td><td align=\"center\">3 (2.5)*<sup>&#167;||</sup>**</td><td align=\"center\">2.4 (3.5)<sup>&#167;||</sup></td><td align=\"center\">- 1.9 (4.8)</td><td align=\"center\">-1.5 (3.3)</td><td align=\"center\">0.42 (4.4)</td><td align=\"center\">0.003</td></tr><tr><td align=\"center\">Core Temperature (&#176;C)</td><td align=\"center\">0.13 (0.8)</td><td align=\"center\">- 0.32 (0.9)</td><td align=\"center\">0.21 (0.9)</td><td align=\"center\">- 0.19(0.6)</td><td align=\"center\">0.08 (0.4)</td><td align=\"center\">0.09 (0.2)</td><td align=\"center\">0.41</td></tr></tbody></table></body></html>", "text": "Pmid= 2496900:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Change in Cardiovascular Variables in Response to Exercise After Vicks Inhalation and IV l-Methamphetamine As Measured by Stress Echocardiography. Data presented as mean (SD).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Measure</td><td align=\"center\">16 Inhalations</td><td align=\"center\">32 Inhalations</td><td align=\"center\">64 Inhalations</td><td align=\"center\">IV l-Meth</td><td align=\"center\">Overall P-Value (time)</td><td align=\"center\">Overall P-Value (dose)</td></tr></thead><tbody><tr><td align=\"left\">Cardiac Output (l/min)</td><td align=\"center\">3.1 (2.0)</td><td align=\"center\">2.4 (2.2)</td><td align=\"center\">2.5 (2.5)</td><td align=\"center\">3.8 (2.3)</td><td align=\"center\">&lt; 0.001</td><td align=\"center\">0.10</td></tr><tr><td align=\"left\">Heart Rate (beats/min)</td><td align=\"center\">73.5 (26.7</td><td align=\"center\">66.3 (21.5)</td><td align=\"center\">64.5 (22.9)</td><td align=\"center\">76.9 (16.8)</td><td align=\"center\">&lt; 0.001</td><td align=\"center\">0.17</td></tr><tr><td align=\"left\">Systolic Blood Pressure (mmHg)</td><td align=\"center\">41.3 (18.7)</td><td align=\"center\">41.6 (42.6)</td><td align=\"center\">52.0 (13.9)</td><td align=\"center\">57.6 (11.6)</td><td align=\"center\">&lt; 0.001</td><td align=\"center\">0.35</td></tr><tr><td align=\"left\">Stroke Volume (ml)</td><td align=\"center\">3.3 (13.2)</td><td align=\"center\">2.5 (13.4)</td><td align=\"center\">2.1 (13.9)</td><td align=\"center\">-0.02 (7.3)</td><td align=\"center\">0.41</td><td align=\"center\">0.90</td></tr><tr><td align=\"left\">LV Internal Diameter (cm)</td><td align=\"center\">-2.6 (2.9)</td><td align=\"center\">-2.1 (3.5)</td><td align=\"center\">-1.8 (4.1)</td><td align=\"center\">-2.0 (4.6)</td><td align=\"center\">0.01</td><td align=\"center\">0.96</td></tr><tr><td align=\"left\">Ejection Fraction (%)</td><td align=\"center\">8.9 (5.8)</td><td align=\"center\">7.8 (7.6)</td><td align=\"center\">6.3 (6.4)</td><td align=\"center\">9.9 (6.5)</td><td align=\"center\">&lt; 0.001</td><td align=\"center\">0.62</td></tr><tr><td align=\"left\">Systolic Wall Stress(kdynes/cm<sup>2</sup>)</td><td align=\"center\">64.5 (62.8)</td><td align=\"center\">51.7 (61.6)</td><td align=\"center\">41.7 (79.3)</td><td align=\"center\">81.7 (90.6)</td><td align=\"center\">0.002</td><td align=\"center\">0.42</td></tr><tr><td align=\"left\">Posterior Wall Thickness (cm)</td><td align=\"center\">- 0.58 (1.4)</td><td align=\"center\">0.67 (1.3)</td><td align=\"center\">0.25 (0.97)</td><td align=\"center\">0.08 (1.5)</td><td align=\"center\">0.49</td><td align=\"center\">0.20</td></tr><tr><td align=\"left\">Septal Wall Thickness (mm)</td><td align=\"center\">0.08 (0.79)</td><td align=\"center\">0.08 (1.5)</td><td align=\"center\">2.0 (3.1)</td><td align=\"center\">0.25 (0.97)</td><td align=\"center\">0.05</td><td align=\"center\">0.04</td></tr></tbody></table></body></html>", "text": "Pmid= 2496900:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Change in Cardiovascular Variables in Response to Inhaler Condition and IV l-Methamphetamine as Measured by Impedance Cardiography.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Measure</td><td align=\"center\">16 Inhalations</td><td align=\"center\">32 Inhalations</td><td align=\"center\">64 Inhalations</td><td align=\"center\">IV l-Meth</td><td align=\"center\">Overall P-Value (time)</td><td align=\"center\">Overall P-Value (dose)</td></tr></thead><tbody><tr><td align=\"left\">Cardiac Output (l/min)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">15 minutes</td><td align=\"center\">-0.53 (0.66)</td><td align=\"center\">-0.46 (1.3)</td><td align=\"center\">-0.56 (0.52)</td><td align=\"center\">-0.01 (0.54)</td><td align=\"center\">0.02</td><td align=\"center\">0.67</td></tr><tr><td align=\"left\">2 Hours</td><td align=\"center\">0.0 (0.67)</td><td align=\"center\">0.05 (1.6)</td><td align=\"center\">0.31 (0.77)</td><td align=\"center\">0.28 (1.0)</td><td align=\"center\">0.32</td><td/></tr><tr><td align=\"left\">Heart Rate (beats/min)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">15 Minutes</td><td align=\"center\">-2.6 (4.9)</td><td align=\"center\">-2.1 (5.8)</td><td align=\"center\">-1.7 (5.9)</td><td align=\"center\">1.0 (5.8)</td><td align=\"center\">0.38</td><td align=\"center\">0.60</td></tr><tr><td align=\"left\">2 Hours</td><td align=\"center\">4.3 (6.0)</td><td align=\"center\">5.4 (11.3)</td><td align=\"center\">4.3 (7.7)</td><td align=\"center\">6.1 (9.5)</td><td align=\"center\">0.003</td><td/></tr><tr><td align=\"left\">Systolic Blood Pressure (mmHg)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">15 Minutes</td><td align=\"center\">1.0 (12.5)</td><td align=\"center\">-1.2 (6.6)</td><td align=\"center\">-3.0 (6.4)</td><td align=\"center\">4.8 (9.0)</td><td align=\"center\">0.76</td><td align=\"center\">0.09</td></tr><tr><td align=\"left\">2 Hours</td><td align=\"center\">1.8 (7.9)</td><td align=\"center\">-0.17 (7.0)</td><td align=\"center\">3.1 (6.9)</td><td align=\"center\">5.9 (6.9)</td><td align=\"center\">0.06</td><td/></tr><tr><td align=\"left\">Diastolic Blood Pressure (mmHg)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">15 Minutes</td><td align=\"center\">0.50 (7.5)</td><td align=\"center\">1.4 (6.7)</td><td align=\"center\">1.2 (6.4)</td><td align=\"center\">4.3 (8.8)</td><td align=\"center\">0.09</td><td align=\"center\">0.23</td></tr><tr><td align=\"left\">2 Hours</td><td align=\"center\">2.2 (4.2)</td><td align=\"center\">2.6 (6.5)</td><td align=\"center\">1.2 (4.9)</td><td align=\"center\">6.5 (8.1)</td><td align=\"center\">0.007</td><td/></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">Stroke Volume</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">15 Minutes</td><td align=\"center\">-3.9 (7.3)</td><td align=\"center\">-4.9 (16.0)</td><td align=\"center\">-6.0 (6.4)</td><td align=\"center\">-1.0 (5.4)</td><td align=\"center\">0.008</td><td align=\"center\">0.66</td></tr><tr><td align=\"left\">2 Hours</td><td align=\"center\">-5.4 (6.6)</td><td align=\"center\">-6.2 (17.5)</td><td align=\"center\">-1.6 (7.8)</td><td align=\"center\">-0.67 (6.4)</td><td align=\"center\">0.02</td><td/></tr><tr><td align=\"left\">Systemic Vascular Resistance (dynes*sec*cm<sup>5</sup>)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">15 Minutes</td><td align=\"center\">106.0 (168.9)</td><td align=\"center\">137.1 (388.5)</td><td align=\"center\">129.1 (169.5)</td><td align=\"center\">48.8 (112.7)</td><td align=\"center\">0.004</td><td align=\"center\">0.89</td></tr><tr><td align=\"left\">2 Hours</td><td align=\"center\">47.2 (140.2)</td><td align=\"center\">72.0 (441.7)</td><td align=\"center\">-10.2 (204.0)</td><td align=\"center\">12.3 (127.2)</td><td align=\"center\">0.36</td><td/></tr><tr><td align=\"left\">Left CardiacWork</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">15 Minutes</td><td align=\"center\">-0.51 (1.0)</td><td align=\"center\">-0.48 (1.6)</td><td align=\"center\">-0.59 (0.64)</td><td align=\"center\">0.44 (0.93)</td><td align=\"center\">0.21</td><td align=\"center\">0.12</td></tr><tr><td align=\"left\">2 Hours</td><td align=\"center\">0.22 (0.91)</td><td align=\"center\">0.23 (2.1)</td><td align=\"center\">0.53 (0.78)</td><td align=\"center\">1.1 (1.5)</td><td align=\"center\">0.03</td><td/></tr><tr><td align=\"left\">LV Ejection Time</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">15 Minutes</td><td align=\"center\">-0.75 (12.4)</td><td align=\"center\">-4.8 (16.4)</td><td align=\"center\">-12.4 (19.1)</td><td align=\"center\">-0.25 (10.4)</td><td align=\"center\">0.19</td><td align=\"center\">0.54</td></tr><tr><td align=\"left\">2 Hours</td><td align=\"center\">-11.8 (16.4)</td><td align=\"center\">-12.1 (26.8)</td><td align=\"center\">-11.8 (19.9)</td><td align=\"center\">-6.4 (26.5)</td><td align=\"center\">0.005</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2496900:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Peak Changes in VAS Subjective Variables in Response to Inhaled l-Methamphetamine, IV phenylephrine and IV l-methamphetamine.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Measure</td><td align=\"center\">16 Inhalations</td><td align=\"center\">32 Inhalations</td><td align=\"center\">64 Inhalations</td><td align=\"center\">PE<sub>1</sub></td><td align=\"center\">PE<sub>2</sub></td><td align=\"center\">IV l-Meth</td><td align=\"center\">Overall P-Value</td></tr></thead><tbody><tr><td align=\"left\">Any Drug Effect</td><td align=\"center\">9.0 (13.9)<sup>&#167;||</sup>**</td><td align=\"center\">7.3 (10.5)<sup>&#167;||</sup>**</td><td align=\"center\">9.8 (7.9)<sup>&#167;||&#182;</sup>**</td><td align=\"center\">1.5 (2.1)</td><td align=\"center\">1.7 (2.4)</td><td align=\"center\">4.5 (8.6)</td><td align=\"center\">0.001</td></tr><tr><td align=\"left\">Bad Drug Effect</td><td align=\"center\">6.8 (13.7)</td><td align=\"center\">2.8 (4.6)</td><td align=\"center\">4.9 (5.0)</td><td align=\"center\">0.33 (0.9)</td><td align=\"center\">1.1 (0.79)</td><td align=\"center\">5.3 (10.7)</td><td align=\"center\">0.07</td></tr><tr><td align=\"left\">Dizziness</td><td align=\"center\">9.3 (14.0)<sup>&#167;||&#182;</sup>**</td><td align=\"center\">6.5 (6.4)<sup>&#182;</sup>**</td><td align=\"center\">9.0 (13.5)<sup>&#167;||&#182;</sup>**</td><td align=\"center\">1.5 (2.9)</td><td align=\"center\">0.92 (2.2)</td><td align=\"center\">-0.67 (5.7)</td><td align=\"center\">0.004</td></tr><tr><td align=\"left\">Good Drug Effect</td><td align=\"center\">5.8 (13.0)<sup>||</sup>**</td><td align=\"center\">5.7 (10.5)**</td><td align=\"center\">9.7 (13.0)<sup>&#167;||&#182;</sup>**</td><td align=\"center\">0.42 (2.9)</td><td align=\"center\">0.25 (1.5)</td><td align=\"center\">2.7 (4.7)</td><td align=\"center\">0.005</td></tr><tr><td align=\"left\">Headache</td><td align=\"center\">5.1 (18.1)</td><td align=\"center\">4.8 (5.1)<sup>||</sup></td><td align=\"center\">12.7 (17.0)<sup>&#167;||&#182;</sup>**</td><td align=\"center\">-0.08 (1.7)</td><td align=\"center\">1.8 (3.3)</td><td align=\"center\">-3.8 (13.4)</td><td align=\"center\">0.02</td></tr><tr><td align=\"left\">Nasal Dryness</td><td align=\"center\">5.2 (16.2)</td><td align=\"center\">3.3 (9.6)</td><td align=\"center\">4.1 (9.9)</td><td align=\"center\">-0.75 (2.1)</td><td align=\"center\">-0.50 (1.7)</td><td align=\"center\">-0.42 (2.7)</td><td align=\"center\">0.20</td></tr><tr><td align=\"left\">Nasal Stuffiness</td><td align=\"center\">1.1 (16.9)</td><td align=\"center\">2.8 (4.8)</td><td align=\"center\">1.4 (6.7)</td><td align=\"center\">0.50 (4.4)</td><td align=\"center\">-1.6 (3.6)</td><td align=\"center\">0.42 (1.2)</td><td align=\"center\">0.88</td></tr></tbody></table></body></html>", "text": "Pmid= 2496900:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Treatments and Dosing Regimens</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Treatment</td><td align=\"center\">Number</td><td align=\"left\">Study medication</td><td align=\"center\">Water volume</td><td align=\"center\">Dosing time pre-meal</td></tr></thead><tbody><tr><td align=\"center\">1</td><td align=\"center\"><italic>n </italic>= 40</td><td align=\"left\">SMC021 0.8 mg</td><td align=\"center\">50 ml</td><td align=\"center\">10 min</td></tr><tr><td align=\"center\">2</td><td align=\"center\"><italic>n </italic>= 40</td><td align=\"left\">SMC021 0.8 mg</td><td align=\"center\">50 ml</td><td align=\"center\">30 min</td></tr><tr><td align=\"center\">3</td><td align=\"center\"><italic>n </italic>= 40</td><td align=\"left\">SMC021 0.8 mg</td><td align=\"center\">50 ml</td><td align=\"center\">60 min</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">4</td><td align=\"center\"><italic>n </italic>= 40</td><td align=\"left\">SMC021 0.8 mg</td><td align=\"center\">200 ml</td><td align=\"center\">10 min</td></tr><tr><td align=\"center\">5</td><td align=\"center\"><italic>n </italic>= 40</td><td align=\"left\">SMC021 0.8 mg</td><td align=\"center\">200 ml</td><td align=\"center\">30 min</td></tr><tr><td align=\"center\">6</td><td align=\"center\"><italic>n </italic>= 40</td><td align=\"left\">SMC021 0.8 mg</td><td align=\"center\">200 ml</td><td align=\"center\">60 min</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">7</td><td align=\"center\"><italic>n </italic>= 10</td><td align=\"left\">Placebo</td><td align=\"center\">200 ml</td><td align=\"center\">10 min</td></tr><tr><td align=\"center\">8</td><td align=\"center\"><italic>n </italic>= 10</td><td align=\"left\">Placebo</td><td align=\"center\">200 ml</td><td align=\"center\">30 min</td></tr><tr><td align=\"center\">9</td><td align=\"center\"><italic>n </italic>= 10</td><td align=\"left\">Placebo</td><td align=\"center\">200 ml</td><td align=\"center\">60 min</td></tr><tr><td align=\"center\">10</td><td align=\"center\"><italic>n </italic>= 10</td><td align=\"left\">Miacalcic<sup>&#174;</sup>200 IU NS</td><td align=\"center\">N/A</td><td align=\"center\">60 min</td></tr></tbody></table></body></html>", "text": "Pmid= 2551583:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of study population (</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\">Mean (SD)</td><td align=\"center\">Range</td></tr></thead><tbody><tr><td align=\"left\">Age (Yrs)</td><td align=\"center\">64.2 (3.5)</td><td align=\"center\">56 &#8211; 70</td></tr><tr><td align=\"left\">Height (m)</td><td align=\"center\">163.9 (5.9)</td><td align=\"center\">151 &#8211; 177</td></tr><tr><td align=\"left\">Weight (kg)</td><td align=\"center\">68.4 (7.8)</td><td align=\"center\">53.4 &#8211; 87.5</td></tr><tr><td align=\"left\">BMI (kg/m<sup>2</sup>)</td><td align=\"center\">25.5 (2.8)</td><td align=\"center\">20.1 &#8211; 30.1</td></tr></tbody></table></body></html>", "text": "Pmid= 2551583:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic profile</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Study medication</td><td align=\"center\">Water Volume</td><td align=\"center\">Dose pre-meal</td><td align=\"center\">AUC<sub>0&#8211;4 </sub>pg/ml &#215; hrs</td><td align=\"center\">C<sub>max </sub>pg/ml</td><td align=\"center\">T<sub>max </sub>minutes</td></tr></thead><tbody><tr><td align=\"left\">SMC021</td><td align=\"center\">50 ml</td><td align=\"center\">10 min</td><td align=\"center\">52.2 (46.0&#8211;59.4)</td><td align=\"center\">103 (89&#8211;118)</td><td align=\"center\">15 (10&#8211;23)</td></tr><tr><td align=\"left\">SMC021</td><td align=\"center\">50 ml</td><td align=\"center\">30 min</td><td align=\"center\">68.9 (60.2&#8211;78.9)</td><td align=\"center\">125 (110&#8211;144)</td><td align=\"center\">15 (15&#8211;30)</td></tr><tr><td align=\"left\">SMC021</td><td align=\"center\">50 ml</td><td align=\"center\">60 min</td><td align=\"center\">74.4 (64.0&#8211;86.5)</td><td align=\"center\">145 (125&#8211;168)</td><td align=\"center\">15 (15&#8211;30)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">SMC021</td><td align=\"center\">200 ml</td><td align=\"center\">10 min</td><td align=\"center\">27.4 (25.2&#8211;29.7)</td><td align=\"center\">52 (45&#8211;59)</td><td align=\"center\">15 (10&#8211;15)</td></tr><tr><td align=\"left\">SMC021</td><td align=\"center\">200 ml</td><td align=\"center\">30 min</td><td align=\"center\">32.9 (29.1&#8211;37.3)</td><td align=\"center\">56 (48&#8211;67)</td><td align=\"center\">15 (15&#8211;30)</td></tr><tr><td align=\"left\">SMC021</td><td align=\"center\">200 ml</td><td align=\"center\">60 min</td><td align=\"center\">33.6 (29.5&#8211;38.1)</td><td align=\"center\">49 (42&#8211;58)</td><td align=\"center\">15 (12.5&#8211;30)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Miacalcic</td><td align=\"center\">N/A</td><td align=\"center\">60 min</td><td align=\"center\">16.4 (13.8&#8211;19.4)</td><td align=\"center\">11.4 (8.3&#8211;15.5)</td><td align=\"center\">15 (10&#8211;15)</td></tr></tbody></table></body></html>", "text": "Pmid= 2551583:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Patient characteristics (N = 1,218)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">&#946;-blockers <break/>(n = 307)</td><td align=\"left\">Thiazide <break/>(n = 196)</td><td align=\"left\">CCBs <break/>(n = 322)</td><td align=\"left\">RAS <break/>(n = 55)</td><td align=\"left\">Others* <break/>(n = 338)</td><td align=\"left\">p value<break/></td></tr></thead><tbody><tr><td align=\"left\">Age (years)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&lt;50</td><td align=\"left\">85 (27.7)</td><td align=\"left\">38 (19.4)</td><td align=\"left\">74 (23.0)</td><td align=\"left\">9 (16.4)</td><td align=\"left\">58 (17.2)</td><td align=\"left\">&lt;0.001</td></tr><tr><td align=\"left\">50&#8211;59</td><td align=\"left\">113 (36.8)</td><td align=\"left\">62 (31.6)</td><td align=\"left\">87 (27.0)</td><td align=\"left\">22 (40.0)</td><td align=\"left\">84 (24.9)</td><td/></tr><tr><td align=\"left\">60&#8211;69</td><td align=\"left\">59 (19.2)</td><td align=\"left\">51 (26.0)</td><td align=\"left\">70 (21.7)</td><td align=\"left\">11 (20.0)</td><td align=\"left\">77 (22.8)</td><td/></tr><tr><td align=\"left\">&#8805; 70</td><td align=\"left\">50 (16.3)</td><td align=\"left\">45 (23.0)</td><td align=\"left\">91 (28.3)</td><td align=\"left\">13 (23.6)</td><td align=\"left\">119 (35.2)</td><td/></tr><tr><td align=\"left\">Mean Age</td><td align=\"left\">56.96</td><td align=\"left\">60.14</td><td align=\"left\">60.80</td><td align=\"left\">60.02</td><td align=\"left\">63.30</td><td align=\"left\">&lt;0.001</td></tr><tr><td align=\"left\">(SD)</td><td align=\"left\">(11.67)</td><td align=\"left\">(11.37)</td><td align=\"left\">(13.21)</td><td align=\"left\">(12.83)</td><td align=\"left\">(13.42)</td><td/></tr><tr><td align=\"left\">(95% CI)</td><td align=\"left\">(55.651,58.27)</td><td align=\"left\">(58.54, 61.74)</td><td align=\"left\">(59.36, 62.25)</td><td align=\"left\">(56.55, 63.49)</td><td align=\"left\">(61.87, 64.74)</td><td/></tr><tr><td align=\"left\">Gender (no./%)</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Female</td><td align=\"left\">200 (65.1)</td><td align=\"left\">124 (63.3)</td><td align=\"left\">168 (52.2)</td><td align=\"left\">33 (60.0)</td><td align=\"left\">189 (55.9)</td><td align=\"left\">0.008</td></tr><tr><td align=\"left\">Male</td><td align=\"left\">107 (34.9)</td><td align=\"left\">72 (36.7)</td><td align=\"left\">154 (47.8)</td><td align=\"left\">22 (40.0)</td><td align=\"left\">149 (44.1)</td><td/></tr><tr><td align=\"left\">Payment</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Fee-waivers</td><td align=\"left\">107 (34.9)</td><td align=\"left\">68 (34.7)</td><td align=\"left\">107 (33.2)</td><td align=\"left\">17 (30.9)</td><td align=\"left\">96 (28.4)</td><td align=\"left\">0.415</td></tr><tr><td align=\"left\">Payers</td><td align=\"left\">200 (65.1)</td><td align=\"left\">128 (65.3)</td><td align=\"left\">215 (66.8)</td><td align=\"left\">38 (69.1)</td><td align=\"left\">242 (71.6)</td><td/></tr><tr><td align=\"left\">District of residence</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Shatin</td><td align=\"left\">85 (27.7)</td><td align=\"left\">44 (22.4)</td><td align=\"left\">84 (26.1)</td><td align=\"left\">12 (21.8)</td><td align=\"left\">135 (39.9)</td><td align=\"left\">&lt;0.001</td></tr><tr><td align=\"left\">Taipo</td><td align=\"left\">31 (10.1)</td><td align=\"left\">13 (6.6)</td><td align=\"left\">52 (16.1)</td><td align=\"left\">5 (9.1)</td><td align=\"left\">37 (10.9)</td><td/></tr><tr><td align=\"left\">Northern</td><td align=\"left\">161 (52.8)</td><td align=\"left\">127 (64.8)</td><td align=\"left\">169 (52.5)</td><td align=\"left\">34 (61.8)</td><td align=\"left\">134 (39.6)</td><td/></tr><tr><td align=\"left\">Others</td><td align=\"left\">30 (9.4)</td><td align=\"left\">12 (6.1)</td><td align=\"left\">17 (5.3)</td><td align=\"left\">4 (7.3)</td><td align=\"left\">32 (9.5)</td><td/></tr><tr><td align=\"left\">Service type</td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">General</td><td align=\"left\">264 (86.0)</td><td align=\"left\">179 (91.3)</td><td align=\"left\">288 (89.4)</td><td align=\"left\">48 (87.3)</td><td align=\"left\">275 (81.4)</td><td align=\"left\">&lt;0.001</td></tr><tr><td align=\"left\">FMSC</td><td align=\"left\">29 (9.4)</td><td align=\"left\">7 (3.6)</td><td align=\"left\">27 (8.4)</td><td align=\"left\">4 (7.3)</td><td align=\"left\">56 (16.6)</td><td/></tr><tr><td align=\"left\">Staff clinic</td><td align=\"left\">14 (4.6)</td><td align=\"left\">10 (5.1)</td><td align=\"left\">7 (2.2)</td><td align=\"left\">3 (5.5)</td><td align=\"left\">7 (2.1)</td><td/></tr><tr><td align=\"left\">Glucose Profile</td><td align=\"left\">5.42</td><td align=\"left\">5.48</td><td align=\"left\">5.46</td><td align=\"left\">5.41</td><td align=\"left\">5.60</td><td align=\"left\">0.786</td></tr><tr><td align=\"left\">(mean &#177; 95% CI)</td><td align=\"left\">(5.34, 5.51)</td><td align=\"left\">(5.38, 5.59)</td><td align=\"left\">(5.37, 5.54)</td><td align=\"left\">(5.20, 5.61)</td><td align=\"left\">(5.52, 5.68)</td><td/></tr><tr><td align=\"left\">Period from drug prescription to blood taking (weeks)</td><td align=\"left\">7.43</td><td align=\"left\">7.00</td><td align=\"left\">7.79</td><td align=\"left\">6.71</td><td align=\"left\">8.00</td><td align=\"left\">0.054**</td></tr><tr><td align=\"left\">Median (IQR)</td><td align=\"left\">(5.86, 10.00)</td><td align=\"left\">(5.18, 8.96)</td><td align=\"left\">(5.57, 10.32)</td><td align=\"left\">(5.00, 10.00)</td><td align=\"left\">(6.00, 12.00)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2551584:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Patterns of glucose profiles by drug group (No./%)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">&#946;-blockers</td><td align=\"left\">Thiazide</td><td align=\"left\">CCBs</td><td align=\"left\">RAS</td><td align=\"left\">Others</td><td align=\"left\">P (&#967;<sup>2</sup>)</td></tr></thead><tbody><tr><td align=\"left\">Glucose (mmol/l)</td><td align=\"left\">(n = 280)</td><td align=\"left\">(n = 180)</td><td align=\"left\">(n = 291)</td><td align=\"left\">(n = 50)</td><td align=\"left\">(n = 296)</td><td/></tr><tr><td align=\"left\">Desirable (&#8804; 6.0)</td><td align=\"left\">236 (84.3)</td><td align=\"left\">153 (85.0)</td><td align=\"left\">253 (86.9)</td><td align=\"left\">42 (84.0)</td><td align=\"left\">229 (77.4)</td><td align=\"left\">0.849</td></tr><tr><td align=\"left\">Borderline (6.1&#8211;6.9)</td><td align=\"left\">35 (12.5)</td><td align=\"left\">22 (12.2)</td><td align=\"left\">28 (9.6)</td><td align=\"left\">5 (10.0)</td><td align=\"left\">59 (19.9)</td><td/></tr><tr><td align=\"left\">Adverse (&#8805; 7.0)</td><td align=\"left\">9 (3.2)</td><td align=\"left\">5 (2.8)</td><td align=\"left\">10 (3.4)</td><td align=\"left\">3 (6.0)</td><td align=\"left\">8 (2.7)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2551584:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>The crude hazard ratios of having above borderline and adverse glucose profiles for each antihypertensive drug group</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">Bivariate Analysis Crude Odds Ratios for above borderline results (95% C.I.) (&#8805; 6.1 mmol/l)</td><td align=\"left\">p value</td><td align=\"left\">Bivariate Analysis Crude Odds Ratios for adverse results (95% C.I.) (&#8805; 7.0 mmol/l)</td><td align=\"left\">p value</td></tr></thead><tbody><tr><td align=\"left\">(1). &#946;-blockers</td><td align=\"left\">0.881 (0.586, 1.323)</td><td align=\"left\">0.540</td><td align=\"left\">0.993 (0.459, 2.150)</td><td align=\"left\">0.986</td></tr><tr><td align=\"left\">(2). Thiazide Diuretics</td><td align=\"left\">0.860 (0.530, 1.397)</td><td align=\"left\">0.543</td><td align=\"left\">0.828 (0.316, 2.168)</td><td align=\"left\">0.700</td></tr><tr><td align=\"left\">(3). CCB</td><td align=\"left\">0.604 (0.390, 0.933)</td><td align=\"left\">0.022</td><td align=\"left\">1.043 (0.494, 2.204)</td><td align=\"left\">0.911</td></tr><tr><td align=\"left\">(4). RAS</td><td align=\"left\">0.720 (0.280, 1.850)</td><td align=\"left\">0.493</td><td align=\"left\">1.944 (0.572, 6.607)</td><td align=\"left\">0.278</td></tr></tbody></table></body></html>", "text": "Pmid= 2551584:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Factors associated with hyperglycemia with above borderline and adverse readings*</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\">Above Borderline readings</td><td align=\"center\" colspan=\"2\">Adverse readings</td></tr><tr><td/><td colspan=\"4\"><hr/></td></tr><tr><td/><td align=\"left\">Odds Ratios (95% CI)</td><td align=\"left\">p</td><td align=\"left\">Odds Ratios (95% CI)</td><td align=\"left\">p</td></tr></thead><tbody><tr><td align=\"left\">Age (years)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&lt;50</td><td align=\"left\">1.0 (ref)</td><td/><td align=\"left\">1.0 (ref)</td><td/></tr><tr><td align=\"left\">50&#8211;59</td><td align=\"left\">1.249 (0.648, 2.408)</td><td align=\"left\">0.506</td><td align=\"left\">1.776 (0.533, 5.919)</td><td align=\"left\">0.349</td></tr><tr><td align=\"left\">60&#8211;69</td><td align=\"left\">1.344 (0.654, 2.759)</td><td align=\"left\">0.421</td><td align=\"left\">0.784 (0.167, 3.685)</td><td align=\"left\">0.758</td></tr><tr><td align=\"left\">&#8805; 70</td><td align=\"left\">2.103 (1.051, 4.207)</td><td align=\"left\">0.036</td><td align=\"left\">1.359 (0.372, 4.962)</td><td align=\"left\">0.643</td></tr><tr><td align=\"left\">Gender</td><td/><td/><td/><td/></tr><tr><td align=\"left\">Male</td><td align=\"left\">1.0 (ref)</td><td/><td align=\"left\">1.0 (ref)</td><td/></tr><tr><td align=\"left\">Female</td><td align=\"left\">1.464 (0.927, 2.313)</td><td align=\"left\">0.102</td><td align=\"left\">0.223 (0.074, 0.674)</td><td align=\"left\">0.008</td></tr><tr><td align=\"left\">Payment status</td><td/><td/><td/><td/></tr><tr><td align=\"left\">Fee waiver</td><td align=\"left\">1.0 (ref)</td><td/><td align=\"left\">1.0 (ref)</td><td/></tr><tr><td align=\"left\">Fee payers</td><td align=\"left\">1.328 (0.789, 2.236)</td><td align=\"left\">0.286</td><td align=\"left\">0.759 (0.320, 1.798)</td><td align=\"left\">0.530</td></tr><tr><td align=\"left\">District of residence</td><td/><td/><td/><td/></tr><tr><td align=\"left\">Shatin</td><td align=\"left\">1.0 (ref)</td><td/><td align=\"left\">1.0 (ref)</td><td/></tr><tr><td align=\"left\">Taipo</td><td align=\"left\">0.967 (0.433, 2.156)</td><td align=\"left\">0.934</td><td align=\"left\">1.676 (0.588, 4.778)</td><td align=\"left\">0.334</td></tr><tr><td align=\"left\">North</td><td align=\"left\">0.707 (0.392, 1.273)</td><td align=\"left\">0.248</td><td align=\"left\">0.311 (0.115, 0.841)</td><td align=\"left\">0.021</td></tr><tr><td align=\"left\">Others</td><td align=\"left\">0.909 (0.363, 2.279)</td><td align=\"left\">0.839</td><td align=\"left\">N/A</td><td align=\"left\">N/A</td></tr><tr><td align=\"left\">Clinics</td><td/><td/><td/><td/></tr><tr><td align=\"left\">GOPC</td><td align=\"left\">1.0 (ref)</td><td/><td/><td/></tr><tr><td align=\"left\">FMSC</td><td align=\"left\">0.652 (0.234, 1.818)</td><td align=\"left\">0.414</td><td align=\"left\">0.299 (0.036, 2.507)</td><td align=\"left\">0.266</td></tr><tr><td align=\"left\">Staff clinics</td><td align=\"left\">2.071 (0.717, 5.984)</td><td align=\"left\">0.179</td><td align=\"left\">0.614 (0.066, 5.732)</td><td align=\"left\">0.668</td></tr><tr><td align=\"left\">Drug class</td><td/><td/><td/><td/></tr><tr><td align=\"left\">RAS</td><td align=\"left\">1.0 (ref)</td><td/><td align=\"left\">1.0 (ref)</td><td/></tr><tr><td align=\"left\">&#946;-blockers</td><td align=\"left\">1.360 (0.497, 3.721)</td><td align=\"left\">0.549</td><td align=\"left\">0.518 (0.125, 2.151)</td><td align=\"left\">0.365</td></tr><tr><td align=\"left\">Thiazide</td><td align=\"left\">1.252 (0.443, 3.537)</td><td align=\"left\">0.672</td><td align=\"left\">0.466 (0.099, 2.190)</td><td align=\"left\">0.334</td></tr><tr><td align=\"left\">CCB</td><td align=\"left\">0.888 (0.320, 2.463)</td><td align=\"left\">0.819</td><td align=\"left\">0.575 (0.140, 2.353)</td><td align=\"left\">0.441</td></tr></tbody></table></body></html>", "text": "Pmid= 2551584:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of doctors who returned a filled-in questionnaire.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td/><td align=\"center\">n (%)</td></tr></thead><tbody><tr><td align=\"left\">Male/female</td><td/><td align=\"center\">321/277 (54/46)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Type of organization</td><td align=\"left\">Publicly run multi-doctor-unit</td><td align=\"center\">486 (82)</td></tr><tr><td/><td align=\"left\">Privately run multi-doctor-unit</td><td align=\"center\">76 (13)</td></tr><tr><td/><td align=\"left\">Business of one\\'s own</td><td align=\"center\">32 (5)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Level of doctor competence</td><td align=\"left\">Specialist in primary health care</td><td align=\"center\">430 (72)</td></tr><tr><td/><td align=\"left\">Resident</td><td align=\"center\">100 (17)</td></tr><tr><td/><td align=\"left\">Intern</td><td align=\"center\">30 (5)</td></tr><tr><td/><td align=\"left\">Any other competence</td><td align=\"center\">40 (7)</td></tr></tbody></table></body></html>", "text": "Pmid= 2556993:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Use of the drug recommendations varies with both type of organization and level of competence.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">Prescribing of a drug for a new diagnosis</td><td align=\"left\">P-value*</td><td align=\"left\">Active change to a recommended drug upon renewal of a prescription</td><td align=\"left\">P-value*</td></tr></thead><tbody><tr><td align=\"left\">Publicly run units</td><td align=\"left\">80 (76&#8211;90)</td><td/><td align=\"left\">50 (20&#8211;70)</td><td/></tr><tr><td align=\"left\">Privately run units</td><td align=\"left\">80 (75&#8211;90)</td><td/><td align=\"left\">50 (20&#8211;79)</td><td/></tr><tr><td align=\"left\">Own business</td><td align=\"left\">65 (50&#8211;80)</td><td align=\"left\">0.0003</td><td align=\"left\">22 (11&#8211;50)</td><td align=\"left\">0.048</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Specialists</td><td align=\"left\">80 (75&#8211;90)</td><td/><td align=\"left\">50 (25&#8211;75)</td><td/></tr><tr><td align=\"left\">Residents</td><td align=\"left\">80 (72&#8211;90)</td><td/><td align=\"left\">30 (10&#8211;50)</td><td/></tr><tr><td align=\"left\">Interns</td><td align=\"left\">80 (55&#8211;90)</td><td align=\"left\">0.81</td><td align=\"left\">10 (0&#8211;28)</td><td align=\"left\">10<sup>-10</sup></td></tr></tbody></table></body></html>", "text": "Pmid= 2556993:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of participants</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Cisplatin</bold></td><td align=\"left\"><bold>Oxaliplatin</bold></td></tr></thead><tbody><tr><td align=\"left\">Gender (m/f)</td><td align=\"left\">13 m/7 f</td><td align=\"left\">20 m/5 f</td></tr><tr><td align=\"left\">Age at time of follow-up (median)</td><td align=\"left\">49 years</td><td align=\"left\">64 years</td></tr><tr><td align=\"left\">Duration of follow-up</td><td align=\"left\">18&#8211;75 months (median 41)</td><td align=\"left\">8&#8211;33 months (median 18)</td></tr><tr><td align=\"left\">Tumour type</td><td align=\"left\">Testicular carcinoma (9)</td><td align=\"left\">Colorectal carcinoma (25)</td></tr><tr><td/><td align=\"left\">Yolk sac carcinoma (1)</td><td/></tr><tr><td/><td align=\"left\">Non small cell lung cancer (1)</td><td/></tr><tr><td/><td align=\"left\">Small cell lung cancer (1)</td><td/></tr><tr><td/><td align=\"left\">Head and neck carcinoma (8)</td><td/></tr><tr><td align=\"left\">Cumulative dose</td><td align=\"left\">300&#8211;600 mg/m<sup>2 </sup>cisplatin (median 350)</td><td align=\"left\">585&#8211;1170 mg/m<sup>2 </sup>oxaliplatin (median 878)</td></tr><tr><td/><td align=\"left\">195&#8211;390 mg/m<sup>2 </sup>Pt</td><td align=\"left\">287&#8211;575 mg/m<sup>2 </sup>Pt</td></tr><tr><td/><td align=\"left\">(median 227)</td><td align=\"left\">(median 431)</td></tr><tr><td align=\"left\">Sodium thiosulfate</td><td align=\"left\">5 head and neck carcinoma patients treated intra-arterially with 600 mg/m<sup>2 </sup>cisplatin</td><td align=\"left\">NA</td></tr><tr><td align=\"left\">Ca/Mg infusion</td><td align=\"left\">NA</td><td align=\"left\">24/25</td></tr><tr><td align=\"left\">GSTM1</td><td align=\"left\">8/20 positive, 12/20 negative</td><td align=\"left\">10/25 positive, 15/25 negative</td></tr><tr><td align=\"left\">GSTT1</td><td align=\"left\">17/20 wildtype, 3/20 negative</td><td align=\"left\">21/25 positive, 4/25 negative</td></tr><tr><td align=\"left\">GSTP1</td><td align=\"left\">12/20<sup>105</sup>Ile/<sup>105</sup>Ile-<italic>GSTP1</italic></td><td align=\"left\">9/25<sup>105</sup>Ile/<sup>105</sup>Ile-<italic>GSTP1</italic></td></tr><tr><td/><td align=\"left\">7/20<sup>105</sup>Val/<sup>105</sup>Ile-<italic>GSTP1</italic></td><td align=\"left\">10/25<sup>105</sup>Val/<sup>105</sup>Ile-<italic>GSTP1</italic></td></tr><tr><td/><td align=\"left\">1/20<sup>105</sup>Val/<sup>105</sup>Val-<italic>GSTP1</italic></td><td align=\"left\">6/25<sup>105</sup>Val/<sup>105</sup>Val-<italic>GSTP1</italic></td></tr></tbody></table></body></html>", "text": "Pmid= 2559818:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Pt concentrations in eight pUF samples before and after storage</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Compound</bold></td><td align=\"center\"><bold>Percentage of plasma Pt recovered in pUF before storage</bold></td><td align=\"center\"><bold>Percentage of plasma Pt recovered in pUF after storage</bold></td><td align=\"center\"><bold>Days of storage</bold></td></tr></thead><tbody><tr><td align=\"left\">Cisplatin</td><td align=\"center\">19.4</td><td align=\"center\">8.1</td><td align=\"center\">278</td></tr><tr><td/><td align=\"center\">19.7</td><td align=\"center\">8.4</td><td align=\"center\">278</td></tr><tr><td/><td align=\"center\">15.1</td><td align=\"center\">5.5</td><td align=\"center\">276</td></tr><tr><td/><td align=\"center\">12.3</td><td align=\"center\">7.4</td><td align=\"center\">276</td></tr><tr><td align=\"left\">Oxaliplatin</td><td align=\"center\">27.8</td><td align=\"center\">21.2</td><td align=\"center\">180</td></tr><tr><td/><td align=\"center\">25.9</td><td align=\"center\">16</td><td align=\"center\">161</td></tr><tr><td/><td align=\"center\">22.9</td><td align=\"center\">15.8</td><td align=\"center\">157</td></tr><tr><td/><td align=\"center\">28.2</td><td align=\"center\">25.2</td><td align=\"center\">144</td></tr></tbody></table></body></html>", "text": "Pmid= 2559818:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pt concentrations in eight pUF samples with and without incubation with STS</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Compound</bold></td><td align=\"center\"><bold>Percentage of plasma Pt recovered in pUF</bold></td><td align=\"center\"><bold>Percentage of plasma Pt recovered in pUF after STS incubation</bold></td><td align=\"center\"><bold>Factor increase of Pt in pUF after STS incubation</bold></td></tr></thead><tbody><tr><td align=\"left\">Cisplatin</td><td align=\"center\">12.4</td><td align=\"center\">17.5</td><td align=\"center\">1.4-fold</td></tr><tr><td/><td align=\"center\">12.7</td><td align=\"center\">34.9</td><td align=\"center\">2.7-fold</td></tr><tr><td/><td align=\"center\">13.2</td><td align=\"center\">30.7</td><td align=\"center\">2.3-fold</td></tr><tr><td/><td align=\"center\">12.5</td><td align=\"center\">36.6</td><td align=\"center\">2.9-fold</td></tr><tr><td align=\"left\">Oxaliplatin</td><td align=\"center\">32.2</td><td align=\"center\">46.2</td><td align=\"center\">1.4-fold</td></tr><tr><td/><td align=\"center\">20</td><td align=\"center\">39.5</td><td align=\"center\">2.0-fold</td></tr><tr><td/><td align=\"center\">26.5</td><td align=\"center\">38.7</td><td align=\"center\">1.5-fold</td></tr><tr><td/><td align=\"center\">27.2</td><td align=\"center\">40.4</td><td align=\"center\">1.5-fold</td></tr></tbody></table></body></html>", "text": "Pmid= 2559818:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Frequency of review of medication charts on general medicine rounds</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\"><bold>No. of Patients Seen on Ward Round</bold></td><td align=\"center\"><bold>Frequency of Medication Chart Review</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Routine Ward Rounds</bold></td><td/><td/></tr><tr><td align=\"left\">A</td><td align=\"center\">7</td><td align=\"center\">100%</td></tr><tr><td align=\"left\">B</td><td align=\"center\">15</td><td align=\"center\">87%</td></tr><tr><td align=\"left\">C</td><td align=\"center\">8</td><td align=\"center\">87%</td></tr><tr><td align=\"left\">D</td><td align=\"center\">11</td><td align=\"center\">82%</td></tr><tr><td align=\"left\">E</td><td align=\"center\">6</td><td align=\"center\">67%</td></tr><tr><td align=\"left\">F</td><td align=\"center\">8</td><td align=\"center\">75%</td></tr><tr><td align=\"left\">G</td><td align=\"center\">11</td><td align=\"center\">73%</td></tr><tr><td align=\"left\">H</td><td align=\"center\">11</td><td align=\"center\">45%</td></tr><tr><td align=\"left\">Mean</td><td align=\"center\">10</td><td align=\"center\">77%</td></tr><tr><td/><td/><td/></tr><tr><td align=\"left\"><bold>Post Admission Rounds</bold></td><td/><td/></tr><tr><td align=\"left\">A</td><td align=\"center\">15</td><td align=\"center\">80%</td></tr><tr><td align=\"left\">B</td><td align=\"center\">12</td><td align=\"center\">67%</td></tr><tr><td align=\"left\">C</td><td align=\"center\">17</td><td align=\"center\">41%</td></tr><tr><td align=\"left\">D</td><td align=\"center\">17</td><td align=\"center\">76%</td></tr><tr><td align=\"left\">E</td><td align=\"center\">11</td><td align=\"center\">64%</td></tr><tr><td align=\"left\">F</td><td align=\"center\">17</td><td align=\"center\">76%</td></tr><tr><td align=\"left\">G</td><td align=\"center\">12</td><td align=\"center\">50%</td></tr><tr><td align=\"left\">H</td><td align=\"center\">21</td><td align=\"center\">67%</td></tr><tr><td align=\"left\">Mean</td><td align=\"center\">15</td><td align=\"center\">65%</td></tr></tbody></table></body></html>", "text": "Pmid= 2566971:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Frequency of review of medication charts on subspecialty ward rounds</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Specialty</bold></td><td align=\"center\"><bold>No. of Patients Seen on Ward Round</bold></td><td align=\"center\"><bold>Frequency of Medication Chart Review</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Haematology</bold></td><td/><td/></tr><tr><td align=\"left\">A</td><td align=\"center\">6</td><td align=\"center\">83%</td></tr><tr><td/><td align=\"center\">3</td><td align=\"center\">100%</td></tr><tr><td align=\"left\">B</td><td align=\"center\">3</td><td align=\"center\">100%</td></tr><tr><td/><td align=\"center\">8</td><td align=\"center\">75%</td></tr><tr><td align=\"left\">Mean</td><td align=\"center\">5</td><td align=\"center\">90%</td></tr><tr><td/><td/><td/></tr><tr><td align=\"left\"><bold>Liver Transplant</bold></td><td/><td/></tr><tr><td align=\"left\">A</td><td align=\"center\">5</td><td align=\"center\">100%</td></tr><tr><td align=\"left\">B</td><td align=\"center\">5</td><td align=\"center\">100%</td></tr><tr><td align=\"left\">C</td><td align=\"center\">4</td><td align=\"center\">75%</td></tr><tr><td align=\"left\">D</td><td align=\"center\">5</td><td align=\"center\">80%</td></tr><tr><td align=\"left\">E</td><td align=\"center\">5</td><td align=\"center\">80%</td></tr><tr><td align=\"left\">Mean</td><td align=\"center\">5</td><td align=\"center\">87%</td></tr><tr><td/><td/><td/></tr><tr><td align=\"left\"><bold>Gastroenterology</bold></td><td/><td/></tr><tr><td align=\"left\">A</td><td align=\"center\">11</td><td align=\"center\">45%</td></tr><tr><td align=\"left\">B</td><td align=\"center\">7</td><td align=\"center\">43%</td></tr><tr><td/><td align=\"center\">5</td><td align=\"center\">80%</td></tr><tr><td align=\"left\">C</td><td align=\"center\">10</td><td align=\"center\">50%</td></tr><tr><td/><td align=\"center\">9</td><td align=\"center\">44%</td></tr><tr><td align=\"left\">Mean</td><td align=\"center\">8</td><td align=\"center\">52%</td></tr><tr><td/><td/><td/></tr><tr><td align=\"left\"><bold>Cardiology</bold></td><td/><td/></tr><tr><td align=\"left\">A</td><td align=\"center\">13</td><td align=\"center\">61%</td></tr><tr><td align=\"left\">B</td><td align=\"center\">4</td><td align=\"center\">75%</td></tr><tr><td align=\"left\">Mean</td><td align=\"center\">8</td><td align=\"center\">68%</td></tr><tr><td/><td/><td/></tr><tr><td align=\"left\"><bold>Renal Medicine</bold></td><td/><td/></tr><tr><td align=\"left\">A</td><td align=\"center\">16</td><td align=\"center\">87%</td></tr></tbody></table></body></html>", "text": "Pmid= 2566971:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Summary table of randomised trials included in the review</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"4\"><bold>Number of:</bold></td><td align=\"center\" colspan=\"2\"><bold>Number of patients</bold></td><td/><td/></tr><tr><td/><td colspan=\"6\"><hr/></td><td/><td/></tr><tr><td align=\"left\"><bold>Pain condition</bold></td><td align=\"center\"><bold>Studies</bold></td><td align=\"center\"><bold>Studies with QS &#8805; 3/5</bold></td><td align=\"center\"><bold>Studies with OPVS &#8805; 9/16</bold></td><td align=\"center\"><bold>Trials of group size &#8805; 100</bold></td><td align=\"center\"><bold>In total</bold></td><td align=\"center\"><bold>Given dexketoprofen</bold></td><td align=\"center\"><bold>Better than placebo/total comparisons</bold></td><td align=\"center\"><bold>At least equivalent to effective analgesic/total comparisons</bold></td></tr></thead><tbody><tr><td align=\"left\">Dental pain</td><td align=\"center\">7</td><td align=\"center\">6</td><td align=\"center\">6</td><td align=\"center\">0</td><td align=\"center\">994</td><td align=\"center\">618</td><td align=\"center\">4/4</td><td align=\"center\">3/4</td></tr><tr><td align=\"left\">Postsurgical</td><td align=\"center\">13</td><td align=\"center\">11</td><td align=\"center\">11</td><td align=\"center\">2</td><td align=\"center\">2185</td><td align=\"center\">1022</td><td align=\"center\">7/7</td><td align=\"center\">11/11</td></tr><tr><td align=\"left\">Renal colic</td><td align=\"center\">3</td><td align=\"center\">3</td><td align=\"center\">3</td><td align=\"center\">3</td><td align=\"center\">838</td><td align=\"center\">526</td><td/><td align=\"center\">3/3</td></tr><tr><td align=\"left\">Gynaecologic pain</td><td align=\"center\">2</td><td align=\"center\">2</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">350</td><td align=\"center\">200</td><td align=\"center\">1/1</td><td align=\"center\">2/2</td></tr><tr><td align=\"left\">Lower limb injury</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">122</td><td align=\"center\">65</td><td/><td align=\"center\">1/1</td></tr><tr><td align=\"left\">Ankle sprain</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">209</td><td align=\"center\">106</td><td/><td align=\"center\">1/1</td></tr><tr><td align=\"left\">Acute bone pain in cancer</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">115</td><td align=\"center\">57</td><td/><td align=\"center\">1/1</td></tr><tr><td align=\"left\">Acute low back pain</td><td align=\"center\">5</td><td align=\"center\">5</td><td align=\"center\">5</td><td align=\"center\">3</td><td align=\"center\">1267</td><td align=\"center\">635</td><td/><td align=\"center\">5/5</td></tr><tr><td align=\"left\">OA/RA</td><td align=\"center\">2</td><td align=\"center\">2</td><td align=\"center\">2</td><td align=\"center\">0</td><td align=\"center\">300</td><td align=\"center\">152</td><td/><td align=\"center\">2/2</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Total</td><td align=\"center\">35</td><td align=\"center\">32</td><td align=\"center\">31</td><td align=\"center\">10</td><td align=\"center\">6380</td><td align=\"center\">3381</td><td align=\"center\">12/12</td><td align=\"center\">29/30</td></tr></tbody></table></body></html>", "text": "Pmid= 2585070:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Results of single dose trials in dental and postsurgical pain for comparison of dexketoprofen with placebo, and dexketoprofen with ketoprofen</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\" colspan=\"7\"><bold>Dexketoprofen versus placebo</bold></td></tr></thead><tbody><tr><td/><td align=\"center\" colspan=\"2\"><bold>Number of</bold></td><td align=\"center\" colspan=\"2\"><bold>Percent of patients with at least 50% pain relief</bold></td><td/><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/><td/></tr><tr><td align=\"left\"><bold>Dexketoprofen dose (mg)</bold></td><td align=\"center\"><bold>Trials</bold></td><td align=\"center\"><bold>Patients</bold></td><td align=\"center\"><bold>Dexketoprofen</bold></td><td align=\"center\"><bold>Placebo</bold></td><td align=\"center\"><bold>Relative benefit (95% CI)</bold></td><td align=\"center\"><bold>NNT (95% CI)</bold></td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\" colspan=\"7\"><bold>All trials</bold></td></tr><tr><td align=\"left\">10/12.5 mg</td><td align=\"center\">5</td><td align=\"center\">462</td><td align=\"center\">45</td><td align=\"center\">17</td><td align=\"center\">3.4 (2.2 to 5.6)</td><td align=\"center\">3.5 (2.7 to 4.9)</td></tr><tr><td align=\"left\">20/25 mg</td><td align=\"center\">5</td><td align=\"center\">455</td><td align=\"center\">50</td><td align=\"center\">17</td><td align=\"center\">3.9 (2.4 to 6.3)</td><td align=\"center\">3.0 (2.4 to 3.9)</td></tr><tr><td align=\"left\">50 mg</td><td align=\"center\">1</td><td align=\"center\">67</td><td align=\"center\">56</td><td align=\"center\">8</td><td align=\"center\">6.7 (1.7 to 26)</td><td align=\"center\">2.1 (1.5 to 3.5)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\" colspan=\"7\"><bold>Dental</bold></td></tr><tr><td align=\"left\">10/12.5 mg</td><td align=\"center\">3</td><td align=\"center\">261</td><td align=\"center\">47</td><td align=\"center\">13</td><td align=\"center\">3.5 (2.2 to 5.6)</td><td align=\"center\">3.0 (2.3 to 4.4)</td></tr><tr><td align=\"left\">20/25 mg</td><td align=\"center\">3</td><td align=\"center\">254</td><td align=\"center\">52</td><td align=\"center\">13</td><td align=\"center\">3.9 (2.4 to 6.3)</td><td align=\"center\">2.6 (2.0 to 3.5)</td></tr><tr><td align=\"left\">50 mg</td><td align=\"center\">1</td><td align=\"center\">67</td><td align=\"center\">56</td><td align=\"center\">8</td><td align=\"center\">6.7 (1.7 to 26)</td><td align=\"center\">2.1 (1.5 to 3.5)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\" colspan=\"7\"><bold>Postsurgical</bold></td></tr><tr><td align=\"left\">10/12.5 mg</td><td align=\"center\">2</td><td align=\"center\">201</td><td align=\"center\">43</td><td align=\"center\">21</td><td align=\"center\">2.1 (1.4 to 3.3)</td><td align=\"center\">4.4 (2.8 to 9.7)</td></tr><tr><td align=\"left\">20/25 mg</td><td align=\"center\">2</td><td align=\"center\">201</td><td align=\"center\">47</td><td align=\"center\">21</td><td align=\"center\">2.3 (1.5 to 3.6)</td><td align=\"center\">3.7 (2.5 to 7.0)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\" colspan=\"7\"><bold>Dexketoprofen versus ketoprofen</bold></td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"2\"><bold>Number of</bold></td><td align=\"center\" colspan=\"2\"><bold>Percent of patients with at least 50% pain relief</bold></td><td/><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/><td/></tr><tr><td align=\"left\"><bold>Dexketoprofen/ketoprofen dose (mg)</bold></td><td align=\"center\"><bold>Trials</bold></td><td align=\"center\"><bold>Patients</bold></td><td align=\"center\"><bold>Dexketoprofen</bold></td><td align=\"center\"><bold>Ketoprofen</bold></td><td align=\"center\"><bold>Relative benefit (95% CI)</bold></td><td align=\"center\"><bold>NNT (95% CI)</bold></td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\"><bold>All trials</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">12.5 vs 50</td><td align=\"center\">3</td><td align=\"center\">287</td><td align=\"center\">44</td><td align=\"center\">35</td><td align=\"center\">0.8 (0.5 to 1.2)</td><td align=\"center\">not calculated</td></tr><tr><td align=\"left\">25 vs 50</td><td align=\"center\">3</td><td align=\"center\">284</td><td align=\"center\">51</td><td align=\"center\">35</td><td align=\"center\">1.1 (0.7 to 1.5)</td><td align=\"center\">not calculated</td></tr><tr><td align=\"left\">50 vs 100</td><td align=\"center\">1</td><td align=\"center\">247</td><td align=\"center\">82</td><td align=\"center\">77</td><td align=\"center\">1.1 (0.9 to 1.2)</td><td align=\"center\">not calculated</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">25/50 vs 50/100</td><td align=\"center\">4</td><td align=\"center\">531</td><td align=\"center\">65</td><td align=\"center\">54</td><td align=\"center\">1.2 (1.1 to 1.4)</td><td align=\"center\">8.8 (5.1 to 33)</td></tr></tbody></table></body></html>", "text": "Pmid= 2585070:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Adverse event withdrawal rates in trials where at least two doses of drug were given</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\"><bold>Dental and postsurgical pain</bold></td><td align=\"center\" colspan=\"2\"><bold>Other acute, back pain, arthritis</bold></td></tr><tr><td/><td colspan=\"4\"><hr/></td></tr><tr><td align=\"center\"><bold>Drug</bold></td><td align=\"center\"><bold>Number of patients</bold></td><td align=\"center\"><bold>Adverse event withdrawal (%)</bold></td><td align=\"center\"><bold>Number of patients</bold></td><td align=\"center\"><bold>Adverse event withdrawal (%)</bold></td></tr></thead><tbody><tr><td align=\"left\">Placebo</td><td align=\"center\">236</td><td align=\"center\">2.5</td><td align=\"center\" colspan=\"2\">no data</td></tr><tr><td align=\"left\">Dexketoprofen</td><td align=\"center\">652</td><td align=\"center\">1.8</td><td align=\"center\">844</td><td align=\"center\">3.2</td></tr><tr><td align=\"left\">Ketoprofen</td><td align=\"center\">301</td><td align=\"center\">1.3</td><td align=\"center\">152</td><td align=\"center\">7.9</td></tr><tr><td align=\"left\">Diclofenac</td><td align=\"center\">80</td><td align=\"center\">0.0</td><td align=\"center\">272</td><td align=\"center\">3.7</td></tr><tr><td align=\"left\">Tramadol</td><td align=\"center\">72</td><td align=\"center\">1.4</td><td align=\"center\">247</td><td align=\"center\">9.7</td></tr><tr><td align=\"left\">Paracetamol + opioid</td><td align=\"center\">100</td><td align=\"center\">0.0</td><td align=\"center\">167</td><td align=\"center\">1.2</td></tr></tbody></table></body></html>", "text": "Pmid= 2585070:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline characteristics of the subjects</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><tbody><tr><td align=\"left\">Glucose (mmol/L)</td><td align=\"left\">5.5 &#177; 1.2</td></tr><tr><td align=\"left\">Insulin (pmol/L)</td><td align=\"left\">55.5 &#177; 46.9</td></tr><tr><td align=\"left\">HOMA</td><td align=\"left\">302 &#177; 259</td></tr><tr><td align=\"left\">Creatinine (mmol/L)</td><td align=\"left\">85 &#177; 17</td></tr><tr><td align=\"left\">C reactive protein (mg/dl)</td><td align=\"left\">2.7 &#177; 3.9</td></tr><tr><td align=\"left\">Fibrinogen (g/L)</td><td align=\"left\">3.3 &#177; 0.6</td></tr><tr><td align=\"left\">Weight (kg)</td><td align=\"left\">82.1 &#177; 12.8</td></tr><tr><td align=\"left\">Height (cm)</td><td align=\"left\">170.2 &#177; 9.8</td></tr><tr><td align=\"left\">Body mass index</td><td align=\"left\">28.5 &#177; 4.2</td></tr><tr><td align=\"left\">Lipid profile</td><td/></tr><tr><td align=\"left\">Total Cholesterol (mmol/L)</td><td align=\"left\">6.7 &#177; 1.3</td></tr><tr><td align=\"left\">LDL-C (mmol/L)</td><td align=\"left\">4.4 &#177; 1.1</td></tr><tr><td align=\"left\">HDL-C (mmol/L)</td><td align=\"left\">1.1 &#177; 0.4</td></tr><tr><td align=\"left\">Triglycerides (mmol/L)</td><td align=\"left\">2.6 &#177; 1.4</td></tr><tr><td align=\"left\">ApoB (g/L)</td><td align=\"left\">1.4 &#177; 0.3</td></tr></tbody></table></body></html>", "text": "Pmid= 2586010:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>described the study design in the 3 parts with the time of meal and dosing of oral calcitonin.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\" colspan=\"13\">Study Design: Timing of Dosing and Meal Intake</td></tr></thead><tbody><tr><td/><td align=\"center\">08:00</td><td align=\"center\">09:00</td><td align=\"center\">13:00</td><td align=\"center\">17:00</td><td align=\"center\">18:00</td><td align=\"center\">22:00</td><td align=\"center\">08:00</td><td align=\"center\">09:00</td><td align=\"center\">13:00</td><td align=\"center\">17:00</td><td align=\"center\">18:00</td><td align=\"center\">22:00</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"left\">Part 1 Morning Dosing</td><td align=\"center\">Dose</td><td align=\"center\">Meal</td><td align=\"center\">Meal</td><td align=\"center\">-</td><td align=\"center\">Meal</td><td align=\"center\">-</td><td align=\"center\">End</td><td align=\"center\">x</td><td align=\"center\">x</td><td align=\"center\">x</td><td align=\"center\">x</td><td align=\"center\">x</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"left\">Part 2 Pre-dinner Dosing</td><td align=\"center\">x</td><td align=\"center\">x</td><td align=\"center\">Meal</td><td align=\"center\">Dose</td><td align=\"center\">Meal</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">Meal</td><td align=\"center\">Meal</td><td align=\"center\">End</td><td align=\"center\">x</td><td align=\"center\">x</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"left\">Part 3 Evening Dosing</td><td align=\"center\">x</td><td align=\"center\">x</td><td align=\"center\">x</td><td align=\"center\">x</td><td align=\"center\">Meal</td><td align=\"center\">Dose</td><td align=\"center\">-</td><td align=\"center\">Meal</td><td align=\"center\">Meal</td><td align=\"center\">-</td><td align=\"center\">Meal</td><td align=\"center\">End</td></tr></tbody></table></body></html>", "text": "Pmid= 2611964:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Age characteristics of study population</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\">Part 1<break/><italic>n </italic>= 42<break/>Morning Dosing</td><td align=\"center\">Part 2<break/><italic>n </italic>= 20<break/>Pre-Dinner Dosing</td><td align=\"center\">Part 3<break/><italic>n </italic>= 19<break/>Evening Dosing</td></tr></thead><tbody><tr><td align=\"left\">Age (years)</td><td align=\"center\">65.5 (3.8)</td><td align=\"center\">64.6 (4.2)</td><td align=\"center\">64.4 (2.9)</td></tr></tbody></table></body></html>", "text": "Pmid= 2611964:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic profile</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\">Part 1<break/><italic>n </italic>= 42<break/>Morning dosing</td><td align=\"center\">Part 2<break/><italic>n </italic>= 20<break/>Pre-dinner dosing</td><td align=\"center\">Part 3<break/><italic>n </italic>= 19<break/>Evening dosing</td></tr></thead><tbody><tr><td align=\"left\">C<sub>max </sub>(pg/ml)</td><td align=\"center\">45.1 (39.1&#8211;52.0)</td><td align=\"center\">44.7 (31.8&#8211;62.9)</td><td align=\"center\">23.8 (16.9&#8211;33.5)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">T<sub>max </sub>(minutes)</td><td align=\"center\">30 (15&#8211;30)</td><td align=\"center\">30 (15&#8211;30)</td><td align=\"center\">30 (30&#8211;33.8)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">AUC<sub>0&#8211;4 hrs</sub></td><td align=\"center\">30.6 (27.2&#8211;34.4)</td><td align=\"center\">36.3 (28.6&#8211;46.1)</td><td align=\"center\">28.1 (21.6&#8211;36.6)</td></tr></tbody></table></body></html>", "text": "Pmid= 2611964:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Subject demographics by treatment allocation</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\"><bold>Panel A</bold></td><td align=\"center\" colspan=\"2\"><bold>Panel B</bold></td><td align=\"center\" colspan=\"2\"><bold>Panel C</bold></td></tr></thead><tbody><tr><td/><td align=\"center\"><bold>Category</bold></td><td align=\"center\"><bold>AVI-014 4 &#956;g/kg</bold></td><td align=\"center\"><bold>AVI-014 4 &#956;g/kg</bold></td><td align=\"center\"><bold>Filgrastim 4 &#956;g/kg</bold></td><td align=\"center\"><bold>AVI-014 8 &#956;g/kg</bold></td><td align=\"center\"><bold>Filgrastim 8 &#956;g/kg</bold></td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td/><td align=\"center\">n</td><td align=\"center\">8</td><td align=\"center\">8</td><td align=\"center\">8</td><td align=\"center\">8</td><td align=\"center\">8</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">Race n (%)</td><td align=\"center\">White</td><td align=\"center\">4 (50.0)</td><td align=\"center\">2 (25.0)</td><td align=\"center\">3 (37.5)</td><td align=\"center\">3 (37.5)</td><td align=\"center\">1 (12.5)</td></tr><tr><td/><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">Black</td><td align=\"center\">4 (50.0)</td><td align=\"center\">6 (75.0)</td><td align=\"center\">5 (62.5)</td><td align=\"center\">5 (62.5)</td><td align=\"center\">7 (87.5)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">Gender n (%)</td><td align=\"center\">Male</td><td align=\"center\">7 (87.5)</td><td align=\"center\">5 (62.5)</td><td align=\"center\">4 (50.0)</td><td align=\"center\">5 (62.5)</td><td align=\"center\">8 (100.0)</td></tr><tr><td/><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">Female</td><td align=\"center\">1 (12.5)</td><td align=\"center\">3 (37.5)</td><td align=\"center\">4 (50.0)</td><td align=\"center\">3 (37.5)</td><td align=\"center\">0 (0.0)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">Age (years)</td><td align=\"center\">Mean (SD)</td><td align=\"center\">33.6 (7.8)</td><td align=\"center\">35.4 (6.6)</td><td align=\"center\">30.3 (5.1)</td><td align=\"center\">33.8 (5.7)</td><td align=\"center\">39.6 (7.3)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">Weight (kg)</td><td align=\"center\">Mean (SD)</td><td align=\"center\">78.3 (10.4)</td><td align=\"center\">81.2 (12.1)</td><td align=\"center\">79.4 (7.9)</td><td align=\"center\">76.3 (6.1)</td><td align=\"center\">90.6 (11.9)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">Height (cm)</td><td align=\"center\">Mean (SD)</td><td align=\"center\">177 (11)</td><td align=\"center\">175 (8)</td><td align=\"center\">170 (10)</td><td align=\"center\">173 (5)</td><td align=\"center\">181 (4)</td></tr></tbody></table></body></html>", "text": "Pmid= 2639539:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic parameters by treatment and dose level</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Treatment</td><td align=\"center\">Dose</td><td align=\"center\">N</td><td align=\"center\">Cmax</td><td align=\"center\">AUC<sub>(0&#8211;72)</sub></td><td align=\"center\">AUC<sub>(0-&#8734;)</sub></td><td align=\"center\">Clearance</td><td align=\"center\">Terminal elimination half life</td><td align=\"center\">Estimated Alpha half life</td><td align=\"center\">Volume of distribution</td><td align=\"center\">Volume of distribution</td><td align=\"center\">Tmax*</td></tr></thead><tbody><tr><td/><td align=\"center\">mcg/kg</td><td/><td align=\"center\">pg/mL</td><td align=\"center\">hr*pg/mL</td><td align=\"center\">hr*pg/mL</td><td align=\"center\">mL/min</td><td align=\"center\">hr</td><td align=\"center\">hr</td><td align=\"center\">L</td><td align=\"center\">L/kg</td><td align=\"center\">hr</td></tr><tr><td colspan=\"12\"><hr/></td></tr><tr><td align=\"center\">AVI-014</td><td align=\"center\">4</td><td align=\"center\">16</td><td align=\"center\">16,944 <italic>(5,804)</italic></td><td align=\"center\">138,993 <italic>(48,262)</italic></td><td align=\"center\">139,818 <italic>(48,332)</italic></td><td align=\"center\">43 <italic>(18)</italic></td><td align=\"center\">15.1 <italic>(3.6)</italic></td><td align=\"center\">3.4 <italic>(0.5)</italic></td><td align=\"center\">58 <italic>(33)</italic></td><td align=\"center\">0.73 <italic>(0.37)</italic></td><td align=\"center\">4.5</td></tr><tr><td colspan=\"12\"><hr/></td></tr><tr><td align=\"center\">Filgrastim</td><td align=\"center\">4</td><td align=\"center\">8</td><td align=\"center\">22,595 <italic>(6,076)</italic></td><td align=\"center\">175,323 <italic>(50,665)</italic></td><td align=\"center\">176,145 <italic>(51,004)</italic></td><td align=\"center\">32 <italic>(8)</italic></td><td align=\"center\">14.7 (<italic>3.9)</italic></td><td align=\"center\">2.8 <italic>(0.6)</italic></td><td align=\"center\">42 <italic>(19)</italic></td><td align=\"center\">0.54 <italic>(0.27)</italic></td><td align=\"center\">5</td></tr><tr><td colspan=\"12\"><hr/></td></tr><tr><td align=\"center\">AVI-014</td><td align=\"center\">8</td><td align=\"center\">8</td><td align=\"center\">31,460 <italic>(7,927)</italic></td><td align=\"center\">312,569 <italic>(81,029)</italic></td><td align=\"center\">313,525 <italic>(81,043)</italic></td><td align=\"center\">35 <italic>(11)</italic></td><td align=\"center\">11.0 <italic>(2.2)</italic></td><td align=\"center\">3.7 <italic>(0.3)</italic></td><td align=\"center\">35 <italic>(18)</italic></td><td align=\"center\">0.45 <italic>(0.23)</italic></td><td align=\"center\">5</td></tr><tr><td colspan=\"12\"><hr/></td></tr><tr><td align=\"center\">Filgrastim</td><td align=\"center\">8</td><td align=\"center\">8</td><td align=\"center\">41,442 <italic>(9,986)</italic></td><td align=\"center\">347,053 <italic>(70,749)</italic></td><td align=\"center\">347,489 <italic>(70,698)</italic></td><td align=\"center\">36 <italic>(10)</italic></td><td align=\"center\">9.8 <italic>(2.3)</italic></td><td align=\"center\">3.1 <italic>(0.5)</italic></td><td align=\"center\">31 <italic>(15)</italic></td><td align=\"center\">0.35 <italic>(0.14)</italic></td><td align=\"center\">6</td></tr></tbody></table></body></html>", "text": "Pmid= 2639539:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic geometric mean ratios of AVI-014/filgrastim at 4 g/kg</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">PK parameter</td><td align=\"center\">Dose mcg/kg</td><td align=\"center\">Geo Mean AVI-014 (n = 16)</td><td align=\"center\">Geo Mean Filgrastin (n = 8)</td><td align=\"center\">P value</td><td align=\"center\">Geo Mean Ratio (90% CI)</td></tr></thead><tbody><tr><td align=\"center\">AUC<sub>(0&#8211;72)</sub></td><td align=\"center\">4</td><td align=\"center\">169.545</td><td align=\"center\">170,259</td><td align=\"center\">0.9766</td><td align=\"center\">1.00 (0.76, 1.31)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Cmax</td><td align=\"center\">4</td><td align=\"center\">18,830</td><td align=\"center\">21,855</td><td align=\"center\">0.2952</td><td align=\"center\">0.86 (0.66, 1.13)</td></tr></tbody></table></body></html>", "text": "Pmid= 2639539:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic Geometric Mean ratios of AVI-014/Filgrastim at 8 g/kg</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>PK parameter</bold></td><td align=\"center\"><bold>Dose &#956;g/kg</bold></td><td align=\"center\"><bold>Geometric Mean AVI-014 (n = 8)</bold></td><td align=\"center\"><bold>Geometric Mean Filgrastin (n = 8)</bold></td><td align=\"center\"><bold>P value</bold></td><td align=\"center\"><bold>Geometric Mean Ratio (90% CI)</bold></td></tr></thead><tbody><tr><td align=\"center\">AUC<sub>(0&#8211;72)</sub></td><td align=\"center\">8</td><td align=\"center\">301,979</td><td align=\"center\">340,837</td><td align=\"center\">0.3669</td><td align=\"center\">0.89 (0.69, 1.14)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Cmax</td><td align=\"center\">8</td><td align=\"center\">30,467</td><td align=\"center\">40,325</td><td align=\"center\">0.0550</td><td align=\"center\">0.76 (0.58, 0.98)</td></tr></tbody></table></body></html>", "text": "Pmid= 2639539:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacodynamic geometric mean ratios of AVI-014/filgrastim at 4 g/kg</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Hematologic</bold></td><td align=\"center\"><bold>Parameter</bold></td><td align=\"center\"><bold>Dose &#956;g/kg</bold></td><td align=\"center\"><bold>Geometric Mean AVI-014 (n = 8)</bold></td><td align=\"center\"><bold>Geometric Mean Filgrastin (n = 8)</bold></td><td align=\"center\"><bold>P value</bold></td><td align=\"center\"><bold>Geometric Mean Ratio (90% CI)</bold></td></tr></thead><tbody><tr><td align=\"center\">WBC</td><td align=\"center\">AUC<sub>(0&#8211;9)</sub></td><td align=\"center\">4</td><td align=\"center\">1343.9</td><td align=\"center\">1193.6</td><td align=\"center\">0.1473</td><td align=\"center\">1.13 (0.98, 1.29)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td/><td align=\"center\">Cmax</td><td align=\"center\">4</td><td align=\"center\">375.1</td><td align=\"center\">326.7</td><td align=\"center\">0.1737</td><td align=\"center\">1.15 (0.97, 1.36)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">ANC</td><td align=\"center\">AUC<sub>(0&#8211;9)</sub></td><td align=\"center\">4</td><td align=\"center\">2146.3</td><td align=\"center\">1560.3</td><td align=\"center\">0.0489</td><td align=\"center\">1.38 (1.06, 1.78)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td/><td align=\"center\">Cmax</td><td align=\"center\">4</td><td align=\"center\">735.9</td><td align=\"center\">515.8</td><td align=\"center\">0.0690</td><td align=\"center\">1.43 (1.04, 1.96)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">CD 34+</td><td align=\"center\">AUC<sub>(0&#8211;6)</sub></td><td align=\"center\">4</td><td align=\"center\">3208.8</td><td align=\"center\">3088.9</td><td align=\"center\">0.9613</td><td align=\"center\">1.04 (0.27, 4.06)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td/><td align=\"center\">Cmax</td><td align=\"center\">4</td><td align=\"center\">1322.7</td><td align=\"center\">1186.3</td><td align=\"center\">0.8875</td><td align=\"center\">1.12 (0.29, 4.24)</td></tr></tbody></table></body></html>", "text": "Pmid= 2639539:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacodynamic geometric mean ratios of AVI-014/filgrastim at 8 g/kg</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Hematologic</bold></td><td align=\"center\"><bold>Parameter</bold></td><td align=\"center\"><bold>Dose &#956;g/kg</bold></td><td align=\"center\"><bold>Geometric Mean AVI-014 (n = 8)</bold></td><td align=\"center\"><bold>Geometric Mean Filgrastin (n = 8)</bold></td><td align=\"center\"><bold>P value</bold></td><td align=\"center\"><bold>Geometric Mean Ratio (90% CI)</bold></td></tr></thead><tbody><tr><td align=\"center\">WBC</td><td align=\"center\">AUC<sub>(0&#8211;9)</sub></td><td align=\"center\">8</td><td align=\"center\">1444.7</td><td align=\"center\">1574.1</td><td align=\"center\">0.3824</td><td align=\"center\">0.92 (0.78, 1.09)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td/><td align=\"center\">Cmax</td><td align=\"center\">8</td><td align=\"center\">415.9</td><td align=\"center\">435.7</td><td align=\"center\">0.6617</td><td align=\"center\">0.95 (0.79, 1.15)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">ANC</td><td align=\"center\">AUC<sub>(0&#8211;9)</sub></td><td align=\"center\">8</td><td align=\"center\">1974.4</td><td align=\"center\">2268.9</td><td align=\"center\">0.4626</td><td align=\"center\">0.87 (0.63, 1.21)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td/><td align=\"center\">Cmax</td><td align=\"center\">8</td><td align=\"center\">661.3</td><td align=\"center\">739.6</td><td align=\"center\">0.6230</td><td align=\"center\">0.89 (0.60, 1.34)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\">CD 34+</td><td align=\"center\">AUC<sub>(0&#8211;6)</sub></td><td align=\"center\">8</td><td align=\"center\">3121.6</td><td align=\"center\">2791.2</td><td align=\"center\">0.8785</td><td align=\"center\">1.12 (0.31, 3.99)</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td/><td align=\"center\">Cmax</td><td align=\"center\">8</td><td align=\"center\">1373.2</td><td align=\"center\">1315.9</td><td align=\"center\">0.9569</td><td align=\"center\">1.04 (0.26, 4.11)</td></tr></tbody></table></body></html>", "text": "Pmid= 2639539:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Source and batch of antibiotics included in the study</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Product Code</bold></td><td align=\"left\"><bold>Batch</bold></td><td align=\"left\"><bold>Manufacturer</bold></td><td align=\"left\"><bold>Distributor</bold></td></tr></thead><tbody><tr><td align=\"left\">AMK-BMS (innovator)</td><td align=\"left\">01J115</td><td align=\"left\">Bristol-Myers Squibb (BMS), Guayaquil, Ecuador</td><td align=\"left\">Bristol-Myers Squibb, Cali, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">AMK-Carlon</td><td align=\"left\">278V0704</td><td align=\"left\">Carlon Ltda, Bogota, Colombia</td><td align=\"left\">Item</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">AMK-Gencol</td><td align=\"left\">0200</td><td align=\"left\">Laboratorios Chalver, Bogota, Colombia</td><td align=\"left\">Genericos de Colombia (Gencol), Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">AMK-Pisa</td><td align=\"left\">121859</td><td align=\"left\">Laboratorios Pisa SA de CV, Guadalajara, Mexico</td><td align=\"left\">Laboratorios ECAR Ltda, Medellin, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">AMK-Scalpi</td><td align=\"left\">AK010348</td><td align=\"left\">Consorcio Farmionni-Lubelca, Bogota, Colombia</td><td align=\"left\">Farmionni Scalpi SA, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">AMK-Sigma (Reference Powder)</td><td align=\"left\">120K1643</td><td align=\"left\">Sigma Chemical Co, St Louis, MO, USA</td><td align=\"left\">Not applicable</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-SP (innovator)</td><td align=\"left\">CB3AMKB04</td><td align=\"left\">Schering-Plough SA (SP), Bogota, Colombia</td><td align=\"left\">Item</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Abbott</td><td align=\"left\">75-024-DK</td><td align=\"left\">Abbott Laboratories, North Chicago, IL, USA</td><td align=\"left\">Not available</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Az pharma</td><td align=\"left\">303030</td><td align=\"left\">Vitrofarma SA, Bogota DC, Colombia</td><td align=\"left\">AZ-Pharma SA, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Biochemie</td><td align=\"left\">07102321</td><td align=\"left\">Biochemie GmbH, Kundl, Austria</td><td align=\"left\">Novartis de Colombia SA, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Biogenta</td><td align=\"left\">0402</td><td align=\"left\">Laboratorios Chalver, Bogot&#225;, Colombia</td><td align=\"left\">Chalver Farmaceutica (Biogenta), Bogota Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Colmed</td><td align=\"left\">01005</td><td align=\"left\">Colmed Internacional, Barranquilla, Colombia</td><td align=\"left\">Procaps SA, Barranquilla, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Genfar</td><td align=\"left\">030703</td><td align=\"left\">Viteco SA, Bogota, Colombia</td><td align=\"left\">Lab. Genericos Farmaceuticos, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Lab America</td><td align=\"left\">0980303</td><td align=\"left\">Arbofarma SA, Bogota, Colombia</td><td align=\"left\">Laboratorios America SA, Medellin, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Labinco</td><td align=\"left\">01013C</td><td align=\"left\">Laboratorios Ryan, Bogota, Colombia</td><td align=\"left\">Laboratorio Internacional (Labinco), Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-La Sante</td><td align=\"left\">0310</td><td align=\"left\">Viteco SA, Bogota, Colombia</td><td align=\"left\">Laboratorios La Sante, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Memphis</td><td align=\"left\">2208I101</td><td align=\"left\">Vitrofarma SA, Bogota, Colombia</td><td align=\"left\">Memphis products SA, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-MK</td><td align=\"left\">3P066</td><td align=\"left\">Vitrofarma SA, Bogota, Colombia</td><td align=\"left\">Tecnoquimica SA (MK), Cali Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Ophalac</td><td align=\"left\">004013</td><td align=\"left\">Vitrofarma SA, Bogota, Colombia</td><td align=\"left\">Laboratorios Farmaceuticos Ophalac, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Pentacoop</td><td align=\"left\">33544</td><td align=\"left\">Laboratorios Ryan, Bogota, Colombia</td><td align=\"left\">Pentacoop SA, Bogota DC, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Recipe</td><td align=\"left\">301094</td><td align=\"left\">Vitrofarma SA, Bogota, Colombia</td><td align=\"left\">Linea Recipe<sup>&#174; </sup>of Laboratorios Bussi&#233; SA, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Scalpi</td><td align=\"left\">GE020619</td><td align=\"left\">Consorcio Farmionni-Lubelca, Bogota, Colombia</td><td align=\"left\">Farmionni Scalpi SA, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">GNT-Sigma (Reference Powder)</td><td align=\"left\">10k1510</td><td align=\"left\">Sigma Chemical Co, St Louis, MO, USA</td><td align=\"left\">Not applicable</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">VAN-Lilly (Innovator)</td><td align=\"left\">A014744</td><td align=\"left\">Eli Lilly &amp; Compa&#241;ia de Mexico, Mexico</td><td align=\"left\">Eli Lilly Interamericana Inc., Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">VAN-Abbott</td><td align=\"left\">03703Z7</td><td align=\"left\">Abbott Laboratories, Chicago, IL, USA</td><td align=\"left\">Abbott Laboratories de Colombia, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">VAN-APP</td><td align=\"left\">120740</td><td align=\"left\">American Pharmaceutical Partners (APP), LA, USA</td><td align=\"left\">Comedica Ltda., Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">VAN-Proclin</td><td align=\"left\">6679</td><td align=\"left\">Laboratorios Northia S.A.C.I.F.I.A, Argentina</td><td align=\"left\">Proclin Pharma SA, Bogota, Colombia</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">VAN-USP</td><td align=\"left\">70900L</td><td align=\"left\">United States Pharmacopeia (USP), Rockville, MD, USA</td><td align=\"left\">Not applicable</td></tr></tbody></table></body></html>", "text": "Pmid= 2640365:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Potency estimate and parameters derived from linear regression with their statistical comparison of generics versus innovator by Curve Fitting Analysis</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Product</bold></td><td align=\"center\"><bold>r</bold><sup>2</sup></td><td align=\"center\"><bold>Intercept [95% CI]</bold></td><td align=\"center\"><bold>P-value</bold></td><td align=\"center\"><bold>Slope [95% CI]</bold></td><td align=\"center\"><bold>P-value</bold></td><td align=\"center\"><bold>Potency Estimate (%)</bold></td></tr></thead><tbody><tr><td align=\"left\">AMK-BMS</td><td align=\"center\">0.99</td><td align=\"center\">9.006 [8.646 to 9.366]</td><td align=\"center\">0.8799</td><td align=\"center\">3.884 [3.619 to 4.148]</td><td align=\"center\">0.6559</td><td align=\"center\">100.00</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">AMK-Carlon</td><td align=\"center\">0.99</td><td align=\"center\">9.082 [8.651 to 9.514]</td><td/><td align=\"center\">3.789 [3.472 to 4.105]</td><td/><td align=\"center\">99.83</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">AMK-Gencol</td><td align=\"center\">0.99</td><td align=\"center\">9.238 [8.738 to 9.737]</td><td/><td align=\"center\">3.731 [3.365 to 4.098]</td><td/><td align=\"center\">100.51</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">AMK-Pisa</td><td align=\"center\">0.99</td><td align=\"center\">9.244 [8.860 to 9.629]</td><td/><td align=\"center\">3.698 [3.416 to 3.980]</td><td/><td align=\"center\">100.31</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">AMK-Scalpi</td><td align=\"center\">0.99</td><td align=\"center\">8.920 [8.552 to 9.287]</td><td/><td align=\"center\">3.935 [3.665 to 4.204]</td><td/><td align=\"center\">99.77</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">AMK-Sigma</td><td align=\"center\">0.99</td><td align=\"center\">8.945 [8.575 to 9.315]</td><td/><td align=\"center\">3.926 [3.655 to 4.198]</td><td/><td align=\"center\">99.89</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-SP</td><td align=\"center\">0.99</td><td align=\"center\">10.44 [10.16 to 10.720]</td><td align=\"center\">0.9472</td><td align=\"center\">3.881 [3.594 to 4.167]</td><td align=\"center\">0.9984</td><td align=\"center\">100.00</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Abbott</td><td align=\"center\">0.98</td><td align=\"center\">10.00 [9.557 to 10.440]</td><td/><td align=\"center\">4.150 [3.695 to 4.605]</td><td/><td align=\"center\">99.72</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Az pharma</td><td align=\"center\">0.98</td><td align=\"center\">10.02 [9.576 to 10.460]</td><td/><td align=\"center\">4.021 [3.570 to 4.473]</td><td/><td align=\"center\">99.68</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Biochemie</td><td align=\"center\">0.98</td><td align=\"center\">10.08 [9.668 to 10.500]</td><td/><td align=\"center\">4.038 [3.613 to 4.463]</td><td/><td align=\"center\">99.75</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Biogenta</td><td align=\"center\">0.98</td><td align=\"center\">10.13 [9.736 to 10.510]</td><td/><td align=\"center\">3.925 [3.526 to 4.324]</td><td/><td align=\"center\">99.74</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Colmed</td><td align=\"center\">0.98</td><td align=\"center\">10.13 [9.701 to 10.550]</td><td/><td align=\"center\">3.918 [3.483 to 4.354]</td><td/><td align=\"center\">99.74</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Genfar</td><td align=\"center\">0.99</td><td align=\"center\">10.04 [9.697 to 10.380]</td><td/><td align=\"center\">4.091 [3.738 to 4.443]</td><td/><td align=\"center\">99.73</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Lab America</td><td align=\"center\">0.99</td><td align=\"center\">10.09 [9.708 to 10.470]</td><td/><td align=\"center\">4.143 [3.754 to 4.532]</td><td/><td align=\"center\">99.79</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Labinco</td><td align=\"center\">0.99</td><td align=\"center\">10.11 [9.749 to 10.470]</td><td/><td align=\"center\">3.994 [3.623 to 4.366]</td><td/><td align=\"center\">99.76</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-La Sante</td><td align=\"center\">0.98</td><td align=\"center\">10.11 [9.668 to 10.550]</td><td/><td align=\"center\">4.106 [3.655 to 4.558]</td><td/><td align=\"center\">99.80</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Memphis</td><td align=\"center\">0.98</td><td align=\"center\">10.15 [9.694 to 10.610]</td><td/><td align=\"center\">3.935 [3.465 to 4.406]</td><td/><td align=\"center\">99.77</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-MK</td><td align=\"center\">0.98</td><td align=\"center\">10.09 [9.672 to 10.510]</td><td/><td align=\"center\">4.146 [3.715 to 4.577]</td><td/><td align=\"center\">99.68</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Ophalac</td><td align=\"center\">0.98</td><td align=\"center\">10.02 [9.571 to 10.460]</td><td/><td align=\"center\">4.006 [3.549 to 4.463]</td><td/><td align=\"center\">99.68</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Pentacoop</td><td align=\"center\">0.98</td><td align=\"center\">10.13 [9.690 to 10.560]</td><td/><td align=\"center\">3.962 [3.514 to 4.409]</td><td/><td align=\"center\">99.76</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Recipe</td><td align=\"center\">0.98</td><td align=\"center\">10.10 [9.700 to 10.510]</td><td/><td align=\"center\">3.926 [3.512 to 4.340]</td><td/><td align=\"center\">99.72</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Scalpi</td><td align=\"center\">0.98</td><td align=\"center\">10.13 [9.720 to 10.540]</td><td/><td align=\"center\">3.919 [3.501 to 4.337]</td><td/><td align=\"center\">99.74</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">GNT-Sigma</td><td align=\"center\">0.98</td><td align=\"center\">10.36 [9.889 to 10.830]</td><td/><td align=\"center\">4.109 [3.629 to 4.590]</td><td/><td align=\"center\">100.02</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">VAN-Lilly</td><td align=\"center\">0.99</td><td align=\"center\">6.320 [5.715 to 6.924]</td><td align=\"center\">0.0201</td><td align=\"center\">5.562 [5.082 to 6.042]</td><td align=\"center\">0.8594</td><td align=\"center\">100.00</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">VAN-Abbott</td><td align=\"center\">0.99</td><td align=\"center\">5.782 [5.248 to 6.316]</td><td/><td align=\"center\">5.558 [5.134 to 5.982]</td><td/><td align=\"center\">98.51</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">VAN-APP</td><td align=\"center\">0.99</td><td align=\"center\">6.281 [5.734 to 6.828]</td><td/><td align=\"center\">5.359 [4.925 to 5.793]</td><td/><td align=\"center\">99.30</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">VAN-Proclin</td><td align=\"center\">0.99</td><td align=\"center\">6.388 [5.721 to 7.054]</td><td/><td align=\"center\">5.462 [4.933 to 5.991]</td><td/><td align=\"center\">99.90</td></tr></tbody></table></body></html>", "text": "Pmid= 2640365:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Precision of the vancomycin bioassay</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Vancomycin concentration (mg/L)</bold></td><td align=\"center\"><bold>Inhibition zone diameters (mean in mm &#177; SD)</bold></td><td align=\"center\"><bold>Coefficient of variation (%) Intra-day</bold></td><td align=\"center\"><bold>Coefficient of variation (%) Inter-day</bold></td></tr></thead><tbody><tr><td align=\"center\">128</td><td align=\"center\">18.00 &#177; 0.04</td><td align=\"center\">8.3</td><td align=\"center\">10.3</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"center\">64</td><td align=\"center\">16.33 &#177; 0.02</td><td align=\"center\">5.6</td><td align=\"center\">10.5</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"center\">32</td><td align=\"center\">14.16 &#177; 0.11</td><td align=\"center\">11.0</td><td align=\"center\">1.0</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"center\">16</td><td align=\"center\">11.62 &#177; 0.37</td><td align=\"center\">7.4*</td><td align=\"center\">2.3</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"center\">8</td><td align=\"center\">9.59 &#177; 0.00</td><td align=\"center\">4.6</td><td align=\"center\">6.5</td></tr></tbody></table></body></html>", "text": "Pmid= 2640365:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Clinical grading of severity of acute propanil poisoning</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Minor</td><td align=\"left\">Asymptomatic or mild symptoms (usually gastrointestinal or sedation) with stable vital signs and no other organ involvement</td></tr></thead><tbody><tr><td align=\"left\">Moderate to severe</td><td align=\"left\">Poisoning requiring intervention (eg. clinical evidence of cyanosis, hypotension (MABP &lt; 70 mmHg), hypoventilation requiring intubation, cardiac arrest or evidence of ischaemia, sedation or coma (GCS &lt; 10), seizures, oliguria)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Death</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2656468:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Clinical outcomes, demographics and clinical features on admission</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Severity of poisoning</td><td align=\"center\">Minor</td><td align=\"center\">Moderate to severe</td><td align=\"center\">Death</td><td align=\"center\">Statistical significance&#167;</td></tr></thead><tbody><tr><td align=\"center\">N/Total (%)</td><td align=\"center\">225/391 (57)</td><td align=\"center\">124/391 (32)</td><td align=\"center\">42/391 (11)</td><td/></tr><tr><td align=\"center\">Gender (M:F)</td><td align=\"center\">139:86</td><td align=\"center\">64:60</td><td align=\"center\">34:8</td><td align=\"center\">P = 0.003</td></tr><tr><td align=\"center\">Age (years)</td><td align=\"center\">24 (20&#8211;34)*<sup>$</sup></td><td align=\"center\">22 (18&#8211;33)*<sup>$</sup></td><td align=\"center\">45 (37&#8211;54)<sup>$#</sup></td><td align=\"center\"><sup>$#</sup>P &lt; 0.001; *P &gt; 0.05</td></tr><tr><td align=\"center\">TTP (hours)</td><td align=\"center\">4.6 (2.7&#8211;-7.1)</td><td align=\"center\">5.3 (3.4&#8211;8.8)</td><td align=\"center\">4.5 (3.4&#8211;5.8)</td><td align=\"center\">P = 0.1431</td></tr><tr><td align=\"center\">GCS</td><td align=\"center\">15 (15-15)*<sup>$</sup></td><td align=\"center\">15 (12&#8211;15)*<sup>$</sup></td><td align=\"center\">7 (3&#8211;13)<sup>$#</sup></td><td align=\"center\"><sup>$# </sup>*P &lt; 0.0001</td></tr><tr><td align=\"center\">MABP (mmHg)</td><td align=\"center\">89 (82&#8211;97)<sup>$#</sup></td><td align=\"center\">83 (76&#8211;90)*<sup>$</sup></td><td align=\"center\">78 (72&#8211;86)*<sup>#</sup></td><td align=\"center\"><sup>$#</sup>P &lt; 0.001; *P &gt; 0.05</td></tr><tr><td align=\"center\">TTD (days)</td><td align=\"center\">2.2 (1.7&#8211;3.1)*</td><td align=\"center\">3.3 (2.6&#8211;5.0)*</td><td align=\"center\">1.5 (1.1&#8211;2.4)</td><td align=\"center\">*P &lt; 0.001</td></tr><tr><td align=\"center\">Admission propanil concentration (&#956;M)</td><td align=\"center\">1.3 (0.0&#8211;7.7)<sup>$</sup>*<break/>(n = 125)</td><td align=\"center\">8.9 (2.8&#8211;35.2)<sup>#</sup>*<break/>(n = 67)</td><td align=\"center\">72.0(45.8&#8211;128.3)<sup>#$</sup><break/>(n = 19)</td><td align=\"center\">*<sup>$#</sup>P &lt; 0.001</td></tr></tbody></table></body></html>", "text": "Pmid= 2656468:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Rawlins' classification system of ADRs</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Type</td><td align=\"left\">Definition</td></tr></thead><tbody><tr><td align=\"left\">A</td><td align=\"left\">Dose-dependent ADRs related to the pharmacological effect of the drug:</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Increased pharmacological effect</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; ADRs that occur secondarily to the desired pharmacological effect</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; ADRs due to other well known pharmacological effects</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">B</td><td align=\"left\">Sensitivity reactions &#8211; not dose-dependent</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Allergic reactions</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Idiosyncratic reaction</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">C</td><td align=\"left\">Long-term ADRs</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Carcinogines</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Teratogenes</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Chronic organ damage</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">D</td><td align=\"left\">Drug-drug interactions</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Pharmacodynamic</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Pharmacokinetic</td></tr><tr><td/><td align=\"left\">&#8195;&#8226; Non-classifiable</td></tr></tbody></table></body></html>", "text": "Pmid= 2656469:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>The analysed studies categorised by study design</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Study design</bold></td><td align=\"left\"><bold>Rank in evidence hierarchy</bold></td><td/><td align=\"left\"><bold>Therapeutic</bold><break/><bold>cases</bold></td><td/><td/></tr></thead><tbody><tr><td/><td/><td align=\"left\"><bold>Antibiotics</bold></td><td align=\"left\"><bold>NSAIDs</bold></td><td align=\"left\"><bold>SSRIs</bold></td><td align=\"left\"><bold>Total</bold></td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Cohort</td><td align=\"left\">4</td><td align=\"left\">5</td><td align=\"left\">4</td><td align=\"left\">1</td><td align=\"left\">10</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Case control</td><td align=\"left\">5</td><td align=\"left\">2</td><td align=\"left\">3</td><td align=\"left\">2</td><td align=\"left\">8</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">PEM*</td><td align=\"left\">6</td><td align=\"left\">2</td><td align=\"left\">9</td><td align=\"left\">4</td><td align=\"left\">15</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">National ADR databases</td><td align=\"left\">7</td><td align=\"left\">7</td><td align=\"left\">14</td><td align=\"left\">11</td><td align=\"left\">32</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Case series</td><td align=\"left\">7</td><td align=\"left\">2</td><td align=\"left\">3</td><td align=\"left\">1</td><td align=\"left\">6</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Case reports</td><td align=\"left\">7</td><td align=\"left\">5</td><td align=\"left\">2</td><td align=\"left\">1</td><td align=\"left\">8</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>Total number of studies</bold></td><td/><td align=\"left\"><bold>23</bold></td><td align=\"left\"><bold>36</bold></td><td align=\"left\"><bold>20</bold></td><td align=\"left\"><bold>79</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2656469:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of studies of the occurrence of ADRs related to antibiotics use</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Reference</bold></td><td align=\"left\"><bold>Setting</bold></td><td align=\"left\"><bold>Medicines</bold></td><td align=\"left\"><bold>ADRs</bold></td><td align=\"left\"><bold>Sampling period</bold></td><td align=\"left\"><bold>Sample size</bold></td><td align=\"left\"><bold>Outcome</bold><break/><bold>measures</bold></td><td align=\"left\"><bold>Results</bold><break/><bold>(95% CI)</bold></td><td align=\"left\"><bold>Type of ADRs</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Case control studies</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Czeizel 1999 [<xref ref-type=\"bibr\" rid=\"B15\">15</xref>]</td><td align=\"left\">HU</td><td align=\"left\">Erythromycin</td><td align=\"left\">Teratology</td><td align=\"left\">1980&#8211;1996</td><td align=\"left\">113 cases/38,151 controls</td><td align=\"left\">OR</td><td align=\"left\">1.1; 0.5&#8211;2.3</td><td align=\"left\">C</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Seeger 2006 [<xref ref-type=\"bibr\" rid=\"B16\">16</xref>]</td><td/><td align=\"left\">Fluoroquinolones</td><td align=\"left\">Achilles tendon rupture</td><td align=\"left\">1997&#8211;2001</td><td align=\"left\">947 cases/<break/>18,940 controls</td><td align=\"left\">OR</td><td align=\"left\">1.2; 0.9&#8211;1.7</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Cohort studies</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Chysky 1991[<xref ref-type=\"bibr\" rid=\"B17\">17</xref>]</td><td align=\"left\">DE</td><td align=\"left\">Ciprofloxacin</td><td align=\"left\">Not specified</td><td align=\"left\">44 days</td><td align=\"left\">634 patients</td><td align=\"left\">% ADRs</td><td align=\"left\">Different categories reported</td><td align=\"left\">A/B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Derby 1993 [<xref ref-type=\"bibr\" rid=\"B18\">18</xref>]</td><td align=\"left\">AU</td><td align=\"left\">Flucloxacillin</td><td align=\"left\">Cholestatic hepatitis</td><td align=\"left\">45 days</td><td align=\"left\">132,087 patients</td><td align=\"left\">PRR/100,000 users</td><td align=\"left\">7.6; 3.5&#8211;13.9</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Jick 1994 [<xref ref-type=\"bibr\" rid=\"B19\">19</xref>]</td><td align=\"left\">AU</td><td align=\"left\">Flucloxacillin</td><td align=\"left\">Cholestatic hepatitis</td><td align=\"left\">1991&#8211;1992</td><td align=\"left\">77,552 patients</td><td align=\"left\">PRR/<break/>100,000 users</td><td align=\"left\">6.5; 2.7&#8211;15.1</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Derby 1993b [<xref ref-type=\"bibr\" rid=\"B20\">20</xref>]</td><td align=\"left\">AU</td><td align=\"left\">Erythromycin</td><td align=\"left\">Cholestatic hepatitis</td><td align=\"left\">-</td><td align=\"left\">366,064 patients</td><td align=\"left\">PRR/100,000 users</td><td align=\"left\">3,6; 1.9&#8211;6.1</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Heymann 2007 [<xref ref-type=\"bibr\" rid=\"B21\">21</xref>]</td><td align=\"left\">Israel</td><td align=\"left\">Penicillins</td><td align=\"left\">Pemphigus</td><td align=\"left\">1997&#8211;2001</td><td align=\"left\">150,000 patients</td><td align=\"left\">OR</td><td align=\"left\">2.03; 1.56&#8211;2.64</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>PEM</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Clark 2001 [<xref ref-type=\"bibr\" rid=\"B22\">22</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Fluoroquinolones</td><td align=\"left\">Cardiovascular events</td><td align=\"left\">1988&#8211;1991</td><td align=\"left\">36,410 patients</td><td align=\"left\">CRR (crude relative risk)</td><td align=\"left\">Atrial fibrillation: 1.0; 0.02 &#8211; 8.92</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Inman1994 [<xref ref-type=\"bibr\" rid=\"B23\">23</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Fluconazole</td><td align=\"left\">All</td><td align=\"left\">1988&#8211;1989</td><td align=\"left\">15,015 patients</td><td align=\"left\">Frequencies</td><td align=\"left\">Different categories reported</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>National ADR databases</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Polimeni 2006 [<xref ref-type=\"bibr\" rid=\"B49\">49</xref>]</td><td align=\"left\">Sicilian</td><td align=\"left\">Antibacterials</td><td align=\"left\">All</td><td align=\"left\">1998&#8211;2002</td><td align=\"left\">1585 cases</td><td align=\"left\">ADRs</td><td align=\"left\">Different categories reported</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Sachs 2006 [<xref ref-type=\"bibr\" rid=\"B24\">24</xref>]</td><td align=\"left\">DE</td><td align=\"left\">Fluoroquinolones</td><td align=\"left\">Anaphylaxis</td><td align=\"left\">1993&#8211;2004</td><td align=\"left\">204 cases</td><td align=\"left\">PRR &gt; 2</td><td align=\"left\">Moxifloxacin: 2.1;<break/>Ofloxacin: 2.3<break/>Ciprofloxacin: 2.3<break/>Levofloxacin: 2.0</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Fleisch 2000 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">CH</td><td align=\"left\">Levofloxacin</td><td align=\"left\">Tendinopathy</td><td align=\"left\">1986&#8211;1999</td><td align=\"left\">19 cases/460 non-cases</td><td align=\"left\">Reporting rate</td><td align=\"left\">Different categories reported</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Leone 2003 [<xref ref-type=\"bibr\" rid=\"B26\">26</xref>]</td><td align=\"left\">IT</td><td align=\"left\">Fluroquinolones</td><td align=\"left\">Not specified</td><td align=\"left\">1999&#8211;2001</td><td align=\"left\">432 cases/<break/>10,011 non cases</td><td align=\"left\">Reporting rate</td><td align=\"left\">Different categories reported</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Pierfitte 2000 [<xref ref-type=\"bibr\" rid=\"B27\">27</xref>]</td><td align=\"left\">FR</td><td align=\"left\">Sparfloxacin</td><td align=\"left\">Phototoxicity</td><td align=\"left\">1994&#8211;1996</td><td align=\"left\">371 cases</td><td align=\"left\">RtR/1000 patients</td><td align=\"left\">0.4</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Frothingham 2005 [<xref ref-type=\"bibr\" rid=\"B28\">28</xref>]</td><td align=\"left\">US</td><td align=\"left\">Gatifloxacin</td><td align=\"left\">Glucose homeostatis abnormalities</td><td align=\"left\">1997&#8211;2003</td><td align=\"left\">453 cases/<break/>1427 non cases</td><td align=\"left\">Reporting rate/10<sup>7 </sup>prescriptions</td><td align=\"left\">477</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Hedenmalm 1996 [<xref ref-type=\"bibr\" rid=\"B29\">29</xref>]</td><td align=\"left\">SE</td><td align=\"left\">Fluorquinolones</td><td align=\"left\">Sensory disturbances</td><td align=\"left\">1965&#8211;1993</td><td align=\"left\">37 cases</td><td align=\"left\">ADRs</td><td align=\"left\">Different categories reported</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Case series</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Abouesh 2002 [<xref ref-type=\"bibr\" rid=\"B30\">30</xref>]</td><td align=\"left\">-</td><td align=\"left\">Fluorquinolones<break/>Macrolides</td><td align=\"left\">Mania</td><td align=\"left\">-</td><td align=\"left\">102 cases</td><td align=\"left\">Case review</td><td align=\"left\">Case review</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Smith 2005 [<xref ref-type=\"bibr\" rid=\"B31\">31</xref>]</td><td align=\"left\">-</td><td align=\"left\">Doxycycline<break/>Minocycline</td><td align=\"left\">ADRs</td><td align=\"left\">1966&#8211;2003</td><td align=\"left\">130 cases</td><td align=\"left\">Incidences</td><td align=\"left\">Doxycycline: 0&#8211;61%<break/>Minocycline: 11.7 &#8211; 83.3%</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Case reports</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">H&#228;llgren 2003 [<xref ref-type=\"bibr\" rid=\"B32\">32</xref>]</td><td align=\"left\">-</td><td align=\"left\">Ciprofloxacin</td><td align=\"left\">Steven-Johnson syndrome</td><td align=\"left\">1988&#8211;2000</td><td align=\"left\">8 cases</td><td align=\"left\">IC pr. 100,000 patients</td><td align=\"left\">0.045</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Warner 2000 [<xref ref-type=\"bibr\" rid=\"B33\">33</xref>]</td><td align=\"left\">-</td><td align=\"left\">Clarithromycin</td><td align=\"left\">Acute Psychotic Stress</td><td align=\"left\">-</td><td align=\"left\">1 case</td><td align=\"left\">Causality assessment</td><td align=\"left\">Possible</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">ADRAC 1992 [<xref ref-type=\"bibr\" rid=\"B34\">34</xref>]</td><td align=\"left\">-</td><td align=\"left\">Flucloxacillin</td><td align=\"left\">Cholestatic hepatitis</td><td align=\"left\">-</td><td align=\"left\">1 case</td><td align=\"left\">Case review</td><td align=\"left\">Case review</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Greco 1997 [<xref ref-type=\"bibr\" rid=\"B35\">35</xref>]</td><td align=\"left\">-</td><td align=\"left\">Clarithromycin</td><td align=\"left\">Glossitis, stomatitis, black tongue</td><td align=\"left\">-</td><td align=\"left\">1 case</td><td align=\"left\">Case review</td><td align=\"left\">Case review</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Bj&#246;rnsson 1996 [<xref ref-type=\"bibr\" rid=\"B36\">36</xref>]</td><td align=\"left\">-</td><td align=\"left\">Doxycycline</td><td align=\"left\">Liver reactions</td><td align=\"left\">1966&#8211;1995</td><td align=\"left\">23 cases</td><td align=\"left\">Causality assessment</td><td align=\"left\">Likely (n = 3)<break/>Possible (n = 8)</td><td align=\"left\">B</td></tr></tbody></table></body></html>", "text": "Pmid= 2656469:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of studies of the occurrence of ADRs related to NSAID use</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Reference</bold></td><td align=\"left\"><bold>Setting</bold></td><td align=\"left\"><bold>Medicines</bold></td><td align=\"left\"><bold>ADRs</bold></td><td align=\"left\"><bold>Sampling period</bold></td><td align=\"left\"><bold>Sample size</bold></td><td align=\"left\"><bold>Outcome measures</bold></td><td align=\"left\"><bold>Results</bold><break/><bold>(95%CI)</bold></td><td align=\"left\"><bold>Type of ADRs</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Case control</bold><break/><bold>studies</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Hernandez-Diaz 2001[<xref ref-type=\"bibr\" rid=\"B37\">37</xref>]</td><td align=\"left\">UK</td><td align=\"left\">NSAIDs</td><td align=\"left\">Gastrointestinal events</td><td align=\"left\">1993&#8211;1998</td><td align=\"left\">2,105 cases/<break/>11,500 controls</td><td align=\"left\">OR</td><td align=\"left\">1.8; 1.3 &#8211; 2.4.</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Mockenhaupt 2003 [<xref ref-type=\"bibr\" rid=\"B38\">38</xref>]</td><td align=\"left\">DE/US</td><td align=\"left\">NSAIDs</td><td align=\"left\">Steven-Johnson syndrome</td><td align=\"left\">1989&#8211;1995</td><td align=\"left\">245 cases/<break/>1147 controls</td><td align=\"left\">PRR</td><td align=\"left\">34, 95; 11&#8211;105</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Lacroix 2004 [<xref ref-type=\"bibr\" rid=\"B39\">39</xref>]</td><td align=\"left\">FR</td><td align=\"left\">NSAIDs</td><td align=\"left\">Liver injury</td><td align=\"left\">1998&#8211;2000</td><td align=\"left\">88 cases/<break/>178 controls</td><td align=\"left\">OR</td><td align=\"left\">Women:<break/>6.49; 1.67&#8211;25.16<break/>Men: 1.06; 0.36&#8211;3.12</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Cohort studies</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Lipworth 2004 [<xref ref-type=\"bibr\" rid=\"B40\">40</xref>]</td><td align=\"left\">DK</td><td align=\"left\">Ibuprofen</td><td align=\"left\">Mortality</td><td align=\"left\">1989&#8211;1995</td><td align=\"left\">113,538<break/>patients</td><td align=\"left\">SMR (standard mortality rate)</td><td align=\"left\">1.21; 1.19&#8211;1.24</td><td align=\"left\">A/B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Ashworth 2004 [<xref ref-type=\"bibr\" rid=\"B41\">41</xref>]</td><td align=\"left\">CA</td><td align=\"left\">Diclofenac<break/>Naproxen<break/>Arthrotec</td><td align=\"left\">Mortality</td><td align=\"left\">1991&#8211;1994</td><td align=\"left\">18,424 patients</td><td align=\"left\">OR</td><td align=\"left\">Arthrotec: 1.4; 0.9&#8211;2.1.<break/>Diclofenac: 2.0; 1.3&#8211;3.1.<break/>Naproxen: 3.0; 1.9&#8211;4.6</td><td align=\"left\">A/B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Morant 2004 [<xref ref-type=\"bibr\" rid=\"B42\">42</xref>]</td><td align=\"left\">UK</td><td align=\"left\">NSAIDs</td><td align=\"left\">Gastrointestinal haemorrhage</td><td align=\"left\">1987&#8211;2001</td><td align=\"left\">628000 patient year</td><td align=\"left\">PRR</td><td align=\"left\">0.84; 0.60 &#8211; 1.17</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Martin 2000 [<xref ref-type=\"bibr\" rid=\"B43\">43</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Meloxicam</td><td align=\"left\">Gastrointestinal events</td><td align=\"left\">1996&#8211;1997</td><td align=\"left\">19,087 patients</td><td align=\"left\">Events/<break/>1000 patient-months of exposure</td><td align=\"left\">Dyspepsia: 28.3<break/>Gastrointestinal haemorrhage: 0.4</td><td align=\"left\">A + B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>National ADR databases</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Lugardon 2004 [<xref ref-type=\"bibr\" rid=\"B44\">44</xref>]</td><td align=\"left\">FR</td><td align=\"left\">COX-2 inhibitors</td><td align=\"left\">Oeso-gastro-duodenal events:</td><td align=\"left\">2000&#8211;2002</td><td align=\"left\">505 cases/<break/>2,525 non-cases</td><td align=\"left\">OR</td><td align=\"left\">14.9; 9.3&#8211;23.7</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Durrieu 2005 [<xref ref-type=\"bibr\" rid=\"B45\">45</xref>]</td><td align=\"left\">FR</td><td align=\"left\">COX-2 inhibitors</td><td align=\"left\">Arterial hypertension</td><td align=\"left\">2000&#8211;2003</td><td align=\"left\">34 cases</td><td align=\"left\">OR</td><td align=\"left\">3.3; 1.6&#8211;6.9.</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Clinard 2004 [<xref ref-type=\"bibr\" rid=\"B46\">46</xref>]</td><td align=\"left\">FR</td><td align=\"left\">NSAIDs</td><td align=\"left\">Excess risk of adverse drug reactions</td><td align=\"left\">1995&#8211;1999</td><td align=\"left\">3983 cases/<break/>54,583 non- cases</td><td align=\"left\">OR</td><td align=\"left\">Different categories reported</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Brinker 2004 [<xref ref-type=\"bibr\" rid=\"B47\">47</xref>]</td><td align=\"left\">US</td><td align=\"left\">COX-2 inhibitors</td><td align=\"left\">Hypertension</td><td align=\"left\">&lt; 2002</td><td align=\"left\">34 cases</td><td align=\"left\">Reporting rate/10<sup>6</sup>person years</td><td align=\"left\">Rofecoxib: 5.0<break/>Celecoxib: 1.3</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">La Grenade 2005 [<xref ref-type=\"bibr\" rid=\"B48\">48</xref>]</td><td align=\"left\">US</td><td align=\"left\">COX-2 inhibitors<break/>Meloxicam</td><td align=\"left\">Steven-Johnson syndrome<break/>Toxic Epidermal Necrolysis</td><td align=\"left\">&lt; 2004</td><td align=\"left\">123 cases</td><td align=\"left\">Reporting rate/10<sup>6</sup>person years</td><td align=\"left\">Valdecoxib: 49<break/>Celecoxib: 6<break/>Rofecoxib: 3</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Polimeni 2006 [<xref ref-type=\"bibr\" rid=\"B49\">49</xref>]</td><td align=\"left\">Sicilian</td><td align=\"left\">NSAIDs</td><td align=\"left\">All</td><td align=\"left\">1998&#8211;2002</td><td align=\"left\">1585 cases</td><td align=\"left\">PRR</td><td align=\"left\">Hepatitis: 14.20<break/>Vasculitis: 7.72<break/>Hypertension: 15.40</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Conforti 2001 [<xref ref-type=\"bibr\" rid=\"B50\">50</xref>]</td><td align=\"left\">IT</td><td align=\"left\">NSAIDs</td><td align=\"left\">Gastrointestinal events</td><td align=\"left\">1996&#8211;1999</td><td align=\"left\">705 cases/<break/>10,608 non cases</td><td align=\"left\">% ADRs</td><td align=\"left\">Nimesulid: 10.4<break/>Diclofenac: 21.2<break/>Ketoprofen: 1.7<break/>Piroxicam: 18.6</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Ahmad 2002 [<xref ref-type=\"bibr\" rid=\"B51\">51</xref>]</td><td align=\"left\">US</td><td align=\"left\">COX-2 inhibitors</td><td align=\"left\">Renal failure</td><td align=\"left\">1969&#8211;2000</td><td align=\"left\">Celecoxib: 122 cases<break/>Rofecoxib: 142 cases</td><td align=\"left\">Case review</td><td align=\"left\">Case review</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Puijenbroek 2000 [<xref ref-type=\"bibr\" rid=\"B52\">52</xref>]</td><td align=\"left\">NL</td><td align=\"left\">NSAIDs<break/>Diuretics</td><td align=\"left\">Drug interactions</td><td align=\"left\">1990&#8211;1999</td><td align=\"left\">305 cases/<break/>9517 non cases</td><td align=\"left\">OR</td><td align=\"left\">OR: 2.0, 1.1&#8211;3.7</td><td align=\"left\">D</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Lapeyre-Mestre 2004 [<xref ref-type=\"bibr\" rid=\"B53\">53</xref>]</td><td align=\"left\">FR/ES</td><td align=\"left\">NSAIDs</td><td align=\"left\">Hepatic events</td><td align=\"left\">1982&#8211;2001</td><td align=\"left\">29,486 cases</td><td align=\"left\">OR</td><td align=\"left\">Different OR calculated for NSAIDs.</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Leone 1999 [<xref ref-type=\"bibr\" rid=\"B54\">54</xref>]</td><td align=\"left\">IT</td><td align=\"left\">Nimesulide</td><td align=\"left\">Renal impairment</td><td align=\"left\">1988&#8211;1997</td><td align=\"left\">11cases/<break/>7438 non cases</td><td align=\"left\">Causality assessment</td><td align=\"left\">Possible (n = 6)<break/>Probable (n = 4)<break/>Certain (n = 1)</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Brown 1998 [<xref ref-type=\"bibr\" rid=\"B55\">55</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Tiaprofenic acid</td><td align=\"left\">Cystitis</td><td align=\"left\">1981&#8211;1996</td><td align=\"left\">221 cases/<break/>1327 non cases</td><td align=\"left\">ADRs/10<sup>5 </sup>prescriptions</td><td align=\"left\">1991: 4.2<break/>1992: 5.9<break/>1993: 4.2<break/>1994: 34.4<break/>1995: 18.5<break/>1996: 6.5</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Verrico 2003 [<xref ref-type=\"bibr\" rid=\"B56\">56</xref>]</td><td align=\"left\">US</td><td align=\"left\">COX2-inhibitors</td><td align=\"left\">Not specified</td><td align=\"left\">1999&#8211;2002</td><td align=\"left\">24 cases</td><td align=\"left\">Causality assessment</td><td align=\"left\">Possible (n = 29)<break/>Probable (n = 16)</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Kahn 1997 [<xref ref-type=\"bibr\" rid=\"B57\">57</xref>]</td><td align=\"left\">US</td><td align=\"left\">NSAIDs</td><td align=\"left\">Necrotizing soft tissue infections</td><td align=\"left\">1969&#8211;1995</td><td align=\"left\">33 cases</td><td align=\"left\">Case review</td><td align=\"left\">N = 26</td><td align=\"left\">C</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>PEM</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2004a [<xref ref-type=\"bibr\" rid=\"B58\">58</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Celecoxib</td><td align=\"left\">Not specified</td><td align=\"left\">2000</td><td align=\"left\">17,458 patients</td><td align=\"left\">IDs (event incidence densitites)</td><td align=\"left\">Dyspepsia = 25.4<break/>Abdominal pain = 10.6</td><td align=\"left\">A + B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2003b [<xref ref-type=\"bibr\" rid=\"B59\">59</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Celecoxib<break/>Meloxicam</td><td align=\"left\">Not specified</td><td align=\"left\">1996&#8211;1997</td><td align=\"left\">34,355 patients</td><td align=\"left\">PRR</td><td align=\"left\">Different categories reported</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2003c [<xref ref-type=\"bibr\" rid=\"B60\">60</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Rofecoxib</td><td align=\"left\">Not specified</td><td align=\"left\">2000</td><td align=\"left\">15,268 patients</td><td align=\"left\">Event rate pr. 1000 patient months exposure</td><td align=\"left\">76 upper GI bleedings and 101 thromboembolic events</td><td align=\"left\">A + B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2004d [<xref ref-type=\"bibr\" rid=\"B61\">61</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Rofecoxib</td><td align=\"left\">Exacerbation of colitis</td><td align=\"left\">1999</td><td align=\"left\">15,268 patients</td><td align=\"left\">IRR</td><td align=\"left\">5.8; 2.7&#8211;11.3</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Kasliwal 2005 [<xref ref-type=\"bibr\" rid=\"B62\">62</xref>]</td><td align=\"left\">UK</td><td align=\"left\">COX-2 inhibitors</td><td align=\"left\">Gastrointestinal +<break/>thromboembolic events</td><td align=\"left\">1999&#8211;2000</td><td align=\"left\">32,726 patients</td><td align=\"left\">PRR</td><td align=\"left\">GI: 1.21; 1.09 &#8211; 1.36.<break/>Thromboembolic: 1.04; 0.50 &#8211; 2.17.</td><td align=\"left\">A + B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2003e [<xref ref-type=\"bibr\" rid=\"B63\">63</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Rofecoxib<break/>Meloxicam</td><td align=\"left\">Thromboembolic events</td><td align=\"left\">1996&#8211;1997</td><td align=\"left\">34,355 patients</td><td align=\"left\">PRR</td><td align=\"left\">1.68; 1.15 &#8211; 2.46.</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2003f [<xref ref-type=\"bibr\" rid=\"B64\">64</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Rofecoxib<break/>Meloxicam</td><td align=\"left\">Upper GI events</td><td align=\"left\">1996&#8211;1997</td><td align=\"left\">34,355 patients</td><td align=\"left\">IR</td><td align=\"left\">0.71; 0.65 &#8211; 0.79.</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2006g [<xref ref-type=\"bibr\" rid=\"B65\">65</xref>]</td><td align=\"left\">UK</td><td align=\"left\">COX-2 inhibitors</td><td align=\"left\">Serious skin reactions</td><td align=\"left\">1999&#8211;2000/</td><td align=\"left\">52,644 patients</td><td align=\"left\">IR/1000 patient-months</td><td align=\"left\">IR: 0.019</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2003h [<xref ref-type=\"bibr\" rid=\"B66\">66</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Celecoxib<break/>Meloxicam</td><td align=\"left\">Gastrointestinal events</td><td align=\"left\">1996&#8211;1997</td><td align=\"left\">36,545 patients</td><td align=\"left\">PRR</td><td align=\"left\">0.77; 0.69 &#8211; 0.85.</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Case series</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Onder 2004 [<xref ref-type=\"bibr\" rid=\"B67\">67</xref>]</td><td align=\"left\">-</td><td align=\"left\">NSAIDs</td><td align=\"left\">Psychiatric ADRs</td><td align=\"left\">1965&#8211;2003</td><td align=\"left\">27 reports with data on 453 cases</td><td align=\"left\">Risk factors</td><td align=\"left\">Age, psychiatric disorders, parturients</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Fraunfelder 2006 [<xref ref-type=\"bibr\" rid=\"B68\">68</xref>]</td><td align=\"left\">-</td><td align=\"left\">NSAIDs</td><td align=\"left\">Ocular ADRs</td><td align=\"left\">-</td><td align=\"left\">569 cases</td><td align=\"left\">Reported ADRs</td><td align=\"left\">Blurred vision, conjunctivitis, visual hallucinations</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Zimer 2007 [<xref ref-type=\"bibr\" rid=\"B69\">69</xref>]</td><td align=\"left\">DE</td><td align=\"left\">Valdecoxib</td><td align=\"left\">Cutaneous adverse reactions</td><td align=\"left\">2002&#8211;2005</td><td align=\"left\">5 cases</td><td align=\"left\">Case review</td><td align=\"left\">Erythematous, facial edema, dyspnea</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Case reports</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Hunter 1999 [<xref ref-type=\"bibr\" rid=\"B70\">70</xref>]</td><td align=\"left\">-</td><td align=\"left\">Bromfenac</td><td align=\"left\">Hepatic Failure</td><td align=\"left\">-</td><td align=\"left\">1 case</td><td align=\"left\">Causality assessment</td><td align=\"left\">Related</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">ADRAC 1998 [<xref ref-type=\"bibr\" rid=\"B71\">71</xref>]</td><td align=\"left\">-</td><td align=\"left\">Diclofenac<break/>Indomethacin<break/>Mefenamic acid</td><td align=\"left\">Closure of fetal ductus arterious</td><td align=\"left\">-</td><td align=\"left\">3 cases</td><td align=\"left\">Case review</td><td align=\"left\">Case review</td><td align=\"left\">C</td></tr></tbody></table></body></html>", "text": "Pmid= 2656469:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Studies of the occurrence of ADRs related to SSRI use</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Reference</bold></td><td align=\"left\"><bold>Setting</bold></td><td align=\"left\"><bold>Medicines</bold></td><td align=\"left\"><bold>ADRs</bold></td><td align=\"left\"><bold>Sampling period</bold></td><td align=\"left\"><bold>Sample size</bold></td><td align=\"left\"><bold>Outcome measures</bold></td><td align=\"left\"><bold>Results</bold><break/><bold>(95% CI)</bold></td><td align=\"left\"><bold>Type of ADRs</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Case-control studies</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Schillevoort 2002 [<xref ref-type=\"bibr\" rid=\"B72\">72</xref>]</td><td align=\"left\">NL</td><td align=\"left\">SSRIs</td><td align=\"left\">Extrapyramidal<break/>Syndromes (EPS)</td><td align=\"left\">1985&#8211;1999</td><td align=\"left\">41cases/1,264 controls</td><td align=\"left\">OR</td><td align=\"left\">2.2; 1.2&#8211;3.9</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Movig 2002 [<xref ref-type=\"bibr\" rid=\"B73\">73</xref>]</td><td align=\"left\">NL</td><td align=\"left\">SSRIs</td><td align=\"left\">Hyponatraemia</td><td align=\"left\">1990&#8211;1998</td><td align=\"left\">203 cases/608 controls</td><td align=\"left\">OR</td><td align=\"left\">3.96; 1.33 &#8211; 11.83</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Cohort study</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Bell 2006 [<xref ref-type=\"bibr\" rid=\"B74\">74</xref>]</td><td align=\"left\">US</td><td align=\"left\">Fluoxetine</td><td align=\"left\">Testosterone levels</td><td align=\"left\">-</td><td align=\"left\">14 patients</td><td align=\"left\">Testosterone level</td><td align=\"left\">No changes</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>National ADR databases</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Trenque 2002 [<xref ref-type=\"bibr\" rid=\"B75\">75</xref>]</td><td align=\"left\">FR</td><td align=\"left\">SSRIs</td><td align=\"left\">Withdrawal syndrome</td><td align=\"left\">&lt; 2000</td><td align=\"left\">60 cases/166,327 non cases</td><td align=\"left\">OR</td><td align=\"left\">5.05, 3.81&#8211;6.68.</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Gony 2003 76]</td><td align=\"left\">FR</td><td align=\"left\">SSRIs</td><td align=\"left\">Extrapyramidal<break/>Symptoms</td><td align=\"left\">1995&#8211;2000</td><td align=\"left\">9 cases</td><td align=\"left\">OR</td><td align=\"left\">2.18; 0.47&#8211;11.35</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Hedenmalm 2006 [<xref ref-type=\"bibr\" rid=\"B77\">77</xref>]</td><td align=\"left\">SE</td><td align=\"left\">SSRIs</td><td align=\"left\">Alopecia</td><td align=\"left\">&lt; 2004</td><td align=\"left\">27 cases</td><td align=\"left\">IC</td><td align=\"left\">Sertraline = 1.63, 0.85&#8211;2.41<break/>Citalopram = 1.22, 0.97&#8211;1.47</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Goldstein 1997 [<xref ref-type=\"bibr\" rid=\"B78\">78</xref>]</td><td align=\"left\">-</td><td align=\"left\">Fluoxetine</td><td align=\"left\">First-trimester exposure on newborns</td><td align=\"left\">&lt; 1996</td><td align=\"left\">796 cases</td><td align=\"left\">Rate %</td><td align=\"left\">5.0</td><td align=\"left\">C</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Spigset 2003 [<xref ref-type=\"bibr\" rid=\"B79\">79</xref>]</td><td align=\"left\">SE</td><td align=\"left\">Nefazodone</td><td align=\"left\">Hepatic injury</td><td align=\"left\">&lt; 2002</td><td align=\"left\">27,542 cases/<break/>2830764 non cases</td><td align=\"left\">IC</td><td align=\"left\">0.42, 0.12&#8211;0.72</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Khan 2003 [<xref ref-type=\"bibr\" rid=\"B80\">80</xref>]</td><td align=\"left\">US</td><td align=\"left\">SSRIs</td><td align=\"left\">Suicide</td><td align=\"left\">1985&#8211;2000</td><td align=\"left\">77 cases/48,277<break/>non cases</td><td align=\"left\">Suicide rate</td><td align=\"left\">0.59, 0.31 &#8211; 0.87</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Egberts 1997 [<xref ref-type=\"bibr\" rid=\"B81\">81</xref>]</td><td align=\"left\">NL</td><td align=\"left\">SSRIs</td><td align=\"left\">Non-puerperal lactation</td><td align=\"left\">1986&#8211;1996</td><td align=\"left\">38cases/14,439 non cases</td><td align=\"left\">OR</td><td align=\"left\">2.7; 6.4&#8211;25.4</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Kvande 2001 [<xref ref-type=\"bibr\" rid=\"B82\">82</xref>]</td><td align=\"left\">NO</td><td align=\"left\">SSRIs</td><td align=\"left\">Pancreatitis</td><td align=\"left\">&lt; 2000</td><td align=\"left\">160 cases</td><td align=\"left\">No. of cases</td><td align=\"left\">160 cases</td><td align=\"left\">B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Stahl 1997 [<xref ref-type=\"bibr\" rid=\"B83\">83</xref>]</td><td align=\"left\">SE</td><td align=\"left\">SSRIs</td><td align=\"left\">Withdrawal reactions</td><td align=\"left\">&lt; 1995</td><td align=\"left\">49, 393 cases</td><td align=\"left\">Number of reports/10<sup>6</sup>/<break/>DDD</td><td align=\"left\">Paroxetine = 1.9<break/>Sertraline = 2.1<break/>Fluoxetine = 0.48</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Spigset 1999 [<xref ref-type=\"bibr\" rid=\"B84\">84</xref>]</td><td align=\"left\">SE</td><td align=\"left\">SSRIs</td><td align=\"left\">Not specified</td><td align=\"left\">1965&#8211;1997</td><td align=\"left\">1202 cases</td><td align=\"left\">ADRs</td><td align=\"left\">Different categories reported</td><td align=\"left\">A + B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Sanz 2005 [<xref ref-type=\"bibr\" rid=\"B85\">85</xref>]</td><td align=\"left\">SE</td><td align=\"left\">SSRIs</td><td align=\"left\">Neonatal withdrawal syndrome</td><td align=\"left\">1968&#8211;2002</td><td align=\"left\">102 cases</td><td align=\"left\">IC</td><td align=\"left\">Paroxetine = 4.07<break/>Sertraline = 1.20<break/>Citalopram = 1.92<break/>Fluoxetin = 1.07</td><td align=\"left\">C</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>PEM</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Price 1996 [<xref ref-type=\"bibr\" rid=\"B86\">86</xref>]</td><td align=\"left\">UK</td><td align=\"left\">SSRIs</td><td align=\"left\">Withdrawal reactions</td><td align=\"left\">1987&#8211;1992</td><td align=\"left\">50,150 patients</td><td align=\"left\">Reports/<break/>1000 prescriptions</td><td align=\"left\">Paroxetine = 0.3<break/>Sertraline = 0.03<break/>Fluvoxamine = 0.03<break/>Fluoxetine = 0.002</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Layton 2001 [<xref ref-type=\"bibr\" rid=\"B87\">87</xref>]</td><td align=\"left\">UK</td><td align=\"left\">SSRIs</td><td align=\"left\">Abnormal bleeding</td><td align=\"left\">1986&#8211;1998</td><td align=\"left\">135,754 patients</td><td align=\"left\">PRR</td><td align=\"left\">Day 1&#8211;30 = 1.38<break/>Month 2&#8211;6 = 1.17</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Edwards 1994 [<xref ref-type=\"bibr\" rid=\"B88\">88</xref>]</td><td align=\"left\">UK</td><td align=\"left\">Fluvoxamine</td><td align=\"left\">All</td><td align=\"left\">1987&#8211;1988</td><td align=\"left\">10,401 patients</td><td align=\"left\">Incidences</td><td/><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">MacKay 1997 [<xref ref-type=\"bibr\" rid=\"B89\">89</xref>]</td><td align=\"left\">UK</td><td align=\"left\">SSRIs</td><td align=\"left\">All</td><td align=\"left\">1988&#8211;1991</td><td align=\"left\">56,145 patients</td><td/><td align=\"left\">Nausea, vomiting, withdrawal symptoms</td><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Case series</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">de Abajo 2006 [<xref ref-type=\"bibr\" rid=\"B90\">90</xref>]</td><td align=\"left\">-</td><td align=\"left\">SSRIs<break/>Venlafaxine</td><td align=\"left\">Bleeding Disorders</td><td align=\"left\">1988&#8211;2003</td><td align=\"left\">1,651 cases/<break/>10,000 controls</td><td align=\"left\">PRR</td><td align=\"left\">3.0, 2.1&#8211;4.4</td><td align=\"left\">A</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Gram 1999 [<xref ref-type=\"bibr\" rid=\"B91\">91</xref>]</td><td align=\"left\">DK</td><td align=\"left\">SSRIs</td><td align=\"left\">Bleeding<break/>Thrombocytopenia</td><td align=\"left\">-</td><td align=\"left\">8 cases</td><td align=\"left\">-</td><td align=\"left\">Case review</td><td align=\"left\">A + B</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Case report</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Demers 2001 [<xref ref-type=\"bibr\" rid=\"B92\">92</xref>]</td><td align=\"left\">-</td><td align=\"left\">Fluvoxamine</td><td align=\"left\">Serotonin syndrome</td><td align=\"left\">-</td><td align=\"left\">1 case</td><td align=\"left\">-</td><td align=\"left\">Case review</td><td align=\"left\">A</td></tr></tbody></table></body></html>", "text": "Pmid= 2656469:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Number of studies categorised by number, design and time of publication</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Year of publication</bold></td><td align=\"left\"><bold>&lt; 1990</bold></td><td align=\"left\"><bold>1991</bold></td><td align=\"left\"><bold>1992</bold></td><td align=\"left\"><bold>1993</bold></td><td align=\"left\"><bold>1994</bold></td><td align=\"left\"><bold>1995</bold></td><td align=\"left\"><bold>1996</bold></td><td align=\"left\"><bold>1997</bold></td><td align=\"left\"><bold>1998</bold></td><td align=\"left\"><bold>1999</bold></td><td align=\"left\"><bold>2000</bold></td><td align=\"left\"><bold>2001</bold></td><td align=\"left\"><bold>2002</bold></td><td align=\"left\"><bold>2003</bold></td><td align=\"left\"><bold>2004</bold></td><td align=\"left\"><bold>2005-</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Study design</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"left\"><bold>Antibiotics</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"left\">Case control studies</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td/><td/><td/><td/><td/><td align=\"right\">1</td></tr><tr><td align=\"left\">Cohort studies</td><td/><td align=\"right\">1</td><td/><td align=\"right\">3</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td></tr><tr><td align=\"left\">National ADR databases</td><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td/><td/><td/><td align=\"right\">2</td><td/><td/><td align=\"right\">1</td><td/><td align=\"right\">2</td></tr><tr><td align=\"left\">PEM*</td><td/><td/><td/><td/><td align=\"right\">1</td><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td/><td/><td/><td/></tr><tr><td align=\"left\">Case series</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td/><td/><td align=\"right\">1</td></tr><tr><td align=\"left\">Case reports</td><td/><td/><td align=\"right\">1</td><td/><td/><td/><td align=\"right\">1</td><td align=\"right\">1</td><td/><td/><td align=\"right\">1</td><td/><td/><td align=\"right\">1</td><td/><td/></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"left\"><bold>NSAIDs</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"left\">Case control studies</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td align=\"right\">1</td><td/><td align=\"right\">1</td><td align=\"right\">1</td><td/></tr><tr><td align=\"left\">Cohort studies</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td/><td/><td/><td align=\"right\">3</td><td/></tr><tr><td align=\"left\">National ADR databases</td><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td align=\"right\">1</td><td align=\"right\">1</td><td align=\"right\">1</td><td align=\"right\">1</td><td align=\"right\">1</td><td align=\"right\">1</td><td align=\"right\">4</td><td align=\"right\">3</td></tr><tr><td align=\"left\">PEM*</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">5</td><td align=\"right\">2</td><td align=\"right\">2</td></tr><tr><td align=\"left\">Case series</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td align=\"right\">2</td></tr><tr><td align=\"left\">Case reports</td><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td align=\"right\">1</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"left\"><bold>SSRIs</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"left\">Case control studies</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">2</td><td/><td/><td/></tr><tr><td align=\"left\">Cohort studies</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td></tr><tr><td align=\"left\">National ADR databases</td><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">3</td><td/><td align=\"right\">1</td><td/><td align=\"right\">1</td><td align=\"right\">1</td><td align=\"right\">3</td><td/><td align=\"right\">2</td></tr><tr><td align=\"left\">PEM*</td><td/><td/><td/><td/><td align=\"right\">1</td><td/><td align=\"right\">1</td><td align=\"right\">1</td><td/><td/><td/><td align=\"right\">1</td><td/><td/><td/><td/></tr><tr><td align=\"left\">Case series</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td/><td/><td/><td/><td/><td align=\"right\">1</td></tr><tr><td align=\"left\">Case reports</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td align=\"right\">1</td><td/><td/><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 2656469:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Reasons for patients who entered the run-in period not proceeding to the Randomisation appointment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Reason</bold></td><td align=\"center\" colspan=\"4\"><bold>Phase of Run-in period</bold></td></tr><tr><td/><td align=\"left\"><bold>Placebo</bold></td><td align=\"left\"><bold>Active</bold></td><td align=\"left\"><bold>Unknown</bold></td><td align=\"left\"><bold>Overall</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Screening blood results</bold></td><td align=\"right\"><bold>1132</bold></td><td align=\"right\"><bold>-</bold></td><td align=\"right\"><bold>-</bold></td><td align=\"right\"><bold>1132</bold></td></tr><tr><td align=\"left\">&#8195;Cholesterol &lt;3.5 mmol/L</td><td align=\"right\">220</td><td align=\"right\">-</td><td align=\"right\">-</td><td align=\"right\">220</td></tr><tr><td align=\"left\">&#8195;Liver function test abnormality*</td><td align=\"right\">656</td><td align=\"right\">-</td><td align=\"right\">-</td><td align=\"right\">656</td></tr><tr><td align=\"left\">&#8195;CK&gt;3 &#215; ULN</td><td align=\"right\">78</td><td align=\"right\">-</td><td align=\"right\">-</td><td align=\"right\">78</td></tr><tr><td align=\"left\">&#8195;Creatinine &gt;200 &#956;mol/L</td><td align=\"right\">192</td><td align=\"right\">-</td><td align=\"right\">-</td><td align=\"right\">192</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Participant vetoed or advised against by patient\\'s physician</bold></td><td align=\"right\"><bold>797</bold></td><td align=\"right\"><bold>577</bold></td><td align=\"right\"><bold>1</bold></td><td align=\"right\"><bold>1375</bold></td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Randomisation appointment cancelled</bold></td><td align=\"right\"><bold>1100</bold></td><td align=\"right\"><bold>1139</bold></td><td align=\"right\"><bold>296</bold></td><td align=\"right\"><bold>2535</bold></td></tr><tr><td align=\"left\">&#8195;MI, angina or stroke during run-in</td><td align=\"right\">7</td><td align=\"right\">24</td><td align=\"right\">0</td><td align=\"right\">31</td></tr><tr><td align=\"left\">&#8195;Died or cancer diagnosed</td><td align=\"right\">18</td><td align=\"right\">29</td><td align=\"right\">2</td><td align=\"right\">49</td></tr><tr><td align=\"left\">&#8195;Myopathy</td><td align=\"right\">0</td><td align=\"right\">2</td><td align=\"right\">0</td><td align=\"right\">2</td></tr><tr><td align=\"left\">&#8195;Other adverse event</td><td align=\"right\">193</td><td align=\"right\">217</td><td align=\"right\">0</td><td align=\"right\">410</td></tr><tr><td align=\"left\">&#8195;Patient wishes</td><td align=\"right\">854</td><td align=\"right\">848</td><td align=\"right\">0</td><td align=\"right\">1702</td></tr><tr><td align=\"left\">&#8195;Other or unknown reason</td><td align=\"right\">28</td><td align=\"right\">19</td><td align=\"right\">294</td><td align=\"right\">341</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Failed to attend randomisation appointment (no reason given)</bold></td><td align=\"right\"><bold>0</bold></td><td align=\"right\"><bold>0</bold></td><td align=\"right\"><bold>3129</bold></td><td align=\"right\"><bold>3129</bold></td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Any of the above</bold></td><td align=\"right\"><bold>3029</bold></td><td align=\"right\"><bold>1716</bold></td><td align=\"right\"><bold>3426</bold></td><td align=\"right\"><bold>8171</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2676245:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Reasons for withdrawal of patients in the run-in period who attended their Randomisation appointment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Reason</bold></td><td align=\"right\"><bold>Overall</bold></td></tr></thead><tbody><tr><td align=\"left\">Cancer diagnosed during run-in</td><td align=\"right\">28</td></tr><tr><td align=\"left\">MI, stroke or hospitalisation for angina during run-in</td><td align=\"right\">94</td></tr><tr><td align=\"left\">Lipid-lowering drug started</td><td align=\"right\">271</td></tr><tr><td align=\"left\">New unexplained muscle symptoms</td><td align=\"right\">531</td></tr><tr><td align=\"left\">Other adverse event</td><td align=\"right\">161</td></tr><tr><td align=\"left\">Patient wishes or long-term adherence in doubt</td><td align=\"right\">2992</td></tr><tr><td align=\"left\">Patient\\'s physician discouraged participation</td><td align=\"right\">25</td></tr><tr><td align=\"left\">Other reasons</td><td align=\"right\">135</td></tr><tr><td/><td/></tr><tr><td align=\"left\"><bold>Any of the above</bold></td><td align=\"right\"><bold>3438</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2676245:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Serious adverse events considered (before unblinding) to be probably due to study simvastatin</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Event</bold></td><td align=\"center\" colspan=\"2\"><bold>Simvastatin-allocated</bold></td><td align=\"center\" colspan=\"2\"><bold>Placebo-allocated</bold></td></tr><tr><td/><td align=\"center\" colspan=\"2\"><bold>(n = 10269)</bold></td><td align=\"center\" colspan=\"2\"><bold>(n = 10267)</bold></td></tr></thead><tbody><tr><td align=\"left\">Myopathy/rhabdomyolysis*</td><td align=\"center\">7</td><td align=\"center\">(0.1%)</td><td align=\"center\">2</td><td align=\"center\">(0.0%)</td></tr><tr><td align=\"left\">Muscle pain/weakness**</td><td align=\"center\">0</td><td align=\"center\">(0.0%)</td><td align=\"center\">1</td><td align=\"center\">(0.0%)</td></tr><tr><td align=\"left\">Hepatitis</td><td align=\"center\">1</td><td align=\"center\">(0.0%)</td><td align=\"center\">1</td><td align=\"center\">(0.0%)</td></tr><tr><td align=\"left\">GI haemorrhage</td><td align=\"center\">1</td><td align=\"center\">(0.0%)</td><td align=\"center\">0</td><td align=\"center\">(0.0%)</td></tr><tr><td align=\"left\">Renal failure</td><td align=\"center\">0</td><td align=\"center\">(0.0%)</td><td align=\"center\">1</td><td align=\"center\">(0.0%)</td></tr><tr><td align=\"left\">Neurological</td><td align=\"center\">0</td><td align=\"center\">(0.0%)</td><td align=\"center\">2</td><td align=\"center\">(0.0%)</td></tr></tbody></table></body></html>", "text": "Pmid= 2676245:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Reasons for randomised patients stopping study simvastatin/placebo tablets</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Reason(s) given</bold></td><td align=\"center\" colspan=\"2\"><bold>Simvastatin-allocated</bold><break/><bold>(n = 10269)</bold></td><td align=\"right\" colspan=\"2\"><bold>Placebo-allocated</bold><break/><bold>(n = 10267)</bold></td><td/></tr></thead><tbody><tr><td align=\"left\">Patient wishes</td><td align=\"right\">2186</td><td align=\"right\">(21.3%)</td><td align=\"right\">2113</td><td align=\"right\">(20.6%)</td><td/></tr><tr><td align=\"left\">Unable or unwilling to attend clinic</td><td align=\"right\">757</td><td align=\"right\">(7.4%)</td><td align=\"right\">745</td><td align=\"right\">(7.3%)</td><td/></tr><tr><td align=\"left\">Non-study statin started</td><td align=\"right\">364</td><td align=\"right\">(3.5%)</td><td align=\"right\">1401</td><td align=\"right\">(13.6%)</td><td/></tr><tr><td align=\"left\">Other contraindicated drug started</td><td align=\"right\">11</td><td align=\"right\">(0.1%)</td><td align=\"right\">50</td><td align=\"right\">(0.5%)</td><td/></tr><tr><td align=\"left\">Poor compliance</td><td align=\"right\">88</td><td align=\"right\">(0.9%)</td><td align=\"right\">120</td><td align=\"right\">(1.2%)</td><td/></tr><tr><td align=\"left\">Raised liver or muscle enzymes**</td><td align=\"right\">57</td><td align=\"right\">(0.6%)</td><td align=\"right\">46</td><td align=\"right\">(0.4%)</td><td/></tr><tr><td align=\"left\">&#8195;Raised liver enzymes</td><td align=\"right\">46</td><td align=\"right\">(0.4%)</td><td align=\"right\">36</td><td align=\"right\">(0.4%)</td><td/></tr><tr><td align=\"left\">&#8195;Raised muscle enzymes</td><td align=\"right\">11</td><td align=\"right\">(0.1%)</td><td align=\"right\">2</td><td align=\"right\">(0.0%)</td><td/></tr><tr><td align=\"left\">Muscle pain or weakness</td><td align=\"right\">60</td><td align=\"right\">(0.6%)</td><td align=\"right\">62</td><td align=\"right\">(0.6%)</td><td/></tr><tr><td align=\"left\">Medical advice</td><td align=\"right\">158</td><td align=\"right\">(1.5%)</td><td align=\"right\">206</td><td align=\"right\">(2.0%)</td><td/></tr><tr><td align=\"left\">Medical diagnosis/treatment/investigation</td><td align=\"right\">143</td><td align=\"right\">(1.4%)</td><td align=\"right\">160</td><td align=\"right\">(1.6%)</td><td/></tr><tr><td align=\"left\">Non-specific adverse events</td><td align=\"right\">110</td><td align=\"right\">(1.1%)</td><td align=\"right\">126</td><td align=\"right\">(1.2%)</td><td/></tr><tr><td align=\"left\">Other adverse events</td><td align=\"right\">229</td><td align=\"right\">(2.2%)</td><td align=\"right\">225</td><td align=\"right\">(2.2%)</td><td/></tr><tr><td align=\"left\">&#8195;Gastrointestinal</td><td align=\"right\">114</td><td align=\"right\">(1.1%)</td><td align=\"right\">104</td><td align=\"right\">(1.0%)</td><td/></tr><tr><td align=\"left\">&#8195;Psychological/psychiatric</td><td align=\"right\">49</td><td align=\"right\">(0.5%)</td><td align=\"right\">54</td><td align=\"right\">(0.5%)</td><td/></tr><tr><td align=\"left\">&#8195;Rash or skin</td><td align=\"right\">22</td><td align=\"right\">(0.2%)</td><td align=\"right\">22</td><td align=\"right\">(0.2%)</td><td/></tr><tr><td align=\"left\">&#8195;Neurological</td><td align=\"right\">10</td><td align=\"right\">(0.1%)</td><td align=\"right\">14</td><td align=\"right\">(0.1%)</td><td/></tr><tr><td align=\"left\">&#8195;Other</td><td align=\"right\">44</td><td align=\"right\">(0.4%)</td><td align=\"right\">43</td><td align=\"right\">(0.4%)</td><td/></tr><tr><td align=\"left\">Other or family reasons</td><td align=\"right\">149</td><td align=\"right\">(1.5%)</td><td align=\"right\">141</td><td align=\"right\">(1.4%)</td><td/></tr><tr><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Any of the above*</bold></td><td align=\"right\"><bold>3440</bold></td><td align=\"right\"><bold>(33.5%)</bold></td><td align=\"right\"><bold>4424</bold></td><td align=\"right\"><bold>(43.1%)</bold></td><td align=\"right\"><bold>P = 0.0000</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2676245:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of 1574 deceased subjects in a random sample of the Swedish population</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Variable<break/><break/></td><td align=\"center\">Subjects with pharmaceutical <break/>drug poisonings<break/>(n = 9)</td><td align=\"center\">Remaining <break/>subjects<break/>(n = 1565)</td><td align=\"center\">P value<break/><break/></td></tr></thead><tbody><tr><td align=\"left\">Number of males (%)</td><td align=\"center\">5 (56%)</td><td align=\"center\">806 (51.5%)</td><td align=\"center\">1.0</td></tr><tr><td align=\"left\">Age, years, median (range)</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Males</td><td align=\"center\">53 (26&#8211;85)</td><td align=\"center\">79 (0&#8211;101)</td><td align=\"center\">0.08</td></tr><tr><td align=\"left\">&#8195;Females</td><td align=\"center\">49 (27&#8211;85)</td><td align=\"center\">84 (0&#8211;104)</td><td align=\"center\">&lt;0.05</td></tr><tr><td align=\"left\">Forensic autopsy performed, n (%)</td><td align=\"center\">7 (78%)</td><td align=\"center\">76 (4.9%)</td><td align=\"center\">&lt;0.01</td></tr><tr><td align=\"left\">Clinical autopsy performed, n (%)</td><td align=\"center\">0 (0%)</td><td align=\"center\">115 (7.3%)</td><td align=\"center\">1.0</td></tr><tr><td align=\"left\">Fatalities in hospital, n (%)</td><td align=\"center\">3 (33%)</td><td align=\"center\">636 (40.6%)</td><td align=\"center\">0.8</td></tr></tbody></table></body></html>", "text": "Pmid= 2679715:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Details of the 9 fatalities classified as pharmaceutical drug poisonings</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Case number<break/><break/></td><td align=\"left\">Sex<break/><break/></td><td align=\"left\">Age<break/><break/></td><td align=\"left\">Type of drug poisoning<break/><break/></td><td align=\"left\">Suspected drugs<break/><break/></td><td align=\"left\">Postmortem femoral<break/>blood concentration<break/>(&#956;g/g)</td></tr></thead><tbody><tr><td align=\"left\">1</td><td align=\"left\">Female</td><td align=\"left\">81</td><td align=\"left\">Intentional</td><td align=\"left\">Nitrazepam</td><td align=\"left\">NA</td></tr><tr><td align=\"left\">2</td><td align=\"left\">Female</td><td align=\"left\">34</td><td align=\"left\">Intentional</td><td align=\"left\">Levomepromazine</td><td align=\"left\">3.6</td></tr><tr><td align=\"left\">3</td><td align=\"left\">Female</td><td align=\"left\">27</td><td align=\"left\">Intentional</td><td align=\"left\">Morphine</td><td align=\"left\">0.18</td></tr><tr><td align=\"left\">4</td><td align=\"left\">Male</td><td align=\"left\">26</td><td align=\"left\">Intentional</td><td align=\"left\">Nitrazepam</td><td align=\"left\">0.7<sup>a</sup></td></tr><tr><td/><td/><td/><td/><td align=\"left\">+ carbamazepine</td><td align=\"left\">17</td></tr><tr><td/><td/><td/><td/><td align=\"left\">+ propoxyphene</td><td align=\"left\">1.2</td></tr><tr><td/><td/><td/><td/><td align=\"left\">+ promethazine</td><td align=\"left\">0.1</td></tr><tr><td align=\"left\">5</td><td align=\"left\">Male<sup>b</sup></td><td align=\"left\">85</td><td align=\"left\">Unintentional</td><td align=\"left\">Digoxin</td><td align=\"left\">NA<sup>c</sup></td></tr><tr><td align=\"left\">6</td><td align=\"left\">Female</td><td align=\"left\">64</td><td align=\"left\">Unintentional</td><td align=\"left\">Amitriptyline</td><td align=\"left\">3</td></tr><tr><td align=\"left\">7</td><td align=\"left\">Male<sup>d</sup></td><td align=\"left\">53</td><td align=\"left\">Unintentional</td><td align=\"left\">Alimemazine</td><td align=\"left\">3.9</td></tr><tr><td align=\"left\">8</td><td align=\"left\">Male</td><td align=\"left\">80</td><td align=\"left\">Unknown intent</td><td align=\"left\">Diazepam</td><td align=\"left\">0.4</td></tr><tr><td align=\"left\">9</td><td align=\"left\">Male<sup>e</sup></td><td align=\"left\">53</td><td align=\"left\">Unknown intent</td><td align=\"left\">Alimemazine</td><td align=\"left\">0.7</td></tr></tbody></table></body></html>", "text": "Pmid= 2679715:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of the study population (N = 520)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\">Male *</td><td align=\"left\">296 (57%)</td></tr></thead><tbody><tr><td align=\"left\">Age **</td><td align=\"left\">65.6 (19&#8211;94)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Number of drugs on admission **</td><td align=\"left\">4.4 (0&#8211;16)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Number of discharge diagnoses **</td><td align=\"left\">5.0 (1&#8211;14)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Renal failure *</td><td align=\"left\">50 (9.6%)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Liver failure *</td><td align=\"left\">52 (10.0%)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Alcohol abuse *</td><td align=\"left\">36 (6.9%)</td></tr></tbody></table></body></html>", "text": "Pmid= 2680808:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Urgency and paths of admission to medical departments</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>No. of patients admitted regardless of ADR (N = 520)</bold></td><td align=\"left\"><bold>No. of patients admitted due to ADR (%) (N = 30)</bold></td></tr></thead><tbody><tr><td align=\"left\">Urgent admissions through Medical Emergency Department</td><td align=\"left\">210</td><td align=\"left\">23 (11.0%) *</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Urgent admissions through Medical Outpatients Department</td><td align=\"left\">48</td><td align=\"left\">3 (6.3%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Urgent transfer from other primary hospitals or departments</td><td align=\"left\">49</td><td align=\"left\">4 (8.2%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Non-urgent/planned admissions</td><td align=\"left\">213</td><td align=\"left\">0 (0%) *</td></tr></tbody></table></body></html>", "text": "Pmid= 2680808:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Departments of admittance of the study population</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Medical departments</bold></td><td align=\"left\"><bold>No. of patients admitted regardless of ADR (N = 520)</bold></td><td align=\"left\"><bold>No. of patients admitted due to ADR (%) (N = 30)</bold></td></tr></thead><tbody><tr><td align=\"left\">Cardiology</td><td align=\"left\">163</td><td align=\"left\">4 (2.5%) *</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Angiology</td><td align=\"left\">74</td><td align=\"left\">0 (0%) **</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Gastroenterology</td><td align=\"left\">72</td><td align=\"left\">13 (18.0%) *, **</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Endocrinology</td><td align=\"left\">68</td><td align=\"left\">6 (8.8%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Haematology ***</td><td align=\"left\">47</td><td align=\"left\">4 (8.5%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Intensive Care Medicine</td><td align=\"left\">38</td><td align=\"left\">2 (5.3%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Nephrology</td><td align=\"left\">32</td><td align=\"left\">1 (3.1%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Pulmonology</td><td align=\"left\">21</td><td align=\"left\">0 (0%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Toxicology</td><td align=\"left\">5</td><td align=\"left\">0 (0%)</td></tr></tbody></table></body></html>", "text": "Pmid= 2680808:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of patients according to ADR on admission</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>No-ADR</bold></td><td align=\"left\"><bold>A-ADR</bold></td><td align=\"left\"><bold>p</bold></td></tr></thead><tbody><tr><td align=\"left\">Number</td><td align=\"left\">490 (94.3%)</td><td align=\"left\">30 (5.7%)</td><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Men</td><td align=\"left\">281 (57.3%)</td><td align=\"left\">15 (50.0%)</td><td align=\"left\">0.494</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Age *</td><td align=\"left\">65.2 (19&#8211;94)</td><td align=\"left\">71.5 (42&#8211;89)</td><td align=\"left\">0.025</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Number of drugs *</td><td align=\"left\">4.3 (0&#8211;16)</td><td align=\"left\">5.6 (1&#8211;12)</td><td align=\"left\">0.273</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Number of diagnoses *</td><td align=\"left\">5.0 (1&#8211;14)</td><td align=\"left\">5.5 (1&#8211;10)</td><td align=\"left\">0.674</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Renal failure</td><td align=\"left\">46 (9.4%)</td><td align=\"left\">4 (13.3%)</td><td align=\"left\">0.419</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Liver failure</td><td align=\"left\">50 (10.2%)</td><td align=\"left\">2 (6.7%)</td><td align=\"left\">0.859</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Alcohol abuse</td><td align=\"left\">34 (6.9%)</td><td align=\"left\">2 (6.7%)</td><td align=\"left\">0.195</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Death</td><td align=\"left\">19 (3.9%)</td><td align=\"left\">0 (0%)</td><td align=\"left\">0.998</td></tr></tbody></table></body></html>", "text": "Pmid= 2680808:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Description of certain ADRs as a cause of admittance</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>ADR (No. of patients)</bold></td><td align=\"left\"><bold>Class of drugs (No. of patients with ADR/No. of patients with potentially preventable ADR)</bold></td></tr></thead><tbody><tr><td align=\"left\">Cardiovascular disorders</td><td/></tr><tr><td align=\"left\">&#8195;Bradycardia (4)</td><td align=\"left\">Beta-adrenergic blocker (2/2) *</td></tr><tr><td/><td align=\"left\">Beta-adrenergic blocker and digoxin (2/2) *</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Gastrointestinal disorder</td><td/></tr><tr><td align=\"left\">&#8195;Gastrointestinal bleeding (12)</td><td align=\"left\">Acetylsalicylic acid (4/4) *</td></tr><tr><td/><td align=\"left\">Acetylsalicylic acid with NSAID (1/1) *</td></tr><tr><td/><td align=\"left\">NSAID (5/4) *</td></tr><tr><td/><td align=\"left\">Warfarin (2/2) *</td></tr><tr><td align=\"left\">&#8195;Liver failure (1)</td><td align=\"left\">Antifungal agent (1/0)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Renal disorders</td><td/></tr><tr><td align=\"left\">&#8195;Renal failure (1)</td><td align=\"left\">Antineoplastic agent (1/0)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Haematological disorders</td><td/></tr><tr><td align=\"left\">&#8195;Anaemia (2)</td><td align=\"left\">Antineoplastic agent (1/1) *</td></tr><tr><td/><td align=\"left\">Immunosuppressive agent (1/1) *</td></tr><tr><td align=\"left\">&#8195;Pancytopenia (1)</td><td align=\"left\">Antineoplastic agent (1/1) *</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Metabolic disorders</td><td/></tr><tr><td align=\"left\">&#8195;Hypoglycaemia (3)</td><td align=\"left\">Insulin (2/2) *</td></tr><tr><td/><td align=\"left\">Insulin and sulphonyurea (1/1) *</td></tr><tr><td align=\"left\">&#8195;Hyperglycaemia (4)</td><td align=\"left\">Corticosteroid (4/4) *</td></tr><tr><td align=\"left\">&#8195;Hypokaliemia (1)</td><td align=\"left\">Diuretic (1/1) *</td></tr><tr><td align=\"left\">&#8195;Hyperkaliemia (1)</td><td align=\"left\">ACE inhibitor and spironolactone (1/1) *</td></tr></tbody></table></body></html>", "text": "Pmid= 2680808:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Demographic characteristics.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\" colspan=\"2\"><bold>Demographic characteristic</bold></td><td align=\"left\"><bold>HX575</bold><break/>(<italic>n </italic>= 40)</td><td align=\"left\"><bold>Comparator</bold><break/>(<italic>n </italic>= 40)</td></tr></thead><tbody><tr><td align=\"left\"><bold>Age </bold>(year)</td><td align=\"left\">Mean</td><td align=\"left\">32.6</td><td align=\"left\">33.4</td></tr><tr><td/><td align=\"left\">SD</td><td align=\"left\">7.4</td><td align=\"left\">6.9</td></tr><tr><td/><td align=\"left\">Range</td><td align=\"left\">20&#8211;46</td><td align=\"left\">20&#8211;44</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Weight </bold>(kg)</td><td align=\"left\">Mean</td><td align=\"left\">78.5</td><td align=\"left\">78.9</td></tr><tr><td/><td align=\"left\">SD</td><td align=\"left\">10.1</td><td align=\"left\">9.1</td></tr><tr><td/><td align=\"left\">Range</td><td align=\"left\">60&#8211;98</td><td align=\"left\">59&#8211;100</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Height </bold>(cm)</td><td align=\"left\">Mean</td><td align=\"left\">179.9</td><td align=\"left\">180.9</td></tr><tr><td/><td align=\"left\">SD</td><td align=\"left\">6.1</td><td align=\"left\">5.7</td></tr><tr><td/><td align=\"left\">Range</td><td align=\"left\">170&#8211;190</td><td align=\"left\">166&#8211;195</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>BMI </bold>(kg/m<sup>2</sup>)</td><td align=\"left\">Mean</td><td align=\"left\">24.19</td><td align=\"left\">24.07</td></tr><tr><td/><td align=\"left\">SD</td><td align=\"left\">2.34</td><td align=\"left\">2.12</td></tr><tr><td/><td align=\"left\">Range</td><td align=\"left\">20.3&#8211;28.3</td><td align=\"left\">20.7&#8211;28.4</td></tr></tbody></table></body></html>", "text": "Pmid= 2695417:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Mean pharmacokinetic parameters after multiple intravenous epoetin doses.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Treatment</bold></td><td/><td align=\"right\"><bold>AUC<sub>&#964; </sub></bold>mIU/mL*h)</td><td align=\"right\"><bold>C<sub>max, ss </sub></bold>(mIU/mL)</td><td align=\"right\"><bold>t<sub>max </sub></bold>(h)</td><td align=\"right\"><bold>C<sub>trough </sub></bold>(mIU/mL)</td><td align=\"right\"><bold>t<sub>1/2 </sub></bold>(h)</td></tr></thead><tbody><tr><td align=\"left\"><bold>HX575</bold></td><td align=\"right\">Mean</td><td align=\"right\">8422</td><td align=\"right\">2189</td><td align=\"right\">0.086</td><td align=\"right\">9.811</td><td align=\"right\">4.14</td></tr><tr><td/><td align=\"right\">SD</td><td align=\"right\">2419</td><td align=\"right\">393.7</td><td align=\"right\">0.019</td><td align=\"right\">2.728</td><td align=\"right\">1.71</td></tr><tr><td/><td align=\"right\">Min</td><td align=\"right\">4327</td><td align=\"right\">1203</td><td align=\"right\">0.083</td><td align=\"right\">5.565</td><td align=\"right\">1.90</td></tr><tr><td/><td align=\"right\">Median</td><td align=\"right\">7930</td><td align=\"right\">2180</td><td align=\"right\">0.083</td><td align=\"right\">9.174</td><td align=\"right\">3.48</td></tr><tr><td/><td align=\"right\">Max</td><td align=\"right\">19321</td><td align=\"right\">3197</td><td align=\"right\">0.200</td><td align=\"right\">18.61</td><td align=\"right\">8.43</td></tr><tr><td/><td align=\"right\">GeoM</td><td align=\"right\">8153</td><td align=\"right\">2153</td><td align=\"right\">-</td><td align=\"right\">9.486</td><td align=\"right\">3.85</td></tr><tr><td/><td align=\"right\">GeoCV</td><td align=\"right\">25.4%</td><td align=\"right\">19.3%</td><td align=\"right\">-</td><td align=\"right\">26.2%</td><td align=\"right\">39.0%</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\"><bold>Comparator</bold></td><td align=\"right\">Mean</td><td align=\"right\">9224</td><td align=\"right\">2262</td><td align=\"right\">0.083</td><td align=\"right\">9.446</td><td align=\"right\">4.74</td></tr><tr><td/><td align=\"right\">SD</td><td align=\"right\">1850</td><td align=\"right\">422.0</td><td align=\"right\">0.000</td><td align=\"right\">2.438</td><td align=\"right\">2.00</td></tr><tr><td/><td align=\"right\">Min</td><td align=\"right\">4977</td><td align=\"right\">1272</td><td align=\"right\">0.083</td><td align=\"right\">5.020</td><td align=\"right\">1.31</td></tr><tr><td/><td align=\"right\">Median</td><td align=\"right\">9181</td><td align=\"right\">2210</td><td align=\"right\">0.083</td><td align=\"right\">9.161</td><td align=\"right\">4.45</td></tr><tr><td/><td align=\"right\">Max</td><td align=\"right\">13268</td><td align=\"right\">3161</td><td align=\"right\">0.083</td><td align=\"right\">15.77</td><td align=\"right\">11.03</td></tr><tr><td/><td align=\"right\">GeoM</td><td align=\"right\">9036</td><td align=\"right\">2222</td><td align=\"right\">-</td><td align=\"right\">9.141</td><td align=\"right\">4.37</td></tr><tr><td/><td align=\"right\">GeoCV</td><td align=\"right\">21.1%</td><td align=\"right\">19.7%</td><td align=\"right\">-</td><td align=\"right\">26.6%</td><td align=\"right\">43.5%</td></tr></tbody></table></body></html>", "text": "Pmid= 2695417:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Ratio (HX575/comparator), 90% confidence intervals, and ANOVA coefficient of variation of pharmacokinetic parameters after multiple epoetin doses.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>PK Parameter</bold></td><td align=\"left\"><bold>Method</bold></td><td align=\"right\"><bold>Ratio </bold>(%)</td><td align=\"center\"><bold>90% CI </bold>(%)</td><td align=\"left\"><bold>ANOVA-CV </bold>(%)</td></tr></thead><tbody><tr><td align=\"left\"><bold>AUC<sub>&#964;</sub></bold></td><td align=\"left\">MWW-log*</td><td align=\"right\">89.2</td><td align=\"center\">82.5&#8211;96.2</td><td align=\"left\">23.3</td></tr><tr><td align=\"left\"><bold>C<sub>max, ss</sub></bold></td><td align=\"left\">MWW-log*</td><td align=\"right\">97.5</td><td align=\"center\">91.1&#8211;104.5</td><td align=\"left\">19.5</td></tr><tr><td align=\"left\"><bold>C<sub>trough</sub></bold></td><td align=\"left\">ANOVA-log</td><td align=\"right\">103.8</td><td align=\"center\">94.0&#8211;114.6</td><td align=\"left\">26.4</td></tr><tr><td align=\"left\"><bold>t<sub>1/2</sub></bold></td><td align=\"left\">MWW-log*</td><td align=\"right\">87.8</td><td align=\"center\">75.3&#8211;100.0</td><td align=\"left\">41.4</td></tr></tbody></table></body></html>", "text": "Pmid= 2695417:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Area under the effect curve (AUEC), AUEC ratio (HX575/comparator), 90% confidence intervals and ANOVA coefficient of variation over days 129 of the study for the AUECs of the haematological parameters.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Haematological parameter</bold></td><td align=\"right\"><bold>HX575</bold></td><td align=\"right\"><bold>Comparator</bold></td><td align=\"right\"><bold>Ratio </bold>(%)</td><td align=\"right\"><bold>90% CI </bold>(%)</td><td align=\"right\"><bold>ANOVA-CV </bold>(%)</td></tr></thead><tbody><tr><td align=\"left\"><bold>AUEC<sub>Hb </sub></bold>(g/dL*h) &#8211; GeoM</td><td align=\"right\">10049.4</td><td align=\"right\">10064.3</td><td align=\"right\">99.9</td><td align=\"right\">98.5&#8211;101.2</td><td align=\"right\">3.6</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>AUEC<sub>Hb </sub></bold>(g/dL*h) &#8211; GeoCV</td><td align=\"right\">3.5%</td><td align=\"right\">3.6%</td><td align=\"right\">-</td><td align=\"right\">-</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>AUEC<sub>RBC </sub></bold>(10<sup>6</sup>/&#956;L*h) &#8211; GeoM</td><td align=\"right\">3318</td><td align=\"right\">3298</td><td align=\"right\">100.6</td><td align=\"right\">98.5&#8211;102.7</td><td align=\"right\">5.4</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>AUEC<sub>RBC </sub></bold>(10<sup>6</sup>/&#956;L*h) &#8211; GeoCV</td><td align=\"right\">5.5%</td><td align=\"right\">5.4%</td><td align=\"right\">-</td><td align=\"right\">-</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>AUEC<sub>HCT </sub></bold>(%*h) &#8211; GeoM</td><td align=\"right\">28796</td><td align=\"right\">28912</td><td align=\"right\">99.6</td><td align=\"right\">98.2&#8211;101.0</td><td align=\"right\">3.7</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>AUEC<sub>HCT </sub></bold>(%*h) &#8211; GeoCV</td><td align=\"right\">4.1%</td><td align=\"right\">3.3%</td><td align=\"right\">-</td><td align=\"right\">--</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>AUEC<sub>RET </sub></bold>(h*10<sup>9</sup>/L) &#8211; GeoM</td><td align=\"right\">85577</td><td align=\"right\">87070</td><td align=\"right\">98.3</td><td align=\"right\">93.0&#8211;103.9</td><td align=\"right\">14.5</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>AUEC<sub>RET </sub></bold>(h*10<sup>9</sup>/L) &#8211; GeoCV</td><td align=\"right\">13.3%</td><td align=\"right\">15.6%</td><td align=\"right\">-</td><td align=\"right\">-</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2695417:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Distribution of patients and prescriptions in the three areas considered.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Section </bold><break/><bold>(n. units)</bold></td><td align=\"center\"><bold>% Patients with antibiotic prescription </bold><break/><bold>(patients with prescription/patient observed)</bold></td><td align=\"center\"><bold>Antibiotic prescriptions </bold><break/><bold>(n.)</bold></td><td align=\"center\"><bold>n. antibiotics/patient </bold><break/><bold>(Mean; Standard Deviation)</bold></td></tr></thead><tbody><tr><td align=\"center\">Medical Section<break/>(16)</td><td align=\"center\">43,1<break/>(155/360)</td><td align=\"center\">221</td><td align=\"center\">1,4 &#177; 0,7</td></tr><tr><td align=\"center\">Surgical Section<break/>(18)</td><td align=\"center\">34,0<break/>(106/312)</td><td align=\"center\">130</td><td align=\"center\">1,2 &#177; 0,4</td></tr><tr><td align=\"center\">Intensive Care Section<break/>(7)</td><td align=\"center\">44,0<break/>(37/84)</td><td align=\"center\">57</td><td align=\"center\">1,5 &#177; 0,6</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"center\"><bold>Total</bold></td><td align=\"center\"><bold>39,4</bold><break/><bold>(298/756)</bold></td><td align=\"center\"><bold>408</bold></td><td align=\"center\"><bold>1,4 &#177; 0,6</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2695418:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>The prevalence of one or more (DP  1) and five or more (DP  5) dispensed drugs related to age and gender.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"3\">DP &#8805; 1</td><td align=\"center\" colspan=\"3\">DP &#8805; 5</td><td align=\"center\" colspan=\"2\">RR for females</td></tr><tr><td/><td colspan=\"3\"><hr/></td><td colspan=\"3\"><hr/></td><td colspan=\"2\"><hr/></td></tr><tr><td/><td align=\"center\">All</td><td align=\"center\">Females</td><td align=\"center\">Males</td><td align=\"center\">All</td><td align=\"center\">Females</td><td align=\"center\">Males</td><td align=\"center\">DP &#8805; 1</td><td align=\"center\">DP &#8805; 5</td></tr><tr><td align=\"left\">Age</td><td align=\"right\">n = 6,146,679</td><td align=\"right\">3,466,243</td><td align=\"right\">2,680,436</td><td align=\"right\">2,227,152</td><td align=\"right\">1,356,934</td><td align=\"right\">870,218</td><td/><td/></tr></thead><tbody><tr><td align=\"left\">0&#8211;9</td><td align=\"right\">57.3</td><td align=\"right\">55.8</td><td align=\"right\">58.8</td><td align=\"right\">6.6</td><td align=\"right\">5.7</td><td align=\"right\">7.3</td><td align=\"right\">0.9</td><td align=\"right\">0.8</td></tr><tr><td align=\"left\">10&#8211;19</td><td align=\"right\">49.0</td><td align=\"right\">58.4</td><td align=\"right\">40.1</td><td align=\"right\">6.2</td><td align=\"right\">8.3</td><td align=\"right\">4.1</td><td align=\"right\">1.5</td><td align=\"right\">2.0</td></tr><tr><td align=\"left\">20&#8211;29</td><td align=\"right\">58.4</td><td align=\"right\">76.4</td><td align=\"right\">41.2</td><td align=\"right\">9.9</td><td align=\"right\">15.2</td><td align=\"right\">5.0</td><td align=\"right\">1.8</td><td align=\"right\">3.1</td></tr><tr><td align=\"left\">30&#8211;39</td><td align=\"right\">62.5</td><td align=\"right\">75.3</td><td align=\"right\">50.3</td><td align=\"right\">13.9</td><td align=\"right\">19.7</td><td align=\"right\">8.4</td><td align=\"right\">1.5</td><td align=\"right\">2.3</td></tr><tr><td align=\"left\">40&#8211;49</td><td align=\"right\">64.3</td><td align=\"right\">73.3</td><td align=\"right\">55.6</td><td align=\"right\">18.4</td><td align=\"right\">23.8</td><td align=\"right\">13.2</td><td align=\"right\">1.3</td><td align=\"right\">1.8</td></tr><tr><td align=\"left\">50&#8211;59</td><td align=\"right\">75.8</td><td align=\"right\">82.5</td><td align=\"right\">69.3</td><td align=\"right\">30.2</td><td align=\"right\">36.3</td><td align=\"right\">24.3</td><td align=\"right\">1.2</td><td align=\"right\">1.5</td></tr><tr><td align=\"left\">60&#8211;69</td><td align=\"right\">80.1</td><td align=\"right\">83.6</td><td align=\"right\">76.5</td><td align=\"right\">42.3</td><td align=\"right\">46.8</td><td align=\"right\">37.7</td><td align=\"right\">1.1</td><td align=\"right\">1.2</td></tr><tr><td align=\"left\">70&#8211;79</td><td align=\"right\">90.8</td><td align=\"right\">92.3</td><td align=\"right\">89.0</td><td align=\"right\">62.4</td><td align=\"right\">65.5</td><td align=\"right\">58.7</td><td align=\"right\">1.0</td><td align=\"right\">1.1</td></tr><tr><td align=\"left\">80&#8211;89</td><td align=\"right\">94.5</td><td align=\"right\">95.1</td><td align=\"right\">93.5</td><td align=\"right\">75.1</td><td align=\"right\">77.3</td><td align=\"right\">71.6</td><td align=\"right\">1.0</td><td align=\"right\">1.1</td></tr><tr><td align=\"left\">90-</td><td align=\"right\">93.3</td><td align=\"right\">93.6</td><td align=\"right\">92.4</td><td align=\"right\">77.7</td><td align=\"right\">79.4</td><td align=\"right\">73.3</td><td align=\"right\">1.0</td><td align=\"right\">1.1</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">Total</td><td align=\"right\">67.4</td><td align=\"right\">75.6</td><td align=\"right\">59.3</td><td align=\"right\">24.4</td><td align=\"right\">29.6</td><td align=\"right\">19.2</td><td align=\"right\">1.3</td><td align=\"right\">1.5</td></tr></tbody></table></body></html>", "text": "Pmid= 2696422:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>The prevalence of five or more (DP  5) dispensed drugs with and without ATC G03</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\" colspan=\"4\">All individuals DP &#8805; 5</td><td align=\"left\" colspan=\"2\">Females DP &#8805; 5</td></tr><tr><td/><td colspan=\"4\"><hr/></td><td colspan=\"2\"><hr/></td></tr><tr><td/><td align=\"left\">All drugs</td><td align=\"left\">ATC G03 excluded</td><td align=\"left\">ATC J01 excluded</td><td align=\"left\">ATC N05 excluded</td><td align=\"left\">All drugs</td><td align=\"left\">ATC G03 excluded</td></tr><tr><td align=\"left\">Age</td><td align=\"right\">n = 2,227,152</td><td align=\"right\">2,131,961</td><td align=\"right\">1,997,440</td><td align=\"right\">2,111,966</td><td align=\"right\">1,356,934</td><td align=\"right\">1,262,497</td></tr></thead><tbody><tr><td align=\"left\">0&#8211;9</td><td align=\"right\">6.6</td><td align=\"right\">6.6</td><td align=\"right\">3.6</td><td align=\"right\">6.5</td><td align=\"right\">5.7</td><td align=\"right\">5.7</td></tr><tr><td align=\"left\">10&#8211;19</td><td align=\"right\">6.2</td><td align=\"right\">5.2</td><td align=\"right\">4.3</td><td align=\"right\">5.9</td><td align=\"right\">8.3</td><td align=\"right\">6.4</td></tr><tr><td align=\"left\">20&#8211;29</td><td align=\"right\">9.9</td><td align=\"right\">8.3</td><td align=\"right\">7.5</td><td align=\"right\">9.1</td><td align=\"right\">15.2</td><td align=\"right\">11.8</td></tr><tr><td align=\"left\">30&#8211;39</td><td align=\"right\">13.9</td><td align=\"right\">12.5</td><td align=\"right\">11.2</td><td align=\"right\">12.8</td><td align=\"right\">19.7</td><td align=\"right\">16.7</td></tr><tr><td align=\"left\">40&#8211;49</td><td align=\"right\">18.4</td><td align=\"right\">17.4</td><td align=\"right\">15.9</td><td align=\"right\">16.8</td><td align=\"right\">23.8</td><td align=\"right\">21.8</td></tr><tr><td align=\"left\">50&#8211;59</td><td align=\"right\">30.2</td><td align=\"right\">28.9</td><td align=\"right\">27.4</td><td align=\"right\">28.3</td><td align=\"right\">36.3</td><td align=\"right\">33.5</td></tr><tr><td align=\"left\">60&#8211;69</td><td align=\"right\">42.3</td><td align=\"right\">41.1</td><td align=\"right\">39.4</td><td align=\"right\">40.4</td><td align=\"right\">46.8</td><td align=\"right\">44.4</td></tr><tr><td align=\"left\">70&#8211;79</td><td align=\"right\">62.4</td><td align=\"right\">61.6</td><td align=\"right\">60.0</td><td align=\"right\">60.2</td><td align=\"right\">65.5</td><td align=\"right\">64.1</td></tr><tr><td align=\"left\">80&#8211;89</td><td align=\"right\">75.1</td><td align=\"right\">74.7</td><td align=\"right\">73.2</td><td align=\"right\">72.7</td><td align=\"right\">77.3</td><td align=\"right\">76.7</td></tr><tr><td align=\"left\">90-</td><td align=\"right\">77.7</td><td align=\"right\">77.4</td><td align=\"right\">75.9</td><td align=\"right\">74.7</td><td align=\"right\">79.4</td><td align=\"right\">79.0</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">Total</td><td align=\"right\">24.4</td><td align=\"right\">23.4</td><td align=\"right\">21.9</td><td align=\"right\">23.2</td><td align=\"right\">29.6</td><td align=\"right\">27.5</td></tr></tbody></table></body></html>", "text": "Pmid= 2696422:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Plasma Pharmacokinetic Parameters for Cocaine and Benzoylecgonine</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Substance</bold><break/>(mean &#177; SD)</td><td align=\"center\"><bold>C<sub>max</sub></bold><break/><bold>(ng/ml)</bold></td><td align=\"center\"><bold>T<sub>max</sub></bold><break/><bold>(hr)</bold></td><td align=\"center\"><bold>AUC</bold><break/><bold>(0-t)</bold><break/><bold>(ng*h/ml)</bold></td><td align=\"center\"><bold>&#955;z</bold><break/><bold>(1/hr)</bold></td><td align=\"center\"><bold>(t<sub>1/2</sub>)z</bold><break/><bold>(hr)</bold></td><td align=\"center\"><bold>AUC</bold><break/><bold>(0-&#8734;)</bold><break/><bold>(ng*h/ml)</bold></td><td align=\"center\"><bold>AUC<sub>ext</sub></bold><break/><bold>(%)</bold></td><td align=\"center\"><bold>CL</bold><break/><bold>(ml/min/kg)</bold></td><td align=\"center\"><bold>Vz</bold><break/><bold>(l/kg)</bold></td></tr></thead><tbody><tr><td align=\"center\"><bold>Cocaine</bold><break/><bold>Pre Selegiline</bold><break/>(session 1)</td><td align=\"center\">721 &#177; 773</td><td align=\"center\">2.66 &#177; 1.74</td><td align=\"center\">2640 &#177; 55.6</td><td align=\"center\">0.453 &#177; 27.9</td><td align=\"center\">1.71 &#177; 0.81</td><td align=\"center\">2680 &#177; 1470</td><td align=\"center\">1.40 &#177; 1.03</td><td align=\"center\">18.3 &#177; 6.17</td><td align=\"center\">2.49 &#177; 0.88</td></tr><tr><td colspan=\"10\"><hr/></td></tr><tr><td align=\"center\"><bold>Cocaine</bold><break/><bold>With Selegiline</bold><break/>(session 2)</td><td align=\"center\">640 &#177; 332</td><td align=\"center\">2.27 &#177; 2.04</td><td align=\"center\">2360 &#177; 499</td><td align=\"center\">0.456 &#177; 0.09</td><td align=\"center\">1.57 &#177; 0.30</td><td align=\"center\">2400 &#177; 487</td><td align=\"center\">1.78 &#177; 1.87</td><td align=\"center\">18.0 &#177; 3.34</td><td align=\"center\">2.44 &#177; 0.64</td></tr><tr><td colspan=\"10\"><hr/></td></tr><tr><td align=\"center\"><bold>Benzoyl-ecgonine</bold><break/><bold>Pre Selegiline</bold><break/>(session 1)</td><td align=\"center\">1045 &#177; 180</td><td align=\"center\">4.79 &#177; 0.50</td><td align=\"center\">13000 &#177; 3030</td><td align=\"center\">0.0928 &#177; 0.023</td><td align=\"center\">8.63 &#177; 5.36</td><td align=\"center\">13600 &#177; 3820</td><td align=\"center\">3.45 &#177; 6.45</td><td/><td/></tr><tr><td colspan=\"10\"><hr/></td></tr><tr><td align=\"center\"><bold>Benzoyl-ecgonine</bold><break/><bold>With Selegiline</bold><break/>(session 2)</td><td align=\"center\">957 &#177; 184</td><td align=\"center\">5.04 &#177; 0.65</td><td align=\"center\">12900 &#177; 3760</td><td align=\"center\">0.0971 &#177; 0.024</td><td align=\"center\">7.52 &#177; 1.82</td><td align=\"center\">13200 &#177; 4180</td><td align=\"center\">2.21 &#177; 2.24</td><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 2731040:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Selegiline and Metabolites Excreted in the 24 Hour Urines from 024, 2448, and 4872 hours After Cocaine (Mean  SD, N = 12)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Drug Assayed</bold></td><td align=\"center\"><bold>0&#8211;24 hours</bold><break/><bold>(day 11)</bold></td><td align=\"center\"><bold>24&#8211;48 hours</bold><break/><bold>(day 12)</bold></td><td align=\"center\"><bold>Statistical p Value</bold><break/><bold>0&#8211;24 vs. 24&#8211;48 hours</bold></td><td align=\"center\"><bold>48&#8211;72 hours</bold><break/><bold>(day 13)</bold></td></tr></thead><tbody><tr><td align=\"left\">Selegiline</td><td align=\"center\">0.109 &#177; 0.073</td><td align=\"center\">0.145 &#177; 0.138</td><td align=\"center\">0.34</td><td align=\"center\">0.063 &#177; 0.097</td></tr><tr><td align=\"left\">Desmethylselegiline</td><td align=\"center\">0.184 &#177; 0.128</td><td align=\"center\">0.188 &#177; 0.162</td><td align=\"center\">0.75</td><td align=\"center\">0.082 &#177; 0.086</td></tr><tr><td align=\"left\">l-Methamphetamine</td><td align=\"center\">6.26 &#177; 2.28</td><td align=\"center\">8.51 &#177; 5.69</td><td align=\"center\">0.20</td><td align=\"center\">4.83 &#177; 1.55</td></tr><tr><td align=\"left\">l-Amphetamine</td><td align=\"center\">2.34 &#177; 0.85</td><td align=\"center\">3.30 &#177; 2.34</td><td align=\"center\">0.18</td><td align=\"center\">2.15 &#177; 0.94</td></tr></tbody></table></body></html>", "text": "Pmid= 2731040:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Physiologic and Subjective Measures  Summary of Peak Changes (Mean  SD for 12 Subjects)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\"><bold>Session 1</bold></td><td align=\"center\" colspan=\"2\"><bold>Session 2</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Measures</bold></td><td align=\"center\"><bold>Peak</bold><break/><bold>Mean &#177; SD</bold></td><td align=\"center\"><bold>Peak Time</bold><break/><bold>(Hr Postdose)</bold></td><td align=\"center\"><bold>Peak</bold><break/><bold>Mean &#177; SD</bold></td><td align=\"center\"><bold>Peak Time</bold><break/><bold>(Hr Postdose)</bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Physiologic Measures</bold></td><td/><td/><td/><td/></tr><tr><td align=\"left\">Systolic Blood Pressure (mmHg)</td><td align=\"center\">17 &#177; 8</td><td align=\"center\">2.2 &#177; 1.9</td><td align=\"center\">17 &#177; 9</td><td align=\"center\">1.9 &#177; 1.7</td></tr><tr><td align=\"left\">Diastolic Blood Pressure (mmHg)</td><td align=\"center\">10 &#177; 5</td><td align=\"center\">2.8 &#177; 2.4</td><td align=\"center\">12 &#177; 6</td><td align=\"center\">2 &#177; 2</td></tr><tr><td align=\"left\">Heart Rate (beats/min)</td><td align=\"center\">26 &#177; 10</td><td align=\"center\">0.8 &#177; 0.9</td><td align=\"center\">27 &#177; 12</td><td align=\"center\">0.9 &#177; 1.7</td></tr><tr><td align=\"left\">Rate Pressure Product (SBP*HR)</td><td align=\"center\">4224 &#177; 1638</td><td align=\"center\">1.4 &#177; 1.5</td><td align=\"center\">4437 &#177; 2333</td><td align=\"center\">0.9 &#177; 1.6</td></tr><tr><td align=\"left\">Respiration Rate (inhal/min)</td><td align=\"center\">3.8 &#177; 4.0</td><td align=\"center\">0.9 &#177; 1.3</td><td align=\"center\">3.8 &#177; 3.6</td><td align=\"center\">0.4 &#177; 0.3</td></tr><tr><td align=\"left\">Skin Temperature (&#176;C)</td><td align=\"center\">-5.4 &#177; 2.7</td><td align=\"center\">0.8 &#177; 0.4</td><td align=\"center\">-5 &#177; 3.2</td><td align=\"center\">1.0 &#177; 1.2</td></tr><tr><td align=\"left\">Core Temperature (&#176;C)</td><td align=\"center\">0.7 &#177; 0.2</td><td align=\"center\">4.5 &#177; 1.6</td><td align=\"center\">0.7 &#177; 0.5</td><td align=\"center\">4.2 &#177; 1.9</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Subjective Measures</bold></td><td/><td/><td/><td/></tr><tr><td align=\"left\">Global Intoxication (0&#8211;100)</td><td align=\"center\">57 &#177; 27</td><td align=\"center\">0.7 &#177; 1</td><td align=\"center\">53 &#177; 23</td><td align=\"center\">0.6 &#177; 0.9</td></tr><tr><td align=\"left\">Cocaine Craving (0&#8211;100)</td><td align=\"center\">33 &#177; 25</td><td align=\"center\">1.1 &#177; 1.3</td><td align=\"center\">20 &#177; 21</td><td align=\"center\">0.6 &#177; 0.7</td></tr><tr><td align=\"left\">Good Drug Effect (0&#8211;100)</td><td align=\"center\">66 &#177; 23</td><td align=\"center\">0.9 &#177; 1.5</td><td align=\"center\">60 &#177; 21</td><td align=\"center\">1 &#177; 1.3</td></tr><tr><td align=\"left\">Bad Drug Effect(0&#8211;100)</td><td align=\"center\">46 &#177; 31</td><td align=\"center\">1.9 &#177; 2.3</td><td align=\"center\">55 &#177; 25</td><td align=\"center\">1.4 &#177; 1.9</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>POMS Scales</bold></td><td/><td/><td/><td/></tr><tr><td align=\"left\">Tension (0&#8211;28)</td><td align=\"center\">7.5 &#177; 6.1</td><td align=\"center\">1 &#177; 0</td><td align=\"center\">4.8 &#177; 3.9</td><td align=\"center\">1 &#177; 0</td></tr><tr><td align=\"left\">Depression (0&#8211;64)</td><td align=\"center\">3 &#177; 6.5</td><td align=\"center\">3 &#177; 0</td><td align=\"center\">1.5 &#177; 2.4</td><td align=\"center\">3 &#177; 0</td></tr><tr><td align=\"left\">Anger (0&#8211;28)</td><td align=\"center\">2.8 &#177; 6.4</td><td align=\"center\">6 &#177; 0</td><td align=\"center\">-2.1 &#177; 5.7*</td><td align=\"center\">6 &#177; 0</td></tr><tr><td align=\"left\">Vigor (0&#8211;32)</td><td align=\"center\">-3.6 &#177; 3.4</td><td align=\"center\">6 &#177; 0</td><td align=\"center\">-3.9 &#177; 6.1</td><td align=\"center\">6 &#177; 0</td></tr><tr><td align=\"left\">Confusion (0&#8211;20)</td><td align=\"center\">2.5 &#177; 2.8</td><td align=\"center\">6 &#177; 0</td><td align=\"center\">2.7 &#177; 4.7</td><td align=\"center\">3 &#177; 0</td></tr><tr><td align=\"left\">Fatigue (0&#8211;28)</td><td align=\"center\">5.9 &#177; 5.9</td><td align=\"center\">6 &#177; 0</td><td align=\"center\">2.8 &#177; 5.3</td><td align=\"center\">6 &#177; 0</td></tr></tbody></table></body></html>", "text": "Pmid= 2731040:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Total Amount of PEA and MHPG (mg) Excreted in the 24 Hour Urine Collection Prior to and After Application of the Selegiline Patch</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Measure</bold></td><td align=\"center\"><bold>Day 3&#8211;4</bold><break/><bold>After Cocaine Preselegiline</bold></td><td align=\"center\"><bold>Day 4&#8211;5</bold><break/><bold>0&#8211;24 hr Postselegiline</bold></td><td align=\"center\"><bold>Day 11&#8211;12</bold><break/><bold>Selegiline Phase</bold><break/><bold>1<sup>st </sup>Day After Cocaine</bold><sup>&#9650;</sup></td><td align=\"center\"><bold>Day 12&#8211;13</bold><break/><bold>Selegiline Phase</bold><break/><bold>2<sup>nd </sup>Day After Cocaine</bold><sup>&#8224;</sup></td><td align=\"center\"><bold>DAY 13&#8211;14</bold><break/><bold>Selegiline Phase</bold><break/><bold>3<sup>rd </sup>Day After Cocaine</bold><sup>&#8225;</sup></td></tr></thead><tbody><tr><td align=\"left\">PEA</td><td align=\"center\">0.003 &#177; 0.004</td><td align=\"center\">0.132 &#177; 0.095*</td><td align=\"center\">0.260 &#177; 0.171****</td><td align=\"center\">0.229 &#177; 0.145****</td><td align=\"center\">0.159 &#177; 0.104**</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">MHPG-S</td><td align=\"center\">1.44 &#177; 0.43</td><td align=\"center\">1.43 &#177; 0.40</td><td align=\"center\">1.09 &#177; 0.23**</td><td align=\"center\">1.07 &#177; 0.40**</td><td align=\"center\">1.01 &#177; 0.33**</td></tr></tbody></table></body></html>", "text": "Pmid= 2731040:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>The demographics and characteristic features of the respondents</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Characteristics</bold></td><td align=\"left\"><bold>Values</bold></td></tr></thead><tbody><tr><td align=\"left\">Median age (years)</td><td align=\"left\">36 (IQR 32&#8211;40)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Median year of first degree qualification (years)</td><td align=\"left\">10 (IQR 4&#8211;15)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Median year of practice in a teaching hospital (years)</td><td align=\"left\">3 (IQR 1.5&#8211;7.0)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Male: female ratio</td><td align=\"left\">59: 40</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Cadre</td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><italic>Interns</italic></td><td align=\"left\">30 (30.3%)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><italic>Junior residents</italic></td><td align=\"left\">29 (29.3%)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><italic>Consultants</italic></td><td align=\"left\">22 (22.2%)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><italic>Senior residents</italic></td><td align=\"left\">18 (18.2%)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Country of undergraduate education</td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><italic>Nigeria</italic></td><td align=\"left\">84 (84.8%)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><italic>Abroad</italic></td><td align=\"left\">15 (15.2%)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Additional qualifications</td><td align=\"left\">37 (37.4%)</td></tr></tbody></table></body></html>", "text": "Pmid= 2731723:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Factors that may discourage doctors from reporting adverse drug reaction</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Factor</bold><sup>a</sup></td><td align=\"left\"><bold>Agree</bold></td><td align=\"left\"><bold>Disagree</bold></td></tr></thead><tbody><tr><td align=\"left\">Concern that the report may be wrong</td><td align=\"left\">47 (47.5%)</td><td align=\"left\">52 (52.5%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Lack of time to fill in a report and a single unreported case may not affect ADR database</td><td align=\"left\">37 (37.4%)</td><td align=\"left\">62 (62.6%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Level of clinical knowledge makes it difficult to decide whether or not an ADR has occurred</td><td align=\"left\">36 (36.4%)</td><td align=\"left\">63 (63.6%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Lack of time to actively look for an ADR while at work</td><td align=\"left\">33 (33.3%)</td><td align=\"left\">66 (66.7%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Don\\'t feel the need to report well recognised actions</td><td align=\"left\">27 (27.2%)</td><td align=\"left\">72 (72.2%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">The absence of fee for reporting</td><td align=\"left\">18 (18.2%)</td><td align=\"left\">81 (81.8%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Concern that a report will generate an extra work</td><td align=\"left\">15 (15.2%)</td><td align=\"left\">84 (84.8%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Fear of the negative impact the report may have on the company that produced or marketed the drug</td><td align=\"left\">15 (15.2%)</td><td align=\"left\">84 (84.8%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Lack of confidence in discussing the ADR with other colleagues</td><td align=\"left\">12 (12.1%)</td><td align=\"left\">87 (87.9%)</td></tr></tbody></table></body></html>", "text": "Pmid= 2731723:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Proportion of respondents that would report hypothetical cases of ADRs in line with the National Pharmacovigilance Centre reporting criteria</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Reaction</bold><sup>a</sup></td><td align=\"center\"><bold>Yes</bold></td><td align=\"center\"><bold>No</bold></td><td align=\"center\"><bold>Don\\'t know</bold></td></tr></thead><tbody><tr><td align=\"left\">Palpitation with Coartem<sup>&#174; </sup>(Yes)<sup>b</sup></td><td align=\"center\">58 (59.2%)</td><td align=\"center\">20 (20.4%)</td><td align=\"center\">20 (20.4%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Skin rashes with roxithromycin (Yes)<sup>b</sup></td><td align=\"center\">54 (55.1%)</td><td align=\"center\">26 (26.5%)</td><td align=\"center\">18 (18.4%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Jaundice with frusemide (Yes)<sup>b</sup></td><td align=\"center\">53 (54.1%)</td><td align=\"center\">21 (21.4%)</td><td align=\"center\">24 (24.5%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Thrombocytopenia with heparin (Yes)<sup>b</sup></td><td align=\"center\">39 (39.8%)</td><td align=\"center\">36 (36.7%)</td><td align=\"center\">23 (23.5%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Hiccup with enalapril (No)<sup>b</sup></td><td align=\"center\">36 (36.7%)</td><td align=\"center\">29 (29.6%)</td><td align=\"center\">33 (33.7%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Gastrointestinal bleed with diclofenac (Yes)<sup>b</sup></td><td align=\"center\">35 (35.7%)</td><td align=\"center\">41 (41.8%)</td><td align=\"center\">22 (22.4%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Headache with isordil dinitrate (No)<sup>b</sup></td><td align=\"center\">33 (33.7%)</td><td align=\"center\">41 (41.8%)</td><td align=\"center\">22 (22.4%)</td></tr></tbody></table></body></html>", "text": "Pmid= 2731723:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Suggested methods of improving ADRs reporting</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Methods</bold></td><td align=\"center\"><bold>Frequency (n = 98)</bold></td><td align=\"center\"><bold>Percentage (%)</bold></td></tr></thead><tbody><tr><td align=\"left\">Continuous medical education, training and refresher study</td><td align=\"center\">94</td><td align=\"center\">95.9</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Instituting and encouraging feedback between patients prescribers and dispensers of drugs</td><td align=\"center\">69</td><td align=\"center\">70.4</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Reminders and increased awareness from the ADR Monitoring Committee</td><td align=\"center\">67</td><td align=\"center\">68.4</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Increasing awareness among other professionals that they could report ADRs</td><td align=\"center\">62</td><td align=\"center\">63.3</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Increased collaboration with other healthcare professionals</td><td align=\"center\">58</td><td align=\"center\">59.2</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">More publicity about reporting scheme in local journals</td><td align=\"center\">56</td><td align=\"center\">57.1</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Encouragement from the ADR Monitoring Committee and various head of departments</td><td align=\"center\">49</td><td align=\"center\">50.0</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Having an ADR specialist in every department</td><td align=\"center\">46</td><td align=\"center\">46.9</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Encouraging on-line or telephone reporting</td><td align=\"center\">45</td><td align=\"center\">45.9</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Alerting all outpatients to watch out for possible ADR when prescribing new drugs</td><td align=\"center\">44</td><td align=\"center\">44.4</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Remuneration for every reported case of ADR</td><td align=\"center\">28</td><td align=\"center\">28.6</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Spending more time on the wards with patients</td><td align=\"center\">26</td><td align=\"center\">26.5</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Making reporting a professional obligation</td><td align=\"center\">25</td><td align=\"center\">25.5</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Incentives to every outpatient that report ADR</td><td align=\"center\">21</td><td align=\"center\">21.4</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Leaving Yellow Cards on the ward for easy accessibility</td><td align=\"center\">6</td><td align=\"center\">6.1</td></tr></tbody></table></body></html>", "text": "Pmid= 2731723:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Risk factor reference values</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Risk factor</bold></td><td align=\"left\"><bold>Reference Values</bold></td></tr></thead><tbody><tr><td align=\"left\">Hypertension <sup>23,34</sup></td><td align=\"left\">Non-diabetic patients &lt;140/90 mm/Hg</td></tr><tr><td/><td align=\"left\">Diabetic patients &lt;130/80 mm/Hg</td></tr><tr><td/><td align=\"left\">Patients with diabetic nephropathy &lt;125/75 mm/Hg</td></tr><tr><td align=\"left\">Diabetes mellitus <sup>34</sup></td><td align=\"left\">Fasting plasma blood glucose &lt;110 mg/dl</td></tr><tr><td/><td align=\"left\">Glycosylated haemoglobin HbA1c 4-6%</td></tr><tr><td align=\"left\">Hyperlipidemia <sup>25</sup></td><td align=\"left\">Low density cholesterol &lt;130 mg/dl</td></tr><tr><td/><td align=\"left\">Total cholesterol &lt;200 mg/dl</td></tr><tr><td/><td align=\"left\">Triglycerides &lt;200 mg/dl</td></tr></tbody></table></body></html>", "text": "Pmid= 2744655:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Categories for assessment of individual risk factors, therapeutic drug monitoring and overall assessment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\" colspan=\"2\"><bold>Individual RF<sup><bold>a </bold></sup>and TDM</bold><sup><bold>b</bold></sup></td><td align=\"left\" colspan=\"2\"><bold>Assessment of overall treatment quality</bold></td></tr><tr><td/><td colspan=\"4\"><hr/></td></tr><tr><td/><td align=\"left\"><bold>Assessment</bold></td><td align=\"left\"><bold>Explanation</bold></td><td align=\"left\"><bold>Assessment</bold></td><td align=\"left\"><bold>Explanation</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>1</bold></td><td align=\"left\">No need for intervention</td><td align=\"left\">Values<sup>d </sup>according to references in more than 2/3 of available values; Values better at discharge than at admission; Disease/RF<sup>a </sup>is treated; no severe pDDIs<sup>c</sup></td><td align=\"left\">Very good RF<sup>a </sup>management</td><td align=\"left\">No improvements necessary</td></tr><tr><td align=\"left\"><bold>2</bold></td><td align=\"left\">Improvement possible</td><td align=\"left\">Values<sup>d </sup>outside of reference range in more than 1/3 of available values; Values worse at discharge; severe pDDIs<sup>c</sup>; RF is treated</td><td align=\"left\">Good RF<sup>a </sup>management</td><td align=\"left\">Up to two individual RFs<sup>a </sup>being assessed as \"improvement possible\" (category 2); no untreated RFs<sup>a </sup>(category 3)</td></tr><tr><td align=\"left\"><bold>3</bold></td><td align=\"left\">Disease untreated</td><td align=\"left\">No drug therapy for RF<sup>a </sup>treatment; no TDM performed, although appropriate</td><td align=\"left\">Improvement in RF<sup>a </sup>management needed</td><td align=\"left\">More than two individual RFs<sup>a </sup>or TDMs<sup>b </sup>being assessed as \"improvement possible\" (category 2) or untreated RF<sup>a </sup>(category 3)</td></tr><tr><td align=\"left\"><bold>4</bold></td><td align=\"left\">No conclusion possible</td><td align=\"left\">Missing data; inconclusive data</td><td align=\"left\">No conclusion possible</td><td align=\"left\">Missing data; inconclusive data</td></tr></tbody></table></body></html>", "text": "Pmid= 2744655:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Sociodemographic characteristics, stages of CKD and length of stay</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\"><bold>Total population n = 102</bold></td><td align=\"center\" colspan=\"2\"><bold>TX<sup><bold>a </bold></sup>subgroup n = 49</bold></td></tr><tr><td/><td colspan=\"4\"><hr/></td></tr><tr><td/><td align=\"center\"><bold>n</bold></td><td align=\"center\"><bold>%</bold></td><td align=\"center\"><bold>n</bold></td><td align=\"center\"><bold>%</bold></td></tr></thead><tbody><tr><td align=\"left\">Men/Women</td><td align=\"center\">67/35</td><td align=\"center\">65.7/34.3</td><td align=\"center\">37/12</td><td align=\"center\">75.5/24.5</td></tr><tr><td align=\"left\">Age, years</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean &#177; SD<sup>b</sup></td><td align=\"center\">55.5 &#177; 13.4</td><td/><td align=\"center\">55.4 &#177; 11.4</td><td/></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">24-86</td><td/><td align=\"center\">29-73</td><td/></tr><tr><td align=\"left\">BMI<sup>c</sup>, kg/m<sup>2</sup></td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean &#177; SD<sup>b</sup></td><td align=\"center\">26.3 &#177; 5.1</td><td/><td align=\"center\">26 &#177; 4.8</td><td/></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">15-40.2</td><td/><td align=\"center\">16-40.2</td><td/></tr><tr><td align=\"left\">Stages of CKD</td><td align=\"center\">n = 80</td><td/><td align=\"center\">n = 44</td><td/></tr><tr><td align=\"left\">&#8195;2</td><td align=\"center\">3</td><td align=\"center\">3.8</td><td align=\"center\">2</td><td align=\"center\">2.3</td></tr><tr><td align=\"left\">&#8195;3</td><td align=\"center\">39</td><td align=\"center\">48.8</td><td align=\"center\">32</td><td align=\"center\">72.7</td></tr><tr><td align=\"left\">&#8195;4</td><td align=\"center\">15</td><td align=\"center\">18.8</td><td align=\"center\">7</td><td align=\"center\">15.9</td></tr><tr><td align=\"left\">&#8195;5</td><td align=\"center\">23</td><td align=\"center\">28.8</td><td align=\"center\">3</td><td align=\"center\">6.8</td></tr><tr><td align=\"left\">Length of stay, days</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mean &#177; SD<sup>b</sup></td><td align=\"center\">14.8 &#177; 10.5</td><td/><td align=\"center\">17.06 &#177; 9.9</td><td/></tr><tr><td align=\"left\">&#8195;Range</td><td align=\"center\">2-47</td><td/><td align=\"center\">2-41</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2744655:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Assessment of individual risk factors and quality of therapeutic drug monitoring</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\"><bold>No need for intervention</bold></td><td align=\"center\" colspan=\"2\"><bold>Improvement possible</bold></td><td align=\"center\" colspan=\"2\"><bold>Disease untreated/</bold><break/><bold>No TDM</bold><sup>a</sup></td><td align=\"center\" colspan=\"2\"><bold>No conclusion possible</bold></td></tr><tr><td/><td align=\"center\"><bold>% (n)</bold></td><td align=\"center\"><bold>95% CI</bold><sup><bold>b</bold></sup></td><td align=\"center\"><bold>% (n)</bold></td><td align=\"center\"><bold>95% CI</bold><sup><bold>b</bold></sup></td><td align=\"center\"><bold>% (n)</bold></td><td align=\"center\"><bold>95% CI</bold><sup><bold>b</bold></sup></td><td align=\"center\"><bold>% (n)</bold></td><td align=\"center\"><bold>95% CI</bold><sup><bold>b</bold></sup></td></tr></thead><tbody><tr><td align=\"left\">Hypertension<break/>n = 90</td><td align=\"center\">17.8 (16)</td><td align=\"center\"><italic>0.10-0.26</italic></td><td align=\"center\">37.8 (34)</td><td align=\"center\"><italic>0.28-0.48</italic></td><td align=\"center\">41.1 (37)</td><td align=\"center\"><italic>0.31-0.51</italic></td><td align=\"center\">3.3 (3)</td><td align=\"center\"><italic>0.00-0.07</italic></td></tr><tr><td align=\"left\">Diabetes mellitus<break/>n = 64</td><td align=\"center\">7.8 (5)</td><td align=\"center\"><italic>0.01-0.14</italic></td><td align=\"center\">42.2 (27)</td><td align=\"center\"><italic>0.30-0.54</italic></td><td align=\"center\">48.4 (31)</td><td align=\"center\"><italic>0.36-0.61</italic></td><td align=\"center\">1.6 (1)</td><td align=\"center\"><italic>0.00-0.05</italic></td></tr><tr><td align=\"left\">Hyperlipidemia<break/>n = 66</td><td align=\"center\">9.1 (6)</td><td align=\"center\"><italic>0.02-0.16</italic></td><td align=\"center\">42.4 (28)</td><td align=\"center\"><italic>0.31-0.54</italic></td><td align=\"center\">45.5 (30)</td><td align=\"center\"><italic>0.33-0.57</italic></td><td align=\"center\">3.0 (2)</td><td align=\"center\"><italic>0.00-0.07</italic></td></tr><tr><td align=\"left\">TDM<sup>a</sup><break/>n = 44</td><td align=\"center\">29.6 (13)</td><td align=\"center\"><italic>0.17-0.45</italic></td><td align=\"center\">34.1 (15)</td><td align=\"center\"><italic>0.20-0.50</italic></td><td align=\"center\">0.0 (0)</td><td align=\"center\"><italic>-</italic></td><td align=\"center\">36.4 (16)</td><td align=\"center\"><italic>0.22-0.52</italic></td></tr></tbody></table></body></html>", "text": "Pmid= 2744655:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Overall assessment of treatment quality</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\" colspan=\"2\"><bold>Very good RF<sup><bold>a </bold></sup>management</bold></td><td align=\"center\" colspan=\"2\"><bold>Good RF<sup><bold>a </bold></sup>management</bold></td><td align=\"center\" colspan=\"2\"><bold>Improvement needed</bold></td><td align=\"center\" colspan=\"2\"><bold>No conclusion possible</bold></td></tr><tr><td/><td align=\"center\"><bold>% (n)</bold></td><td align=\"center\"><bold>95% CI</bold><sup><bold>b</bold></sup></td><td align=\"center\"><bold>% (n)</bold></td><td align=\"center\"><bold>95% CI</bold><sup><bold>b</bold></sup></td><td align=\"center\"><bold>% (n)</bold></td><td align=\"center\"><bold>95% CI</bold><sup><bold>b</bold></sup></td><td align=\"center\"><bold>% (n)</bold></td><td align=\"center\"><bold>95% CI</bold><sup><bold>b</bold></sup></td></tr></thead><tbody><tr><td align=\"left\">Total n = 102</td><td align=\"center\">19.6 (20)</td><td align=\"center\"><italic>0.12-0.27</italic></td><td align=\"center\">39.2 (40)</td><td align=\"center\"><italic>0.30-0.49</italic></td><td align=\"center\">37.3 (38)</td><td align=\"center\"><italic>0.28-0.47</italic></td><td align=\"center\">3.9 (4)</td><td align=\"center\"><italic>0.00-0.08</italic></td></tr><tr><td align=\"left\">TX<sup>c </sup>subgroup<break/>n = 49</td><td align=\"center\">16.3 (8)</td><td align=\"center\"><italic>0.06-0.27</italic></td><td align=\"center\">32.7 (16)</td><td align=\"center\"><italic>0.20-0.46</italic></td><td align=\"center\">49.0 (24)</td><td align=\"center\"><italic>0.35-0.63</italic></td><td align=\"center\">2.0 (1)</td><td align=\"center\"><italic>0.00-0.06</italic></td></tr></tbody></table></body></html>", "text": "Pmid= 2744655:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Quantitative drug use and potential drug-drug interactions at hospital admission and discharge</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\" colspan=\"2\"><bold>Admission</bold></td><td align=\"left\" colspan=\"2\"><bold>Discharge</bold></td><td/></tr><tr><td align=\"left\"><bold>Total study population n = 102</bold></td><td align=\"left\"><bold>Mean &#177; SD</bold><sup><bold>a</bold></sup></td><td align=\"left\"><bold>Range</bold></td><td align=\"left\"><bold>Mean &#177; SD</bold><sup><bold>a</bold></sup></td><td align=\"left\"><bold>Range</bold></td><td align=\"left\"><bold>P-value</bold><sup><bold>b</bold></sup></td></tr></thead><tbody><tr><td align=\"left\">Number of drugs per patient</td><td align=\"left\">10.9 &#177; 4.2</td><td align=\"left\">0-20</td><td align=\"left\">12.1 &#177; 4.3</td><td align=\"left\">2-21</td><td align=\"left\">&lt;0.0001*</td></tr><tr><td align=\"left\">Number of pDDIs<sup>c </sup>per patient</td><td align=\"left\">1.9 &#177; 1.9</td><td align=\"left\">0-8</td><td align=\"left\">2.7 &#177; 2.5</td><td align=\"left\">0-11</td><td align=\"left\">&lt;0.0001*</td></tr><tr><td align=\"left\">Number of pDDIs<sup>c </sup>per drug prescribed</td><td align=\"left\">0.2 &#177; 0.2</td><td align=\"left\">0-0.83</td><td align=\"left\">0.2 &#177; 0.2</td><td align=\"left\">0-0.64</td><td align=\"left\">0.0016*</td></tr><tr><td align=\"left\">TX<sup>d </sup>subgroup n = 49</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Number of drugs per patient</td><td align=\"left\">12.6 &#177; 3.1</td><td align=\"left\">4-20</td><td align=\"left\">13.3 &#177; 3.2</td><td align=\"left\">5-20</td><td align=\"left\">0.055</td></tr><tr><td align=\"left\">Number of pDDIs<sup>c </sup>per patient</td><td align=\"left\">1.8 &#177; 2.4</td><td align=\"left\">0-8</td><td align=\"left\">2.7 &#177; 2.8</td><td align=\"left\">0-11</td><td align=\"left\">0.014*</td></tr><tr><td align=\"left\">Number of pDDIs<sup>c </sup>per drug prescribed</td><td align=\"left\">0.1 &#177; 0.1</td><td align=\"left\">0-0.53</td><td align=\"left\">0.2 &#177; 0.2</td><td align=\"left\">0-0,64</td><td align=\"left\">0.014*</td></tr></tbody></table></body></html>", "text": "Pmid= 2744655:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>ATEC scores at beginning at beginning of phase 1 and end of phase 2, for those who completed phase 2.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td/><td align=\"center\"><bold>Initial</bold></td><td align=\"center\"><bold>St dev</bold></td><td align=\"center\"><bold>Final</bold></td><td align=\"center\"><bold>St dev</bold></td><td align=\"left\"><bold>% change</bold></td></tr></thead><tbody><tr><td align=\"center\"><bold>I. SPLC</bold></td><td align=\"left\">7 rounds</td><td align=\"center\">13.4</td><td align=\"center\">7.7</td><td align=\"center\">10.6</td><td align=\"center\">7.0</td><td align=\"left\">-21%***</td></tr><tr><td/><td align=\"left\">1 round</td><td align=\"center\">12.0</td><td align=\"center\">8.4</td><td align=\"center\">10.5</td><td align=\"center\">8.9</td><td align=\"left\">-13%</td></tr><tr><td align=\"center\"><bold>II. Sociability</bold></td><td align=\"left\">7 rounds</td><td align=\"center\">16.6</td><td align=\"center\">8.5</td><td align=\"center\">12.1</td><td align=\"center\">6.5</td><td align=\"left\">-27%***</td></tr><tr><td/><td align=\"left\">1 round</td><td align=\"center\">14.9</td><td align=\"center\">6.8</td><td align=\"center\">11.2</td><td align=\"center\">6.5</td><td align=\"left\">-25%*</td></tr><tr><td align=\"center\"><bold>III. Sensory/Cognitive Awareness</bold></td><td align=\"left\">7 rounds</td><td align=\"center\">16.0</td><td align=\"center\">7.4</td><td align=\"center\">11.7</td><td align=\"center\">7.9</td><td align=\"left\">-27%***</td></tr><tr><td/><td align=\"left\">1 round</td><td align=\"center\">13.0</td><td align=\"center\">6.8</td><td align=\"center\">9.6</td><td align=\"center\">5.9</td><td align=\"left\">-26%*</td></tr><tr><td align=\"center\"><bold>IV. Health/Physical/Behavior</bold></td><td align=\"left\">7 rounds</td><td align=\"center\">29.9</td><td align=\"center\">14.4</td><td align=\"center\">21.6</td><td align=\"center\">10.1</td><td align=\"left\">-28%**</td></tr><tr><td/><td align=\"left\">1 round</td><td align=\"center\">21.5</td><td align=\"center\">9.4</td><td align=\"center\">18.3</td><td align=\"center\">9.2</td><td align=\"left\">-15%</td></tr><tr><td align=\"center\"><bold>ATEC Total</bold></td><td align=\"left\">7 rounds</td><td align=\"center\">80.8</td><td align=\"center\">24.0</td><td align=\"center\">60.14</td><td align=\"center\">27.9</td><td align=\"left\">-26%***</td></tr><tr><td/><td align=\"left\">1 round</td><td align=\"center\">66.2</td><td align=\"center\">20.7</td><td align=\"center\">53.4</td><td align=\"center\">23.5</td><td align=\"left\">-19%**</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Results of PDD-BI evaluations by Parents N = 25 for the 7-round group, and N = 15 for the 1-round group.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td/><td align=\"center\"><bold>Initial</bold></td><td align=\"center\"><bold>St. Dev</bold></td><td align=\"center\"><bold>Final</bold></td><td align=\"center\"><bold>St. Dev</bold></td><td align=\"left\"><bold>% Change</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Maladaptive Behaviors</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Sensory/Perceptual Approach Behaviors</td><td align=\"right\">7 Rounds</td><td align=\"center\">22.8</td><td align=\"center\">14.7</td><td align=\"center\">17.8</td><td align=\"center\">13.9</td><td align=\"left\">-22%*</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">20.0</td><td align=\"center\">13.6</td><td align=\"center\">13.7</td><td align=\"center\">13.4</td><td align=\"left\">-31%**</td></tr><tr><td align=\"left\">Ritualisms/Resistance to Change</td><td align=\"right\">7 Rounds</td><td align=\"center\">13.9</td><td align=\"center\">10.5</td><td align=\"center\">10.0</td><td align=\"center\">7.8</td><td align=\"left\">-28%**</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">15.0</td><td align=\"center\">8.5</td><td align=\"center\">11.5</td><td align=\"center\">8.2</td><td align=\"left\">-23%**</td></tr><tr><td align=\"left\">Arousal Regulation Problems</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">17.9</td><td align=\"center\">9.0</td><td align=\"center\">13.9</td><td align=\"center\">8.5</td><td align=\"left\">-22%**</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">14.9</td><td align=\"center\">6.6</td><td align=\"center\">12.1</td><td align=\"center\">8.8</td><td align=\"left\">-19%</td></tr><tr><td align=\"left\">Specific Fears</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">21.7</td><td align=\"center\">16.0</td><td align=\"center\">14.6</td><td align=\"center\">12.1</td><td align=\"left\">-33%**</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">18.7</td><td align=\"center\">10.3</td><td align=\"center\">15.9</td><td align=\"center\">11.1</td><td align=\"left\">-15%</td></tr><tr><td align=\"left\">Aggressiveness</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">13.4</td><td align=\"center\">9.8</td><td align=\"center\">9.8</td><td align=\"center\">6.7</td><td align=\"left\">-27%*</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">11.4</td><td align=\"center\">8.1</td><td align=\"center\">8.4</td><td align=\"center\">7.2</td><td align=\"left\">-26%*</td></tr><tr><td align=\"left\">Social Pragmatic Problems</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">16.9</td><td align=\"center\">9.2</td><td align=\"center\">14.5</td><td align=\"center\">9.2</td><td align=\"left\">-14%</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">13.9</td><td align=\"center\">7.5</td><td align=\"center\">9.9</td><td align=\"center\">7.5</td><td align=\"left\">-29%**</td></tr><tr><td align=\"left\">Semantic/Pragmatic Problems</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">15.2</td><td align=\"center\">7.6</td><td align=\"center\">12.5</td><td align=\"center\">7.3</td><td align=\"left\">-18%</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">11.1</td><td align=\"center\">5.6</td><td align=\"center\">9.6</td><td align=\"center\">4.5</td><td align=\"left\">-13%</td></tr><tr><td align=\"left\"><bold>AWP/C Composite Sensory+Ritual+SocPrag+Semantic+ Arousal+Fears+Agg</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">105.</td><td align=\"center\">58.6</td><td align=\"center\">79.5</td><td align=\"center\">49.9</td><td align=\"left\">-24%***</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">93.8</td><td align=\"center\">29.5</td><td align=\"center\">71.6</td><td align=\"center\">38.8</td><td align=\"left\">-24%***</td></tr><tr><td align=\"left\"><bold>Adaptive Behaviors:</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Social Approach Behaviors</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">63.8</td><td align=\"center\">20.6</td><td align=\"center\">70.8</td><td align=\"center\">23.6</td><td align=\"left\">11%**</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">68.2</td><td align=\"center\">25.4</td><td align=\"center\">72.6</td><td align=\"center\">20.2</td><td align=\"left\">6%</td></tr><tr><td align=\"left\" colspan=\"7\">Express (Phonological &amp; Semantic Pragmatic)</td></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">41.4</td><td align=\"center\">28.2</td><td align=\"center\">43.6</td><td align=\"center\">27.1</td><td align=\"left\">+5%</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">44.0</td><td align=\"center\">34.9</td><td align=\"center\">51.3</td><td align=\"center\">31.5</td><td align=\"left\">+17%*</td></tr><tr><td align=\"left\">Learning, Memory, and Receptive Language</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">22.7</td><td align=\"center\">8.1</td><td align=\"center\">25.4</td><td align=\"center\">8.7</td><td align=\"left\">12%*</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">23.2</td><td align=\"center\">10.1</td><td align=\"center\">26.5</td><td align=\"center\">8.9</td><td align=\"left\">14%**</td></tr><tr><td align=\"left\"><bold>REXSCA/C Composite SocialApp+Express+LMRL</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">127</td><td align=\"center\">52.7</td><td align=\"center\">139</td><td align=\"center\">54.5</td><td align=\"left\">9%**</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">135</td><td align=\"center\">65.5</td><td align=\"center\">150</td><td align=\"center\">53.6</td><td align=\"left\">11%*</td></tr><tr><td align=\"right\" colspan=\"2\"><bold>Autism Composite (Sensory, Ritual &amp; Social Problems - Social Approach Behaviors - Expressive Language)</bold></td><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"right\">7 Rounds</td><td align=\"center\">-53.1</td><td align=\"center\">66.4</td><td align=\"center\">-73.3</td><td align=\"center\">67.9</td><td align=\"left\">38%**</td></tr><tr><td/><td align=\"right\">1 Round</td><td align=\"center\">-63.5</td><td align=\"center\">65.1</td><td align=\"center\">-88.8</td><td align=\"center\">58.3</td><td align=\"left\">40%**</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Scores of Autism Severity Scale by parents at the beginning of Phase 2 and the end of Phase 2.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"right\"><bold>Initial</bold></td><td align=\"right\"><bold>St dev</bold></td><td align=\"right\"><bold>Final</bold></td><td align=\"right\"><bold>St dev</bold></td><td align=\"right\"><bold>% change</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>7 Rounds</bold></td><td align=\"right\">5.2</td><td align=\"right\">2.2</td><td align=\"right\">4.2</td><td align=\"right\">2.0</td><td align=\"right\">-19%***</td></tr><tr><td align=\"left\"><bold>1 Round</bold></td><td align=\"right\">5.5</td><td align=\"right\">2.7</td><td align=\"right\">4.5</td><td align=\"right\">2.6</td><td align=\"right\">-18%**</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>ADOS Scores at beginning and end of Phase 1 for 7-round group (n = 26) and 1-round group (n = 15).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Initial</bold></td><td align=\"left\"><bold>Final</bold></td><td align=\"left\"><bold>% change</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Communication</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">7 Rounds</td><td align=\"left\">7.8</td><td align=\"left\">7.1</td><td align=\"left\">-9%</td></tr><tr><td align=\"left\">1 Round</td><td align=\"left\">6.7</td><td align=\"left\">5.9</td><td align=\"left\">-11%</td></tr><tr><td align=\"left\"><bold>Sociability</bold></td><td/><td/><td/></tr><tr><td align=\"left\">7 Rounds</td><td align=\"left\">9.3</td><td align=\"left\">8.3</td><td align=\"left\">-10%**</td></tr><tr><td align=\"left\">1 Round</td><td align=\"left\">8.1</td><td align=\"left\">7.9</td><td align=\"left\">-2%</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Communication + Sociability</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">7 Rounds</td><td align=\"left\">17.0</td><td align=\"left\">15.4</td><td align=\"left\">-9%***</td></tr><tr><td align=\"left\">1 Round</td><td align=\"left\">14.7</td><td align=\"left\">13.7</td><td align=\"left\">-7%</td></tr><tr><td align=\"left\"><bold>Play</bold></td><td/><td/><td/></tr><tr><td align=\"left\">7 Rounds</td><td align=\"left\">3.2</td><td align=\"left\">3.0</td><td align=\"left\">-5%</td></tr><tr><td align=\"left\">1 Round</td><td align=\"left\">2.8</td><td align=\"left\">2.8</td><td align=\"left\">0%</td></tr><tr><td align=\"left\"><bold>SBRI</bold></td><td/><td/><td/></tr><tr><td align=\"left\">7 Rounds</td><td align=\"left\">3.9</td><td align=\"left\">3.5</td><td align=\"left\">-9%</td></tr><tr><td align=\"left\">1 Round</td><td align=\"left\">3.5</td><td align=\"left\">3.5</td><td align=\"left\">-2%</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Results of \"Parent Global Impression\" questionnaire, administered at end of Phase 2.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"right\"><bold>7 rounds (n = 24)</bold></td><td align=\"right\"><bold>1 round (n = 12)</bold></td></tr></thead><tbody><tr><td align=\"center\"><bold>Overall</bold></td><td align=\"right\">1.7</td><td align=\"right\">1.6</td></tr><tr><td align=\"center\"><bold>Expressive Language</bold></td><td align=\"right\">2.0</td><td align=\"right\">1.6</td></tr><tr><td align=\"center\"><bold>Receptive Language</bold></td><td align=\"right\">1.8</td><td align=\"right\">1.9</td></tr><tr><td align=\"center\"><bold>Cognition/Thinking</bold></td><td align=\"right\">1.8</td><td align=\"right\">1.8</td></tr><tr><td align=\"center\"><bold>Play Skills</bold></td><td align=\"right\">1.5</td><td align=\"right\">1.6</td></tr><tr><td align=\"center\"><bold>Sociability</bold></td><td align=\"right\">1.3</td><td align=\"right\">1.8</td></tr><tr><td align=\"center\"><bold>Eye Contact</bold></td><td align=\"right\">1.1</td><td align=\"right\">0.8</td></tr><tr><td align=\"center\"><bold>Tantruming</bold></td><td align=\"right\">0.5</td><td align=\"right\">0.3</td></tr><tr><td align=\"center\"><bold>Stools/Gastrointestinal</bold></td><td/><td/></tr><tr><td align=\"center\"><bold>Isssues</bold></td><td align=\"right\">0.0</td><td align=\"right\">-0.2</td></tr><tr><td align=\"center\"><bold>Sleep</bold></td><td align=\"right\">-0.3</td><td align=\"right\">-0.1</td></tr><tr><td align=\"center\"><bold>Hyperactivity</bold></td><td align=\"right\">-0.5</td><td align=\"right\">-0.1</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Results of \"Parent Global Impressions\" questionnaire, for the \"Overall\" category</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Rating</bold></td><td align=\"left\"><bold>7-round group</bold></td><td align=\"left\"><bold>1 round</bold></td><td align=\"left\"><bold>Both groups combined</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Much Better</bold></td><td align=\"left\">29%</td><td align=\"left\">27%</td><td align=\"left\">28%</td></tr><tr><td align=\"left\"><bold>Better</bold></td><td align=\"left\">33%</td><td align=\"left\">27%</td><td align=\"left\">31%</td></tr><tr><td align=\"left\"><bold>Slightly Better</bold></td><td align=\"left\">25%</td><td align=\"left\">27%</td><td align=\"left\">28%</td></tr><tr><td align=\"left\"><bold>No Change</bold></td><td align=\"left\">4%</td><td align=\"left\">18%</td><td align=\"left\">8%</td></tr><tr><td align=\"left\"><bold>Slightly Worse</bold></td><td align=\"left\">4%</td><td align=\"left\">0%</td><td align=\"left\">3%</td></tr><tr><td align=\"left\"><bold>Worse</bold></td><td align=\"left\">4%</td><td align=\"left\">0%</td><td align=\"left\">3%</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of changes in autism severity scores, combining both 1-round and 7-round groups</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>% Improved</bold></td><td align=\"left\"><bold>% No Change</bold></td><td align=\"left\"><bold>% Worsened</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>ATEC</bold></td><td align=\"left\">96%</td><td align=\"left\">2%</td><td align=\"left\">2%</td></tr><tr><td align=\"left\"><bold>SAS</bold></td><td align=\"left\">61%</td><td align=\"left\">33%</td><td align=\"left\">6%</td></tr><tr><td align=\"left\"><bold>ADOS (Comm. + Social)</bold></td><td align=\"left\">68%</td><td align=\"left\">15%</td><td align=\"left\">17%</td></tr><tr><td align=\"left\"><bold>PDD-BI (modified</bold></td><td align=\"left\">75%</td><td align=\"left\">2%</td><td align=\"left\">22%</td></tr><tr><td align=\"left\"><bold>Autism Composite)</bold></td><td/><td/><td/></tr><tr><td align=\"left\"><bold>Parent Global Impression</bold></td><td align=\"left\">86%</td><td align=\"left\">8%</td><td align=\"left\">6%</td></tr><tr><td align=\"left\"><bold>Average of all 5 assessments</bold></td><td align=\"left\">77%</td><td align=\"left\">12%</td><td align=\"left\">11%</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Correlation of Initial Severity Scores (pre vs. pre)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>ATEC</bold></td><td align=\"left\"><bold>SAS</bold></td><td align=\"left\"><bold>ADOS (Social + Communication)</bold></td><td align=\"left\"><bold>PDD-BI (modified autism)</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>ATEC</bold></td><td align=\"left\">1</td><td/><td/><td/></tr><tr><td align=\"left\"><bold>SAS</bold></td><td align=\"left\">0.70</td><td align=\"left\">1</td><td/><td/></tr><tr><td align=\"left\"><bold>ADOS</bold></td><td align=\"left\">0.60</td><td align=\"left\">0.60</td><td align=\"left\">1</td><td/></tr><tr><td align=\"left\"><bold>PDD-BI</bold></td><td align=\"left\">0.87</td><td align=\"left\">0.72</td><td align=\"left\">0.67</td><td align=\"left\">1</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 8"}
{"html": "<!DOCTYPE html><html><body><h1>Correlation of Final Severity Scores (post vs. post)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>ATEC</bold></td><td align=\"left\"><bold>SAS</bold></td><td align=\"left\"><bold>ADOS (Social + Communication)</bold></td><td align=\"left\"><bold>PDD-BI (modified autism)</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>ATEC</bold></td><td align=\"left\">1</td><td/><td/><td/></tr><tr><td align=\"left\"><bold>SAS</bold></td><td align=\"left\">0.74</td><td align=\"left\">1</td><td/><td/></tr><tr><td align=\"left\"><bold>ADOS</bold></td><td align=\"left\">0.66</td><td align=\"left\">0.73</td><td align=\"left\">1</td><td/></tr><tr><td align=\"left\"><bold>PDD-BI</bold></td><td align=\"left\">0.94</td><td align=\"left\">0.73</td><td align=\"left\">0.63</td><td align=\"left\">1</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 9"}
{"html": "<!DOCTYPE html><html><body><h1>Regression Analyses of Changes in Autism Severity vs. Urinary Metal Excretion (after 9</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Adjusted R<sup>2</sup></bold></td><td align=\"left\"><bold>P-value</bold></td><td align=\"left\"><bold>Equation</bold></td><td align=\"left\"><bold>Most significant variables</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Change in PDD-BI (n = 32)</bold></td><td align=\"left\">0.59</td><td align=\"left\">0.002</td><td align=\"left\">7-rnd group (17.9 -2.62 Pb9 +0.230 Sn9 +102Tl9 -135Sb9 - 1.01 As9 -0.0695 Dglut)<break/>1-rnd group (-32.7 -0.564 Pb9 +0.0755Sn9 +17.4 Tl9 +13.8 Sb9 -0.476 As9 +0.045 Dglut)</td><td align=\"left\">7-rnd group: Dglut***, As9**, Sb9**, Tl9**, Pb9*</td></tr><tr><td/><td/><td/><td/><td align=\"left\">1-round group: No significant terms</td></tr><tr><td align=\"left\"><bold>Change in ATEC (n = 32)</bold></td><td align=\"left\">0.25</td><td align=\"left\">0.02</td><td align=\"left\">7-rnd group (1.93 -7.82 Hg9 -0.352 As9)<break/>1-rnd group (-4.91 -0.672 Hg9 -0.260 As9)</td><td align=\"left\">7-rnd group: Hg9**, As9*</td></tr><tr><td/><td/><td/><td/><td align=\"left\">1-rnd group: No significant terms</td></tr><tr><td align=\"left\"><bold>Change in SAS (n = 29)</bold></td><td align=\"left\">0.22</td><td align=\"left\">n.s.</td><td align=\"left\">(not listed since not significant)</td><td/></tr><tr><td align=\"left\"><bold>Change in ADOS (comm.. + social) (n = 32)</bold></td><td align=\"left\">0.18</td><td align=\"left\">n.s.</td><td align=\"left\">(not listed since not significant)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 10"}
{"html": "<!DOCTYPE html><html><body><h1>Regression Analyses of Changes in Autism Severity vs. Urinary Metal Excretion (after 9</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Adjusted R<sup>2</sup></bold></td><td align=\"left\"><bold>P-value</bold></td><td align=\"left\"><bold>Equation</bold></td><td align=\"left\"><bold>Most significant variables</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Change in PDD-BI (n = 20)</bold></td><td align=\"left\">0.75</td><td align=\"left\">0.0006</td><td align=\"left\">10.25 -2.48Pb9 +0.169Sn9 +113.5Tl9 -119.1Sb9 - 1.199As9 +0.726Al9 - 0.0608DGlut</td><td align=\"left\">Tl9**, As9**, DGlut**, Pb9*, Sb9*</td></tr><tr><td align=\"left\"><bold>Change in ATEC (n = 20)</bold></td><td align=\"left\">0.44</td><td align=\"left\">0.006</td><td align=\"left\">9.41 -0.663Pb9 -8.80Hg9- 0.352As9</td><td align=\"left\">Hg9**, As9*</td></tr><tr><td align=\"left\"><bold>Change in SAS (n = 18)</bold></td><td align=\"left\">0.57</td><td align=\"left\">0.002</td><td align=\"left\">-1.01 +0.0985Pb9- -0.00169DGlut</td><td align=\"left\">Tl9**, Pb9*, DGlut*</td></tr><tr><td align=\"left\"><bold>Change in ADOS (comm.. + social) (n = 20)</bold></td><td align=\"left\">0.28</td><td align=\"left\">0.02</td><td align=\"left\">-1.91+00.0472As9 - 0.0877Al9</td><td align=\"left\">As9*, Al9*</td></tr></tbody></table></body></html>", "text": "Pmid= 2770991:Table= Table 11"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of Participants</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Total</bold></td><td align=\"left\"><bold>Phase 2 - treatment</bold></td><td align=\"left\"><bold>Phase 2 - placebo</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Total Participants</bold></td><td align=\"left\">77</td><td align=\"left\">26</td><td align=\"left\">15</td></tr><tr><td align=\"left\"><bold>Male</bold></td><td align=\"left\">69</td><td align=\"left\">24</td><td align=\"left\">14</td></tr><tr><td align=\"left\"><bold>Female</bold></td><td align=\"left\">8</td><td align=\"left\">2</td><td align=\"left\">1</td></tr><tr><td align=\"left\"><bold>Age (years)</bold></td><td align=\"left\">6.3</td><td align=\"left\">6.7</td><td align=\"left\">6.5</td></tr><tr><td align=\"left\"><bold>Diagnosis</bold></td><td align=\"left\">95% autism, 3% PDD/NOS, 3% Asperger\\'s</td><td align=\"left\">96% Autism, 4% Aspergers</td><td align=\"left\">100% Autism</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Urinary excretion of toxic metals in Phase 1, at baseline, after 1</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Element</bold></td><td align=\"right\"><bold>Baseline</bold></td><td align=\"right\"><bold>1</bold><sup><bold>st </bold></sup><bold>Dose</bold></td><td align=\"right\"><bold>9</bold><sup><bold>th </bold></sup><bold>Dose</bold></td><td align=\"right\"><bold>1</bold><sup><bold>st </bold></sup><bold>dose vs. baseline</bold></td><td align=\"right\"><bold>9</bold><sup><bold>th </bold></sup><bold>dose vs. baseline</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Pb</bold></td><td align=\"right\">1.3 +/- 2.3</td><td align=\"right\">10. +/- 19.</td><td align=\"right\">9.2 +/- 7.8</td><td align=\"right\"><bold>713%***</bold></td><td align=\"right\"><bold>638%***</bold></td></tr><tr><td align=\"left\"><bold>Sn</bold></td><td align=\"right\">2.3 +/- 3.4</td><td align=\"right\">8.0 +/- 13</td><td align=\"right\">9.7 +/- 24</td><td align=\"right\"><bold>241%***</bold></td><td align=\"right\"><bold>314%*</bold></td></tr><tr><td align=\"left\"><bold>Bi</bold></td><td align=\"right\">0.18 +/- 0.45</td><td align=\"right\">0.47 +/- 1.4</td><td align=\"right\">0.41 +/- 1.0</td><td align=\"right\"><bold>161%+</bold></td><td align=\"right\"><bold>128%*</bold></td></tr><tr><td align=\"left\"><bold>U</bold></td><td align=\"right\">0.015 +/- .04</td><td align=\"right\">0.036 +/- .09</td><td align=\"right\">0.031 +/- .1</td><td align=\"right\">104%</td><td align=\"right\">111%</td></tr><tr><td align=\"left\"><bold>Hg</bold></td><td align=\"right\">0.86 +/- .92</td><td align=\"right\">1.5 +/- 1.4</td><td align=\"right\">0.97 +/- 0.88</td><td align=\"right\"><bold>70%**</bold></td><td align=\"right\"><bold>13%</bold></td></tr><tr><td align=\"left\"><bold>Tl</bold></td><td align=\"right\">0.15 +/- 0.12</td><td align=\"right\">0.25 +/- 0.18</td><td align=\"right\">0.21 +/- 0.19</td><td align=\"right\"><bold>67%***</bold></td><td align=\"right\"><bold>42%**</bold></td></tr><tr><td align=\"left\"><bold>Sb</bold></td><td align=\"right\">0.10 +/- 0.10</td><td align=\"right\">0.15 +/- 0.19</td><td align=\"right\">0.14 +/- 0.20</td><td align=\"right\"><bold>49%*</bold></td><td align=\"right\"><bold>42%+</bold></td></tr><tr><td align=\"left\"><bold>W</bold></td><td align=\"right\">0.39 +/- 0.29</td><td align=\"right\">0.59 +/- 0.63</td><td align=\"right\">0.46 +/- 0.50</td><td align=\"right\"><bold>51%**</bold></td><td align=\"right\"><bold>18%*</bold></td></tr><tr><td align=\"left\"><bold>Al</bold></td><td align=\"right\">16 +/- 21</td><td align=\"right\">18 +/- 23</td><td align=\"right\">19 +/- 33</td><td align=\"right\">11%</td><td align=\"right\">21%</td></tr><tr><td align=\"left\"><bold>Ni</bold></td><td align=\"right\">6.7 +/- 5.1</td><td align=\"right\">5.5 +/- 3.6</td><td align=\"right\">7.6 +/- 4.3</td><td align=\"right\"><bold>-18%*</bold></td><td align=\"right\">12%</td></tr><tr><td align=\"left\"><bold>Cd</bold></td><td align=\"right\">0.38 +/- 0.24</td><td align=\"right\">0.40 +/- 0.24</td><td align=\"right\">0.33 +/- 0.23</td><td align=\"right\">5%</td><td align=\"right\">-14%</td></tr><tr><td align=\"left\"><bold>As</bold></td><td align=\"right\">32 +/- 20</td><td align=\"right\">32 +/- 18</td><td align=\"right\">25 +/- 18</td><td align=\"right\">0%</td><td align=\"right\"><bold>-19%*</bold></td></tr><tr><td align=\"left\"><bold>creatinine</bold></td><td align=\"right\">94 +/- 52</td><td align=\"right\">62 +/- 39</td><td align=\"right\">80 +/- 43</td><td align=\"right\"><bold>-34%***</bold></td><td align=\"right\"><bold>-15%*</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Comparison of change in average urine excretion compared to baseline for participants who completed six rounds of phase 2 (n = 20).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Element</bold></td><td align=\"right\"><bold>Baseline (mcg/g- creatinine)</bold></td><td align=\"right\"><bold>Change after 1</bold><sup><bold>st </bold></sup><bold>dose</bold></td><td align=\"right\"><bold>Change after 9</bold><sup><bold>th </bold></sup><bold>dose</bold></td><td align=\"right\"><bold>Change after round 2</bold></td><td align=\"right\"><bold>Change after round 4</bold></td><td align=\"right\"><bold>Change after round 6</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Pb</bold></td><td align=\"right\">0.64</td><td align=\"right\"><bold>935%***</bold></td><td align=\"right\"><bold>1562%***</bold></td><td align=\"right\"><bold>1001%***</bold></td><td align=\"right\"><bold>1063%***</bold></td><td align=\"right\"><bold>1005%***</bold></td></tr><tr><td align=\"left\"><bold>Sn</bold></td><td align=\"right\">3.5</td><td align=\"right\"><bold>118%*</bold></td><td align=\"right\">269%</td><td align=\"right\">205%</td><td align=\"right\">213%</td><td align=\"right\">115%</td></tr><tr><td align=\"left\"><bold>Bi</bold></td><td align=\"right\">0.06</td><td align=\"right\">312%</td><td align=\"right\">296%</td><td align=\"right\">787%</td><td align=\"right\">261%</td><td align=\"right\">11%</td></tr><tr><td align=\"left\"><bold>U</bold></td><td align=\"right\">0.014</td><td align=\"right\">29%</td><td align=\"right\">79%</td><td align=\"right\">-32%</td><td align=\"right\">-11%</td><td align=\"right\"><bold>282%+</bold></td></tr><tr><td align=\"left\"><bold>Hg</bold></td><td align=\"right\">0.85</td><td align=\"right\"><bold>120%*</bold></td><td align=\"right\">37%</td><td align=\"right\"><bold>98%***</bold></td><td align=\"right\">70%</td><td align=\"right\"><bold>59%+</bold></td></tr><tr><td align=\"left\"><bold>Tl</bold></td><td align=\"right\">0.16</td><td align=\"right\"><bold>54%**</bold></td><td align=\"right\"><bold>44%*</bold></td><td align=\"right\">13%</td><td align=\"right\">18%</td><td align=\"right\">28%</td></tr><tr><td align=\"left\"><bold>Sb</bold></td><td align=\"right\">0.10</td><td align=\"right\"><bold>67%+</bold></td><td align=\"right\">26%</td><td align=\"right\">9%</td><td align=\"right\">23%</td><td align=\"right\">27%</td></tr><tr><td align=\"left\"><bold>W</bold></td><td align=\"right\">0.41</td><td align=\"right\"><bold>36%+</bold></td><td align=\"right\">-11%</td><td align=\"right\">14%</td><td align=\"right\">52%</td><td align=\"right\">25%</td></tr><tr><td align=\"left\"><bold>Al</bold></td><td align=\"right\">8.3</td><td align=\"right\">125%</td><td align=\"right\">1%</td><td align=\"right\">26%</td><td align=\"right\">38%</td><td align=\"right\">-12%</td></tr><tr><td align=\"left\"><bold>Ni</bold></td><td align=\"right\">5.8</td><td align=\"right\">-2%</td><td align=\"right\">25%</td><td align=\"right\"><bold>36%+</bold></td><td align=\"right\">68%*</td><td align=\"right\">25%</td></tr><tr><td align=\"left\"><bold>Cd</bold></td><td align=\"right\">0.35</td><td align=\"right\">14%</td><td align=\"right\"><bold>-32%*</bold></td><td align=\"right\">-7%</td><td align=\"right\">0%</td><td align=\"right\">-17%</td></tr><tr><td align=\"left\"><bold>As</bold></td><td align=\"right\">31</td><td align=\"right\">4%</td><td align=\"right\">-13%</td><td align=\"right\"><bold>-39%***</bold></td><td align=\"right\"><bold>-42%***</bold></td><td align=\"right\"><bold>-31%+</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Significant Correlations of Baseline Urinary Metal Excretion with Baseline Urinary Metal Excretion (only correlations >0.31 in magnitude are listed, corresponding to p = 0.01 on an individual comparison basis)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Metal</bold></td><td align=\"left\"><bold>Correlations</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Pb</bold></td><td align=\"left\">Tl (0.37), As (0.44), Al (0.41)</td></tr><tr><td align=\"left\"><bold>Sn</bold></td><td align=\"left\">Tl (0.36), Sb (0.34)</td></tr><tr><td align=\"left\"><bold>Hg</bold></td><td align=\"left\">Sb(0.42)</td></tr><tr><td align=\"left\"><bold>Tl</bold></td><td align=\"left\">Sn (0.36)</td></tr><tr><td align=\"left\"><bold>Sb</bold></td><td align=\"left\">Sn (0.34), Hg (0.42)</td></tr><tr><td align=\"left\"><bold>W</bold></td><td align=\"left\">none</td></tr><tr><td align=\"left\"><bold>Al</bold></td><td align=\"left\">Pb(0.41)</td></tr><tr><td align=\"left\"><bold>Cd</bold></td><td align=\"left\">none</td></tr><tr><td align=\"left\"><bold>As</bold></td><td align=\"left\">Pb(0.44)</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Significant Correlations of Phase 1, 9</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Metal</bold></td><td align=\"left\"><bold>Correlations</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Pb</bold></td><td align=\"left\">Tl(0.47), Sb(0.35), Al (0.56)</td></tr><tr><td align=\"left\"><bold>Sn</bold></td><td align=\"left\">none</td></tr><tr><td align=\"left\"><bold>Hg</bold></td><td align=\"left\">none</td></tr><tr><td align=\"left\"><bold>Tl</bold></td><td align=\"left\">Pb(0.47)</td></tr><tr><td align=\"left\"><bold>Sb</bold></td><td align=\"left\">Pb(0.35), Cd(0.67), Al (0.63)</td></tr><tr><td align=\"left\"><bold>W</bold></td><td align=\"left\">None</td></tr><tr><td align=\"left\"><bold>Al</bold></td><td align=\"left\">Pb (0.56), Sb (0.63), Cd (0.67)</td></tr><tr><td align=\"left\"><bold>Cd</bold></td><td align=\"left\">Sb (0.67), Al (0.67)</td></tr><tr><td align=\"left\"><bold>As</bold></td><td align=\"left\">Pb (0.56), Sb (0.63), Cd (0.67)</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Significant Correlations of Phase 1, 9</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Metal at 9</bold><sup><bold>th </bold></sup><bold>dose</bold></td><td align=\"left\"><bold>Correlations with baseline excretion</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Pb</bold></td><td align=\"left\">Pb(0.40), Tl(0.51),</td></tr><tr><td align=\"left\"><bold>Sn</bold></td><td align=\"left\">W(0.38)</td></tr><tr><td align=\"left\"><bold>Hg</bold></td><td align=\"left\">none</td></tr><tr><td align=\"left\"><bold>Tl</bold></td><td align=\"left\">Tl(0.54), W(0.31)</td></tr><tr><td align=\"left\"><bold>Sb</bold></td><td align=\"left\">Pb(0.81), Tl(0.34), As(0.40), Al(0.38)</td></tr><tr><td align=\"left\"><bold>W</bold></td><td align=\"left\">None</td></tr><tr><td align=\"left\"><bold>Al</bold></td><td align=\"left\">Pb(0.59), As(0.33), Al(0.35)</td></tr><tr><td align=\"left\"><bold>Cd</bold></td><td align=\"left\">Pb(0.62), As(0.42), Cd(0.38), Al (0.40)</td></tr><tr><td align=\"left\"><bold>As</bold></td><td align=\"left\">Pb(0.59), As(0.33), Al(0.35)</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Comparison of average urine excretion of essential and other minerals compared to baseline.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"right\"><bold>Baseline</bold></td><td align=\"right\"><bold>st dev</bold></td><td align=\"right\"><bold>Change after 1</bold><sup><bold>st </bold></sup><bold>dose</bold></td><td align=\"right\"><bold>Change after 9</bold><sup><bold>th </bold></sup><bold>dose</bold></td><td align=\"right\"><bold>RDA for 4-8 yr (mg)</bold></td><td align=\"right\"><bold>% of RDA lost #</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Cu</bold></td><td align=\"right\">0.022</td><td align=\"right\">0.008</td><td align=\"right\">74%***</td><td align=\"right\">129%***</td><td align=\"right\">0.44</td><td align=\"right\">3%</td></tr><tr><td align=\"left\"><bold>K</bold></td><td align=\"right\">2187</td><td align=\"right\">1491</td><td align=\"right\"><bold>110%***</bold></td><td align=\"right\"><bold>48%**</bold></td><td align=\"right\">1500</td><td align=\"right\"><bold>57%</bold></td></tr><tr><td align=\"left\"><bold>Fe</bold></td><td align=\"right\">0.016</td><td align=\"right\">0.055</td><td align=\"right\">93%+</td><td align=\"right\">64%</td><td align=\"right\">10</td><td align=\"right\">0.1%</td></tr><tr><td align=\"left\"><bold>Mn</bold></td><td align=\"right\">0.0023</td><td align=\"right\">0.0016</td><td align=\"right\">77%***</td><td align=\"right\">37%*</td><td align=\"right\">1.5</td><td align=\"right\">&lt;0.1%</td></tr><tr><td align=\"left\"><bold>Zi</bold></td><td align=\"right\">0.00034</td><td align=\"right\">0.00069</td><td align=\"right\">90%</td><td align=\"right\">13%</td><td align=\"right\">n/a</td><td/></tr><tr><td align=\"left\"><bold>Li</bold></td><td align=\"right\">0.10</td><td align=\"right\">0.10</td><td align=\"right\">51%</td><td align=\"right\">50%</td><td align=\"right\">n/a</td><td/></tr><tr><td align=\"left\"><bold>V</bold></td><td align=\"right\">0.025</td><td align=\"right\">0.013</td><td align=\"right\">49%***</td><td align=\"right\">10%</td><td/><td/></tr><tr><td align=\"left\"><bold>Cr</bold></td><td align=\"right\">0.091</td><td align=\"right\">0.044</td><td align=\"right\"><bold>47%***</bold></td><td align=\"right\">11%</td><td align=\"right\">0.015</td><td align=\"right\"><bold>88%</bold></td></tr><tr><td align=\"left\"><bold>Zn</bold></td><td align=\"right\">0.81</td><td align=\"right\">0.49</td><td align=\"right\">8%</td><td align=\"right\">30%***</td><td align=\"right\">5</td><td align=\"right\">2%</td></tr><tr><td align=\"left\"><bold>Na</bold></td><td align=\"right\">3901</td><td align=\"right\">2018</td><td align=\"right\">35%***</td><td align=\"right\">3%</td><td align=\"right\">n/a</td><td/></tr><tr><td align=\"left\"><bold>B</bold></td><td align=\"right\">2.5</td><td align=\"right\">2.0</td><td align=\"right\">25%*</td><td align=\"right\">11%</td><td align=\"right\">n/a</td><td/></tr><tr><td align=\"left\"><bold>Ba</bold></td><td align=\"right\">0.0050</td><td align=\"right\">0.0052</td><td align=\"right\">12%</td><td align=\"right\">22%</td><td align=\"right\">n/a</td><td/></tr><tr><td align=\"left\"><bold>S</bold></td><td align=\"right\">1140</td><td align=\"right\">694</td><td align=\"right\">3%</td><td align=\"right\">9%</td><td align=\"right\">n/a</td><td/></tr><tr><td align=\"left\"><bold>Mg</bold></td><td align=\"right\">168</td><td align=\"right\">64</td><td align=\"right\">-5%</td><td align=\"right\">17%*</td><td align=\"right\">130</td><td align=\"right\">4%</td></tr><tr><td align=\"left\"><bold>Se</bold></td><td align=\"right\">0.20</td><td align=\"right\">0.16</td><td align=\"right\">3%</td><td align=\"right\">0%</td><td align=\"right\">30</td><td align=\"right\">6%</td></tr><tr><td align=\"left\"><bold>Co</bold></td><td align=\"right\">0.0014</td><td align=\"right\">0.0013</td><td align=\"right\">-4%</td><td align=\"right\">4%</td><td align=\"right\">n/a</td><td/></tr><tr><td align=\"left\"><bold>Ca</bold></td><td align=\"right\">137</td><td align=\"right\">115</td><td align=\"right\">-6%</td><td align=\"right\">3%</td><td align=\"right\">800</td><td align=\"right\">no extra loss</td></tr><tr><td align=\"left\"><bold>St</bold></td><td align=\"right\">0.25</td><td align=\"right\">0.15</td><td align=\"right\">-5%</td><td align=\"right\">0%</td><td align=\"right\">n/a</td><td/></tr><tr><td align=\"left\"><bold>P</bold></td><td align=\"right\">1160</td><td align=\"right\">627</td><td align=\"right\">-5%</td><td align=\"right\">-4%</td><td align=\"right\">500</td><td align=\"right\">No extraloss</td></tr><tr><td align=\"left\"><bold>Mo</bold></td><td align=\"right\">0.13</td><td align=\"right\">0.13</td><td align=\"right\">-5%</td><td align=\"right\">-33%*</td><td align=\"right\">0.022</td><td align=\"right\">No extra loss</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Glutathione levels before and 1-2 months after 1</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><tbody><tr><td/><td align=\"left\"><bold>Average Glutathione Level</bold></td><td align=\"left\"><bold>Range</bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\"><bold>Baseline - all (n = 72)</bold></td><td align=\"left\">501 +/- 246</td><td align=\"left\">31-1033</td></tr><tr><td align=\"left\"><bold>Baseline - those with a 2</bold><sup><bold>nd </bold></sup><bold>measurement in phase 2 (n = 38)</bold></td><td align=\"left\">523 +/- 280</td><td align=\"left\">31-1033</td></tr><tr><td align=\"left\"><bold>1-2 months after 1</bold><sup><bold>st </bold></sup><bold>round DMSA (n = 38)</bold></td><td align=\"left\">478 +/- 83</td><td align=\"left\">355-695</td></tr><tr><td align=\"left\"><bold>Immunosciences Reference Range for Adults</bold></td><td/><td align=\"left\">427-714</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 8"}
{"html": "<!DOCTYPE html><html><body><h1>Regression analysis of initial glutathione and change in glutathione (from before and after phase 1).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Adjusted R</bold><sup><bold>2</bold></sup></td><td align=\"left\"><bold>P-Value</bold></td><td align=\"left\"><bold>Equation</bold></td><td align=\"left\"><bold>Most Significant variables</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Glutathione (n = 59)</bold></td><td align=\"left\">0.25</td><td align=\"left\">0.003</td><td align=\"left\">378.7-48.8 PbB + 3.67AsB -219 CdB +2.49 Sn9 +369 TlB -69.9 Hg9 -4.32 As9 +598 Cd9</td><td align=\"left\">Cd9**, PbB*, Sn9*, Tl9*, As9*</td></tr><tr><td align=\"left\"><bold>Change in glutathione (n = 37)</bold></td><td align=\"left\">0.29</td><td align=\"left\">0.002</td><td align=\"left\">104-2.26Sn9+87.8Hg9-669Cd9</td><td align=\"left\">Cd**</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 9"}
{"html": "<!DOCTYPE html><html><body><h1>Complete Blood Count and Chemistry Panel at baseline (N = 77).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"right\"><bold>Average Value</bold></td><td align=\"right\"><bold>Stnd Dev</bold></td><td align=\"right\"><bold>% Below RR</bold></td><td align=\"right\"><bold>% Above RR</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>WBC (k/mm3)</bold></td><td align=\"right\">8.04</td><td align=\"right\">2.90</td><td align=\"right\">1%</td><td align=\"right\">9%</td></tr><tr><td align=\"left\"><bold>RBC (m/mm3)</bold></td><td align=\"right\">4.56</td><td align=\"right\">0.29</td><td align=\"right\">4%</td><td align=\"right\">1%</td></tr><tr><td align=\"left\"><bold>HEMOGLOBIN(g/dL)</bold></td><td align=\"right\">13.0</td><td align=\"right\">0.76</td><td align=\"right\">1%</td><td align=\"right\">3%</td></tr><tr><td align=\"left\"><bold>Hematocrit (%)</bold></td><td align=\"right\">37.9</td><td align=\"right\">2.27</td><td align=\"right\">1%</td><td align=\"right\">1%</td></tr><tr><td align=\"left\"><bold>MCV (fL)</bold></td><td align=\"right\">83.3</td><td align=\"right\">3.21</td><td align=\"right\">0%</td><td align=\"right\">4%</td></tr><tr><td align=\"left\"><bold>MCH (pg)</bold></td><td align=\"right\">28.6</td><td align=\"right\">1.16</td><td align=\"right\">3%</td><td align=\"right\">3%</td></tr><tr><td align=\"left\"><bold>MCHC (g/dL)</bold></td><td align=\"right\">34.4</td><td align=\"right\">0.73</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>RDW (%)</bold></td><td align=\"right\">13.4</td><td align=\"right\">0.70</td><td align=\"right\">0%</td><td align=\"right\">4%</td></tr><tr><td align=\"left\"><bold>Platelet count (k/mm3)</bold></td><td align=\"right\">388</td><td align=\"right\">208</td><td align=\"right\">1%</td><td align=\"right\"><bold>18%</bold></td></tr><tr><td align=\"left\"><bold>MPV (fL)</bold></td><td align=\"right\">8.53</td><td align=\"right\">1.02</td><td align=\"right\">8%</td><td align=\"right\">3%</td></tr><tr><td align=\"left\"><bold>Seg Neutrophils</bold></td><td align=\"right\">44.5</td><td align=\"right\">12.6</td><td align=\"right\">8%</td><td align=\"right\">9%</td></tr><tr><td align=\"left\"><bold>Lymphocytes (%)</bold></td><td align=\"right\">44.7</td><td align=\"right\">11.6</td><td align=\"right\">12%</td><td align=\"right\">13%</td></tr><tr><td align=\"left\"><bold>Monocytes (%)</bold></td><td align=\"right\">7.15</td><td align=\"right\">1.91</td><td align=\"right\">0%</td><td align=\"right\">3%</td></tr><tr><td align=\"left\"><bold>Eosinophils (%)</bold></td><td align=\"right\">3.42</td><td align=\"right\">2.55</td><td align=\"right\">0%</td><td align=\"right\">8%</td></tr><tr><td align=\"left\"><bold>Basophils (%)</bold></td><td align=\"right\">0.41</td><td align=\"right\">0.52</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Abs Neutrophil (K/uL)</bold></td><td align=\"right\">3.80</td><td align=\"right\">2.35</td><td align=\"right\">0%</td><td align=\"right\">8%</td></tr><tr><td align=\"left\"><bold>Abs lympocyte (k/uL)</bold></td><td align=\"right\">3.29</td><td align=\"right\">0.87</td><td align=\"right\">1%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Abs Monocyte (k/uL)</bold></td><td align=\"right\">0.55</td><td align=\"right\">0.21</td><td align=\"right\">0%</td><td align=\"right\">1%</td></tr><tr><td align=\"left\"><bold>Abs Eosinophil (k/uL)</bold></td><td align=\"right\">0.24</td><td align=\"right\">0.17</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Abs Basophil (k/uL)</bold></td><td align=\"right\">0.02</td><td align=\"right\">0.04</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Glucose (mg/dL)</bold></td><td align=\"right\">87.9</td><td align=\"right\">14.9</td><td align=\"right\">3%</td><td align=\"right\">16%</td></tr><tr><td align=\"left\"><bold>Urea Nitrogen (mg/dL)</bold></td><td align=\"right\">13.7</td><td align=\"right\">4.18</td><td align=\"right\">1%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Creatinine</bold></td><td align=\"right\">0.50</td><td align=\"right\">0.09</td><td align=\"right\"><bold>22%</bold></td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Bun/Creat Ratio</bold></td><td align=\"right\">28.0</td><td align=\"right\">8.45</td><td align=\"right\">0%</td><td align=\"right\"><bold>43%</bold></td></tr><tr><td align=\"left\"><bold>Uric Acid (mg/dL)</bold></td><td align=\"right\">3.93</td><td align=\"right\">0.82</td><td align=\"right\">1%</td><td align=\"right\">4%</td></tr><tr><td align=\"left\"><bold>Sodium (mmol/L)</bold></td><td align=\"right\">140</td><td align=\"right\">2.33</td><td align=\"right\">1%</td><td align=\"right\">1%</td></tr><tr><td align=\"left\"><bold>Potassium (mmol/L)</bold></td><td align=\"right\">4.39</td><td align=\"right\">0.45</td><td align=\"right\">0%</td><td align=\"right\">4%</td></tr><tr><td align=\"left\"><bold>Chloride (mmol/L)</bold></td><td align=\"right\">104</td><td align=\"right\">2.20</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>CO2 (mmol/L)</bold></td><td align=\"right\">22.3</td><td align=\"right\">2.28</td><td align=\"right\">9%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Anion gap</bold></td><td align=\"right\">13.6</td><td align=\"right\">2.52</td><td align=\"right\">0%</td><td align=\"right\">3%</td></tr><tr><td align=\"left\"><bold>Osmolality (mOs/kg)</bold></td><td align=\"right\">284</td><td align=\"right\">5.15</td><td align=\"right\">1%</td><td align=\"right\">1%</td></tr><tr><td align=\"left\"><bold>Protein (g/dL)</bold></td><td align=\"right\">7.23</td><td align=\"right\">0.48</td><td align=\"right\">0%</td><td align=\"right\">3%</td></tr><tr><td align=\"left\"><bold>Albumin (g/dL)</bold></td><td align=\"right\">4.57</td><td align=\"right\">0.21</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Globulin (g/dL)</bold></td><td align=\"right\">2.70</td><td align=\"right\">0.34</td><td align=\"right\">0%</td><td align=\"right\">1%</td></tr><tr><td align=\"left\"><bold>Alb/Glob Rat</bold></td><td align=\"right\">1.73</td><td align=\"right\">0.23</td><td align=\"right\">0%</td><td align=\"right\">6%</td></tr><tr><td align=\"left\"><bold>Cholesterol (mg/dL)</bold></td><td align=\"right\">150</td><td align=\"right\">25.2</td><td align=\"right\">0%</td><td align=\"right\">14%</td></tr><tr><td align=\"left\"><bold>Triglyceride (mg/dL)</bold></td><td align=\"right\">100</td><td align=\"right\">62.2</td><td align=\"right\">0%</td><td align=\"right\">13%</td></tr><tr><td align=\"left\"><bold>Calcium (mg/dL)</bold></td><td align=\"right\">10.0</td><td align=\"right\">0.37</td><td align=\"right\">0%</td><td align=\"right\">3%</td></tr><tr><td align=\"left\"><bold>Phosphorus (mg/dL)</bold></td><td align=\"right\">5.04</td><td align=\"right\">0.61</td><td align=\"right\">0%</td><td align=\"right\">9%</td></tr><tr><td align=\"left\"><bold>Alkaline Phosphate (IU/L)</bold></td><td align=\"right\">237</td><td align=\"right\">64.9</td><td align=\"right\">0%</td><td align=\"right\">8%</td></tr><tr><td align=\"left\"><bold>GGT (IU/L)</bold></td><td align=\"right\">10.3</td><td align=\"right\">3.13</td><td align=\"right\">0%</td><td align=\"right\">1%</td></tr><tr><td align=\"left\"><bold>ALT (IU/L)</bold></td><td align=\"right\">20.1</td><td align=\"right\">8.03</td><td align=\"right\">0%</td><td align=\"right\">4%</td></tr><tr><td align=\"left\"><bold>AST (IU/L)</bold></td><td align=\"right\">35.2</td><td align=\"right\">8.45</td><td align=\"right\">0%</td><td align=\"right\">6%</td></tr><tr><td align=\"left\"><bold>Lactic Dehydrogenase (IU/L)</bold></td><td align=\"right\">253</td><td align=\"right\">56.2</td><td align=\"right\">1%</td><td align=\"right\">6%</td></tr><tr><td align=\"left\"><bold>Bilirubin (mg/dL)</bold></td><td align=\"right\">0.34</td><td align=\"right\">0.25</td><td align=\"right\">8%</td><td align=\"right\">0%</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 10"}
{"html": "<!DOCTYPE html><html><body><h1>Complete Blood Count and Chemistry Panel at baseline and after 1 round of DMSA (N = 41).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"right\"><bold>Baseline Average Value</bold></td><td align=\"right\"><bold>Stnd Dev</bold></td><td align=\"right\"><bold>% Below RR</bold></td><td align=\"right\"><bold>% Above RR</bold></td><td align=\"right\"><bold>% change After 1</bold><sup><bold>st </bold></sup><bold>DMSA</bold></td><td align=\"right\"><bold>% Below RR</bold></td><td align=\"right\"><bold>% Above RR</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>WBC (k/mm3)</bold></td><td align=\"right\">7.76</td><td align=\"right\">2.50</td><td align=\"right\">0%</td><td align=\"right\">12%</td><td align=\"right\">-3%</td><td align=\"right\">5%</td><td align=\"right\">2%</td></tr><tr><td align=\"left\"><bold>RBC (m/mm3)</bold></td><td align=\"right\">4.60</td><td align=\"right\">0.27</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>HEMOGLOBIN(g/dL)</bold></td><td align=\"right\">13.2</td><td align=\"right\">0.69</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">1%</td><td align=\"right\">0%</td><td align=\"right\">5%</td></tr><tr><td align=\"left\"><bold>Hematocrit (%)</bold></td><td align=\"right\">38.5</td><td align=\"right\">2.05</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>MCV (fL)</bold></td><td align=\"right\">83.8</td><td align=\"right\">2.94</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">2%</td></tr><tr><td align=\"left\"><bold>MCH (pg)</bold></td><td align=\"right\">28.7</td><td align=\"right\">0.98</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">2%</td></tr><tr><td align=\"left\"><bold>MCHC (g/dL)</bold></td><td align=\"right\">34.3</td><td align=\"right\">0.72</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>RDW (%) Platelet count</bold></td><td align=\"right\">13.4</td><td align=\"right\">0.55</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">7%</td></tr><tr><td align=\"left\"><bold>(k/mm3)</bold></td><td align=\"right\">424</td><td align=\"right\">274</td><td align=\"right\"><bold>2%</bold></td><td align=\"right\"><bold>29%</bold></td><td align=\"right\"><bold>-7%</bold></td><td align=\"right\"><bold>0%</bold></td><td align=\"right\"><bold>12%</bold></td></tr><tr><td align=\"left\"><bold>MPV (fL)</bold></td><td align=\"right\">8.59</td><td align=\"right\">1.14</td><td align=\"right\">10%</td><td align=\"right\">5%</td><td align=\"right\">1%</td><td align=\"right\">10%</td><td align=\"right\">2%</td></tr><tr><td align=\"left\"><bold>Seg Neutrophils</bold></td><td align=\"right\">42.6</td><td align=\"right\">11.9</td><td align=\"right\">15%</td><td align=\"right\">2%</td><td align=\"right\">3%</td><td align=\"right\">20%</td><td align=\"right\">7%</td></tr><tr><td align=\"left\"><bold>Lymphocytes (%)</bold></td><td align=\"right\">46.2</td><td align=\"right\">11.1</td><td align=\"right\">5%</td><td align=\"right\">17%</td><td align=\"right\">-4%</td><td align=\"right\">7%</td><td align=\"right\">22%</td></tr><tr><td align=\"left\"><bold>Monocytes (%)</bold></td><td align=\"right\">7.27</td><td align=\"right\">2.01</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">5%</td><td align=\"right\">2%</td><td align=\"right\">7%</td></tr><tr><td align=\"left\"><bold>Eosinophils (%)</bold></td><td align=\"right\">3.78</td><td align=\"right\">2.91</td><td align=\"right\">0%</td><td align=\"right\">10%</td><td align=\"right\">-1%</td><td align=\"right\">0%</td><td align=\"right\">10%</td></tr><tr><td align=\"left\"><bold>Basophils (%) Abs Neutrophil</bold></td><td align=\"right\">0.39</td><td align=\"right\">0.54</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">25%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>(K/uL) Abs lympocyte</bold></td><td align=\"right\">3.34</td><td align=\"right\">1.53</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">2%</td><td align=\"right\">5%</td><td align=\"right\">5%</td></tr><tr><td align=\"left\"><bold>(k/uL) Abs Monocyte</bold></td><td align=\"right\">3.28</td><td align=\"right\">0.86</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>(k/uL) Abs Eosinophil</bold></td><td align=\"right\">0.53</td><td align=\"right\">0.17</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">9%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>(k/uL)</bold></td><td align=\"right\">0.24</td><td align=\"right\">0.17</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">28%</td><td align=\"right\">0%</td><td align=\"right\">5%</td></tr><tr><td align=\"left\"><bold>Abs Basophil (k/uL)</bold></td><td align=\"right\">0.01</td><td align=\"right\">0.03</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">140%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Glucose (mg/dL) Urea Nitrogen</bold></td><td align=\"right\">85.3</td><td align=\"right\">12.5</td><td align=\"right\">5%</td><td align=\"right\">15%</td><td align=\"right\">-4%</td><td align=\"right\">5%</td><td align=\"right\">7%</td></tr><tr><td align=\"left\"><bold>(mg/dL)</bold></td><td align=\"right\">13.9</td><td align=\"right\">4.18</td><td align=\"right\">2%</td><td align=\"right\">0%</td><td align=\"right\">-8%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Creatinine</bold></td><td align=\"right\">0.50</td><td align=\"right\">0.08</td><td align=\"right\"><bold>20%</bold></td><td align=\"right\"><bold>0%</bold></td><td align=\"right\"><bold>-5%</bold></td><td align=\"right\"><bold>22%</bold></td><td align=\"right\"><bold>0%</bold></td></tr><tr><td align=\"left\"><bold>Bun/Creat Ratio</bold></td><td align=\"right\">28.4</td><td align=\"right\">9.40</td><td align=\"right\"><bold>0%</bold></td><td align=\"right\"><bold>39%</bold></td><td align=\"right\"><bold>-8%</bold></td><td align=\"right\"><bold>2%</bold></td><td align=\"right\"><bold>32%</bold></td></tr><tr><td align=\"left\"><bold>Uric Acid (mg/dL)</bold></td><td align=\"right\">3.73</td><td align=\"right\">0.80</td><td align=\"right\">2%</td><td align=\"right\">2%</td><td align=\"right\">13%</td><td align=\"right\">7%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Sodium (mmol/L)</bold></td><td align=\"right\">139</td><td align=\"right\">2.11</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">-2%</td><td align=\"right\">2%</td><td align=\"right\">2%</td></tr><tr><td align=\"left\"><bold>Potassium (mmol/L)</bold></td><td align=\"right\">4.41</td><td align=\"right\">0.46</td><td align=\"right\">0%</td><td align=\"right\">5%</td><td align=\"right\">-2%</td><td align=\"right\">0%</td><td align=\"right\">10%</td></tr><tr><td align=\"left\"><bold>Chloride (mmol/L)</bold></td><td align=\"right\">103</td><td align=\"right\">1.71</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">-2%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>CO2 (mmol/L)</bold></td><td align=\"right\">22.8</td><td align=\"right\">1.96</td><td align=\"right\">5%</td><td align=\"right\">0%</td><td align=\"right\">-5%</td><td align=\"right\">20%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Anion gap Osmolality</bold></td><td align=\"right\">13.3</td><td align=\"right\">2.42</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">2%</td><td align=\"right\">0%</td><td align=\"right\">5%</td></tr><tr><td align=\"left\"><bold>(mOs/kg)</bold></td><td align=\"right\">284</td><td align=\"right\">4.83</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">12%</td><td align=\"right\">2%</td><td align=\"right\">2%</td></tr><tr><td align=\"left\"><bold>Protein (g/dL)</bold></td><td align=\"right\">7.17</td><td align=\"right\">0.53</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">5%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Albumin (g/dL)</bold></td><td align=\"right\">4.60</td><td align=\"right\">0.21</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">5%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Globulin (g/dL)</bold></td><td align=\"right\">2.65</td><td align=\"right\">0.31</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">6%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Alb/Glob Rat</bold></td><td align=\"right\">1.77</td><td align=\"right\">0.23</td><td align=\"right\">0%</td><td align=\"right\">12%</td><td align=\"right\">4%</td><td align=\"right\">0%</td><td align=\"right\">5%</td></tr><tr><td align=\"left\"><bold>Cholesterol (mg/dL)</bold></td><td align=\"right\">147</td><td align=\"right\">30.1</td><td align=\"right\">0%</td><td align=\"right\">15%</td><td align=\"right\">19%</td><td align=\"right\">0%</td><td align=\"right\">29%</td></tr><tr><td align=\"left\"><bold>Triglyceride (mg/dL)</bold></td><td align=\"right\">87.8</td><td align=\"right\">50.0</td><td align=\"right\">0%</td><td align=\"right\">7%</td><td align=\"right\">30%</td><td align=\"right\">0%</td><td align=\"right\">12%</td></tr><tr><td align=\"left\"><bold>Calcium (mg/dL)</bold></td><td align=\"right\">10.1</td><td align=\"right\">0.37</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">-4%</td><td align=\"right\">0%</td><td align=\"right\">10%</td></tr><tr><td align=\"left\"><bold>Phosphorus (mg/dL)</bold></td><td align=\"right\">5.09</td><td align=\"right\">0.67</td><td align=\"right\">0%</td><td align=\"right\">10%</td><td align=\"right\">4%</td><td align=\"right\">0%</td><td align=\"right\">12%</td></tr><tr><td align=\"left\"><bold>Alkaline Phosphate (IU/L)</bold></td><td align=\"right\">228</td><td align=\"right\">64.1</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">7%</td><td align=\"right\">0%</td><td align=\"right\">20%</td></tr><tr><td align=\"left\"><bold>GGT (IU/L)</bold></td><td align=\"right\">10.2</td><td align=\"right\">2.99</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">12%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>ALT (IU/L)</bold></td><td align=\"right\">20.2</td><td align=\"right\">7.29</td><td align=\"right\">0%</td><td align=\"right\">2%</td><td align=\"right\">7%</td><td align=\"right\">0%</td><td align=\"right\">5%</td></tr><tr><td align=\"left\"><bold>AST (IU/L)</bold></td><td align=\"right\">34.4</td><td align=\"right\">5.54</td><td align=\"right\">0%</td><td align=\"right\">0%</td><td align=\"right\">3%</td><td align=\"right\">0%</td><td align=\"right\">0%</td></tr><tr><td align=\"left\"><bold>Lactic Dehydrogenase (IU/L)</bold></td><td align=\"right\">243</td><td align=\"right\">43.2</td><td align=\"right\">2%</td><td align=\"right\">0%</td><td align=\"right\">14%</td><td align=\"right\">2%</td><td align=\"right\">15%</td></tr><tr><td align=\"left\"><bold>Bilirubin (mg/dL)</bold></td><td align=\"right\">0.33</td><td align=\"right\">0.31</td><td align=\"right\">10%</td><td align=\"right\">0%</td><td align=\"right\">-12%</td><td align=\"right\">5%</td><td align=\"right\">2%</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 11"}
{"html": "<!DOCTYPE html><html><body><h1>Stepwise linear regression analysis of change in platelet count (from baseline to beginning of phase 2, 1-2 months after DMSA therapy), based on excretion of metals after the 9</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Adjusted R</bold><sup><bold>2</bold></sup></td><td align=\"left\"><bold>P- value</bold></td><td align=\"left\"><bold>Equation</bold></td><td align=\"left\"><bold>Most Significant Variables</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Change in platelet count (both groups, n = 32)</bold></td><td align=\"left\">0.41</td><td align=\"left\">0.02</td><td align=\"left\">7rnd group (3.71-331Tl9 +256Sb9+2.89As9-256Cd9-0.118Dglut) 1rnd group (-81.6 +28.3Tl9- 174Sb9+0.194As9+259Cd9+0.193Dglut)</td><td align=\"left\">7rnd - (Tl9***, As9**, Cd9*, Dglut*), 1rnd- (Dglut*)</td></tr><tr><td align=\"left\"><bold>Change in platelet count (7-rnd group only, n = 20)</bold></td><td align=\"left\">0.41</td><td align=\"left\">0.02</td><td align=\"left\">3.71 -331 Tl9 +256Sb9 +2.89 As9 -256 Cd9 -0.118 DGlut</td><td align=\"left\">Tl9**, As9**, Cd*, DGlut*</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 12"}
{"html": "<!DOCTYPE html><html><body><h1>Medical History, as reported by parents (n = 73)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><tbody><tr><td align=\"left\"><bold>Maternal Fish Consumption (servings/month)</bold></td><td align=\"left\">2.85 +/- 2.9</td></tr><tr><td align=\"left\"><bold>Mercury Amalgams present during pregnancy</bold></td><td align=\"left\">3.12 +/- 3.5</td></tr><tr><td align=\"left\"><bold>Mercury amalgams placed during pregnancy</bold></td><td align=\"left\">3%</td></tr><tr><td align=\"left\"><bold>Mercury amalgams removed during pregnancy</bold></td><td align=\"left\">2%</td></tr><tr><td align=\"left\"><bold>Placed during Nursing</bold></td><td align=\"left\">2%</td></tr><tr><td align=\"left\"><bold>Removed during Nursing</bold></td><td align=\"left\">2%</td></tr><tr><td align=\"left\"><bold>Antibiotic usage during pregnancy (rounds)</bold></td><td align=\"left\">0.67 +/- 1.5</td></tr><tr><td align=\"left\"><bold>Antibiotic usage during nursing (rounds)</bold></td><td align=\"left\">0.39 +/- 0.83</td></tr><tr><td align=\"left\"><bold>Child usage of oral antibiotics</bold></td><td/></tr><tr><td align=\"left\"><bold>0-6 months</bold></td><td align=\"left\">0.76 +/- 1.2</td></tr><tr><td align=\"left\"><bold>7-12 months</bold></td><td align=\"left\">1.63 +/- 2.9</td></tr><tr><td align=\"left\"><bold>12-24 months</bold></td><td align=\"left\">2.04 +/- 3.0</td></tr><tr><td align=\"left\"><bold>24-36 months</bold></td><td align=\"left\">1.82 +/- 2.0</td></tr><tr><td align=\"left\"><bold>Total 0-36 months</bold></td><td align=\"left\">5.4 +/- 6.1</td></tr><tr><td align=\"left\"><bold>Ear Infections 0-36 months</bold></td><td align=\"left\">3.5 +/- 4.3</td></tr><tr><td align=\"left\"><bold>Blood Type</bold></td><td align=\"left\">33% A+, 4% A-, 11% B+, 2%B- 4%AB+, 22%O+, 22%O-</td></tr><tr><td align=\"left\"><bold>Rhogam use</bold></td><td align=\"left\">18%</td></tr><tr><td align=\"left\"><bold>Reactions to vaccines</bold></td><td align=\"left\">38% none, 44% mild, 10% moderate, 7% severe</td></tr><tr><td align=\"left\"><bold>Eating/Licking Paint</bold></td><td align=\"left\">7% mild, 4% moderate, 5% severe</td></tr><tr><td align=\"left\"><bold>Pica</bold></td><td align=\"left\">16% mild, 8% moderate, 16% severe</td></tr><tr><td align=\"left\"><bold>Pregnancy Complications</bold></td><td align=\"left\">31% mild, 9% moderate, 9% severe</td></tr><tr><td align=\"left\"><bold>Birth Complications</bold></td><td align=\"left\">23% mild, 11% moderate, 11% severe</td></tr><tr><td align=\"left\"><bold>Childhood Illness</bold></td><td align=\"left\">10% mild, 4% moderate, 6% severe</td></tr><tr><td align=\"left\"><bold>Regression</bold></td><td align=\"left\">28% no regression, 30% possible regression age 18.2 +/- 7.8 mo, 42% regression (age 20.8 +/- 16 mo</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 13"}
{"html": "<!DOCTYPE html><html><body><h1>Correlations of symptoms of \"Eating/licking paint\" and \"pica\" with symptoms of autism and urinary excretion of metals (at baseline or immediately after the 9</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Eating/Licking Paint</bold></td><td align=\"left\"><bold>Pica</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>ATEC Total</bold></td><td align=\"left\">n.s.</td><td align=\"left\">0.33</td></tr><tr><td align=\"left\"><bold>ADOS Total</bold></td><td align=\"left\">0.39</td><td align=\"left\">0.43</td></tr><tr><td align=\"left\"><bold>SAS</bold></td><td align=\"left\">0.54</td><td align=\"left\">0.63</td></tr><tr><td align=\"left\"><bold>PDD-BI - modified Autism subscale</bold></td><td align=\"left\">0.51</td><td align=\"left\">0.54</td></tr><tr><td/><td/><td/></tr><tr><td align=\"left\"><bold>Pb-b</bold></td><td align=\"left\">n.s.</td><td align=\"left\">0.32</td></tr><tr><td align=\"left\"><bold>Pb-9</bold></td><td align=\"left\">0.62</td><td align=\"left\">0.40</td></tr><tr><td align=\"left\"><bold>Sn-b</bold></td><td align=\"left\">0.35</td><td align=\"left\">0.34</td></tr><tr><td align=\"left\"><bold>Tl-b</bold></td><td align=\"left\">0.29</td><td align=\"left\">0.38</td></tr><tr><td align=\"left\"><bold>Tl-9</bold></td><td align=\"left\">0.39</td><td align=\"left\">0.33</td></tr><tr><td align=\"left\"><bold>Sb-b</bold></td><td align=\"left\">0.49</td><td align=\"left\">0.45</td></tr><tr><td align=\"left\"><bold>W-b</bold></td><td align=\"left\">0.31</td><td align=\"left\">0.45</td></tr><tr><td align=\"left\"><bold>Al-9</bold></td><td align=\"left\">0.38</td><td align=\"left\">n.s.</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 14"}
{"html": "<!DOCTYPE html><html><body><h1>Correlation of initial glutathione with urinary excretion of toxic metals.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"right\"><bold>Baseline</bold></td><td align=\"right\"><bold>1st dose</bold></td><td align=\"right\"><bold>9th dose</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Cd</bold></td><td align=\"right\">-0.08</td><td align=\"right\">0.21</td><td align=\"right\">0.30</td></tr><tr><td align=\"left\"><bold>Al</bold></td><td align=\"right\">0.17</td><td align=\"right\">0.21</td><td align=\"right\">0.29</td></tr><tr><td align=\"left\"><bold>Pb</bold></td><td align=\"right\">0.20</td><td align=\"right\">0.18</td><td align=\"right\">0.25</td></tr><tr><td align=\"left\"><bold>W</bold></td><td align=\"right\">0.14</td><td align=\"right\">-0.05</td><td align=\"right\">0.23</td></tr><tr><td align=\"left\"><bold>Sb</bold></td><td align=\"right\">0.26</td><td align=\"right\">0.22</td><td align=\"right\">0.22</td></tr><tr><td align=\"left\"><bold>Sn</bold></td><td align=\"right\">-0.04</td><td align=\"right\">0.11</td><td align=\"right\">0.21</td></tr><tr><td align=\"left\"><bold>U</bold></td><td align=\"right\">0.11</td><td align=\"right\">0.25</td><td align=\"right\">0.20</td></tr><tr><td align=\"left\"><bold>Tl</bold></td><td align=\"right\">0.15</td><td align=\"right\">0.06</td><td align=\"right\">0.18</td></tr><tr><td align=\"left\"><bold>Bi</bold></td><td align=\"right\">-0.07</td><td align=\"right\">0.09</td><td align=\"right\">0.12</td></tr><tr><td align=\"left\"><bold>Ni</bold></td><td align=\"right\">-0.08</td><td align=\"right\">0.00</td><td align=\"right\">0.10</td></tr><tr><td align=\"left\"><bold>As</bold></td><td align=\"right\">0.06</td><td align=\"right\">-0.04</td><td align=\"right\">-0.10</td></tr><tr><td align=\"left\"><bold>Hg</bold></td><td align=\"right\">0.17</td><td align=\"right\">-0.30</td><td align=\"right\">-0.27</td></tr></tbody></table></body></html>", "text": "Pmid= 2774660:Table= Table 15"}
{"html": "<!DOCTYPE html><html><body><h1>representative results of detoxification studies</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Time prior CPO induction</th><th align=\"left\">Group<sup>1</sup></th><th align=\"center\">Score</th><th align=\"center\">Mortality<break/>(%)</th><th align=\"center\">Severe reaction<break/>(%)</th></tr></thead><tbody><tr><td/><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">untreated<sup>2</sup></td><td align=\"center\">3.6</td><td align=\"center\">62.5</td><td align=\"center\">37.5</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">TBS</td><td align=\"center\">3.8</td><td align=\"center\">75</td><td align=\"center\">25</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">POPC</td><td align=\"center\">3.9</td><td align=\"center\">87.5</td><td align=\"center\">12.5</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">5 min</td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">Atropine+2PAM<sup>3</sup></td><td align=\"center\">0.5*</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">BL-3050<sup>4</sup></td><td align=\"center\">1.3*</td><td align=\"center\">12.5</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">3 hours</td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">Atropine+2PAM<sup>3</sup></td><td align=\"center\">2.1</td><td align=\"center\">25</td><td align=\"center\">12.5</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">BL-3050<sup>4</sup></td><td align=\"center\">1.3*</td><td align=\"center\">12.5</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">rePON1-TBS<sup>4</sup></td><td align=\"center\">1.4*</td><td align=\"center\">12.5</td><td align=\"center\">12.5</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">14 hours</td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">BL-3050<sup>4</sup></td><td align=\"center\">3.0</td><td align=\"center\">50</td><td align=\"center\">25</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">rePON1-TBS<sup>4</sup></td><td align=\"center\">1.8*</td><td align=\"center\">0</td><td align=\"center\">12.5</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\">rePON1-TBS<sup>5</sup></td><td align=\"center\">1.1*</td><td align=\"center\">12.5</td><td align=\"center\">12.5</td></tr></tbody></table></body></html>", "text": "Pmid= 2785756:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic variables and their definitions</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">T<sub>max</sub></th><th align=\"left\">The time to the first occurrence of the maximum plasma concentration</th></tr></thead><tbody><tr><td align=\"left\"><bold>C<sub>max</sub></bold></td><td align=\"left\">The observed maximum plasma concentration</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC<sub>0-t</sub></bold></td><td align=\"left\">AUC to the last measurable plasma concentration (Cp), calculated by the linear trapezoidal rule</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC<sub>0-inf</sub></bold></td><td align=\"left\">AUC calculated by linear trapezoidal rule to the last measurable Cp with additional area calculated from Cp/Kel. Kel is the elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least-squares regression of log (concentration) against time</td></tr></tbody></table></body></html>", "text": "Pmid= 2796637:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>C</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Sodium ibuprofen<break/>(n = 22)</th><th align=\"left\">Ibuprofen/poloxamer<break/>(n = 22)</th><th align=\"left\">Standard ibuprofen<break/>(n = 22)</th></tr></thead><tbody><tr><td align=\"left\"><bold>C<sub>max </sub>(&#956;g/mL)</bold></td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Arithmetic mean</td><td align=\"left\">43.01</td><td align=\"left\">36.06</td><td align=\"left\">32.84</td></tr><tr><td align=\"left\">&#8195;Geometric LS mean</td><td align=\"left\">41.47</td><td align=\"left\">35.22</td><td align=\"left\">31.88</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC<sub>0-t </sub>(&#956;g/mL/h)</bold></td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Arithmetic mean</td><td align=\"left\">120.57</td><td align=\"left\">124.10</td><td align=\"left\">119.10</td></tr><tr><td align=\"left\">&#8195;Geometric LS mean</td><td align=\"left\">117.79</td><td align=\"left\">120.55</td><td align=\"left\">115.28</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC<sub>0-inf </sub>(&#956;g/mL/h)</bold></td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Arithmetic mean</td><td align=\"left\">122.88</td><td align=\"left\">126.72</td><td align=\"left\">121.99</td></tr><tr><td align=\"left\">&#8195;Geometric LS mean</td><td align=\"left\">119.73</td><td align=\"left\">122.75</td><td align=\"left\">117.71</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>T<sub>max </sub>(min)</bold></td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Median</td><td align=\"left\">35</td><td align=\"left\">75</td><td align=\"left\">90</td></tr></tbody></table></body></html>", "text": "Pmid= 2796637:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Statistical analyses of partial AUC data</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Sodium ibuprofen<break/>(geometric means)</th><th align=\"left\">Ibuprofen/ poloxamer<break/>(geometric means)</th><th align=\"left\">Standard ibuprofen<break/>(geometric means)</th><th align=\"left\">Ratio (%)<break/>sodium ibuprofen/ standard ibuprofen</th><th align=\"left\">90% confidence interval</th><th align=\"left\">Ratio (%)<break/>ibuprofen/ poloxamer/ standard ibuprofen</th><th align=\"left\">90% confidence interval</th></tr></thead><tbody><tr><td align=\"left\">AUC 0-0.08 (&#956;g/h/mL)</td><td align=\"left\">Not estimated</td><td align=\"left\">Not estimated</td><td align=\"left\">Not estimated</td><td align=\"left\">Not estimated</td><td align=\"left\">Not estimated</td><td align=\"left\">Not estimated</td><td align=\"left\">Not estimated</td></tr><tr><td align=\"left\">AUC 0-0.17 (&#956;g/h/mL)</td><td align=\"left\">0.06</td><td align=\"left\">0.03</td><td align=\"left\">0.03</td><td align=\"left\">217.32</td><td align=\"left\">95.29-495.60</td><td align=\"left\">118.65</td><td align=\"left\">49.21-286.08</td></tr><tr><td align=\"left\">AUC 0-0.25 (&#956;g/h/mL)</td><td align=\"left\">0.49</td><td align=\"left\">0.13</td><td align=\"left\">0.09</td><td align=\"left\">529.77</td><td align=\"left\">262.01-1071.16</td><td align=\"left\">138.56</td><td align=\"left\">68.53-280.17</td></tr><tr><td align=\"left\">AUC 0-0.33 (&#956;g/h/mL)</td><td align=\"left\">1.61</td><td align=\"left\">0.50</td><td align=\"left\">0.18</td><td align=\"left\">905.93</td><td align=\"left\">462.33-1775.19</td><td align=\"left\">278.80</td><td align=\"left\">142.28-546.31</td></tr><tr><td align=\"left\">AUC 0-0.42 (&#956;g/h/mL)</td><td align=\"left\">3.57</td><td align=\"left\">1.24</td><td align=\"left\">0.55</td><td align=\"left\">644.02</td><td align=\"left\">362.66-1143.69</td><td align=\"left\">224.33</td><td align=\"left\">126.32-398.37</td></tr><tr><td align=\"left\">AUC 0-0.50 (&#956;g/h/mL)</td><td align=\"left\">6.09</td><td align=\"left\">2.34</td><td align=\"left\">1.31</td><td align=\"left\">466.40</td><td align=\"left\">287.78-755.90</td><td align=\"left\">179.01</td><td align=\"left\">110.45-290.13</td></tr><tr><td align=\"left\">AUC 0-0.58 (&#956;g/h/mL)</td><td align=\"left\">8.99</td><td align=\"left\">3.72</td><td align=\"left\">2.30</td><td align=\"left\">390.44</td><td align=\"left\">251.21-606.85</td><td align=\"left\">161.71</td><td align=\"left\">104.04-251.34</td></tr><tr><td align=\"left\">AUC 0-0.67 (&#956;g/h/mL)</td><td align=\"left\">12.08</td><td align=\"left\">5.39</td><td align=\"left\">3.52</td><td align=\"left\">343.55</td><td align=\"left\">227.18-519.53</td><td align=\"left\">153.34</td><td align=\"left\">101.40-231.89</td></tr><tr><td align=\"left\">AUC 0-0.83 (&#956;g/h/mL)</td><td align=\"left\">18.03</td><td align=\"left\">9.24</td><td align=\"left\">6.36</td><td align=\"left\">283.49</td><td align=\"left\">195.09-411.95</td><td align=\"left\">145.21</td><td align=\"left\">99.93-211.00</td></tr><tr><td align=\"left\">AUC 0-1.00 (&#956;g/h/mL)</td><td align=\"left\">23.71</td><td align=\"left\">13.65</td><td align=\"left\">9.54</td><td align=\"left\">248.48</td><td align=\"left\">176.57-349.68</td><td align=\"left\">143.08</td><td align=\"left\">101.67-201.35</td></tr></tbody></table></body></html>", "text": "Pmid= 2796637:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Reporting randomised controlled clinical trials according to different items in CONSORT checklist.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Paper section and Topic</th><th align=\"left\">Item number</th><th align=\"left\">n RCTs<break/>(N = 92)</th><th align=\"left\">(%)</th></tr></thead><tbody><tr><td align=\"left\"><bold><italic>Title and abstract</italic></bold></td><td align=\"left\">1</td><td align=\"left\">64</td><td align=\"left\">(69.6)</td></tr><tr><td align=\"left\"><bold><italic>Introduction</italic></bold></td><td/><td/><td/></tr><tr><td align=\"left\">Background</td><td align=\"left\">2</td><td align=\"left\">67</td><td align=\"left\">(72.8)</td></tr><tr><td align=\"left\"><bold><italic>Methods</italic></bold></td><td/><td/><td/></tr><tr><td align=\"left\">Participants</td><td align=\"left\">3</td><td align=\"left\">86</td><td align=\"left\">(93.5)</td></tr><tr><td align=\"left\">Interventions</td><td align=\"left\">4</td><td align=\"left\">90</td><td align=\"left\">(97.8)</td></tr><tr><td align=\"left\">Objectives</td><td align=\"left\">5</td><td align=\"left\">11</td><td align=\"left\">(12.0)</td></tr><tr><td align=\"left\">Outcomes</td><td align=\"left\">6</td><td align=\"left\">10</td><td align=\"left\">(10.9)</td></tr><tr><td align=\"left\">Sample size</td><td align=\"left\">7</td><td align=\"left\">11</td><td align=\"left\">(12.0)</td></tr><tr><td align=\"left\">Randomisation</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Sequence generation</td><td align=\"left\">8</td><td align=\"left\">22</td><td align=\"left\">(23.9)</td></tr><tr><td align=\"left\">&#8195;Allocation concealment</td><td align=\"left\">9</td><td align=\"left\">5</td><td align=\"left\">(5.4)</td></tr><tr><td align=\"left\">&#8195;Implementation</td><td align=\"left\">10</td><td align=\"left\">1</td><td align=\"left\">(1.1)</td></tr><tr><td align=\"left\">Blinding (masking)</td><td align=\"left\">11</td><td align=\"left\">75</td><td align=\"left\">(81.5)</td></tr><tr><td align=\"left\">Statistical methods</td><td align=\"left\">12</td><td align=\"left\">84</td><td align=\"left\">(91.3)</td></tr><tr><td align=\"left\"><bold><italic>Results</italic></bold></td><td/><td/><td/></tr><tr><td align=\"left\">Participant flow</td><td align=\"left\">13</td><td align=\"left\">62</td><td align=\"left\">(67.4)</td></tr><tr><td align=\"left\">Recruitment</td><td align=\"left\">14</td><td align=\"left\">11</td><td align=\"left\">(12.0)</td></tr><tr><td align=\"left\">Baseline data</td><td align=\"left\">15</td><td align=\"left\">73</td><td align=\"left\">(79.3)</td></tr><tr><td align=\"left\">Numbers analysed</td><td align=\"left\">16</td><td align=\"left\">24</td><td align=\"left\">(26.0)</td></tr><tr><td align=\"left\">Outcomes and estimation</td><td align=\"left\">17</td><td align=\"left\">40</td><td align=\"left\">(43.5)</td></tr><tr><td align=\"left\">Ancillary analyses</td><td align=\"left\">18</td><td align=\"left\">48</td><td align=\"left\">(52.2)</td></tr><tr><td align=\"left\">Adverse events</td><td align=\"left\">19</td><td align=\"left\">88</td><td align=\"left\">(95.6)</td></tr><tr><td align=\"left\"><bold><italic>Discussion</italic></bold></td><td/><td/><td/></tr><tr><td align=\"left\">Interpretation</td><td align=\"left\">20</td><td align=\"left\">23</td><td align=\"left\">(25.0)</td></tr><tr><td align=\"left\">Generalization</td><td align=\"left\">21</td><td align=\"left\">13</td><td align=\"left\">(14.1)</td></tr><tr><td align=\"left\">Overall evidence</td><td align=\"left\">22</td><td align=\"left\">62</td><td align=\"left\">(67.4)</td></tr></tbody></table></body></html>", "text": "Pmid= 2822812:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Quality of reporting according to compared groups in randomised clinical trials.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">RCT (n = 92)</th><th align=\"center\">CONSORT checklist<break/>Mean score (sd)</th></tr></thead><tbody><tr><td align=\"left\"><bold><italic>Placebo control group</italic></bold></td><td/></tr><tr><td/><td/></tr><tr><td align=\"left\">Yes (n = 42)</td><td align=\"center\">11.36 (2.59)</td></tr><tr><td align=\"left\">No (n = 50)</td><td align=\"center\">9.92 (2.67)</td></tr><tr><td/><td/></tr><tr><td align=\"left\"><italic>Statistical significance</italic></td><td align=\"center\">p = 0.011</td></tr><tr><td align=\"left\"><bold><italic>Analgesics compared</italic></bold></td><td/></tr><tr><td/><td/></tr><tr><td align=\"left\">NSAIDs (n = 46)</td><td align=\"center\">10.59 (3.01)</td></tr><tr><td align=\"left\">Opioids (n = 10)</td><td align=\"center\">11.70 (2.31)</td></tr><tr><td align=\"left\">NSAIDs <italic>vs</italic>. Opioids (n = 19)</td><td align=\"center\">10.11 (2.28)</td></tr><tr><td align=\"left\">NSAIDs + opioids <italic>vs</italic>. NSAIDs and/or opioids (n = 17)</td><td align=\"center\">10.41 (2.57)</td></tr><tr><td/><td/></tr><tr><td align=\"left\"><italic>Statistical significance</italic></td><td align=\"center\">p = 0.511</td></tr></tbody></table></body></html>", "text": "Pmid= 2822812:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Mean (SD) overall scores for CONSORT checklist according to impact factor (IF) of the medical journals.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">IF<break/>journals</th><th align=\"center\">No IF journals<break/>(n = 16)</th><th align=\"center\">Low<break/>IF journals<break/>(n = 36)</th><th align=\"center\">High<break/>IF journals<break/>(n = 40)</th><th align=\"center\">Total<break/>journals<break/>(N = 92)</th></tr></thead><tbody><tr><td align=\"center\"><bold>CONSORT</bold><break/><bold>Mean (SD)</bold></td><td align=\"center\">8.9 (2.3)&#8224;</td><td align=\"center\">10.1 (2.1)&#8224;&#8224;</td><td align=\"center\">11.6 (3.0)</td><td align=\"center\">10.5 (2.7)</td></tr></tbody></table></body></html>", "text": "Pmid= 2822812:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Evaluation of the range of concentrations for Meropenem (USP standard)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\" colspan=\"2\">Concentration Range</th><th align=\"center\" colspan=\"3\">Equation</th></tr></thead><tbody><tr><td align=\"center\"><bold>From</bold></td><td align=\"center\"><bold>To</bold></td><td align=\"center\"><bold>Slope</bold></td><td align=\"center\"><bold>Intercept</bold></td><td align=\"center\"><bold>R<sup>2</sup></bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\"><bold>C1</bold></td><td align=\"center\">C9</td><td align=\"center\">3.8469</td><td align=\"center\">15.355</td><td align=\"center\">0.995</td></tr><tr><td align=\"center\"><bold>C1</bold></td><td align=\"center\">C5</td><td align=\"center\">4.288</td><td align=\"center\">13.36</td><td align=\"center\">0.9861</td></tr><tr><td align=\"center\"><bold>C2</bold></td><td align=\"center\">C6</td><td align=\"center\">3.4631</td><td align=\"center\">16.437</td><td align=\"center\">0.9911</td></tr><tr><td align=\"center\"><bold>C3</bold></td><td align=\"center\">C7</td><td align=\"center\">3.5659</td><td align=\"center\">15.967</td><td align=\"center\">0.9881</td></tr><tr><td align=\"center\"><bold>C4</bold></td><td align=\"center\">C8</td><td align=\"center\">3.6377</td><td align=\"center\">15.735</td><td align=\"center\">0.9878</td></tr><tr><td align=\"center\"><bold>C5</bold></td><td align=\"center\"><bold>C9</bold></td><td align=\"center\"><bold>3.8575</bold></td><td align=\"center\"><bold>15.374</bold></td><td align=\"center\"><bold>0.9976</bold></td></tr><tr><td align=\"center\"><bold>C6</bold></td><td align=\"center\">C10</td><td align=\"center\">3.9901</td><td align=\"center\">15.42</td><td align=\"center\">0.9945</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Evaluation of the range of concentrations of Piperacillin (USP standard)/Tazobactam</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\" colspan=\"2\">Concentration Range</th><th align=\"center\" colspan=\"3\">Equation</th></tr></thead><tbody><tr><td align=\"center\"><bold>From</bold></td><td align=\"center\"><bold>To</bold></td><td align=\"center\"><bold>Slope</bold></td><td align=\"center\"><bold>Intercept</bold></td><td align=\"center\"><bold>R<sup>2</sup></bold></td></tr><tr><td align=\"center\"><bold>C5</bold></td><td align=\"center\"><bold>C9</bold></td><td align=\"center\"><bold>2.5554</bold></td><td align=\"center\"><bold>9.8253</bold></td><td align=\"center\"><bold>0.9989</bold></td></tr><tr><td align=\"center\">C6</td><td align=\"center\">C10</td><td align=\"center\">2.7968</td><td align=\"center\">9.1638</td><td align=\"center\">0.992</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Evaluation of linearity for Meropenem and Piperacillin/Tazobactam</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\" colspan=\"2\">Experimental t</th><th align=\"center\">Theoretical t</th><th align=\"center\">Decision</th></tr><tr><th/><th/><th colspan=\"2\"><hr/></th><th/><th/></tr><tr><th align=\"center\">Test</th><th align=\"center\">HYPOTHESIS</th><th align=\"center\">Meropenem</th><th align=\"center\">Piperacillin</th><th/><th/></tr></thead><tbody><tr><td align=\"center\"><bold>Slope</bold></td><td align=\"center\">H<sub>0</sub>: m = 0</td><td/><td align=\"center\">2.684</td><td align=\"center\">2.16</td><td align=\"center\">Reject H<sub>0</sub></td></tr><tr><td/><td align=\"center\">H<sub>1</sub>: m &#8800; 0</td><td align=\"center\">7.677</td><td/><td/><td/></tr><tr><td align=\"center\"><bold>Intercept</bold></td><td align=\"center\">H<sub>0</sub>: b = 0</td><td/><td align=\"center\">18.025</td><td/><td align=\"center\">Reject H<sub>0</sub></td></tr><tr><td/><td align=\"center\">H<sub>1</sub>: b &#8800; 0</td><td align=\"center\">47.901</td><td/><td align=\"center\">2.16</td><td/></tr><tr><td align=\"center\"><bold>Correlation</bold></td><td align=\"center\">H<sub>0</sub>: R = 0</td><td align=\"center\">58.41</td><td align=\"center\">23.381</td><td align=\"center\">2.16</td><td align=\"center\">Reject H<sub>0</sub></td></tr><tr><td/><td align=\"center\">H<sub>1</sub>: R &#8800; 0</td><td/><td/><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Regression analysis by analysis of variance (ANOVA).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\" colspan=\"2\">Experimental t</th><th/><th/></tr><tr><th/><th/><th colspan=\"2\"><hr/></th><th/><th/></tr><tr><th align=\"center\">Test</th><th align=\"center\">HYPOTHESIS</th><th align=\"center\">Meropenem</th><th align=\"center\">Piperacillin</th><th align=\"center\">Theoretical t</th><th align=\"center\">Decision</th></tr></thead><tbody><tr><td/><td align=\"center\">H<sub>0</sub>: There is no regression</td><td align=\"center\">3494.54</td><td align=\"center\">324.89</td><td align=\"center\">3.67</td><td align=\"center\">Reject H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>Regression</bold></td><td align=\"center\">H<sub>1</sub>: There is regression</td><td/><td/><td/><td/></tr><tr><td/><td align=\"center\">H<sub>0</sub>: There is no deviation</td><td/><td/><td/><td/></tr><tr><td align=\"center\"><bold>Linearity</bold></td><td align=\"center\">from linearity</td><td/><td/><td/><td/></tr><tr><td align=\"center\"><bold>Deviation</bold></td><td align=\"center\">H<sub>1</sub>: There is a deviation</td><td align=\"center\">0.3513</td><td align=\"center\">3.71</td><td align=\"center\">3.71</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td/><td align=\"center\">from linearity</td><td/><td/><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>ANOVA of the reproducibility of assays using Meropenem and Piperacillin/Tazobactam</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Concentration</th><th align=\"center\" colspan=\"2\">Experimental F</th><th align=\"center\">Theoretical F</th><th align=\"center\">Decision</th></tr><tr><th/><th colspan=\"2\"><hr/></th><th/><th/></tr><tr><th/><th align=\"center\">Meropenem</th><th align=\"center\">Piperacillin</th><th/><th/></tr></thead><tbody><tr><td align=\"center\"><bold>C1</bold></td><td align=\"center\">2.9136</td><td align=\"center\">2.684</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C2</bold></td><td align=\"center\">3.9852</td><td align=\"center\">3.025</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C3</bold></td><td align=\"center\">1.1247</td><td align=\"center\">1.009</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C4</bold></td><td align=\"center\">0.4746</td><td align=\"center\">0.395</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C5</bold></td><td align=\"center\">0.4938</td><td align=\"center\">0.412</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>ANOVA of the between-days precision of assays using Meropenem and Piperacillin/Tazobactam</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Concentration</th><th align=\"center\" colspan=\"2\">Experimental F</th><th align=\"center\">Theoretical F</th><th align=\"center\">Decision</th></tr><tr><th/><th colspan=\"2\"><hr/></th><th/><th/></tr><tr><th/><th align=\"center\">Meropenem</th><th align=\"center\">Piperacillin</th><th/><th/></tr></thead><tbody><tr><td align=\"center\"><bold>C1</bold></td><td align=\"center\">0.2747</td><td align=\"center\">0.6425</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C2</bold></td><td align=\"center\">0.0169</td><td align=\"center\">0.2342</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C3</bold></td><td align=\"center\">0.6447</td><td align=\"center\">0.4756</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C4</bold></td><td align=\"center\">0.8572</td><td align=\"center\">0.9325</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C5</bold></td><td align=\"center\">0.0712</td><td align=\"center\">0.123</td><td align=\"center\">5.99</td><td align=\"center\">Accept H<sub>0</sub></td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Stability of Meropenem and Piperacillin/Tazobactam in water for injection at 37C</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Time</th><th align=\"center\" colspan=\"3\">Meropenem</th><th align=\"center\" colspan=\"3\">Piperacillin/Tazobactam</th></tr><tr><th/><th colspan=\"6\"><hr/></th></tr><tr><th/><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th></tr></thead><tbody><tr><td align=\"center\">0 hours</td><td align=\"center\">4.1977</td><td align=\"center\">16.556</td><td align=\"center\">0.9922</td><td align=\"center\">2.7549</td><td align=\"center\">9.2827</td><td align=\"center\">0.9969</td></tr><tr><td align=\"center\">6 hours</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">2.717</td><td align=\"center\">14.247</td><td align=\"center\">0.9946</td></tr><tr><td align=\"center\">12 hours</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">2.7162</td><td align=\"center\">16.39</td><td align=\"center\">0.9986</td></tr><tr><td align=\"center\">24 hours</td><td align=\"center\">4.4628</td><td align=\"center\">15.921</td><td align=\"center\">0.9976</td><td align=\"center\">2.6777</td><td align=\"center\">9.4456</td><td align=\"center\">0.9896</td></tr><tr><td align=\"center\">48 hours</td><td align=\"center\">4.1291</td><td align=\"center\">13.257</td><td align=\"center\">0.9847</td><td align=\"center\">3.2429</td><td align=\"center\">7.1086</td><td align=\"center\">0.9806</td></tr><tr><td align=\"center\">6 days</td><td align=\"center\">4.1659</td><td align=\"center\">5.671</td><td align=\"center\">0.9998</td><td align=\"center\">2.5459</td><td align=\"center\">7.0209</td><td align=\"center\">0.9603</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Stability of Piperacillin/Tazobactam in water for injection at 4C and 25C</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Time</th><th align=\"center\" colspan=\"3\">4&#176;C</th><th align=\"center\" colspan=\"3\">25&#176;C</th></tr><tr><th/><th colspan=\"6\"><hr/></th></tr><tr><th/><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th></tr></thead><tbody><tr><td align=\"center\">0 hours</td><td align=\"center\">2.8549</td><td align=\"center\">9.2827</td><td align=\"center\">0.9969</td><td align=\"center\">2.7549</td><td align=\"center\">9.2827</td><td align=\"center\">0.9969</td></tr><tr><td align=\"center\">6 hours</td><td align=\"center\">2.8705</td><td align=\"center\">10.204</td><td align=\"center\">0.9949</td><td align=\"center\">2.7902</td><td align=\"center\">10.32</td><td align=\"center\">0.9892</td></tr><tr><td align=\"center\">12 hours</td><td align=\"center\">2.8234</td><td align=\"center\">13.45</td><td align=\"center\">0.9895</td><td align=\"center\">2.7247</td><td align=\"center\">13.355</td><td align=\"center\">0.9838</td></tr><tr><td align=\"center\">24 hours</td><td align=\"center\">2.8507</td><td align=\"center\">10.185</td><td align=\"center\">0.99</td><td align=\"center\">2.7927</td><td align=\"center\">9.4542</td><td align=\"center\">0.9908</td></tr><tr><td align=\"center\">48 hours</td><td align=\"center\">2.8802</td><td align=\"center\">8.9856</td><td align=\"center\">0.9955</td><td align=\"center\">2.8346</td><td align=\"center\">9.4962</td><td align=\"center\">0.9929</td></tr><tr><td align=\"center\">6 days</td><td align=\"center\">2.8158</td><td align=\"center\">9.4177</td><td align=\"center\">0.9987</td><td align=\"center\">2.8067</td><td align=\"center\">7.2892</td><td align=\"center\">0.9995</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 8"}
{"html": "<!DOCTYPE html><html><body><h1>Contents of the commercial samples</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Samples</th><th align=\"center\" colspan=\"2\">Piperacillin/Tazobactam</th><th align=\"center\" colspan=\"2\">Meropenem</th></tr><tr><th/><th colspan=\"4\"><hr/></th></tr><tr><th/><th align=\"center\">Group 1</th><th align=\"center\">Group 2</th><th align=\"center\">Group 1</th><th align=\"center\">Group 2</th></tr></thead><tbody><tr><td align=\"center\">1</td><td align=\"center\">103.9</td><td align=\"center\">103.6</td><td align=\"center\">100.85</td><td align=\"center\">107.5</td></tr><tr><td align=\"center\">2</td><td align=\"center\">99.0</td><td align=\"center\">115.8</td><td align=\"center\">94.9</td><td align=\"center\">109.5</td></tr><tr><td align=\"center\">3</td><td align=\"center\">116.0</td><td align=\"center\">109.7</td><td align=\"center\">93.52</td><td align=\"center\">105.3</td></tr><tr><td align=\"center\">4</td><td align=\"center\">110.8</td><td align=\"center\">109.4</td><td align=\"center\">94.30</td><td align=\"center\">116.9</td></tr><tr><td align=\"center\">5</td><td align=\"center\">119.2</td><td align=\"center\">108.7</td><td align=\"center\">91.92</td><td align=\"center\">104.5</td></tr><tr><td align=\"center\">6</td><td align=\"center\">1156</td><td align=\"center\">105.3</td><td align=\"center\">97.75</td><td align=\"center\">105.9</td></tr><tr><td align=\"center\">7</td><td align=\"center\">110.6</td><td align=\"center\">110.5</td><td align=\"center\">94.02</td><td align=\"center\">107.2</td></tr><tr><td align=\"center\">8</td><td align=\"center\">113.9</td><td align=\"center\">111.3</td><td align=\"center\">94.64</td><td align=\"center\">115.7</td></tr><tr><td align=\"center\">9</td><td align=\"center\">114.7</td><td align=\"center\">104.2</td><td align=\"center\">90.76</td><td align=\"center\">107.2</td></tr><tr><td align=\"center\">10</td><td align=\"center\">116.2</td><td align=\"center\">107.9</td><td align=\"center\">92.89</td><td align=\"center\">103.3</td></tr><tr><td align=\"center\">11</td><td align=\"center\">111.2</td><td align=\"center\">116.8</td><td align=\"center\">93.32</td><td align=\"center\">105.7</td></tr><tr><td align=\"center\">12</td><td align=\"center\">112.4</td><td align=\"center\">117.6</td><td align=\"center\">95.28</td><td align=\"center\">107.1</td></tr><tr><td align=\"center\">13</td><td align=\"center\">114.6</td><td align=\"center\">114.3</td><td align=\"center\">95.29</td><td align=\"center\">102.5</td></tr><tr><td align=\"center\">14</td><td align=\"center\">116.2</td><td align=\"center\">108.9</td><td align=\"center\">92.86</td><td align=\"center\">103.4</td></tr><tr><td align=\"center\">15</td><td align=\"center\">108.2</td><td align=\"center\">110.1</td><td align=\"center\">93.43</td><td align=\"center\">106.2</td></tr><tr><td align=\"center\">16</td><td align=\"center\">114.1</td><td align=\"center\">108.5</td><td align=\"center\">93.84</td><td align=\"center\">104.5</td></tr><tr><td align=\"center\">17</td><td align=\"center\">117.9</td><td align=\"center\">112.6</td><td align=\"center\">94.22</td><td align=\"center\">105.1</td></tr><tr><td align=\"center\">18</td><td align=\"center\">110.3</td><td align=\"center\">104.9</td><td align=\"center\">97.32</td><td align=\"center\">106.7</td></tr><tr><td align=\"center\">19</td><td align=\"center\">114.8</td><td/><td/><td align=\"center\">105.8</td></tr><tr><td align=\"center\">20</td><td align=\"center\">111.9</td><td/><td/><td align=\"center\">107.1</td></tr><tr><td align=\"center\">21</td><td align=\"center\">109.9</td><td/><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 9"}
{"html": "<!DOCTYPE html><html><body><h1>Determination of MIC and MLC for Meropenem</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><tbody><tr><td align=\"center\"><bold>Strain</bold></td><td align=\"center\" colspan=\"3\"><bold>MIC (&#956;g/ml)</bold></td><td align=\"center\" colspan=\"3\"><bold>MLC (&#956;g/ml)</bold></td></tr><tr><td/><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\"><bold>Std</bold></td><td align=\"center\"><bold>M1</bold></td><td align=\"center\"><bold>M2</bold></td><td align=\"center\"><bold>Std</bold></td><td align=\"center\"><bold>M1</bold></td><td align=\"center\"><bold>M2</bold></td></tr><tr><td/><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>151</td><td align=\"center\">3.9</td><td align=\"center\">3.9</td><td align=\"center\">3.9</td><td align=\"center\">7.8</td><td align=\"center\">7.8</td><td align=\"center\">7.8</td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>157</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>ATCC 25619</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>74</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>142</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td></tr><tr><td align=\"left\"><italic>A</italic>. <italic>baumanii </italic>59</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td></tr><tr><td align=\"left\"><italic>A</italic>. <italic>baumanii </italic>147</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td></tr><tr><td align=\"left\"><italic>A</italic>. <italic>baumanii </italic>173</td><td align=\"center\">0.98</td><td align=\"center\">0.98</td><td align=\"center\">0.98</td><td align=\"center\">1.95</td><td align=\"center\">1.95</td><td align=\"center\">1.95</td></tr><tr><td align=\"left\"><italic>A</italic>. <italic>baumanii </italic>189</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td></tr><tr><td align=\"left\"><italic>E. coli </italic>39</td><td align=\"center\">3.91</td><td align=\"center\">3.91</td><td align=\"center\">3.91</td><td align=\"center\">7.8</td><td align=\"center\">7.8</td><td align=\"center\">7.8</td></tr><tr><td align=\"left\"><italic>E. coli </italic>50</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td></tr><tr><td align=\"left\"><italic>E. coli </italic>69</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td></tr><tr><td align=\"left\"><italic>E. coli </italic>ATCC 13706</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td></tr><tr><td align=\"left\"><italic>S</italic>. <italic>faecalis</italic></td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td></tr><tr><td align=\"left\"><italic>S</italic>. <italic>faecalis </italic>ATCC 29212</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td></tr><tr><td align=\"left\"><italic>S</italic>. <italic>faecalis </italic>ATCC 319623</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td></tr><tr><td align=\"left\"><italic>E</italic>. <italic>gallinarum</italic></td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>1</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>43</td><td align=\"center\">250</td><td align=\"center\">250</td><td align=\"center\">250</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td><td align=\"center\">&#8805; 500</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>63</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>65</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">15.6</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td><td align=\"center\">31.3</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>207</td><td align=\"center\">3.9</td><td align=\"center\">3.9</td><td align=\"center\">3.9</td><td align=\"center\">7.8</td><td align=\"center\">7.8</td><td align=\"center\">7.8</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>ATCC10031</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">250</td><td align=\"center\">250</td><td align=\"center\">250</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 10"}
{"html": "<!DOCTYPE html><html><body><h1>Determination of MIC and MLC for Piperacillin/Tazobactam</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Strain</th><th align=\"center\" colspan=\"3\">MIC (&#956;g/ml)</th><th align=\"center\" colspan=\"3\">MLC (&#956;g/ml)</th></tr><tr><th/><th colspan=\"6\"><hr/></th></tr><tr><th/><th align=\"center\">Std</th><th align=\"center\">M1</th><th align=\"center\">M2</th><th align=\"center\">Std</th><th align=\"center\">M1</th><th align=\"center\">M2</th></tr></thead><tbody><tr><td align=\"left\"><italic>A</italic>. <italic>baumanii </italic>(<italic>A. b</italic>.) 59</td><td align=\"center\">500</td><td align=\"center\">500</td><td align=\"center\">500</td><td align=\"center\">1000</td><td align=\"center\">1000</td><td align=\"center\">1000</td></tr><tr><td align=\"left\"><italic>A</italic>. <italic>baumanii </italic>139</td><td align=\"center\">500</td><td align=\"center\">500</td><td align=\"center\">500</td><td align=\"center\">1000</td><td align=\"center\">1000</td><td align=\"center\">1000</td></tr><tr><td align=\"left\"><italic>A</italic>. <italic>baumanii </italic>147</td><td align=\"center\">500</td><td align=\"center\">500</td><td align=\"center\">500</td><td align=\"center\">1000</td><td align=\"center\">1000</td><td align=\"center\">1000</td></tr><tr><td align=\"left\"><italic>A</italic>. <italic>baumanii </italic>173</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td></tr><tr><td align=\"left\"><italic>S</italic>. <italic>faecalis </italic>(<italic>S. f</italic>.)</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">31.25</td><td align=\"center\">31.25</td><td align=\"center\">31.25</td></tr><tr><td align=\"left\"><italic>S</italic>. <italic>faecalis </italic>ATCC 29212</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">250</td><td align=\"center\">250</td><td align=\"center\">250</td></tr><tr><td align=\"left\"><italic>S</italic>. <italic>faecalis </italic>ATCC 319623</td><td align=\"center\">1000</td><td align=\"center\">1000</td><td align=\"center\">1000</td><td align=\"center\">&gt;1000</td><td align=\"center\">&gt;1000</td><td align=\"center\">&gt;1000</td></tr><tr><td align=\"left\"><italic>E. gallinarum </italic>(<italic>E. g</italic>.)</td><td align=\"center\">3.95</td><td align=\"center\">3.95</td><td align=\"center\">3.95</td><td align=\"center\">7.81</td><td align=\"center\">7.81</td><td align=\"center\">7.81</td></tr><tr><td align=\"left\"><italic>E. coli </italic>(<italic>E. c</italic>.) 39</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">7.81</td><td align=\"center\">7.81</td><td align=\"center\">7.81</td></tr><tr><td align=\"left\"><italic>E. coli </italic>50</td><td align=\"center\">1000</td><td align=\"center\">1000</td><td align=\"center\">1000</td><td/><td/><td/></tr><tr><td align=\"left\"><italic>E. coli </italic>69</td><td align=\"center\">62.25</td><td align=\"center\">62.25</td><td align=\"center\">62.25</td><td align=\"center\">250</td><td align=\"center\">250</td><td align=\"center\">250</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>(<italic>K. p.) </italic>1</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">62.51</td><td align=\"center\">62.51</td><td align=\"center\">62.51</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>43</td><td align=\"center\">R</td><td align=\"center\">R</td><td align=\"center\">R</td><td align=\"center\">R</td><td align=\"center\">R</td><td align=\"center\">R</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>63</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">1000</td><td align=\"center\">1000</td><td align=\"center\">1000</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>65</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">500</td><td align=\"center\">500</td><td align=\"center\">500</td></tr><tr><td align=\"left\"><italic>K. pneumoniae </italic>207</td><td align=\"center\">R</td><td align=\"center\">R</td><td align=\"center\">R</td><td align=\"center\">R</td><td align=\"center\">R</td><td align=\"center\">R</td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>(<italic>P. a</italic>.) 42</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">7.81</td><td align=\"center\">7.81</td><td align=\"center\">7.81</td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>74</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">250</td><td align=\"center\">250</td><td align=\"center\">250</td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>151</td><td align=\"center\">31.25</td><td align=\"center\">31.25</td><td align=\"center\">31.25</td><td align=\"center\">62.51</td><td align=\"center\">62.51</td><td align=\"center\">62.51</td></tr><tr><td align=\"left\"><italic>Ps</italic>. <italic>aeruginosa </italic>157</td><td align=\"center\">62.51</td><td align=\"center\">62.51</td><td align=\"center\">62.51</td><td align=\"center\">125</td><td align=\"center\">125</td><td align=\"center\">125</td></tr><tr><td align=\"left\"><italic>St. aureus </italic>(<italic>S. a</italic>.) <italic>287</italic></td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">7.81</td><td align=\"center\">7.81</td><td align=\"center\">7.81</td></tr><tr><td align=\"left\"><italic>St. aureus 291</italic></td><td align=\"center\">31.25</td><td align=\"center\">31.25</td><td align=\"center\">31.25</td><td align=\"center\">62.51</td><td align=\"center\">62.51</td><td align=\"center\">62.51</td></tr><tr><td align=\"left\"><italic>St. aureus 25923</italic></td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">Nd</td><td align=\"center\">31.25</td><td align=\"center\">31.25</td><td align=\"center\">31.25</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 11"}
{"html": "<!DOCTYPE html><html><body><h1>Critical concentrations for different samples of Meropenem against different microorganisms.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Sample</th><th align=\"center\" colspan=\"6\">Critical Concentration (&#956;g/ml)</th></tr><tr><th/><th colspan=\"6\"><hr/></th></tr><tr><th/><th align=\"center\"><italic>P. a</italic>. 151</th><th align=\"center\"><italic>P. a</italic>. 157</th><th align=\"center\"><italic>E. c</italic>. 69</th><th align=\"center\"><italic>E. c</italic>. 50</th><th align=\"center\"><italic>A. b</italic>. 147</th><th align=\"center\"><italic>K. b</italic>. 63</th></tr></thead><tbody><tr><td align=\"center\"><bold>Standard</bold></td><td align=\"center\">3.253</td><td align=\"center\">0.437</td><td align=\"center\">0.512</td><td align=\"center\">0.439</td><td align=\"center\">1.533</td><td align=\"center\">0.107</td></tr><tr><td align=\"center\"><bold>M1</bold></td><td align=\"center\">3.474</td><td align=\"center\">0.467</td><td align=\"center\">0.547</td><td align=\"center\">0.469</td><td align=\"center\">1.637</td><td align=\"center\">0.114</td></tr><tr><td align=\"center\"><bold>M2</bold></td><td align=\"center\">3.461</td><td align=\"center\">0.465</td><td align=\"center\">0.545</td><td align=\"center\">0.467</td><td align=\"center\">1.631</td><td align=\"center\">0.114</td></tr><tr><td align=\"center\"><bold>M3</bold></td><td align=\"center\">3.490</td><td align=\"center\">0.469</td><td align=\"center\">0.549</td><td align=\"center\">0.471</td><td align=\"center\">1.645</td><td align=\"center\">0.115</td></tr><tr><td align=\"center\"><bold>M4</bold></td><td align=\"center\">3.660</td><td align=\"center\">0.492</td><td align=\"center\">0.576</td><td align=\"center\">0.494</td><td align=\"center\">1.725</td><td align=\"center\">0.120</td></tr><tr><td align=\"center\"><bold>M5</bold></td><td align=\"center\">3.377</td><td align=\"center\">0.454</td><td align=\"center\">0.531</td><td align=\"center\">0.456</td><td align=\"center\">1.591</td><td align=\"center\">0.111</td></tr><tr><td align=\"center\"><bold>M6</bold></td><td align=\"center\">3.403</td><td align=\"center\">0.457</td><td align=\"center\">0.536</td><td align=\"center\">0.459</td><td align=\"center\">1.604</td><td align=\"center\">0.112</td></tr><tr><td align=\"center\"><bold>M7</bold></td><td align=\"center\">3.461</td><td align=\"center\">0.465</td><td align=\"center\">0.545</td><td align=\"center\">0.467</td><td align=\"center\">1.631</td><td align=\"center\">0.114</td></tr><tr><td align=\"center\"><bold>M8</bold></td><td align=\"center\">3.692</td><td align=\"center\">0.496</td><td align=\"center\">0.581</td><td align=\"center\">0.498</td><td align=\"center\">1.740</td><td align=\"center\">0.121</td></tr><tr><td align=\"center\"><bold>M9</bold></td><td align=\"center\">3.445</td><td align=\"center\">0.463</td><td align=\"center\">0.542</td><td align=\"center\">0.465</td><td align=\"center\">1.623</td><td align=\"center\">0.113</td></tr><tr><td align=\"center\"><bold>M10</bold></td><td align=\"center\">3.390</td><td align=\"center\">0.455</td><td align=\"center\">0.534</td><td align=\"center\">0.457</td><td align=\"center\">1.597</td><td align=\"center\">0.111</td></tr><tr><td align=\"center\"><bold>M11</bold></td><td align=\"center\">3.409</td><td align=\"center\">0.458</td><td align=\"center\">0.537</td><td align=\"center\">0.460</td><td align=\"center\">1.607</td><td align=\"center\">0.112</td></tr><tr><td align=\"center\"><bold>M12</bold></td><td align=\"center\">3.445</td><td align=\"center\">0.463</td><td align=\"center\">0.542</td><td align=\"center\">0.465</td><td align=\"center\">1.623</td><td align=\"center\">0.113</td></tr><tr><td align=\"center\"><bold>M13</bold></td><td align=\"center\">3.377</td><td align=\"center\">0.454</td><td align=\"center\">0.531</td><td align=\"center\">0.456</td><td align=\"center\">1.591</td><td align=\"center\">0.111</td></tr><tr><td align=\"center\"><bold>M14</bold></td><td align=\"center\">3.338</td><td align=\"center\">0.448</td><td align=\"center\">0.525</td><td align=\"center\">0.450</td><td align=\"center\">1.573</td><td align=\"center\">0.110</td></tr><tr><td align=\"center\"><bold>M15</bold></td><td align=\"center\">3.425</td><td align=\"center\">0.460</td><td align=\"center\">0.539</td><td align=\"center\">0.462</td><td align=\"center\">1.614</td><td align=\"center\">0.113</td></tr><tr><td align=\"center\"><bold>M16</bold></td><td align=\"center\">3.373</td><td align=\"center\">0.453</td><td align=\"center\">0.531</td><td align=\"center\">0.455</td><td align=\"center\">1.590</td><td align=\"center\">0.111</td></tr><tr><td align=\"center\"><bold>M17</bold></td><td align=\"center\">3.380</td><td align=\"center\">0.454</td><td align=\"center\">0.532</td><td align=\"center\">0.456</td><td align=\"center\">1.593</td><td align=\"center\">0.111</td></tr><tr><td align=\"center\"><bold>M18</bold></td><td align=\"center\">3.419</td><td align=\"center\">0.459</td><td align=\"center\">0.538</td><td align=\"center\">0.461</td><td align=\"center\">1.611</td><td align=\"center\">0.112</td></tr><tr><td align=\"center\"><bold>M19</bold></td><td align=\"center\">3.455</td><td align=\"center\">0.464</td><td align=\"center\">0.544</td><td align=\"center\">0.466</td><td align=\"center\">1.628</td><td align=\"center\">0.114</td></tr><tr><td align=\"center\"><bold>M20</bold></td><td align=\"center\">3.435</td><td align=\"center\">0.461</td><td align=\"center\">0.541</td><td align=\"center\">0.464</td><td align=\"center\">1.619</td><td align=\"center\">0.113</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 12"}
{"html": "<!DOCTYPE html><html><body><h1>Critical concentrations of different samples of Piperacillin/Tazobactam against various microorganisms.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Sample</th><th align=\"center\" colspan=\"7\">Critical Concentration (&#956;g/ml)</th></tr><tr><th/><th colspan=\"7\"><hr/></th></tr><tr><th/><th align=\"center\"><bold><italic>S. f</italic></bold>.</th><th align=\"center\"><italic>S. f</italic>. 29212</th><th align=\"center\"><bold><italic>E. g</italic></bold>.</th><th align=\"center\"><italic>P. a </italic>42</th><th align=\"center\"><italic>P. a </italic>74</th><th align=\"center\"><italic>P. a</italic>. 151</th><th align=\"center\"><italic>S. a</italic>. 287</th></tr></thead><tbody><tr><td align=\"center\">Standard</td><td align=\"center\">16.069</td><td align=\"center\">29.648</td><td align=\"center\">26.182</td><td align=\"center\">23.714</td><td align=\"center\">24.210</td><td align=\"center\">17.458</td><td align=\"center\">35.400</td></tr><tr><td align=\"center\">M1</td><td align=\"center\">16.696</td><td align=\"center\">30.775</td><td align=\"center\">27.386</td><td align=\"center\">24.662</td><td align=\"center\">25.348</td><td align=\"center\">18.296</td><td align=\"center\">36.887</td></tr><tr><td align=\"center\">M2</td><td align=\"center\">18.399</td><td align=\"center\">33.918</td><td align=\"center\">29.847</td><td align=\"center\">27.200</td><td align=\"center\">27.745</td><td align=\"center\">19.955</td><td align=\"center\">40.604</td></tr><tr><td align=\"center\">M3</td><td align=\"center\">17.500</td><td align=\"center\">32.198</td><td align=\"center\">28.303</td><td align=\"center\">25.611</td><td align=\"center\">26.268</td><td align=\"center\">18.977</td><td align=\"center\">38.586</td></tr><tr><td align=\"center\">M4</td><td align=\"center\">17.451</td><td align=\"center\">32.228</td><td align=\"center\">28.512</td><td align=\"center\">25.658</td><td align=\"center\">26.244</td><td align=\"center\">18.977</td><td align=\"center\">38.444</td></tr><tr><td align=\"center\">M5</td><td align=\"center\">17.403</td><td align=\"center\">32.020</td><td align=\"center\">28.355</td><td align=\"center\">25.706</td><td align=\"center\">26.147</td><td align=\"center\">18.907</td><td align=\"center\">38.374</td></tr><tr><td align=\"center\">M6</td><td align=\"center\">16.809</td><td align=\"center\">31.042</td><td align=\"center\">27.439</td><td align=\"center\">24.876</td><td align=\"center\">25.324</td><td align=\"center\">18.296</td><td align=\"center\">37.170</td></tr><tr><td align=\"center\">M7</td><td align=\"center\">17.516</td><td align=\"center\">32.554</td><td align=\"center\">28.695</td><td align=\"center\">26.061</td><td align=\"center\">26.583</td><td align=\"center\">19.117</td><td align=\"center\">38.869</td></tr><tr><td align=\"center\">M8</td><td align=\"center\">18.014</td><td align=\"center\">33.325</td><td align=\"center\">29.559</td><td align=\"center\">26.749</td><td align=\"center\">27.261</td><td align=\"center\">19.588</td><td align=\"center\">39.648</td></tr><tr><td align=\"center\">M9</td><td align=\"center\">16.905</td><td align=\"center\">31.160</td><td align=\"center\">27.465</td><td align=\"center\">25.018</td><td align=\"center\">25.614</td><td align=\"center\">18.401</td><td align=\"center\">37.099</td></tr><tr><td align=\"center\">M10</td><td align=\"center\">17.098</td><td align=\"center\">31.694</td><td align=\"center\">27.936</td><td align=\"center\">25.255</td><td align=\"center\">25.760</td><td align=\"center\">18.663</td><td align=\"center\">37.949</td></tr><tr><td align=\"center\">M11</td><td align=\"center\">18.576</td><td align=\"center\">34.214</td><td align=\"center\">30.319</td><td align=\"center\">27.318</td><td align=\"center\">28.036</td><td align=\"center\">20.252</td><td align=\"center\">41.029</td></tr><tr><td align=\"center\">M12</td><td align=\"center\">19.107</td><td align=\"center\">35.311</td><td align=\"center\">31.340</td><td align=\"center\">28.290</td><td align=\"center\">28.810</td><td align=\"center\">20.793</td><td align=\"center\">42.197</td></tr><tr><td align=\"center\">M13</td><td align=\"center\">18.174</td><td align=\"center\">33.503</td><td align=\"center\">29.769</td><td align=\"center\">26.820</td><td align=\"center\">27.358</td><td align=\"center\">19.867</td><td align=\"center\">40.214</td></tr><tr><td align=\"center\">M14</td><td align=\"center\">17.500</td><td align=\"center\">32.376</td><td align=\"center\">28.721</td><td align=\"center\">25.777</td><td align=\"center\">26.244</td><td align=\"center\">19.047</td><td align=\"center\">38.728</td></tr><tr><td align=\"center\">M15</td><td align=\"center\">17.757</td><td align=\"center\">32.880</td><td align=\"center\">28.983</td><td align=\"center\">26.275</td><td align=\"center\">26.752</td><td align=\"center\">19.344</td><td align=\"center\">39.082</td></tr><tr><td align=\"center\">M16</td><td align=\"center\">17.355</td><td align=\"center\">31.991</td><td align=\"center\">28.303</td><td align=\"center\">25.540</td><td align=\"center\">26.026</td><td align=\"center\">18.855</td><td align=\"center\">38.232</td></tr><tr><td align=\"center\">M17</td><td align=\"center\">17.982</td><td align=\"center\">32.939</td><td align=\"center\">29.245</td><td align=\"center\">26.512</td><td align=\"center\">26.922</td><td align=\"center\">19.501</td><td align=\"center\">39.613</td></tr><tr><td align=\"center\">M18</td><td align=\"center\">16.937</td><td align=\"center\">31.427</td><td align=\"center\">27.727</td><td align=\"center\">24.947</td><td align=\"center\">25.639</td><td align=\"center\">18.418</td><td align=\"center\">37.276</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 13"}
{"html": "<!DOCTYPE html><html><body><h1>Ratio of sample CC/standard CC for Meropenem</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Sample</th><th align=\"center\" colspan=\"6\">Sample CC/standard CC ratio</th><th align=\"center\">Ratio Median</th><th align=\"center\">Content</th></tr><tr><th/><th colspan=\"6\"><hr/></th><th/><th/></tr><tr><th/><th align=\"center\"><italic>P. a</italic>. 151</th><th align=\"center\"><italic>P. a</italic>. 157</th><th align=\"center\"><italic>E. c</italic>. 69</th><th align=\"center\"><italic>E. c</italic>. 50</th><th align=\"center\"><italic>A. b</italic>. 147</th><th align=\"center\"><italic>K. b</italic>. 63</th><th/><th/></tr></thead><tbody><tr><td align=\"center\">M1</td><td align=\"center\">106.8</td><td align=\"center\">106.9</td><td align=\"center\">106.8</td><td align=\"center\">106.8</td><td align=\"center\">106.8</td><td align=\"center\">106.5</td><td align=\"center\">106.8</td><td align=\"center\">107.5</td></tr><tr><td align=\"center\">M2</td><td align=\"center\">106.4</td><td align=\"center\">106.4</td><td align=\"center\">106.4</td><td align=\"center\">106.4</td><td align=\"center\">106.4</td><td align=\"center\">106.5</td><td align=\"center\">106.4</td><td align=\"center\">109.5</td></tr><tr><td align=\"center\">M3</td><td align=\"center\">107.3</td><td align=\"center\">107.3</td><td align=\"center\">107.2</td><td align=\"center\">107.3</td><td align=\"center\">107.3</td><td align=\"center\">107.5</td><td align=\"center\">112.5</td><td align=\"center\">105.3</td></tr><tr><td align=\"center\">M4</td><td align=\"center\">112.5</td><td align=\"center\">112.6</td><td align=\"center\">112.5</td><td align=\"center\">112.5</td><td align=\"center\">112.5</td><td align=\"center\">112.1</td><td align=\"center\">103.8</td><td align=\"center\">116.9</td></tr><tr><td align=\"center\">M5</td><td align=\"center\">103.8</td><td align=\"center\">103.9</td><td align=\"center\">103.7</td><td align=\"center\">103.9</td><td align=\"center\">103.8</td><td align=\"center\">103.7</td><td align=\"center\">104.6</td><td align=\"center\">104.5</td></tr><tr><td align=\"center\">M6</td><td align=\"center\">104.6</td><td align=\"center\">104.6</td><td align=\"center\">104.7</td><td align=\"center\">104.6</td><td align=\"center\">104.6</td><td align=\"center\">104.7</td><td align=\"center\">106.4</td><td align=\"center\">105.9</td></tr><tr><td align=\"center\">M7</td><td align=\"center\">106.4</td><td align=\"center\">106.4</td><td align=\"center\">106.4</td><td align=\"center\">106.4</td><td align=\"center\">106.4</td><td align=\"center\">106.5</td><td align=\"center\">113.4</td><td align=\"center\">107.2</td></tr><tr><td align=\"center\">M8</td><td align=\"center\">113.5</td><td align=\"center\">113.5</td><td align=\"center\">113.5</td><td align=\"center\">113.4</td><td align=\"center\">113.5</td><td align=\"center\">113.1</td><td align=\"center\">105.9</td><td align=\"center\">115.7</td></tr><tr><td align=\"center\">M9</td><td align=\"center\">105.9</td><td align=\"center\">105.9</td><td align=\"center\">105.9</td><td align=\"center\">105.9</td><td align=\"center\">105.9</td><td align=\"center\">105.6</td><td align=\"center\">104.1</td><td align=\"center\">107.2</td></tr><tr><td align=\"center\">M10</td><td align=\"center\">104.2</td><td align=\"center\">104.1</td><td align=\"center\">104.3</td><td align=\"center\">104.1</td><td align=\"center\">104.2</td><td align=\"center\">103.7</td><td align=\"center\">104.8</td><td align=\"center\">103.3</td></tr><tr><td align=\"center\">M11</td><td align=\"center\">104.8</td><td align=\"center\">104.8</td><td align=\"center\">104.9</td><td align=\"center\">104.8</td><td align=\"center\">104.8</td><td align=\"center\">104.7</td><td align=\"center\">105.9</td><td align=\"center\">105.7</td></tr><tr><td align=\"center\">M12</td><td align=\"center\">105.9</td><td align=\"center\">105.9</td><td align=\"center\">105.9</td><td align=\"center\">105.9</td><td align=\"center\">105.9</td><td align=\"center\">105.6</td><td align=\"center\">103.8</td><td align=\"center\">107.1</td></tr><tr><td align=\"center\">M13</td><td align=\"center\">103.8</td><td align=\"center\">103.9</td><td align=\"center\">103.7</td><td align=\"center\">103.9</td><td align=\"center\">103.8</td><td align=\"center\">103.7</td><td align=\"center\">102.6</td><td align=\"center\">102.5</td></tr><tr><td align=\"center\">M14</td><td align=\"center\">102.6</td><td align=\"center\">102.5</td><td align=\"center\">102.5</td><td align=\"center\">102.5</td><td align=\"center\">102.6</td><td align=\"center\">102.8</td><td align=\"center\">105.3</td><td align=\"center\">103.4</td></tr><tr><td align=\"center\">M15</td><td align=\"center\">105.3</td><td align=\"center\">105.3</td><td align=\"center\">105.3</td><td align=\"center\">105.2</td><td align=\"center\">105.3</td><td align=\"center\">105.6</td><td align=\"center\">103.7</td><td align=\"center\">106.2</td></tr><tr><td align=\"center\">M16</td><td align=\"center\">103.7</td><td align=\"center\">103.7</td><td align=\"center\">103.7</td><td align=\"center\">103.6</td><td align=\"center\">103.7</td><td align=\"center\">103.7</td><td align=\"center\">103.9</td><td align=\"center\">104.5</td></tr><tr><td align=\"center\">M17</td><td align=\"center\">103.9</td><td align=\"center\">103.9</td><td align=\"center\">103.9</td><td align=\"center\">103.9</td><td align=\"center\">103.9</td><td align=\"center\">103.7</td><td align=\"center\">105.0</td><td align=\"center\">105.1</td></tr><tr><td align=\"center\">M18</td><td align=\"center\">105.1</td><td align=\"center\">105.0</td><td align=\"center\">105.1</td><td align=\"center\">105.0</td><td align=\"center\">105.1</td><td align=\"center\">104.7</td><td align=\"center\">106.3</td><td align=\"center\">106.7</td></tr><tr><td align=\"center\">M19</td><td align=\"center\">106.2</td><td align=\"center\">106.2</td><td align=\"center\">106.3</td><td align=\"center\">106.2</td><td align=\"center\">106.2</td><td align=\"center\">106.5</td><td align=\"center\">105.6</td><td align=\"center\">105.8</td></tr><tr><td align=\"center\">M20</td><td align=\"center\">105.6</td><td align=\"center\">105.5</td><td align=\"center\">105.7</td><td align=\"center\">105.7</td><td align=\"center\">105.6</td><td align=\"center\">105.6</td><td align=\"center\">103.8</td><td align=\"center\">107.1</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 14"}
{"html": "<!DOCTYPE html><html><body><h1>Ratio of sample CC/standard CC for Piperacillin/Tazobactam</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Sample</th><th align=\"center\" colspan=\"7\">Sample CC/standard CC ratio</th><th align=\"center\">Ratio Median</th><th align=\"center\">Content</th></tr><tr><th/><th colspan=\"7\"><hr/></th><th/><th/></tr><tr><th/><th align=\"center\"><bold><italic>S. f</italic></bold>.</th><th align=\"center\"><italic>S. f</italic>. 29212</th><th align=\"center\"><bold><italic>E. g</italic></bold>.</th><th align=\"center\"><italic>P. a</italic>. 42</th><th align=\"center\"><italic>P. a</italic>. 74</th><th align=\"center\"><italic>P. a</italic>. 151</th><th align=\"center\"><italic>S. a</italic>. 287</th><th/><th/></tr></thead><tbody><tr><td align=\"center\">M1</td><td align=\"center\">103.9</td><td align=\"center\">103.8</td><td align=\"center\">104.6</td><td align=\"center\">104.0</td><td align=\"center\">104.7</td><td align=\"center\">104.8</td><td align=\"center\">104.2</td><td align=\"center\">104.3</td><td align=\"center\">103.6</td></tr><tr><td align=\"center\">M2</td><td align=\"center\">114.5</td><td align=\"center\">114.4</td><td align=\"center\">114.0</td><td align=\"center\">114.7</td><td align=\"center\">114.6</td><td align=\"center\">114.3</td><td align=\"center\">114.7</td><td align=\"center\">114.5</td><td align=\"center\">115.8</td></tr><tr><td align=\"center\">M3</td><td align=\"center\">108.9</td><td align=\"center\">108.6</td><td align=\"center\">108.1</td><td align=\"center\">108.0</td><td align=\"center\">108.5</td><td align=\"center\">108.7</td><td align=\"center\">109.0</td><td align=\"center\">108.5</td><td align=\"center\">109.7</td></tr><tr><td align=\"center\">M4</td><td align=\"center\">108.6</td><td align=\"center\">108.7</td><td align=\"center\">108.9</td><td align=\"center\">108.2</td><td align=\"center\">108.4</td><td align=\"center\">108.7</td><td align=\"center\">108.6</td><td align=\"center\">108.6</td><td align=\"center\">109.4</td></tr><tr><td align=\"center\">M5</td><td align=\"center\">108.3</td><td align=\"center\">108.0</td><td align=\"center\">108.3</td><td align=\"center\">108.4</td><td align=\"center\">108.0</td><td align=\"center\">108.3</td><td align=\"center\">108.4</td><td align=\"center\">108.3</td><td align=\"center\">108.7</td></tr><tr><td align=\"center\">M6</td><td align=\"center\">104.6</td><td align=\"center\">104.7</td><td align=\"center\">104.8</td><td align=\"center\">104.9</td><td align=\"center\">104.6</td><td align=\"center\">104.8</td><td align=\"center\">105.0</td><td align=\"center\">104.8</td><td align=\"center\">105.3</td></tr><tr><td align=\"center\">M7</td><td align=\"center\">109.0</td><td align=\"center\">109.8</td><td align=\"center\">109.6</td><td align=\"center\">109.9</td><td align=\"center\">109.8</td><td align=\"center\">109.5</td><td align=\"center\">109.8</td><td align=\"center\">109.6</td><td align=\"center\">110.5</td></tr><tr><td align=\"center\">M8</td><td align=\"center\">112.1</td><td align=\"center\">112.4</td><td align=\"center\">112.9</td><td align=\"center\">112.8</td><td align=\"center\">112.6</td><td align=\"center\">112.2</td><td align=\"center\">112.0</td><td align=\"center\">112.4</td><td align=\"center\">111.3</td></tr><tr><td align=\"center\">M9</td><td align=\"center\">105.2</td><td align=\"center\">105.1</td><td align=\"center\">104.9</td><td align=\"center\">105.5</td><td align=\"center\">105.8</td><td align=\"center\">105.4</td><td align=\"center\">104.8</td><td align=\"center\">105.3</td><td align=\"center\">104.2</td></tr><tr><td align=\"center\">M10</td><td align=\"center\">106.4</td><td align=\"center\">106.9</td><td align=\"center\">106.7</td><td align=\"center\">106.5</td><td align=\"center\">106.4</td><td align=\"center\">106.9</td><td align=\"center\">107.2</td><td align=\"center\">106.7</td><td align=\"center\">107.9</td></tr><tr><td align=\"center\">M11</td><td align=\"center\">115.6</td><td align=\"center\">115.4</td><td align=\"center\">115.8</td><td align=\"center\">115.2</td><td align=\"center\">115.8</td><td align=\"center\">116.0</td><td align=\"center\">115.9</td><td align=\"center\">115.7</td><td align=\"center\">116.8</td></tr><tr><td align=\"center\">M12</td><td align=\"center\">118.9</td><td align=\"center\">119.1</td><td align=\"center\">119.7</td><td align=\"center\">119.3</td><td align=\"center\">119.0</td><td align=\"center\">119.1</td><td align=\"center\">119.2</td><td align=\"center\">119.2</td><td align=\"center\">117.6</td></tr><tr><td align=\"center\">M13</td><td align=\"center\">113.1</td><td align=\"center\">113.0</td><td align=\"center\">113.7</td><td align=\"center\">113.1</td><td align=\"center\">113.0</td><td align=\"center\">113.8</td><td align=\"center\">113.6</td><td align=\"center\">113.3</td><td align=\"center\">114.3</td></tr><tr><td align=\"center\">M14</td><td align=\"center\">108.9</td><td align=\"center\">109.2</td><td align=\"center\">109.7</td><td align=\"center\">108.7</td><td align=\"center\">108.4</td><td align=\"center\">109.1</td><td align=\"center\">109.4</td><td align=\"center\">109.1</td><td align=\"center\">110.1</td></tr><tr><td align=\"center\">M15</td><td align=\"center\">110.5</td><td align=\"center\">110.9</td><td align=\"center\">110.7</td><td align=\"center\">110.8</td><td align=\"center\">110.5</td><td align=\"center\">110.8</td><td align=\"center\">110.4</td><td align=\"center\">110.7</td><td align=\"center\">110.1</td></tr><tr><td align=\"center\">M16</td><td align=\"center\">108.0</td><td align=\"center\">107.9</td><td align=\"center\">108.1</td><td align=\"center\">107.7</td><td align=\"center\">107.5</td><td align=\"center\">108.0</td><td align=\"center\">108.0</td><td align=\"center\">107.9</td><td align=\"center\">108.5</td></tr><tr><td align=\"center\">M17</td><td align=\"center\">111.9</td><td align=\"center\">111.1</td><td align=\"center\">111.7</td><td align=\"center\">111.8</td><td align=\"center\">111.2</td><td align=\"center\">111.7</td><td align=\"center\">111.9</td><td align=\"center\">111.6</td><td align=\"center\">112.6</td></tr><tr><td align=\"center\">M18</td><td align=\"center\">105.4</td><td align=\"center\">106.0</td><td align=\"center\">105.9</td><td align=\"center\">105.2</td><td align=\"center\">105.9</td><td align=\"center\">105.5</td><td align=\"center\">105.3</td><td align=\"center\">105.6</td><td align=\"center\">104.9</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 15"}
{"html": "<!DOCTYPE html><html><body><h1>Spontaneous mutant production in the diffusion gel assay for Meropenem</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Sample</th><th align=\"center\" colspan=\"2\"><italic>A. b</italic>. 189</th><th align=\"center\" colspan=\"2\"><italic>E. c</italic>. 39</th><th align=\"center\" colspan=\"2\"><italic>E. c</italic>. 69</th><th align=\"center\" colspan=\"2\"><italic>K. p</italic>. 43</th><th align=\"center\" colspan=\"2\"><italic>K. p</italic>. 63</th></tr><tr><th/><th colspan=\"10\"><hr/></th></tr><tr><th/><th align=\"center\">Median</th><th align=\"center\">&#948;</th><th align=\"center\">Median</th><th align=\"center\">&#948;</th><th align=\"center\">Median</th><th align=\"center\">&#948;</th><th align=\"center\">Median</th><th align=\"center\">&#948;</th><th align=\"center\">Median</th><th align=\"center\">&#948;</th></tr></thead><tbody><tr><td align=\"left\">Standard</td><td align=\"center\">25.333</td><td align=\"center\">1.366</td><td align=\"center\">205.333</td><td align=\"center\">5.354</td><td align=\"center\">43.333</td><td align=\"center\">2.582</td><td align=\"center\">43.333</td><td align=\"center\">2.582</td><td align=\"center\">203.167</td><td align=\"center\">2.137</td></tr><tr><td align=\"left\">M1</td><td align=\"center\">29.333</td><td align=\"center\">1.528</td><td align=\"center\">209.667</td><td align=\"center\">2.082</td><td align=\"center\">40.333</td><td align=\"center\">1.528</td><td align=\"center\">40.333</td><td align=\"center\">1.528</td><td align=\"center\">182.667</td><td align=\"center\">2.517</td></tr><tr><td align=\"left\">M2</td><td align=\"center\">22.667</td><td align=\"center\">1.528</td><td align=\"center\">207.333</td><td align=\"center\">1.528</td><td align=\"center\">46.333</td><td align=\"center\">3.055</td><td align=\"center\">46.333</td><td align=\"center\">3.055</td><td align=\"center\">198.667</td><td align=\"center\">4.041</td></tr><tr><td align=\"left\">M3</td><td align=\"center\">26.667</td><td align=\"center\">2.082</td><td align=\"center\">210.333</td><td align=\"center\">1.527</td><td align=\"center\">43.667</td><td align=\"center\">1.155</td><td align=\"center\">43.667</td><td align=\"center\">1.155</td><td align=\"center\">213.667</td><td align=\"center\">4.163</td></tr><tr><td align=\"left\">M4</td><td align=\"center\">22.000</td><td align=\"center\">2.000</td><td align=\"center\">208.000</td><td align=\"center\">2.000</td><td align=\"center\">44.667</td><td align=\"center\">1.528</td><td align=\"center\">44.667</td><td align=\"center\">1.528</td><td align=\"center\">200.000</td><td align=\"center\">6.245</td></tr><tr><td align=\"left\">M5</td><td align=\"center\">29.000</td><td align=\"center\">1.000</td><td align=\"center\">205.000</td><td align=\"center\">2.000</td><td align=\"center\">46.667</td><td align=\"center\">1.528</td><td align=\"center\">46.667</td><td align=\"center\">1.528</td><td align=\"center\">213.000</td><td align=\"center\">6.000</td></tr><tr><td align=\"left\">M6</td><td align=\"center\">29.333</td><td align=\"center\">2.082</td><td align=\"center\">209.667</td><td align=\"center\">1.155</td><td align=\"center\">41.333</td><td align=\"center\">1.528</td><td align=\"center\">41.333</td><td align=\"center\">1.528</td><td align=\"center\">196.667</td><td align=\"center\">7.095</td></tr><tr><td align=\"left\">M7</td><td align=\"center\">27.000</td><td align=\"center\">3.000</td><td align=\"center\">207.667</td><td align=\"center\">1.155</td><td align=\"center\">44.000</td><td align=\"center\">2.000</td><td align=\"center\">44.000</td><td align=\"center\">2.000</td><td align=\"center\">213.333</td><td align=\"center\">8.021</td></tr><tr><td align=\"left\">M8</td><td align=\"center\">23.000</td><td align=\"center\">2.000</td><td align=\"center\">207.667</td><td align=\"center\">1.155</td><td align=\"center\">45.667</td><td align=\"center\">1.528</td><td align=\"center\">45.667</td><td align=\"center\">1.528</td><td align=\"center\">202.333</td><td align=\"center\">6.110</td></tr><tr><td align=\"left\">M9</td><td align=\"center\">23.000</td><td align=\"center\">2.000</td><td align=\"center\">204.667</td><td align=\"center\">1.528</td><td align=\"center\">46.000</td><td align=\"center\">2.000</td><td align=\"center\">46.000</td><td align=\"center\">2.000</td><td align=\"center\">198.667</td><td align=\"center\">6.807</td></tr><tr><td align=\"left\">M10</td><td align=\"center\">29.000</td><td align=\"center\">2.000</td><td align=\"center\">202.333</td><td align=\"center\">2.517</td><td align=\"center\">47.667</td><td align=\"center\">1.528</td><td align=\"center\">47.667</td><td align=\"center\">1.528</td><td align=\"center\">213.667</td><td align=\"center\">8.083</td></tr><tr><td align=\"left\">M11</td><td align=\"center\">24.667</td><td align=\"center\">1.528</td><td align=\"center\">203.000</td><td align=\"center\">3.000</td><td align=\"center\">44.333</td><td align=\"center\">1.155</td><td align=\"center\">44.333</td><td align=\"center\">1.155</td><td align=\"center\">203.333</td><td align=\"center\">8.737</td></tr><tr><td align=\"left\">M12</td><td align=\"center\">26.667</td><td align=\"center\">1.528</td><td align=\"center\">210.000</td><td align=\"center\">1.000</td><td align=\"center\">40.000</td><td align=\"center\">1.000</td><td align=\"center\">40.000</td><td align=\"center\">1.000</td><td align=\"center\">188.333</td><td align=\"center\">4.163</td></tr><tr><td align=\"left\">M13</td><td align=\"center\">29.000</td><td align=\"center\">1.000</td><td align=\"center\">209.333</td><td align=\"center\">2.517</td><td align=\"center\">40.333</td><td align=\"center\">1.528</td><td align=\"center\">40.333</td><td align=\"center\">1.528</td><td align=\"center\">198.667</td><td align=\"center\">5.686</td></tr><tr><td align=\"left\">M14</td><td align=\"center\">24.667</td><td align=\"center\">1.155</td><td align=\"center\">202.667</td><td align=\"center\">3.786</td><td align=\"center\">44.333</td><td align=\"center\">1.528</td><td align=\"center\">44.333</td><td align=\"center\">1.528</td><td align=\"center\">203.667</td><td align=\"center\">6.110</td></tr><tr><td align=\"left\">M15</td><td align=\"center\">21.333</td><td align=\"center\">1.528</td><td align=\"center\">205.000</td><td align=\"center\">1.000</td><td align=\"center\">41.000</td><td align=\"center\">1.000</td><td align=\"center\">41.000</td><td align=\"center\">1.000</td><td align=\"center\">215.333</td><td align=\"center\">6.028</td></tr><tr><td align=\"left\">M16</td><td align=\"center\">28.333</td><td align=\"center\">1.155</td><td align=\"center\">208.667</td><td align=\"center\">1.528</td><td align=\"center\">44.667</td><td align=\"center\">1.528</td><td align=\"center\">44.667</td><td align=\"center\">1.528</td><td align=\"center\">199.000</td><td align=\"center\">4.000</td></tr><tr><td align=\"left\">M17</td><td align=\"center\">29.333</td><td align=\"center\">2.333</td><td align=\"center\">212.000</td><td align=\"center\">3.000</td><td align=\"center\">43.333</td><td align=\"center\">1.155</td><td align=\"center\">43.333</td><td align=\"center\">1.155</td><td align=\"center\">201.333</td><td align=\"center\">3.512</td></tr><tr><td align=\"left\">M18</td><td align=\"center\">23.667</td><td align=\"center\">1.155</td><td align=\"center\">205.000</td><td align=\"center\">1.000</td><td align=\"center\">46.000</td><td align=\"center\">1.000</td><td align=\"center\">46.000</td><td align=\"center\">1.000</td><td align=\"center\">209.000</td><td align=\"center\">9.165</td></tr><tr><td align=\"left\">M19</td><td align=\"center\">21.333</td><td align=\"center\">1.155</td><td align=\"center\">203.000</td><td align=\"center\">3.000</td><td align=\"center\">40.000</td><td align=\"center\">1.000</td><td align=\"center\">40.000</td><td align=\"center\">1.000</td><td align=\"center\">218.333</td><td align=\"center\">3.055</td></tr><tr><td align=\"left\">M20</td><td align=\"center\">23.333</td><td align=\"center\">2.516</td><td align=\"center\">204.667</td><td align=\"center\">2.082</td><td align=\"center\">45.667</td><td align=\"center\">1.155</td><td align=\"center\">45.667</td><td align=\"center\">1.155</td><td align=\"center\">210.333</td><td align=\"center\">7.095</td></tr><tr><td colspan=\"11\"><hr/></td></tr><tr><td align=\"left\">F</td><td align=\"center\" colspan=\"2\">8.715</td><td align=\"center\" colspan=\"2\">3.571</td><td align=\"center\" colspan=\"2\">6.076</td><td align=\"center\" colspan=\"2\">4.683</td><td align=\"center\" colspan=\"2\">7.294</td></tr><tr><td align=\"left\">Prob.</td><td align=\"center\" colspan=\"2\">0.000</td><td align=\"center\" colspan=\"2\">0.000</td><td align=\"center\" colspan=\"2\">0.000</td><td align=\"center\" colspan=\"2\">0.000</td><td align=\"center\" colspan=\"2\">0.000</td></tr><tr><td align=\"left\">V C F</td><td align=\"center\" colspan=\"2\">1.808</td><td align=\"center\" colspan=\"2\">1.808</td><td align=\"center\" colspan=\"2\">1.808</td><td align=\"center\" colspan=\"2\">1.808</td><td align=\"center\" colspan=\"2\">1.808</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 16"}
{"html": "<!DOCTYPE html><html><body><h1>Spontaneous mutant production in the diffusion gel assay for Piperacillin/Tazobactam</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Sample</th><th align=\"center\" colspan=\"2\"><italic>A. b</italic>. 189</th><th align=\"center\" colspan=\"2\"><italic>P. a</italic>. 54</th></tr><tr><th/><th colspan=\"4\"><hr/></th></tr><tr><th/><th align=\"center\">Median</th><th align=\"center\">&#948;</th><th align=\"center\">Median</th><th align=\"center\">&#948;</th></tr></thead><tbody><tr><td align=\"left\">Standard</td><td align=\"center\">125.17</td><td align=\"center\">1.472</td><td align=\"center\">110.00</td><td align=\"center\">9.381</td></tr><tr><td align=\"left\">M1</td><td align=\"center\">127.00</td><td align=\"center\">1.000</td><td align=\"center\">109.33</td><td align=\"center\">1.528</td></tr><tr><td align=\"left\">M9</td><td align=\"center\">123.67</td><td align=\"center\">2.517</td><td align=\"center\">104.67</td><td align=\"center\">1.528</td></tr><tr><td align=\"left\">M18</td><td align=\"center\">124.33</td><td align=\"center\">1.528</td><td align=\"center\">105.00</td><td align=\"center\">1.000</td></tr><tr><td align=\"left\">M6</td><td align=\"center\">125.67</td><td align=\"center\">1.528</td><td align=\"center\">109.67</td><td align=\"center\">1.155</td></tr><tr><td align=\"left\">M10</td><td align=\"center\">127.67</td><td align=\"center\">3.055</td><td align=\"center\">102.33</td><td align=\"center\">2.517</td></tr><tr><td align=\"left\">M16</td><td align=\"center\">128.33</td><td align=\"center\">1.528</td><td align=\"center\">109.67</td><td align=\"center\">0.577</td></tr><tr><td align=\"left\">M5</td><td align=\"center\">128.00</td><td align=\"center\">1.000</td><td align=\"center\">105.00</td><td align=\"center\">2.000</td></tr><tr><td align=\"left\">M14</td><td align=\"center\">124.33</td><td align=\"center\">1.155</td><td align=\"center\">101.67</td><td align=\"center\">2.082</td></tr><tr><td align=\"left\">M4</td><td align=\"center\">122.67</td><td align=\"center\">0.577</td><td align=\"center\">108.00</td><td align=\"center\">2.000</td></tr><tr><td align=\"left\">M3</td><td align=\"center\">125.67</td><td align=\"center\">2.082</td><td align=\"center\">111.00</td><td align=\"center\">1.732</td></tr><tr><td align=\"left\">M15</td><td align=\"center\">123.33</td><td align=\"center\">2.082</td><td align=\"center\">105.00</td><td align=\"center\">1.000</td></tr><tr><td align=\"left\">M7</td><td align=\"center\">127.67</td><td align=\"center\">1.528</td><td align=\"center\">107.67</td><td align=\"center\">1.155</td></tr><tr><td align=\"left\">M8</td><td align=\"center\">123.00</td><td align=\"center\">1.732</td><td align=\"center\">107.67</td><td align=\"center\">1.155</td></tr><tr><td align=\"left\">M17</td><td align=\"center\">129.33</td><td align=\"center\">5.859</td><td align=\"center\">108.67</td><td align=\"center\">1.528</td></tr><tr><td align=\"left\">M13</td><td align=\"center\">126.67</td><td align=\"center\">1.155</td><td align=\"center\">107.00</td><td align=\"center\">2.000</td></tr><tr><td align=\"left\">M2</td><td align=\"center\">123.33</td><td align=\"center\">1.528</td><td align=\"center\">107.33</td><td align=\"center\">1.528</td></tr><tr><td align=\"left\">M11</td><td align=\"center\">125.33</td><td align=\"center\">1.528</td><td align=\"center\">103.00</td><td align=\"center\">3.000</td></tr><tr><td align=\"left\">M12</td><td align=\"center\">125.67</td><td align=\"center\">2.517</td><td align=\"center\">110.00</td><td align=\"center\">1.000</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">F</td><td align=\"center\" colspan=\"2\">2.657</td><td align=\"center\" colspan=\"2\">1.898</td></tr><tr><td align=\"left\">prob.</td><td align=\"center\" colspan=\"2\">0.005</td><td align=\"center\" colspan=\"2\">0.045</td></tr></tbody></table></body></html>", "text": "Pmid= 2830186:Table= Table 17"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of the primary health care units according to the questionnaire (n = 22).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\">Number of units (%)</th><th align=\"center\">Number of not responding units</th></tr></thead><tbody><tr><td align=\"left\">Physician as head of unit</td><td/><td align=\"center\">10 (48)</td><td align=\"center\">1</td></tr><tr><td align=\"left\">Size of the unit (number of patients served)</td><td align=\"right\">&lt;5000</td><td align=\"center\">1 (5)</td><td align=\"center\">0</td></tr><tr><td/><td align=\"right\">5000-10000</td><td align=\"center\">2 (9)</td><td/></tr><tr><td/><td align=\"right\">10000-15000</td><td align=\"center\">4 (18)</td><td/></tr><tr><td/><td align=\"right\">15000-20000</td><td align=\"center\">9 (41)</td><td/></tr><tr><td/><td align=\"right\">&gt;20000</td><td align=\"center\">6 (27)</td><td/></tr><tr><td align=\"left\">Temporary physicians</td><td/><td align=\"center\">12 (55)</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Drug information from the pharmaceutical industry</td><td/><td align=\"center\">17 (81)</td><td align=\"center\">1</td></tr><tr><td align=\"left\">Producer-independent drug information</td><td/><td align=\"center\">19 (86)</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Education on prescribing for newly employed physicians</td><td/><td align=\"center\">16 (76)</td><td align=\"center\">1</td></tr></tbody></table></body></html>", "text": "Pmid= 2831842:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Correlation between number of prescribing objectives adhered to and factors investigated in the questionnaire</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Number of prescribing objectives adhered to median (25<sup>th</sup>-75<sup>th </sup>percentile)</th><th align=\"center\">P-value</th></tr></thead><tbody><tr><td/><td align=\"center\">Yes</td><td align=\"center\">No</td><td/></tr><tr><td align=\"left\">Size of the unit</td><td align=\"center\">NA</td><td align=\"center\">NA</td><td align=\"center\">0.14</td></tr><tr><td align=\"left\">Physician as head of the unit</td><td align=\"center\">2.5 (1-3.25)</td><td align=\"center\">1 (0-2)</td><td align=\"center\">0.013</td></tr><tr><td align=\"left\">Temporary physicians</td><td align=\"center\">1 (0-2)</td><td align=\"center\">2 (1-3)</td><td align=\"center\">0.051</td></tr><tr><td align=\"left\">Drug information from the pharmaceutical industry</td><td align=\"center\">1 (0-2)</td><td align=\"center\">3.5 (2.25-4.75)</td><td align=\"center\">0.005</td></tr><tr><td align=\"left\">Producer-independent drug information</td><td align=\"center\">2 (1-3)</td><td align=\"center\">0</td><td align=\"center\">0.043</td></tr><tr><td align=\"left\">Education on prescribing for newly employed physicians</td><td align=\"center\">1 (0-2)</td><td align=\"center\">3 (1.5-4)</td><td align=\"center\">0.034</td></tr></tbody></table></body></html>", "text": "Pmid= 2831842:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of drug information from the pharmaceutical industry in units receiving this kind of information (n = 17)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\">Number of primary health care units<break/>n (%)</th></tr></thead><tbody><tr><td align=\"left\">Frequency of visits</td><td align=\"left\">Once a week</td><td align=\"center\">4 (24)</td></tr><tr><td/><td align=\"left\">&gt;Once a month</td><td align=\"center\">4 (24)</td></tr><tr><td/><td align=\"left\">&lt;Once a month</td><td align=\"center\">9 (53)</td></tr><tr><td align=\"left\">Attending professions</td><td align=\"left\">Physicians only</td><td align=\"center\">3 (18)</td></tr><tr><td/><td align=\"left\">Physicians and nurses</td><td align=\"center\">5 (29)</td></tr><tr><td/><td align=\"left\">All personnel</td><td align=\"center\">9 (53)</td></tr><tr><td align=\"left\">Time of information</td><td align=\"left\">Lunch &#8805;50% of occasions</td><td align=\"center\">13 (81)</td></tr><tr><td/><td align=\"left\">Working hours &#8804;50% of occasions</td><td align=\"center\">14 (88)</td></tr></tbody></table></body></html>", "text": "Pmid= 2831842:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Results on the regional prescribing objectives in primary health care units with or without drug information from the pharmaceutical industry.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Without drug information from the pharmaceutical industry<break/>(n = 4)</th><th align=\"center\">With drug information from the pharmaceutical industry<break/>(n = 17)</th><th align=\"center\">P-value*</th></tr></thead><tbody><tr><td align=\"left\">Generic omeprazole of PPIs</td><td align=\"center\">77 (73-89)</td><td align=\"center\">77 (72-81)</td><td align=\"center\">0.59</td></tr><tr><td align=\"left\">ACEIs of ACEIs and ARBs</td><td align=\"center\">62 (52-72)</td><td align=\"center\">59 (54-61)</td><td align=\"center\">0.72</td></tr><tr><td align=\"left\">Generic simvastatin of statins</td><td align=\"center\">84 (81-92)</td><td align=\"center\">75 (71-80)</td><td align=\"center\">0.016</td></tr><tr><td align=\"left\">SSRI of antidepressants</td><td align=\"center\">77 (74-78)</td><td align=\"center\">71 (69-74)</td><td align=\"center\">0.020</td></tr><tr><td align=\"left\">Non-escitalopram of SSRIs</td><td align=\"center\">96 (94-97)</td><td align=\"center\">94 (91-96)</td><td align=\"center\">0.21</td></tr><tr><td align=\"left\">Generic mirtazapin of mirtazapins</td><td align=\"center\">84 (78-93)</td><td align=\"center\">85 (77-91)</td><td align=\"center\">0.86</td></tr></tbody></table></body></html>", "text": "Pmid= 2831842:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of the experimental data and the model analysis.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Reference</th><th align=\"left\">Solute</th><th align=\"left\">log K<sub>ow </sub>(ref)</th><th align=\"left\">F<sub>A </sub>(kg/min/kg)</th><th align=\"left\">K<sub>ad-bld</sub></th><th align=\"left\">Comments</th></tr></thead><tbody><tr><td align=\"left\">Oberg [<xref ref-type=\"bibr\" rid=\"B16\">16</xref>]</td><td align=\"left\">PCB 2,4,4\\'</td><td align=\"left\">5.67 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.15</td><td align=\"left\">314</td><td align=\"left\">Simultaneous chemical measurements</td></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,2\\',5,5\\'</td><td align=\"left\">5.84 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.05</td><td align=\"left\">89</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 3,3\\',4,4\\'</td><td align=\"left\">6.36 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.08</td><td align=\"left\">136</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,2\\',3,4,5\\'</td><td align=\"left\">6.29 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.08</td><td align=\"left\">136</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,2\\',4,5,5\\'</td><td align=\"left\">6.38 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.035</td><td align=\"left\">132</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,3,3\\',4,4\\'</td><td align=\"left\">6.65 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.04</td><td align=\"left\">263</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,3\\',4,4\\',5</td><td align=\"left\">6.74 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.03</td><td align=\"left\">226</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,2\\',3,4,4\\',5</td><td align=\"left\">6.83 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.012</td><td align=\"left\">226</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,2\\',4,4\\',5\\'</td><td align=\"left\">6.92 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.013</td><td align=\"left\">226</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,3,3\\',4,4\\',5</td><td align=\"left\">7.18 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.015</td><td align=\"left\">292</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,3,3\\',4,4\\',5\\'</td><td align=\"left\">7.18 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.012</td><td align=\"left\">263</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,2\\',3,3,4,4\\',5</td><td align=\"left\">7.27 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.007</td><td align=\"left\">263</td><td/></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">PCB 2,2\\',3,4,4\\',5,5\\'</td><td align=\"left\">7.36 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.005</td><td align=\"left\">263</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Muhlebach [<xref ref-type=\"bibr\" rid=\"B23\">23</xref>]</td><td align=\"left\">PCB 2,2\\',4,4\\',5,5\\'</td><td align=\"left\">6.92 [<xref ref-type=\"bibr\" rid=\"B25\">25</xref>]</td><td align=\"left\">0.02</td><td align=\"left\">319</td><td align=\"left\"><sup>14</sup>C, Chemical, not metabolized</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Ebling [<xref ref-type=\"bibr\" rid=\"B36\">36</xref>]</td><td align=\"left\">Thiopental</td><td align=\"left\">2.85 [<xref ref-type=\"bibr\" rid=\"B37\">37</xref>]</td><td align=\"left\">0.18</td><td align=\"left\">6.5</td><td align=\"left\">Chemical</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Dallas [<xref ref-type=\"bibr\" rid=\"B38\">38</xref>]</td><td align=\"left\">Perchloroethylene</td><td align=\"left\">3.13 [<xref ref-type=\"bibr\" rid=\"B39\">39</xref>]</td><td align=\"left\">0.25</td><td align=\"left\">124</td><td align=\"left\">Chemical</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Parham [<xref ref-type=\"bibr\" rid=\"B40\">40</xref>]</td><td align=\"left\">Dichlorodiphenylsulfone</td><td align=\"left\">3.9 (est)</td><td align=\"left\">0.12</td><td align=\"left\">89</td><td align=\"left\"><sup>14</sup>C, low metabolite</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Yamaguchi [<xref ref-type=\"bibr\" rid=\"B41\">41</xref>]</td><td align=\"left\">Hexachlorobenzene</td><td align=\"left\">5.46 [<xref ref-type=\"bibr\" rid=\"B42\">42</xref>]</td><td align=\"left\">0.12</td><td align=\"left\">80</td><td align=\"left\">Chemical measurements\\n</td></tr><tr><td/><td colspan=\"4\"><hr/></td><td/></tr><tr><td/><td align=\"left\">Hexabromobenzene</td><td align=\"left\">6.07 [<xref ref-type=\"bibr\" rid=\"B43\">43</xref>]</td><td align=\"left\">0.03</td><td align=\"left\">27</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Wang [<xref ref-type=\"bibr\" rid=\"B5\">5</xref>]</td><td align=\"left\">TCDD 2,3,7,8</td><td align=\"left\">5.95 [<xref ref-type=\"bibr\" rid=\"B44\">44</xref>]</td><td align=\"left\">0.02</td><td align=\"left\">80</td><td align=\"left\"><sup>3</sup>H, low metabolite</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Kedderis [<xref ref-type=\"bibr\" rid=\"B35\">35</xref>]</td><td align=\"left\">TBDD 2,3,7,8</td><td align=\"left\">6.5 [<xref ref-type=\"bibr\" rid=\"B44\">44</xref>]</td><td align=\"left\">0.0024</td><td align=\"left\">89</td><td align=\"left\"><sup>3</sup>H, low metabolite</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Komsta [<xref ref-type=\"bibr\" rid=\"B45\">45</xref>]</td><td align=\"left\">PCDE 2,2\\',4,4\\',5</td><td align=\"left\">6.38 [<xref ref-type=\"bibr\" rid=\"B46\">46</xref>]</td><td align=\"left\">0.015</td><td align=\"left\">40</td><td align=\"left\">Chemical</td></tr></tbody></table></body></html>", "text": "Pmid= 2845558:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Therapeutic Aim and Disease Category</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">prevention</th><th align=\"left\">to reduce risk of disabling or imparing events</th></tr></thead><tbody><tr><td align=\"left\"><bold>treatment</bold></td><td align=\"left\">to cure diseases, to substitute missing substances</td></tr><tr><td/><td align=\"left\">indispensable to life, to modify or relieve symptoms</td></tr><tr><td/><td align=\"left\"><bold>severity grading of the diseases:</bold></td></tr><tr><td/><td align=\"left\">I. acute life-threatening or severe chronic disease</td></tr><tr><td/><td align=\"left\">II. rehabilitation</td></tr><tr><td/><td align=\"left\">III. less severe acute or chronic disease</td></tr><tr><td/><td align=\"left\">IV. application outside a treatment context</td></tr></tbody></table></body></html>", "text": "Pmid= 2858124:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Modifier</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">prevention</th><th/><th/></tr></thead><tbody><tr><td align=\"left\"><bold>NNT</bold></td><td align=\"left\"><bold>ARR</bold></td><td align=\"left\"><bold>Modifier</bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">&lt;20</td><td align=\"left\">5-100%</td><td align=\"left\">2.0</td></tr><tr><td align=\"left\">20 - &lt;50</td><td align=\"left\">&lt;5%</td><td align=\"left\">1.75</td></tr><tr><td align=\"left\">50 - &lt;100</td><td align=\"left\">&lt;2%</td><td align=\"left\">1.5</td></tr><tr><td align=\"left\">100 - &lt;175</td><td align=\"left\">&lt;1%</td><td align=\"left\">1.25</td></tr><tr><td align=\"left\">175 - &lt;300</td><td align=\"left\">&lt;0.57%</td><td align=\"left\">1.0</td></tr><tr><td align=\"left\">300 - &lt;500</td><td align=\"left\">&lt;0.33%</td><td align=\"left\">0.75</td></tr><tr><td align=\"left\">500 - &lt;1000</td><td align=\"left\">&lt;0.2%</td><td align=\"left\">0.5</td></tr><tr><td align=\"left\">&#8805;1000</td><td align=\"left\">&lt;0.1%</td><td align=\"left\">0.25</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\"><bold>treatment</bold></td><td/><td/></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\"><bold>NNT</bold></td><td align=\"left\"><bold>ARR</bold></td><td align=\"left\"><bold>Modifier</bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">&lt;3</td><td align=\"left\">&gt;30%</td><td align=\"left\">2.0</td></tr><tr><td align=\"left\">3 - &lt;10</td><td align=\"left\">10-30%</td><td align=\"left\">1.5</td></tr><tr><td align=\"left\">&#8805;10</td><td align=\"left\">&lt;10%</td><td align=\"left\">1.0</td></tr></tbody></table></body></html>", "text": "Pmid= 2858124:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1></h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">RCTs showing evidence of</th><th align=\"center\">number of RCT</th><th align=\"center\">patient relevant outcome</th><th align=\"center\">surrogate outcome</th></tr></thead><tbody><tr><td/><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td align=\"left\"><bold>superiority</bold></td><td align=\"center\"><bold>1</bold></td><td align=\"center\"><bold>+5.0</bold></td><td align=\"center\"><bold>+2.5</bold></td></tr><tr><td/><td align=\"center\"><bold>&#8805;2</bold></td><td align=\"center\"><bold>+7.5</bold></td><td align=\"center\"><bold>+3.75</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td><break/></td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td><bold>non-inferiority/equivalence </bold><break/>(in the presence of other RCT showing superiority)</td><td align=\"center\"><bold>1</bold></td><td align=\"center\"><bold>-1.67</bold></td><td align=\"center\"><bold>-0.83</bold></td></tr><tr><td/><td align=\"center\"><bold>&#8805;2</bold></td><td align=\"center\"><bold>-2.5</bold></td><td align=\"center\"><bold>-1.25</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><break/><bold>non-inferiority/equivalence </bold><break/>(in the absence of other RCT)</td><td align=\"center\"><bold>any</bold></td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td><break/></td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td align=\"left\"><bold>non-inferiority/equivalence </bold><break/>(in the presence of other RCT showing inferiority)</td><td align=\"center\"><bold>1</bold></td><td align=\"center\"><bold>+1.67</bold></td><td align=\"center\"><bold>+0.83</bold></td></tr><tr><td/><td align=\"center\"><bold>&#8805;2</bold></td><td align=\"center\"><bold>+2.5</bold></td><td align=\"center\"><bold>+1.25</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"/><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td><bold>inferiority</bold></td><td align=\"center\"><bold>1</bold></td><td align=\"center\"><bold>-5.0</bold></td><td align=\"center\"><bold>-2.5</bold></td></tr><tr><td/><td align=\"center\"><bold>&#8805;2</bold></td><td align=\"center\"><bold>-7.5</bold></td><td align=\"center\"><bold>-3.75</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>sum</bold></td><td/><td align=\"center\" colspan=\"2\"><bold>...</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>modifier</bold></td><td/><td align=\"center\" colspan=\"2\"><bold>...</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>efficiency score</bold></td><td/><td align=\"center\" colspan=\"2\"><bold>...</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2858124:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Risk-Profile</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">severity grading</th><th align=\"center\">frequency</th><th align=\"center\">therapy investigated</th><th align=\"center\">therapeutic standard</th></tr></thead><tbody><tr><td align=\"left\"><bold>adverse events (AE)</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>grades 5 + 4</bold></td><td align=\"center\">&#8805;10%</td><td align=\"center\"><bold>-4.0</bold></td><td align=\"center\"><bold>-4.0</bold></td></tr><tr><td align=\"left\">&#8195;(death related to AE or life-threatening AE or disabling AE)</td><td align=\"center\">&#8805;1%</td><td align=\"center\"><bold>-3.0</bold></td><td align=\"center\"><bold>-3.0</bold></td></tr><tr><td/><td align=\"center\">&#8805;0.1%</td><td align=\"center\"><bold>-2.0</bold></td><td align=\"center\"><bold>-2.0</bold></td></tr><tr><td/><td align=\"center\">&lt;0.1%</td><td align=\"center\"><bold>-1.0</bold></td><td align=\"center\"><bold>-1.0</bold></td></tr><tr><td/><td align=\"center\">0</td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>grade 3 </bold></td><td align=\"center\">&#8805;10%</td><td align=\"center\"><bold>-2.5</bold></td><td align=\"center\"><bold>-2.5</bold></td></tr><tr><td align=\"left\">&#8195;(severe and undesirable AE)</td><td align=\"center\">&#8805;1%</td><td align=\"center\"><bold>-2.0</bold></td><td align=\"center\"><bold>-2.0</bold></td></tr><tr><td/><td align=\"center\">&#8805;0.1%</td><td align=\"center\"><bold>-1.0</bold></td><td align=\"center\"><bold>-1.0</bold></td></tr><tr><td/><td align=\"center\">&lt;0.1%</td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td/><td align=\"center\">0</td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>grades 2 + 1</bold></td><td align=\"center\">&#8805;10%</td><td align=\"center\"><bold>-1.5</bold></td><td align=\"center\"><bold>-1.5</bold></td></tr><tr><td align=\"left\">&#8195;(moderate AE or mild AE)</td><td align=\"center\">&#8805;1%</td><td align=\"center\"><bold>-1.0</bold></td><td align=\"center\"><bold>-1.0</bold></td></tr><tr><td/><td align=\"center\">&#8805;0.1%</td><td align=\"center\"><bold>-0.5</bold></td><td align=\"center\"><bold>-0.5</bold></td></tr><tr><td/><td align=\"center\">&lt;0.1%</td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td/><td align=\"center\">0</td><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Interactions</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">frequent or serious clinical consequence</td><td/><td align=\"center\"><bold>-2.0</bold></td><td align=\"center\"><bold>-2.0</bold></td></tr><tr><td align=\"left\">occasional or may have clinical consequence</td><td/><td align=\"center\"><bold>-1.5</bold></td><td align=\"center\"><bold>-1.5</bold></td></tr><tr><td align=\"left\">dose change</td><td/><td align=\"center\"><bold>-1.0</bold></td><td align=\"center\"><bold>-1.0</bold></td></tr><tr><td align=\"left\">unlikely/probably or no clinical consequence</td><td/><td align=\"center\"><bold>0</bold></td><td align=\"center\"><bold>0</bold></td></tr><tr><td align=\"left\">no information available</td><td/><td align=\"center\"><bold>-1.0</bold></td><td align=\"center\"><bold>-1.0</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>sum</bold></td><td/><td align=\"center\"><bold>...</bold></td><td align=\"center\"><bold>...</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>risk score</bold></td><td/><td align=\"center\" colspan=\"2\"><bold>...</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 2858124:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Intentional drug overdose presentations to hospital in Ireland involving distalgesic</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\">n</th><th align=\"center\">% of all IDO presentations</th><th align=\"center\">% of paracetamol-related IDO presentations</th></tr></thead><tbody><tr><td align=\"left\">Sex</td><td align=\"left\">Male</td><td align=\"center\">448</td><td align=\"center\">2.7%</td><td align=\"center\">10.9%</td></tr><tr><td/><td align=\"left\">Female</td><td align=\"center\">864</td><td align=\"center\">3.3%</td><td align=\"center\">9.7%</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Age</td><td align=\"left\">&lt;15 years</td><td align=\"center\">42</td><td align=\"center\">4.7%</td><td align=\"center\">9.5%</td></tr><tr><td/><td align=\"left\">15-24 years</td><td align=\"center\">488</td><td align=\"center\">3.6%</td><td align=\"center\">8.9%</td></tr><tr><td/><td align=\"left\">25-44 years</td><td align=\"center\">556</td><td align=\"center\">2.8%</td><td align=\"center\">10.6%</td></tr><tr><td/><td align=\"left\">45-64 years</td><td align=\"center\">213</td><td align=\"center\">2.7%</td><td align=\"center\">12.4%</td></tr><tr><td/><td align=\"left\">65 years+</td><td align=\"center\">13</td><td align=\"center\">1.6%</td><td align=\"center\">8.3%</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Year</td><td align=\"left\">2003</td><td align=\"center\">386</td><td align=\"center\">5.0%</td><td align=\"center\">16.2%</td></tr><tr><td/><td align=\"left\">2004</td><td align=\"center\">356</td><td align=\"center\">4.9%</td><td align=\"center\">15.7%</td></tr><tr><td/><td align=\"left\">2005</td><td align=\"center\">371</td><td align=\"center\">5.3%</td><td align=\"center\">16.5%</td></tr><tr><td/><td align=\"left\">2006</td><td align=\"center\">109</td><td align=\"center\">1.6%</td><td align=\"center\">5.5%</td></tr><tr><td/><td align=\"left\">2007</td><td align=\"center\">64</td><td align=\"center\">0.9%</td><td align=\"center\">3.2%</td></tr><tr><td/><td align=\"left\">2008</td><td align=\"center\">26</td><td align=\"center\">0.4%</td><td align=\"center\">1.2%</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Total</td><td/><td align=\"center\">1312</td><td align=\"center\">3.1%</td><td align=\"center\">10.0%</td></tr></tbody></table></body></html>", "text": "Pmid= 2858125:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Use of analgesics in intentional drug overdose presentations to hospital in Ireland before and after the withdrawal of distalgesic</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Drug involved in presentations</th><th align=\"center\"><bold>2003-5</bold><sup>1</sup></th><th align=\"center\"><bold>2006-8</bold><sup>1</sup></th><th align=\"center\"><bold>Change</bold><sup>1</sup></th><th align=\"left\"><bold>Relative change</bold><sup>2</sup></th><th align=\"center\"><bold>(95% CI)</bold><sup>2</sup></th></tr></thead><tbody><tr><td align=\"left\">Distalgesic</td><td align=\"center\">10.0</td><td align=\"center\">1.6</td><td align=\"center\">-8.4</td><td align=\"left\">-83.5%<sup>3</sup></td><td align=\"center\">(-85.7, -81.0%)</td></tr><tr><td align=\"left\">Other prescription compound analgesics</td><td align=\"center\">4.2</td><td align=\"center\">5.9</td><td align=\"center\">+1.7</td><td align=\"left\">+43.5%<sup>3</sup></td><td align=\"center\">(+28.6, +60.1%)</td></tr><tr><td align=\"left\">Solpadeine</td><td align=\"center\">6.3</td><td align=\"center\">6.5</td><td align=\"center\">+0.2</td><td align=\"left\">+2.6%</td><td align=\"center\">(-6.7, +12.8%)</td></tr><tr><td align=\"left\">Any paracetamol</td><td align=\"center\">61.3</td><td align=\"center\">51.5</td><td align=\"center\">-9.8</td><td align=\"left\">-16.4%<sup>3</sup></td><td align=\"center\">(-19.0, -13.7%)</td></tr></tbody></table></body></html>", "text": "Pmid= 2858125:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>SAQ factor definitions and example items</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Factor definition</th><th align=\"left\">Example of items included in factor</th></tr></thead><tbody><tr><td align=\"left\"><bold><italic>Job satisfaction: </italic></bold>positivity about the work experience</td><td align=\"left\">I like my job<break/>This pharmacy is a good workplace</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Teamwork climate: </italic></bold>perceived quality of collaboration between personnel</td><td align=\"left\">I receive the support I need from other staff in this pharmacy to help the customers.<break/>The staff members at this pharmacy work together as a well-functioning team.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Safety climate: </italic></bold>perceptions of a strong and proactive organizational commitment to safety</td><td align=\"left\">I would feel safe as a customer here.<break/>Dispensing errors are handled in a correct way at this pharmacy.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Perceptions of management</italic></bold>: approval of managerial action</td><td align=\"left\">The management of this pharmacy supports me in my daily work.<break/>The management of this pharmacy would not consciously endanger patient safety.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Stress recognition: </italic></bold>acknowledgement of how performance is influenced by stressors</td><td align=\"left\">I am less efficient at work when I am tired.<break/>I am more likely to make mistakes in stressful or unpleasant situations.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Working conditions: </italic></bold>perceived quality of the work environment and logistical support (staffing, training, etc.)</td><td align=\"left\">This pharmacy does a good job of training new staff members.<break/>Newly employed staff is monitored adequately in this pharmacy</td></tr></tbody></table></body></html>", "text": "Pmid= 2868807:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Translation and adaptation of the Swedish SAQ Community pharmacy version</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">SAQ version</th><th/><th/><th align=\"left\">Comments</th></tr></thead><tbody><tr><td align=\"left\"><bold>Original</bold></td><td align=\"left\"><bold>Swedish Community pharmacy</bold></td><td align=\"left\"><bold>Back-translation of Swedish version</bold></td><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Team work:</italic></bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">My input is well received in this clinical area.</td><td align=\"left\">Mina synpunkter och f&#246;rslag - min input - tas v&#228;l emot p&#229; det h&#228;r apoteket.</td><td align=\"left\">My views and suggestions - my input - is well received in this pharmacy.</td><td align=\"left\">The word \"input\" is sometimes used in Swedish, and it was hence kept but supported by an explanatory Swedish wording.</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">In this pharmacy, it is difficult to speak up if I perceive a problem with patient care.</td><td align=\"left\">Om jag uppt&#228;cker problem med l&#228;kemedelshanteringen &#228;r det sv&#229;rt att s&#228;ga ifr&#229;n p&#229; det h&#228;r apoteket. (Med l&#228;kemedelshantering avses all verksamhet som har med l&#228;kemedel att g&#246;ra, som exempelvis varuhantering och expedition, i b&#229;de receptur och egenv&#229;rd).</td><td align=\"left\">If I detect problems with medication management, it is difficult to address this, in this pharmacy. (The term \"medication management\" refers to all activities that have to do with medication, such as product management and expediting of both prescriptions and over-the -counter products).</td><td align=\"left\">The original \"patient care\" was transformed into \"handling medications\", since patient care is difficult to interpret in this context; in Swedish pharmacies. The statement was also supported by an explanatory sentence, clarifying the definition of \"handling medications\".</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Safety climate:</italic></bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">I would feel safe being treated here as a patient</td><td align=\"left\">Jag skulle k&#228;nna mig trygg som kund h&#228;r.</td><td align=\"left\">I would feel safe as a customer here.</td><td align=\"left\">Customer, rather than patient, is the common word in Swedish community pharmacies.</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">I receive appropriate feedback about my performance.</td><td align=\"left\">Jag f&#229;r konstruktiv &#229;terkoppling - feedback - p&#229; det arbete jag utf&#246;r.</td><td align=\"left\">I receive constructive feedback for the work I do.</td><td align=\"left\">The word \"feedback\" is sometimes used in Swedish, and it was hence kept but supported by an explanatory Swedish wording.</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">In this pharmacy, it is difficult to discuss errors.</td><td align=\"left\">P&#229; det h&#228;r apoteket &#228;r det sv&#229;rt att diskutera misstag.</td><td align=\"left\">In this pharmacy it is difficult to discuss mistakes.</td><td align=\"left\">Mistakes include not only errors but also near misses.</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Stress Recognition:</italic></bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Fatigue impairs my performance during emergency situations.</td><td align=\"left\">Tr&#246;tthet f&#246;rs&#228;mrar min arbetsinsats i pressade situationer.</td><td align=\"left\">Fatigue impairs my performance in trying situations.</td><td align=\"left\">Emergency situations are rare in community pharmacies.</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold><italic>Working conditions:</italic></bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">All the necessary information for therapeutic decisions is routinely available to me.</td><td align=\"left\">Jag har rutinm&#228;ssigt tillg&#229;ng till den information som kr&#228;vs f&#246;r att bed&#246;ma huruvida en f&#246;rskrivning &#228;r rimlig.</td><td align=\"left\">I normally have access to the information needed for judging whether a prescription is reasonable.</td><td align=\"left\">The original sentence is not relevant in Swedish pharmacies and had to be rephrased.</td></tr></tbody></table></body></html>", "text": "Pmid= 2868807:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Sample Characteristics of Respondents in Swedish SAQ Community pharmacy version</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th/><th align=\"center\" colspan=\"2\">Gender</th><th align=\"center\" colspan=\"3\">Age</th></tr><tr><th align=\"left\">Pharmacy Position</th><th align=\"center\">N</th><th align=\"center\">%</th><th align=\"center\">N</th><th align=\"center\">% female</th><th align=\"center\">N</th><th align=\"center\">Mean</th><th align=\"center\">Range</th></tr></thead><tbody><tr><td align=\"left\">Head of pharmacy/Head of group of pharmacies</td><td align=\"center\">102</td><td align=\"center\">2.5</td><td align=\"center\">102</td><td align=\"center\">87</td><td align=\"center\">102</td><td align=\"center\">52</td><td align=\"center\">28 - 65</td></tr><tr><td align=\"left\">Pharmacist responsible for quality and patient safety issues*</td><td align=\"center\">582</td><td align=\"center\">14.2</td><td align=\"center\">582</td><td align=\"center\">94</td><td align=\"center\">582</td><td align=\"center\">52</td><td align=\"center\">25 - 67</td></tr><tr><td align=\"left\">Pharmacist or prescriptionist</td><td align=\"center\">2183</td><td align=\"center\">53.4</td><td align=\"center\">2182</td><td align=\"center\">96</td><td align=\"center\">2167</td><td align=\"center\">49</td><td align=\"center\">23 - 69</td></tr><tr><td align=\"left\">Pharmacy technician</td><td align=\"center\">1042</td><td align=\"center\">25.5</td><td align=\"center\">1042</td><td align=\"center\">98</td><td align=\"center\">1011</td><td align=\"center\">51</td><td align=\"center\">22 - 66</td></tr><tr><td align=\"left\">Pharmacy assistant</td><td align=\"center\">50</td><td align=\"center\">1.2</td><td align=\"center\">50</td><td align=\"center\">90</td><td align=\"center\">47</td><td align=\"center\">39</td><td align=\"center\">21 - 64</td></tr><tr><td align=\"left\">Other</td><td align=\"center\">94</td><td align=\"center\">2.3</td><td align=\"center\">94</td><td align=\"center\">90</td><td align=\"center\">93</td><td align=\"center\">42</td><td align=\"center\">21 - 62</td></tr><tr><td align=\"left\"><bold><italic>Total</italic></bold></td><td align=\"center\">4053</td><td align=\"center\">99.1</td><td align=\"center\">4052</td><td align=\"center\">96</td><td align=\"center\">4021</td><td align=\"center\">50</td><td align=\"center\">21 - 69</td></tr><tr><td align=\"left\"><bold><italic>Missing</italic></bold></td><td align=\"center\">37</td><td align=\"center\">0.9</td><td align=\"center\">38</td><td/><td align=\"center\">69</td><td/><td/></tr><tr><td align=\"left\"><bold>Total</bold></td><td align=\"center\">4090</td><td align=\"center\">100</td><td align=\"center\">4090</td><td/><td align=\"center\">4090</td><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 2868807:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Scale Psychometrics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Scale Descriptives</th><th align=\"center\">Reliability; internal consistency</th></tr><tr><th align=\"left\">Scale</th><th align=\"center\">M</th><th align=\"center\">SD</th><th align=\"center\">% positive</th><th align=\"center\">&#945;</th></tr></thead><tbody><tr><td align=\"left\">Teamwork Climate</td><td align=\"center\">83.20</td><td align=\"center\">18.26</td><td align=\"center\">78.08</td><td align=\"center\">.81</td></tr><tr><td align=\"left\">Safety Climate</td><td align=\"center\">80.43</td><td align=\"center\">15.61</td><td align=\"center\">72.33</td><td align=\"center\">.75</td></tr><tr><td align=\"left\">Job Satisfaction</td><td align=\"center\">82.62</td><td align=\"center\">20.17</td><td align=\"center\">76.49</td><td align=\"center\">.89</td></tr><tr><td align=\"left\">Perceptions of Management</td><td align=\"center\">70.25</td><td align=\"center\">21.64</td><td align=\"center\">53.58</td><td align=\"center\">.72</td></tr><tr><td align=\"left\">Stress Recognition</td><td align=\"center\">72.15</td><td align=\"center\">22.73</td><td align=\"center\">66.28</td><td align=\"center\">.86</td></tr><tr><td align=\"left\">Working Conditions</td><td align=\"center\">73.23</td><td align=\"center\">20.83</td><td align=\"center\">57.91</td><td align=\"center\">.72</td></tr></tbody></table></body></html>", "text": "Pmid= 2868807:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>AMOS Goodness of Fit</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Full sample of Swedish Pharmacies (n = 828)</th><th align=\"center\">Swedish Pharmacies with at least 5 respondents (n = 343)</th><th align=\"center\">Swedish Pharmacies with at least 5 respondents and 60% response rate (n = 252)</th><th align=\"center\">Swedish Pharmacies with less than 5 staff (n = 282)</th><th align=\"center\">Non-pharmacy data from units using English SAQ<break/>(n = 203)</th></tr></thead><tbody><tr><td align=\"left\">Administered (n)</td><td align=\"center\">6,683</td><td align=\"center\">4,436</td><td align=\"center\">2,759</td><td align=\"center\">738</td><td align=\"center\">16,184</td></tr><tr><td align=\"left\">Completed (n)</td><td align=\"center\">4,090</td><td align=\"center\">2,923</td><td align=\"center\">2,144</td><td align=\"center\">738</td><td align=\"center\">10,843</td></tr><tr><td align=\"left\">Response rate</td><td align=\"center\">61.22%</td><td align=\"center\">65.89%</td><td align=\"center\">77.71%</td><td align=\"center\">72.36%</td><td align=\"center\">67.00%</td></tr><tr><td align=\"left\">Grouping factor</td><td align=\"center\">Pharmacy</td><td align=\"center\">Pharmacy</td><td align=\"center\">Pharmacy</td><td align=\"center\">Not grouped</td><td align=\"center\">Nursing unit</td></tr><tr><td align=\"left\">CFI</td><td align=\"center\">.903</td><td align=\"center\">.902</td><td align=\"center\">.900</td><td align=\"center\">.886</td><td align=\"center\">.900</td></tr><tr><td align=\"left\">RMSEA</td><td align=\"center\">.057</td><td align=\"center\">057</td><td align=\"center\">.059</td><td align=\"center\">.060</td><td align=\"center\">.050</td></tr></tbody></table></body></html>", "text": "Pmid= 2868807:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Intercorrelations for the Scales</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Teamwork Climate</th><th align=\"center\">Safety Climate</th><th align=\"center\">Job Satisfaction</th><th align=\"center\">Perceptions of Management</th><th align=\"center\">Stress Recognition</th><th align=\"center\">Working Conditions</th></tr></thead><tbody><tr><td align=\"left\"><bold>Teamwork Climate</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Safety Climate</bold></td><td align=\"center\">.68; .68</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Job Satisfaction</bold></td><td align=\"center\">.65; .73</td><td align=\"center\">.65; .66</td><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Perceptions of Managements</bold></td><td align=\"center\">.49; .42</td><td align=\"center\">.57; .51</td><td align=\"center\">.58; .55</td><td/><td/><td/></tr><tr><td align=\"left\"><bold>Stress Recognition</bold></td><td align=\"center\">-.08; -0.04</td><td align=\"center\">-.12; -0.03 ns</td><td align=\"center\">-.13; -0.09 ns</td><td align=\"center\">-.15; -0.17</td><td/><td/></tr><tr><td align=\"left\"><bold>Working Conditions</bold></td><td align=\"center\">.49; .53</td><td align=\"center\">.58; .58</td><td align=\"center\">.54; .54</td><td align=\"center\">.63; .60</td><td align=\"center\">-0.12; -0.17</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2868807:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Composition of the homeopathic-complex Traumeel S</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Component</th><th align=\"center\">Homeopathic dilution</th><th align=\"center\">Quantity per tablet</th></tr></thead><tbody><tr><td align=\"left\">Arnica Montana</td><td align=\"center\">D2</td><td align=\"center\">150 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Calendula officinalis</td><td align=\"center\">D2</td><td align=\"center\">150 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Atropa belladonna</td><td align=\"center\">D4</td><td align=\"center\">7.5 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Aconitum napellus</td><td align=\"center\">D3</td><td align=\"center\">30 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Bellis perennis</td><td align=\"center\">D2</td><td align=\"center\">60 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Hypericum perforatum</td><td align=\"center\">D2</td><td align=\"center\">30 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Echinacea angustifolia</td><td align=\"center\">D2</td><td align=\"center\">60 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Echinacea purpurea</td><td align=\"center\">D2</td><td align=\"center\">60 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Hepar sulfuris</td><td align=\"center\">D8</td><td align=\"center\">300 pg</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Symphytum officinale</td><td align=\"center\">D8</td><td align=\"center\">240 pg</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Matricaria Chamomilla</td><td align=\"center\">D3</td><td align=\"center\">24 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Achillea millefolium</td><td align=\"center\">D3</td><td align=\"center\">15 &#956;g</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Mercurius solubilis Hahnemanni</td><td align=\"center\">D8</td><td align=\"center\">300 pg</td></tr></tbody></table></body></html>", "text": "Pmid= 2873239:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline demographic and clinical variables of the Traumeel S</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Traumeel S<sup>&#174;</sup><break/>(n = 39)</th><th align=\"center\">Placebo<break/>(n = 40)</th></tr></thead><tbody><tr><td align=\"left\">Clinical Center:</td><td/><td/></tr><tr><td align=\"left\">&#8195;SZMC*</td><td align=\"center\">33</td><td align=\"center\">34</td></tr><tr><td align=\"left\">&#8195;MMC**</td><td align=\"center\">6</td><td align=\"center\">6</td></tr><tr><td align=\"left\">Age (y)</td><td/><td/></tr><tr><td align=\"left\">&#8195;Mean (SD)</td><td align=\"center\">48.1 (16.7)</td><td align=\"center\">45.2 (18.7)</td></tr><tr><td align=\"left\">&#8195;&lt; 50</td><td align=\"center\">17</td><td align=\"center\">19</td></tr><tr><td align=\"left\">&#8195;&#8805; 50</td><td align=\"center\">22</td><td align=\"center\">21</td></tr><tr><td align=\"left\">Sex (%)</td><td/><td/></tr><tr><td align=\"left\">&#8195;M</td><td align=\"center\">8 (20.5)</td><td align=\"center\">8 (20.0)</td></tr><tr><td align=\"left\">&#8195;F</td><td align=\"center\">31 (79.5)</td><td align=\"center\">32 (80.0)</td></tr><tr><td align=\"left\">Ethnicity/Origin (%)</td><td/><td/></tr><tr><td align=\"left\">&#8195;Europe/America</td><td align=\"center\">12 (30.8)</td><td align=\"center\">9 (22.5)</td></tr><tr><td align=\"left\">&#8195;Asia/Africa</td><td align=\"center\">21 (53.9)</td><td align=\"center\">25 (62.5)</td></tr><tr><td align=\"left\">&#8195;Israeli Arab</td><td align=\"center\">2 (5.1)</td><td align=\"center\">0</td></tr><tr><td align=\"left\">&#8195;Mixed</td><td align=\"center\">2 (5.1)</td><td align=\"center\">2 (5.0)</td></tr><tr><td align=\"left\">&#8195;Other</td><td align=\"center\">2 (5.1)</td><td align=\"center\">4 (10.0)</td></tr><tr><td align=\"left\">BMI</td><td/><td/></tr><tr><td align=\"left\">&#8195;Mean (SD)</td><td align=\"center\">24.7 (4.1)<sup>&#8224;</sup></td><td align=\"center\">24.3 (4.0)<sup>&#8224;</sup></td></tr><tr><td align=\"left\">&#8195;&lt; 24</td><td align=\"center\">20</td><td align=\"center\">23</td></tr><tr><td align=\"left\">&#8195;&#8805; 24</td><td align=\"center\">18</td><td align=\"center\">16</td></tr><tr><td align=\"left\">Pain before surgery</td><td/><td/></tr><tr><td align=\"left\">&#8195;Mean (SD)</td><td align=\"center\">5.4 (2.8)</td><td align=\"center\">5.7 (2.6)<sup>&#8224;</sup></td></tr><tr><td align=\"left\">&#8195;&lt; 6</td><td align=\"center\">19</td><td align=\"center\">18</td></tr><tr><td align=\"left\">&#8195;&#8805; 6</td><td align=\"center\">20</td><td align=\"center\">21</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Laterality (%)</td><td/><td/></tr><tr><td align=\"left\">&#8195;Right</td><td align=\"center\">21 (53.9)</td><td align=\"center\">14 (35.9)<sup>&#8224;</sup></td></tr><tr><td align=\"left\">&#8195;Left</td><td align=\"center\">16 (41.0)</td><td align=\"center\">24 (61.5)</td></tr><tr><td align=\"left\">&#8195;Bilateral<sup>#</sup></td><td align=\"center\">2 (5.1)</td><td align=\"center\">1 (2.6)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Type of surgery (%)</td><td/><td/></tr><tr><td align=\"left\">&#8195;Chevron - only</td><td align=\"center\">9<sup>&#8224; </sup>(23.0)</td><td align=\"center\">10<sup>&#8224;&#8224; </sup>(26.3)</td></tr><tr><td align=\"left\">&#8195;Additional</td><td align=\"center\">17 (43.5)</td><td align=\"center\">18 (47.3)</td></tr><tr><td align=\"left\">&#8195;osteotomy</td><td/><td/></tr><tr><td align=\"left\">&#8195;Triple or</td><td align=\"center\">13 (33.3)</td><td align=\"center\">10 (26.3)</td></tr><tr><td align=\"left\">&#8195;proximal</td><td/><td/></tr><tr><td align=\"left\">&#8195;osteotomy</td><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 2873239:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pain score stratified for type of surgery.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Chevron-only</th><th align=\"center\" colspan=\"2\">Additional osteotomy</th><th align=\"center\" colspan=\"2\">Triple or proximal osteotomy</th></tr></thead><tbody><tr><td align=\"right\"><bold><underline>AUC</underline></bold></td><td align=\"right\"><bold>Traumeel (n = 9)</bold></td><td align=\"right\"><bold>Placebo (n = 10)</bold></td><td align=\"right\"><bold>Traumeel (n = 17)</bold></td><td align=\"right\"><bold>Placebo (n = 18)</bold></td><td align=\"right\"><bold>Traumeel (n = 13)</bold></td><td align=\"right\"><bold>Placebo (n = 10)</bold></td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"right\">Mean</td><td align=\"center\">46.1</td><td align=\"center\">61.8</td><td align=\"center\">63.1</td><td align=\"center\">59.5</td><td align=\"center\">51.6</td><td align=\"center\">49.2</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"right\">SD</td><td align=\"center\">23.4</td><td align=\"center\">34.1</td><td align=\"center\">25.6</td><td align=\"center\">55.5</td><td align=\"center\">49.0</td><td align=\"center\">49.0</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"right\">p-value</td><td align=\"center\" colspan=\"2\">0.35</td><td align=\"center\" colspan=\"2\">0.69</td><td align=\"center\" colspan=\"2\">0.88</td></tr></tbody></table></body></html>", "text": "Pmid= 2873239:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Primary outcomes</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">weeks</th><th align=\"center\">0</th><th align=\"center\">4</th><th align=\"center\">8</th><th align=\"center\">11</th><th align=\"center\">24</th><th align=\"center\">52</th></tr></thead><tbody><tr><td align=\"center\">flexion angle</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">132.2 &#177; 12.4</td><td align=\"center\">140.5 &#177; 8.03</td><td align=\"center\">142.9 &#177; 8.25</td><td align=\"center\">144.75 &#177; 7.41</td><td align=\"center\">144.35 &#177; 8.11</td><td align=\"center\">141.4 &#177; 7.74</td></tr><tr><td/><td align=\"center\">% variation</td><td align=\"center\">0</td><td align=\"center\">5.8</td><td align=\"center\">7.61</td><td align=\"center\">9</td><td align=\"center\">8.7</td><td align=\"center\">6.5</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">*</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">VAS after 50 m walking</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">27.7 &#177; 21.7</td><td align=\"center\">23.4 &#177; 16.4</td><td align=\"center\">16.5 &#177; 17.7</td><td align=\"center\">9.7 &#177; 14.3</td><td align=\"center\">9.8 &#177; 12.1</td><td align=\"center\">8.7 &#177; 12.2</td></tr><tr><td/><td align=\"center\">% variation</td><td align=\"center\">0</td><td align=\"center\">-30.49</td><td align=\"center\">-53.5</td><td align=\"center\">-65.0</td><td align=\"center\">-66.67</td><td align=\"center\">-64.65</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">VAS after 5 min rest</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">21.9 &#177; 21.3</td><td align=\"center\">18.8 &#177; 17.9</td><td align=\"center\">13.4 &#177; 16.1</td><td align=\"center\">8.8 &#177; 13.1</td><td align=\"center\">8.2 &#177; 13.7</td><td align=\"center\">8.1 &#177; 11.7</td></tr><tr><td/><td align=\"center\">% variation</td><td align=\"center\">0</td><td align=\"center\">-14.4</td><td align=\"center\">-38.6</td><td align=\"center\">-60</td><td align=\"center\">-62.6</td><td align=\"center\">-63</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">VAS up &amp; down stair walking</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">41 &#177; 23.3</td><td align=\"center\">27.3 &#177; 16.2</td><td align=\"center\">18.6 &#177; 17.9</td><td align=\"center\">15.6 &#177; 17.2</td><td align=\"center\">12.8 &#177; 15.2</td><td align=\"center\">16.7 &#177; 17</td></tr><tr><td/><td align=\"center\">% variation</td><td align=\"center\">0</td><td align=\"center\">-33.5</td><td align=\"center\">-54.6</td><td align=\"center\">-62</td><td align=\"center\">-68.7</td><td align=\"center\">-59.3</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">*</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">VAS ROM exercise</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">42.1 &#177; 25.4</td><td align=\"center\">29.3 &#177; 16.8</td><td align=\"center\">19.6 &#177; 17.8</td><td align=\"center\">13.0 &#177; 14.2</td><td align=\"center\">14.1 &#177; 15.8</td><td align=\"center\">14.9 &#177; 13.4</td></tr><tr><td/><td align=\"center\">%variation</td><td align=\"center\">0</td><td align=\"center\">-30.49</td><td align=\"center\">-53.5</td><td align=\"center\">-69.3</td><td align=\"center\">-66.67</td><td align=\"center\">-64.65</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">*</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">C2C</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">39.7 &#177; 9.3</td><td align=\"center\">32.3 &#177; 11.7</td><td align=\"center\">31.4 &#177; 10.7</td><td/><td align=\"center\">30.8 &#177; 9.8</td><td align=\"center\">31.9 &#177; 10.9</td></tr><tr><td/><td align=\"center\">%variation</td><td align=\"center\">0</td><td align=\"center\">-18.64</td><td align=\"center\">-20.91</td><td/><td align=\"center\">-22.41</td><td align=\"center\">-19.65</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td align=\"center\">*</td><td/><td align=\"center\">*</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2873929:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Secondary Outcomes</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">weeks</th><th align=\"center\">0</th><th align=\"center\">4</th><th align=\"center\">8</th><th align=\"center\">11</th><th align=\"center\">24</th><th align=\"center\">52</th></tr></thead><tbody><tr><td align=\"center\">WOMAC total</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">35.53 &#177; 15.03</td><td align=\"center\">39.75 &#177; 16.69</td><td align=\"center\">29.65 &#177; 20.4</td><td align=\"center\">23.4 &#177; 16.53</td><td align=\"center\">27.25 &#177; 19.68</td><td align=\"center\">26.74 &#177; 18.7</td></tr><tr><td/><td align=\"center\">% variation</td><td align=\"center\">0</td><td align=\"center\">11.88</td><td align=\"center\">-16.55</td><td align=\"center\">-34.14</td><td align=\"center\">-23.3</td><td align=\"center\">-24.75</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">WOMAC pain</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">3.47 &#177; 1.77</td><td align=\"center\">3.5 &#177; 1.47</td><td align=\"center\">2.45 &#177; 1.7</td><td align=\"center\">2.3 &#177; 1.3</td><td align=\"center\">2.4 &#177; 1.85</td><td align=\"center\">2.53 &#177; 1.43</td></tr><tr><td/><td align=\"center\">% variation</td><td align=\"center\">0</td><td align=\"center\">0.95</td><td align=\"center\">-29.33</td><td align=\"center\">-33.66</td><td align=\"center\">-30.78</td><td align=\"center\">-27.13</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">Pain at rest</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">14.85 &#177; 12.4</td><td align=\"center\">15.15 &#177; 8.03</td><td align=\"center\">14.15 &#177; 8.25</td><td align=\"center\">7.25 &#177; 7.41</td><td align=\"center\">6.85 &#177; 8.11</td><td align=\"center\">6.65 &#177; 7.74</td></tr><tr><td/><td align=\"center\">% variation</td><td align=\"center\">0</td><td align=\"center\">2.02</td><td align=\"center\">-4.71</td><td align=\"center\">-51.18</td><td align=\"center\">-53.87</td><td align=\"center\">-55.22</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">Pain while walking</td><td align=\"center\">Ave &#177; SD</td><td align=\"center\">32.1 &#177; 12.4</td><td align=\"center\">21.9 &#177; 8.03</td><td align=\"center\">18.5 &#177; 8.25</td><td align=\"center\">11.5 &#177; 7.41</td><td align=\"center\">11.8 &#177; 8.11</td><td align=\"center\">11.4 &#177; 7.74</td></tr><tr><td/><td align=\"center\">% variation</td><td align=\"center\">0</td><td align=\"center\">-31.8</td><td align=\"center\">-42.5</td><td align=\"center\">-64.3</td><td align=\"center\">-63.4</td><td align=\"center\">-64.5</td></tr><tr><td/><td align=\"center\">*: p &#8249; 0.05</td><td/><td/><td/><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">*</td></tr></tbody></table></body></html>", "text": "Pmid= 2873929:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Mean derived pharmacokinetic profiles of ibuprofen and paracetamol after administration of the fixed-dose combination tablet compared with monotherapy (Study 1)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Ibuprofen (combination)</th><th align=\"center\">Ibuprofen (monotherapy)</th><th align=\"center\">Paracetamol (combination)</th><th align=\"center\">Paracetamol (monotherapy)</th></tr></thead><tbody><tr><td align=\"left\"><bold>n</bold></td><td align=\"center\">25</td><td align=\"center\">25</td><td align=\"center\">25</td><td align=\"center\">25</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>t</bold><sub><bold>max</bold></sub><bold>, hrs </bold>(median difference [minutes], 95% CI)</td><td align=\"center\">1.25<sup>a</sup><break/>(7.5, -15.0-37.5)</td><td align=\"center\">1.25<sup>a</sup></td><td align=\"center\">0.50<sup>a</sup><break/>(-15.0, -30.0-0.0)</td><td align=\"center\">0.67<sup>a</sup></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>t</bold><sub><bold>1/2</bold></sub><bold>, hrs</bold></td><td align=\"center\">1.95</td><td align=\"center\">1.97</td><td align=\"center\">2.83</td><td align=\"center\">2.66</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>C</bold><sub><bold>max</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1</bold></sup></td><td align=\"center\">32.04</td><td align=\"center\">30.89</td><td align=\"center\">18.48</td><td align=\"center\">17.49</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">LS geometric means (ratio test/reference [%], 90% CI)</td><td align=\"center\">31.46 (104.29, 95.90-113.41)</td><td align=\"center\">30.16</td><td align=\"center\">17.58 (104.14, 91.32-118.76)</td><td align=\"center\">16.88</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC</bold><sub><bold>0-t</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1</bold></sup><bold>.hr</bold></td><td align=\"center\">118.32</td><td align=\"center\">111.59</td><td align=\"center\">51.69</td><td align=\"center\">49.47</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">LS geometric means (ratio test/reference [%], 90% CI)</td><td align=\"center\">116.51 (107.08, 103.20-111.11)</td><td align=\"center\">108.80</td><td align=\"center\">50.27 (104.10, 100.08-108.29)</td><td align=\"center\">48.29</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC</bold><sub><bold>0-inf</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1</bold></sup><bold>.hr</bold></td><td align=\"center\">120.92</td><td align=\"center\">114.09</td><td align=\"center\">54.49</td><td align=\"center\">51.85</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">LS geometric means (ratio test/reference [%], 90% CI)</td><td align=\"center\">118.82 (106.99, 103.26-110.85)</td><td align=\"center\">111.06</td><td align=\"center\">52.95 (104.6, 100.56-108.82)</td><td align=\"center\">50.62</td></tr></tbody></table></body></html>", "text": "Pmid= 2906415:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Mean derived pharmacokinetic profiles for ibuprofen and paracetamol after administration of the fixed-dose combination tables in the fed and fasted states (Study 1)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Ibuprofen</th><th align=\"center\" colspan=\"2\">Paracetamol</th></tr><tr><th/><th align=\"center\">Fed</th><th align=\"center\">Fasted</th><th align=\"center\">Fed</th><th align=\"center\">Fasted</th></tr></thead><tbody><tr><td align=\"left\"><bold>n</bold></td><td align=\"center\">25</td><td align=\"center\">25</td><td align=\"center\">25</td><td align=\"center\">25</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>t</bold><sub><bold>max</bold></sub><bold>, hrs</bold></td><td align=\"center\">2.00<sup>a</sup></td><td align=\"center\">1.25<sup>a</sup></td><td align=\"center\">1.50<sup>a</sup></td><td align=\"center\">0.50<sup>a</sup></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Median difference [minutes] fed vs fasted, 95% CI</td><td align=\"center\" colspan=\"2\">25.0, 0.0-45.0</td><td align=\"center\" colspan=\"2\">55.0, 30.0-80.0</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>t</bold><sub><bold>1/2</bold></sub><bold>, hrs</bold></td><td align=\"center\">2.25</td><td align=\"center\">1.95</td><td align=\"center\">2.73</td><td align=\"center\">2.83</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>C</bold><sub><bold>max</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1</bold></sup></td><td align=\"center\">24.74</td><td align=\"center\">32.04</td><td align=\"center\">11.14</td><td align=\"center\">18.48</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">LS geometric mean</td><td align=\"center\">24.03</td><td align=\"center\">31.46</td><td align=\"center\">10.71</td><td align=\"center\">17.58</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Ratio fed/fasted (%), 90% CI</td><td align=\"center\" colspan=\"2\">76.38, 70.25-83.06</td><td align=\"center\" colspan=\"2\">60.92, 53.43-69.46</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC</bold><sub><bold>0-t</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1</bold></sup><bold>.hr</bold></td><td align=\"center\">103.91</td><td align=\"center\">118.32</td><td align=\"center\">46.45</td><td align=\"center\">51.69</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">LS geometric mean</td><td align=\"center\">101.6 2</td><td align=\"center\">116.51</td><td align=\"center\">45.69</td><td align=\"center\">50.27</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Ratio fed/fasted (%), 90% CI</td><td align=\"center\" colspan=\"2\">87.22, 84.06-90.49</td><td align=\"center\" colspan=\"2\">90.89, 87.38-94.54</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC</bold><sub><bold>0-inf</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1</bold></sup><bold>.hr</bold></td><td align=\"center\">109.03</td><td align=\"center\">120.92</td><td align=\"center\">49.51</td><td align=\"center\">54.49</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">LS geometric mean</td><td align=\"center\">106.04</td><td align=\"center\">118.82</td><td align=\"center\">48.72</td><td align=\"center\">52.95</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Ratio fed/fasted (%), 90% CI</td><td align=\"center\" colspan=\"2\">89.25, 86.14-92.46</td><td align=\"center\" colspan=\"2\">92.01, 88.45-95.71</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Kel</bold></td><td align=\"center\">0.328</td><td align=\"center\">0.361</td><td align=\"center\">0.258</td><td align=\"center\">0.251</td></tr></tbody></table></body></html>", "text": "Pmid= 2906415:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Mean derived comparison of the single-dose pharmacokinetic parameters in subjects allocated to the twice or three times daily dosing regimen (Study 2; Day 2)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Ibuprofen</th><th align=\"center\" colspan=\"2\">Paracetamol</th></tr><tr><th/><th align=\"center\">Twice daily</th><th align=\"center\">Three times daily</th><th align=\"center\">Twice daily</th><th align=\"center\">Three times daily</th></tr></thead><tbody><tr><td align=\"left\"><bold>n</bold></td><td align=\"center\">26</td><td align=\"center\">26</td><td align=\"center\">26</td><td align=\"center\">26</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>t</bold><sub><bold>max</bold></sub><bold>, hrs</bold></td><td align=\"center\">1.75<sup>a</sup></td><td align=\"center\">1.25<sup>a</sup></td><td align=\"center\">0.67<sup>a</sup></td><td align=\"center\">0.67<sup>a</sup></td></tr><tr><td align=\"left\"><bold>C</bold><sub><bold>max</bold></sub><bold>, &#956;g.mL<sup>-1 </sup>(sd)</bold></td><td align=\"center\">32.53 (6.15)</td><td align=\"center\">36.66 (8.14)</td><td align=\"center\">14.74 (5.76)</td><td align=\"center\">15.86 (4.76)</td></tr><tr><td align=\"left\"><bold>AUC</bold><sub><bold>0-t</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1</bold></sup><bold>.hr (sd)</bold></td><td align=\"center\">128.29 (23.60)</td><td align=\"center\">124.01 (23.35)</td><td align=\"center\">46.98 (12.42)</td><td align=\"center\">47.58 (12.79)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC</bold><sub><bold>0-inf</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1</bold></sup><bold>.hr (sd)</bold></td><td align=\"center\">130.67 (24.61)</td><td align=\"center\">132.27 (25.54)</td><td align=\"center\">49.23 (12.99)</td><td align=\"center\">52.49 (14.06)</td></tr></tbody></table></body></html>", "text": "Pmid= 2906415:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Comparison of the mean-derived pharmacokinetic parameters for ibuprofen and paracetamol after administration of the fixed-dose combination tablets, twice or three times daily for 3 days (Study 2; Day 4)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Ibuprofen</th><th align=\"center\" colspan=\"2\">Paracetamol</th></tr><tr><th/><th align=\"center\">Twice daily</th><th align=\"center\">Three times daily</th><th align=\"center\">Twice daily</th><th align=\"center\">Three times daily</th></tr></thead><tbody><tr><td align=\"left\"><bold>n</bold></td><td align=\"center\">26</td><td align=\"center\">26</td><td align=\"center\">26</td><td align=\"center\">26</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>t</bold><sub><bold>max</bold></sub><bold>, hrs</bold></td><td align=\"center\">1.50<sup>a</sup></td><td align=\"center\">1.50<sup>a</sup></td><td align=\"center\">0.67<sup>a</sup></td><td align=\"center\">0.67<sup>a</sup></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>C</bold><sub><bold>max</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1 </bold></sup><bold>(sd)</bold></td><td align=\"center\">33.4 (6.12)</td><td align=\"center\">33.55 (7.32)</td><td align=\"center\">16.09 (5.14)</td><td align=\"center\">15.87 (5.26)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>C</bold><sub><bold>min</bold></sub><bold>, &#956;g,mL</bold><sup><bold>-1 </bold></sup><bold>(sd)</bold></td><td align=\"center\">0.72 (0.42)</td><td align=\"center\">2.64 (1.24)</td><td align=\"center\">0.74 (0.25)</td><td align=\"center\">1.87 (0.79)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>C</bold><sub><bold>av</bold></sub><bold>, &#956;g.mL</bold><sup><bold>-1 </bold></sup><bold>(sd)</bold></td><td align=\"center\">9.61 (1.96)</td><td align=\"center\">13.69 (2.73)</td><td align=\"center\">4.07 (1.05)</td><td align=\"center\">5.86 (1.68)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Fluctuation (sd)</bold></td><td align=\"center\">3.44 (0.65)</td><td align=\"center\">2.26 (0.50)</td><td align=\"center\">3.83 (1.02)</td><td align=\"center\">2.47 (0.83)</td></tr><tr><td align=\"left\"><bold>(C</bold><sub><bold>max</bold></sub><bold>-C</bold><sub><bold>min</bold></sub><bold>)/C</bold><sub><bold>av</bold></sub></td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Swing (sd)</bold><break/><bold>(C</bold><sub><bold>max</bold></sub><bold>-C</bold><sub><bold>min</bold></sub><bold>)/C</bold><sub><bold>min</bold></sub></td><td align=\"center\">62.47 (40.28)</td><td align=\"center\">14.90 (8.72)</td><td align=\"center\">22.81 (10.05)</td><td align=\"center\">8.73 (4.78)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC</bold><sub><bold>0-t</bold></sub>,<break/><bold>&#956;g.mL</bold><sup><bold>-1</bold></sup><bold>.hr (sd)</bold></td><td align=\"center\">230.73 (47.00)</td><td align=\"center\">328.60 (65.71)</td><td align=\"center\">97.67 (25.13)</td><td align=\"center\">140.80 (40.30)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>AUC</bold><sub><bold>tau</bold></sub>,<break/><bold>&#956;g.mL</bold><sup><bold>-1</bold></sup><bold>.hr (sd)</bold></td><td align=\"center\">118.12 (24.23)</td><td align=\"center\">114.26 (22.77)</td><td align=\"center\">51.72 (12.89)</td><td align=\"center\">50.74 (13.29)</td></tr></tbody></table></body></html>", "text": "Pmid= 2906415:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Distribution of patients and median percent of medication doses taken according to the epidemiological characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" colspan=\"2\">Epidemiological characteristics</th><th align=\"center\">n</th><th align=\"center\">Median % of doses taken</th><th align=\"center\">p</th></tr></thead><tbody><tr><td align=\"left\">Sex</td><td align=\"left\">Female</td><td align=\"center\">28</td><td align=\"center\">85.00</td><td align=\"center\">0.604<sup>a</sup></td></tr><tr><td/><td align=\"left\">Male</td><td align=\"center\">9</td><td align=\"center\">92.00</td><td/></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Age groups</td><td align=\"left\">15-25 years</td><td align=\"center\">3</td><td align=\"center\">85.00</td><td align=\"center\">0.838<sup>b</sup></td></tr><tr><td/><td align=\"left\">26-35 years</td><td align=\"center\">14</td><td align=\"center\">88.50</td><td/></tr><tr><td/><td align=\"left\">36-45 years</td><td align=\"center\">11</td><td align=\"center\">85.00</td><td/></tr><tr><td/><td align=\"left\">&gt;45 years</td><td align=\"center\">9</td><td align=\"center\">92.00</td><td/></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Educational level</td><td align=\"left\">Non scolarised</td><td align=\"center\">8</td><td align=\"center\">82.00</td><td align=\"center\">0.536<sup>b</sup></td></tr><tr><td/><td align=\"left\">Primary level</td><td align=\"center\">12</td><td align=\"center\">92.00</td><td/></tr><tr><td/><td align=\"left\">Secondary level</td><td align=\"center\">16</td><td align=\"center\">89.00</td><td/></tr><tr><td/><td align=\"left\">Universitary level</td><td align=\"center\">1</td><td align=\"center\">85.00</td><td/></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Triple ARVs therapy received</td><td align=\"left\">2 NRTIs + 1 NNRTI</td><td align=\"center\">35</td><td align=\"center\">85.00</td><td align=\"center\">0.638<sup>c</sup></td></tr><tr><td/><td align=\"left\">2 NRTIs + 1 PI</td><td align=\"center\">2</td><td align=\"center\">46.00</td><td/></tr><tr><td/><td/><td/><td/><td/></tr><tr><td/><td align=\"left\">Fixed combination</td><td align=\"center\">17</td><td align=\"center\">85.00</td><td align=\"center\">0.626<sup>c</sup></td></tr><tr><td/><td align=\"left\">Non fixed combination</td><td align=\"center\">20</td><td align=\"center\">87.00</td><td/></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">ARVs procurement</td><td align=\"left\">Offered ARVs free of charge</td><td align=\"center\">16</td><td align=\"center\">85.00</td><td align=\"center\">0.269<sup>c</sup></td></tr><tr><td/><td align=\"left\">Fixed participation of 11$/month</td><td align=\"center\">21</td><td align=\"center\">92.00</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2949664:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Patient demographics at baseline (Safety population)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\">Oxycodone PR<break/>(n = 295)</th><th align=\"center\">Oxycodone PR/naloxone PR<break/>(n = 292)</th><th align=\"center\">Total<break/>(n = 587)</th></tr></thead><tbody><tr><td align=\"left\">Age (years)</td><td align=\"left\">Mean (SD)</td><td align=\"center\">58.3 (11.52)</td><td align=\"center\">57.5 (11.27)</td><td align=\"center\">57.9 (11.40)</td></tr><tr><td/><td align=\"left\">Median</td><td align=\"center\">58</td><td align=\"center\">58</td><td align=\"center\">58</td></tr><tr><td/><td align=\"left\">Min, Max</td><td align=\"center\">25, 87</td><td align=\"center\">29, 84</td><td align=\"center\">25, 87</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Age group, n (%)</td><td align=\"left\">&#8804; 65</td><td align=\"center\">216 (73.2)</td><td align=\"center\">221 (75.7)</td><td align=\"center\">437 (74.4)</td></tr><tr><td/><td align=\"left\">&gt; 65</td><td align=\"center\">79 (26.8)</td><td align=\"center\">71 (24.3)</td><td align=\"center\">150 (25.6)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Sex, n (%)</td><td align=\"left\">Male</td><td align=\"center\">108 (36.6)</td><td align=\"center\">102 (34.9)</td><td align=\"center\">210 (35.8)</td></tr><tr><td/><td align=\"left\">Female</td><td align=\"center\">187 (63.4)</td><td align=\"center\">190 (65.1)</td><td align=\"center\">377 (64.2)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Race, n (%)</td><td align=\"left\">Caucasian</td><td align=\"center\">293 (99.3)</td><td align=\"center\">292 (100.0)</td><td align=\"center\">585 (99.7)</td></tr><tr><td/><td align=\"left\">Black</td><td align=\"center\">1 (0.3)</td><td align=\"center\">0 (0.0)</td><td align=\"center\">1 (0.2)</td></tr><tr><td/><td align=\"left\">Other</td><td align=\"center\">1 (0.3)</td><td align=\"center\">0 (0.0)</td><td align=\"center\">1 (0.2)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Weight (kg)</td><td align=\"left\">Mean (SD)</td><td align=\"center\">84.7 (20.52)</td><td align=\"center\">84.2 (18.03)</td><td align=\"center\">84.4 (19.31)</td></tr><tr><td/><td align=\"left\">Median</td><td align=\"center\">83</td><td align=\"center\">80.6</td><td align=\"center\">82</td></tr><tr><td/><td align=\"left\">Min, Max</td><td align=\"center\">44, 174</td><td align=\"center\">47.5, 147</td><td align=\"center\">44, 174</td></tr></tbody></table></body></html>", "text": "Pmid= 2955588:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Mean pain intensity over the previous 24 hours at each study visit (per-protocol population; non-last observation carried forward analysis)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Name (visit)</th><th align=\"center\" colspan=\"4\"><underline>Pain Intensity Scale score</underline></th></tr><tr><th/><th/><th align=\"center\">Oxycodone PR</th><th align=\"center\">Oxycodone/Naloxone PR</th><th align=\"center\">Total</th></tr></thead><tbody><tr><td align=\"left\"><bold>Randomisation</bold><break/><bold>(Visit 3)</bold></td><td align=\"left\">N</td><td align=\"center\">208</td><td align=\"center\">221</td><td align=\"center\">429</td></tr><tr><td/><td align=\"left\">Mean (SD)</td><td align=\"center\">3.3 (0.97)</td><td align=\"center\">3.4 (1.07)</td><td align=\"center\">3.4 (1.02)</td></tr><tr><td/><td align=\"left\">Median</td><td align=\"center\">3.0</td><td align=\"center\">3.0</td><td align=\"center\">3.0</td></tr><tr><td/><td align=\"left\">Min, Max</td><td align=\"center\">0.0, 7.0</td><td align=\"center\">0.0, 9.0</td><td align=\"center\">0.0, 9.0</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Week 1</bold><break/><bold>(Visit 4)</bold></td><td align=\"left\">N</td><td align=\"center\">208</td><td align=\"center\">220</td><td align=\"center\">428</td></tr><tr><td/><td align=\"left\">Mean (SD)</td><td align=\"center\">3.5 (1.3)</td><td align=\"center\">3.6 (1.51)</td><td align=\"center\">3.6 (1.41)</td></tr><tr><td/><td align=\"left\">Median</td><td align=\"center\">3.0</td><td align=\"center\">4.0</td><td align=\"center\">4.0</td></tr><tr><td/><td align=\"left\">Min, Max</td><td align=\"center\">0.0, 7.0</td><td align=\"center\">0.0, 9.0</td><td align=\"center\">0.0, 9.0</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Week 4</bold><break/><bold>(Visit 6)</bold></td><td align=\"left\">N</td><td align=\"center\">208</td><td align=\"center\">220</td><td align=\"center\">428</td></tr><tr><td/><td align=\"left\">Mean (SD)</td><td align=\"center\">3.5 (1.37)</td><td align=\"center\">3.5 (1.51)</td><td align=\"center\">3.5 (1.44)</td></tr><tr><td/><td align=\"left\">Median</td><td align=\"center\">3.0</td><td align=\"center\">4.0</td><td align=\"center\">3.5</td></tr><tr><td/><td align=\"left\">Min, Max</td><td align=\"center\">0.0, 7.0</td><td align=\"center\">0.0, 9.0</td><td align=\"center\">0.0, 9.0</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Week 12</bold><break/><bold>(Visit 8)</bold></td><td align=\"left\">N</td><td align=\"center\">204</td><td align=\"center\">220</td><td align=\"center\">424</td></tr><tr><td/><td align=\"left\">Mean (SD)</td><td align=\"center\">3.5 (1.53)</td><td align=\"center\">3.6 (1.78)</td><td align=\"center\">3.6 (1.67)</td></tr><tr><td/><td align=\"left\">Median</td><td align=\"center\">4.0</td><td align=\"center\">4.0</td><td align=\"center\">4.0</td></tr><tr><td/><td align=\"left\">Min, Max</td><td align=\"center\">0.0, 8.0</td><td align=\"center\">0.0, 9.0</td><td align=\"center\">0.0, 9.0</td></tr></tbody></table></body></html>", "text": "Pmid= 2955588:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Incidence of adverse events by organ class ( 10%) and preferred term ( 1%; Safety population)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Oxycodone PR n = 295<break/>n (%)</th><th align=\"center\">Oxycodone/naloxone PR n = 292<break/>n (%)</th><th align=\"center\">Total<break/>n = 587<break/>n (%)</th></tr></thead><tbody><tr><td align=\"left\"><bold>Gastrointestinal disorders</bold></td><td align=\"center\"><bold>64 (21.7)</bold></td><td align=\"center\"><bold>61 (20.9)</bold></td><td align=\"center\"><bold>125 (21.3)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Dry mouth</td><td align=\"center\">3 (1.0)</td><td align=\"center\">3 (1.0)</td><td align=\"center\">6 (1.0)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Diarrhoea</td><td align=\"center\">11 (3.7)</td><td align=\"center\">15 (5.1)</td><td align=\"center\">(26) 4.4</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Constipation</td><td align=\"center\">10 (3.4)</td><td align=\"center\">2 (0.7)</td><td align=\"center\">12 (2.0)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Upper abdominal pain</td><td align=\"center\">4 (1.4)</td><td align=\"center\">6 (2.1)</td><td align=\"center\">10 (1.7)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Abdominal pain</td><td align=\"center\">7 (2.4)</td><td align=\"center\">11 (3.8)</td><td align=\"center\">18 (3.1)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Vomiting</td><td align=\"center\">8 (2.7)</td><td align=\"center\">5 (1.7)</td><td align=\"center\">13 (2.2)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Nausea</td><td align=\"center\">25 (8.5)</td><td align=\"center\">23 (7.9)</td><td align=\"center\">48 (8.2)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>General disorders and administrative site conditions</bold></td><td align=\"center\"><bold>26 (8.8)</bold></td><td align=\"center\"><bold>34 (11.6)</bold></td><td align=\"center\"><bold>60 (10.2)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Pain</td><td align=\"center\">5 (1.7)</td><td align=\"center\">9 (3.1)</td><td align=\"center\">14 (2.4)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Peripheral oedema</td><td align=\"center\">4 (1.4)</td><td align=\"center\">5 (1.7)</td><td align=\"center\">9 (1.5)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Fatigue</td><td align=\"center\">7 (2.4)</td><td align=\"center\">6 (2.1)</td><td align=\"center\">13 (2.2)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Chills</td><td align=\"center\">3 (1.0)</td><td align=\"center\">5 (1.7)</td><td align=\"center\">8 (1.4)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Infections and infestations</bold></td><td align=\"center\"><bold>56 (19.0)</bold></td><td align=\"center\"><bold>47 (16.1)</bold></td><td align=\"center\"><bold>103 (17.5)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Nasopharyngitis</td><td align=\"center\">10 (3.4)</td><td align=\"center\">4 (1.7)</td><td align=\"center\">103 (17.5)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Lower respiratory tract infection</td><td align=\"center\">3 (1.0)</td><td align=\"center\">3 (1.0)</td><td align=\"center\">6 (1.0)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Gastroenteritis</td><td align=\"center\">7 (2.4)</td><td align=\"center\">5 (1.7)</td><td align=\"center\">12 (2.0)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Bronchitis</td><td align=\"center\">3 (1.0)</td><td align=\"center\">3 (1.0)</td><td align=\"center\">6 (1.0)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Urinary tract infection</td><td align=\"center\">6 (2.0)</td><td align=\"center\">13 (4.5)</td><td align=\"center\">19 (3.2)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Musculoskeletal and connective tissue disorders</bold></td><td align=\"center\"><bold>34 (11.5)</bold></td><td align=\"center\"><bold>39 (13.4)</bold></td><td align=\"center\"><bold>73 (12.4)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Back pain</td><td align=\"center\">9 (3.1)</td><td align=\"center\">11 (3.8)</td><td align=\"center\">20 (3.4)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Arthralgia</td><td align=\"center\">5 (1.7)</td><td align=\"center\">6 (2.1)</td><td align=\"center\">11 (1.9)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Myalgia</td><td align=\"center\">2 (0.7)</td><td align=\"center\">4 (1.4)</td><td align=\"center\">6 (1.0)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Nervous system disorders</bold></td><td align=\"center\"><bold>35 (11.9)</bold></td><td align=\"center\"><bold>40 (13.7)</bold></td><td align=\"center\"><bold>75 (12.8)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Sciatica</td><td align=\"center\">1 (0.3)</td><td align=\"center\">6 (2.1)</td><td align=\"center\">7 (1.2)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Headache</td><td align=\"center\">11 (3.7)</td><td align=\"center\">12 (4.1)</td><td align=\"center\">23 (3.9)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Dizziness</td><td align=\"center\">10 (3.4)</td><td align=\"center\">5 (1.7)</td><td align=\"center\">15 (2.6)</td></tr></tbody></table></body></html>", "text": "Pmid= 2955588:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Subject Demographics by Treatment Sequence (ITT Population)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Prolastin/Prolastin-C (n = 12)</th><th align=\"center\">Prolastin-C/Prolastin (n = 12)</th><th align=\"center\">All Subjects (n = 24)</th></tr></thead><tbody><tr><td align=\"left\">Mean age, y (SD)</td><td align=\"center\">57.0 (9.33)</td><td align=\"center\">58.4 (6.86)</td><td align=\"center\">57.7 (8.04)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Mean body weight, kg (SD)</td><td align=\"center\">81.4 (15.37)</td><td align=\"center\">89.7 (19.49)</td><td align=\"center\">85.5 (17.67)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Male gender, n (%)</td><td align=\"center\">4 (33.3)</td><td align=\"center\">6 (50.0)</td><td align=\"center\">10 (41.7)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Female gender, n (%)</td><td align=\"center\">8 (66.7)</td><td align=\"center\">6 (50.0)</td><td align=\"center\">14 (58.3)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Time since AAT deficiency diagnosis, y (SD)</td><td align=\"center\">8.69 (6.96)</td><td align=\"center\">9.10 (6.02)</td><td align=\"center\">8.89 (6.37)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Mean pre-augmentation alpha<sub>1</sub>-PI plasma level, &#956;M (SD)</td><td align=\"center\">5.29 (1.90)</td><td align=\"center\">4.92 (2.01)</td><td align=\"center\">5.11 (1.92)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Mean baseline alpha<sub>1</sub>-PI serum level, &#956;M (SD)*</td><td align=\"center\">17.7 (3.26)</td><td align=\"center\">19.8 (4.38)</td><td align=\"center\">18.7 (3.91)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Mean FEV<sub>1 </sub>predicted, % (SD)</td><td align=\"center\">43.8 (13.2)</td><td align=\"center\">41.8 (13.8)</td><td align=\"center\">42.8 (13.3)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Deficiency genotype, n (%)</td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;PiZZ</td><td align=\"center\">12 (100)</td><td align=\"center\">11 (91.7)</td><td align=\"center\">23 (95.8)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;PiSZ</td><td align=\"center\">0</td><td align=\"center\">1 (8.3)</td><td align=\"center\">1 (4.2)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Prior Prolastin therapy, n (%)</td><td align=\"center\">12 (100)</td><td align=\"center\">12 (100)</td><td align=\"center\">24 (100)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Medical history, n (%)<sup>&#8224;</sup></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Obstructive pulmonary diseases<sup>&#8225;</sup></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;COPD</td><td align=\"center\">8 (66.7)</td><td align=\"center\">7 (58.3)</td><td align=\"center\">15 (62.5)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Emphysema</td><td align=\"center\">6 (50.0)</td><td align=\"center\">7 (58.3)</td><td align=\"center\">13 (54.2)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Bronchiectasis</td><td align=\"center\">3 (25.0)</td><td align=\"center\">2 (16.7)</td><td align=\"center\">5 (20.8)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Asthma</td><td align=\"center\">3 (25.0)</td><td align=\"center\">3 (25.0)</td><td align=\"center\">6 (25.0)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Other conditions</td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Headache</td><td align=\"center\">3 (25.0)</td><td align=\"center\">4 (33.3)</td><td align=\"center\">7 (29.2)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Pneumonia</td><td align=\"center\">2 (16.7)</td><td align=\"center\">3 (25.0)</td><td align=\"center\">5 (20.8)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Depression</td><td align=\"center\">2 (16.7)</td><td align=\"center\">3 (25.0)</td><td align=\"center\">5 (20.8)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Hypertension</td><td align=\"center\">2 (16.7)</td><td align=\"center\">3 (25.0)</td><td align=\"center\">5 (20.8)</td></tr></tbody></table></body></html>", "text": "Pmid= 2958874:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of Pharmacokinetic Parameters of Plasma Alpha</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Prolastin-C 60 mg/kg</th><th align=\"center\">Prolastin 60 mg/kg</th></tr></thead><tbody><tr><td align=\"left\">Mean AUC<sub>0-7 days</sub>, mg*h/mL (% CV)</td><td align=\"center\">155.9 (17)</td><td align=\"center\">152.4 (16)</td></tr><tr><td/><td align=\"center\">n = 23</td><td align=\"center\">n = 22</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Mean C<sub>max, </sub>mg/mL (% CV)</td><td align=\"center\">1.797 (10)</td><td align=\"center\">1.848 (15)</td></tr><tr><td/><td align=\"center\">n = 22</td><td align=\"center\">n = 23</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Median adjusted t<sub>max</sub>, hr (range)</td><td align=\"center\">0.673 (0.23-2.59)</td><td align=\"center\">0.820 (0.25-2.90)</td></tr><tr><td/><td align=\"center\">n = 22</td><td align=\"center\">n = 23</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Mean t<sub>&#189;</sub>, hr (% CV)</td><td align=\"center\">146.3 (16)</td><td align=\"center\">139.3 (18)</td></tr><tr><td/><td align=\"center\">n = 22</td><td align=\"center\">n = 22</td></tr></tbody></table></body></html>", "text": "Pmid= 2958874:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Ratio of Point Estimates and 90% CIs for AUC</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"4\">Geometric least squares mean ratio: Prolastin-C versus Prolastin</th></tr><tr><th/><th colspan=\"4\"><hr/></th></tr><tr><th/><th align=\"center\" colspan=\"2\">Potency assay</th><th align=\"center\" colspan=\"2\">Content assay</th></tr><tr><th/><th colspan=\"4\"><hr/></th></tr><tr><th/><th align=\"center\">Point estimate</th><th align=\"center\">90% CI</th><th align=\"center\">Point estimate</th><th align=\"center\">90% CI</th></tr></thead><tbody><tr><td align=\"left\"><bold>AUC<sub>0-7 days</sub>, mg*h/mL</bold></td><td align=\"center\">1.03</td><td align=\"center\">0.97-1.09</td><td align=\"center\">0.98</td><td align=\"center\">0.95-1.02</td></tr></tbody></table></body></html>", "text": "Pmid= 2958874:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of Steady-State Trough Concentrations of Plasma Alpha</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Prolastin-C 60 mg/kg</th><th align=\"center\">Prolastin 60 mg/kg</th></tr></thead><tbody><tr><td align=\"left\">Mean C<sub>trough</sub>, &#956;M (% CV)</td><td align=\"center\">16.9 (14)</td><td align=\"center\">16.7 (16)</td></tr><tr><td/><td align=\"center\">n = 23</td><td align=\"center\">n = 24</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Subjects with mean C<sub>trough </sub>&#8805; 11 &#956;M</td><td align=\"center\">23/23 (100%)</td><td align=\"center\">24/24 (100%)</td></tr></tbody></table></body></html>", "text": "Pmid= 2958874:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of AEs</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Double-blind Crossover Phase</th><th align=\"center\">Open-label Phase</th></tr></thead><tbody><tr><td/><td align=\"center\"><bold>Prolastin-C (n = 24)</bold><break/><bold>8 Weeks</bold></td><td align=\"center\"><bold>Prolastin (n = 24)</bold><break/><bold>8 Weeks</bold></td><td align=\"center\"><bold>Prolastin-C (n = 24)</bold><break/><bold>8 Weeks</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>AEs by subject</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Any AE, n (%)</td><td align=\"center\">11 (45.8)</td><td align=\"center\">9 (37.5)</td><td align=\"center\">11 (45.8)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>AEs by total number and rate per infusion</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Total number of AEs (rate per infusion)</td><td align=\"center\">22 (0.117)</td><td align=\"center\">15 (0.078)</td><td align=\"center\">14 (0.073)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Total number of AEs occurring in &#8805; 2 subjects (rate per infusion)</td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Upper respiratory tract infection</td><td align=\"center\">2 (0.011)</td><td align=\"center\">1 (0.005)</td><td align=\"center\">1 (0.005)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Urinary tract infection</td><td align=\"center\">1 (0.005)</td><td align=\"center\">0</td><td align=\"center\">2 (0.010)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Headache</td><td align=\"center\">1 (0.005)</td><td align=\"center\">2 (0.010)</td><td align=\"center\">0</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Rales</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">2 (0.010)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;Arthralgia</td><td align=\"center\">0</td><td align=\"center\">2 (0.010)</td><td align=\"center\">0</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">AEs leading to withdrawal</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Total number of SAEs (rate per infusion)</td><td align=\"center\">0</td><td align=\"center\">2 (0.010)</td><td align=\"center\">0</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Deaths</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">0</td></tr></tbody></table></body></html>", "text": "Pmid= 2958874:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Background characteristics of the study companies in the 2004 and 2008 surveys.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Survey 2004<break/>n of respondents (%)</th><th align=\"center\">Survey 2008<break/>n of respondents (%)</th><th align=\"center\">P-value</th></tr></thead><tbody><tr><td align=\"left\"><bold>Number of companies</bold></td><td/><td/><td align=\"center\">1.000</td></tr><tr><td align=\"left\">All</td><td align=\"center\">23</td><td align=\"center\">22</td><td/></tr><tr><td align=\"left\">Original products</td><td align=\"center\">16 (70)</td><td align=\"center\">16 (73)</td><td/></tr><tr><td align=\"left\">Generic products</td><td align=\"center\">7 (30)</td><td align=\"center\">6 (27)</td><td/></tr><tr><td align=\"left\"><bold>Number of employees</bold></td><td/><td/><td/></tr><tr><td align=\"left\">Original product companies</td><td/><td/><td align=\"center\">0.732</td></tr><tr><td align=\"left\">&#8804;19</td><td align=\"center\">1 (7)</td><td align=\"center\">4 (25)</td><td/></tr><tr><td align=\"left\">20-49</td><td align=\"center\">1 (7)</td><td align=\"center\">2 (13)</td><td/></tr><tr><td align=\"left\">50-99</td><td align=\"center\">7 (50)</td><td align=\"center\">5 (31)</td><td/></tr><tr><td align=\"left\">100-149</td><td align=\"center\">2 (14)</td><td align=\"center\">2 (13)</td><td/></tr><tr><td align=\"left\">&#8805;150</td><td align=\"center\">3 (22)</td><td align=\"center\">3 (19)</td><td/></tr><tr><td align=\"left\">Generic product companies</td><td/><td/><td align=\"center\">0.470</td></tr><tr><td align=\"left\">&#8804;19</td><td align=\"center\">5 (71)</td><td align=\"center\">2 (40)</td><td/></tr><tr><td align=\"left\">20-49</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">50-99</td><td align=\"center\">2 (29)</td><td align=\"center\">1 (20)</td><td/></tr><tr><td align=\"left\">100-149</td><td align=\"center\">-</td><td align=\"center\">1 (20)</td><td/></tr><tr><td align=\"left\">&#8805;150</td><td align=\"center\">-</td><td align=\"center\">1 (20)</td><td/></tr><tr><td align=\"left\"><bold>Turnover of the companies (&#8364;)</bold><sup>a</sup></td><td/><td/><td/></tr><tr><td align=\"left\">Original product companies</td><td/><td/><td align=\"center\">0.381</td></tr><tr><td align=\"left\">&#8804;1,000,000</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">1,000,001-20,000,000</td><td align=\"center\">1 (7)</td><td align=\"center\">6 (37)</td><td/></tr><tr><td align=\"left\">20,000,001-40,000,000</td><td align=\"center\">5 (36)</td><td align=\"center\">2 (13)</td><td/></tr><tr><td align=\"left\">40,000,001-60,000,000</td><td align=\"center\">3 (22)</td><td align=\"center\">3 (19)</td><td/></tr><tr><td align=\"left\">60,000,001-80,000,000</td><td align=\"center\">2 (14)</td><td align=\"center\">1 (6)</td><td/></tr><tr><td align=\"left\">80,000,001-100,000,000</td><td align=\"center\">1 (7)</td><td align=\"center\">2 (13)</td><td/></tr><tr><td align=\"left\">&#8805;100,000,001</td><td align=\"center\">2 (14)</td><td align=\"center\">2 (13)</td><td/></tr><tr><td align=\"left\">Generic product companies</td><td/><td/><td align=\"center\">0.755</td></tr><tr><td align=\"left\">&#8804;1,000,000</td><td align=\"center\">1 (14)</td><td align=\"center\">1 (17)</td><td/></tr><tr><td align=\"left\">1,000,001-20,000,000</td><td align=\"center\">5 (72)</td><td align=\"center\">3 (50)</td><td/></tr><tr><td align=\"left\">20,000,001-40,000,000</td><td align=\"center\">1 (14)</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">40,000,001-60,000,000</td><td align=\"center\">-</td><td align=\"center\">1 (17)</td><td/></tr><tr><td align=\"left\">60,000,001-80,000,000</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">80,000,001-100,000,000</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">&#8805;100,000,001</td><td align=\"center\">-</td><td align=\"center\">1 (17)</td><td/></tr><tr><td align=\"left\" colspan=\"3\"><bold>Median proportion (%) of turnover coming from the sale of pharmaceutical products included on the list of interchangeable medicines</bold><sup>b</sup></td><td/></tr><tr><td align=\"left\">All</td><td align=\"center\">25 (range 1.5-100)</td><td align=\"center\">11 (range 1-93)</td><td align=\"center\">0.749</td></tr><tr><td align=\"left\">Original product companies</td><td align=\"center\">23 (range 1.5-80)</td><td align=\"center\">8.5 (range 1-70)</td><td align=\"center\">0.527</td></tr><tr><td align=\"left\">Generic product companies</td><td align=\"center\">30 (range 5-100)</td><td align=\"center\">45 (range 5.4-93)</td><td align=\"center\">0.836</td></tr><tr><td align=\"left\" colspan=\"3\"><bold>Median proportion (%) of turnover coming from the sale of pharmaceutical products included in the price corridor</bold><sup>b</sup></td><td/></tr><tr><td align=\"left\">All</td><td align=\"center\">10 (range 0-90)</td><td align=\"center\">8.2 (range 0-90)</td><td align=\"center\">0.767</td></tr><tr><td align=\"left\">Original product companies</td><td align=\"center\">7.5 (range 0-50)</td><td align=\"center\">3.5 (range 0-70)</td><td align=\"center\">0.608</td></tr><tr><td align=\"left\">Generic product companies</td><td align=\"center\">30 (range 5-90)</td><td align=\"center\">45 (range 5.4-90)</td><td align=\"center\">0.836</td></tr><tr><td align=\"left\" colspan=\"3\"><bold>Median market share (%) in the Finnish pharmaceutical market</bold><sup>b</sup></td><td/></tr><tr><td align=\"left\">All</td><td align=\"center\">1.9 (range 0.1-10)</td><td align=\"center\">1.9 (range 0.1-9)</td><td align=\"center\">0.904</td></tr><tr><td align=\"left\">Original product companies</td><td align=\"center\">3.8 (range 0.6-10)</td><td align=\"center\">2.0 (range 0.3-8)</td><td align=\"center\">0.354</td></tr><tr><td align=\"left\">Generic product companies</td><td align=\"center\">0.3 (range 0.1-2)</td><td align=\"center\">0.3 (range 0.1-9)</td><td align=\"center\">0.662</td></tr></tbody></table></body></html>", "text": "Pmid= 2974660:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Impact of generic substitution on the number of employees in the pharmaceutical companies.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"4\">Survey 2004</th><th align=\"center\" colspan=\"4\">Survey 2008</th></tr><tr><th/><th align=\"center\">Original product companies<break/>n (%)</th><th align=\"center\">Generic product companies<break/>n (%)</th><th align=\"center\">Total<break/>n (%)</th><th align=\"center\">P-value</th><th align=\"center\">Original product companies<break/>n (%)</th><th align=\"center\">Generic product companies<break/>n (%)</th><th align=\"center\">Total<break/>n (%)</th><th align=\"center\">P-value</th></tr></thead><tbody><tr><td align=\"left\"><italic>Has generic substitution influenced the number of employees in your company?</italic>*</td><td/><td/><td align=\"center\">0.063</td><td/><td/><td/><td/><td align=\"center\">0.814</td></tr><tr><td align=\"left\">No</td><td align=\"center\">7 (44)</td><td align=\"center\">2 (29)</td><td align=\"center\">9 (39)</td><td/><td align=\"center\">7 (44)</td><td align=\"center\">4 (67)</td><td align=\"center\">11 (50)</td><td/></tr><tr><td align=\"left\">Number of employees has decreased</td><td align=\"center\">6 (37)</td><td align=\"center\">2 (29)</td><td align=\"center\">8 (35)</td><td/><td align=\"center\">7 (44)</td><td align=\"center\">2 (33)</td><td align=\"center\">9 (41)</td><td/></tr><tr><td align=\"left\">Number of employees has increased</td><td align=\"center\">-</td><td align=\"center\">3 (43)</td><td align=\"center\">3 (13)</td><td/><td align=\"center\">2 (12)</td><td align=\"center\">-</td><td align=\"center\">2 (9)</td><td/></tr><tr><td align=\"left\">Some other impact<sup>a</sup></td><td align=\"center\">3 (19)</td><td align=\"center\">-</td><td align=\"center\">3 (13)</td><td/><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">Total</td><td align=\"center\">16 (100)</td><td align=\"center\">7 (100)</td><td align=\"center\">23 (100)</td><td/><td align=\"center\">16 (100)</td><td align=\"center\">6 (100)</td><td align=\"center\">22 (100)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2974660:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Companies' departments most impacted on the number of employees by the introduction of generic substitution.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Survey 2004</th><th align=\"center\">Survey 2008</th></tr><tr><th/><th align=\"center\">Pharmaceutical companies<break/>(n = 11)<sup>a</sup><break/>n (%)<sup>b</sup></th><th align=\"center\">Pharmaceutical companies<break/>(n = 11)<break/>n(%)<sup>b</sup></th></tr></thead><tbody><tr><td align=\"left\"><bold>Number of employees has decreased</bold></td><td/><td/></tr><tr><td align=\"left\">Sales and marketing</td><td align=\"center\">6 (54)</td><td align=\"center\">8 (73)</td></tr><tr><td align=\"left\">Marketing authorization and reimbursement</td><td align=\"center\">-</td><td align=\"center\">1 (9)</td></tr><tr><td align=\"left\">Research and development</td><td align=\"center\">-</td><td align=\"center\">1 (9)</td></tr><tr><td align=\"left\">Logistics</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">Management</td><td align=\"center\">-</td><td align=\"center\">1 (9)</td></tr><tr><td align=\"left\"><bold>Number of employees has increased</bold></td><td/><td/></tr><tr><td align=\"left\">Sales and marketing</td><td align=\"center\">3 (27)</td><td align=\"center\">1 (9)</td></tr><tr><td align=\"left\">Marketing authorization and reimbursement</td><td align=\"center\">-</td><td align=\"center\">1 (9)</td></tr><tr><td align=\"left\">Research and development</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">Logistics</td><td align=\"center\">1 (9)</td><td align=\"center\">-</td></tr><tr><td align=\"left\">Management</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\"><bold>Some other impact</bold></td><td/><td/></tr><tr><td align=\"left\">Sales and marketing</td><td align=\"center\">2 (18)</td><td align=\"center\">-</td></tr></tbody></table></body></html>", "text": "Pmid= 2974660:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Impact of generic substitution on the marketing of pharmaceutical products in the pharmaceutical companies.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"4\">Survey 2004</th><th align=\"center\" colspan=\"4\">Survey 2008</th></tr><tr><th/><th align=\"center\">Original product companies<break/>n (%)</th><th align=\"center\">Generic product companies<break/>n (%)</th><th align=\"center\">Total<break/>n (%)</th><th align=\"center\">P-value</th><th align=\"center\">Original product companies<break/>n (%)</th><th align=\"center\">Generic product companies<break/>n (%)</th><th align=\"center\">Total<break/>n (%)</th><th align=\"center\">P-value</th></tr></thead><tbody><tr><td align=\"left\"><italic>Has generic substitution influenced the amount of prescription medicine marketing?</italic>*</td><td/><td/><td/><td align=\"center\">0.103</td><td/><td/><td/><td align=\"center\">1.000</td></tr><tr><td align=\"left\">No</td><td align=\"center\">7 (44)</td><td align=\"center\">4 (57)</td><td align=\"center\">11 (48)</td><td/><td align=\"center\">7 (44)</td><td align=\"center\">3 (50)</td><td align=\"center\">10 (45)</td><td/></tr><tr><td align=\"left\">Marketing has decreased</td><td align=\"center\">7 (44)</td><td align=\"center\">1 (14)</td><td align=\"center\">8 (35)</td><td/><td align=\"center\">8 (50)</td><td align=\"center\">3 (50)</td><td align=\"center\">11 (50)</td><td/></tr><tr><td align=\"left\">Marketing has increased</td><td align=\"center\">-</td><td align=\"center\">2 (29)</td><td align=\"center\">2 (9)</td><td/><td align=\"center\">1 (6)</td><td align=\"center\">-</td><td align=\"center\">1 (5)</td><td/></tr><tr><td align=\"left\">Some other impact<sup>a</sup></td><td align=\"center\">2 (12)</td><td align=\"center\">-</td><td align=\"center\">2 (9)</td><td/><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">Total</td><td align=\"center\">16 (100)</td><td align=\"center\">7 (100)</td><td align=\"center\">23 (100)</td><td/><td align=\"center\">16 (100)</td><td align=\"center\">6 (100)</td><td align=\"center\">22 (100)</td><td/></tr><tr><td align=\"left\"><italic>Has generic substitution influenced prescription medicine representatives\\' visits to pharmacies?</italic>**</td><td/><td/><td/><td align=\"center\">0.120</td><td/><td/><td/><td align=\"center\">0.619</td></tr><tr><td align=\"left\">No</td><td align=\"center\">9 (60)</td><td align=\"center\">2 (29)</td><td align=\"center\">11 (50)</td><td/><td align=\"center\">10 (62)</td><td align=\"center\">5 (83)</td><td align=\"center\">15 (68)</td><td/></tr><tr><td align=\"left\">Visits have decreased</td><td align=\"center\">2 (13)</td><td align=\"center\">-</td><td align=\"center\">2 (9)</td><td/><td align=\"center\">2 (13)</td><td align=\"center\">1 (17)</td><td align=\"center\">3 (14)</td><td/></tr><tr><td align=\"left\">Visits have increased</td><td align=\"center\">3 (20)</td><td align=\"center\">5 (71)</td><td align=\"center\">8 (36)</td><td/><td align=\"center\">4 (25)</td><td align=\"center\">-</td><td align=\"center\">4 (18)</td><td/></tr><tr><td align=\"left\">Some other impact<sup>b</sup></td><td align=\"center\">1 (7)</td><td align=\"center\">-</td><td align=\"center\">1 (5)</td><td/><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">Total</td><td align=\"center\">15 (100)</td><td align=\"center\">7 (100)</td><td align=\"center\">22 (100)</td><td/><td align=\"center\">16 (100)</td><td align=\"center\">6 (100)</td><td align=\"center\">22 (100)</td><td/></tr><tr><td align=\"left\"><italic>Has generic substitution influenced prescription medicine representatives\\' visits to physicians?</italic>***</td><td/><td/><td/><td align=\"center\">1.000</td><td/><td/><td/><td align=\"center\">0.802</td></tr><tr><td align=\"left\">No</td><td align=\"center\">10 (63)</td><td align=\"center\">5 (71)</td><td align=\"center\">15 (65)</td><td/><td align=\"center\">9 (60)</td><td align=\"center\">4 (67)</td><td align=\"center\">13 (62)</td><td/></tr><tr><td align=\"left\">Visits have decreased</td><td align=\"center\">5 (31)</td><td align=\"center\">2 (29)</td><td align=\"center\">7 (31)</td><td/><td align=\"center\">5 (33)</td><td align=\"center\">1 (17)</td><td align=\"center\">6 (29)</td><td/></tr><tr><td align=\"left\">Visits have increased</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td/><td align=\"center\">1 (7)</td><td align=\"center\">1 (17)</td><td align=\"center\">2 (9)</td><td/></tr><tr><td align=\"left\">Some other impact<sup>c</sup></td><td align=\"center\">1 (6)</td><td align=\"center\">-</td><td align=\"center\">1 (4)</td><td/><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">Total</td><td align=\"center\">16 (100)</td><td align=\"center\">7 (100)</td><td align=\"center\">23 (100)</td><td/><td align=\"center\">15 (100)</td><td align=\"center\">6 (100)</td><td align=\"center\">21 (100)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2974660:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Impact of generic substitution on the range of sales packages on the market in the pharmaceutical companies.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"4\">Survey 2004</th><th align=\"center\" colspan=\"4\">Survey 2008</th></tr><tr><th/><th align=\"center\">Original product companies<break/>n (%)</th><th align=\"center\">Generic product companies<break/>n (%)</th><th align=\"center\">Total<break/>n (%)</th><th align=\"center\">P-value</th><th align=\"center\">Original product companies<break/>n (%)</th><th align=\"center\">Generic product companies<break/>n (%)</th><th align=\"center\">Total<break/>n (%)</th><th align=\"center\">P-value</th></tr></thead><tbody><tr><td align=\"left\"><italic>Has generic substitution influenced the number of different sales packages of pharmaceutical products on the pharmaceutical market in your company?</italic>*</td><td/><td/><td/><td align=\"center\">0.318</td><td/><td/><td/><td align=\"center\">0.347</td></tr><tr><td align=\"left\">No</td><td align=\"center\">8 (53)</td><td align=\"center\">4 (57)</td><td align=\"center\">12 (54)</td><td/><td align=\"center\">8 (57)</td><td align=\"center\">2 (33)</td><td align=\"center\">10 (50)</td><td/></tr><tr><td align=\"left\">The number of packages has decreased</td><td align=\"center\">7 (47)</td><td align=\"center\">2 (29)</td><td align=\"center\">9 (41)</td><td/><td align=\"center\">5 (36)</td><td align=\"center\">2 (33)</td><td align=\"center\">7 (35)</td><td/></tr><tr><td align=\"left\">The number of packages has increased</td><td align=\"center\">-</td><td align=\"center\">1 (14)</td><td align=\"center\">1 (5)</td><td/><td align=\"center\">1 (7)</td><td align=\"center\">2 (33)</td><td align=\"center\">3 (15)</td><td/></tr><tr><td align=\"left\">Total</td><td align=\"center\">15 (100)</td><td align=\"center\">7 (100</td><td align=\"center\">22 (100)</td><td/><td align=\"center\">14 (100)</td><td align=\"center\">6 (100)</td><td align=\"center\">20 (100)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2974660:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Impact of generic substitution on research and development of new pharmaceutical products</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"4\">Survey 2004</th><th align=\"center\" colspan=\"4\">Survey 2008</th></tr><tr><th/><th align=\"center\">Original product companies<break/>n (%)<sup>a</sup></th><th align=\"center\">Generic product companies<break/>n (%)</th><th align=\"center\">Total<break/>n (%)<sup>b</sup></th><th align=\"center\">P-value</th><th align=\"center\">Original product companies<break/>n (%)</th><th align=\"center\">Generic product companies<break/>n (%)</th><th align=\"center\">Total<break/>n (%)</th><th align=\"center\">P-value</th></tr></thead><tbody><tr><td align=\"left\"><italic>Has generic substitution influenced the research and development of new pharmaceutical products in Finland in your company?</italic>*</td><td/><td/><td/><td align=\"center\">0.161</td><td/><td/><td/><td align=\"center\">0.154</td></tr><tr><td align=\"left\">No</td><td align=\"center\">8 (57)</td><td align=\"center\">2 (67)</td><td align=\"center\">10 (59)</td><td/><td align=\"center\">8 (67)</td><td align=\"center\">3 (75)</td><td align=\"center\">11 (69)</td><td/></tr><tr><td align=\"left\">Research and development has decreased</td><td align=\"center\">5 (36)</td><td align=\"center\">-</td><td align=\"center\">5 (29)</td><td/><td align=\"center\">4 (33)</td><td align=\"center\">-</td><td align=\"center\">4 (25)</td><td/></tr><tr><td align=\"left\">Research and development has increased</td><td align=\"center\">-</td><td align=\"center\">1 (33)</td><td align=\"center\">1 (6)</td><td/><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td/></tr><tr><td align=\"left\">Some other impact<sup>c</sup></td><td align=\"center\">2 (14)</td><td align=\"center\">-</td><td align=\"center\">2 (12)</td><td/><td align=\"center\">-</td><td align=\"center\">1 (25)</td><td align=\"center\">1 (6)</td><td/></tr><tr><td align=\"left\">Total</td><td align=\"center\">14 (107)</td><td align=\"center\">3 (100)</td><td align=\"center\">17 (106)</td><td/><td align=\"center\">12 (100)</td><td align=\"center\">4 (100)</td><td align=\"center\">16 (100)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 2974660:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Impact of generic substitution on the storage of pharmaceutical products by the pharmaceutical companies.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"4\">Survey 2004</th><th align=\"center\" colspan=\"4\">Survey 2008</th></tr><tr><th/><th align=\"center\">Original product companies<break/>(n = 16)<break/>n (%)<sup>a</sup></th><th align=\"center\">Generic product companies<break/>(n = 7)<break/>n (%)<sup>a</sup></th><th align=\"center\">Total<break/>(n = 23)<break/>n (%)<sup>a</sup></th><th align=\"center\">P-value</th><th align=\"center\">Original product companies<break/>(n = 15)<break/>n (%)<sup>a</sup></th><th align=\"center\">Generic product companies<break/>(n = 6)<break/>n (%)<sup>a</sup></th><th align=\"center\">Total<break/>(n = 21)<break/>n (%)<sup>a</sup></th><th align=\"center\">P-value</th></tr></thead><tbody><tr><td align=\"left\"><italic>Has generic substitution influenced the storage of pharmaceutical products by your company?</italic></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">No*</td><td align=\"center\">4 (25)</td><td align=\"center\">3 (43)</td><td align=\"center\">7 (30)</td><td align=\"center\">0.626</td><td align=\"center\">10 (67)</td><td align=\"center\">3 (50)</td><td align=\"center\">13 (62)</td><td align=\"center\">0.631</td></tr><tr><td align=\"left\">It has caused over-stocking**</td><td align=\"center\">9 (56)</td><td align=\"center\">2 (29)</td><td align=\"center\">11 (48)</td><td align=\"center\">0.371</td><td align=\"center\">4 (27)</td><td align=\"center\">1 (17)</td><td align=\"center\">5 (24)</td><td align=\"center\">1.000</td></tr><tr><td align=\"left\">It has caused problems with the expiry date of pharmaceutical products***</td><td align=\"center\">7 (44)</td><td align=\"center\">4 (57)</td><td align=\"center\">11 (48)</td><td align=\"center\">0.667</td><td align=\"center\">3 (20)</td><td align=\"center\">3 (50)</td><td align=\"center\">6 (29)</td><td align=\"center\">0.291</td></tr><tr><td align=\"left\">It has caused over-stocking of obligatory stocks<sup>b </sup>****</td><td align=\"center\">4 (25)</td><td align=\"center\">1 (14)</td><td align=\"center\">5 (22)</td><td align=\"center\">1.000</td><td align=\"center\">3 (20)</td><td align=\"center\">-</td><td align=\"center\">3 (14)</td><td align=\"center\">0.526</td></tr><tr><td align=\"left\">It has caused problems with the availability of pharmaceutical products*****</td><td align=\"center\">4 (25)</td><td align=\"center\">1 (14)</td><td align=\"center\">5 (22)</td><td align=\"center\">1.000</td><td align=\"center\">2 (13)</td><td align=\"center\">3 (50)</td><td align=\"center\">5 (24)</td><td align=\"center\">0.115</td></tr><tr><td align=\"left\">It has complicated the execution of obligatory storage<sup>b </sup>******</td><td align=\"center\">2 (12)</td><td align=\"center\">1 (14)</td><td align=\"center\">3 (13)</td><td align=\"center\">0.684</td><td align=\"center\">2 (13)</td><td align=\"center\">1 (17)</td><td align=\"center\">3 (14)</td><td align=\"center\">1.000</td></tr><tr><td align=\"left\">It has increased returns of pharmaceutical products from pharmacies after the new price corridor is determined<sup>c</sup></td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">2 (13)</td><td align=\"center\">1 (17)</td><td align=\"center\">3 (14)</td><td align=\"center\">1.000</td></tr></tbody></table></body></html>", "text": "Pmid= 2974660:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Actual dose and summary of calculation of active content as a percentage of target (n = 28, pharmacokinetic population)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Parameter</th><th align=\"center\" colspan=\"3\">Formulation</th></tr><tr><th/><th colspan=\"3\"><hr/></th></tr><tr><th/><th align=\"center\">A</th><th align=\"center\">B</th><th align=\"center\">C</th></tr></thead><tbody><tr><td align=\"left\">Actual dose (geometric mean [CV%] mg)</td><td align=\"center\">3.695 (3.26)</td><td align=\"center\">3.591 (2.92)</td><td align=\"center\">3.662 (3.95)</td></tr><tr><td align=\"left\">Active content (AC), mg</td><td align=\"center\">6.0</td><td align=\"center\">7.7</td><td align=\"center\">8.2</td></tr><tr><td align=\"left\">Container volume (V), mL</td><td align=\"center\">1.03</td><td align=\"center\">1.0</td><td align=\"center\">-</td></tr><tr><td align=\"left\">Concentration (AC/V), mg/mL</td><td align=\"center\">5.825</td><td align=\"center\">7.7</td><td align=\"center\">5.43</td></tr><tr><td align=\"left\">Target concentration (T), mg/mL</td><td align=\"center\">5.83</td><td align=\"center\">8.0</td><td align=\"center\">-</td></tr><tr><td align=\"left\">Percentage of target concentration<break/>A and B: 100 &#215; [AC/V]/T<break/>C: 100 &#215; [AC/T]</td><td align=\"center\">99.92</td><td align=\"center\">96.25</td><td align=\"center\">93.18</td></tr></tbody></table></body></html>", "text": "Pmid= 2987775:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Estimates with 95% confidence intervals for ratios of geometric means in pharmacokinetic (PK) parameters of recombinant human growth hormone (r-hGH) in serum (n = 28, PK population)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Statistic</th><th align=\"left\">Formulation</th><th align=\"center\">AUC<sub>0-t</sub>, ng/mL*h</th><th align=\"center\">C<sub>max</sub>, ng/mL</th><th align=\"center\">AUC<sub>0-t adj</sub>, ng/mL*h</th><th align=\"center\">C<sub>max adj</sub>, ng/mL</th></tr><tr><th/><th/><th/><th/><th colspan=\"2\"><hr/></th></tr><tr><th/><th/><th/><th/><th align=\"center\" colspan=\"2\">Adjusted for actual dose</th></tr></thead><tbody><tr><td align=\"left\">Least squares geometric mean</td><td align=\"left\">A</td><td align=\"center\">293.1</td><td align=\"center\">39.52</td><td align=\"center\">317.4</td><td align=\"center\">42.80</td></tr><tr><td/><td align=\"left\">B</td><td align=\"center\">277.7</td><td align=\"center\">39.57</td><td align=\"center\">309.5</td><td align=\"center\">44.09</td></tr><tr><td/><td align=\"left\">C</td><td align=\"center\">280.1</td><td align=\"center\">41.43</td><td align=\"center\">306.1</td><td align=\"center\">45.26</td></tr><tr><td align=\"left\">CV%</td><td/><td align=\"center\">12.2</td><td align=\"center\">16.2</td><td align=\"center\">12.3</td><td align=\"center\">16.2</td></tr><tr><td align=\"left\">Ratio estimate (95% CI)</td><td align=\"left\">A/C</td><td align=\"center\">1.05<break/>(0.98, 1.12)</td><td align=\"center\">0.95<break/>(0.88, 1.04)</td><td align=\"center\">1.04<break/>(0.97, 1.11)</td><td align=\"center\">0.95<break/>(0.87, 1.03)</td></tr><tr><td/><td align=\"left\">B/C</td><td align=\"center\">0.99<break/>(0.93, 1.06)</td><td align=\"center\">0.96<break/>(0.88, 1.04)</td><td align=\"center\">1.01<break/>(0.95, 1.08)</td><td align=\"center\">0.97<break/>(0.89, 1.06)</td></tr><tr><td align=\"left\">Ratio estimate (95% CI) (corrected for active content)</td><td align=\"left\">A/C<sup>a</sup></td><td align=\"center\">0.98<break/>(0.91, 1.04)</td><td align=\"center\">0.89<break/>(0.82, 0.97)</td><td align=\"center\">0.97<break/>(0.91, 1.03)</td><td align=\"center\">0.88<break/>(0.81, 0.96)</td></tr><tr><td/><td align=\"left\">B/C<sup>b</sup></td><td align=\"center\">0.96<break/>(0.90, 1.02)</td><td align=\"center\">0.93<break/>(0.85, 1.01)</td><td align=\"center\">0.98<break/>(0.92, 1.05)</td><td align=\"center\">0.94<break/>(0.87, 1.03)</td></tr></tbody></table></body></html>", "text": "Pmid= 2987775:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic (PK) parameters of recombinant human growth hormone (r-hGH) in serum (n = 28, PK population)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Parameter</th><th align=\"center\" colspan=\"3\">Formulation</th></tr><tr><th/><th colspan=\"3\"><hr/></th></tr><tr><th/><th align=\"center\">A</th><th align=\"center\">B</th><th align=\"center\">C</th></tr></thead><tbody><tr><td align=\"left\">AUC<sub>0-t</sub>, ng/mL*h</td><td align=\"center\">295 (23.1)<break/>191-474</td><td align=\"center\">279 (26.2)<break/>120-381</td><td align=\"center\">281 (23.6)<break/>165-411</td></tr><tr><td align=\"left\">C<sub>max</sub>, ng/mL</td><td align=\"center\">39.8 (28.0)<break/>21.9-70.9</td><td align=\"center\">39.8 (31.6)<break/>18.9-67.8</td><td align=\"center\">41.6 (31.1)<break/>18.4-75.6</td></tr><tr><td align=\"left\">AUC<sub>0-&#8734;</sub>, ng/mL*h</td><td align=\"center\">306 (23.3)<break/>200-480</td><td align=\"center\">291 (24.2)<break/>135-386</td><td align=\"center\">291 (23.3)<break/>170-418</td></tr><tr><td align=\"left\">t<sub>max</sub>, h</td><td align=\"center\">4.0<break/>2.0-7.0</td><td align=\"center\">4.0<break/>2.0-6.0</td><td align=\"center\">4.0<break/>2.0-6.0</td></tr><tr><td align=\"left\">t<sub>1/2</sub>, h</td><td align=\"center\">2.19 (32.0)<break/>1.24-5.38</td><td align=\"center\">2.22 (27.2)<break/>1.42-4.11</td><td align=\"center\">2.05 (30.2)<break/>1.18-3.85</td></tr><tr><td align=\"left\">V<sub>z/f</sub>, L</td><td align=\"center\">41.2 (41.3)<break/>18.3-117.9</td><td align=\"center\">44.0 (45.3)<break/>24.2-132.5</td><td align=\"center\">40.7 (40.5)<break/>19.8-90.6</td></tr><tr><td align=\"left\">CL/f, L/h</td><td align=\"center\">13.1 (23.3)<break/>8.3-20.0</td><td align=\"center\">13.7 (24.2)<break/>10.4-29.5</td><td align=\"center\">13.8 (23.3)<break/>9.6-23.5</td></tr></tbody></table></body></html>", "text": "Pmid= 2987775:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Injection-site reactions, by number of events (n = 30, safety population)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Formulation</th><th align=\"center\">Overall</th></tr><tr><th/><th colspan=\"3\"><hr/></th><th/></tr><tr><th/><th align=\"center\">A</th><th align=\"center\">B</th><th align=\"center\">C</th><th/></tr></thead><tbody><tr><td align=\"left\">Redness</td><td align=\"center\">12</td><td align=\"center\">7</td><td align=\"center\">8</td><td align=\"center\">27</td></tr><tr><td align=\"left\">Bruising</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">2</td></tr><tr><td align=\"left\">Itching</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">2</td></tr><tr><td align=\"left\">Swelling</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Induration</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Total</td><td align=\"center\">14</td><td align=\"center\">8</td><td align=\"center\">9</td><td align=\"center\">31</td></tr></tbody></table></body></html>", "text": "Pmid= 2987775:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Treatment-emergent and treatment-related adverse events (AEs) (n = 30, safety population)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Formulation</th><th align=\"center\">Overall</th></tr><tr><th/><th colspan=\"3\"><hr/></th><th/></tr><tr><th/><th align=\"center\">A</th><th align=\"center\">B</th><th align=\"center\">C</th><th/></tr></thead><tbody><tr><td align=\"left\">Subjects experiencing a treatment-emergent AE, n (%)</td><td align=\"center\">19/30 (63.3)</td><td align=\"center\">16/29 (55.2)</td><td align=\"center\">18/29 (62.1)</td><td align=\"center\">26/30 (86.7)</td></tr><tr><td align=\"left\">Treatment-emergent AEs, n</td><td align=\"center\">35</td><td align=\"center\">27</td><td align=\"center\">29</td><td align=\"center\">91</td></tr><tr><td align=\"left\"><italic>Treatment-related AEs</italic></td><td/><td/><td/><td/></tr><tr><td align=\"left\">Total, n</td><td align=\"center\">24</td><td align=\"center\">12</td><td align=\"center\">20</td><td align=\"center\">56</td></tr><tr><td align=\"left\">&#8195;Nausea</td><td align=\"center\">12</td><td align=\"center\">4</td><td align=\"center\">9</td><td align=\"center\">25</td></tr><tr><td align=\"left\">&#8195;Headache</td><td align=\"center\">2</td><td align=\"center\">4</td><td align=\"center\">5</td><td align=\"center\">11</td></tr><tr><td align=\"left\">&#8195;Dizziness</td><td align=\"center\">4</td><td align=\"center\">2</td><td align=\"center\">2</td><td align=\"center\">8</td></tr><tr><td align=\"left\">&#8195;Vomiting</td><td align=\"center\">2</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">3</td></tr><tr><td align=\"left\">&#8195;Upper abdominal pain</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Abdominal pain</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Peripheral oedema</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Abdominal discomfort</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Tachycardia</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Pain in extremity</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Asthenia</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">0</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Injection site bruising</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;Tremor</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1</td><td align=\"center\">1</td></tr></tbody></table></body></html>", "text": "Pmid= 2987775:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>The prevalence of dispensed drugs, polypharmacy, and excessive polypharmacy</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Age group</th><th align=\"center\" colspan=\"4\">DP&#8805;1</th><th align=\"center\" colspan=\"4\">DP&#8805;5</th><th align=\"center\" colspan=\"4\">DP&#8805;10</th></tr><tr><th/><th colspan=\"4\"><hr/></th><th colspan=\"4\"><hr/></th><th colspan=\"4\"><hr/></th></tr><tr><th/><th align=\"right\">2005</th><th align=\"right\">2006</th><th align=\"right\">2007</th><th align=\"right\">2008</th><th align=\"right\">2005</th><th align=\"right\">2006</th><th align=\"right\">2007</th><th align=\"right\">2008</th><th align=\"right\">2005</th><th align=\"right\">2006</th><th align=\"right\">2007</th><th align=\"right\">2008</th></tr></thead><tbody><tr><td align=\"left\">0-9</td><td align=\"right\">0.183</td><td align=\"right\">0.194</td><td align=\"right\">0.184</td><td align=\"right\">0.188</td><td align=\"right\">0.005</td><td align=\"right\">0.005</td><td align=\"right\">0.005</td><td align=\"right\">0.005</td><td align=\"right\">0.000</td><td align=\"right\">0.000</td><td align=\"right\">0.000</td><td align=\"right\">0.000</td></tr><tr><td align=\"left\">10-19</td><td align=\"right\">0.214</td><td align=\"right\">0.223</td><td align=\"right\">0.228</td><td align=\"right\">0.238</td><td align=\"right\">0.008</td><td align=\"right\">0.008</td><td align=\"right\">0.008</td><td align=\"right\">0.008</td><td align=\"right\">0.000</td><td align=\"right\">0.000</td><td align=\"right\">0.000</td><td align=\"right\">0.001</td></tr><tr><td align=\"left\">20-29</td><td align=\"right\">0.314</td><td align=\"right\">0.313</td><td align=\"right\">0.308</td><td align=\"right\">0.304</td><td align=\"right\">0.016</td><td align=\"right\">0.017</td><td align=\"right\">0.017</td><td align=\"right\">0.017</td><td align=\"right\">0.001</td><td align=\"right\">0.001</td><td align=\"right\">0.001</td><td align=\"right\">0.001</td></tr><tr><td align=\"left\">30-39</td><td align=\"right\">0.332</td><td align=\"right\">0.337</td><td align=\"right\">0.335</td><td align=\"right\">0.333</td><td align=\"right\">0.029</td><td align=\"right\">0.029</td><td align=\"right\">0.029</td><td align=\"right\">0.030</td><td align=\"right\">0.003</td><td align=\"right\">0.003</td><td align=\"right\">0.003</td><td align=\"right\">0.004</td></tr><tr><td align=\"left\">40-49</td><td align=\"right\">0.390</td><td align=\"right\">0.396</td><td align=\"right\">0.395</td><td align=\"right\">0.394</td><td align=\"right\">0.053</td><td align=\"right\">0.054</td><td align=\"right\">0.055</td><td align=\"right\">0.056</td><td align=\"right\">0.008</td><td align=\"right\">0.008</td><td align=\"right\">0.009</td><td align=\"right\">0.009</td></tr><tr><td align=\"left\">50-59</td><td align=\"right\">0.533</td><td align=\"right\">0.536</td><td align=\"right\">0.537</td><td align=\"right\">0.536</td><td align=\"right\">0.113</td><td align=\"right\">0.115</td><td align=\"right\">0.117</td><td align=\"right\">0.119</td><td align=\"right\">0.019</td><td align=\"right\">0.020</td><td align=\"right\">0.020</td><td align=\"right\">0.021</td></tr><tr><td align=\"left\">60-69</td><td align=\"right\">0.640</td><td align=\"right\">0.649</td><td align=\"right\">0.657</td><td align=\"right\">0.662</td><td align=\"right\">0.197</td><td align=\"right\">0.202</td><td align=\"right\">0.209</td><td align=\"right\">0.214</td><td align=\"right\">0.037</td><td align=\"right\">0.039</td><td align=\"right\">0.040</td><td align=\"right\">0.041</td></tr><tr><td align=\"left\">70-79</td><td align=\"right\">0.784</td><td align=\"right\">0.789</td><td align=\"right\">0.794</td><td align=\"right\">0.797</td><td align=\"right\">0.350</td><td align=\"right\">0.359</td><td align=\"right\">0.367</td><td align=\"right\">0.376</td><td align=\"right\">0.078</td><td align=\"right\">0.083</td><td align=\"right\">0.085</td><td align=\"right\">0.088</td></tr><tr><td align=\"left\">80-89</td><td align=\"right\">0.833</td><td align=\"right\">0.843</td><td align=\"right\">0.849</td><td align=\"right\">0.853</td><td align=\"right\">0.475</td><td align=\"right\">0.492</td><td align=\"right\">0.504</td><td align=\"right\">0.514</td><td align=\"right\">0.121</td><td align=\"right\">0.139</td><td align=\"right\">0.143</td><td align=\"right\">0.147</td></tr><tr><td align=\"left\">90-</td><td align=\"right\">0.780</td><td align=\"right\">0.790</td><td align=\"right\">0.790</td><td align=\"right\">0.795</td><td align=\"right\">0.494</td><td align=\"right\">0.524</td><td align=\"right\">0.524</td><td align=\"right\">0.532</td><td align=\"right\">0.126</td><td align=\"right\">0.159</td><td align=\"right\">0.160</td><td align=\"right\">0.162</td></tr><tr><td align=\"left\">Total</td><td align=\"right\">0.426</td><td align=\"right\">0.433</td><td align=\"right\">0.433</td><td align=\"right\">0.436</td><td align=\"right\">0.102</td><td align=\"right\">0.105</td><td align=\"right\">0.108</td><td align=\"right\">0.111</td><td align=\"right\">0.021</td><td align=\"right\">0.022</td><td align=\"right\">0.023</td><td align=\"right\">0.024</td></tr></tbody></table></body></html>", "text": "Pmid= 3014875:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Number of individuals with polypharmacy, and excessive polypharmacy</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Age group</th><th align=\"center\" colspan=\"4\">DP&#8805;5</th><th align=\"center\" colspan=\"4\">DP&#8805;10</th></tr><tr><th/><th colspan=\"4\"><hr/></th><th colspan=\"4\"><hr/></th></tr><tr><th/><th align=\"right\">2005</th><th align=\"right\">2006</th><th align=\"right\">2007</th><th align=\"right\">2008</th><th align=\"right\">2005</th><th align=\"right\">2006</th><th align=\"right\">2007</th><th align=\"right\">2008</th></tr></thead><tbody><tr><td align=\"left\">0-9</td><td align=\"right\">4,698</td><td align=\"right\">4,829</td><td align=\"right\">4,529</td><td align=\"right\">4,653</td><td align=\"right\">243</td><td align=\"right\">235</td><td align=\"right\">246</td><td align=\"right\">230</td></tr><tr><td align=\"left\">10-19</td><td align=\"right\">9,082</td><td align=\"right\">8,974</td><td align=\"right\">9,300</td><td align=\"right\">9,693</td><td align=\"right\">579</td><td align=\"right\">578</td><td align=\"right\">574</td><td align=\"right\">620</td></tr><tr><td align=\"left\">20-29</td><td align=\"right\">17,598</td><td align=\"right\">17,993</td><td align=\"right\">18,481</td><td align=\"right\">18,930</td><td align=\"right\">1,486</td><td align=\"right\">1,598</td><td align=\"right\">1,601</td><td align=\"right\">1,646</td></tr><tr><td align=\"left\">30-39</td><td align=\"right\">35,926</td><td align=\"right\">36,118</td><td align=\"right\">35,857</td><td align=\"right\">36,297</td><td align=\"right\">4,129</td><td align=\"right\">4,312</td><td align=\"right\">4,230</td><td align=\"right\">4,345</td></tr><tr><td align=\"left\">40-49</td><td align=\"right\">64,044</td><td align=\"right\">66,952</td><td align=\"right\">69,170</td><td align=\"right\">70,883</td><td align=\"right\">9,666</td><td align=\"right\">10,058</td><td align=\"right\">10,730</td><td align=\"right\">10,919</td></tr><tr><td align=\"left\">50-59</td><td align=\"right\">137,191</td><td align=\"right\">137,651</td><td align=\"right\">138,873</td><td align=\"right\">139,519</td><td align=\"right\">22,785</td><td align=\"right\">23,587</td><td align=\"right\">23,763</td><td align=\"right\">24,142</td></tr><tr><td align=\"left\">60-69</td><td align=\"right\">191,510</td><td align=\"right\">205,066</td><td align=\"right\">220,723</td><td align=\"right\">234,603</td><td align=\"right\">36,053</td><td align=\"right\">39,159</td><td align=\"right\">42,206</td><td align=\"right\">44,942</td></tr><tr><td align=\"left\">70-79</td><td align=\"right\">231,413</td><td align=\"right\">236,654</td><td align=\"right\">242,252</td><td align=\"right\">250,348</td><td align=\"right\">51,575</td><td align=\"right\">54,790</td><td align=\"right\">56,488</td><td align=\"right\">58,788</td></tr><tr><td align=\"left\">80-89</td><td align=\"right\">195,172</td><td align=\"right\">203,814</td><td align=\"right\">208,939</td><td align=\"right\">213,207</td><td align=\"right\">49,833</td><td align=\"right\">57,490</td><td align=\"right\">59,282</td><td align=\"right\">61,060</td></tr><tr><td align=\"left\">90-</td><td align=\"right\">36,315</td><td align=\"right\">39,228</td><td align=\"right\">39,985</td><td align=\"right\">41,191</td><td align=\"right\">9,269</td><td align=\"right\">11,884</td><td align=\"right\">12,197</td><td align=\"right\">12,552</td></tr><tr><td align=\"left\">Total</td><td align=\"right\">922,949</td><td align=\"right\">957,279</td><td align=\"right\">988,109</td><td align=\"right\">1,019,324</td><td align=\"right\">185,618</td><td align=\"right\">203,691</td><td align=\"right\">211,317</td><td align=\"right\">219,244</td></tr></tbody></table></body></html>", "text": "Pmid= 3014875:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic parameters for free phenoxodiol following a single bolus dose of 5 mg/kg infused intravenously over 5 minutes.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Patient</th><th align=\"left\">Kel</th><th align=\"left\">T1/2 (h)</th><th align=\"left\">AUC<sub>0-t </sub>(&#956;g.h/ml)</th><th align=\"left\">AUC<sub>0-inf </sub>(&#956;g.h/ml)</th><th align=\"left\">Cl (L/h)</th><th align=\"left\">Vd (L/kg)</th></tr></thead><tbody><tr><td align=\"left\">1</td><td align=\"left\">1.25</td><td align=\"left\">0.55</td><td align=\"left\">1.49</td><td align=\"left\">1.55 (4.1%)*</td><td align=\"left\">1.50</td><td align=\"left\">1.20</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">2</td><td align=\"left\">2.42</td><td align=\"left\">0.28</td><td align=\"left\">0.40</td><td align=\"left\">0.40 (1.2%)</td><td align=\"left\">7.01</td><td align=\"left\">2.90</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">3</td><td align=\"left\">1.59</td><td align=\"left\">0.43</td><td align=\"left\">1.04</td><td align=\"left\">1.05 (13.2%)</td><td align=\"left\">2.22</td><td align=\"left\">1.40</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">4</td><td align=\"left\">1.24</td><td align=\"left\">0.56</td><td align=\"left\">1.65</td><td align=\"left\">1.66 (10.3)</td><td align=\"left\">1.24</td><td align=\"left\">1.00</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">5</td><td align=\"left\">0.39</td><td align=\"left\">1.74</td><td align=\"left\">2.59</td><td align=\"left\">2.59 (11.3)</td><td align=\"left\">0.46</td><td align=\"left\">1.17</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">6</td><td align=\"left\">1.54</td><td align=\"left\">0.45</td><td align=\"left\">1.21</td><td align=\"left\">1.22 (11.8%)</td><td align=\"left\">2.46</td><td align=\"left\">1.60</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">Mean &#177; SD</td><td align=\"left\">1.41 &#177; 0.66</td><td align=\"left\">0.67 &#177; 0.53</td><td align=\"left\">1.40 &#177; 0.73</td><td align=\"left\">1.41 &#177; 0.73 (8.7%)</td><td align=\"left\">2.48 &#177; 2.33</td><td align=\"left\">1.55 &#177; 0.69</td></tr></tbody></table></body></html>", "text": "Pmid= 3045896:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic parameters for total phenoxodiol following a single bolus dose of 5 mg/kg infused intravenously over 5 minutes.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Patient</th><th align=\"left\">Kel</th><th align=\"left\">T1/2 (h)</th><th align=\"left\">AUC<sub>0-t </sub>(&#956;g.h/ml)</th><th align=\"left\">AUC<sub>0-inf </sub>(&#956;g.h/ml)</th><th align=\"left\">Cl (L/h)</th><th align=\"left\">Vd (L/kg)</th></tr></thead><tbody><tr><td align=\"left\">1</td><td align=\"left\">0.21</td><td align=\"left\">3.33</td><td align=\"left\">27.10</td><td align=\"left\">37.76</td><td align=\"left\">0.06</td><td align=\"left\">0.31</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">2</td><td align=\"left\">0.25</td><td align=\"left\">2.71</td><td align=\"left\">33.47</td><td align=\"left\">34.64</td><td align=\"left\">0.05</td><td align=\"left\">0.21</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">3</td><td align=\"left\">0.37</td><td align=\"left\">1.85</td><td align=\"left\">7.45</td><td align=\"left\">7.93</td><td align=\"left\">0.29</td><td align=\"left\">0.80</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">4</td><td align=\"left\">0.29</td><td align=\"left\">2.32</td><td align=\"left\">14.19</td><td align=\"left\">16.13</td><td align=\"left\">0.15</td><td align=\"left\">0.50</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">5</td><td align=\"left\">0.35</td><td align=\"left\">1.98</td><td align=\"left\">21.12</td><td align=\"left\">22.83</td><td align=\"left\">0.15</td><td align=\"left\">0.45</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">6</td><td align=\"left\">0.09</td><td align=\"left\">6.98</td><td align=\"left\">10.37</td><td align=\"left\">10.37</td><td align=\"left\">0.16</td><td align=\"left\">1.60</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">Mean &#177; SD</td><td align=\"left\">0.26 &#177; 0.10</td><td align=\"left\">3.19 &#177; 1.93</td><td align=\"left\">18.93 &#177; 10.11</td><td align=\"left\">21.61 &#177; 12.45</td><td align=\"left\">0.15 &#177; 0.08</td><td align=\"left\">0.64 &#177; 0.51</td></tr></tbody></table></body></html>", "text": "Pmid= 3045896:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic parameters for free phenoxodiol infused at a dose of 2 mg/kg/h.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Css (&#956;g/ml)</th><th align=\"center\"><bold>Time to ss </bold><bold>(h)</bold></th><th align=\"center\">Acc T1/2 (h)</th><th align=\"center\">Cl (L/h)</th></tr></thead><tbody><tr><td align=\"center\">1</td><td align=\"center\">0.92</td><td align=\"center\">0.67</td><td align=\"center\">0.13</td><td align=\"center\">1.08</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">2</td><td align=\"center\">0.65</td><td align=\"center\">1.00</td><td align=\"center\">0.20</td><td align=\"center\">1.53</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">4</td><td align=\"center\">0.77</td><td align=\"center\">1.00</td><td align=\"center\">0.20</td><td align=\"center\">1.28</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">5</td><td align=\"center\">0.66</td><td align=\"center\">1.00</td><td align=\"center\">0.20</td><td align=\"center\">1.51</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">6</td><td align=\"center\">0.96</td><td align=\"center\">0.67</td><td align=\"center\">0.13</td><td align=\"center\">1.03</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">Mean &#177; SD</td><td align=\"center\">0.79 &#177; 0.14</td><td align=\"center\">0.87 &#177; 0.18</td><td align=\"center\">0.17 &#177; 0.04</td><td align=\"center\">1.29 &#177; 0.23</td></tr></tbody></table></body></html>", "text": "Pmid= 3045896:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic parameters for total phenoxodiol infused at a dose of 2 mg/kg/h.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Patient number</th><th align=\"center\">Css (&#956;g/ml)</th><th align=\"center\">Time to ss (h)</th><th align=\"center\">Acc T1/2 (h)</th><th align=\"center\">Cl (L/h)</th></tr></thead><tbody><tr><td align=\"center\">1*</td><td align=\"center\">14.74</td><td align=\"center\">3.66</td><td align=\"center\">0.73</td><td align=\"center\">0.06</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">2*</td><td align=\"center\">32.31</td><td align=\"center\">4.00</td><td align=\"center\">0.80</td><td align=\"center\">0.03</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">4</td><td align=\"center\">13.33</td><td align=\"center\">2.00</td><td align=\"center\">0.40</td><td align=\"center\">0.07</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">5</td><td align=\"center\">14.80</td><td align=\"center\">2.00</td><td align=\"center\">0.40</td><td align=\"center\">0.07</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">6</td><td align=\"center\">12.04</td><td align=\"center\">2.33</td><td align=\"center\">0.47</td><td align=\"center\">0.08</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">Mean &#177; SD</td><td align=\"center\">17.45 &#177; 8.38</td><td align=\"center\">2.78 &#177; 0.96</td><td align=\"center\">0.56 &#177; 0.19</td><td align=\"center\">0.06 &#177; 0.01</td></tr></tbody></table></body></html>", "text": "Pmid= 3045896:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of all participants (independent of complaints), participants with constipations and participants with diarrhoea, and comparisons between subjects with and without diarrhoea and with and without constipation.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Characteristics</th><th align=\"center\">All participants<break/>n = 4622</th><th align=\"center\">Participants with constipation<break/>n = 640</th><th align=\"center\">Participants with diarrhoea<break/>n = 407</th></tr></thead><tbody><tr><td align=\"left\">Age (years)</td><td align=\"center\">49.4 (13.8)</td><td align=\"center\">52.2 (15.1)***</td><td align=\"center\">50.7 (13.7)&#8224;</td></tr><tr><td align=\"left\">Gender (male) (%)</td><td align=\"center\">43.6</td><td align=\"center\">21.3***</td><td align=\"center\">50.4**</td></tr><tr><td align=\"left\">Body mass index (kg/m<sup>2</sup>) [0.2%]</td><td align=\"center\">26.9 (4.2)</td><td align=\"center\">26.1(4.1)***</td><td align=\"center\">27.2 (4.1)*</td></tr><tr><td align=\"left\">Cohabiting (%) [14.9%]</td><td align=\"center\">89.3</td><td align=\"center\">87.9</td><td align=\"center\">86.2*</td></tr><tr><td align=\"left\">Years of education [1.0%]</td><td align=\"center\">12.2 (3.5)</td><td align=\"center\">12.0 (3.5) &#8224;</td><td align=\"center\">11.7 (3.4) *</td></tr><tr><td align=\"left\">Physical activity (breathless) (%) [7.2%] &lt;1 hr/1-2 hrs/&gt;3 hrs a week</td><td align=\"center\">58.8/27.0/14.2</td><td align=\"center\">60.9/27.7/11.4 *</td><td align=\"center\">60.6/26.9/12.5</td></tr><tr><td align=\"left\">Cups of coffee/day [1.0%]</td><td align=\"center\">3.7 (2.8)</td><td align=\"center\">3.4 (2.6) *</td><td align=\"center\">3.8 (2.9)</td></tr><tr><td align=\"left\">Frequency of use of alcohol &#164; [0.8%]</td><td align=\"center\">4.4 (1.7)</td><td align=\"center\">4.1 *** (1.7)</td><td align=\"center\">4.6 * (1.7)</td></tr><tr><td align=\"left\">Use of alcohol &gt;1 time/week (%)</td><td align=\"center\">10.6</td><td align=\"center\">8.2 *</td><td align=\"center\">12.9 &#8224;</td></tr><tr><td align=\"left\">Smoking habits (%) [0.6%] Never/Past/Current</td><td align=\"center\">44.5/27.2/28.3</td><td align=\"center\">46.1/27.4/26.5</td><td align=\"center\">35.9/31.4/32.7 ***</td></tr><tr><td align=\"left\">Asthma (%) [2.1%]</td><td align=\"center\">8.7</td><td align=\"center\">10.6 *</td><td align=\"center\">9.8</td></tr><tr><td align=\"left\">Allergic rhinitis (%) [15.4%]</td><td align=\"center\">12.9</td><td align=\"center\">13.6</td><td align=\"center\">13.5</td></tr><tr><td align=\"left\">Bronchitis (%) [3.5%]</td><td align=\"center\">2.5</td><td align=\"center\">2.7</td><td align=\"center\">2.5</td></tr><tr><td align=\"left\">Diabetes (%) [2.5%]</td><td align=\"center\">2.1</td><td align=\"center\">3.3 *</td><td align=\"center\">3.4 &#8224;</td></tr><tr><td align=\"left\">Osteoporosis (%) [3.3%]</td><td align=\"center\">2.4</td><td align=\"center\">4.7 ***</td><td align=\"center\">3.7 &#8224;</td></tr><tr><td align=\"left\">Myocardial infarction (%) [2.4%]</td><td align=\"center\">2.8</td><td align=\"center\">2.8</td><td align=\"center\">3.7</td></tr><tr><td align=\"left\">Angina pectoris (%) [2.4%]</td><td align=\"center\">3.7</td><td align=\"center\">6.1 *</td><td align=\"center\">4.2</td></tr><tr><td align=\"left\">Cerebral stroke (%) [2.5%]</td><td align=\"center\">2.0</td><td align=\"center\">3.1 *</td><td align=\"center\">3.7 *</td></tr><tr><td align=\"left\">Epilepsy (%) [0.8%]</td><td align=\"center\">1.6</td><td align=\"center\">2.4 &#8224;</td><td align=\"center\">1.7</td></tr><tr><td align=\"left\">Multiple sclerosis (%) [4.0%]</td><td align=\"center\">0.5</td><td align=\"center\">1.5 **</td><td align=\"center\">0.7</td></tr><tr><td align=\"left\">Musculoskeletal complaints &#167;</td><td align=\"center\">2.2 (2.2)</td><td align=\"center\">2.6 (2.4) ***</td><td align=\"center\">2.7 (2.4) ***</td></tr><tr><td align=\"left\">HSCL 10 # [6.4%]</td><td align=\"center\">1.3 (0.4)</td><td align=\"center\">1.4 (0.5) ***</td><td align=\"center\">1.4 (0.5) ***</td></tr><tr><td align=\"left\">Use of drugs (Yes) (%)</td><td align=\"center\">62.5</td><td align=\"center\">72,5 ***</td><td align=\"center\">70.3 ***</td></tr><tr><td align=\"left\">Number of drugs</td><td align=\"center\">1.34 (1.56)</td><td align=\"center\">1.64 (1.67) ***</td><td align=\"center\">1.70 (1.78)***</td></tr><tr><td align=\"left\">Number of drugs (%) 0 drug/1 drug/2 or 3 drugs/&#8805;4</td><td align=\"center\">37.5/28.3/24.5/9.8</td><td align=\"center\">27.5/30.3/29.7/12.5***</td><td align=\"center\">29.7/29.0/25.8/15.5***</td></tr></tbody></table></body></html>", "text": "Pmid= 3049147:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>The prevalence of constipation and diarrhoea among users and non-users of drugs significantly associated with the complaints (bivariate analyses, all participants)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">ATC level</th><th align=\"left\">ATC code</th><th align=\"left\">Name of drug group/chemical substance</th><th align=\"center\">Prevalence (%) Users/non users</th><th align=\"center\">Statistics (p-value)</th></tr></thead><tbody><tr><td align=\"left\">Constipation</td><td align=\"left\">Level 4</td><td align=\"left\">C10AA</td><td align=\"left\">HMG CoA reductase inhibitors</td><td align=\"center\">18.5/13.6</td><td align=\"center\">0.033</td></tr><tr><td/><td/><td align=\"left\">M01AE</td><td align=\"left\">Propionic acid derivatives</td><td align=\"center\">18.7/13.3</td><td align=\"center\">0.001</td></tr><tr><td/><td/><td align=\"left\">N06AA</td><td align=\"left\">Non-selective monoamine reuptake inhibitors</td><td align=\"center\">23.2/13.7</td><td align=\"center\">0.050</td></tr><tr><td/><td align=\"left\">Level 5</td><td align=\"left\">C01AA04</td><td align=\"left\">Digitoxin</td><td align=\"center\">38.5/13.8</td><td align=\"center\">0.025</td></tr><tr><td/><td/><td align=\"left\">C01DA02</td><td align=\"left\">Glyceryl trinitrate</td><td align=\"center\">27.3/13.7</td><td align=\"center\">0.015</td></tr><tr><td/><td/><td align=\"left\">C03CA01</td><td align=\"left\">Furosemide</td><td align=\"center\">29.2/13.6</td><td align=\"center\">0.001</td></tr><tr><td/><td/><td align=\"left\">C10AA05</td><td align=\"left\">Atorvastatin</td><td align=\"center\">21.4/13.7</td><td align=\"center\">0.037</td></tr><tr><td/><td/><td align=\"left\">G03CX01</td><td align=\"left\">Tibolone</td><td align=\"center\">40.0/13.8</td><td align=\"center\">0.038</td></tr><tr><td/><td/><td align=\"left\">H03AA01</td><td align=\"left\">Levothyroxine sodium</td><td align=\"center\">28.1/13.4</td><td align=\"center\">&lt;0.001</td></tr><tr><td/><td/><td align=\"left\">M01AE01</td><td align=\"left\">Ibuprofen</td><td align=\"center\">19.4/13.3</td><td align=\"center\">0.001</td></tr><tr><td align=\"left\">Diarrhoea</td><td align=\"left\">Level 4</td><td align=\"left\">C10AA</td><td align=\"left\">HMG CoA reductase inhibitors</td><td align=\"center\">12.7/8.6</td><td align=\"center\">0.031</td></tr><tr><td/><td/><td align=\"left\">R06AD</td><td align=\"left\">Phenothiazine derivatives</td><td align=\"center\">28.6/8.7</td><td align=\"center\">0.029</td></tr><tr><td/><td align=\"left\">Level 5</td><td align=\"left\">A10BA02</td><td align=\"left\">Metformin</td><td align=\"center\">30.8/8.7</td><td align=\"center\">0.022</td></tr><tr><td/><td/><td align=\"left\">C03EA01</td><td align=\"left\">Hydrochlorothiazide and potassium-sparing agents</td><td align=\"center\">25.0/8.7</td><td align=\"center\">0.009</td></tr><tr><td/><td/><td align=\"left\">C07AB02</td><td align=\"left\">Metoprolol</td><td align=\"center\">13.3/8.6</td><td align=\"center\">0.026</td></tr><tr><td/><td/><td align=\"left\">N03AF01</td><td align=\"left\">Carbamazepine</td><td align=\"center\">25.0/8.7</td><td align=\"center\">0.009</td></tr><tr><td/><td/><td align=\"left\">N05AN01</td><td align=\"left\">Lithium</td><td align=\"center\">33.3/8.7</td><td align=\"center\">0.017</td></tr><tr><td/><td/><td align=\"left\">N06AB05</td><td align=\"left\">Paroxetine</td><td align=\"center\">19.6/8.7</td><td align=\"center\">0.012</td></tr><tr><td/><td/><td align=\"left\">R03BA01</td><td align=\"left\">Beclometasone</td><td align=\"center\">28.6/8.7</td><td align=\"center\">0.029</td></tr></tbody></table></body></html>", "text": "Pmid= 3049147:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Independent predictors for constipation and diarrhoea</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Independent predictor</th><th align=\"center\" colspan=\"3\">OR</th></tr><tr><th/><th/><th colspan=\"3\"><hr/></th></tr><tr><th/><th/><th align=\"center\">Estimates</th><th align=\"center\">95% CI</th><th align=\"center\">p-value</th></tr></thead><tbody><tr><td align=\"left\">Constipation</td><td align=\"left\">Use of drug</td><td align=\"center\">1.30</td><td align=\"center\">1.06 to 1.59</td><td align=\"center\">0.012</td></tr><tr><td/><td align=\"left\">Gender (women)</td><td align=\"center\">3.24</td><td align=\"center\">2.61 to 4.02</td><td align=\"center\">&lt;0.001</td></tr><tr><td/><td align=\"left\">Age (years)</td><td align=\"center\">1.01</td><td align=\"center\">1.003 to 1.02</td><td align=\"center\">0.005</td></tr><tr><td/><td align=\"left\">BMI (body mass index)</td><td align=\"center\">0.95</td><td align=\"center\">0.93 to 0.97</td><td align=\"center\">&lt;0.001</td></tr><tr><td/><td align=\"left\">Frequency of use of alcohol</td><td align=\"center\">0.94</td><td align=\"center\">0.89 to 0.99</td><td align=\"center\">0.024</td></tr><tr><td/><td align=\"left\">Musculoskeletal complaints</td><td align=\"center\">1.04</td><td align=\"center\">1.002 to 1.09</td><td align=\"center\">0.042</td></tr><tr><td/><td align=\"left\">Angina pectoris</td><td align=\"center\">1.86</td><td align=\"center\">1.21 to 2.85</td><td align=\"center\">0.004</td></tr><tr><td/><td align=\"left\">Multiple sclerosis</td><td align=\"center\">2.41</td><td align=\"center\">1.03 to 5.66</td><td align=\"center\">0.043</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Diarrhoea</td><td align=\"left\">Use of drugs</td><td align=\"center\">1.37</td><td align=\"center\">1.08 to 1.74</td><td align=\"center\">0.011</td></tr><tr><td/><td align=\"left\">Gender (Women)</td><td align=\"center\">0.69</td><td align=\"center\">0.55 to 0.86</td><td align=\"center\">0.001</td></tr><tr><td/><td align=\"left\">Age (years)</td><td align=\"center\">0.999</td><td align=\"center\">0.99 to 1.01</td><td align=\"center\">0.824 (ns)</td></tr><tr><td/><td align=\"left\">Frequency of use of alcohol</td><td align=\"center\">1.10</td><td align=\"center\">1.03 to 1.17</td><td align=\"center\">0.006</td></tr><tr><td/><td align=\"left\">Years of education/schooling</td><td align=\"center\">0.96</td><td align=\"center\">0.93 to 0.995</td><td align=\"center\">0.023</td></tr><tr><td/><td align=\"left\">HSCL 10 (Mood disorders)</td><td align=\"center\">1.70</td><td align=\"center\">1.37 to 2.11</td><td align=\"center\">&lt;0.001</td></tr><tr><td/><td align=\"left\">Osteoporosis</td><td align=\"center\">2.20</td><td align=\"center\">1.21 to 3.97</td><td align=\"center\">0.009</td></tr></tbody></table></body></html>", "text": "Pmid= 3049147:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Number of drugs as predictors for constipation and diarrhoea</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Number of drugs</th><th align=\"center\" colspan=\"3\">OR</th></tr><tr><th/><th/><th colspan=\"3\"><hr/></th></tr><tr><th/><th/><th align=\"center\">Estimates</th><th align=\"center\">95% CI</th><th align=\"center\">p-value</th></tr></thead><tbody><tr><td align=\"left\">Constipation</td><td align=\"left\">None</td><td align=\"center\">1.00</td><td/><td/></tr><tr><td/><td align=\"left\">Using one drug</td><td align=\"center\">1.34</td><td align=\"center\">1.07 to 1.69</td><td align=\"center\">0.012</td></tr><tr><td/><td align=\"left\">Using two or three drugs</td><td align=\"center\">1.26</td><td align=\"center\">0.99 to 1.61</td><td align=\"center\">0.062</td></tr><tr><td/><td align=\"left\">Using four or more drugs</td><td align=\"center\">1.21</td><td align=\"center\">0.85 to 1.71</td><td align=\"center\">0.288</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Diarrhoea</td><td align=\"left\">None</td><td align=\"center\">1.00</td><td/><td/></tr><tr><td/><td align=\"left\">Using one drug</td><td align=\"center\">1.31</td><td align=\"center\">0.995 to 1.73</td><td align=\"center\">0.055</td></tr><tr><td/><td align=\"left\">Using two or three drugs</td><td align=\"center\">1.30</td><td align=\"center\">0.96 to 1.75</td><td align=\"center\">0.087</td></tr><tr><td/><td align=\"left\">Using four or more drugs</td><td align=\"center\">1.91</td><td align=\"center\">1.31 to 2.78</td><td align=\"center\">0.001</td></tr></tbody></table></body></html>", "text": "Pmid= 3049147:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Observed prevalence (in per cent) of constipation and diarrhoea in users and non-users of drugs, calculated prevalence if treatment is stopped or started, and changes of prevalence (average risk difference) with 95% CI when stopping and starting treatment (multivariable analyses, 4586 and 4268 cases available for the analyses of constipation and diarrhoea respectively)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Abdominal complaint</th><th align=\"left\">Predictor</th><th align=\"center\">Observed prevalence in nonusers</th><th align=\"center\">Calculated prevalence if starting treatment</th><th align=\"center\">Increased prevalence<break/>(95% CI)</th><th align=\"center\">Observed prevalence in users</th><th align=\"center\">Calculated prevalence if stopping treatment</th><th align=\"center\">Reduced prevalence<break/>(95% CI)</th></tr></thead><tbody><tr><td align=\"left\">Constipation</td><td align=\"left\">Use of drugs</td><td align=\"center\">10.2</td><td align=\"center\">12.7</td><td align=\"center\">2.5</td><td align=\"center\">15.9</td><td align=\"center\">12.8</td><td align=\"center\">3.0</td></tr><tr><td/><td/><td/><td/><td align=\"center\">(0.6 to 4.4)</td><td/><td/><td align=\"center\">(0.7 to 5.3)</td></tr><tr><td/><td align=\"left\">Furosemide</td><td align=\"center\">13.5</td><td align=\"center\">24.3</td><td align=\"center\">10.7</td><td align=\"center\">28.6</td><td align=\"center\">16.5</td><td align=\"center\">12.1</td></tr><tr><td/><td/><td/><td/><td align=\"center\">(0.0 to 21.5)</td><td/><td/><td align=\"center\">(0.6 to 23.6)</td></tr><tr><td/><td align=\"left\">Levothyroxine sodium</td><td align=\"center\">13.3</td><td align=\"center\">18.7</td><td align=\"center\">5.4</td><td align=\"center\">26.8</td><td align=\"center\">19.5</td><td align=\"center\">7.3</td></tr><tr><td/><td/><td/><td/><td align=\"center\">(-0.2 to 11.1)</td><td/><td/><td align=\"center\">(0.0 to 14.6)</td></tr><tr><td/><td align=\"left\">Ibuprofen</td><td align=\"center\">13.1</td><td align=\"center\">18.4</td><td align=\"center\">5.3</td><td align=\"center\">19.8</td><td align=\"center\">14.0</td><td align=\"center\">5.8</td></tr><tr><td/><td/><td/><td/><td align=\"center\">(1.6 to 9.1)</td><td/><td/><td align=\"center\">(1.7 to 9.8)</td></tr><tr><td align=\"left\">Diarrhoea</td><td align=\"left\">Use of drugs</td><td align=\"center\">7.1</td><td align=\"center\">9.5</td><td align=\"center\">2.3</td><td align=\"center\">10.2</td><td align=\"center\">7.7</td><td align=\"center\">2.5</td></tr><tr><td/><td/><td/><td/><td align=\"center\">(0.6 to 4.1)</td><td/><td/><td align=\"center\">(0.7 to 4.3)</td></tr><tr><td/><td align=\"left\">Lithium</td><td align=\"center\">8.9</td><td align=\"center\">36.2</td><td align=\"center\">27.2</td><td align=\"center\">36.4</td><td align=\"center\">8.9</td><td align=\"center\">27.5</td></tr><tr><td/><td/><td/><td/><td align=\"center\">(-0.7 to 55.1)</td><td/><td/><td align=\"center\">(-0.6 to 55.5)</td></tr><tr><td/><td align=\"left\">Carbamazepine</td><td align=\"center\">8.9</td><td align=\"center\">27.7</td><td align=\"center\">18.8</td><td align=\"center\">28.6</td><td align=\"center\">9.4</td><td align=\"center\">19.2</td></tr><tr><td/><td/><td/><td/><td align=\"center\">(-0.1 to 37.7)</td><td/><td/><td align=\"center\">(0.3 to 38.1)</td></tr></tbody></table></body></html>", "text": "Pmid= 3049147:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Child-Pugh classification of hepatic impairment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Points scored for observed findings</th></tr><tr><th/><th colspan=\"3\"><hr/></th></tr><tr><th/><th align=\"center\">1 point</th><th align=\"center\">2 points</th><th align=\"center\">3 points</th></tr></thead><tbody><tr><td align=\"left\">Encephalopathy grade*</td><td align=\"center\">Absent</td><td align=\"center\">1 or 2</td><td align=\"center\">3 or 4</td></tr><tr><td align=\"left\">Ascites</td><td align=\"center\">Absent</td><td align=\"center\">Slight</td><td align=\"center\">Moderate</td></tr><tr><td align=\"left\">Serum bilirubin (&#956;mol/L)</td><td align=\"center\">&lt;34.2</td><td align=\"center\">34.2-51.3</td><td align=\"center\">&gt;51.3</td></tr><tr><td align=\"left\">Serum albumin (g/L)</td><td align=\"center\">&gt;35</td><td align=\"center\">28-35</td><td align=\"center\">&lt;28</td></tr><tr><td align=\"left\">Prothrombin time (INR)</td><td align=\"center\">&lt;1.16</td><td align=\"center\">1.16-1.56</td><td align=\"center\">&gt;1.56</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"center\" colspan=\"4\"><bold>Classification</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Child-Pugh grade</td><td align=\"center\">Child-Pugh A</td><td align=\"center\">Child-Pugh B</td><td align=\"center\">Child-Pugh C</td></tr><tr><td align=\"left\">Points required</td><td align=\"center\">5-6</td><td align=\"center\">7-9</td><td align=\"center\">10-15</td></tr></tbody></table></body></html>", "text": "Pmid= 3070638:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Demographic and baseline characteristics for subjects in the hepatic and renal impairment studies</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\" colspan=\"3\">Degree of hepatic impairment</th><th/><th align=\"center\" colspan=\"3\">Degree of renal impairment</th></tr><tr><th/><th/><th colspan=\"3\"><hr/></th><th/><th colspan=\"3\"><hr/></th></tr><tr><th/><th align=\"center\">Normal hepatic function (n = 8)</th><th align=\"center\">Mild (n = 8)</th><th align=\"center\">Moderate (n = 8)</th><th align=\"center\">Severe (n = 8)</th><th align=\"center\">Normal renal function (n = 18)</th><th align=\"center\">Mild (n = 12)</th><th align=\"center\">Moderate (n = 9)</th><th align=\"center\">Severe (n = 9)</th></tr></thead><tbody><tr><td align=\"left\">Male, n (%)</td><td align=\"center\">5 (63)</td><td align=\"center\">6 (75)</td><td align=\"center\">5 (63)</td><td align=\"center\">5 (63)</td><td align=\"center\">13 (72)</td><td align=\"center\">9 (75)</td><td align=\"center\">7 (78)</td><td align=\"center\">7 (78)</td></tr><tr><td align=\"left\">Female, n (%)</td><td align=\"center\">3 (38)</td><td align=\"center\">2 (25)</td><td align=\"center\">3 (38)</td><td align=\"center\">3 (38)</td><td align=\"center\">5 (28)</td><td align=\"center\">3 (25)</td><td align=\"center\">2 (22)</td><td align=\"center\">2 (22)</td></tr><tr><td align=\"left\">Mean age, years (range)</td><td align=\"center\">58.4 (55-62)</td><td align=\"center\">56 (45-63)</td><td align=\"center\">59.3 (49-68)</td><td align=\"center\">52 (37-67)</td><td align=\"center\">60 (47-71)</td><td align=\"center\">58 (38-71)</td><td align=\"center\">60 (48-69)</td><td align=\"center\">57 (32-69)</td></tr></tbody></table></body></html>", "text": "Pmid= 3070638:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic parameters of zibotentan in subjects with normal renal function and varying degrees of renal impairment, normal hepatic function and varying degrees of hepatic impairment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\" colspan=\"3\">Degree of hepatic impairment</th><th/><th align=\"center\" colspan=\"3\">Degree of renal impairment</th></tr><tr><th/><th/><th colspan=\"3\"><hr/></th><th/><th colspan=\"3\"><hr/></th></tr><tr><th align=\"left\">PK parameter</th><th align=\"center\">Normal hepatic function (n = 8)</th><th align=\"center\">Mild (n = 8)</th><th align=\"center\">Moderate (n = 8)</th><th align=\"center\">Severe (n = 8)</th><th align=\"center\">Normal renal function (n = 18)</th><th align=\"center\">Mild (n = 12)</th><th align=\"center\">Moderate (n = 9)</th><th align=\"center\">Severe (n = 9)</th></tr></thead><tbody><tr><td align=\"left\">AUC<sub>(0-t) </sub>(ng&#183;h/mL)*</td><td align=\"center\">5460 (46.2)</td><td align=\"center\">7560 (65.1)</td><td align=\"center\">7850 (50.3)</td><td align=\"center\">15100 (49.8)</td><td align=\"center\">5560 (36.9)</td><td align=\"center\">6910 (57.5)</td><td align=\"center\">9090 (35.2)</td><td align=\"center\">9640 (37.7)</td></tr><tr><td align=\"left\">AUC (ng&#183;h/mL)*</td><td align=\"center\">5480 (46.0)</td><td align=\"center\">7680 (68.8)</td><td align=\"center\">7940 (50.7)</td><td align=\"center\">15900 (52.9)</td><td align=\"center\">5490 (39.0)<sup>$</sup></td><td align=\"center\">6950 (58.3)</td><td align=\"center\">8710 (3.8)<sup>&#163;</sup></td><td align=\"center\">9750 (38.8)</td></tr><tr><td align=\"left\">C<sub>max </sub>(ng/mL)*</td><td align=\"center\">566 (25.6)</td><td align=\"center\">526 (22.3)</td><td align=\"center\">505 (23.0)</td><td align=\"center\">536 (30.2)</td><td align=\"center\">545 (22.7)</td><td align=\"center\">531 (28.8)</td><td align=\"center\">550 (9.9)</td><td align=\"center\">619 (20.6)</td></tr><tr><td align=\"left\">t<sub>max </sub>(h)<sup>&#8224;</sup></td><td align=\"center\">2 (1-2)</td><td align=\"center\">2 (1-4)</td><td align=\"center\">2 (1-6)</td><td align=\"center\">2 (1-4)</td><td align=\"center\">1 (1-3)</td><td align=\"center\">1 (1-4)</td><td align=\"center\">2 (1-8)</td><td align=\"center\">1 (1-3)</td></tr><tr><td align=\"left\">t<sub>1/2 </sub>(h)<sup>&#8225;</sup></td><td align=\"center\">9.3 (3.6)</td><td align=\"center\">13.0 (9.4)</td><td align=\"center\">14.6 (6.5)</td><td align=\"center\">24.8 (10.9)</td><td align=\"center\">10.8 (2.7)<sup>$</sup></td><td align=\"center\">11.3 (4.0)</td><td align=\"center\">13.5 (4.3)<sup>&#163;</sup></td><td align=\"center\">13.2 (4.7)</td></tr><tr><td align=\"left\">CL/F (mL/min)<sup>&#8225;</sup></td><td align=\"center\">33.2 (15.6)</td><td align=\"center\">25.0 (12.1)</td><td align=\"center\">23.6 (14.2)</td><td align=\"center\">11.9 (7.3)</td><td align=\"center\">32.7 (14.2)<sup>$</sup></td><td align=\"center\">27.9 (18.9)</td><td align=\"center\">20.1 (6.5)<sup>&#163;</sup></td><td align=\"center\">18.2 (6.5)</td></tr><tr><td align=\"left\">V<sub>ss</sub>/F (L)<sup>&#8225;</sup></td><td align=\"center\">19.0 (6.1)</td><td align=\"center\">19.8 (3.1)</td><td align=\"center\">21.2 (7.2)</td><td align=\"center\">21.9 (7.1)</td><td align=\"center\">22.6 (7.0)<sup>$</sup></td><td align=\"center\">20.8 (5.8)</td><td align=\"center\">19.3 (2.0)<sup>&#163;</sup></td><td align=\"center\">17.8 (3.4)</td></tr><tr><td align=\"left\">Fu (%)<sup>&#8225;</sup></td><td align=\"center\">22.5 (7.5)</td><td align=\"center\">23.4 (4.0)</td><td align=\"center\">20.2 (4.8)</td><td align=\"center\">29.2 (9.4)</td><td align=\"center\">22.8 (6.2)</td><td align=\"center\">25.4 (6.7)</td><td align=\"center\">26.6 (2.9)</td><td align=\"center\">27.9 (5.3)</td></tr><tr><td align=\"left\">CL<sub>R </sub>(mL/min)<sup>&#8225;</sup></td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">17.4 (13.9)<sup>$</sup></td><td align=\"center\">10.3 (16.8)</td><td align=\"center\">3.2 (5.6)<sup>&#163;</sup></td><td align=\"center\">2.3 (2.7)<sup>&#163;</sup></td></tr><tr><td align=\"left\">Fe (%)<sup>&#8225;</sup></td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">47.2 (18.0)</td><td align=\"center\">27.1 (19.5)</td><td align=\"center\">12.7 (16.9)</td><td align=\"center\">10.5 (9.0)<sup>&#163;</sup></td></tr><tr><td align=\"left\">Free C<sub>max </sub>(ng/mL)*</td><td align=\"center\">121 (58.7)</td><td align=\"center\">123 (21.9)</td><td align=\"center\">97.3 (32.4)</td><td align=\"center\">149.2 (52.6)</td><td align=\"center\">121 (32.3)</td><td align=\"center\">131 (22.9)</td><td align=\"center\">145 (13.4)</td><td align=\"center\">170 (18.2)</td></tr><tr><td align=\"left\">Free AUC (ng&#183;h/mL)*</td><td align=\"center\">1170 (69.3)</td><td align=\"center\">1800 (54.7)</td><td align=\"center\">1460 (56.5)</td><td align=\"center\">4430 (40.0)</td><td align=\"center\">1230 (39.1)<sup>$</sup></td><td align=\"center\">1720 (60.6)</td><td align=\"center\">2260 (34.5)<sup>&#163;</sup></td><td align=\"center\">2680 (38.9)</td></tr><tr><td align=\"left\">Unbound CL/F (mL/min)<sup>&#8225;</sup></td><td align=\"center\">167 (98.4)</td><td align=\"center\">103 (46.8)</td><td align=\"center\">129 (69.8)</td><td align=\"center\">40 (14.7)</td><td align=\"center\">146 (67.3)<sup>$</sup></td><td align=\"center\">115 (83.8)</td><td align=\"center\">77.4 (24.1)<sup>&#163;</sup></td><td align=\"center\">65.8 (22.3)</td></tr></tbody></table></body></html>", "text": "Pmid= 3070638:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Ratios of pharmacokinetic parameters of zibotentan in subjects with varying degrees of renal impairment compared with subjects with normal renal function, and in subjects with varying degrees of hepatic impairment compared with subjects with normal hepatic function</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Degree of hepatic impairment*</th><th align=\"center\" colspan=\"3\"><bold>Degree of renal impairment</bold><sup><bold>&#8224;</bold></sup></th></tr><tr><th/><th colspan=\"6\"><hr/></th></tr><tr><th align=\"left\">PK parameter</th><th align=\"center\">Mild</th><th align=\"center\">Moderate</th><th align=\"center\">Severe</th><th align=\"center\">Mild</th><th align=\"center\">Moderate</th><th align=\"center\">Severe</th></tr></thead><tbody><tr><td align=\"left\">C<sub>max </sub>ratio (90% CI)</td><td align=\"center\">0.93 (0.75-1.15)</td><td align=\"center\">0.89 (0.72-1.10)</td><td align=\"center\">0.95 (0.77-1.17)</td><td align=\"center\">1.07 (0.97-1.19)</td><td align=\"center\">1.09 (0.96-1.24)</td><td align=\"center\">1.12 (0.96-1.30)</td></tr><tr><td align=\"left\">AUC ratio (90% CI)</td><td align=\"center\">1.40 (0.91-2.17)</td><td align=\"center\">1.45 (0.94-2.24)</td><td align=\"center\">2.90 (1.88-4.49)</td><td align=\"center\">1.66 (1.38-1.99)</td><td align=\"center\">1.89 (1.50-2.39)</td><td align=\"center\">2.17 (1.64-2.86)</td></tr><tr><td align=\"left\">t<sub>1/2 </sub>difference, h (90% CI)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">1.87 (0.06-3.68)**</td><td align=\"center\">2.37 (0.08-4.66)**</td><td align=\"center\">2.87 (0.1-5.64)**</td></tr></tbody></table></body></html>", "text": "Pmid= 3070638:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>AEs reported in >1 subject with normal hepatic function and varying degrees of hepatic impairment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\" colspan=\"3\">Degree of hepatic impairment</th></tr><tr><th/><th/><th colspan=\"3\"><hr/></th></tr><tr><th align=\"left\">Adverse event, n (%)</th><th align=\"center\">Normal hepatic function (n = 8)</th><th align=\"center\">Mild (n = 8)</th><th align=\"center\">Moderate (n = 8)</th><th align=\"center\">Severe (n = 8)</th></tr></thead><tbody><tr><td align=\"left\">Any AE</td><td align=\"center\">1 (13)</td><td align=\"center\">1 (13)</td><td align=\"center\">3 (38)</td><td align=\"center\">4 (50)</td></tr><tr><td align=\"left\">Headache</td><td align=\"center\">1 (13)</td><td align=\"center\">1 (13)</td><td align=\"center\">2 (25)</td><td align=\"center\">3 (38)</td></tr><tr><td align=\"left\">Vomiting</td><td align=\"center\">1 (13)</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1 (13)</td></tr></tbody></table></body></html>", "text": "Pmid= 3070638:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>AEs reported in >1 subject with normal renal function and varying degrees of renal impairment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\" colspan=\"3\">Degree of renal impairment</th></tr><tr><th align=\"left\">Adverse event, n (%)</th><th align=\"center\">Normal renal function (n = 18)</th><th align=\"center\">Mild (n = 12)</th><th align=\"center\">Moderate (n = 9)</th><th align=\"center\">Severe (n = 9)</th></tr></thead><tbody><tr><td align=\"left\">Any AE</td><td align=\"center\">14 (78)</td><td align=\"center\">7 (58)</td><td align=\"center\">8 (89)</td><td align=\"center\">7 (78)</td></tr><tr><td align=\"left\">Headache</td><td align=\"center\">14 (78)</td><td align=\"center\">6 (50)</td><td align=\"center\">5 (56)</td><td align=\"center\">4 (44)</td></tr><tr><td align=\"left\">Nasopharyngitis</td><td align=\"center\">1 (6)</td><td align=\"center\">1 (8)</td><td align=\"center\">2 (22)</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Fatigue</td><td align=\"center\">0</td><td align=\"center\">1 (8)</td><td align=\"center\">1 (11)</td><td align=\"center\">2 (22)</td></tr><tr><td align=\"left\">Somnolence</td><td align=\"center\">2 (11)</td><td align=\"center\">1 (8)</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Nausea</td><td align=\"center\">1 (6)</td><td align=\"center\">1 (8)</td><td align=\"center\">0</td><td align=\"center\">1 (11)</td></tr><tr><td align=\"left\">Neck pain</td><td align=\"center\">0</td><td align=\"center\">2 (17)</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Back pain</td><td align=\"center\">1 (6)</td><td align=\"center\">1 (8)</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Dizziness</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">2 (22)</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Dyspepsia</td><td align=\"center\">1 (6)</td><td align=\"center\">0</td><td align=\"center\">0</td><td align=\"center\">1 (11)</td></tr></tbody></table></body></html>", "text": "Pmid= 3070638:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Description of the nine pharmacists' practices.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" colspan=\"2\">Dimension 1: Screening and chronic disease management</th></tr></thead><tbody><tr><td align=\"left\"><bold>The pharmaceutical consultation</bold></td><td align=\"left\">Individual interview in a confidential area to inform and counsel the patient by explaining the treatment, its side effects, and drug interactions, and any follow-up to be adopted.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Therapeutic education</bold></td><td align=\"left\">Practical tools for the patient to acquire skills to manage their disease and its care and supervision in partnership with health-care providers.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>The pharmacist as a coordinator of care</bold></td><td align=\"left\">A protocol allowing the community pharmacist, chosen by the patient, to periodically renew chronic treatments, adjust dosage (if necessary), and make medication-use reviews (side effects, observance, follow-up) at a doctor\\'s request or with his consent.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Screening</bold></td><td align=\"left\">Offering screening procedures for certain ailments to patients using easily administered tests such as blood pressure, expiratory flow rate, and blood-sugar levels.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\"><bold>Dimension 2: Medication surveillance</bold></td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>The electronic pharmaceutical record (e-pr)</bold></td><td align=\"left\">Making an electronic file for each patient containing all drugs dispensed to the patient during the last four months for his or her own personal consumption, with or without medical prescription, in any pharmacy that is equipped for such recording.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>The pharmaceutical opinion</bold></td><td align=\"left\">A professional opinion, under the pharmacist\\'s authority, on the pharmaceutical appropriateness of one or a series of treatments to be dispensed by the pharmacist. This is to be communicated on a standardized form to the prescriber of the medication and/or to the patient when the pharmacist recommends a revision or to justify his refusal to dispense a medication as prescribed.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\"><bold>Dimension 3: Pharmacy-prescribed medication</bold></td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Prescription for minor ailments</bold></td><td align=\"left\">Dispensing certain medications without a medical prescription or advising patients to consult a doctor, following appropriate questioning of the patient to determine the gravity of the symptoms of his or her ailment.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Sales of over-the-counter drugs</bold></td><td align=\"left\">Direct public access to medications referred to as \"pharmaceutical products\" in specific, clearly identified locations in very close proximity to where medications are dispensed, and providing the public with information from respected health-care authorities relative to the appropriate use of these products.</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\"><bold>Dimension 4: Participation in health-care networks</bold></td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Pharmacotherapeutic consultation groups</bold></td><td align=\"left\">Group discussions with GPs and/or other specialists to discuss the clinical situation of patients for whom they jointly provide care, such as in the framework of health-care networks.</td></tr></tbody></table></body></html>", "text": "Pmid= 3115856:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Demographic and clinical characteristics of patients identified in the French PharmacoVigilance Database with type 2 diabetes.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\"><italic>Total population N = 2295 (%)</italic></th><th align=\"left\"><italic>TZD exposed N = 161 (%)</italic></th><th align=\"left\"><italic>TZD not exposed N = 2134 (%)</italic></th></tr></thead><tbody><tr><td align=\"left\"><bold>Age </bold>(years)</td><td align=\"left\">67.2 (13.4)<break/>[19-97]</td><td align=\"left\">63.3 (14.2)****<break/>[32-87]</td><td align=\"left\">67.5 (13.8)<break/>[19-97]</td></tr><tr><td align=\"left\"><bold>Gender </bold>(men)</td><td align=\"left\">1155 (49.7)</td><td align=\"left\">92 (57.1)</td><td align=\"left\">1063 (49.8)</td></tr><tr><td align=\"left\"><bold>Cardiovascular comorbidities</bold></td><td/><td/><td/></tr><tr><td align=\"left\">Cardiac arrhythmia</td><td align=\"left\">128 (5.58)</td><td align=\"left\">8 (5)</td><td align=\"left\">120 (5.6)</td></tr><tr><td align=\"left\">Cardiac insufficiency</td><td align=\"left\">248 (10.81)</td><td align=\"left\">9 (<italic>5.6)*</italic></td><td align=\"left\">239 (<italic>11.2)</italic></td></tr><tr><td align=\"left\">Hypertension</td><td align=\"left\">596 (25.97)</td><td align=\"left\">33 (<italic>20.5)</italic></td><td align=\"left\">563 (<italic>26.4)</italic></td></tr><tr><td align=\"left\">Metabolic disorders</td><td align=\"left\">621 (27.06)</td><td align=\"left\">30 (18.7)*</td><td align=\"left\">591 (27.7)</td></tr><tr><td align=\"left\">Angina pectoris</td><td align=\"left\">154 (6.71)</td><td align=\"left\">6 (<italic>3.7)</italic></td><td align=\"left\">148 (<italic>6.9)</italic></td></tr><tr><td align=\"left\">Atherosclerosis</td><td align=\"left\">6 (0.26)</td><td align=\"left\">0 (0)</td><td align=\"left\">6 (0.28)</td></tr><tr><td align=\"left\">Obesity</td><td align=\"left\">76 (3.31)</td><td align=\"left\">10 (6.2)*</td><td align=\"left\">66 (3.1)</td></tr><tr><td align=\"left\">Heart valve disorders</td><td align=\"left\">7 (0.31)</td><td align=\"left\">1 (0.6)</td><td align=\"left\">6 (0.28)</td></tr><tr><td align=\"left\">Renal disorders</td><td align=\"left\">62 (2.7)</td><td align=\"left\">2 (1.2)</td><td align=\"left\">60 (2.8)</td></tr><tr><td align=\"left\"><bold>Drugs used for type 2 diabetes</bold></td><td/><td/><td/></tr><tr><td align=\"left\">Sulfamides</td><td align=\"left\">1227 (53.46)</td><td align=\"left\">44 (27.33)****</td><td align=\"left\">1183 (55.43)</td></tr><tr><td align=\"left\">Alpha glucosidase inhibitor</td><td align=\"left\">207 (9.02)</td><td align=\"left\">4 (2.48)**</td><td align=\"left\">203 (9.5)</td></tr><tr><td align=\"left\">Glinides</td><td align=\"left\">192 (8.37)</td><td align=\"left\">6 (3.7)*</td><td align=\"left\">186 (8.7)</td></tr><tr><td align=\"left\">Metformin</td><td align=\"left\">900 (39.22)</td><td align=\"left\">58(36)</td><td align=\"left\">842 (39.5)</td></tr><tr><td align=\"left\">Benfluorex</td><td align=\"left\">227 (9.89)</td><td align=\"left\">4 (2.5)**</td><td align=\"left\">223 (10.45)</td></tr><tr><td align=\"left\">Insulin</td><td align=\"left\">115 (5.01)</td><td align=\"left\">4 (2.94)</td><td align=\"left\">111 (5.20)</td></tr><tr><td align=\"left\"><bold>Cardiovascular drugs</bold></td><td/><td/><td/></tr><tr><td align=\"left\">Diuretics</td><td align=\"left\">627 (27.32)</td><td align=\"left\">34 (21.1)</td><td align=\"left\">593 (27.7)</td></tr><tr><td align=\"left\">ACE inhibitors</td><td align=\"left\">456 (19.87)</td><td align=\"left\">20 (12.4)*</td><td align=\"left\">436 (20.4)</td></tr><tr><td align=\"left\">Angiotensin II inhibitors</td><td align=\"left\">339 (14.77)</td><td align=\"left\">23 (14.3)</td><td align=\"left\">316 (14.8)</td></tr><tr><td align=\"left\">Digitalics</td><td align=\"left\">105 (4.58)</td><td align=\"left\">3 (1.9)</td><td align=\"left\">102 (4.8)</td></tr><tr><td align=\"left\">Betablockers</td><td align=\"left\">300 (13.07)</td><td align=\"left\">9 (5.6)**</td><td align=\"left\">291 (13.6)</td></tr><tr><td align=\"left\">Calcium inhibitors</td><td align=\"left\">321 (13.99)</td><td align=\"left\">16 (9.94)</td><td align=\"left\">305 (14.3)</td></tr><tr><td align=\"left\">Trinitrin</td><td align=\"left\">48 (2.09)</td><td align=\"left\">3 (1.9)</td><td align=\"left\">45 (2.1)</td></tr><tr><td align=\"left\">Amiodarone</td><td align=\"left\">103 (4.49)</td><td align=\"left\">2 (1.24)*</td><td align=\"left\">101 (4.73)</td></tr><tr><td align=\"left\">Central antihypertensive drugs</td><td align=\"left\">73 (3.18)</td><td align=\"left\">5 (3.1)</td><td align=\"left\">68 (3.2)</td></tr><tr><td align=\"left\">Antiarrythmia drugs</td><td align=\"left\">25 (1.09)</td><td align=\"left\">1 (0.6)</td><td align=\"left\">24 (1.12)</td></tr><tr><td align=\"left\"><bold>Other drugs</bold></td><td/><td/><td/></tr><tr><td align=\"left\">Steroidal and Non Steroidal Anti-Inflammatory Drugs</td><td align=\"left\">232 (10.1)</td><td align=\"left\">8 (4.96)*</td><td align=\"left\">224 (10.5)</td></tr><tr><td align=\"left\">Statins</td><td align=\"left\">403 (17.56)</td><td align=\"left\">17 (10.6)*</td><td align=\"left\">386 (16.8)</td></tr><tr><td align=\"left\">Fibrates</td><td align=\"left\">142 (6.19)</td><td align=\"left\">7 (4.35</td><td align=\"left\">135 (6.3)</td></tr></tbody></table></body></html>", "text": "Pmid= 3119167:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Number and percentage of adverse drug reactions reported in the 161 patients exposed to thiazolidinediones in the French PharmacoVigilance database from 2002 to 2006.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">System Organ Classification terms</th><th align=\"left\">Number of patients (%)</th></tr></thead><tbody><tr><td align=\"left\">Body as a whole - general disorders 1810</td><td align=\"left\">69 (42.8)</td></tr><tr><td align=\"left\">Metabolic and nutritional disorders 0800</td><td align=\"left\">64 (39.7)</td></tr><tr><td align=\"left\">Cardiovascular disorders, general 1010; Myo-, endo-, pericardial &amp; valve disorders 1020; Heart rate and rhythm disorders 1030</td><td align=\"left\">42 (26.1)</td></tr><tr><td align=\"left\">Skin and appendages disorders 0100</td><td align=\"left\">35 (21.7)</td></tr><tr><td align=\"left\">Central &amp; peripheral nervous system disorders 0410</td><td align=\"left\">33 (20.5)</td></tr><tr><td align=\"left\">Red blood cell disorders 1210; White cell and reticulo-endotelial system disorders 1220; Platelet, bleeding &amp; clotting disorders 1230</td><td align=\"left\">26 (16.1)</td></tr><tr><td align=\"left\">Gastro-intestinal system disorders 0600</td><td align=\"left\">21 (13.0)</td></tr><tr><td align=\"left\">Liver and biliary system disorders 0700</td><td align=\"left\">15 (9.3)</td></tr><tr><td align=\"left\">Psychiatric disorders 0500</td><td align=\"left\">13 (8.1)</td></tr><tr><td align=\"left\">Respiratory system disorders 1100</td><td align=\"left\">11 (6.8)</td></tr><tr><td align=\"left\">Urinary system disorders 1300</td><td align=\"left\">7 (4.3)</td></tr><tr><td align=\"left\">Vascular (extra-cardiac) disorders 1040</td><td align=\"left\">6 (3.7)</td></tr><tr><td align=\"left\">Vision disorders 0431; Hearing and vestibular disorders 0432; Special senses other, disorders 0433</td><td align=\"left\">5 (3.1)</td></tr><tr><td align=\"left\">Endocrine disorders 0900</td><td align=\"left\">4 (2.5)</td></tr><tr><td align=\"left\">Immune system</td><td align=\"left\">3 (1.9)</td></tr><tr><td align=\"left\">Muscular-skeletal system disorders 0200</td><td align=\"left\">2 (1.2)</td></tr><tr><td align=\"left\">Fetal disorders 1500</td><td align=\"left\">2 (1.2)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Total number of adverse drug reactions</td><td align=\"left\">358</td></tr></tbody></table></body></html>", "text": "Pmid= 3119167:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Results of the multiple logistic regression models concerning the association between TZD exposure and 4 ADRs: Heart Failure, Myocardial Infarction, Edema and Hepatitis.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Heart failure</th><th align=\"left\">Odds ratio</th><th align=\"left\">(95% CI)</th><th align=\"left\">P</th></tr></thead><tbody><tr><td align=\"left\">Age</td><td align=\"left\">1.04</td><td align=\"left\">(0.99 - 1.09)</td><td align=\"left\">0.0705</td></tr><tr><td align=\"left\"><bold>Obesity</bold></td><td align=\"left\"><bold>5.69</bold></td><td align=\"left\"><bold>(1.34 - 24.20)</bold></td><td align=\"left\"><bold>0.0185</bold></td></tr><tr><td align=\"left\"><bold>Thiazolidinediones</bold></td><td align=\"left\"><bold>65.39</bold></td><td align=\"left\"><bold>(17.678 - 241.93)</bold></td><td align=\"left\"><bold>&lt;0.0001</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><italic>Hosmer and Lemeshow procedure </italic></td><td align=\"left\"><italic>0.32</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Myocardial infarction</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Age</td><td align=\"left\">0.97</td><td align=\"left\">(0.95 - 1.00)</td><td align=\"left\">0.1076</td></tr><tr><td align=\"left\">Gender</td><td align=\"left\">1.73</td><td align=\"left\">(0.78 - 3.84)</td><td align=\"left\">0.1727</td></tr><tr><td align=\"left\">Thiazolidinediones</td><td align=\"left\">0.42</td><td align=\"left\">(0.05 - 3.17)</td><td align=\"left\">0.4039</td></tr><tr><td align=\"left\"><bold>Heart valve disorders</bold></td><td align=\"left\"><bold>25.95</bold></td><td align=\"left\"><bold>(2.63 - 255.47)</bold></td><td align=\"left\"><bold>0.0053</bold></td></tr><tr><td align=\"left\">Hypertension</td><td align=\"left\">0.34</td><td align=\"left\">(0.09 - 1.19)</td><td align=\"left\">0.0929</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><italic>Hosmer and Lemeshow procedure </italic></td><td align=\"left\"><italic>0.8254</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Edema</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Obesity</td><td align=\"left\">1.89</td><td align=\"left\">(0.58 - 6.17)</td><td align=\"left\">0.2863</td></tr><tr><td align=\"left\"><bold>Thiazolidinediones</bold></td><td align=\"left\"><bold>25.09</bold></td><td align=\"left\"><bold>(13.50 - 46.63)</bold></td><td align=\"left\"><bold>&lt;0.0001</bold></td></tr><tr><td align=\"left\">Biguanides</td><td align=\"left\">0.42</td><td align=\"left\">(0.20 - 0.87)</td><td align=\"left\">0.02</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><italic>Hosmer and Lemeshow procedure </italic></td><td align=\"left\"><italic>0.8043</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Hepatitis</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Age</td><td align=\"left\">0.99</td><td align=\"left\">(0.97 - 1.00)</td><td align=\"left\">0.1167</td></tr><tr><td align=\"left\">Angina pectoris</td><td align=\"left\">0.43</td><td align=\"left\">(0.13 - 1.39)</td><td align=\"left\">0.1620</td></tr><tr><td align=\"left\">Cardiac arrhythmia</td><td align=\"left\">0.36</td><td align=\"left\">(0.08 - 1.52)</td><td align=\"left\">0.1686</td></tr><tr><td align=\"left\">Cardiac insufficiency</td><td align=\"left\">0.58</td><td align=\"left\">(0.25 - 1.37)</td><td align=\"left\">0.2217</td></tr><tr><td align=\"left\">Thiazolidinediones</td><td align=\"left\">0.84</td><td align=\"left\">(0.40 - 1.78)</td><td align=\"left\">0.6645</td></tr><tr><td align=\"left\"><bold>Non Steroidal Anti-Inflammatory Drugs</bold></td><td align=\"left\"><bold>1.85</bold></td><td align=\"left\"><bold>(1.13 - 3.01)</bold></td><td align=\"left\"><bold>0.0134</bold></td></tr><tr><td align=\"left\">Diuretics</td><td align=\"left\">0.58</td><td align=\"left\">(0.32 - 1.06)</td><td align=\"left\">0.0796</td></tr><tr><td align=\"left\">Calcium inhibitors</td><td align=\"left\">0.63</td><td align=\"left\">(0.32 -1.23)</td><td align=\"left\">0.1798</td></tr><tr><td align=\"left\">Angiotensin II inhibitors</td><td align=\"left\">0.68</td><td align=\"left\">(0.35 - 1.32)</td><td align=\"left\">0.2804</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><italic>Hosmer and Lemeshow procedure </italic></td><td align=\"left\"><italic>0.4397</italic></td></tr></tbody></table></body></html>", "text": "Pmid= 3119167:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Patient characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">CHF<break/>n = 82 018</th><th align=\"center\">CHF using spironolactone<break/>n = 12,344</th></tr></thead><tbody><tr><td align=\"left\">Age group</td><td/><td/></tr><tr><td align=\"left\">&#8195;&lt;20</td><td align=\"center\">518 (0.6%)</td><td align=\"center\">11 (0.1%)</td></tr><tr><td align=\"left\">&#8195;20-39</td><td align=\"center\">1,366 (1.7%)</td><td align=\"center\">62 (0.5%)</td></tr><tr><td align=\"left\">&#8195;40-59</td><td align=\"center\">6,114 (7.5%)</td><td align=\"center\">716 (5.8%)</td></tr><tr><td align=\"left\">&#8195;60-79</td><td align=\"center\">31,499 (38.4%)</td><td align=\"center\">5,093 (41.3%)</td></tr><tr><td align=\"left\">&#8195;80+</td><td align=\"center\">42,521 (51.8%)</td><td align=\"center\">6,462 (52.3%)</td></tr><tr><td align=\"left\">Average age (SD)</td><td align=\"center\">77.2 (14.1)</td><td align=\"center\">78.5 (11.4)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Gender</td><td/><td/></tr><tr><td align=\"left\">&#8195;- male</td><td align=\"center\">39,132 (47.7%)</td><td align=\"center\">6,368 (51.6%)</td></tr><tr><td align=\"left\">&#8195;- Female</td><td align=\"center\">42,886 (52.3%)</td><td align=\"center\">5,976 (48.4%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Average Von Korff score (SD)</td><td align=\"center\">7.6 (3.4)</td><td align=\"center\">8.8 (2.9)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Selected drug use</td><td/><td/></tr><tr><td align=\"left\">&#8195;- ACE</td><td align=\"center\">49,140 (59.9%)</td><td align=\"center\">9,493 (76.9%)</td></tr><tr><td align=\"left\">&#8195;- ARB</td><td align=\"center\">23,326 (28.4%)</td><td align=\"center\">4,455 (36.1%)</td></tr><tr><td align=\"left\">&#8195;- &#946;-blocker</td><td align=\"center\">48,772 (59.5%)</td><td align=\"center\">9,260 (75.0%)</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Concomitant use with</td><td/><td/></tr><tr><td align=\"left\">&#8195;- ACE</td><td/><td align=\"center\">6,702 (54.3%)</td></tr><tr><td align=\"left\">&#8195;- ARB</td><td/><td align=\"center\">2,654 (21.5%)</td></tr><tr><td align=\"left\">&#8195;- &#946;-blocker</td><td/><td align=\"center\">7,217 (58.5%)</td></tr></tbody></table></body></html>", "text": "Pmid= 3121672:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Incidence of adverse events</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Spironolactone users</th><th align=\"center\">Spironolactone non-users</th></tr></thead><tbody><tr><td align=\"left\">Hyperkalemia</td><td align=\"center\">408/12,344<break/>(3.3%)</td><td align=\"center\">955/69,674<break/>(1.4%)*</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Breast complications in men</td><td align=\"center\">158/6,368<break/>(2.5%)</td><td align=\"center\">380/32,764<break/>(1.2%)*</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Breast hypertrophy in men (gynecomastia)</td><td align=\"center\">117/6,368<break/>(1.8%)</td><td align=\"center\">233/32,764<break/>(0.7%)*</td></tr></tbody></table></body></html>", "text": "Pmid= 3121672:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Treatment compliance</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Compliance</th></tr><tr><th/><th colspan=\"2\"><hr/></th></tr><tr><th/><th align=\"center\">50%</th><th align=\"center\">80%</th></tr></thead><tbody><tr><td align=\"left\">ACE</td><td align=\"center\">66.4%</td><td align=\"center\">56.1%</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">ARB</td><td align=\"center\">68.1%</td><td align=\"center\">57.0%</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">&#946;-blockers</td><td align=\"center\">71.1%</td><td align=\"center\">59.7%</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Spironolactone</td><td align=\"center\">58.4%*</td><td align=\"center\">45.6%*</td></tr></tbody></table></body></html>", "text": "Pmid= 3121672:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Treatment persistence</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Persistence</th></tr><tr><th/><th colspan=\"3\"><hr/></th></tr><tr><th/><th align=\"center\">3 months</th><th align=\"center\">6 months</th><th align=\"center\">12 months</th></tr></thead><tbody><tr><td align=\"left\">ACE</td><td align=\"center\">83.6%</td><td align=\"center\">75.3%</td><td align=\"center\">64.5%</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">ARB</td><td align=\"center\">84.8%</td><td align=\"center\">77.5%</td><td align=\"center\">66.3%</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#946;-blockers</td><td align=\"center\">86.3%</td><td align=\"center\">80.0%</td><td align=\"center\">70.4%</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Spironolactone</td><td align=\"center\">76.3%*</td><td align=\"center\">65.3%*</td><td align=\"center\">50.7%*</td></tr></tbody></table></body></html>", "text": "Pmid= 3121672:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Subject demographics for the study population (all enrolled subjects)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Characteristic</th><th align=\"center\">Regimen A (n = 12)</th><th align=\"center\">Regimen B (n = 15)</th></tr></thead><tbody><tr><td align=\"left\">Male, n (%)</td><td align=\"center\">12 (100)</td><td align=\"center\">15 (100)</td></tr><tr><td align=\"left\">Caucasian, n (%)</td><td align=\"center\">12 (100)</td><td align=\"center\">15 (100)</td></tr><tr><td align=\"left\">Age, years (median [range])</td><td align=\"center\">33 (25-44)</td><td align=\"center\">33 (21-44)</td></tr><tr><td align=\"left\">Body height, cm (median [range])</td><td align=\"center\">184 (169-192)</td><td align=\"center\">180 (168-185)</td></tr><tr><td align=\"left\">Body weight, kg (median [range])</td><td align=\"center\">83 (66-95)</td><td align=\"center\">75 (61-97)</td></tr><tr><td align=\"left\">Body mass index, kg/m<sup>2 </sup>(median [range])</td><td align=\"center\">25 (23-28)</td><td align=\"center\">24 (21-30)</td></tr><tr><td align=\"left\">Smoking status, n</td><td/><td/></tr><tr><td align=\"left\">&#8195;Ex-smoker</td><td align=\"center\">2</td><td align=\"center\">4</td></tr><tr><td align=\"left\">&#8195;Current</td><td align=\"center\">3</td><td align=\"center\">6</td></tr><tr><td align=\"left\">&#8195;Never</td><td align=\"center\">7</td><td align=\"center\">5</td></tr></tbody></table></body></html>", "text": "Pmid= 3127977:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Geometric means (68% inter-percentile range) of the main pharmacokinetic variables for roflumilast and roflumilast N-oxide at steady state</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Regimen A</th><th align=\"center\">Regimen B</th></tr></thead><tbody><tr><td/><td align=\"center\"><bold>Day 11 (roflumilast alone)</bold><break/><bold>(n = 12)</bold></td><td align=\"center\"><bold>Day 18 (roflumilast plus formoterol)</bold><break/><bold>(n = 12)</bold></td><td align=\"center\"><bold>Day 18 (formoterol plus roflumilast)</bold><break/><bold>(n = 12)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Roflumilast</bold></td><td/><td/><td/></tr><tr><td align=\"left\">C <sub>trough</sub> (&#956;g/L)</td><td align=\"center\">0.53 (0.33-0.85)</td><td align=\"center\">0.50 (0.29-0.86)</td><td align=\"center\">0.37 (0.18-0.77)</td></tr><tr><td align=\"left\">C<sub>max </sub>(&#956;g/L)</td><td align=\"center\">6.89 (4.94-9.62)</td><td align=\"center\">6.43 (4.79-8.63)</td><td align=\"center\">5.92 (4.27-8.22)</td></tr><tr><td align=\"left\">AUC<sub>&#964; </sub>(&#956;g.h/L)</td><td align=\"center\">35.8 (27.8-46.1)</td><td align=\"center\">36.9 (28.1-48.4)</td><td align=\"center\">31.8 (21.2-47.7)</td></tr><tr><td align=\"left\">CL/F (L/h)</td><td align=\"center\">13.9 (10.8-17.9)</td><td align=\"center\">13.5 (10.3-17.7)</td><td align=\"center\">15.7 (10.4-23.5)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Roflumilast N-oxide</bold></td><td/><td/><td/></tr><tr><td align=\"left\">C <sub>trough</sub> (&#956;g/L)</td><td align=\"center\">12.43 (8.24-18.76)</td><td align=\"center\">12.72 (8.18-19.79)</td><td align=\"center\">10.66 (6.29-18.06)</td></tr><tr><td align=\"left\">AUC<sub>&#964; </sub>(&#956;g.h/L)</td><td align=\"center\">417 (299-582)</td><td align=\"center\">414 (293-584)</td><td align=\"center\">369 (254-537)</td></tr><tr><td align=\"left\">C<sub>max </sub>(&#956;g/L)</td><td align=\"center\">23.3 (17.3-31.3)</td><td align=\"center\">23.7 (17.2-32.6)</td><td align=\"center\">22.04 (15.9-30.5)</td></tr></tbody></table></body></html>", "text": "Pmid= 3127977:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Geometric means (68% inter-percentile range) of the main pharmacokinetic variables for formoterol at steady state</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Regimen B</th><th align=\"center\">Regimen A</th></tr></thead><tbody><tr><td/><td align=\"center\"><bold>Day 8 (formoterol alone)</bold><break/><bold>(n = 13)</bold></td><td align=\"center\"><bold>Day 18 (formoterol plus roflumilast)</bold><break/><bold>(n = 12)</bold></td><td align=\"center\"><bold>Day 18 (roflumilast plus formoterol)</bold><break/><bold>(n = 12)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Formoterol</bold></td><td/><td/><td/></tr><tr><td align=\"left\">C<sub>trough </sub>(&#956;g/L)</td><td align=\"center\">4.12 (3.05-5.57)</td><td align=\"center\">3.94 (3.13-4.96)</td><td align=\"center\">4.23 (2.43-7.38)</td></tr><tr><td align=\"left\">C<sub>max </sub>(&#956;g/L)</td><td align=\"center\">16.7 (11.5-24.3)</td><td align=\"center\">17.2 (12.3-24.1)</td><td align=\"center\">18.7 (14.3-24.6)</td></tr><tr><td align=\"left\">AUC<sub>&#964; </sub>(&#956;g.h/L)</td><td align=\"center\">96.7 (72.8-128)</td><td align=\"center\">93.1 (72.7-119)</td><td align=\"center\">93.2 (72.9-119)</td></tr></tbody></table></body></html>", "text": "Pmid= 3127977:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacodynamic measures - Regimen A: treatment medians and treatment contrasts</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" colspan=\"9\">Untransformed pre-dose morning values</th></tr></thead><tbody><tr><td/><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\" colspan=\"5\"><bold>Point estimate (95% CI)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Variable</bold></td><td align=\"center\"><bold>Day 1</bold></td><td align=\"center\"><bold>Day 11 (R)</bold></td><td align=\"center\"><bold>Day 18 (R+F)</bold></td><td align=\"center\"><bold>Day 11-Day 1</bold></td><td align=\"center\" colspan=\"2\"><bold>Day 18-Day 11</bold></td><td align=\"center\" colspan=\"2\"><bold>Day 18-Day 1</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">HR (bpm)</td><td align=\"center\">59</td><td align=\"center\">63</td><td align=\"center\">61</td><td align=\"center\">3 (-5 to 8)</td><td align=\"center\" colspan=\"2\">1 (-1 to 6)</td><td align=\"center\" colspan=\"2\">5 (-2 to 10)</td></tr><tr><td align=\"left\">PEP (ms)</td><td align=\"center\">106</td><td align=\"center\">94</td><td align=\"center\">95</td><td align=\"center\">-3 (-17 to 10)</td><td align=\"center\" colspan=\"2\">-4 (-13 to 6)</td><td align=\"center\" colspan=\"2\">-8 (-19 to 6)</td></tr><tr><td align=\"left\">QS2 (ms)</td><td align=\"center\">435</td><td align=\"center\">423</td><td align=\"center\">430</td><td align=\"center\">-10 (-21 to 2)</td><td align=\"center\" colspan=\"2\">-1 (-14 to 12)</td><td align=\"center\" colspan=\"2\">-12 (-23 to 4)</td></tr><tr><td align=\"left\">dZ/dt (&#937;/s)</td><td align=\"center\">1.82</td><td align=\"center\">1.67</td><td align=\"center\">1.77</td><td align=\"center\">-0.06 (-0.29 to 0.16)</td><td align=\"center\" colspan=\"2\">0.03 (-0.08 to 0.12)</td><td align=\"center\" colspan=\"2\">-0.05 (-0.26 to 0.15)</td></tr><tr><td align=\"left\">CO (L/min)</td><td align=\"center\">10.4</td><td align=\"center\">9.1</td><td align=\"center\">10.4</td><td align=\"center\">-0.6 (-1.7 to 0.5)</td><td align=\"center\" colspan=\"2\">0.1 (-1.0 to 1.7)</td><td align=\"center\" colspan=\"2\">-0.3 (-1.0 to 0.6)</td></tr><tr><td align=\"left\">TPR (dyn.s.cm<sup>-5</sup>)</td><td align=\"center\">755</td><td align=\"center\">838</td><td align=\"center\">706</td><td align=\"center\">14 (-98 to 121)</td><td align=\"center\" colspan=\"2\">-12 (-121 to 85)</td><td align=\"center\" colspan=\"2\">-4 (-93 to 84)</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\" colspan=\"9\"><bold>Untransformed post-dose maximum and minimum values</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"4\"><bold>d</bold><sub><bold>max </bold></sub><bold>(U)</bold></td><td align=\"center\" colspan=\"4\"><bold>d</bold><sub><bold>min </bold></sub><bold>(U)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\"><bold>Point estimate (95% CI)</bold></td><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\"><bold>Point estimate (95% CI)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Variable</bold></td><td align=\"center\"><bold>Day 1</bold></td><td align=\"center\"><bold>Day 11 (R)</bold></td><td align=\"center\"><bold>Day 18 (R+F)</bold></td><td align=\"center\"><bold>Day 11-Day 1</bold></td><td align=\"center\"><bold>Day 1</bold></td><td align=\"center\"><bold>Day 11 (R)</bold></td><td align=\"center\"><bold>Day 18 (R+F)</bold></td><td align=\"center\"><bold>Day 11-Day 1</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">HR (bpm)</td><td align=\"center\">62</td><td align=\"center\">64</td><td align=\"center\">70</td><td align=\"center\">3 (-4 to 6)</td><td align=\"center\">52</td><td align=\"center\">54</td><td align=\"center\">61</td><td align=\"center\">4 (1 to 7)</td></tr><tr><td align=\"left\">PEP (ms)</td><td align=\"center\">119</td><td align=\"center\">121</td><td align=\"center\">114</td><td align=\"center\">3 (-7 to 11)</td><td align=\"center\">86</td><td align=\"center\">86</td><td align=\"center\">81</td><td align=\"center\">0 (-9 to 13)</td></tr><tr><td align=\"left\">QS2 (ms)</td><td align=\"center\">457</td><td align=\"center\">454</td><td align=\"center\">432</td><td align=\"center\">-1 (-11 to 11)</td><td align=\"center\">416</td><td align=\"center\">410</td><td align=\"center\">399</td><td align=\"center\">-9 (-21 to 8)</td></tr><tr><td align=\"left\">dZ/dt (&#937;/s)</td><td align=\"center\">2.09</td><td align=\"center\">1.93</td><td align=\"center\">2.06</td><td align=\"center\">-0.05 (-0.25 to 0.15)</td><td align=\"center\">1.59</td><td align=\"center\">1.56</td><td align=\"center\">1.62</td><td align=\"center\">0.03 (-0.18 to 0.20)</td></tr><tr><td align=\"left\">CO (L/min)</td><td align=\"center\">10.3</td><td align=\"center\">10.6</td><td align=\"center\">11.7</td><td align=\"center\">0.2 (-1.1 to 1.4)</td><td align=\"center\">7.6</td><td align=\"center\">8.3</td><td align=\"center\">8.8</td><td align=\"center\">-0.4 (-1.2 to 0.4)</td></tr><tr><td align=\"left\">TPR (dyn.s.cm<sup>-5</sup>)</td><td align=\"center\">1013</td><td align=\"center\">934</td><td align=\"center\">877</td><td align=\"center\">47 (-124 to 178)</td><td align=\"center\">762</td><td align=\"center\">733</td><td align=\"center\">603</td><td align=\"center\">-18 (-96 to 43)</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\" colspan=\"9\"><bold>Day 1-matched post-dose maximum and minimum values</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"4\"><bold>d</bold><sub><bold>max </bold></sub><bold>(&#948;)</bold></td><td align=\"center\" colspan=\"4\"><bold>d</bold><sub><bold>min </bold></sub><bold>(&#948;)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\"><bold>Point estimate (95% CI)</bold></td><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\"><bold>Point estimate (95% CI)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Variable</bold></td><td/><td align=\"center\"><bold>Day 11 (R)</bold></td><td align=\"center\"><bold>Day 18 (R+F)</bold></td><td align=\"center\"><bold>Day 18-Day 11</bold></td><td/><td align=\"center\"><bold>Day 11 (R)</bold></td><td align=\"center\"><bold>Day 18 (R+F)</bold></td><td align=\"center\"><bold>Day 18-Day 11</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">HR (bpm)</td><td/><td align=\"center\">9</td><td align=\"center\">14</td><td align=\"center\">5 (-1 to 11)</td><td/><td align=\"center\">-4</td><td align=\"center\">0</td><td align=\"center\">5 (1 to 9)</td></tr><tr><td align=\"left\">PEP (ms)</td><td/><td align=\"center\">25</td><td align=\"center\">19</td><td align=\"center\">-8 (-19 to 4)</td><td/><td align=\"center\">-27</td><td align=\"center\">-30</td><td align=\"center\">-2 (-11 to 10)</td></tr><tr><td align=\"left\">QS2 (ms)</td><td/><td align=\"center\">19</td><td align=\"center\">4</td><td align=\"center\">-15 (-31 to -8)</td><td/><td align=\"center\">-34</td><td align=\"center\">-47</td><td align=\"center\">-14 (-29 to 1)</td></tr><tr><td align=\"left\">dZ/dt (&#937;/s)</td><td/><td align=\"center\">0.28</td><td align=\"center\">0.32</td><td align=\"center\">0.08 (-0.07 to 0.22)</td><td/><td align=\"center\">-0.10</td><td align=\"center\">-0.26</td><td align=\"center\">0.05 (-0.12 to 0.21)</td></tr><tr><td align=\"left\">CO (L/min)</td><td/><td align=\"center\">1.6</td><td align=\"center\">2.6</td><td align=\"center\">0.8 (-0.7 to 2.3)</td><td/><td align=\"center\">-1.7</td><td align=\"center\">-1.2</td><td align=\"center\">0.3 (-0.6 to 1.8)</td></tr><tr><td align=\"left\">TPR (dyn.s.cm<sup>-5</sup>)</td><td/><td align=\"center\">126</td><td align=\"center\">108</td><td align=\"center\">-42 (-179 to 77)</td><td/><td align=\"center\">-128</td><td align=\"center\">-168</td><td align=\"center\">-42 (-131 to 43)</td></tr></tbody></table></body></html>", "text": "Pmid= 3127977:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacodynamic measures - Regimen B: treatment medians and treatment contrasts</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" colspan=\"9\">Untransformed pre-dose morning values</th></tr></thead><tbody><tr><td/><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\" colspan=\"5\"><bold>Point estimate (95% CI)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Variable</bold></td><td align=\"center\"><bold>Day 1</bold></td><td align=\"center\"><bold>Day 8 (F)</bold></td><td align=\"center\"><bold>Day 18 (F+R)</bold></td><td align=\"center\"><bold>Day 8-Day 1</bold></td><td align=\"center\" colspan=\"2\"><bold>Day 18-Day 8</bold></td><td align=\"center\" colspan=\"2\"><bold>Day 18-Day 1</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">HR (bpm)</td><td align=\"center\">58</td><td align=\"center\">66</td><td align=\"center\">62</td><td align=\"center\">5 (2 to 9)</td><td align=\"center\" colspan=\"2\">-1 (-4 to 3)</td><td align=\"center\" colspan=\"2\">4 (2 to 7)</td></tr><tr><td align=\"left\">PEP (ms)</td><td align=\"center\">105</td><td align=\"center\">97</td><td align=\"center\">98</td><td align=\"center\">-7 (-22 to 7)</td><td align=\"center\" colspan=\"2\">3 (-9 to 17)</td><td align=\"center\" colspan=\"2\">-5 (-19 to 20)</td></tr><tr><td align=\"left\">QS2 (ms)</td><td align=\"center\">434</td><td align=\"center\">431</td><td align=\"center\">445</td><td align=\"center\">-4 (-18 to 9)</td><td align=\"center\" colspan=\"2\">4 (-7 to 13)</td><td align=\"center\" colspan=\"2\">2 (-13 to 16)</td></tr><tr><td align=\"left\">dZ/dt (&#937;/s)</td><td align=\"center\">1.81</td><td align=\"center\">1.94</td><td align=\"center\">1.82</td><td align=\"center\">0.06 (-0.07 to 0.19)</td><td align=\"center\" colspan=\"2\">-0.08 (-0.37 to 0.07)</td><td align=\"center\" colspan=\"2\">-0.03 (-0.30 to 0.16)</td></tr><tr><td align=\"left\">CO (L/min)</td><td align=\"center\">9.7</td><td align=\"center\">9.7</td><td align=\"center\">10.3</td><td align=\"center\">0.7 (-0.9 to 2.0)</td><td align=\"center\" colspan=\"2\">-0.5 (-1.7 to 0.6)</td><td align=\"center\" colspan=\"2\">0.3 (-1.7 to 2.1)</td></tr><tr><td align=\"left\">TPR (dyn.s.cm<sup>-5</sup>)</td><td align=\"center\">657</td><td align=\"center\">668</td><td align=\"center\">709</td><td align=\"center\">-18 (-198 to 70)</td><td align=\"center\" colspan=\"2\">28 (-80 to 100)</td><td align=\"center\" colspan=\"2\">-36 (-186 to 105)</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\" colspan=\"9\"><bold>Untransformed post-dose maximum and minimum values</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"4\"><bold>d</bold><sub><bold>max </bold></sub><bold>(U)</bold></td><td align=\"center\" colspan=\"4\"><bold>d</bold><sub><bold>min </bold></sub><bold>(U)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\"><bold>Point estimate (95% CI)</bold></td><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\"><bold>Point estimate (95% CI)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Variable</bold></td><td align=\"center\"><bold>Day 1</bold></td><td align=\"center\"><bold>Day 8 (F)</bold></td><td align=\"center\"><bold>Day 18 (F+R)</bold></td><td align=\"center\"><bold>Day 8-Day 1</bold></td><td align=\"center\"><bold>Day 1</bold></td><td align=\"center\"><bold>Day 8 (F)</bold></td><td align=\"center\"><bold>Day 18 (F+R)</bold></td><td align=\"center\"><bold>Day 8-Day 1</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">HR (bpm)</td><td align=\"center\">62</td><td align=\"center\">72</td><td align=\"center\">72</td><td align=\"center\">9 (5 to 11)</td><td align=\"center\">51</td><td align=\"center\">62</td><td align=\"center\">60</td><td align=\"center\">7 (3 to 10)</td></tr><tr><td align=\"left\">PEP (ms)</td><td align=\"center\">122</td><td align=\"center\">117</td><td align=\"center\">116</td><td align=\"center\">-4 (-14 to 2)</td><td align=\"center\">87</td><td align=\"center\">84</td><td align=\"center\">85</td><td align=\"center\">0 (-7 to 6)</td></tr><tr><td align=\"left\">QS2 (ms)</td><td align=\"center\">459</td><td align=\"center\">440</td><td align=\"center\">445</td><td align=\"center\">-14 (-27 to 4)</td><td align=\"center\">424</td><td align=\"center\">408</td><td align=\"center\">410</td><td align=\"center\">-13 (-22 to -3)</td></tr><tr><td align=\"left\">dZ/dt (&#937;/s)</td><td align=\"center\">2.05</td><td align=\"center\">2.10</td><td align=\"center\">2.20</td><td align=\"center\">0.01 (-0.15 to 0.21)</td><td align=\"center\">1.53</td><td align=\"center\">1.64</td><td align=\"center\">1.60</td><td align=\"center\">0.03 (-0.13 to 0.17)</td></tr><tr><td align=\"left\">CO (L/min)</td><td align=\"center\">9.8</td><td align=\"center\">11.8</td><td align=\"center\">11.8</td><td align=\"center\">1.7 (0.6 to 2.6)</td><td align=\"center\">8.4</td><td align=\"center\">8.2</td><td align=\"center\">8.0</td><td align=\"center\">0.5 (-0.5 to 1.4)</td></tr><tr><td align=\"left\">TPR (dyn.s.cm<sup>-5</sup>)</td><td align=\"center\">870</td><td align=\"center\">882</td><td align=\"center\">865</td><td align=\"center\">-49 (-160 to 80)</td><td align=\"center\">655</td><td align=\"center\">561</td><td align=\"center\">556</td><td align=\"center\">-96 (-188 to -24)</td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\" colspan=\"9\"><bold>Day 1-matched post-dose maximum and minimum values</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"4\"><bold>d</bold><sub><bold>max </bold></sub><bold>(&#948;)</bold></td><td align=\"center\" colspan=\"4\"><bold>d</bold><sub><bold>min </bold></sub><bold>(&#948;)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\"><bold>Point estimate (95% CI)</bold></td><td align=\"center\" colspan=\"3\"><bold>Median</bold></td><td align=\"center\"><bold>Point estimate (95% CI)</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>Variable</bold></td><td/><td align=\"center\"><bold>Day 8 (F)</bold></td><td align=\"center\"><bold>Day 18 (F+R)</bold></td><td align=\"center\"><bold>Day 18-Day 8</bold></td><td/><td align=\"center\"><bold>Day 8 (F)</bold></td><td align=\"center\"><bold>Day 18 (F+R)</bold></td><td align=\"center\"><bold>Day 18-Day 8</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\">HR (bpm)</td><td/><td align=\"center\">16</td><td align=\"center\">14</td><td align=\"center\">-2 (-6 to 2)</td><td/><td align=\"center\">-2</td><td align=\"center\">-3</td><td align=\"center\">-1 (-2 to 1)</td></tr><tr><td align=\"left\">PEP (ms)</td><td/><td align=\"center\">25</td><td align=\"center\">21</td><td align=\"center\">3 (-19 to 4)</td><td/><td align=\"center\">-26</td><td align=\"center\">-25</td><td align=\"center\">0 (-4 to 4)</td></tr><tr><td align=\"left\">QS2 (ms)</td><td/><td align=\"center\">13</td><td align=\"center\">15</td><td align=\"center\">4 (-7 to 13)</td><td/><td align=\"center\">-47</td><td align=\"center\">-37</td><td align=\"center\">8 (-1 to 15)</td></tr><tr><td align=\"left\">dZ/dt (&#937;/s)</td><td/><td align=\"center\">0.32</td><td align=\"center\">0.28</td><td align=\"center\">0.05 (-0.16 to 0.17)</td><td/><td align=\"center\">-0.29</td><td align=\"center\">-0.37</td><td align=\"center\">-0.05 (-0.27 to 0.15)</td></tr><tr><td align=\"left\">CO (L/min)</td><td/><td align=\"center\">2.9</td><td align=\"center\">3.3</td><td align=\"center\">0.0 (-1.0 to 1.5)</td><td/><td align=\"center\">-0.6</td><td align=\"center\">-0.6</td><td align=\"center\">-0.4 (-1.3 to 0.6)</td></tr><tr><td align=\"left\">TPR (dyn.s.cm<sup>-5</sup>)</td><td/><td align=\"center\">61</td><td align=\"center\">66</td><td align=\"center\">-18 (-95 to 73)</td><td/><td align=\"center\">-221</td><td align=\"center\">-224</td><td align=\"center\">-42 (-107 to 35)</td></tr></tbody></table></body></html>", "text": "Pmid= 3127977:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline Population Characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Indomethacin</th><th align=\"center\">Ibuprofen</th></tr></thead><tbody><tr><td align=\"left\"><bold>Birth Weight, grams (mean)</bold></td><td align=\"center\">1048</td><td align=\"center\">1083</td></tr><tr><td align=\"left\"><bold>Birth Weight Categories, n (%)</bold></td><td/><td/></tr><tr><td align=\"left\">&#8195;&#8195;&#8804; 750 grams</td><td align=\"center\">54 (33)</td><td align=\"center\">56 (30)</td></tr><tr><td align=\"left\">&#8195;751 - 1000 grams</td><td align=\"center\">38 (23)</td><td align=\"center\">41 (22)</td></tr><tr><td align=\"left\">&#8195;1001 - 1500 grams</td><td align=\"center\">51 (31)</td><td align=\"center\">54 (29)</td></tr><tr><td align=\"left\">&#8195;&#8195;&gt; 1500 grams</td><td align=\"center\">22 (13)</td><td align=\"center\">35 (19)</td></tr><tr><td align=\"left\"><bold>Gestational Age, weeks (mean)</bold></td><td align=\"center\">27.7</td><td align=\"center\">27.8</td></tr><tr><td align=\"left\"><bold>Gestational Age Categories, n (%)</bold></td><td/><td/></tr><tr><td align=\"left\">&#8195;&#8195;&lt; 25 weeks</td><td align=\"center\">33 (20)</td><td align=\"center\">34 (18)</td></tr><tr><td align=\"left\">&#8195;25 - 27 6/7 weeks</td><td align=\"center\">61 (37)</td><td align=\"center\">68 (37)</td></tr><tr><td align=\"left\">&#8195;28 - 29 6/7 weeks</td><td align=\"center\">35 (21)</td><td align=\"center\">37 (20)</td></tr><tr><td align=\"left\">&#8195;&#8195;&#8805; 30 weeks</td><td align=\"center\">36 (22)</td><td align=\"center\">47 (25)</td></tr><tr><td align=\"left\"><bold>Gender</bold></td><td/><td/></tr><tr><td align=\"left\">&#8195;&#8195;Male</td><td align=\"center\">82 (50)</td><td align=\"center\">108 (58) *</td></tr><tr><td align=\"left\">&#8195;Female</td><td align=\"center\">83 (50)</td><td align=\"center\">78 (42)</td></tr><tr><td align=\"left\"><bold>Number of courses, n (%)</bold></td><td align=\"center\">165</td><td align=\"center\">185</td></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;1</td><td align=\"center\">101 (61)</td><td align=\"center\">118 (63)</td></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;2</td><td align=\"center\">41 (25)</td><td align=\"center\">28 (15)</td></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;3</td><td align=\"center\">19 (12)</td><td align=\"center\">37 (20)</td></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;4</td><td align=\"center\">4 (2)</td><td align=\"center\">2 (1)</td></tr><tr><td align=\"left\"><bold>Baseline urine output, mL/kg/h mean (SD)</bold></td><td align=\"center\">3.9 (1.4)</td><td align=\"center\">4.2 (1.6)</td></tr><tr><td align=\"left\"><bold>Baseline creatinine, mg/dL mean (SD)</bold></td><td align=\"center\">0.96 (0.2)</td><td align=\"center\">0.93 (0.2)</td></tr></tbody></table></body></html>", "text": "Pmid= 3150255:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Secondary Outcomes According to Treatment Group</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Indomethacin</th><th align=\"center\">Ibuprofen</th><th/></tr></thead><tbody><tr><td/><td align=\"center\"><bold>(N = 161)</bold></td><td align=\"center\"><bold>(N = 182)</bold></td><td align=\"center\"><bold>p value</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Day of Life at Start of Treatment (mean, SD)</bold></td><td align=\"center\">3.3 &#177; 2.3</td><td align=\"center\">3.5 &#177; 2.7</td><td align=\"center\">NS</td></tr><tr><td align=\"left\"><bold>PDA Closed, n (%)</bold></td><td align=\"center\">109 (68)</td><td align=\"center\">129 (71)</td><td align=\"center\">0.4</td></tr><tr><td align=\"left\"><bold>PDA Ligation, n (%)</bold></td><td align=\"center\">45 (28)</td><td align=\"center\">38 (21)</td><td align=\"center\">0.1</td></tr><tr><td align=\"left\"><bold>BPD, n (%)</bold></td><td align=\"center\">72 (45)</td><td align=\"center\">90 (49)</td><td align=\"center\">0.2</td></tr><tr><td align=\"left\"><bold>NEC-related conditions, any, n (%)</bold></td><td align=\"center\">27 (17)</td><td align=\"center\">32 (18)</td><td align=\"center\">0.8</td></tr><tr><td align=\"left\">&#8195;&#8195;NEC, n (%)</td><td align=\"center\">6 (4)</td><td align=\"center\">15 (8)</td><td align=\"center\">0.08</td></tr><tr><td align=\"left\">&#8195;NEC-Like Illness (%)</td><td align=\"center\">13 (8)</td><td align=\"center\">5 (3)</td><td align=\"center\">0.03*</td></tr><tr><td align=\"left\">&#8195;Spontaneous Intestinal Perforations, n (%)</td><td align=\"center\">8 (5)</td><td align=\"center\">12 (7)</td><td align=\"center\">0.5</td></tr><tr><td align=\"left\"><bold>ROP, n (%)</bold></td><td align=\"center\">65 (52)</td><td align=\"center\">41 (30)</td><td align=\"center\">&lt;0.001*</td></tr><tr><td align=\"left\">&#8195;&#8195;Severe ROP: Grades III-V</td><td align=\"center\">15 (12)</td><td align=\"center\">15 (11)</td><td align=\"center\">0.8</td></tr><tr><td align=\"left\"><bold>IVH, any, n (%)</bold></td><td align=\"center\">58 (36)</td><td align=\"center\">57 (31)</td><td align=\"center\">0.4</td></tr><tr><td align=\"left\">&#8195;&#8195;Severe IVH: Grade III/IV</td><td align=\"center\">12 (8)</td><td align=\"center\">12 (9)</td><td align=\"center\">0.6</td></tr><tr><td align=\"left\"><bold>PVL</bold></td><td align=\"center\">4 (2.4)</td><td align=\"center\">3 (1.6)</td><td align=\"center\">0.4</td></tr><tr><td align=\"left\"><bold>Death, n (%)</bold></td><td align=\"center\">12 (7)</td><td align=\"center\">16 (9)</td><td align=\"center\">0.4</td></tr></tbody></table></body></html>", "text": "Pmid= 3150255:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Treatment Efficacy by Number of Treatment Courses</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Indomethacin</th><th align=\"center\" colspan=\"3\">Ibuprofen</th></tr></thead><tbody><tr><td align=\"left\"><bold>Number of Courses Used</bold></td><td align=\"center\"><bold>1</bold></td><td align=\"center\"><bold>2</bold></td><td align=\"center\"><bold>3</bold></td><td align=\"center\"><bold>1</bold></td><td align=\"center\"><bold>2</bold></td><td align=\"center\"><bold>3</bold></td></tr><tr><td align=\"left\"><bold>Total N</bold></td><td align=\"center\">101</td><td align=\"center\">41</td><td align=\"center\">19</td><td align=\"center\">118</td><td align=\"center\">28</td><td align=\"center\">37</td></tr><tr><td align=\"left\"><bold>PDA Closed, n (%)</bold></td><td align=\"center\">89 (88.1)</td><td align=\"center\">18 (43.9)</td><td align=\"center\">3 (15.8)</td><td align=\"center\">108 (92.3)</td><td align=\"center\">15 (53.6)</td><td align=\"center\">7 (18.9)</td></tr><tr><td align=\"left\"><bold>PDA Ligations</bold></td><td align=\"center\">8 (7.9)</td><td align=\"center\">22 (53.7)*</td><td align=\"center\">15 (78.9)</td><td align=\"center\">3 (2.6)</td><td align=\"center\">8 (28.6)*</td><td align=\"center\">26 (70.3)</td></tr></tbody></table></body></html>", "text": "Pmid= 3150255:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Treatment Start Day</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Indomethacin</th><th align=\"center\">Ibuprofen</th></tr></thead><tbody><tr><td align=\"left\"><bold>Initial Day of Treatment</bold></td><td/><td/></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;<bold>Median</bold></td><td align=\"center\">3</td><td align=\"center\">3</td></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;<bold>Mean</bold></td><td align=\"center\">3.3</td><td align=\"center\">3.5</td></tr><tr><td align=\"left\">&#8195;&#8195;<bold>Minimum</bold></td><td align=\"center\">1</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;&#8195;<bold>Maximum</bold></td><td align=\"center\">18</td><td align=\"center\">22</td></tr><tr><td align=\"left\">&#8195;<bold>Interquartile range</bold></td><td align=\"center\">2</td><td align=\"center\">2</td></tr><tr><td align=\"left\"><bold>Days between 1st and 2nd courses</bold></td><td/><td/></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;<bold>Median</bold></td><td align=\"center\">1</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;<bold>Mean</bold></td><td align=\"center\">4.1</td><td align=\"center\">2.7</td></tr><tr><td align=\"left\">&#8195;&#8195;<bold>Minimum</bold></td><td align=\"center\">1</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;&#8195;<bold>Maximum</bold></td><td align=\"center\">32</td><td align=\"center\">18</td></tr><tr><td align=\"left\">&#8195;<bold>Interquartile range</bold></td><td align=\"center\">2</td><td align=\"center\">0</td></tr><tr><td align=\"left\"><bold>Days between 2nd and 3rd courses</bold></td><td/><td/></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;<bold>Median</bold></td><td align=\"center\">1</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;&#8195;&#8195;<bold>Mean</bold></td><td align=\"center\">1.9</td><td align=\"center\">2.6</td></tr><tr><td align=\"left\">&#8195;&#8195;<bold>Minimum</bold></td><td align=\"center\">1</td><td align=\"center\">1</td></tr><tr><td align=\"left\">&#8195;&#8195;<bold>Maximum</bold></td><td align=\"center\">9</td><td align=\"center\">13</td></tr><tr><td align=\"left\">&#8195;<bold>Interquartile range</bold></td><td align=\"center\">0</td><td align=\"center\">2</td></tr></tbody></table></body></html>", "text": "Pmid= 3150255:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Effect of Each Initial Treatment Course on Renal Function</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Indomethacin</th><th align=\"center\" colspan=\"3\">Ibuprofen</th><th align=\"center\" colspan=\"2\">Comparison between treatments on changes from baseline (ANOVA)</th></tr></thead><tbody><tr><td/><td align=\"center\"><bold>Baseline</bold></td><td align=\"center\"><bold>1st course</bold></td><td align=\"center\"><bold>p value for change with indomethacin (t-test)</bold></td><td align=\"center\"><bold>Baseline</bold></td><td align=\"center\"><bold>1st course</bold></td><td align=\"center\"><bold>p value for change with ibuprofen (t-test)</bold></td><td align=\"center\"><bold>p value for main treatment effect</bold></td><td align=\"center\"><bold>p value for treatment - time interaction</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"center\">Urine output (mL/kg/hr; mean &#177; SD)</td><td align=\"center\">3.9 &#177; 1.4</td><td align=\"center\">3.6 &#177; 1.4</td><td align=\"center\"><italic>0.033 </italic>*</td><td align=\"center\">4.2 &#177; 1.6</td><td align=\"center\">4.0 &#177; 1.4</td><td align=\"center\"><italic>0.24</italic></td><td align=\"center\"><italic>0.51</italic></td><td align=\"center\"><italic>0.50</italic></td></tr><tr><td align=\"center\">Serum Creatinine (mg/dL; mean + SD)</td><td align=\"center\">0.96 &#177; 0.21</td><td align=\"center\">1.06 &#177; 0.24</td><td align=\"center\"><italic>&lt;0.001</italic>*</td><td align=\"center\">0.93 &#177; 0.2</td><td align=\"center\">0.98 &#177; 0.24</td><td align=\"center\"><italic>0.005 </italic>*</td><td align=\"center\"><italic>0.039</italic>*</td><td align=\"center\"><italic>0.047 </italic>*</td></tr></tbody></table></body></html>", "text": "Pmid= 3150255:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Evaluation of the range of concentrations for Vancomycin (USP standard)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\" colspan=\"2\">Concentration Range</th><th align=\"center\" colspan=\"3\">Equation</th></tr></thead><tbody><tr><td align=\"center\"><bold>From</bold></td><td align=\"center\"><bold>To</bold></td><td align=\"center\"><bold>Slope</bold></td><td align=\"center\"><bold>Intercept</bold></td><td align=\"center\"><bold>R <sup>2</sup></bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">C1</td><td align=\"center\">C6</td><td align=\"center\">2.462680435</td><td align=\"center\">6.415123505</td><td align=\"center\">0.996221756</td></tr><tr><td align=\"center\">C2</td><td align=\"center\">C7</td><td align=\"center\">2.324635129</td><td align=\"center\">7.259328533</td><td align=\"center\">0.989384179</td></tr><tr><td align=\"center\"><bold>C3</bold></td><td align=\"center\"><bold>C8</bold></td><td align=\"center\"><bold>2.270224777</bold></td><td align=\"center\"><bold>7.362386326</bold></td><td align=\"center\"><bold>0.990682625</bold></td></tr><tr><td align=\"center\">C4</td><td align=\"center\">C9</td><td align=\"center\">2.367915749</td><td align=\"center\">6.864768679</td><td align=\"center\">0.98750859</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Evaluation of the pH effect on linearity</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">pH</th><th align=\"center\">Equation</th><th align=\"center\">R<sup>2</sup></th><th align=\"center\">Incubation Time</th></tr></thead><tbody><tr><td align=\"center\">5.4</td><td align=\"center\">y = 1.8463x + 14.882</td><td align=\"center\">0.9806</td><td align=\"center\">8 hours</td></tr><tr><td align=\"center\">5.9</td><td align=\"center\">y = 2.3895x + 19.128</td><td align=\"center\">0.9898</td><td align=\"center\">8 hours</td></tr><tr><td align=\"center\"><bold>6.4</bold></td><td align=\"center\"><bold>y = 1.5517x + 11.817</bold></td><td align=\"center\"><bold>0.9977</bold></td><td align=\"center\"><bold>8 </bold>hours</td></tr><tr><td align=\"center\"><bold>6.5</bold></td><td align=\"center\"><bold>y = 2.134x + 7.4113</bold></td><td align=\"center\"><bold>0.9975</bold></td><td align=\"center\"><bold>8 </bold>hours</td></tr><tr><td align=\"center\">7</td><td align=\"center\">y = 1.7824 + 11.212</td><td align=\"center\">0.9794</td><td align=\"center\">9 hours</td></tr><tr><td align=\"center\">7.5</td><td align=\"center\">y = 1.875x + 11.009</td><td align=\"center\">0.9663</td><td align=\"center\">10 hours</td></tr><tr><td align=\"center\">8</td><td align=\"center\">y = 2.3651x + 9.3311</td><td align=\"center\">0.9763</td><td align=\"center\">11 hours</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Evaluation of the linearity of Vancomycin</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Test</th><th align=\"center\">HYPOTHESIS</th><th align=\"center\">Experimental t</th><th align=\"center\">Theoretical t</th><th align=\"center\">Decision</th></tr></thead><tbody><tr><td align=\"center\"><bold>Slope</bold></td><td align=\"center\">H<sub>0</sub>: m = 0<break/>H<sub>1</sub>: m &#8800;0</td><td align=\"center\">19.7</td><td align=\"center\">2.120</td><td align=\"center\">Reject H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>Intercept</bold></td><td align=\"center\">H<sub>0</sub>: b = 0<break/>H<sub>1</sub>: b &#8800;0</td><td align=\"center\">125.3</td><td align=\"center\">2.120</td><td align=\"center\">Reject H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>Correlation</bold></td><td align=\"center\">H<sub>0</sub>: R = 0<break/>H<sub>1</sub>: R &#8800; 0</td><td align=\"center\">67.5</td><td align=\"center\">2.120</td><td align=\"center\">Reject H<sub>0</sub></td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Regression analysis by analysis of variance (ANOVA).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Test</th><th align=\"center\">HYPOTHESIS</th><th align=\"center\">Experimental t</th><th align=\"center\">Theoretical t</th><th align=\"center\">Decision</th></tr></thead><tbody><tr><td align=\"center\"><bold>Regression</bold></td><td align=\"center\">H<sub>0</sub>: There is no regression<break/>H<sub>1</sub>: There is regression</td><td align=\"center\">146.6</td><td align=\"center\">4.670</td><td align=\"center\">Reject H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>Deviation from Linearity</bold></td><td align=\"center\">H<sub>0</sub>: There is no deviation from linearity<break/>H<sub>1</sub>: There is a deviation from linearity</td><td align=\"center\">-3.0</td><td align=\"center\">3.71</td><td align=\"center\">Accept H<sub>0</sub></td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Reproducibility of assays using Vancomycin (Cochran Test)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Concentration (mg/ml)</th><th align=\"center\">251.25</th><th align=\"center\">165.63</th><th align=\"center\">62.85</th><th align=\"center\">31.41</th><th align=\"center\">15.70</th><th align=\"center\">7.85</th></tr></thead><tbody><tr><td align=\"center\"><bold>Standard deviation</bold></td><td align=\"center\">0.096</td><td align=\"center\">0.076</td><td align=\"center\">0.237</td><td align=\"center\">0.084</td><td align=\"center\">0.100</td><td align=\"center\">0.270</td></tr><tr><td align=\"center\"><bold>Variance Coefficient (%)</bold></td><td align=\"center\">0.4759</td><td align=\"center\">0.408422</td><td align=\"center\">1.4576</td><td align=\"center\">0.559623</td><td align=\"center\">0.7061</td><td align=\"center\">2.2425</td></tr><tr><td align=\"center\"><bold>Variance (S<sup>2</sup>)</bold></td><td align=\"center\">0.0092</td><td align=\"center\">0.00583</td><td align=\"center\">0.0113</td><td align=\"center\">0.00707</td><td align=\"center\">0.0099</td><td align=\"center\">0.01213</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"center\"><bold>Sum (S<sup>2</sup>)</bold></td><td/><td/><td/><td/><td/><td align=\"center\">0.05544</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>ANOVA of the between-day precision of assays using Vancomycin</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Concentration</th><th align=\"center\">Experimental F</th><th align=\"center\">Theoretical F</th><th align=\"center\">Decision</th></tr></thead><tbody><tr><td align=\"center\"><bold>C1</bold></td><td align=\"center\">0.041</td><td align=\"center\">4.96</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C2</bold></td><td align=\"center\">0.047</td><td align=\"center\">4.96</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C3</bold></td><td align=\"center\">0.069</td><td align=\"center\">4.96</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C4</bold></td><td align=\"center\">0.093</td><td align=\"center\">4.96</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C5</bold></td><td align=\"center\">0.128</td><td align=\"center\">4.96</td><td align=\"center\">Accept H<sub>0</sub></td></tr><tr><td align=\"center\"><bold>C6</bold></td><td align=\"center\">0.182</td><td align=\"center\">4.96</td><td align=\"center\">Accept H<sub>0</sub></td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Stability of Vancomycin in water for injection at 4C, 18C and 37C</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Time</th><th align=\"center\" colspan=\"3\">4&#176;C</th><th align=\"center\" colspan=\"3\">18&#176;C</th><th align=\"center\" colspan=\"3\">37&#176;C</th></tr><tr><th/><th colspan=\"9\"><hr/></th></tr><tr><th/><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th></tr></thead><tbody><tr><td align=\"center\">0 h</td><td align=\"center\">1.5177</td><td align=\"center\">12.556</td><td align=\"center\">0.9913</td><td align=\"center\">1.5177</td><td align=\"center\">12.556</td><td align=\"center\">0.9913</td><td align=\"center\">1.5177</td><td align=\"center\">12.556</td><td align=\"center\">0.9913</td></tr><tr><td align=\"center\">24 h</td><td align=\"center\">1.5305</td><td align=\"center\">12.543</td><td align=\"center\">0.9908</td><td align=\"center\">1.5241</td><td align=\"center\">12.518</td><td align=\"center\">0.9916</td><td align=\"center\">1.5063</td><td align=\"center\">12.5210</td><td align=\"center\">0.9900</td></tr><tr><td align=\"center\">48 h</td><td align=\"center\">1.522</td><td align=\"center\">12.544</td><td align=\"center\">0.9919</td><td align=\"center\">1.518</td><td align=\"center\">12.501</td><td align=\"center\">0.9926</td><td align=\"center\">1.4936</td><td align=\"center\">12.495</td><td align=\"center\">0.9924</td></tr><tr><td align=\"center\">86 h</td><td align=\"center\">1.5224</td><td align=\"center\">12.509</td><td align=\"center\">0.9916</td><td align=\"center\">1.5178</td><td align=\"center\">12.461</td><td align=\"center\">0.9924</td><td align=\"center\">1.4981</td><td align=\"center\">12.4720</td><td align=\"center\">0.9928</td></tr><tr><td align=\"center\">7 days</td><td align=\"center\">1.5165</td><td align=\"center\">12.4780</td><td align=\"center\">0.9919</td><td align=\"center\">1.5217</td><td align=\"center\">12.342</td><td align=\"center\">0.9935</td><td align=\"center\">1.4742</td><td align=\"center\">12.3040</td><td align=\"center\">0.9904</td></tr><tr><td align=\"center\">15 days</td><td align=\"center\">1.5247</td><td align=\"center\">12.3460</td><td align=\"center\">0.9921</td><td align=\"center\">1.5041</td><td align=\"center\">12.273</td><td align=\"center\">0.9923</td><td align=\"center\">1.4425</td><td align=\"center\">12.1980</td><td align=\"center\">0.9916</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Stability of Vancomycin in phosphate buffer, pH 4</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Time</th><th align=\"center\" colspan=\"3\">4&#176;C</th><th align=\"center\" colspan=\"3\">18&#176;C</th><th align=\"center\" colspan=\"3\">37&#176;C</th></tr><tr><th/><th colspan=\"9\"><hr/></th></tr><tr><th/><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th></tr></thead><tbody><tr><td align=\"center\">0 h</td><td align=\"center\">1.4807</td><td align=\"center\">12.799</td><td align=\"center\">0.9916</td><td align=\"center\">1.4807</td><td align=\"center\">12.799</td><td align=\"center\">0.9916</td><td align=\"center\">1.4807</td><td align=\"center\">12.799</td><td align=\"center\">0.9916</td></tr><tr><td align=\"center\">24 h</td><td align=\"center\">1.4910</td><td align=\"center\">12.7640</td><td align=\"center\">0.9917</td><td align=\"center\">1.4833</td><td align=\"center\">12.764</td><td align=\"center\">0.9917</td><td align=\"center\">1.5195</td><td align=\"center\">12.5150</td><td align=\"center\">0.9916</td></tr><tr><td align=\"center\">48 h</td><td align=\"center\">1.487</td><td align=\"center\">12.733</td><td align=\"center\">0.9924</td><td align=\"center\">1.4747</td><td align=\"center\">12.716</td><td align=\"center\">0.9928</td><td align=\"center\">1.509</td><td align=\"center\">12.497</td><td align=\"center\">0.9922</td></tr><tr><td align=\"center\">86 h</td><td align=\"center\">1.4787</td><td align=\"center\">12.7260</td><td align=\"center\">0.9933</td><td align=\"center\">1.4701</td><td align=\"center\">12.689</td><td align=\"center\">0.9927</td><td align=\"center\">1.5057</td><td align=\"center\">12.4700</td><td align=\"center\">0.9915</td></tr><tr><td align=\"center\">7 days</td><td align=\"center\">1.4804</td><td align=\"center\">12.6510</td><td align=\"center\">0.9925</td><td align=\"center\">1.4766</td><td align=\"center\">12.571</td><td align=\"center\">0.9931</td><td align=\"center\">1.4966</td><td align=\"center\">12.3800</td><td align=\"center\">0.9922</td></tr><tr><td align=\"center\">15 days</td><td align=\"center\">1.4826</td><td align=\"center\">12.5170</td><td align=\"center\">0.9937</td><td align=\"center\">1.4566</td><td align=\"center\">12.505</td><td align=\"center\">0.9932</td><td align=\"center\">1.4887</td><td align=\"center\">12.2510</td><td align=\"center\">0.9926</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 8"}
{"html": "<!DOCTYPE html><html><body><h1>Stability of Vancomycin in phosphate buffer, pH 4</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Time</th><th align=\"center\" colspan=\"3\">Phosphate Buffer, pH 4.5</th><th align=\"center\" colspan=\"3\">Water For Injection</th></tr><tr><th/><th colspan=\"6\"><hr/></th></tr><tr><th/><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th><th align=\"center\">Slope</th><th align=\"center\">Intercept</th><th align=\"center\">R<sup>2</sup></th></tr></thead><tbody><tr><td align=\"center\">0 h</td><td align=\"center\">1.4807</td><td align=\"center\">12.799</td><td align=\"center\">0.9916</td><td align=\"center\">1.5177</td><td align=\"center\">12.556</td><td align=\"center\">0.9913</td></tr><tr><td align=\"center\">24 h</td><td align=\"center\">1.5268</td><td align=\"center\">12.4310</td><td align=\"center\">0.9909</td><td align=\"center\">1.5059</td><td align=\"center\">12.4640</td><td align=\"center\">0.9905</td></tr><tr><td align=\"center\">48 h</td><td align=\"center\">1.4924</td><td align=\"center\">12.479</td><td align=\"center\">0.9912</td><td align=\"center\">1.4907</td><td align=\"center\">12.409</td><td align=\"center\">0.993</td></tr><tr><td align=\"center\">86 h</td><td align=\"center\">1.4894</td><td align=\"center\">12.4530</td><td align=\"center\">0.9914</td><td align=\"center\">1.4939</td><td align=\"center\">12.3520</td><td align=\"center\">0.9930</td></tr><tr><td align=\"center\">7 days</td><td align=\"center\">1.4515</td><td align=\"center\">12.3970</td><td align=\"center\">0.9869</td><td align=\"center\">1.4569</td><td align=\"center\">12.3230</td><td align=\"center\">0.9897</td></tr><tr><td align=\"center\">15 days</td><td align=\"center\">1.4226</td><td align=\"center\">12.3060</td><td align=\"center\">0.9855</td><td align=\"center\">1.4343</td><td align=\"center\">12.2370</td><td align=\"center\">0.9907</td></tr><tr><td align=\"center\">30 days</td><td align=\"center\">NDA</td><td/><td/><td align=\"center\">NDA</td><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 9"}
{"html": "<!DOCTYPE html><html><body><h1>Potency of the commercial samples of vancomycin</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Samples</th><th align=\"center\">Potency</th></tr></thead><tbody><tr><td align=\"center\">1</td><td/></tr><tr><td align=\"center\">2</td><td align=\"center\">0.995</td></tr><tr><td align=\"center\">3</td><td align=\"center\">1.012</td></tr><tr><td align=\"center\">4</td><td align=\"center\">1.005</td></tr><tr><td align=\"center\">5</td><td align=\"center\">1.100</td></tr><tr><td align=\"center\">6</td><td align=\"center\">0.936</td></tr><tr><td align=\"center\">7</td><td align=\"center\">1.124</td></tr><tr><td align=\"center\">8</td><td align=\"center\">1.032</td></tr><tr><td align=\"center\">9</td><td/></tr><tr><td align=\"center\">10</td><td align=\"center\">1.064</td></tr><tr><td align=\"center\">11</td><td/></tr><tr><td align=\"center\">12</td><td align=\"center\">1.019</td></tr><tr><td align=\"center\">13</td><td align=\"center\">1.023</td></tr><tr><td align=\"center\">14</td><td align=\"center\">1.150</td></tr><tr><td align=\"center\">15</td><td align=\"center\">1.108</td></tr><tr><td align=\"center\">16</td><td align=\"center\">0.9859</td></tr><tr><td align=\"center\">17</td><td align=\"center\">1.107</td></tr><tr><td align=\"center\">18</td><td align=\"center\">1.047</td></tr><tr><td align=\"center\">19</td><td/></tr><tr><td align=\"center\">20</td><td align=\"center\">0.981</td></tr><tr><td align=\"center\">21</td><td align=\"center\">1.019</td></tr><tr><td align=\"center\">22</td><td align=\"center\">1.011</td></tr><tr><td align=\"center\">23</td><td/></tr><tr><td align=\"center\">24</td><td align=\"center\">1.003</td></tr><tr><td align=\"center\">25</td><td align=\"center\">1.023</td></tr><tr><td align=\"center\">26</td><td align=\"center\">1.011</td></tr><tr><td align=\"center\">27</td><td align=\"center\">0.961</td></tr><tr><td align=\"center\">28</td><td/></tr><tr><td align=\"center\">29</td><td align=\"center\">1.062</td></tr><tr><td align=\"center\">30</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 10"}
{"html": "<!DOCTYPE html><html><body><h1>Determination of MICs and MBCs for Vancomycin (USP standard)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Microorganism</th><th align=\"center\" colspan=\"3\">MIC (&#956;g/ml)</th><th align=\"center\" colspan=\"3\">MBC (&#956;g/ml)</th></tr><tr><th/><th colspan=\"6\"><hr/></th></tr><tr><th/><th align=\"center\">Std</th><th align=\"center\">M1</th><th align=\"center\">M2</th><th align=\"center\">Std</th><th align=\"center\">M1</th><th align=\"center\">M2</th></tr></thead><tbody><tr><td align=\"center\"><italic>A. baumanii </italic>59</td><td align=\"center\">62.06</td><td align=\"center\">62.06</td><td align=\"center\">62.06</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td></tr><tr><td align=\"center\"><italic>A. baumanii </italic>139</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">248.25</td><td align=\"center\">248.25</td><td align=\"center\">248.25</td></tr><tr><td align=\"center\"><italic>A. baumanii </italic>147</td><td align=\"center\">993</td><td align=\"center\">993</td><td align=\"center\">993</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td></tr><tr><td align=\"center\"><italic>A. baumanii </italic>173</td><td align=\"center\">62.06</td><td align=\"center\">62.06</td><td align=\"center\">62.06</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td></tr><tr><td align=\"center\"><italic>E. faecalis</italic></td><td align=\"center\">1.93</td><td align=\"center\">1.93</td><td align=\"center\">1.93</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td></tr><tr><td align=\"center\"><italic>E. faecalis </italic>ATCC 29212</td><td align=\"center\">7.76</td><td align=\"center\">7.76</td><td align=\"center\">7.76</td><td align=\"center\">15.52</td><td align=\"center\">15.52</td><td align=\"center\">15.52</td></tr><tr><td align=\"center\"><italic>E. faecalis </italic>319623</td><td align=\"center\">62.06</td><td align=\"center\">62.06</td><td align=\"center\">62.06</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td></tr><tr><td align=\"center\"><italic>E. gallinarum</italic></td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td></tr><tr><td align=\"center\"><italic>E. coli </italic>39</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">248.25</td><td align=\"center\">248.25</td><td align=\"center\">248.25</td></tr><tr><td align=\"center\"><italic>E. coli </italic>50</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">124.13</td><td align=\"center\">248.25</td><td align=\"center\">248.25</td><td align=\"center\">248.25</td></tr><tr><td align=\"center\"><italic>E. coli </italic>69</td><td align=\"center\">496.50</td><td align=\"center\">496.50</td><td align=\"center\">496.50</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td></tr><tr><td align=\"center\"><italic>K. pneumoniae </italic>1</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">496.50</td><td align=\"center\">496.50</td><td align=\"center\">496.50</td></tr><tr><td align=\"center\"><italic>K. pneumoniae </italic>43</td><td align=\"center\">496.5</td><td align=\"center\">496.5</td><td align=\"center\">496.5</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td></tr><tr><td align=\"center\"><italic>K. pneumoniae </italic>63</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td></tr><tr><td align=\"center\"><italic>K. pneumoniae </italic>65</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td></tr><tr><td align=\"center\"><italic>K. pneumoniae </italic>207</td><td align=\"center\">496.00</td><td align=\"center\">496.00</td><td align=\"center\">496.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td></tr><tr><td align=\"center\"><italic>Ps. aeruginosa </italic>42</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td></tr><tr><td align=\"center\"><italic>Ps. aeruginosa </italic>74</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td></tr><tr><td align=\"center\"><italic>Ps. aeruginosa </italic>151</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td></tr><tr><td align=\"center\"><italic>Ps. aeruginosa </italic>157</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td></tr><tr><td align=\"center\"><italic>Ps. aeruginosa </italic>HE1</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">ND</td><td align=\"center\">ND</td><td align=\"center\">ND</td></tr><tr><td align=\"center\"><italic>St. Aureus </italic>287</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td></tr><tr><td align=\"center\"><italic>St. Aureus </italic>291</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td></tr><tr><td align=\"center\"><italic>St. Aureus </italic>ATCC 25923</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">1.94</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td><td align=\"center\">3.88</td></tr><tr><td align=\"center\"><italic>M. morganii </italic>HE2</td><td align=\"center\">496.50</td><td align=\"center\">496.50</td><td align=\"center\">496.50</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td><td align=\"center\">993.00</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 11"}
{"html": "<!DOCTYPE html><html><body><h1>Critical concentrations (g/ml) of different samples of Vancomycin against various microorganisms.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Sample</th><th align=\"center\"><bold><italic>E. f</italic></bold>.</th><th align=\"center\"><italic>E. f</italic>. 29212</th><th align=\"center\"><italic>E. f</italic>. 319623</th><th align=\"center\"><italic>A. b</italic>. 59</th><th align=\"center\"><bold><italic>E. g</italic></bold>.</th><th align=\"center\"><italic>P. a</italic>. 43</th><th align=\"center\"><italic>P. a</italic>. 74</th><th align=\"center\"><italic>S. a</italic>. 281</th><th align=\"center\"><italic>S. a</italic>. 291</th><th align=\"center\"><italic>S. a</italic>. 25923</th></tr></thead><tbody><tr><td align=\"center\">Standard</td><td align=\"center\">13.251</td><td align=\"center\">14.098</td><td align=\"center\">26.733</td><td align=\"center\">7.712</td><td align=\"center\">14.725</td><td align=\"center\">10.932</td><td align=\"center\">8.586</td><td align=\"center\">9.951</td><td align=\"center\">12.473</td><td align=\"center\">13.108</td></tr><tr><td align=\"center\">M2</td><td align=\"center\">13.332</td><td align=\"center\">14.173</td><td align=\"center\">26.826</td><td align=\"center\">7.735</td><td align=\"center\">14.850</td><td align=\"center\">10.988</td><td align=\"center\">8.646</td><td align=\"center\">10.044</td><td align=\"center\">12.558</td><td align=\"center\">13.164</td></tr><tr><td align=\"center\">M3</td><td align=\"center\">13.050</td><td align=\"center\">14.170</td><td align=\"center\">26.505</td><td align=\"center\">7.759</td><td align=\"center\">14.993</td><td align=\"center\">10.977</td><td align=\"center\">8.745</td><td align=\"center\">10.032</td><td align=\"center\">12.764</td><td align=\"center\">13.410</td></tr><tr><td align=\"center\">M4</td><td align=\"center\">13.166</td><td align=\"center\">14.041</td><td align=\"center\">26.630</td><td align=\"center\">7.670</td><td align=\"center\">15.076</td><td align=\"center\">10.870</td><td align=\"center\">8.635</td><td align=\"center\">9.991</td><td align=\"center\">12.682</td><td align=\"center\">13.202</td></tr><tr><td align=\"center\">M5</td><td align=\"center\">12.961</td><td align=\"center\">14.566</td><td align=\"center\">26.160</td><td align=\"center\">8.305</td><td align=\"center\">14.798</td><td align=\"center\">11.716</td><td align=\"center\">9.474</td><td align=\"center\">10.941</td><td align=\"center\">13.753</td><td align=\"center\">14.662</td></tr><tr><td align=\"center\">M6</td><td align=\"center\">14.495</td><td align=\"center\">13.338</td><td align=\"center\">28.017</td><td align=\"center\">7.355</td><td align=\"center\">13.974</td><td align=\"center\">10.308</td><td align=\"center\">8.016</td><td align=\"center\">9.280</td><td align=\"center\">11.725</td><td align=\"center\">12.324</td></tr><tr><td align=\"center\">M7</td><td align=\"center\">12.523</td><td align=\"center\">14.237</td><td align=\"center\">26.540</td><td align=\"center\">7.856</td><td align=\"center\">16.029</td><td align=\"center\">12.348</td><td align=\"center\">9.666</td><td align=\"center\">11.143</td><td align=\"center\">14.076</td><td align=\"center\">14.729</td></tr><tr><td align=\"center\">M8</td><td align=\"center\">13.441</td><td align=\"center\">13.627</td><td align=\"center\">27.530</td><td align=\"center\">8.053</td><td align=\"center\">15.008</td><td align=\"center\">11.248</td><td align=\"center\">8.903</td><td align=\"center\">10.138</td><td align=\"center\">13.220</td><td align=\"center\">13.440</td></tr><tr><td align=\"center\">M13</td><td align=\"center\">13.052</td><td align=\"center\">14.193</td><td align=\"center\">26.574</td><td align=\"center\">8.003</td><td align=\"center\">14.955</td><td align=\"center\">11.146</td><td align=\"center\">8.908</td><td align=\"center\">10.306</td><td align=\"center\">12.713</td><td align=\"center\">13.489</td></tr><tr><td align=\"center\">M14</td><td align=\"center\">13.792</td><td align=\"center\">15.904</td><td align=\"center\">28.612</td><td align=\"center\">8.481</td><td align=\"center\">15.291</td><td align=\"center\">12.621</td><td align=\"center\">9.897</td><td align=\"center\">11.480</td><td align=\"center\">14.454</td><td align=\"center\">15.286</td></tr><tr><td align=\"center\">M15</td><td align=\"center\">13.791</td><td align=\"center\">15.673</td><td align=\"center\">27.431</td><td align=\"center\">8.190</td><td align=\"center\">15.700</td><td align=\"center\">11.969</td><td align=\"center\">9.500</td><td align=\"center\">11.015</td><td align=\"center\">13.820</td><td align=\"center\">14.539</td></tr><tr><td align=\"center\">M16</td><td align=\"center\">13.483</td><td align=\"center\">14.326</td><td align=\"center\">26.535</td><td align=\"center\">7.698</td><td align=\"center\">14.991</td><td align=\"center\">10.743</td><td align=\"center\">8.458</td><td align=\"center\">9.795</td><td align=\"center\">12.363</td><td align=\"center\">12.986</td></tr><tr><td align=\"center\">M17</td><td align=\"center\">13.720</td><td align=\"center\">15.128</td><td align=\"center\">27.261</td><td align=\"center\">8.068</td><td align=\"center\">15.794</td><td align=\"center\">12.163</td><td align=\"center\">9.519</td><td align=\"center\">11.006</td><td align=\"center\">13.786</td><td align=\"center\">14.510</td></tr><tr><td align=\"center\">M18</td><td align=\"center\">13.697</td><td align=\"center\">14.790</td><td align=\"center\">26.915</td><td align=\"center\">7.720</td><td align=\"center\">15.196</td><td align=\"center\">11.671</td><td align=\"center\">8.965</td><td align=\"center\">10.384</td><td align=\"center\">13.427</td><td align=\"center\">13.807</td></tr><tr><td align=\"center\">M20</td><td align=\"center\">13.568</td><td align=\"center\">14.405</td><td align=\"center\">27.117</td><td align=\"center\">7.660</td><td align=\"center\">14.535</td><td align=\"center\">10.760</td><td align=\"center\">8.506</td><td align=\"center\">9.835</td><td align=\"center\">12.249</td><td align=\"center\">12.886</td></tr><tr><td align=\"center\">M21</td><td align=\"center\">13.192</td><td align=\"center\">14.632</td><td align=\"center\">26.985</td><td align=\"center\">7.857</td><td align=\"center\">16.048</td><td align=\"center\">11.178</td><td align=\"center\">8.759</td><td align=\"center\">10.091</td><td align=\"center\">12.625</td><td align=\"center\">13.413</td></tr><tr><td align=\"center\">M22</td><td align=\"center\">14.067</td><td align=\"center\">13.946</td><td align=\"center\">26.536</td><td align=\"center\">7.774</td><td align=\"center\">15.571</td><td align=\"center\">11.309</td><td align=\"center\">8.741</td><td align=\"center\">10.057</td><td align=\"center\">12.769</td><td align=\"center\">13.437</td></tr><tr><td align=\"center\">M24</td><td align=\"center\">13.334</td><td align=\"center\">14.046</td><td align=\"center\">26.701</td><td align=\"center\">7.856</td><td align=\"center\">14.655</td><td align=\"center\">10.895</td><td align=\"center\">8.639</td><td align=\"center\">10.016</td><td align=\"center\">12.418</td><td align=\"center\">13.125</td></tr><tr><td align=\"center\">M26</td><td align=\"center\">13.882</td><td align=\"center\">14.592</td><td align=\"center\">26.519</td><td align=\"center\">7.638</td><td align=\"center\">15.409</td><td align=\"center\">11.116</td><td align=\"center\">8.739</td><td align=\"center\">10.038</td><td align=\"center\">12.671</td><td align=\"center\">13.299</td></tr><tr><td align=\"center\">M27</td><td align=\"center\">12.741</td><td align=\"center\">13.544</td><td align=\"center\">25.775</td><td align=\"center\">7.474</td><td align=\"center\">14.126</td><td align=\"center\">10.499</td><td align=\"center\">8.326</td><td align=\"center\">9.612</td><td align=\"center\">12.200</td><td align=\"center\">12.595</td></tr><tr><td align=\"center\">M29</td><td align=\"center\">13.571</td><td align=\"center\">14.008</td><td align=\"center\">26.770</td><td align=\"center\">8.274</td><td align=\"center\">15.281</td><td align=\"center\">11.105</td><td align=\"center\">9.143</td><td align=\"center\">10.404</td><td align=\"center\">12.998</td><td align=\"center\">13.887</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 12"}
{"html": "<!DOCTYPE html><html><body><h1>Ratios of sample CC/standard CC for Vancomycin</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">SAMPLE</th><th align=\"center\" colspan=\"10\">MICROORGANISMS</th><th align=\"center\">Ratio Median</th><th align=\"center\">Potency</th></tr><tr><th/><th colspan=\"10\"><hr/></th><th/><th/></tr><tr><th/><th align=\"center\"><bold><italic>E. f</italic></bold>.</th><th align=\"center\"><italic>E. f</italic>. 29212</th><th align=\"center\"><italic>E. f</italic>. 319623</th><th align=\"center\"><italic>A. b</italic>. 59</th><th align=\"center\"><bold><italic>E. g</italic></bold>.</th><th align=\"center\"><italic>P. a</italic>. 43</th><th align=\"center\"><italic>P. a</italic>. 74</th><th align=\"center\"><italic>S. a</italic>. 281</th><th align=\"center\"><italic>S. a</italic>. 291</th><th align=\"center\"><italic>S. a</italic>. 25923</th><th/><th/></tr></thead><tbody><tr><td align=\"center\">Standard</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"center\">M2</td><td align=\"center\">1.006</td><td align=\"center\">1.005</td><td align=\"center\">1.003</td><td align=\"center\">1.003</td><td align=\"center\">1.008</td><td align=\"center\">1.005</td><td align=\"center\">1.007</td><td align=\"center\">1.009</td><td align=\"center\">1.007</td><td align=\"center\">1.004</td><td align=\"center\">1.006</td><td align=\"center\">0.995</td></tr><tr><td align=\"center\">M3</td><td align=\"center\">0.985</td><td align=\"center\">1.005</td><td align=\"center\">0.991</td><td align=\"center\">1.006</td><td align=\"center\">1.018</td><td align=\"center\">1.004</td><td align=\"center\">1.018</td><td align=\"center\">1.008</td><td align=\"center\">1.023</td><td align=\"center\">1.023</td><td align=\"center\">1.008</td><td align=\"center\">1.012</td></tr><tr><td align=\"center\">M4</td><td align=\"center\">0.994</td><td align=\"center\">0.996</td><td align=\"center\">0.996</td><td align=\"center\">0.995</td><td align=\"center\">1.024</td><td align=\"center\">0.994</td><td align=\"center\">1.006</td><td align=\"center\">1.004</td><td align=\"center\">1.017</td><td align=\"center\">1.007</td><td align=\"center\">1.003</td><td align=\"center\">1.005</td></tr><tr><td align=\"center\">M5</td><td align=\"center\">0.978</td><td align=\"center\">1.033</td><td align=\"center\">0.979</td><td align=\"center\">1.077</td><td align=\"center\">1.005</td><td align=\"center\">1.072</td><td align=\"center\">1.103</td><td align=\"center\">1.100</td><td align=\"center\">1.103</td><td align=\"center\">1.119</td><td align=\"center\">1.057</td><td align=\"center\">1.100</td></tr><tr><td align=\"center\">M6</td><td align=\"center\">1.094</td><td align=\"center\">0.946</td><td align=\"center\">1.048</td><td align=\"center\">0.954</td><td align=\"center\">0.949</td><td align=\"center\">0.943</td><td align=\"center\">0.934</td><td align=\"center\">0.933</td><td align=\"center\">0.940</td><td align=\"center\">0.940</td><td align=\"center\">0.968</td><td align=\"center\">0.936</td></tr><tr><td align=\"center\">M7</td><td align=\"center\">0.945</td><td align=\"center\">1.010</td><td align=\"center\">0.993</td><td align=\"center\">1.019</td><td align=\"center\">1.089</td><td align=\"center\">1.130</td><td align=\"center\">1.126</td><td align=\"center\">1.120</td><td align=\"center\">1.128</td><td align=\"center\">1.124</td><td align=\"center\">1.068</td><td align=\"center\">1.124</td></tr><tr><td align=\"center\">M8</td><td align=\"center\">1.014</td><td align=\"center\">0.967</td><td align=\"center\">1.030</td><td align=\"center\">1.044</td><td align=\"center\">1.019</td><td align=\"center\">1.029</td><td align=\"center\">1.037</td><td align=\"center\">1.019</td><td align=\"center\">1.060</td><td align=\"center\">1.025</td><td align=\"center\">1.024</td><td align=\"center\">1.032</td></tr><tr><td align=\"center\">M13</td><td align=\"center\">0.985</td><td align=\"center\">1.007</td><td align=\"center\">0.994</td><td align=\"center\">1.038</td><td align=\"center\">1.016</td><td align=\"center\">1.020</td><td align=\"center\">1.038</td><td align=\"center\">1.036</td><td align=\"center\">1.019</td><td align=\"center\">1.029</td><td align=\"center\">1.018</td><td align=\"center\">1.023</td></tr><tr><td align=\"center\">M14</td><td align=\"center\">1.041</td><td align=\"center\">1.128</td><td align=\"center\">1.070</td><td align=\"center\">1.100</td><td align=\"center\">1.038</td><td align=\"center\">1.155</td><td align=\"center\">1.153</td><td align=\"center\">1.154</td><td align=\"center\">1.159</td><td align=\"center\">1.166</td><td align=\"center\">1.116</td><td align=\"center\">1.150</td></tr><tr><td align=\"center\">M15</td><td align=\"center\">1.041</td><td align=\"center\">1.112</td><td align=\"center\">1.026</td><td align=\"center\">1.062</td><td align=\"center\">1.066</td><td align=\"center\">1.095</td><td align=\"center\">1.106</td><td align=\"center\">1.107</td><td align=\"center\">1.108</td><td align=\"center\">1.109</td><td align=\"center\">1.083</td><td align=\"center\">1.108</td></tr><tr><td align=\"center\">M16</td><td align=\"center\">1.018</td><td align=\"center\">1.016</td><td align=\"center\">0.993</td><td align=\"center\">0.998</td><td align=\"center\">1.018</td><td align=\"center\">0.983</td><td align=\"center\">0.985</td><td align=\"center\">0.984</td><td align=\"center\">0.991</td><td align=\"center\">0.991</td><td align=\"center\">0.998</td><td align=\"center\">0.986</td></tr><tr><td align=\"center\">M17</td><td align=\"center\">1.035</td><td align=\"center\">1.073</td><td align=\"center\">1.020</td><td align=\"center\">1.046</td><td align=\"center\">1.073</td><td align=\"center\">1.113</td><td align=\"center\">1.109</td><td align=\"center\">1.106</td><td align=\"center\">1.105</td><td align=\"center\">1.107</td><td align=\"center\">1.079</td><td align=\"center\">1.107</td></tr><tr><td align=\"center\">M18</td><td align=\"center\">1.034</td><td align=\"center\">1.049</td><td align=\"center\">1.007</td><td align=\"center\">1.001</td><td align=\"center\">1.032</td><td align=\"center\">1.068</td><td align=\"center\">1.044</td><td align=\"center\">1.044</td><td align=\"center\">1.076</td><td align=\"center\">1.053</td><td align=\"center\">1.041</td><td align=\"center\">1.047</td></tr><tr><td align=\"center\">M20</td><td align=\"center\">1.024</td><td align=\"center\">1.022</td><td align=\"center\">1.014</td><td align=\"center\">0.993</td><td align=\"center\">0.987</td><td align=\"center\">0.984</td><td align=\"center\">0.991</td><td align=\"center\">0.988</td><td align=\"center\">0.982</td><td align=\"center\">0.983</td><td align=\"center\">0.997</td><td align=\"center\">0.981</td></tr><tr><td align=\"center\">M21</td><td align=\"center\">0.996</td><td align=\"center\">1.038</td><td align=\"center\">1.009</td><td align=\"center\">1.019</td><td align=\"center\">1.090</td><td align=\"center\">1.023</td><td align=\"center\">1.020</td><td align=\"center\">1.014</td><td align=\"center\">1.012</td><td align=\"center\">1.023</td><td align=\"center\">1.024</td><td align=\"center\">1.019</td></tr><tr><td align=\"center\">M22</td><td align=\"center\">1.062</td><td align=\"center\">0.989</td><td align=\"center\">0.993</td><td align=\"center\">1.008</td><td align=\"center\">1.057</td><td align=\"center\">1.035</td><td align=\"center\">1.018</td><td align=\"center\">1.011</td><td align=\"center\">1.024</td><td align=\"center\">1.025</td><td align=\"center\">1.022</td><td align=\"center\">1.011</td></tr><tr><td align=\"center\">M24</td><td align=\"center\">1.006</td><td align=\"center\">0.996</td><td align=\"center\">0.999</td><td align=\"center\">1.019</td><td align=\"center\">0.995</td><td align=\"center\">0.997</td><td align=\"center\">1.006</td><td align=\"center\">1.006</td><td align=\"center\">0.996</td><td align=\"center\">1.001</td><td align=\"center\">1.002</td><td align=\"center\">1.003</td></tr><tr><td align=\"center\">M26</td><td align=\"center\">1.048</td><td align=\"center\">1.035</td><td align=\"center\">0.992</td><td align=\"center\">0.990</td><td align=\"center\">1.046</td><td align=\"center\">1.017</td><td align=\"center\">1.018</td><td align=\"center\">1.009</td><td align=\"center\">1.016</td><td align=\"center\">1.015</td><td align=\"center\">1.019</td><td align=\"center\">1.011</td></tr><tr><td align=\"center\">M27</td><td align=\"center\">0.962</td><td align=\"center\">0.961</td><td align=\"center\">0.964</td><td align=\"center\">0.969</td><td align=\"center\">0.959</td><td align=\"center\">0.960</td><td align=\"center\">0.970</td><td align=\"center\">0.966</td><td align=\"center\">0.978</td><td align=\"center\">0.961</td><td align=\"center\">0.965</td><td align=\"center\">0.961</td></tr><tr><td align=\"center\">M29</td><td align=\"center\">1.024</td><td align=\"center\">0.994</td><td align=\"center\">1.001</td><td align=\"center\">1.073</td><td align=\"center\">1.038</td><td align=\"center\">1.016</td><td align=\"center\">1.065</td><td align=\"center\">1.046</td><td align=\"center\">1.042</td><td align=\"center\">1.059</td><td align=\"center\">1.036</td><td align=\"center\">1.062</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 13"}
{"html": "<!DOCTYPE html><html><body><h1>Spontaneous mutant production in the diffusion gel assay for vancomycin products</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Sample</th><th align=\"center\" colspan=\"2\">Mutants of <italic>A. baumanii </italic>54</th><th align=\"center\" colspan=\"2\">Mutants of <italic>E. gallinarum</italic></th></tr><tr><th/><th colspan=\"4\"><hr/></th></tr><tr><th/><th align=\"center\">Median</th><th align=\"center\">&#963;</th><th align=\"center\">Median</th><th align=\"center\">&#963;</th></tr></thead><tbody><tr><td align=\"center\">Standard</td><td align=\"center\">106.17</td><td align=\"center\">1.47</td><td align=\"center\">96.500</td><td align=\"center\">5.089</td></tr><tr><td align=\"center\">M2</td><td align=\"center\">111.00</td><td align=\"center\">1.00</td><td align=\"center\">100.667</td><td align=\"center\">2.082</td></tr><tr><td align=\"center\">M3</td><td align=\"center\">104.33</td><td align=\"center\">1.53</td><td align=\"center\">98.333</td><td align=\"center\">1.528</td></tr><tr><td align=\"center\">M4</td><td align=\"center\">106.67</td><td align=\"center\">2.08</td><td align=\"center\">104.667</td><td align=\"center\">5.686</td></tr><tr><td align=\"center\">M5</td><td align=\"center\">103.67</td><td align=\"center\">0.58</td><td align=\"center\">99.000</td><td align=\"center\">2.000</td></tr><tr><td align=\"center\">M6</td><td align=\"center\">109.00</td><td align=\"center\">1.00</td><td align=\"center\">96.000</td><td align=\"center\">2.000</td></tr><tr><td align=\"center\">M7</td><td align=\"center\">110.67</td><td align=\"center\">1.53</td><td align=\"center\">100.667</td><td align=\"center\">1.155</td></tr><tr><td align=\"center\">M8</td><td align=\"center\">108.67</td><td align=\"center\">1.53</td><td align=\"center\">98.667</td><td align=\"center\">1.155</td></tr><tr><td align=\"center\">M10</td><td align=\"center\">104.00</td><td align=\"center\">1.73</td><td align=\"center\">95.667</td><td align=\"center\">1.528</td></tr><tr><td align=\"center\">M12</td><td align=\"center\">110.67</td><td align=\"center\">1.53</td><td align=\"center\">93.333</td><td align=\"center\">2.517</td></tr><tr><td align=\"center\">M13</td><td align=\"center\">106.33</td><td align=\"center\">1.53</td><td align=\"center\">94.000</td><td align=\"center\">3.000</td></tr><tr><td align=\"center\">M14</td><td align=\"center\">106.67</td><td align=\"center\">2.52</td><td align=\"center\">101.000</td><td align=\"center\">1.000</td></tr><tr><td align=\"center\">M15</td><td align=\"center\">110.67</td><td align=\"center\">1.15</td><td align=\"center\">99.333</td><td align=\"center\">1.155</td></tr><tr><td align=\"center\">M17</td><td align=\"center\">105.33</td><td align=\"center\">1.15</td><td align=\"center\">93.667</td><td align=\"center\">3.786</td></tr><tr><td align=\"center\">M18</td><td align=\"center\">104.33</td><td align=\"center\">2.08</td><td align=\"center\">96.000</td><td align=\"center\">1.000</td></tr><tr><td align=\"center\">M20</td><td align=\"center\">109.33</td><td align=\"center\">1.53</td><td align=\"center\">100.667</td><td align=\"center\">0.577</td></tr><tr><td align=\"center\">M22</td><td align=\"center\">112.00</td><td align=\"center\">1.00</td><td align=\"center\">103.000</td><td align=\"center\">3.000</td></tr><tr><td align=\"center\">M24</td><td align=\"center\">105.33</td><td align=\"center\">1.53</td><td align=\"center\">96.000</td><td align=\"center\">1.000</td></tr><tr><td align=\"center\">M26</td><td align=\"center\">109.33</td><td align=\"center\">1.53</td><td align=\"center\">100.667</td><td align=\"center\">0.577</td></tr><tr><td align=\"center\">M27</td><td align=\"center\">112.00</td><td align=\"center\">1.00</td><td align=\"center\">103.000</td><td align=\"center\">3.000</td></tr><tr><td align=\"center\">M29</td><td align=\"center\">105.33</td><td align=\"center\">1.53</td><td align=\"center\">96.000</td><td align=\"center\">1.000</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">F</td><td align=\"center\" colspan=\"2\">10.026</td><td align=\"center\" colspan=\"2\">4.424</td></tr><tr><td align=\"center\">Prob.</td><td align=\"center\" colspan=\"2\">0.001</td><td align=\"center\" colspan=\"2\">0.005</td></tr><tr><td align=\"center\">VCF</td><td align=\"center\" colspan=\"2\">1.706</td><td align=\"center\" colspan=\"2\">1.706</td></tr></tbody></table></body></html>", "text": "Pmid= 3158544:Table= Table 14"}
{"html": "<!DOCTYPE html><html><body><h1>Demographic and clinical data of patients on continuous veno-venous haemodiafiltration administered ciprofloxacin</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Sex</th><th align=\"left\">Age</th><th align=\"left\">Diagnosis</th><th align=\"left\">Infective<break/>pathogen</th><th align=\"left\">APACHE II score(initial/highest)</th><th align=\"left\">CVVHDF Duration(days)</th><th align=\"left\">ICU Mortality Outcome</th></tr></thead><tbody><tr><td align=\"left\">1</td><td align=\"left\">M</td><td align=\"left\">60</td><td align=\"left\">Intestinal Obstruction, Hemicolectomy</td><td align=\"left\"><italic>Escherichia coli</italic></td><td align=\"left\">26</td><td align=\"left\">6</td><td align=\"left\">Survived</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">2</td><td align=\"left\">F</td><td align=\"left\">77</td><td align=\"left\">Neutropaenic sepsis</td><td align=\"left\"><italic>Pseudomonas aeruginosa</italic></td><td align=\"left\">27</td><td align=\"left\">5</td><td align=\"left\">Died</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">3</td><td align=\"left\">F</td><td align=\"left\">68</td><td align=\"left\">Intestinal obstruction, post-operative sepsis and acute renal failure</td><td align=\"left\"><italic>Pseudomonas aeruginos</italic>a</td><td align=\"left\">28</td><td align=\"left\">14</td><td align=\"left\">Survived</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">4</td><td align=\"left\">M</td><td align=\"left\">47</td><td align=\"left\">Acute pancreatitis, sepsis</td><td align=\"left\"><italic>Escherichia Coli</italic></td><td align=\"left\">25</td><td align=\"left\">14</td><td align=\"left\">Survived</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">5</td><td align=\"left\">F</td><td align=\"left\">71</td><td align=\"left\">ESRD with severe sepsis</td><td align=\"left\">Empiric cover</td><td align=\"left\">27</td><td align=\"left\">8</td><td align=\"left\">Died</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">6</td><td align=\"left\">M</td><td align=\"left\">57</td><td align=\"left\">Hepatic cirrhosis with severe sepsis</td><td align=\"left\"><italic>Pseudomonas Aeruginosa, Enterococcus faecalis</italic></td><td align=\"left\">29</td><td align=\"left\">7</td><td align=\"left\">Survived</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">7</td><td align=\"left\">M</td><td align=\"left\">28</td><td align=\"left\">Acute liver failure with severe sepsis</td><td align=\"left\"><italic>Pseudomonas aeruginosa</italic></td><td align=\"left\">30</td><td align=\"left\">11</td><td align=\"left\">Survived</td></tr></tbody></table></body></html>", "text": "Pmid= 3161942:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Estimates of pharmacokinetic parameters obtained from multiple ciprofloxacin serum concentrations in a dosage interval using non-compartmental methods</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Patient<break/>Profile</th><th align=\"left\">Dose<break/>(mg)</th><th align=\"left\">Dosage<break/>Interval<break/>(hours)</th><th align=\"left\">T<sub>1/2 </sub>(hrs)</th><th align=\"left\">k<break/>(hr<sup>-1</sup>)</th><th align=\"left\">AUC<sub>0-&#964;</sub>*<break/><sub>(&#964; = dosage</sub><break/><sub>interval)</sub><break/>(mg.hr/L)</th><th align=\"left\">TBC (Dose/AUC)<break/>(L/hr)</th><th align=\"left\">Vd<sub>ss</sub><break/>(L)</th></tr></thead><tbody><tr><td align=\"left\">1.A</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">35.2</td><td align=\"left\">0.020</td><td align=\"left\">35.4</td><td align=\"left\">11.3</td><td align=\"left\">524</td></tr><tr><td align=\"left\">1.B</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">39.4</td><td align=\"left\">0.018</td><td align=\"left\">38.3</td><td align=\"left\">10.4</td><td align=\"left\">555</td></tr><tr><td align=\"left\"><bold>Mean</bold></td><td/><td/><td align=\"left\"><bold>37.3</bold></td><td align=\"left\"><bold>0.019</bold></td><td align=\"left\"><bold>36.8</bold></td><td align=\"left\"><bold>10.9</bold></td><td align=\"left\"><bold>539</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">2.A</td><td align=\"left\">200</td><td align=\"left\">12</td><td align=\"left\">5.15</td><td align=\"left\">0.135</td><td align=\"left\">15.2</td><td align=\"left\">13.2</td><td align=\"left\">104</td></tr><tr><td align=\"left\">2.B</td><td align=\"left\">200</td><td align=\"left\">12</td><td align=\"left\">13.8</td><td align=\"left\">0.050</td><td align=\"left\">16.5</td><td align=\"left\">12.2</td><td align=\"left\">215</td></tr><tr><td align=\"left\">2.C</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">12.4</td><td align=\"left\">0.056</td><td align=\"left\">51.8</td><td align=\"left\">7.72</td><td/></tr><tr><td align=\"left\"><bold>Mean</bold></td><td/><td/><td align=\"left\"><bold>10.5</bold></td><td align=\"left\"><bold>0.080</bold></td><td/><td align=\"left\"><bold>11.0</bold></td><td align=\"left\"><bold>160</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">3.A</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">5.97</td><td align=\"left\">0.116</td><td align=\"left\">38.9</td><td align=\"left\">10.3</td><td align=\"left\">79.5</td></tr><tr><td align=\"left\">3.B</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">7.50</td><td align=\"left\">0.092</td><td align=\"left\">40.2</td><td align=\"left\">10.0</td><td align=\"left\">97.3</td></tr><tr><td align=\"left\"><bold>Mean</bold></td><td/><td/><td align=\"left\"><bold>6.73</bold></td><td align=\"left\"><bold>0.104</bold></td><td align=\"left\"><bold>39.5</bold></td><td align=\"left\"><bold>10.1</bold></td><td align=\"left\"><bold>88.4</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">4.A</td><td align=\"left\">400</td><td align=\"left\">24</td><td align=\"left\">24.7</td><td align=\"left\">0.028</td><td align=\"left\">129</td><td align=\"left\">3.10</td><td align=\"left\">111</td></tr><tr><td align=\"left\">4.B</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">27.2</td><td align=\"left\">0.026</td><td align=\"left\">81.5</td><td align=\"left\">4.91</td><td/></tr><tr><td align=\"left\"><bold>Mean</bold></td><td/><td/><td align=\"left\"><bold>25.9</bold></td><td align=\"left\"><bold>0.027</bold></td><td/><td align=\"left\"><bold>4.00</bold></td><td/></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">5.A</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">8.44</td><td align=\"left\">0.082</td><td align=\"left\">40.4</td><td align=\"left\">9.90</td><td align=\"left\">107</td></tr><tr><td align=\"left\">5.B</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">5.77</td><td align=\"left\">0.120</td><td align=\"left\">37.8</td><td align=\"left\">10.6</td><td align=\"left\">81.1</td></tr><tr><td align=\"left\">5.C</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">6.80</td><td align=\"left\">0.102</td><td align=\"left\">40.9</td><td align=\"left\">9.78</td><td align=\"left\">88.2</td></tr><tr><td align=\"left\"><bold>Mean</bold></td><td/><td/><td align=\"left\"><bold>7.00</bold></td><td align=\"left\"><bold>0.101</bold></td><td align=\"left\"><bold>39.7</bold></td><td align=\"left\"><bold>10.1</bold></td><td align=\"left\"><bold>92.2</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">6.A</td><td align=\"left\">400</td><td align=\"left\">24</td><td align=\"left\">14.0</td><td align=\"left\">0.050</td><td align=\"left\">43.4</td><td align=\"left\">9.22</td><td align=\"left\">175</td></tr><tr><td align=\"left\">6.B</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">14.7</td><td align=\"left\">0.047</td><td align=\"left\">54.0</td><td align=\"left\">7.40</td><td align=\"left\">151</td></tr><tr><td align=\"left\">6.C</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">16.5</td><td align=\"left\">0.042</td><td align=\"left\">49.6</td><td align=\"left\">8.06</td><td/></tr><tr><td align=\"left\"><bold>Mean</bold></td><td/><td/><td align=\"left\"><bold>15.0</bold></td><td align=\"left\"><bold>0.046</bold></td><td/><td align=\"left\"><bold>8.23</bold></td><td align=\"left\"><bold>163</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">7.A</td><td align=\"left\">400</td><td align=\"left\">24</td><td align=\"left\">15.1</td><td align=\"left\">0.046</td><td align=\"left\">50.6</td><td align=\"left\">7.91</td><td align=\"left\">164</td></tr><tr><td align=\"left\">7.B</td><td align=\"left\">400</td><td align=\"left\">12</td><td align=\"left\">10.4</td><td align=\"left\">0.067</td><td align=\"left\">39.4</td><td align=\"left\">10.1</td><td align=\"left\">139</td></tr><tr><td align=\"left\"><bold>Mean</bold></td><td/><td/><td align=\"left\"><bold>12.7</bold></td><td align=\"left\"><bold>0.056</bold></td><td/><td align=\"left\"><bold>9.00</bold></td><td align=\"left\"><bold>151</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 3161942:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Ciprofloxacin and Creatinine Clearance by continuous veno-venous haemodiafiltration.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Patient</th><th align=\"left\">Cl<sub>CVVHDF</sub><break/>(L/hr)</th><th align=\"left\">Cl<sub>CREAT</sub><break/>(L/hr)</th><th align=\"left\">F<sub>CVVHDF</sub></th><th align=\"left\">Measured effluent<break/>fluid rate<break/>(L/hr)</th><th align=\"left\">Total Body<break/>Clearance<break/>(L/hr)</th></tr></thead><tbody><tr><td align=\"left\">1 A</td><td align=\"left\">2.8</td><td align=\"left\">2.9</td><td align=\"left\">0.25</td><td align=\"left\">4.0</td><td align=\"left\">11.3</td></tr><tr><td align=\"left\">2 C</td><td align=\"left\">2.4</td><td align=\"left\">2.6</td><td align=\"left\">0.31</td><td align=\"left\">3.4</td><td align=\"left\">7.72</td></tr><tr><td align=\"left\">3 B</td><td align=\"left\">2.7</td><td align=\"left\">2.9</td><td align=\"left\">0.27</td><td align=\"left\">3.9</td><td align=\"left\">9.96</td></tr><tr><td align=\"left\">4 A</td><td align=\"left\">2.3</td><td align=\"left\">2.3</td><td align=\"left\">0.74</td><td align=\"left\">2.9</td><td align=\"left\">3.10</td></tr><tr><td align=\"left\">5 A</td><td align=\"left\">2.2</td><td align=\"left\">2.6</td><td align=\"left\">0.22</td><td align=\"left\">3.0</td><td align=\"left\">9.90</td></tr><tr><td align=\"left\">6 C</td><td align=\"left\">2.1</td><td align=\"left\">2.4</td><td align=\"left\">0.26</td><td align=\"left\">2.9</td><td align=\"left\">8.06</td></tr><tr><td align=\"left\">7 B</td><td align=\"left\">2.8</td><td align=\"left\">2.9</td><td align=\"left\">0.28</td><td align=\"left\">4.0</td><td align=\"left\">10.1</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>Mean +/- SD</bold></td><td align=\"left\"><bold>2.47 +/- 0.29</bold></td><td align=\"left\"><bold>2.66 +/- 0.25</bold></td><td align=\"left\"><bold>0.26 &#177; 0.03*</bold></td><td align=\"left\"><bold>3.35 +/- 0.50</bold></td><td align=\"left\"><bold>8.60 &#177; 2.7</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 3161942:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Cpmax/MIC ratios for representative MICs for patients treated with 400 mg ciprofloxacin every 12 hours during critical illness and continuous veno-venous haemodiafiltration therapy.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Patient<break/>ID</th><th align=\"left\">Cpmax/MIC ratio<break/>(MIC = O.5 mg/L)</th><th align=\"left\">AUC<sub>0-24</sub>/MIC ratio<break/>(MIC = O.5 mg/L)</th></tr></thead><tbody><tr><td align=\"left\">1</td><td align=\"left\">10.3</td><td align=\"left\">147</td></tr><tr><td align=\"left\">2</td><td align=\"left\">10.2</td><td align=\"left\">207</td></tr><tr><td align=\"left\">3</td><td align=\"left\">12.8</td><td align=\"left\">158</td></tr><tr><td align=\"left\">5</td><td align=\"left\">14.6</td><td align=\"left\">159</td></tr><tr><td align=\"left\">6</td><td align=\"left\">10.0</td><td align=\"left\">199</td></tr></tbody></table></body></html>", "text": "Pmid= 3161942:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Group demographics in sample I</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Buprenorphine<break/>(n = 14)</th><th align=\"left\">Methadone<break/>(n = 12)</th><th align=\"left\">Healthy control<break/>(n = 14)</th><th align=\"left\">Group comparison <italic>p</italic>-values</th></tr></thead><tbody><tr><td align=\"left\">Age (<italic>M </italic>&#177; <italic>SD</italic>)</td><td align=\"left\">30 &#177; 7</td><td align=\"left\">31 &#177; 8</td><td align=\"left\">29 &#177; 10</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Sex (female/male)</td><td align=\"left\">36%/64%</td><td align=\"left\">50%/50%</td><td align=\"left\">50%/50%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Intelligence<sup>a </sup>(<italic>M &#177; SD</italic>)</td><td align=\"left\">101 &#177; 11</td><td align=\"left\">98 &#177; 9</td><td align=\"left\">105 &#177; 8</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Education, years</td><td align=\"left\">10 &#177; 2</td><td align=\"left\">10 &#177; 1</td><td align=\"left\">13 &#177; 1</td><td align=\"left\">BN &amp; M &lt; HC ***</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Main opioid of abuse used within last month at T1 (%)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Buprenorphine</td><td align=\"left\">93%</td><td align=\"left\">83%?</td><td align=\"left\">-</td><td align=\"left\"><italic>ns<sup>b</sup></italic></td></tr><tr><td align=\"left\">&#8195;Heroin</td><td align=\"left\">7%</td><td align=\"left\">17%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns<sup>b</sup></italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Days in opioid substitution treatment at test (<italic>M &#177; SD</italic>)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;T1</td><td align=\"left\">21 &#177; 15</td><td align=\"left\">20 &#177; 14</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td align=\"left\">&#8195;T2</td><td align=\"left\">210 &#177; 20</td><td align=\"left\">200 &#177; 28</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td align=\"left\">&#8195;T3</td><td align=\"left\">414 &#177; 46</td><td align=\"left\">405 &#177; 31</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Examined in inpatient settings %</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;T1</td><td align=\"left\">21%</td><td align=\"left\">25%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td align=\"left\">&#8195;T2</td><td align=\"left\">7%</td><td align=\"left\">0%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td align=\"left\">&#8195;T3</td><td align=\"left\">7%</td><td align=\"left\">8%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Participants with high frequency of use of any substance of abuse <sup>c </sup>%</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;T1</td><td align=\"left\">86%</td><td align=\"left\">67%</td><td align=\"left\">14%</td><td align=\"left\">BN &gt; HC ***; M &gt; HC *</td></tr><tr><td align=\"left\">&#8195;T2</td><td align=\"left\">29%</td><td align=\"left\">42%</td><td align=\"left\">7%</td><td align=\"left\"><italic>ns </italic>; <italic>ns</italic></td></tr><tr><td align=\"left\">&#8195;T3</td><td align=\"left\">36%</td><td align=\"left\">33%</td><td align=\"left\">7%</td><td align=\"left\"><italic>ns </italic>; <italic>ns</italic></td></tr><tr><td/><td align=\"left\">T2 &lt; T1**</td><td align=\"left\">T3 &lt; T1*</td><td/><td/></tr><tr><td/><td align=\"left\">T3 &lt; T1*</td><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Participants with the past month extra doses of any opioid <sup>d</sup>, %</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;T1</td><td align=\"left\">86%</td><td align=\"left\">92%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td align=\"left\">&#8195;T2</td><td align=\"left\">29%</td><td align=\"left\">33%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td align=\"left\">&#8195;T3</td><td align=\"left\">36%</td><td align=\"left\">33%</td><td align=\"left\">-</td><td align=\"left\"><italic>ns</italic><sup>b</sup></td></tr><tr><td/><td align=\"left\">T2 &lt; T1**</td><td align=\"left\">T2 &lt; T1**</td><td/><td/></tr><tr><td/><td align=\"left\">T3 &lt; T1*</td><td align=\"left\">T3 &lt; T1**</td><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Participants with the past month nicotine use (daily)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;T1</td><td align=\"left\">100%</td><td align=\"left\">100%</td><td align=\"left\">36%</td><td align=\"left\">BN &amp; M &gt; HC ***</td></tr><tr><td align=\"left\">&#8195;T2</td><td align=\"left\">100%</td><td align=\"left\">100%</td><td align=\"left\">36%</td><td align=\"left\">BN &amp; M &gt; HC ***</td></tr><tr><td align=\"left\">&#8195;T3</td><td align=\"left\">100%</td><td align=\"left\">93%</td><td align=\"left\">29%</td><td align=\"left\">BN &gt; HC **; M &gt; HC ***</td></tr></tbody></table></body></html>", "text": "Pmid= 3176473:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Medications given to participants within the last 24 h before testing in sample I</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Buprenorphine<break/>(n = 14)</th><th align=\"left\">Methadone<break/>(n = 12)</th><th align=\"left\">Healthy control<break/>(n = 14)</th><th align=\"left\">Group or time point comparison <italic>p</italic>-values</th></tr></thead><tbody><tr><td align=\"left\">Opioid agonist drug, dose</td><td/><td/><td/><td/></tr><tr><td align=\"left\">Buprenorphine (<italic>M </italic>&#177; <italic>SD</italic>;<break/>(range) )</td><td/><td/><td/><td/></tr><tr><td align=\"left\">T1</td><td align=\"left\">16 &#177; 3 mg<break/>(12 - 24 mg)</td><td align=\"left\">-</td><td align=\"left\">-</td><td align=\"left\">-</td></tr><tr><td align=\"left\">T2</td><td align=\"left\">20 &#177; 5 mg<break/>(14 - 28 mg)</td><td align=\"left\">-</td><td align=\"left\">-</td><td align=\"left\">T2 &gt; T1**</td></tr><tr><td align=\"left\">T3<break/>Methadone (<italic>M </italic>&#177; <italic>SD</italic>;(range) )</td><td align=\"left\">21 &#177; 6 mg<break/>(6 - 28 mg)</td><td align=\"left\">-</td><td align=\"left\">-</td><td align=\"left\">T3 &gt; T1**</td></tr><tr><td align=\"left\">T1</td><td align=\"left\">-</td><td align=\"left\">71 &#177; 39 mg<break/>(30 - 135 mg)</td><td align=\"left\">-</td><td align=\"left\">-</td></tr><tr><td align=\"left\">T2</td><td align=\"left\">-</td><td align=\"left\">127 &#177; 36 mg<break/>(80 - 180 mg)</td><td align=\"left\">-</td><td align=\"left\">T2 &gt; T1 ***</td></tr><tr><td align=\"left\">T3</td><td align=\"left\">-</td><td align=\"left\">135 &#177; 34 mg<break/>(75 - 180 mg)</td><td align=\"left\">-</td><td align=\"left\">T3 &gt; T1 ***</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Participants treated with BZD medication</td><td/><td/><td align=\"left\">\\'</td><td/></tr><tr><td align=\"left\">T1</td><td align=\"left\">79%</td><td align=\"left\">100%</td><td align=\"left\">0%</td><td align=\"left\">BN &amp; M &gt; HC ***</td></tr><tr><td align=\"left\">BZD dose at T1 (<italic>M </italic>&#177; <italic>SD</italic>)</td><td align=\"left\">20 &#177; 17 mg</td><td align=\"left\">21 &#177; 11 mg</td><td align=\"left\">-</td><td align=\"left\"><italic>ns </italic><sup>a</sup></td></tr><tr><td align=\"left\">T2</td><td align=\"left\">71%</td><td align=\"left\">100%</td><td align=\"left\">0%</td><td align=\"left\">BN &amp; M &gt; HC ***</td></tr><tr><td align=\"left\">BZD dose at T2 (<italic>M </italic>&#177; <italic>SD</italic>)</td><td align=\"left\">16 &#177; 11 mg</td><td align=\"left\">22 &#177; 11 mg</td><td align=\"left\">-</td><td align=\"left\"><italic>ns </italic><sup>a</sup></td></tr><tr><td align=\"left\">T3</td><td align=\"left\">64%</td><td align=\"left\">100%</td><td align=\"left\">0%</td><td align=\"left\">BN &amp; M &gt; HC ***</td></tr><tr><td align=\"left\">BZD dose at T3 (<italic>M </italic>&#177; <italic>SD</italic>)</td><td align=\"left\">13 &#177; 12 mg</td><td align=\"left\">22 &#177; 9. mg</td><td align=\"left\">-</td><td align=\"left\">BN &lt; M *</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Number of other medications with possible cognitive effects <sup>b</sup><break/>(<italic>M </italic>&#177; <italic>SD </italic>(range))</td><td/><td/><td/><td/></tr><tr><td align=\"left\">T1</td><td align=\"left\">1.9 &#177; 1.1<break/>(0 - 4)</td><td align=\"left\">3.0 &#177; 1.3<break/>(0 - 5)</td><td align=\"left\">0.2 &#177; 0.4<break/>(0 - 1)</td><td align=\"left\">BN &amp; M &gt; HC ***<sup>; </sup>M &gt; BN *</td></tr><tr><td align=\"left\">T2</td><td align=\"left\">1.9 &#177; 1.2<break/>(0 - 3)</td><td align=\"left\">2.3 &#177; 0.8<break/>(1 - 4)</td><td align=\"left\">0.2 &#177; 0.4<break/>(0 -1)</td><td align=\"left\">BN &amp; M &gt; HC ***</td></tr><tr><td align=\"left\">T3</td><td align=\"left\">1.8 &#177; 1.3<break/>(0 -4)</td><td align=\"left\">2.2 &#177; 1.0<break/>(1 -4)</td><td align=\"left\">0.2 &#177; 0.4<break/>(0 -1)</td><td align=\"left\">BN &amp; M &gt; HC ***</td></tr></tbody></table></body></html>", "text": "Pmid= 3176473:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Group demographics in sample II</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Buprenorphine or Buprenorphine/<break/>Naloxone<break/>(<italic>n </italic>= 18)</th><th align=\"left\">Methadone<break/>(<italic>n </italic>= 18)</th><th align=\"left\">Group or time point comparison <italic>p</italic>-values</th></tr></thead><tbody><tr><td align=\"left\">Age, years at T1<break/>(<italic>M &#177; SD</italic>)</td><td align=\"left\">30 &#177; 8</td><td align=\"left\">32 &#177; 8</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Sex: females/males, %</td><td align=\"left\">28/72%</td><td align=\"left\">33/67%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Verbal IQ <sup>a</sup><break/>(<italic>M &#177; SD</italic>)</td><td align=\"left\">101 &#177; 8</td><td align=\"left\">100 &#177; 11</td><td align=\"left\"><italic>ns </italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Education, years<break/>(<italic>M &#177; SD</italic>)</td><td align=\"left\">10 &#177; 2</td><td align=\"left\">11 &#177; 1</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Participants with early neurobehavioral problems %</td><td align=\"left\">33%</td><td align=\"left\">28%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Examined in inpatient settings %</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;T2</td><td align=\"left\">6%</td><td align=\"left\">6%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">&#8195;T3</td><td align=\"left\">11%</td><td align=\"left\">11%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Participants with high frequency use of any substance of abuse % <sup>b</sup></td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;T2</td><td align=\"left\">44%</td><td align=\"left\">39%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">&#8195;T3</td><td align=\"left\">44%</td><td align=\"left\">44%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Participants with recent month extra doses of any opioid % <sup>c</sup></td><td/><td/><td/></tr><tr><td align=\"left\">T2</td><td align=\"left\">36%</td><td align=\"left\">36%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">T3</td><td align=\"left\">36%</td><td align=\"left\">43%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Nicotine, participants using daily, %</td><td/><td/><td/></tr><tr><td align=\"left\">T2</td><td align=\"left\">100%</td><td align=\"left\">100%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">T3</td><td align=\"left\">100%</td><td align=\"left\">100%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Days in opioid substitution treatment at test (<italic>M &#177; SD</italic>)</td><td/><td/><td/></tr><tr><td align=\"left\">T2</td><td align=\"left\">211 &#177; 19</td><td align=\"left\">196 &#177; 27</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"left\">T3</td><td align=\"left\">411 &#177; 43</td><td align=\"left\">405 &#177; 29</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Age of onset, any substance abuse (<italic>M &#177; SD</italic>)</td><td align=\"left\">16 &#177; 4</td><td align=\"left\">15 &#177; 3</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Age of onset, opioid abuse<break/>(<italic>M &#177; SD</italic>)</td><td align=\"left\">19 &#177; 5</td><td align=\"left\">19 &#177; 4</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Participants with lifetime alcohol abuse</td><td align=\"left\">72%</td><td align=\"left\">83%</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Years of any substance abuse at T1 (<italic>M &#177; SD</italic>)</td><td align=\"left\">15 &#177; 7</td><td align=\"left\">17 &#177; 7</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Years of alcohol abuse at T1<break/>(<italic>M &#177; SD</italic>)</td><td align=\"left\">3 &#177; 4</td><td align=\"left\">3 &#177; 3</td><td align=\"left\"><italic>ns<sup>b</sup></italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Years of opioid abuse at T1, years (<italic>M &#177; SD</italic>)</td><td align=\"left\">10 &#177; 7</td><td align=\"left\">12 &#177; 7</td><td align=\"left\"><italic>ns</italic></td></tr></tbody></table></body></html>", "text": "Pmid= 3176473:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Medications given to participants within the last 24 h before testing in sample II</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Buprenorphine or Buprenorphine/<break/>Naloxone<break/>(<italic>n </italic>= 18)</th><th align=\"left\">Methadone<break/>(<italic>n </italic>= 18)</th><th align=\"left\">Group or time point comparison <italic>p</italic>-values</th></tr></thead><tbody><tr><td align=\"left\">Opioid drug, dose<break/>(<italic>M </italic>&#177; <italic>SD </italic>(range) )</td><td/><td/><td/></tr><tr><td align=\"left\">T2</td><td align=\"left\">22 &#177; 5 mg<break/>( 10 - 28 mg)</td><td align=\"left\">-</td><td align=\"left\">T2 vs. T3, <italic>ns</italic></td></tr><tr><td align=\"left\">T3</td><td align=\"left\">21 &#177; 6 mg<break/>( 6 - 30 mg)</td><td align=\"left\">-</td><td/></tr><tr><td align=\"left\">T2</td><td align=\"left\">-</td><td align=\"left\">119. &#177; 33 mg<break/>(80 - 180 mg)</td><td align=\"left\">T2 vs. T3, <italic>ns</italic></td></tr><tr><td align=\"left\">T3</td><td align=\"left\">-</td><td align=\"left\">129 &#177; 33 mg<break/>(75 - 180 mg)</td><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Participants using BZD medication</td><td/><td/><td/></tr><tr><td align=\"left\">T2/T3</td><td align=\"left\">78%/67%</td><td align=\"left\">89%/94%</td><td align=\"left\"><italic>ns/ns</italic></td></tr><tr><td align=\"left\">BZD dose at T2 (<italic>M </italic>&#177; <italic>SD </italic>(range))</td><td align=\"left\">20 &#177; 16 mg<break/>(0 - 60 mg)</td><td align=\"left\">21 &#177; 16 mg<break/>(0 - 70 mg)</td><td align=\"left\">T2 vs. T3, <italic>ns</italic><break/><italic>ns</italic></td></tr><tr><td align=\"left\">BZD dose at T3 (<italic>M </italic>&#177; <italic>SD </italic>(range))</td><td align=\"left\">16 &#177; 14 mg<break/>(0 - 40 mg)</td><td align=\"left\">20 &#177; 10 mg<break/>(0 - 40 mg)</td><td align=\"left\"><italic>ns</italic><break/>T2 vs. T3, <italic>ns</italic></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Number of other medications with possible cognitive effects <sup>a</sup></td><td/><td/><td/></tr><tr><td align=\"left\">T2/T3 (<italic>M </italic>&#177; <italic>SD </italic>; (range))</td><td align=\"left\">1.8 &#177; 1.1 (0 - 3)</td><td align=\"left\">2.2 &#177; 0.7 (1 -4)</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td/><td align=\"left\">1.9 &#177; 1.4 (0 - 4)</td><td align=\"left\">2.0 &#177; 1.0 (1 - 4)</td><td align=\"left\"><italic>ns </italic></td></tr><tr><td/><td/><td/><td align=\"left\">T2 vs. T3, <italic>ns</italic></td></tr></tbody></table></body></html>", "text": "Pmid= 3176473:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Group comparisons of cognitive performances using repeated measures ANOVA in sample I</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">TAP Tonic Alertness/simple reaction time (ms)</th><th/><th/><th/><th/></tr><tr><th align=\"center\">T1</th><th align=\"left\">232 &#177; 25</th><th align=\"left\">261 &#177; 21</th><th align=\"left\">238 &#177; 22</th><th align=\"left\">Group, <italic>p </italic>= 0.002</th></tr><tr><th align=\"center\">T2</th><th align=\"left\">236 &#177; 18</th><th align=\"left\">263 &#177; 21</th><th align=\"left\">233 &#177; 21<sup>a</sup></th><th align=\"left\">Time, <italic>ns</italic></th></tr><tr><th align=\"center\">T3</th><th align=\"left\">242 &#177; 25</th><th align=\"left\">267 &#177; 36</th><th align=\"left\">241 &#177; 25</th><th align=\"left\">Group &#215; Time, <italic>ns</italic></th></tr></thead><tbody><tr><td align=\"center\">TAP Phasic Alertness/ reaction time with warning signal (ms)</td><td/><td/><td/><td/></tr><tr><td align=\"center\">T1</td><td align=\"left\">227 &#177; 24</td><td align=\"left\">244 &#177; 20</td><td align=\"left\">226 &#177; 21</td><td align=\"left\"><bold>Group, <italic>p </italic>= 0.005</bold></td></tr><tr><td align=\"center\">T2</td><td align=\"left\">229 &#177; 21</td><td align=\"left\">255 &#177; 28</td><td align=\"left\">224 &#177; 21 <sup>a</sup></td><td align=\"left\">Time, <italic>ns</italic></td></tr><tr><td align=\"center\">T3</td><td align=\"left\">229 &#177; 19</td><td align=\"left\">254 &#177; 45</td><td align=\"left\">225 &#177; 22</td><td align=\"left\">Group &#215; Time, <italic>ns</italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">TAP Go-NoGo reaction time (ms)</td><td/><td/><td/><td/></tr><tr><td align=\"center\">T1</td><td align=\"left\">490 &#177; 50</td><td align=\"left\">548 &#177; 74</td><td align=\"left\">460 &#177; 41</td><td align=\"left\"><bold>Group, <italic>p </italic>= 0.001</bold></td></tr><tr><td align=\"center\">T2</td><td align=\"left\">480 &#177; 42</td><td align=\"left\">548 &#177; 104</td><td align=\"left\">443 &#177; 72 <sup>a</sup></td><td align=\"left\"><bold>Group, <italic>p </italic>= 0.002</bold></td></tr><tr><td align=\"center\">T3</td><td align=\"left\">493 &#177; 43</td><td align=\"left\">529 &#177; 63</td><td align=\"left\">462 &#177; 47</td><td align=\"left\"><bold>Age, <italic>p </italic>= 0.022</bold></td></tr><tr><td/><td/><td/><td/><td align=\"left\">Time, <italic>ns</italic></td></tr><tr><td/><td/><td/><td/><td align=\"left\">Group &#215; Time, <italic>ns</italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">TAP Go-NoGo errors</td><td/><td/><td/><td/></tr><tr><td align=\"center\">T1</td><td align=\"left\">1.1 &#177; 1.3</td><td align=\"left\">0.7 &#177; 0.6</td><td align=\"left\">0.5 &#177; 0.5</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"center\">T2</td><td align=\"left\">0.5 &#177; 0.7</td><td align=\"left\">1.0 &#177; 0.9</td><td align=\"left\">0.5 &#177; 0.8 <sup>a</sup></td><td align=\"left\"><italic>ns</italic></td></tr><tr><td align=\"center\">T3</td><td align=\"left\">0.6 &#177; 0.8</td><td align=\"left\">0.5 &#177; 1.0</td><td align=\"left\">0.2 &#177; 0.4</td><td align=\"left\"><italic>ns</italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">The Letter-Number Sequencing</td><td/><td/><td/><td/></tr><tr><td align=\"center\">T1</td><td align=\"left\">8.4 &#177; 2.2</td><td align=\"left\">9.3 &#177; 2.4</td><td align=\"left\">11.8 &#177; 3.4</td><td align=\"left\"><bold>Group, <italic>p </italic>= 0.009</bold></td></tr><tr><td align=\"center\">T2</td><td align=\"left\">8.8 &#177; 2.2</td><td align=\"left\">8.5 &#177; 2.3</td><td align=\"left\">11.6 &#177; 3.0</td><td align=\"left\">Time, <italic>ns</italic></td></tr><tr><td align=\"center\">T3</td><td align=\"left\">10.6 &#177; 2.2</td><td align=\"left\">8.8 &#177; 2.4</td><td align=\"left\">11.2 &#177; 3.2</td><td align=\"left\"><bold>Group &#215; Time, <italic>p </italic>= 0.007</bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">The PASAT</td><td/><td/><td/><td/></tr><tr><td align=\"center\">T1</td><td align=\"left\">32.4 &#177; 10.5</td><td align=\"left\">31.0 &#177; 8.5</td><td align=\"left\">46.3 &#177; 9.7</td><td align=\"left\"><bold>Group, <italic>p </italic>= 0.001</bold></td></tr><tr><td align=\"center\">T2</td><td align=\"left\">35.0 &#177; 6.8</td><td align=\"left\">33.4 &#177; 10.1</td><td align=\"left\">45.8 &#177; 9.0 <sup>a</sup></td><td align=\"left\"><bold>Time, <italic>p </italic>= 0.013</bold></td></tr><tr><td align=\"center\">T3</td><td align=\"left\">35.8 &#177; 10.0</td><td align=\"left\">34.9 &#177; 11.0</td><td align=\"left\">49.8 &#177; 8.4</td><td align=\"left\">Group &#215; Time, <italic>ns</italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">Logical memory, immediate</td><td/><td/><td/><td/></tr><tr><td align=\"center\">T1</td><td align=\"left\">12.8 &#177; 2.6</td><td align=\"left\">14.9 &#177; 4.5</td><td align=\"left\">15.9 &#177; 3.3</td><td align=\"left\"><bold>Group, <italic>p </italic>= 0.016</bold></td></tr><tr><td align=\"center\">T2</td><td align=\"left\">13.8 &#177; 3.1</td><td align=\"left\">14.8 &#177; 3.7</td><td align=\"left\">16.3 &#177; 3.2</td><td align=\"left\">Time, <italic>ns</italic></td></tr><tr><td align=\"center\">T3</td><td align=\"left\">15.5 &#177; 4.1</td><td align=\"left\">14.3 &#177; 4.3</td><td align=\"left\">17.9 &#177; 2.9</td><td align=\"left\">Group &#215; Time, <italic>ns</italic></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"center\">Logical memory, delayed</td><td/><td/><td/><td/></tr><tr><td align=\"center\">T1</td><td align=\"left\">11.8 &#177; 3.0</td><td align=\"left\">13.1 &#177; 4.0</td><td align=\"left\">13.9 &#177; 4.0</td><td align=\"left\"><bold>Group, <italic>p </italic>= 0.013</bold></td></tr><tr><td align=\"center\">T2</td><td align=\"left\">12.0 &#177; 4.0</td><td align=\"left\">13.7 &#177; 4.0</td><td align=\"left\">15.6 &#177; 3.1</td><td align=\"left\">Time, <italic>ns</italic></td></tr><tr><td align=\"center\">T3</td><td align=\"left\">12.4 &#177; 4.1</td><td align=\"left\">11.8 &#177; 4.7</td><td align=\"left\">15.9 &#177; 3.6</td><td align=\"left\">Group &#215; Time, <italic>ns</italic></td></tr></tbody></table></body></html>", "text": "Pmid= 3176473:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Significant correlations between medication variables and other non-cognitive variables in sample II</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Medication variables</th><th align=\"left\">Substance abuse variables</th><th align=\"left\">Demographic variables</th></tr></thead><tbody><tr><td align=\"left\">Benzodiazepine dose (T2)</td><td align=\"left\">Frequency of substance abuse in the past month<break/><bold>.36 ( <italic>p </italic>= 0.033)</bold></td><td align=\"left\">Age<break/><bold>-.34 (<italic>p </italic>= 0.040)</bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Benzodiazepine dose (T3)</td><td align=\"left\">Frequency of substance abuse in the past month<break/><bold>.50 (<italic>p </italic>= 0.002)</bold></td><td align=\"left\">Age<break/><bold>-.33 (<italic>p </italic>= 0.048)</bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Number of other psychoactive drugs (T2)</td><td/><td/></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">Number of other psychoactive drugs (T3)</td><td align=\"left\">Years of opioid abuse<break/><bold>-.37 (<italic>p </italic>= 0.028)</bold></td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3176473:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Highest correlations between cognitive and non-cognitive variables in sample II</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Domain or test</th><th align=\"left\">Medication variables</th><th align=\"left\">Substance abuse variables</th><th align=\"left\">Demographic variables</th><th align=\"left\">Significant correlations after controlling for two other correlates</th></tr></thead><tbody><tr><td align=\"left\">Attention (T2)</td><td align=\"left\">Opioid substitution drug<break/>.<bold>48 (<italic>p </italic>= 0.003)</bold><break/>Number of other psychoactive drugs (T2)<break/>.24</td><td align=\"left\">Opioid abuse onset age<break/>.25</td><td/><td align=\"left\">Opioid substitution drug<break/><bold>.46, (<italic>p </italic>= 0.004)</bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Attention (T3)</td><td align=\"left\">Opioid substitution drug<break/>.<bold>37 (<italic>p </italic>= .024)</bold></td><td align=\"left\">Opioid abuse onset age .28</td><td align=\"left\">Age<break/>.26</td><td align=\"left\">Opioid substitution drug<break/>.<bold>37, (<italic>p </italic>= 0.021)</bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">The Letter-Number Sequencing Task (T2)</td><td align=\"left\">Number of other psychoactive drugs<break/>.25</td><td align=\"left\">Frequency of substance abuse in the past month<break/><bold>-49 (<italic>p</italic>= .002)</bold></td><td align=\"left\">Verbal IQ<break/>.29</td><td align=\"left\">Frequency of substance abuse in the past month<break/><bold>-44 (<italic>p </italic>= .005)</bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">The Letter-Number Sequencing Task (T3)</td><td align=\"left\">Benzodiazepine dose<break/><bold>.-38</bold></td><td align=\"left\">Frequency of substance abuse in the past month<break/><bold>.-34 (<italic>p </italic>= .044)</bold><break/>Years of opioid abuse .28</td><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Change score in the Letter-Number Sequencing Task (T3 - T2)</td><td align=\"left\">Opioid substitution drug<break/>.<bold>34 (<italic>p </italic>= .039)</bold></td><td/><td align=\"left\">Change in the opioid agonist dose<break/>-.33<break/>Change in the number of psychoactive drugs<break/>-.24</td><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Verbal memory (T2)</td><td align=\"left\">Number of other psychoactive drugs (T2)<break/>.25</td><td align=\"left\">Frequency of substance abuse in the past month<break/><bold>-. 34 (<italic>p </italic>= .044)</bold></td><td align=\"left\">Verbal IQ<break/>.28</td><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Verbal memory (T3)</td><td align=\"left\">Number of other psychoactive drugs (T3)<break/>.31</td><td/><td align=\"left\">Verbal IQ<break/>.32<break/>Years of education<break/>.27</td><td align=\"left\">Number of other psychoactive drugs<break/><bold>.34 (<italic>p </italic>= .035)</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 3176473:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Description of the reporting of adverse reactions from the randomized primary healthcare units in 2008</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Control units<break/>(n = 74)</th><th align=\"center\">Intervention units<break/>(n = 77)</th><th align=\"center\">P-value</th></tr></thead><tbody><tr><td align=\"left\">Total number of reports</td><td align=\"center\">52</td><td align=\"center\">79</td><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Number of reporting units (% of all units)</td><td align=\"center\">30 (40.5%)</td><td align=\"center\">37 (48.1%)</td><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Mean number of reports per unit (&#177; SD)**</td><td align=\"center\">0.70 &#177; 1.21</td><td align=\"center\">1.03 &#177; 2.46</td><td align=\"center\">0.34</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Total number of high quality reports (% of all reports)*</td><td align=\"center\">15 (29%)</td><td align=\"center\">37 (48%)</td><td/></tr><tr><td align=\"right\"><italic>Serious</italic></td><td align=\"center\"><italic>4</italic></td><td align=\"center\"><italic>12</italic></td><td/></tr><tr><td align=\"right\"><italic>Unexpected</italic></td><td align=\"center\"><italic>13</italic></td><td align=\"center\"><italic>20</italic></td><td/></tr><tr><td align=\"right\"><italic>New drug and not</italic><break/><italic>common ADR*</italic></td><td align=\"center\"><italic>4</italic></td><td align=\"center\"><italic>7</italic></td><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Mean number of high quality reports per unit (&#177; SD)</td><td align=\"center\">0.20 &#177; 0.57</td><td align=\"center\">0.47 &#177; 0.94</td><td align=\"center\">0.048</td></tr></tbody></table></body></html>", "text": "Pmid= 3182972:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Description of high quality reports concerning substances reported more than once</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Age (years)</th><th align=\"center\">Sex</th><th align=\"center\">Suspected substance/s</th><th align=\"center\">Dose</th><th align=\"center\">ADR diagnosis</th><th align=\"center\">Serious*</th><th align=\"center\">Unexpected*</th><th align=\"center\">New drug and not common ADR**</th><th align=\"center\">Treatment duration</th><th align=\"center\">Time to ADR onset</th><th align=\"center\">Positive dechallange</th><th align=\"left\">Concomitant medication</th><th align=\"center\">Causality<break/>assessment*</th></tr></thead><tbody><tr><td align=\"center\">55</td><td align=\"center\">F</td><td align=\"left\">Acetylsalicylic acid/caffeine</td><td align=\"center\">500/50 mg</td><td align=\"left\">Pruritus</td><td align=\"center\">N</td><td align=\"center\">Y</td><td align=\"center\">N</td><td align=\"center\">1 dose</td><td align=\"center\">Hours</td><td align=\"center\">NR</td><td align=\"left\">NR</td><td align=\"center\">Probable</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">63</td><td align=\"center\">F</td><td align=\"left\">Acetylsalicylic acid</td><td align=\"center\">NR</td><td align=\"left\">Haemorrhagic gastric ulcer</td><td align=\"center\">Y</td><td align=\"center\">N</td><td align=\"center\">N</td><td align=\"center\">NR</td><td align=\"center\">NR</td><td align=\"center\">Y</td><td align=\"left\">Candesartan</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">80</td><td align=\"center\">F</td><td align=\"left\">Acetylsalicylic acid</td><td align=\"center\">NR</td><td align=\"left\">Gastrointestinal<break/>haemorrhage</td><td align=\"center\">Y</td><td align=\"center\">N</td><td align=\"center\">N</td><td align=\"center\">8 weeks</td><td align=\"center\">8 weeks</td><td align=\"center\">Died</td><td align=\"left\">NR</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">56</td><td align=\"center\">F</td><td align=\"left\">Citalopram</td><td align=\"center\">60 mg</td><td align=\"left\">Nail disorder</td><td align=\"center\">N</td><td align=\"center\">Y</td><td align=\"center\">N</td><td align=\"center\">NR</td><td align=\"center\">NR</td><td align=\"center\">Medication continued</td><td align=\"left\">Folic acid<break/>Propiomazine<break/>Diazepam<break/>Levothyroxine</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">78</td><td align=\"center\">F</td><td align=\"left\">Citalopram<break/>Enalapril<break/>Dextropropoxyphene<break/>Omeprazole<break/>Bendroflumethiazide</td><td align=\"center\">20 mg<break/>15 mg<break/>150 mg<break/>20 mg<break/>5 mg</td><td align=\"left\">Hyponatraemia<break/>Confusion</td><td align=\"center\">Y</td><td align=\"center\">N</td><td align=\"center\">N</td><td align=\"center\">NR</td><td align=\"center\">NR</td><td align=\"center\">Medication continued</td><td align=\"left\">Dipyridamole<break/>Budesonide/<break/>formoterol<break/>Tiotropium<break/>Cholecalciferol/calcium<break/>Macrogol, combinations<break/>Vitamin B-complex<break/>Paracetamol<break/>Cyanocobalamin<break/>Sodium picosulfate<break/>Ferrous sulphate<break/>Levothyroxine<break/>Antacids, salt combination<break/>Acetylcysteine</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">38</td><td align=\"center\">F</td><td align=\"left\">Enalapril</td><td align=\"center\">5 mg</td><td align=\"left\">Yawning</td><td align=\"center\">N</td><td align=\"center\">Y</td><td align=\"center\">N</td><td align=\"center\">3 weeks</td><td align=\"center\">Days</td><td align=\"center\">Y</td><td align=\"left\">N</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">69</td><td align=\"center\">F</td><td align=\"left\">Enalapril</td><td align=\"center\">20 mg</td><td align=\"left\">Diplopia</td><td align=\"center\">N</td><td align=\"center\">Y</td><td align=\"center\">N</td><td align=\"center\">NR</td><td align=\"center\">NR</td><td align=\"center\">Medication continued</td><td align=\"left\">N</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">35</td><td align=\"center\">F</td><td align=\"left\">Levonorgestrel</td><td align=\"center\">NR</td><td align=\"left\">Fatigue<break/>Myalgia</td><td align=\"center\">N</td><td align=\"center\">Y<break/>Y</td><td align=\"center\">N</td><td align=\"center\">15 months</td><td align=\"center\">Days</td><td align=\"center\">Y</td><td align=\"left\">Paracetamol<break/>Tramadol</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">38</td><td align=\"center\">F</td><td align=\"left\">Levonorgestrel</td><td align=\"center\">NR</td><td align=\"left\">Ectopic pregnancy</td><td align=\"center\">Y</td><td align=\"center\">N</td><td align=\"center\">N</td><td align=\"center\">4 years</td><td align=\"center\">4 years</td><td align=\"center\">Y</td><td align=\"left\">N</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">49</td><td align=\"center\">M</td><td align=\"left\">Varenicline</td><td align=\"center\">1 mg</td><td align=\"left\">Thrombophlebitis</td><td align=\"center\">N</td><td align=\"center\">Y</td><td align=\"center\">Y</td><td align=\"center\">2 months</td><td align=\"center\">2 months</td><td align=\"center\">NR</td><td align=\"left\">Atenolol</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">61</td><td align=\"center\">F</td><td align=\"left\">Varenicline</td><td align=\"center\">2 mg</td><td align=\"left\">Confusion</td><td align=\"center\">N</td><td align=\"center\">Y</td><td align=\"center\">Y</td><td align=\"center\">2 weeks</td><td align=\"center\">NR</td><td align=\"center\">Y</td><td align=\"left\">Dipyridamole<break/>Simvastatin</td><td align=\"center\">Possible</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">62</td><td align=\"center\">F</td><td align=\"left\">Varenicline</td><td align=\"center\">NR</td><td align=\"left\">Macula-degeneration</td><td align=\"center\">N</td><td align=\"center\">Y</td><td align=\"center\">Y</td><td align=\"center\">4 months</td><td align=\"center\">5 months</td><td align=\"center\">NR</td><td align=\"left\">NR</td><td align=\"center\">Unclassifiable</td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"center\">66</td><td align=\"center\">F</td><td align=\"left\">Varenicline</td><td align=\"center\">NR</td><td align=\"left\">Oedema legs</td><td align=\"center\">Y</td><td align=\"center\">Y</td><td align=\"center\">Y</td><td align=\"center\">5 weeks</td><td align=\"center\">4 weeks</td><td align=\"center\">N</td><td align=\"left\">Naproxen<break/>Omeprazole<break/>Folic acid</td><td align=\"center\">Possible</td></tr></tbody></table></body></html>", "text": "Pmid= 3182972:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of the 12 studies included for meta-analysis</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Study</th><th align=\"left\">Total Sample Size(n)</th><th align=\"left\"><bold>Adverse effects</bold><sup><bold>&#165;</bold></sup></th><th align=\"left\">Mean Age</th><th align=\"left\">% Male</th><th align=\"left\">Trial Duration with 1 mg BID dose(Weeks)</th><th align=\"left\">Size of Trial group</th><th align=\"left\">Size of Control Group</th><th align=\"center\" colspan=\"7\"><bold>Cochrane risk of bias assessment</bold><sup><bold>&#167;</bold></sup></th></tr><tr><th/><th/><th/><th/><th/><th/><th/><th/><th colspan=\"7\"><hr/></th></tr><tr><th/><th/><th/><th/><th/><th/><th/><th/><th align=\"left\">P</th><th align=\"left\">Q</th><th align=\"left\">R</th><th align=\"left\">S</th><th align=\"left\">T</th><th align=\"left\">U</th><th align=\"left\">Overall score</th></tr></thead><tbody><tr><td align=\"left\"><bold>Gonzales et al (2006)</bold><sup><bold>32 </bold></sup></td><td align=\"left\">696</td><td align=\"left\">A, B, C</td><td align=\"left\">42.55</td><td align=\"left\">52.05</td><td align=\"left\">12</td><td align=\"left\">352</td><td align=\"left\">344</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">6/6</td></tr><tr><td align=\"left\"><bold>Jorenby et al(2006)</bold><sup><bold>29 </bold></sup></td><td align=\"left\">685</td><td align=\"left\">A, B, C</td><td align=\"left\">43.45</td><td align=\"left\">56.65</td><td align=\"left\">12</td><td align=\"left\">344</td><td align=\"left\">341</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">5/6</td></tr><tr><td align=\"left\"><bold>Oncken et al(2006)</bold><sup><bold>27</bold></sup></td><td align=\"left\">259</td><td align=\"left\">A, B, C</td><td align=\"left\">41.1</td><td align=\"left\">50.2</td><td align=\"left\">12</td><td align=\"left\">130</td><td align=\"left\">129</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">0</td><td align=\"left\">4/6</td></tr><tr><td align=\"left\"><bold>Nides et al(2006)</bold><sup><bold>25</bold></sup></td><td align=\"left\">248</td><td align=\"left\">A, B</td><td align=\"left\">41.7</td><td align=\"left\">51.2</td><td align=\"left\">6</td><td align=\"left\">125</td><td align=\"left\">123</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">4/6</td></tr><tr><td align=\"left\"><bold>Nakamura et al(2007)</bold><sup><bold>30</bold></sup></td><td align=\"left\">310</td><td align=\"left\">A, B</td><td align=\"left\">40</td><td align=\"left\">77.6</td><td align=\"left\">12</td><td align=\"left\">156</td><td align=\"left\">154</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">6/6</td></tr><tr><td align=\"left\"><bold>Tsai et al(2007)</bold><sup><bold>28</bold></sup></td><td align=\"left\">250</td><td align=\"left\">A, B</td><td align=\"left\">40.3</td><td align=\"left\">88.8</td><td align=\"left\">12</td><td align=\"left\">126</td><td align=\"left\">124</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">4/6</td></tr><tr><td align=\"left\"><bold>Williams et al(2007)</bold><sup><bold>26</bold></sup></td><td align=\"left\">377</td><td align=\"left\">A, B, C</td><td align=\"left\">47.7</td><td align=\"left\">48.6</td><td align=\"left\">52</td><td align=\"left\">251</td><td align=\"left\">126</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">4/6</td></tr><tr><td align=\"left\"><bold>Niaura et al(2008)</bold><sup><bold>34</bold></sup></td><td align=\"left\">312</td><td align=\"left\">A</td><td align=\"left\">41.8</td><td align=\"left\">51.9</td><td align=\"left\">12</td><td align=\"left\">157</td><td align=\"left\">155</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">5/6</td></tr><tr><td align=\"left\"><bold>Wang et al(2009)</bold><sup><bold>33 </bold></sup></td><td align=\"left\">333</td><td align=\"left\">A</td><td align=\"left\">38.7</td><td align=\"left\">96.7</td><td align=\"left\">12</td><td align=\"left\">165</td><td align=\"left\">168</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">4/6</td></tr><tr><td align=\"left\"><bold>Rigotti et al(2010)</bold><sup><bold>31</bold></sup></td><td align=\"left\">714</td><td align=\"left\">A, B</td><td align=\"left\">56.45</td><td align=\"left\">78.7</td><td align=\"left\">12</td><td align=\"left\">355</td><td align=\"left\">359</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">5/6</td></tr><tr><td align=\"left\"><bold>Fagerstrom et al(2010)</bold><sup><bold>8</bold></sup></td><td align=\"left\">431</td><td align=\"left\">A</td><td align=\"left\">43.9</td><td align=\"left\">89.3</td><td align=\"left\">12</td><td align=\"left\">213</td><td align=\"left\">218</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">6/6</td></tr><tr><td align=\"left\"><bold>Tashkin et al(2010)</bold><sup><bold>24 </bold></sup></td><td align=\"left\">499</td><td align=\"left\">A, C</td><td align=\"left\">57.2</td><td align=\"left\">62.3</td><td align=\"left\">12</td><td align=\"left\">248</td><td align=\"left\">251</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">0</td><td align=\"left\">4/6</td></tr></tbody></table></body></html>", "text": "Pmid= 3192741:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline characteristics of patients on statin therapy and non-statin therapy</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Statin<break/>(n = 107)</th><th align=\"center\">Non-Statin<break/>(n = 656)</th><th align=\"center\"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align=\"left\">Age, mean &#177; SD (yrs)</td><td align=\"center\">68.8 &#177; 11.0</td><td align=\"center\">49.3 &#177; 21.7</td><td align=\"center\">&lt; 0.0001</td></tr><tr><td align=\"left\">Female gender, no. (%)</td><td align=\"center\">44 (41.1)</td><td align=\"center\">164 (25)</td><td align=\"center\">0.0005</td></tr><tr><td align=\"left\">APACHE II, mean &#177; SD</td><td align=\"center\">27.2 &#177; 6.9</td><td align=\"center\">23.0 &#177; 8.1</td><td align=\"center\">&lt; 0.0001</td></tr><tr><td align=\"left\">SOFA day 1, mean &#177; SD</td><td align=\"center\">9.3 &#177; 3.2</td><td align=\"center\">9.2 &#177; 3.5</td><td align=\"center\">0.92</td></tr><tr><td align=\"left\">Creatinine, mean &#177; SD, &#956;mol/L*</td><td align=\"center\">200.8 &#177; 152.6</td><td align=\"center\">152.3 &#177; 152.1</td><td align=\"center\">0.002</td></tr><tr><td align=\"left\">Platelets, mean &#177; SD, x10<sup>9</sup>/L</td><td align=\"center\">270.7 &#177; 117.8</td><td align=\"center\">193.3 &#177; 123.3</td><td align=\"center\">0.0001</td></tr><tr><td align=\"left\">Bilirubin, mean &#177; SD, &#956;mol/l</td><td align=\"center\">26.4 &#177; 63.6</td><td align=\"center\">31.6 &#177; 55.2</td><td align=\"center\">0.50</td></tr><tr><td align=\"left\">INR, mean &#177; SD</td><td align=\"center\">1.5 &#177; 0.7</td><td align=\"center\">1.5 &#177; 0.9</td><td align=\"center\">0.72</td></tr><tr><td align=\"left\">GCS, mean &#177; SD</td><td align=\"center\">9.4 &#177; 4.5</td><td align=\"center\">8.5 &#177; 4.0</td><td align=\"center\">0.05</td></tr><tr><td align=\"left\">ICU admission category, no. (%)</td><td/><td/><td/></tr><tr><td align=\"center\">Postoperative</td><td align=\"center\">4 (3.7)</td><td align=\"center\">119 (18.1)</td><td align=\"center\">0.0002</td></tr><tr><td align=\"center\">Nonoperative</td><td align=\"center\">103 (96.3)</td><td align=\"center\">537 (81.9)</td><td/></tr><tr><td align=\"left\">History of diabetes, no. (%)</td><td align=\"center\">84 (78.5)</td><td align=\"center\">219 (33.4)</td><td align=\"center\">&lt; 0.0001</td></tr><tr><td align=\"left\">Mechanically ventilated, no. (%)</td><td align=\"center\">92 (86.0)</td><td align=\"center\">591 (90.1)</td><td align=\"center\">0.20</td></tr><tr><td align=\"left\">Vasopressors, no. (%)</td><td align=\"center\">73 (68.2)</td><td align=\"center\">423 (64.5)</td><td align=\"center\">0.45</td></tr><tr><td align=\"left\">Sepsis, no. (%)</td><td align=\"center\">28 (26.2)</td><td align=\"center\">166 (25.3)</td><td align=\"center\">0.85</td></tr><tr><td align=\"left\">Severe sepsis, no. (%)</td><td align=\"center\">26 (24.3)</td><td align=\"center\">207 (31.5)</td><td align=\"center\">0.13</td></tr><tr><td align=\"left\">Chronic respiratory, no. (%)</td><td align=\"center\">33 (30.8)</td><td align=\"center\">124 (18.9)</td><td align=\"center\">0.005</td></tr><tr><td align=\"left\">Chronic cardiac, no. (%)</td><td align=\"center\">54 (50.5)</td><td align=\"center\">103 (15.7)</td><td align=\"center\">&lt; 0.0001</td></tr><tr><td align=\"left\">Chronic renal, no. (%)</td><td align=\"center\">29 (27.1)</td><td align=\"center\">74 (11.3)</td><td align=\"center\">&lt; 0.0001</td></tr><tr><td align=\"left\">Chronic liver, no. (%)</td><td align=\"center\">4 (3.7)</td><td align=\"center\">50 (7.6)</td><td align=\"center\">0.15</td></tr><tr><td align=\"left\">Chronic immunocompromised, no. (%)</td><td align=\"center\">10 (9.4)</td><td align=\"center\">56 (8.5)</td><td align=\"center\">0.78</td></tr></tbody></table></body></html>", "text": "Pmid= 3199769:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Association between statin use and primary outcomes compared with the non-statin group using adjusted analyses</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Statin<break/>n = 107</th><th align=\"center\">Non-statin<break/>n = 656</th><th align=\"center\">Adjusted odds ratio (aOR)<sup>a</sup></th><th align=\"center\">95% confidence interval</th><th align=\"center\"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align=\"left\">ICU mortality, no. (%)</td><td align=\"center\">19/107 (17.8)</td><td align=\"center\">108/656 (16.5)</td><td align=\"center\">0.84</td><td align=\"center\">(0.47 - 1.51)</td><td align=\"center\">0.56</td></tr><tr><td align=\"left\">&#8195;Dose &lt; 40 mg</td><td align=\"center\">7/47 (14.9)</td><td align=\"center\">108/656 (16.5)</td><td align=\"center\">0.67</td><td align=\"center\">(0.28 - 1.63)</td><td align=\"center\">0.43</td></tr><tr><td align=\"left\">&#8195;Dose &#8805; 40 mg</td><td align=\"center\">12/60 (20.0)</td><td align=\"center\">108/656 (16.5)</td><td align=\"center\">0.97</td><td align=\"center\">(0.48 - 1.99)</td><td align=\"center\">0.98</td></tr><tr><td align=\"left\">Hospital mortality, no. (%)</td><td align=\"center\">42/107 (39.3)</td><td align=\"center\">200/656 (30.5)</td><td align=\"center\">0.60</td><td align=\"center\">(0.36 - 0.99)</td><td align=\"center\">0.05</td></tr><tr><td align=\"left\">&#8195;Dose &lt; 40 mg</td><td align=\"center\">19/47 (40.4)</td><td align=\"center\">200/656 (30.5)</td><td align=\"center\">0.69</td><td align=\"center\">(0.35 - 1.40)</td><td align=\"center\">0.30</td></tr><tr><td align=\"left\">&#8195;Dose &#8805; 40 mg</td><td align=\"center\">23/60 (38.3)</td><td align=\"center\">200/656 (30.5)</td><td align=\"center\">0.53</td><td align=\"center\">(0.28 - 1.00)</td><td align=\"center\">0.05</td></tr></tbody></table></body></html>", "text": "Pmid= 3199769:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Association between statin therapy and hospital mortality, stratified by different relevant characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Statin<break/>n = 107</th><th align=\"center\">Non-statin<break/>n = 656</th><th align=\"center\">Adjusted odds ratio (aOR)<sup>a</sup></th><th align=\"center\">95% confidence interval</th><th align=\"left\"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align=\"left\">Hospital mortality, no. (%)</td><td align=\"left\">42/107 (39.3)</td><td align=\"center\">200/656 (30.5)</td><td align=\"center\">0.60</td><td align=\"center\">(0.36 - 0.99)</td><td align=\"center\">0.05</td></tr><tr><td align=\"left\">Stratified by age, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;&#8804; 58 yrs</td><td align=\"center\">6/14 (42.9)</td><td align=\"center\">62/374 (16.6)</td><td align=\"center\">0.73</td><td align=\"center\">(0.19 - 2.81)</td><td align=\"center\">0.64</td></tr><tr><td align=\"left\">&#8195;&gt; 58 yrs</td><td align=\"center\">36/93 (38.7)</td><td align=\"center\">138/282 (49.0)</td><td align=\"center\">0.58</td><td align=\"center\">(0.35 - 0.97)</td><td align=\"center\">0.04</td></tr><tr><td align=\"left\">Gender, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Male</td><td align=\"center\">21/63 (33.3)</td><td align=\"center\">126/492 (25.6)</td><td align=\"center\">0.56</td><td align=\"center\">(0.29 - 1.08)</td><td align=\"center\">0.08</td></tr><tr><td align=\"left\">&#8195;Female</td><td align=\"center\">21/44 (47.7)</td><td align=\"center\">74/164 (45.0)</td><td align=\"center\">0.74</td><td align=\"center\">(0.35 - 1.58)</td><td align=\"center\">0.43</td></tr><tr><td align=\"left\">Admission category, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Postoperative</td><td align=\"center\">1/4 (25.0)</td><td align=\"center\">19/119 (16.0)</td><td align=\"center\">0.75</td><td align=\"center\">(0.04 - 14.82)</td><td align=\"center\">0.85</td></tr><tr><td align=\"left\">&#8195;Nonoperative</td><td align=\"center\">41/103 (40.0)</td><td align=\"center\">181/537 (34.0)</td><td align=\"center\">0.62</td><td align=\"center\">(0.34 - 1.03)</td><td align=\"center\">0.06</td></tr><tr><td align=\"left\">APACHE II, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;APACHE&#8804; 22</td><td align=\"center\">8/33 (24.2)</td><td align=\"center\">53/370 (14.3)</td><td align=\"center\">0.77</td><td align=\"center\">(0.27 - 2.21)</td><td align=\"center\">0.63</td></tr><tr><td align=\"left\">&#8195;APACHE&gt;22</td><td align=\"center\">34/74 (46.0)</td><td align=\"center\">147/286 (51.4)</td><td align=\"center\">0.54</td><td align=\"center\">(0.31 - 0.96)</td><td align=\"center\">0.03</td></tr><tr><td align=\"left\">SOFA, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;&#8804; 9</td><td align=\"center\">13/58 (22.4)</td><td align=\"center\">63/346 (18.2)</td><td align=\"center\">0.55</td><td align=\"center\">(0.26 - 1.17)</td><td align=\"center\">0.12</td></tr><tr><td align=\"left\">&#8195;&gt; 9</td><td align=\"center\">29/49 (59.1)</td><td align=\"center\">137/310 (44.2)</td><td align=\"center\">0.73</td><td align=\"center\">(0.36 - 1.48)</td><td align=\"center\">0.38</td></tr><tr><td align=\"left\">History of diabetes, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Yes</td><td align=\"center\">31/84 (37.0)</td><td align=\"center\">106/209 (48.4)</td><td align=\"center\">0.52</td><td align=\"center\">(0.30 - 0.90)</td><td align=\"center\">0.02</td></tr><tr><td align=\"left\">&#8195;No</td><td align=\"center\">11/23 (47.8)</td><td align=\"center\">94/437 (21.5)</td><td align=\"center\">1.31</td><td align=\"center\">(0.49 - 3.54)</td><td align=\"center\">0.59</td></tr><tr><td align=\"left\">History of cardiovascular, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Yes</td><td align=\"center\">23/54 (42.6)</td><td align=\"center\">58/103 (56.3)</td><td align=\"center\">0.59</td><td align=\"center\">(0.3 - 1.2)</td><td align=\"center\">0.13</td></tr><tr><td align=\"left\">&#8195;No</td><td align=\"center\">19/53 (35.9)</td><td align=\"center\">142/553 (25.7)</td><td align=\"center\">0.52</td><td align=\"center\">(0.27 - 1)</td><td align=\"center\">0.06</td></tr><tr><td align=\"left\">Vasopressor therapy, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Yes</td><td align=\"center\">31/73 (42.5)</td><td align=\"center\">151/423 (35.7)</td><td align=\"center\">0.53</td><td align=\"center\">(0.29 - 0.97)</td><td align=\"center\">0.04</td></tr><tr><td align=\"left\">&#8195;No</td><td align=\"center\">23/34 (67.7)</td><td align=\"center\">184/233 (79.0)</td><td align=\"center\">0.92</td><td align=\"center\">(0.37 - 2.25)</td><td align=\"center\">0.84</td></tr><tr><td align=\"left\">Sepsis, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Yes</td><td align=\"center\">12/28 (43.0)</td><td align=\"center\">88/166 (53.0)</td><td align=\"center\">0.64</td><td align=\"center\">(0.26 - 1.58)</td><td align=\"center\">0.33</td></tr><tr><td align=\"left\">&#8195;No</td><td align=\"center\">30/79 (38.0)</td><td align=\"center\">112/490 (23.0)</td><td align=\"center\">0.72</td><td align=\"center\">(0.41 - 1.28)</td><td align=\"center\">0.26</td></tr><tr><td align=\"left\">Severe sepsis and septic shock no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Yes</td><td align=\"center\">14/26 (53.9)</td><td align=\"center\">84/207 (40.6)</td><td align=\"center\">0.22</td><td align=\"center\">(0.07 - 0.66</td><td align=\"center\">0.007</td></tr><tr><td align=\"left\">&#8195;No</td><td align=\"center\">28/81 (34.6)</td><td align=\"center\">116/449 (25.7)</td><td align=\"center\">0.78</td><td align=\"center\">(0.45 - 1.37)</td><td align=\"center\">0.38</td></tr><tr><td align=\"left\">Creatinine, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;&#8804; 100 &#956;mol/L</td><td align=\"center\">4/26 (15.4)</td><td align=\"center\">70/351 (20.0)</td><td align=\"center\">0.14</td><td align=\"center\">(0.04 - 0.51)</td><td align=\"center\">0.002</td></tr><tr><td align=\"left\">&#8195;&gt; 100 &#956;mol/L</td><td align=\"center\">38/81 (47.0)</td><td align=\"center\">130/305 (43.0)</td><td align=\"center\">1.01</td><td align=\"center\">(0.58 - 1.77)</td><td align=\"center\">0.96</td></tr><tr><td align=\"left\">Platelets, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;&#8804; 180</td><td align=\"center\">12/25 (48.0)</td><td align=\"center\">125/358 (35.0)</td><td align=\"center\">0.62</td><td align=\"center\">(0.24 - 1.62)</td><td align=\"center\">0.33</td></tr><tr><td align=\"left\">&#8195;&gt; 180</td><td align=\"center\">30/82 (36.6)</td><td align=\"center\">75/298 (25.2)</td><td align=\"center\">0.78</td><td align=\"center\">(0.43 - 1.42)</td><td align=\"center\">0.42</td></tr><tr><td align=\"left\">Bilirubin, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;&#8804; 16 &#956;mol/L</td><td align=\"center\">10/38 (26.3)</td><td align=\"center\">54/212 (25.5)</td><td align=\"center\">0.49</td><td align=\"center\">(0.21 - 1.20)</td><td align=\"center\">0.11</td></tr><tr><td align=\"left\">&#8195;&gt; 16 &#956;mol/L</td><td align=\"center\">10/22 (45.5)</td><td align=\"center\">73/223 (32.7)</td><td align=\"center\">0.67</td><td align=\"center\">(0.23 - 1.97)</td><td align=\"center\">0.47</td></tr><tr><td align=\"left\">INR, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;&#8804;1.2</td><td align=\"center\">20/59 (34.0)</td><td align=\"center\">68/312 (21.8)</td><td align=\"center\">0.79</td><td align=\"center\">(0.40 - 1.58)</td><td align=\"center\">0.51</td></tr><tr><td align=\"left\">&#8195;&gt;1.2</td><td align=\"center\">22/48 (45.8)</td><td align=\"center\">132/344 (38.4)</td><td align=\"center\">0.53</td><td align=\"center\">(0.26 - 1.09)</td><td align=\"center\">0.09</td></tr><tr><td align=\"left\">GCS, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;&#8804; 9</td><td align=\"center\">19/50 (38.0)</td><td align=\"center\">114/364 (31.3)</td><td align=\"center\">0.34</td><td align=\"center\">(0.17 - 0.71)</td><td align=\"center\">0.004</td></tr><tr><td align=\"left\">&#8195;&gt; 9</td><td align=\"center\">23/57 (40.4)</td><td align=\"center\">86/292 (29.5)</td><td align=\"center\">092</td><td align=\"center\">(0.46 - 1.85)</td><td align=\"center\">0.81</td></tr><tr><td align=\"left\">Length of stay, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;&#8804; 5 days</td><td align=\"center\">4/39 (10.3)</td><td align=\"center\">32/192 (16.7)</td><td align=\"center\">0.40</td><td align=\"center\">(0.13 - 1.28)</td><td align=\"center\">0.12</td></tr><tr><td align=\"left\">&#8195;&gt; 5 days</td><td align=\"center\">38/68 (55.9)</td><td align=\"center\">168/464 (36.2)</td><td align=\"center\">0.63</td><td align=\"center\">(0.34 - 1.19)</td><td align=\"center\">0.16</td></tr><tr><td align=\"left\">Mechanical ventilation, no. (%)</td><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Yes</td><td align=\"center\">40/92 (43.5)</td><td align=\"center\">183/591 (31.0)</td><td align=\"center\">0.66</td><td align=\"center\">(0.34 - 1.10)</td><td align=\"center\">0.11</td></tr><tr><td align=\"left\">&#8195;No</td><td align=\"center\">2/15 (13.3)</td><td align=\"center\">17/65 (26.2)</td><td align=\"center\">0.75</td><td align=\"center\">(0.09 - 6.43)</td><td align=\"center\">0.79</td></tr><tr><td align=\"left\">Simvastatin, no. (%)</td><td align=\"center\">12/44 (27.3)</td><td align=\"center\">200/656 (30.5)</td><td align=\"center\">0.37</td><td align=\"center\">(0.17 - 0.81)</td><td align=\"center\">0.01</td></tr><tr><td align=\"left\">Atorvastatin, no. (%)</td><td align=\"center\">30/63 (47.6)</td><td align=\"center\">200/656 (30.5)</td><td align=\"center\">0.80</td><td align=\"center\">(0.84 - 1.46)</td><td align=\"center\">0.47</td></tr></tbody></table></body></html>", "text": "Pmid= 3199769:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Association between statin use and outcomes stratified by statin dose</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Statin therapy n = 107</th><th align=\"center\">Non-statin therapy n = 656</th><th align=\"center\">Adjusted odds ratio (aOR)<sup>a</sup></th><th align=\"center\">95% confidence interval</th><th align=\"center\"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align=\"left\">Sepsis, no.%</td><td align=\"center\">32/107 (29.9)</td><td align=\"center\">280/656 (42.7)</td><td align=\"center\">0.84</td><td align=\"center\">(0.51 - 1.37)</td><td align=\"center\">0.49</td></tr><tr><td align=\"left\">&#8195;Dose &lt; 40 mg</td><td align=\"center\">16/47 (34.0)</td><td align=\"center\">280/656 (42.7)</td><td align=\"center\">1.11</td><td align=\"center\">(0.57 - 2.20)</td><td align=\"center\">0.74</td></tr><tr><td align=\"left\">&#8195;Dose &#8805; 40 mg</td><td align=\"center\">16/60 (25.7)</td><td align=\"center\">280/656 (42.7)</td><td align=\"center\">0.67</td><td align=\"center\">(0.36 - 1.30)</td><td align=\"center\">0.22</td></tr><tr><td align=\"left\">Severe sepsis, no. %</td><td align=\"center\">26/107 (24.3)</td><td align=\"center\">207/656 (31.6)</td><td align=\"center\">0.87</td><td align=\"center\">(0.51 - 1.50)</td><td align=\"center\">0.60</td></tr><tr><td align=\"left\">&#8195;Dose &lt; 40 mg</td><td align=\"center\">11/47 (23.4)</td><td align=\"center\">207/656 (31.6)</td><td align=\"center\">0.88</td><td align=\"center\">(0.42 - 1.90)</td><td align=\"center\">0.74</td></tr><tr><td align=\"left\">&#8195;Dose &#8805; 40 mg</td><td align=\"center\">15/60 (25.0)</td><td align=\"center\">207/656 (31.6)</td><td align=\"center\">0.85</td><td align=\"center\">(0.44 - 1.65)</td><td align=\"center\">0.64</td></tr><tr><td align=\"left\">ICU LOS, mean &#177; SD, days</td><td align=\"center\">10.2 &#177; 12.7</td><td align=\"center\">11.3 &#177; 10.6</td><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">0.33</td></tr><tr><td align=\"left\">Hospital LOS, mean &#177; SD, days</td><td align=\"center\">67.6 &#177; 118.1</td><td align=\"center\">58.6 &#177; 81.4</td><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">0.37</td></tr><tr><td align=\"left\">MVD, mean &#177; SD, days</td><td align=\"center\">9.0 &#177; 11.9</td><td align=\"center\">10.1 &#177; 10.3</td><td align=\"center\">*</td><td align=\"center\">*</td><td align=\"center\">0.33</td></tr></tbody></table></body></html>", "text": "Pmid= 3199769:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Sales of antidepressants (N06A) in the Nordic Countries during 1995-2008 in DDD*/1000 inhabitants per day [</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\">Denmark</th><th align=\"left\">Finland</th><th align=\"left\">Iceland</th><th align=\"left\">Norway</th><th align=\"left\">Sweden</th></tr></thead><tbody><tr><td align=\"left\">1995</td><td align=\"left\">18.3</td><td align=\"left\">20.3</td><td align=\"left\">33.0</td><td align=\"left\">22.5</td><td align=\"left\">27.8</td></tr><tr><td align=\"left\">2000</td><td align=\"left\">34.7</td><td align=\"left\">35.5</td><td align=\"left\">70.5</td><td align=\"left\">41.0</td><td align=\"left\">48.8</td></tr><tr><td align=\"left\">2004</td><td align=\"left\">55.2</td><td align=\"left\">49.9</td><td align=\"left\">91.9</td><td align=\"left\">52.4</td><td align=\"left\">64.6</td></tr><tr><td align=\"left\">2005</td><td align=\"left\">59.9</td><td align=\"left\">52.1</td><td align=\"left\">94.8</td><td align=\"left\">51.8</td><td align=\"left\">66.1</td></tr><tr><td align=\"left\">2006</td><td align=\"left\">64.7</td><td align=\"left\">55.5</td><td align=\"left\">92.6</td><td align=\"left\">52.7</td><td align=\"left\">69.7</td></tr><tr><td align=\"left\">2007</td><td align=\"left\">69.9</td><td align=\"left\">61.1</td><td align=\"left\">95.4</td><td align=\"left\">54.8</td><td align=\"left\">72.1</td></tr><tr><td align=\"left\">2008</td><td align=\"left\">73.4</td><td align=\"left\">63.9</td><td align=\"left\">94.7</td><td align=\"left\">55.1</td><td align=\"left\">73.7</td></tr></tbody></table></body></html>", "text": "Pmid= 3215951:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Reports and ADRs of antidepressant medication to an open web site according to the system organ class of psychiatric system</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Antidepressant ATC code N06A</th><th align=\"left\">Reports (N) Total = 442</th><th align=\"left\">ADRs (N) Total = 2392</th><th align=\"left\">Psychiatric ADRs (N) Total = 878</th><th align=\"left\">ADRs/report</th><th align=\"left\">Most common psychiatric ADR (%)</th></tr></thead><tbody><tr><td align=\"left\">Sertraline<sup>a</sup></td><td align=\"left\">116</td><td align=\"left\">626</td><td align=\"left\">226</td><td align=\"left\">5.4</td><td align=\"left\">Anxiety 5.9</td></tr><tr><td align=\"left\">N06AB06</td><td/><td/><td/><td/><td align=\"left\">Sensation of unreality 4.0</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Insomnia 3.0</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Uneasiness/nervousness 2.6</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Irritability, aggressiveness 2.2</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Suicidal behavior 1.9</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Citalopram<sup>a</sup></td><td align=\"left\">107</td><td align=\"left\">570</td><td align=\"left\">226</td><td align=\"left\">5.3</td><td align=\"left\">Anxiety 7.9</td></tr><tr><td align=\"left\">N06AB04</td><td/><td/><td/><td/><td align=\"left\">Insomnia 3.7</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Sensation of unreality 2.8</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Suicidal behavior 2.5</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Uneasiness/nervousness 2.5</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Depression 2.1</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Irritability, aggressiveness 2.1</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Venlafaxine<sup>b</sup></td><td align=\"left\">78</td><td align=\"left\">505</td><td align=\"left\">171</td><td align=\"left\">6.5</td><td align=\"left\">Anxiety 4.2</td></tr><tr><td align=\"left\">N06AX16</td><td/><td/><td/><td/><td align=\"left\">Suicidal behavior 3.2</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Uneasiness/nervousness 2.8</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Sensation of unreality 2.8</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Insomnia 2.4</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Paroxetine<sup>a</sup></td><td align=\"left\">58</td><td align=\"left\">327</td><td align=\"left\">121</td><td align=\"left\">5.6</td><td align=\"left\">Anxiety 5.2</td></tr><tr><td align=\"left\">N06AB05</td><td/><td/><td/><td/><td align=\"left\">Irritability, aggressiveness 3.4</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Suicidal behavior 3.1</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Insomnia 2.3</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Depression 2.1</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Mirtazapine<sup>b</sup></td><td align=\"left\">34</td><td align=\"left\">131</td><td align=\"left\">46</td><td align=\"left\">3.9</td><td align=\"left\">Anxiety 6.9</td></tr><tr><td align=\"left\">N06AX11</td><td/><td/><td/><td/><td align=\"left\">Insomnia 6.1</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Irritability, aggressiveness 3.1</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Suicidal behavior 2.3</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Uneasiness/nervousness 2.3</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Fluoxetine<sup>a</sup></td><td align=\"left\">28</td><td align=\"left\">120</td><td align=\"left\">39</td><td align=\"left\">4.3</td><td align=\"left\">Anxiety 5.0</td></tr><tr><td align=\"left\">N06AB03</td><td/><td/><td/><td/><td align=\"left\">Irritability, aggressiveness 2.5</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Suicidal behavior 2.5</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Insomnia 2.5</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">Escitalopram<sup>a</sup></td><td align=\"left\">21</td><td align=\"left\">113</td><td align=\"left\">49</td><td align=\"left\">5.4</td><td align=\"left\">Anxiety 7.1</td></tr><tr><td align=\"left\">N06AB10</td><td/><td/><td/><td/><td align=\"left\">Sensation of unreality 6.2</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Insomnia 5.3</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Depression 3.5</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Irritability, aggressiveness 3.5</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Suicidal behavior 2.7</td></tr><tr><td/><td/><td/><td/><td/><td align=\"left\">Uneasiness/nervousness 2.7</td></tr></tbody></table></body></html>", "text": "Pmid= 3215951:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Consumer reported psychiatric ADRs (N = 878) to KILEN according to age and gender (N) and (%)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Gender</th><th align=\"center\" colspan=\"9\">Age group</th></tr></thead><tbody><tr><td/><td align=\"left\"><bold>15-29</bold></td><td align=\"left\"><bold>30-39</bold></td><td align=\"left\"><bold>40-49</bold></td><td align=\"left\"><bold>50-59</bold></td><td align=\"left\"><bold>60-69</bold></td><td align=\"left\"><bold>70-79</bold></td><td align=\"left\"><bold>80-89</bold></td><td align=\"left\"><bold>No age</bold></td><td align=\"left\"><bold>Total</bold></td></tr><tr><td colspan=\"10\"><hr/></td></tr><tr><td align=\"left\">Female</td><td align=\"left\">150 (17.1)</td><td align=\"left\">235 (26.8)</td><td align=\"left\">151 (17.2)</td><td align=\"left\">42 (4.8)</td><td align=\"left\">17 (1.9)</td><td align=\"left\">10 (1.1)</td><td align=\"left\">-</td><td align=\"left\">17 (1.9)</td><td align=\"left\">622 (70.8)</td></tr><tr><td align=\"left\">Male</td><td align=\"left\">46 (5.2)</td><td align=\"left\">53 (6.0)</td><td align=\"left\">64 (7.3)</td><td align=\"left\">30 (3.4)</td><td align=\"left\">10 (1.1)</td><td align=\"left\">-</td><td align=\"left\">3 (0.3)</td><td align=\"left\">2 (0.2)</td><td align=\"left\">208 (23.7)</td></tr><tr><td align=\"left\">Not given</td><td align=\"left\">9 (1.0)</td><td align=\"left\">16 (1.8)</td><td align=\"left\">14 (1.6)</td><td align=\"left\">-</td><td align=\"left\">-</td><td align=\"left\">-</td><td align=\"left\">-</td><td align=\"left\">9 (1.0)</td><td align=\"left\">48 (5.5)</td></tr><tr><td align=\"left\">Total</td><td align=\"left\">550 (23.6)</td><td align=\"left\">804 (34.5)</td><td align=\"left\">515 (22.1)</td><td align=\"left\">242 (10.4)</td><td align=\"left\">85 (3.6)</td><td align=\"left\">23 (1.0)</td><td/><td align=\"left\">44 (1.9)</td><td align=\"left\">878</td></tr></tbody></table></body></html>", "text": "Pmid= 3215951:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Reported antidepressant psychiatric ADRs to KILEN during different stages of treatment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Type of reported psychiatric adverse drug reaction and frequency (N)</th><th align=\"center\">During treatment (%)</th><th align=\"center\">During discontinuation treatment (%)</th><th align=\"center\">After treatment (%)</th></tr></thead><tbody><tr><td align=\"left\">Anxiety (139)</td><td align=\"center\">40</td><td align=\"center\">34</td><td align=\"center\">26</td></tr><tr><td align=\"left\">Sensation of unreality (57)</td><td align=\"center\">54</td><td align=\"center\">25</td><td align=\"center\">21</td></tr><tr><td align=\"left\">Insomnia (72)</td><td align=\"center\">54</td><td align=\"center\">28</td><td align=\"center\">18</td></tr><tr><td align=\"left\">Uneasiness/nervousness (50)</td><td align=\"center\">50</td><td align=\"center\">30</td><td align=\"center\">20</td></tr><tr><td align=\"left\">Irritability/aggressiveness (45)</td><td align=\"center\">49</td><td align=\"center\">33</td><td align=\"center\">18</td></tr><tr><td align=\"left\">Suicidal behaviour (59)</td><td align=\"center\">68</td><td align=\"center\">19</td><td align=\"center\">13</td></tr><tr><td align=\"left\">Depression (20)</td><td align=\"center\">25</td><td align=\"center\">45</td><td align=\"center\">30</td></tr></tbody></table></body></html>", "text": "Pmid= 3215951:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Internet reported antidepressant psychiatric ADRs to KILEN according to age and gender (%)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Sertraline</th><th align=\"center\">Citalopram</th><th align=\"center\">Venlafaxine</th><th align=\"center\">Paroxetine</th><th align=\"center\">Mirtazapine</th><th align=\"center\">Fluoxetine</th><th align=\"center\">Escitalopram</th></tr></thead><tbody><tr><td align=\"left\">Gender</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Female</td><td align=\"center\">67.3</td><td align=\"center\">82.7</td><td align=\"center\">68.4</td><td align=\"center\">67.8</td><td align=\"center\">52.1</td><td align=\"center\">71.8</td><td align=\"center\">65.3</td></tr><tr><td align=\"left\">Male</td><td align=\"center\">27.8</td><td align=\"center\">16.4</td><td align=\"center\">21.6</td><td align=\"center\">28.9</td><td align=\"center\">43.5</td><td align=\"center\">25.6</td><td align=\"center\">12.2</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"left\">Age group</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;15-29</td><td align=\"center\">26.5</td><td align=\"center\">12.4</td><td align=\"center\">20.5</td><td align=\"center\">33.1</td><td align=\"center\">37.0</td><td align=\"center\">30.8</td><td align=\"center\">26.5</td></tr><tr><td align=\"left\">&#8195;&#8195;Female</td><td align=\"center\">16.8</td><td align=\"center\">9.7</td><td align=\"center\">15.8</td><td align=\"center\">24.0</td><td align=\"center\">37.0</td><td align=\"center\">30.8</td><td align=\"center\">10.2</td></tr><tr><td align=\"left\">&#8195;&#8195;Male</td><td align=\"center\">7.1</td><td align=\"center\">2.6</td><td align=\"center\">4.1</td><td align=\"center\">9.1</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">12.2</td></tr><tr><td align=\"left\">&#8195;30-39</td><td align=\"center\">45.5</td><td align=\"center\">39.8</td><td align=\"center\">27.5</td><td align=\"center\">30.6</td><td align=\"center\">14.0</td><td align=\"center\">17.9</td><td align=\"center\">28.6</td></tr><tr><td align=\"left\">&#8195;&#8195;Female</td><td align=\"center\">27.4</td><td align=\"center\">36.7</td><td align=\"center\">27.5</td><td align=\"center\">23.1</td><td align=\"center\">-</td><td align=\"center\">2.6</td><td align=\"center\">28.6</td></tr><tr><td align=\"left\">&#8195;&#8195;Male</td><td align=\"center\">13.3</td><td align=\"center\">2.2</td><td align=\"center\">-</td><td align=\"center\">5.0</td><td align=\"center\">14.0</td><td align=\"center\">15.4</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;40-49</td><td align=\"center\">12.8</td><td align=\"center\">27.9</td><td align=\"center\">38.6</td><td align=\"center\">28.1</td><td align=\"center\">4.6</td><td align=\"center\">38.5</td><td align=\"center\">40.8</td></tr><tr><td align=\"left\">&#8195;&#8195;Female</td><td align=\"center\">11.8</td><td align=\"center\">21.2</td><td align=\"center\">19.3</td><td align=\"center\">13.2</td><td align=\"center\">2.3</td><td align=\"center\">35.9</td><td align=\"center\">24.5</td></tr><tr><td align=\"left\">&#8195;&#8195;Male</td><td align=\"center\">0.9</td><td align=\"center\">6.6</td><td align=\"center\">15.8</td><td align=\"center\">14.9</td><td align=\"center\">2.3</td><td align=\"center\">2.6</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;50-59</td><td align=\"center\">7.5</td><td align=\"center\">12.4</td><td align=\"center\">5.5</td><td align=\"center\">3.3</td><td align=\"center\">26.4</td><td align=\"center\">2.6</td><td align=\"center\">2.0</td></tr><tr><td align=\"left\">&#8195;&#8195;Female</td><td align=\"center\">2.6</td><td align=\"center\">8.4</td><td align=\"center\">3.6</td><td align=\"center\">3.3</td><td align=\"center\">11.1</td><td align=\"center\">2.6</td><td align=\"center\">2.0</td></tr><tr><td align=\"left\">&#8195;&#8195;Male</td><td align=\"center\">4.9</td><td align=\"center\">4.0</td><td align=\"center\">1.9</td><td align=\"center\">-</td><td align=\"center\">15.3</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;60-69</td><td align=\"center\">4.9</td><td align=\"center\">3.5</td><td align=\"center\">-</td><td align=\"center\">1.6</td><td align=\"center\">14.9</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;&#8195;Female</td><td align=\"center\">4.0</td><td align=\"center\">2.6</td><td align=\"center\">-</td><td align=\"center\">1.6</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;&#8195;Male</td><td align=\"center\">0.9</td><td align=\"center\">0.9</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">14.9</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;70-79</td><td align=\"center\">2.0</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;&#8195;Female</td><td align=\"center\">2.0</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;&#8195;Male</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;80-89</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">7.7</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;&#8195;Female</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td align=\"left\">&#8195;&#8195;Male</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">7.7</td><td/></tr><tr><td align=\"left\">No age given</td><td align=\"center\">0.8</td><td align=\"center\">4.0</td><td align=\"center\">7.9</td><td align=\"center\">3.9</td><td align=\"center\">3.1</td><td align=\"center\">2.5</td><td align=\"center\">2.1</td></tr></tbody></table></body></html>", "text": "Pmid= 3215951:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Knowledge, attitudes and practices (KAP)-surveys about AMR in the hospital setting as reported in the English literature</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Author</th><th align=\"left\">Country</th><th align=\"left\">Participants</th><th align=\"left\">Main findings</th></tr></thead><tbody><tr><td align=\"left\">Pulcini <italic>et al</italic>., 2010</td><td align=\"left\">Scotland, France</td><td align=\"left\">Junior doctors<break/>(n = 139)</td><td align=\"left\">95% agreed AMR is a national problem, 63% agreed so for their own clinical practice. Only 26% knew the correct local prevalence of methicillin-resistant <italic>S. aureus</italic></td></tr><tr><td align=\"left\">Guerra <italic>et al</italic>., 2007</td><td align=\"left\">Brazil</td><td align=\"left\">Mainly residents<break/>(n = 310)</td><td align=\"left\">95% agreed AMR is a problem and 87% that AMs are overprescribed</td></tr><tr><td align=\"left\">Giblin <italic>et al</italic>., 2004</td><td align=\"left\">USA</td><td align=\"left\">Health care workers<break/>(n = 117*)</td><td align=\"left\">95% agreed that AMR is a national problem, 65% agreed for in their own practice</td></tr><tr><td align=\"left\">Srinisavan <italic>et al</italic>., 2004</td><td align=\"left\">USA</td><td align=\"left\">House-staff physicians (other than paediatricians) (n = 179)</td><td align=\"left\">88% agreed that AMs are overused in general, 72% agreed so for their own hospital</td></tr><tr><td align=\"left\">Wester <italic>et al</italic>. 2002</td><td align=\"left\">USA</td><td align=\"left\">Internal medicine doctors<break/>(n = 490)</td><td align=\"left\">87% considered AMR as very important national problem</td></tr></tbody></table></body></html>", "text": "Pmid= 3231801:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Professional profile of the participants in the two hospitals of Lima, Peru</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Characteristic</th><th align=\"center\">Cayetano Heredia hospital (n = 132)</th><th align=\"center\">Arzobispo Loayza Hospital (n = 124)</th><th align=\"center\">Total<break/>(n = 256)</th></tr></thead><tbody><tr><td align=\"left\"><bold>Working time in hospitals</bold></td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;0 - 4 years</td><td align=\"center\">74 (56)</td><td align=\"center\">66 (53)</td><td align=\"center\">140 (55)</td></tr><tr><td align=\"left\">&#8195;&#8805; 5 years</td><td align=\"center\">58 (44)</td><td align=\"center\">58 (47)</td><td align=\"center\">116 (45)</td></tr><tr><td align=\"left\">Hospital department</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Medicine</td><td align=\"center\">66 (50.0)</td><td align=\"center\">76 (61)</td><td align=\"center\">142 (55)</td></tr><tr><td align=\"left\">&#8195;Surgery</td><td align=\"center\">39 (30)*</td><td align=\"center\">14 (11)*</td><td align=\"center\">53 (21)</td></tr><tr><td align=\"left\">&#8195;O&amp;B</td><td align=\"center\">15 (11)</td><td align=\"center\">17 (14)</td><td align=\"center\">32 (13)</td></tr><tr><td align=\"left\">&#8195;Paediatrics</td><td align=\"center\">12 (9)</td><td align=\"center\">17 (14)</td><td align=\"center\">29 (11)</td></tr><tr><td align=\"left\">Position</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Resident (in training)</td><td align=\"center\">64 (48)</td><td align=\"center\">71 (57)</td><td align=\"center\">135 (53)</td></tr><tr><td align=\"left\">&#8195;Attending physician</td><td align=\"center\">68 (52)</td><td align=\"center\">53 (43)</td><td align=\"center\">121 (47)</td></tr></tbody></table></body></html>", "text": "Pmid= 3231801:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Immunogenicity assay characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th/><th align=\"center\" colspan=\"2\">Drug Tolerance<sup>&#8224;</sup></th></tr><tr><th/><th/><th/><th colspan=\"2\"><hr/></th></tr><tr><th align=\"left\">Assay</th><th align=\"center\">Assay Sensitivity*</th><th align=\"center\">LLRD</th><th align=\"center\">Anti-panitumumab</th><th align=\"center\">Panitumumab</th></tr></thead><tbody><tr><td align=\"left\">ELISA</td><td align=\"center\">10 ng/mL</td><td align=\"center\">60 ng/mL</td><td align=\"center\">60 ng/mL<break/>500 ng/mL</td><td align=\"center\">9 &#956;g/mL<break/>81 &#956;g/mL</td></tr><tr><td align=\"left\">Biacore</td><td align=\"center\">1.8 &#956;g/mL</td><td align=\"center\">1.8 &#956;g/mL</td><td align=\"center\">4 &#956;g/mL<break/>20 &#956;g/mL</td><td align=\"center\">1.9 &#956;g/mL<break/>7.8 &#956;g/mL</td></tr><tr><td align=\"left\">Bioassay</td><td align=\"center\">~62.5 ng/mL</td><td align=\"center\">~125 ng/mL</td><td align=\"center\">~1 &#956;g/mL</td><td align=\"center\">~2.5 &#956;g/mL</td></tr></tbody></table></body></html>", "text": "Pmid= 3231982:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Incidence of anti-panitumumab antibodies</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Wild-Type <italic>KRAS</italic></th><th align=\"center\" colspan=\"2\">Mutant <italic>KRAS</italic></th><th align=\"center\" colspan=\"2\">All Patients*</th></tr><tr><th/><th colspan=\"6\"><hr/></th></tr><tr><th/><th align=\"center\">Either Biacore or ELISA</th><th align=\"center\">Bioassay</th><th align=\"center\">Either Biacore or ELISA</th><th align=\"center\">Bioassay</th><th align=\"center\">Either Biacore or ELISA</th><th align=\"center\">Bioassay</th></tr></thead><tbody><tr><td align=\"left\" colspan=\"7\"><bold>Total Antibody Incidence, n<sub>1</sub>/n<sub>2 </sub>(%)</bold></td></tr><tr><td align=\"left\">20050184</td><td align=\"center\">6/48 (12.5)</td><td align=\"center\">1/48 (2.1)</td><td align=\"center\">0/37 (0)</td><td align=\"center\">0/37 (0)</td><td align=\"center\">6/93 (6.5)</td><td align=\"center\">1/93 (1.1)</td></tr><tr><td align=\"left\">20060277</td><td align=\"center\">0/64 (0)</td><td align=\"center\">0/64 (0)</td><td align=\"center\">1/45 (2.2)</td><td align=\"center\">1/45 (2.2)</td><td align=\"center\">1/115 (0.9)</td><td align=\"center\">1/115 (0.9)</td></tr><tr><td align=\"left\">20050181</td><td align=\"center\">11/288 (3.8)</td><td align=\"center\">0/288 (0)</td><td align=\"center\">9/223 (4.0)</td><td align=\"center\">1/223 (0.4)</td><td align=\"center\">22/559 (3.9)</td><td align=\"center\">1/559 (0.2)</td></tr><tr><td align=\"left\">20050203 (Pmab + OX)</td><td align=\"center\">21/308 (6.8)</td><td align=\"center\">3/308 (1.0)</td><td align=\"center\">10/206 (4.9)</td><td align=\"center\">1/206 (0.5)</td><td align=\"center\">36/558 (6.5)</td><td align=\"center\">4/558 (0.7)</td></tr><tr><td align=\"left\">Pmab + IRI</td><td align=\"center\">17/400 (4.3)</td><td align=\"center\">1/400 (0.3)</td><td align=\"center\">10/305 (3.3)</td><td align=\"center\">2/305 (3.3)</td><td align=\"center\">29/767 (3.8)</td><td align=\"center\">3/767 (0.4)</td></tr><tr><td align=\"left\">Pmab + IRI or OX</td><td align=\"center\">38/708 (5.4)</td><td align=\"center\">4/708 (0.6)</td><td align=\"center\">20/511 (3.9)</td><td align=\"center\">3/511 (0.6)</td><td align=\"center\">65/1325 (4.9)</td><td align=\"center\">7/1325 (0.5)</td></tr><tr><td align=\"left\" colspan=\"7\"><bold>Pre-existing Antibody Incidence, n<sub>3</sub>/n<sub>4 </sub>(%)</bold></td></tr><tr><td align=\"left\">20050184</td><td align=\"center\">4/48 (8.3)</td><td align=\"center\">1/48 (2.1)</td><td align=\"center\">0/37 (0)</td><td align=\"center\">0/37 (0)</td><td align=\"center\">4/93 (4.3)</td><td align=\"center\">1/93 (1.1)</td></tr><tr><td align=\"left\">20060277</td><td align=\"center\">0/64 (0)</td><td align=\"center\">0/64 (0)</td><td align=\"center\">1/45 (2.2)</td><td align=\"center\">1/45 (2.2)</td><td align=\"center\">1/115 (0.9)</td><td align=\"center\">1/115 (0.9)</td></tr><tr><td align=\"left\">20050181</td><td align=\"center\">11/252 (4.4)</td><td align=\"center\">0/252 (0)</td><td align=\"center\">7/210 (3.3)</td><td align=\"center\">1/210 (0.5)</td><td align=\"center\">19/506 (3.8)</td><td align=\"center\">1/506 (0.2)</td></tr><tr><td align=\"left\">20050203 (Pmab + OX)</td><td align=\"center\">11/282 (3.9)</td><td align=\"center\">2/282 (0.7)</td><td align=\"center\">7/188 (3.7)</td><td align=\"center\">0/188 (0)</td><td align=\"center\">22/511 (4.3)</td><td align=\"center\">2/511 (0.4)</td></tr><tr><td align=\"left\">Pmab + IRI</td><td align=\"center\">15/364 (4.1)</td><td align=\"center\">1/364 (0.3)</td><td align=\"center\">8/292 (2.7)</td><td align=\"center\">2/292 (0.7)</td><td align=\"center\">24/714 (3.4)</td><td align=\"center\">3/714 (0.4)</td></tr><tr><td align=\"left\">Pmab + IRI or OX</td><td align=\"center\">26/646 (4.0)</td><td align=\"center\">3/646 (0.5)</td><td align=\"center\">15/480 (3.1)</td><td align=\"center\">2/480 (0.4)</td><td align=\"center\">46/1225 (3.8)</td><td align=\"center\">5/1225 (0.4)</td></tr><tr><td align=\"left\" colspan=\"7\"><bold>Developing Antibody Incidence, n<sub>5</sub>/n<sub>6 </sub>(%)</bold></td></tr><tr><td align=\"left\">20050184</td><td align=\"center\">2/37 (5.4)</td><td align=\"center\">0/37 (0)</td><td align=\"center\">0/26 (0)</td><td align=\"center\">0/26 (0)</td><td align=\"center\">2/68 (2.9)</td><td align=\"center\">0/68 (0)</td></tr><tr><td align=\"left\">20060277</td><td align=\"center\">0/42 (0)</td><td align=\"center\">0/42 (0)</td><td align=\"center\">0/30 (0)</td><td align=\"center\">0/30 (0)</td><td align=\"center\">0/75 (0)</td><td align=\"center\">0/75 (0)</td></tr><tr><td align=\"left\">20050181</td><td align=\"center\">0/255 (0)</td><td align=\"center\">0/255 (0)</td><td align=\"center\">3/205 (1.5)</td><td align=\"center\">0/205 (0)</td><td align=\"center\">4/501 (0.8)</td><td align=\"center\">0/501 (0)</td></tr><tr><td align=\"left\">20050203 (Pmab + OX)</td><td align=\"center\">10/264 (3.8)</td><td align=\"center\">1/264 (0.4)</td><td align=\"center\">3/178 (1.7)</td><td align=\"center\">1/178 (0.6)</td><td align=\"center\">14/480 (2.9)</td><td align=\"center\">2/480 (0.4)</td></tr><tr><td align=\"left\">Pmab + IRI</td><td align=\"center\">2/334 (0.6)</td><td align=\"center\">0/334 (0)</td><td align=\"center\">3/261 (1.1)</td><td align=\"center\">0/261 (0)</td><td align=\"center\">6/644 (0.9)</td><td align=\"center\">0/644 (0)</td></tr><tr><td align=\"left\">Pmab + IRI or OX</td><td align=\"center\">12/598 (2.0)</td><td align=\"center\">1/598 (0.2)</td><td align=\"center\">6/439 (1.4)</td><td align=\"center\">1/439 (0.2)</td><td align=\"center\">20/1124 (1.8)</td><td align=\"center\">2/1124 (0.2)</td></tr></tbody></table></body></html>", "text": "Pmid= 3231982:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Distribution of the observed concentrations of panitumumab relative to the 90% predictive interval</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Distribution in Relation to 90% Prediction Interval</th><th align=\"center\" colspan=\"4\">Antibody-Positive Patients</th><th align=\"center\" colspan=\"4\">Antibody-Negative Patients</th><th align=\"center\"><italic>P</italic>-value<sup>&#8224;</sup></th></tr><tr><th/><th colspan=\"4\"><hr/></th><th colspan=\"4\"><hr/></th><th/></tr><tr><th/><th align=\"center\">N</th><th align=\"center\">%</th><th align=\"center\">95% CI</th><th align=\"center\"><italic>P</italic>-value*</th><th align=\"center\">N</th><th align=\"center\">%</th><th align=\"center\">95% CI</th><th align=\"center\"><italic>P</italic>-value*</th><th/></tr></thead><tbody><tr><td align=\"left\">Below</td><td align=\"center\">2</td><td align=\"center\">5.3</td><td align=\"center\">0.6 -17.8</td><td align=\"center\">0.07</td><td align=\"center\">3</td><td align=\"center\">4.4</td><td align=\"center\">0.9 - 12.4</td><td align=\"center\">0.13</td><td align=\"center\">0.88</td></tr><tr><td align=\"left\">Above</td><td align=\"center\">5</td><td align=\"center\">13.2</td><td align=\"center\">4.4 - 28.1</td><td/><td align=\"center\">7</td><td align=\"center\">10.3</td><td align=\"center\">4.2 - 20.1</td><td/><td/></tr><tr><td align=\"left\">Within</td><td align=\"center\">31</td><td align=\"center\">81.6</td><td align=\"center\">65.7 - 92.3</td><td/><td align=\"center\">58</td><td align=\"center\">85.3</td><td align=\"center\">74.6 - 92.7</td><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 3231982:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of adverse events (safety analysis set*)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Antibody Negative<break/>(N = 1317)</th><th align=\"center\">Antibody Positive<break/>(N = 65)</th><th align=\"center\">Predose Positive<break/>(N = 46)</th><th align=\"center\">Developing Antibody Positive<break/>(N = 21)</th></tr></thead><tbody><tr><td align=\"left\">Patients with any adverse event<bold><sup>&#8224;</sup></bold>, n (%)</td><td align=\"center\">1312 (100)</td><td align=\"center\">65 (100)</td><td align=\"center\">46 (100)</td><td align=\"center\">21 (100)</td></tr><tr><td align=\"left\">&#8195;Worst grade of 3<bold><sup>&#8225;</sup></bold></td><td align=\"center\">716 (54)</td><td align=\"center\">26 (40)</td><td align=\"center\">18 (39)</td><td align=\"center\">8 (38)</td></tr><tr><td align=\"left\">&#8195;Worst grade of 4<bold><sup>&#8225;</sup></bold></td><td align=\"center\">264 (20)</td><td align=\"center\">18 (28)</td><td align=\"center\">15 (33)</td><td align=\"center\">4 (19)</td></tr><tr><td align=\"left\">&#8195;Worst grade of 5<bold><sup>&#8225;</sup></bold></td><td align=\"center\">82 (6)</td><td align=\"center\">6 (9)</td><td align=\"center\">2 (4)</td><td align=\"center\">4 (19)</td></tr><tr><td align=\"left\">&#8195;Any serious adverse event</td><td align=\"center\">544 (41)</td><td align=\"center\">32 (49)</td><td align=\"center\">23 (50)</td><td align=\"center\">10 (48)</td></tr><tr><td align=\"left\">Patients with any adverse event leading to permanent discontinuation of any study drug, n (%)</td><td align=\"center\">299 (23)</td><td align=\"center\">16 (25)</td><td align=\"center\">8 (17)</td><td align=\"center\">8 (38)</td></tr><tr><td align=\"left\">&#8195;Not serious</td><td align=\"center\">217 (16)</td><td align=\"center\">12 (18)</td><td align=\"center\">6 (13)</td><td align=\"center\">6 (29)</td></tr><tr><td align=\"left\">&#8195;Serious</td><td align=\"center\">108 (8)</td><td align=\"center\">6 (9)</td><td align=\"center\">3 (7)</td><td align=\"center\">3 (14)</td></tr><tr><td align=\"left\">Patients with any treatment-related adverse event<sup>&#167;</sup>, n (%)</td><td align=\"center\">1298 (99)</td><td align=\"center\">65 (100)</td><td align=\"center\">46 (100)</td><td align=\"center\">21 (100)</td></tr><tr><td align=\"left\">&#8195;Worst grade of 3<bold><sup>&#8225;</sup></bold></td><td align=\"center\">739 (56)</td><td align=\"center\">30 (46)</td><td align=\"center\">20 (43)</td><td align=\"center\">11 (52)</td></tr><tr><td align=\"left\">&#8195;Worst grade of 4<bold><sup>&#8225;</sup></bold></td><td align=\"center\">204 (15)</td><td align=\"center\">15 (23)</td><td align=\"center\">13 (28)</td><td align=\"center\">2 (10)</td></tr><tr><td align=\"left\">&#8195;Worst grade of 5<bold><sup>&#8225;</sup></bold></td><td align=\"center\">13 (1)</td><td align=\"center\">1 (2)</td><td align=\"center\">0</td><td align=\"center\">1 (5)</td></tr><tr><td align=\"left\">&#8195;Any serious adverse event</td><td align=\"center\">314 (24)</td><td align=\"center\">20 (31)</td><td align=\"center\">14 (30)</td><td align=\"center\">6 (29)</td></tr><tr><td align=\"left\">Patients with any adverse event leading to permanent discontinuation of any study drug, n (%)</td><td align=\"center\">251 (19)</td><td align=\"center\">11 (17)</td><td align=\"center\">5 (11)</td><td align=\"center\">6 (29)</td></tr><tr><td align=\"left\">&#8195;Not serious</td><td align=\"center\">200 (15)</td><td align=\"center\">9 (14)</td><td align=\"center\">4 (9)</td><td align=\"center\">5 (24)</td></tr><tr><td align=\"left\">&#8195;Serious</td><td align=\"center\">64 (5)</td><td align=\"center\">2 (3)</td><td align=\"center\">1 (2)</td><td align=\"center\">1 (5)</td></tr></tbody></table></body></html>", "text": "Pmid= 3231982:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Demographic characteristics of 1, 104 respondents</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Number </th></tr></thead><tbody><tr><td align=\"left\"><bold>Age (years) (N = 1, 103)*</bold></td><td/></tr><tr><td align=\"left\">&#8195;18-29</td><td align=\"center\">218 </td></tr><tr><td align=\"left\">&#8195;30-49</td><td align=\"center\">438 </td></tr><tr><td align=\"left\">&#8195;50-69</td><td align=\"center\">334 </td></tr><tr><td align=\"left\">&#8195;&#8805;70</td><td align=\"center\">113 </td></tr><tr><td align=\"left\"><bold>Male</bold></td><td align=\"center\">532 </td></tr><tr><td align=\"left\"><bold>Presence of chronic disease(s)</bold></td><td align=\"center\">215 </td></tr><tr><td align=\"left\"><bold>Education (N = 1, 096)*</bold></td><td/></tr><tr><td align=\"left\">&#8195;Primary or below</td><td align=\"center\">164 </td></tr><tr><td align=\"left\">&#8195;Secondary</td><td align=\"center\">604 </td></tr><tr><td align=\"left\">&#8195;Tertiary or above</td><td align=\"center\">328 </td></tr><tr><td align=\"left\"><bold>Family monthly income (HKD) (N = 823)<sup># </sup>*</bold></td><td/></tr><tr><td align=\"left\">&#8195;&#8804; $5, 999</td><td align=\"center\">83 (10.1)</td></tr><tr><td align=\"left\">&#8195;$6, 000- $9, 999</td><td align=\"center\">73 (8.9)</td></tr><tr><td align=\"left\">&#8195;$10, 000-$29, 999</td><td align=\"center\">424 (51.5)</td></tr><tr><td align=\"left\">&#8195;$30, 000-$59, 999</td><td align=\"center\">172 (20.9)</td></tr><tr><td align=\"left\">&#8195;$60, 000 or above</td><td align=\"center\">71 (8.6)</td></tr></tbody></table></body></html>", "text": "Pmid= 3252282:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Factors affecting knowledge score on self-medication</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"4\">Univariate analysis (Chi-square) Knowledge Score</th><th align=\"center\" colspan=\"2\">Multivariate analysis (Logistic regression) Knowledge Score &lt; 4</th></tr></thead><tbody><tr><td/><td align=\"left\"><bold>&lt; 4</bold></td><td align=\"left\"><bold>&#8805;4</bold></td><td align=\"left\"><bold>X<sup>2</sup></bold></td><td align=\"left\"><bold>P</bold></td><td align=\"left\"><bold>OR (95% CI)</bold></td><td align=\"left\"><bold>P</bold></td></tr><tr><td/><td align=\"left\"><bold>n (%)</bold></td><td align=\"left\"><bold>n (%)</bold></td><td/><td/><td/><td/></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\"><bold>Age</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">18-29</td><td align=\"left\">64 (15.9)</td><td align=\"left\">154 (22.4)</td><td align=\"right\">49.05</td><td align=\"left\">&lt; 0.001</td><td align=\"left\">reference</td><td align=\"left\">0.893</td></tr><tr><td align=\"left\">30-59</td><td align=\"left\">208 (51.6)</td><td align=\"left\">434 (63.0)</td><td/><td/><td align=\"left\">0.97 (0.64-1.47)</td><td align=\"right\">0.042</td></tr><tr><td align=\"left\">60 or above</td><td align=\"left\">131 (32.5)</td><td align=\"left\">101 (14.7)</td><td/><td/><td align=\"left\">1.82 (1.02-3.26)</td><td/></tr><tr><td align=\"left\"><bold>Gender</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Male</td><td align=\"left\">191 (47.5)</td><td align=\"left\">340 (49.3)</td><td align=\"right\">0.316</td><td align=\"left\">0.616</td><td align=\"left\">0.91 (0.67-1.23)</td><td align=\"left\">0.529</td></tr><tr><td align=\"left\">Female</td><td align=\"left\">211 (52.5)</td><td align=\"left\">350 (50.7)</td><td/><td/><td align=\"left\">reference</td><td/></tr><tr><td align=\"left\"><bold>Education</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">No schooling/primary</td><td align=\"left\">100 (25.1)</td><td align=\"left\">61 (8.9)</td><td align=\"right\">64.74</td><td align=\"left\">&lt; 0.001</td><td align=\"left\">3.19 (1.78-5.72)</td><td align=\"left\">&lt; 0.001</td></tr><tr><td align=\"left\">Secondary</td><td align=\"left\">218 (54.6)</td><td align=\"left\">379 (55.2)</td><td/><td/><td align=\"left\">1.50 (1.03-2.19)</td><td align=\"left\">0.035</td></tr><tr><td align=\"left\">Diploma/degree</td><td align=\"left\">81 (20.3)</td><td align=\"left\">246 (35.9)</td><td/><td/><td align=\"left\">reference</td><td/></tr><tr><td align=\"left\"><bold>Monthly household income (HK$)</bold><sup>#</sup></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&lt; $2000-$5999</td><td align=\"left\">37 (13.4)</td><td align=\"left\">45 (8.3)</td><td align=\"right\">11.98</td><td align=\"left\">0.007</td><td align=\"left\">0.90 (0.48-1.68)</td><td align=\"left\">0.746</td></tr><tr><td align=\"left\">$6000-$9999</td><td align=\"left\">27 (9.8)</td><td align=\"left\">46 (8.5)</td><td/><td/><td align=\"left\">0.99 (0.55-1.78)</td><td align=\"left\">0.973</td></tr><tr><td align=\"left\">$10000-$24999</td><td align=\"left\">130 (47.1)</td><td align=\"left\">231 (42.5)</td><td/><td/><td align=\"left\">1.20 (0.83-1.73)</td><td align=\"left\">0.336</td></tr><tr><td align=\"left\">&#8805;$25000</td><td align=\"left\">82 (29.7)</td><td align=\"left\">221 (40.7)</td><td/><td/><td align=\"left\">reference</td><td/></tr><tr><td align=\"left\"><bold>Presence of chronic illness</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Yes</td><td align=\"left\">309 (76.9)</td><td align=\"left\">571 (82.9)</td><td align=\"right\">5.88</td><td align=\"left\">0.017</td><td align=\"left\">1.03 (0.68-1.57)</td><td align=\"left\">0.877</td></tr><tr><td align=\"left\">No</td><td align=\"left\">93 (23.1)</td><td align=\"left\">118 (17.1)</td><td/><td/><td align=\"left\">reference</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3252282:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Factors affecting amount spent in purchasing western and Chinese OTC products</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"6\">Western OTC products</th><th align=\"center\" colspan=\"6\">Chinese OTC products</th></tr></thead><tbody><tr><td/><td/><td align=\"left\" colspan=\"3\"><bold>Univariate analysis (Chi-square)</bold></td><td align=\"center\" colspan=\"2\"><bold>Multivariate Analysis (Logistic Regression)</bold></td><td align=\"left\" colspan=\"3\"><bold>Univariate analysis (Chi-square)</bold></td><td align=\"center\" colspan=\"3\"><bold>Multivariate Analysis (Logistic Regression)</bold></td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td/><td align=\"left\"><bold>&#8804; $100</bold><break/><bold>n (%)</bold></td><td align=\"left\"><bold>$101 or above</bold><break/><bold>n (%)</bold></td><td align=\"left\"><bold>X<sup>2</sup></bold></td><td align=\"left\"><bold>P</bold></td><td align=\"left\"><bold>$101 or above</bold><break/><bold>OR (95% CI)</bold></td><td align=\"left\"><bold>P</bold></td><td align=\"left\"><bold>&#8804; $100</bold><break/><bold>n (%)</bold></td><td align=\"left\"><bold>$101 or above</bold><break/><bold>n (%)</bold></td><td align=\"left\"><bold>X<sup>2</sup></bold></td><td align=\"left\"><bold>P</bold></td><td align=\"left\"><bold>$101 or above</bold><break/><bold>OR (95% CI)</bold></td><td align=\"left\"><bold>P</bold></td></tr><tr><td colspan=\"13\"><hr/></td></tr><tr><td align=\"left\"><bold>Age (yrs)</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">18-29</td><td align=\"left\">34 (22.5)</td><td align=\"left\">5 (13.9)</td><td align=\"left\">1.61</td><td align=\"left\">0.446</td><td/><td/><td align=\"left\">5 (14.3)</td><td align=\"left\">4 (10.3)</td><td align=\"left\">0.28</td><td align=\"left\">0.868</td><td/><td/></tr><tr><td align=\"left\">30-59</td><td align=\"left\">99 (65.6)</td><td align=\"left\">25 (69.4)</td><td/><td/><td/><td/><td align=\"left\">23 (65.7)</td><td align=\"left\">27 (69.2)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">60 or above</td><td align=\"left\">18 (11.9)</td><td align=\"left\">6 (16.7)</td><td/><td/><td/><td/><td align=\"left\">7 (20.0)</td><td align=\"left\">8 (20.5)</td><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Gender</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Male</td><td align=\"left\">74 (49.3)</td><td align=\"left\">12 (33.3)</td><td align=\"left\">2.99</td><td align=\"left\">0.096</td><td align=\"left\">0.54 (0.25-1.19)</td><td align=\"left\">0.126</td><td align=\"left\">18 (50.0)</td><td align=\"left\">12 (30.8)</td><td align=\"left\">0.29</td><td align=\"left\">0.104</td><td align=\"left\">0.50 (0.19-1.31)</td><td align=\"left\">0.157</td></tr><tr><td align=\"left\">Female</td><td align=\"left\">76 (50.7)</td><td align=\"left\">24 (66.7)</td><td/><td/><td align=\"left\">reference</td><td/><td align=\"left\">18 (50.0)</td><td align=\"left\">27 (69.2)</td><td/><td/><td align=\"left\">reference</td><td/></tr><tr><td align=\"left\"><bold>Education</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">No schooling/primary</td><td align=\"left\">14 (9.3)</td><td align=\"left\">3 (8.3)</td><td align=\"left\">0.11</td><td align=\"left\">0.949</td><td/><td/><td align=\"left\">5 (14.3)</td><td align=\"left\">8 (21.1)</td><td align=\"left\">0.86</td><td align=\"left\">0.651</td><td/><td/></tr><tr><td align=\"left\">Secondary</td><td align=\"left\">79 (52.7)</td><td align=\"left\">20 (55.6)</td><td/><td/><td/><td/><td align=\"left\">18 (51.4)</td><td align=\"left\">20 (52.6)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">Diploma/degree</td><td align=\"left\">57 (38.0)</td><td align=\"left\">13 (36.1)</td><td/><td/><td/><td/><td align=\"left\">12 (34.3)</td><td align=\"left\">10 (26.3)</td><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Monthly household income (HK$)</bold><sup>#</sup></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&lt; $2000-$5999</td><td align=\"left\">7 (5.4)</td><td align=\"left\">2 (8.0)</td><td align=\"left\">3.05</td><td align=\"left\">0.384</td><td/><td/><td align=\"left\">1 (3.8)</td><td align=\"left\">4 (14.8)</td><td align=\"left\">2.16</td><td align=\"left\">0.339</td><td/><td/></tr><tr><td align=\"left\">$6000-$9999</td><td align=\"left\">12 (9.2)</td><td align=\"left\">0</td><td/><td/><td/><td/><td align=\"left\">0</td><td align=\"left\">0</td><td/><td/><td/><td/></tr><tr><td align=\"left\">$10000-$24999</td><td align=\"left\">56 (43.1)</td><td align=\"left\">10 (40.0)</td><td/><td/><td/><td/><td align=\"left\">15 (57.7)</td><td align=\"left\">12 (44.4)</td><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8805;$25000</td><td align=\"left\">55 (42.3)</td><td align=\"left\">13 (52.0)</td><td/><td/><td/><td/><td align=\"left\">10 (38.5)</td><td align=\"left\">11 (40.7)</td><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Presence of chronic illness</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">Yes</td><td align=\"left\">22(14.6)</td><td align=\"left\">14 (38.9)</td><td align=\"left\">11.06</td><td align=\"left\">0.002</td><td align=\"left\">3.58 (1.58-8.09)</td><td align=\"left\">0.002</td><td align=\"left\">9 (25.0)</td><td align=\"left\">20 (51.3)</td><td align=\"left\">5.45</td><td align=\"left\">0.032</td><td align=\"left\">2.94 (1.08-7.95)</td><td align=\"left\">0.034</td></tr><tr><td align=\"left\">No</td><td align=\"left\">129 (85.4)</td><td align=\"left\">22 (61.1)</td><td/><td/><td align=\"left\">reference</td><td/><td align=\"left\">27 (75.0)</td><td align=\"left\">19 (48.7)</td><td/><td/><td align=\"left\">reference</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3252282:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Behaviours related to self-care and the potential barriers of respondents with chronic conditions</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\" colspan=\"4\">Frequency in performing behaviours related to self-care</th></tr></thead><tbody><tr><td/><td align=\"center\"><bold>Always/</bold><break/><bold>Most of the time</bold><break/><bold>n (%)</bold></td><td align=\"center\"><bold>Sometimes</bold><break/><bold>n (%)</bold></td><td align=\"center\"><bold>Not very often/Never</bold><break/><bold>n (%)</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Disease progress monitoring#</td><td align=\"center\">180 (84.5%)</td><td align=\"center\">12 (5.6%)</td><td align=\"center\">21 (9.9%)</td></tr><tr><td align=\"left\">Medication compliance</td><td align=\"center\">188 (90.4%)</td><td align=\"center\">8 (3.8%)</td><td align=\"center\">12 (5.8%)</td></tr><tr><td align=\"left\">Clinic follow-up compliance</td><td align=\"center\">187 (89.9%)</td><td align=\"center\">7 (3.4%)</td><td align=\"center\">14 (6.7%)</td></tr><tr><td align=\"left\">Lifestyle modification</td><td align=\"center\">158 (74.9%)</td><td align=\"center\">28 (13.3%)</td><td align=\"center\">25 (11.8%)</td></tr><tr><td align=\"left\">Obtain emotional support</td><td align=\"center\">84 (44.7%)</td><td align=\"center\">27 (14.4%)</td><td align=\"center\">77 (41.0%)</td></tr><tr><td align=\"left\">Obtain caregiver support</td><td align=\"center\">124 (63.9%)</td><td align=\"center\">23 (11.9%)</td><td align=\"center\">47 (24.2%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"center\" colspan=\"4\"><bold>Potential barriers inhibiting self-care of chronic conditions</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td/><td align=\"center\"><bold>n (%)</bold></td><td/><td/></tr><tr><td align=\"left\">Lack of disease knowledge (n = 204)</td><td align=\"center\">88 (43.1%)</td><td/><td/></tr><tr><td align=\"left\">Lack of monitoring equipment (n = 205)</td><td align=\"center\">85 (41.5%)</td><td/><td/></tr><tr><td align=\"left\">Unstable health status (n = 207)</td><td align=\"center\">84 (40.6%)</td><td/><td/></tr><tr><td align=\"left\">Lack of family/friend\\'s support (n = 212)</td><td align=\"center\">70 (33.0%)</td><td/><td/></tr><tr><td align=\"left\">Lack of motivation (n = 203)</td><td align=\"center\">62 (30.5%)</td><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 3252282:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of study population</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Total</th><th align=\"center\" colspan=\"2\">Patients who refused GS</th><th align=\"center\" colspan=\"2\">Patients who allowed GS</th><th align=\"center\" colspan=\"2\">Patients who had refused and allowed GS</th><th align=\"center\" colspan=\"2\">Patients who had no experience with GS</th></tr></thead><tbody><tr><td/><td align=\"right\"><bold>No</bold>.</td><td align=\"left\"><bold>(%)</bold></td><td align=\"right\"><bold>No</bold>.</td><td align=\"left\"><bold>(%)</bold></td><td align=\"right\"><bold>No</bold>.</td><td align=\"left\"><bold>(%)</bold></td><td align=\"right\"><bold>No</bold>.</td><td align=\"left\"><bold>(%)</bold></td><td align=\"right\"><bold>No</bold>.</td><td align=\"left\"><bold>(%)</bold></td></tr><tr><td colspan=\"11\"><hr/></td></tr><tr><td align=\"left\"><bold>All</bold></td><td align=\"right\">1844</td><td align=\"left\">(100)</td><td align=\"right\">159</td><td align=\"left\">(9)</td><td align=\"right\">633</td><td align=\"left\">(34)</td><td align=\"right\">301</td><td align=\"left\">(16)</td><td align=\"right\">751</td><td align=\"left\">(41)</td></tr><tr><td align=\"left\"><bold>Sex</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;<bold>Male</bold></td><td align=\"right\">826</td><td align=\"left\">(45)</td><td align=\"right\">54</td><td align=\"left\">(34)</td><td align=\"right\">254</td><td align=\"left\">(40)</td><td align=\"right\">130</td><td align=\"left\">(43)</td><td align=\"right\">388</td><td align=\"left\">(52)</td></tr><tr><td align=\"left\">&#8195;<bold>Female</bold></td><td align=\"right\">1018</td><td align=\"left\">(55)</td><td align=\"right\">105</td><td align=\"left\">(66)</td><td align=\"right\">379</td><td align=\"left\">(60)</td><td align=\"right\">171</td><td align=\"left\">(57)</td><td align=\"right\">363</td><td align=\"left\">(48)</td></tr><tr><td align=\"left\"><bold>Age, yr</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;<bold>18-59</bold></td><td align=\"right\">1118</td><td align=\"left\">(61)</td><td align=\"right\">70</td><td align=\"left\">(45)</td><td align=\"right\">404</td><td align=\"left\">(64)</td><td align=\"right\">154</td><td align=\"left\">(52)</td><td align=\"right\">490</td><td align=\"left\">(66)</td></tr><tr><td align=\"left\">&#8195;<bold>60-94</bold></td><td align=\"right\">706</td><td align=\"left\">(39)</td><td align=\"right\">87</td><td align=\"left\">(55)</td><td align=\"right\">227</td><td align=\"left\">(36)</td><td align=\"right\">145</td><td align=\"left\">(48)</td><td align=\"right\">247</td><td align=\"left\">(34)</td></tr><tr><td align=\"left\">&#8195;<bold>Not reported</bold></td><td align=\"right\">20</td><td/><td align=\"right\">2</td><td/><td align=\"right\">2</td><td/><td align=\"right\">2</td><td/><td align=\"right\">14</td><td/></tr><tr><td align=\"left\">&#8195;<bold>Mean (SD)</bold></td><td align=\"right\">54</td><td align=\"left\">(17)</td><td align=\"right\">61</td><td align=\"left\">(18)</td><td align=\"right\">53</td><td align=\"left\">(16)</td><td align=\"right\">57</td><td align=\"left\">(19)</td><td align=\"right\">52</td><td align=\"left\">(17)</td></tr><tr><td align=\"left\">&#8195;<bold>Median</bold></td><td align=\"right\">55</td><td/><td align=\"right\">62</td><td/><td align=\"right\">53</td><td/><td align=\"right\">59</td><td/><td align=\"right\">52</td><td/></tr><tr><td align=\"left\" colspan=\"2\"><bold>Regularly uses prescription drugs</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;<bold>Yes</bold></td><td align=\"right\">1085</td><td align=\"left\">(59)</td><td align=\"right\">140</td><td align=\"left\">(88)</td><td align=\"right\">440</td><td align=\"left\">(70)</td><td align=\"right\">239</td><td align=\"left\">(80)</td><td align=\"right\">266</td><td align=\"left\">(36)</td></tr><tr><td align=\"left\">&#8195;<bold>No</bold></td><td align=\"right\">748</td><td align=\"left\">(41)</td><td align=\"right\">19</td><td align=\"left\">(12)</td><td align=\"right\">190</td><td align=\"left\">(30)</td><td align=\"right\">60</td><td align=\"left\">(20)</td><td align=\"right\">479</td><td align=\"left\">(64)</td></tr><tr><td align=\"left\">&#8195;<bold>Not reported</bold></td><td align=\"right\">11</td><td/><td align=\"right\">0</td><td/><td align=\"right\">3</td><td/><td align=\"right\">2</td><td/><td align=\"right\">6</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3262749:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Three most important factors that influence the choice of prescription medicines</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th/><th align=\"center\" colspan=\"6\">Factors related to medicines</th></tr><tr><th/><th/><th/><th align=\"center\" colspan=\"2\">Price</th><th align=\"center\" colspan=\"2\">Familiarity</th><th align=\"center\" colspan=\"2\">Availability</th></tr></thead><tbody><tr><td/><td/><td align=\"right\"><bold>No</bold>.</td><td align=\"right\"><bold>No</bold>.</td><td align=\"left\"><bold>%</bold></td><td align=\"right\"><bold>No</bold>.</td><td align=\"left\"><bold>%</bold></td><td align=\"right\"><bold>No</bold>.</td><td align=\"left\"><bold>%</bold></td></tr><tr><td colspan=\"9\"><hr/></td></tr><tr><td align=\"left\"><bold>All respondents</bold></td><td/><td align=\"right\">1551</td><td align=\"right\">1112</td><td align=\"left\">(72)</td><td align=\"right\">874</td><td align=\"left\">(56)</td><td align=\"right\">643</td><td align=\"left\">(42)</td></tr><tr><td align=\"left\">Gender</td><td align=\"left\">Men</td><td align=\"right\">688</td><td align=\"right\">492</td><td align=\"left\">(72)</td><td align=\"right\">366</td><td align=\"left\">(53)</td><td align=\"right\">298</td><td align=\"left\">(43)</td></tr><tr><td/><td align=\"left\">Women</td><td align=\"right\">863</td><td align=\"right\">620</td><td align=\"left\">(72)</td><td align=\"right\">508</td><td align=\"left\">(59)</td><td align=\"right\">345</td><td align=\"left\">(40)</td></tr><tr><td align=\"left\">Prescription medicines in</td><td align=\"left\">Yes</td><td align=\"right\">919</td><td align=\"right\">633</td><td align=\"left\">(69)</td><td align=\"right\">474</td><td align=\"left\">(52)</td><td align=\"right\">403</td><td align=\"left\">(44)</td></tr><tr><td align=\"left\">regular use</td><td align=\"left\">No</td><td align=\"right\">624</td><td align=\"right\">472</td><td align=\"left\">(76)</td><td align=\"right\">396</td><td align=\"left\">(64)</td><td align=\"right\">237</td><td align=\"left\">(38)</td></tr><tr><td align=\"left\">Age, years</td><td align=\"left\">&lt; 60</td><td align=\"right\">952</td><td align=\"right\">742</td><td align=\"left\">(78)</td><td align=\"right\">554</td><td align=\"left\">(58)</td><td align=\"right\">402</td><td align=\"left\">(42)</td></tr><tr><td/><td align=\"left\">&#8805; 60</td><td align=\"right\">585</td><td align=\"right\">363</td><td align=\"left\">(62)</td><td align=\"right\">314</td><td align=\"left\">(54)</td><td align=\"right\">230</td><td align=\"left\">(39)</td></tr><tr><td align=\"left\" colspan=\"2\"><bold>Patients who had refused GS</bold></td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">All</td><td/><td align=\"right\">134</td><td align=\"right\">60</td><td align=\"left\">(45)</td><td align=\"right\">95</td><td align=\"left\">(71)</td><td align=\"right\">50</td><td align=\"left\">(37)</td></tr><tr><td align=\"left\">Gender</td><td align=\"left\">Men</td><td align=\"right\">45</td><td align=\"right\">21</td><td align=\"left\">(47)</td><td align=\"right\">32</td><td align=\"left\">(71)</td><td align=\"right\">15</td><td align=\"left\">(33)</td></tr><tr><td/><td align=\"left\">Women</td><td align=\"right\">89</td><td align=\"right\">39</td><td align=\"left\">(44)</td><td align=\"right\">63</td><td align=\"left\">(71)</td><td align=\"right\">35</td><td align=\"left\">(39)</td></tr><tr><td align=\"left\">Prescription medicines in</td><td align=\"left\">Yes</td><td align=\"right\">117</td><td align=\"right\">52</td><td align=\"left\">(44)</td><td align=\"right\">85</td><td align=\"left\">(73)</td><td align=\"right\">44</td><td align=\"left\">(38)</td></tr><tr><td align=\"left\">regular use</td><td align=\"left\">No</td><td align=\"right\">17</td><td align=\"right\">8</td><td align=\"left\">(47)</td><td align=\"right\">10</td><td align=\"left\">(59)</td><td align=\"right\">6</td><td align=\"left\">(35)</td></tr><tr><td align=\"left\">Age, years</td><td align=\"left\">&lt; 60</td><td align=\"right\">63</td><td align=\"right\">36</td><td align=\"left\">(57)</td><td align=\"right\">45</td><td align=\"left\">(71)</td><td align=\"right\">23</td><td align=\"left\">(37)</td></tr><tr><td/><td align=\"left\">&#8805; 60</td><td align=\"right\">70</td><td align=\"right\">24</td><td align=\"left\">(34)</td><td align=\"right\">49</td><td align=\"left\">(70)</td><td align=\"right\">26</td><td align=\"left\">(37)</td></tr><tr><td align=\"left\" colspan=\"2\"><bold>Patients who had allowed GS</bold></td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">All</td><td/><td align=\"right\">538</td><td align=\"right\">448</td><td align=\"left\">(83)</td><td align=\"right\">242</td><td align=\"left\">(45)</td><td align=\"right\">203</td><td align=\"left\">(38)</td></tr><tr><td align=\"left\">Gender</td><td align=\"left\">Men</td><td align=\"right\">212</td><td align=\"right\">170</td><td align=\"left\">(80)</td><td align=\"right\">87</td><td align=\"left\">(41)</td><td align=\"right\">84</td><td align=\"left\">(40)</td></tr><tr><td/><td align=\"left\">Women</td><td align=\"right\">326</td><td align=\"right\">278</td><td align=\"left\">(85)</td><td align=\"right\">155</td><td align=\"left\">(48)</td><td align=\"right\">119</td><td align=\"left\">(37)</td></tr><tr><td align=\"left\">Prescription medicines in</td><td align=\"left\">Yes</td><td align=\"right\">380</td><td align=\"right\">308</td><td align=\"left\">(81)</td><td align=\"right\">159</td><td align=\"left\">(42)</td><td align=\"right\">151</td><td align=\"left\">(40)</td></tr><tr><td align=\"left\">regular use</td><td align=\"left\">No</td><td align=\"right\">155</td><td align=\"right\">137</td><td align=\"left\">(88)</td><td align=\"right\">82</td><td align=\"left\">(53)</td><td align=\"right\">50</td><td align=\"left\">(32)</td></tr><tr><td align=\"left\">Age, years</td><td align=\"left\">&lt; 60</td><td align=\"right\">340</td><td align=\"right\">297</td><td align=\"left\">(87)</td><td align=\"right\">159</td><td align=\"left\">(47)</td><td align=\"right\">133</td><td align=\"left\">(39)</td></tr><tr><td/><td align=\"left\">&#8805; 60</td><td align=\"right\">196</td><td align=\"right\">150</td><td align=\"left\">(77)</td><td align=\"right\">83</td><td align=\"left\">(42)</td><td align=\"right\">69</td><td align=\"left\">(35)</td></tr><tr><td align=\"left\" colspan=\"3\"><bold>Patients who had refused and allowed GS</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">All</td><td/><td align=\"right\">251</td><td align=\"right\">178</td><td align=\"left\">(71)</td><td align=\"right\">137</td><td align=\"left\">(55)</td><td align=\"right\">119</td><td align=\"left\">(47)</td></tr><tr><td align=\"left\">Gender</td><td align=\"left\">Men</td><td align=\"right\">108</td><td align=\"right\">81</td><td align=\"left\">(75)</td><td align=\"right\">46</td><td align=\"left\">(43)</td><td align=\"right\">52</td><td align=\"left\">(48)</td></tr><tr><td/><td align=\"left\">Women</td><td align=\"right\">143</td><td align=\"right\">97</td><td align=\"left\">(68)</td><td align=\"right\">91</td><td align=\"left\">(64)</td><td align=\"right\">67</td><td align=\"left\">(47)</td></tr><tr><td align=\"left\">Prescription medicines in</td><td align=\"left\">Yes</td><td align=\"right\">200</td><td align=\"right\">137</td><td align=\"left\">(69)</td><td align=\"right\">103</td><td align=\"left\">(52)</td><td align=\"right\">103</td><td align=\"left\">(52)</td></tr><tr><td align=\"left\">regular use</td><td align=\"left\">No</td><td align=\"right\">49</td><td align=\"right\">39</td><td align=\"left\">(80)</td><td align=\"right\">32</td><td align=\"left\">(65)</td><td align=\"right\">16</td><td align=\"left\">(33)</td></tr><tr><td align=\"left\">Age, years</td><td align=\"left\">&lt; 60</td><td align=\"right\">124</td><td align=\"right\">101</td><td align=\"left\">(82)</td><td align=\"right\">76</td><td align=\"left\">(61)</td><td align=\"right\">58</td><td align=\"left\">(47)</td></tr><tr><td/><td align=\"left\">&#8805; 60</td><td align=\"right\">125</td><td align=\"right\">76</td><td align=\"left\">(61)</td><td align=\"right\">60</td><td align=\"left\">(48)</td><td align=\"right\">60</td><td align=\"left\">(48)</td></tr><tr><td align=\"left\"><bold>No experience</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">All</td><td/><td align=\"right\">628</td><td align=\"right\">426</td><td align=\"left\">(68)</td><td align=\"right\">400</td><td align=\"left\">(64)</td><td align=\"right\">271</td><td align=\"left\">(43)</td></tr><tr><td align=\"left\">Gender</td><td align=\"left\">Men</td><td align=\"right\">323</td><td align=\"right\">220</td><td align=\"left\">(68)</td><td align=\"right\">201</td><td align=\"left\">(62)</td><td align=\"right\">147</td><td align=\"left\">(46)</td></tr><tr><td/><td align=\"left\">Women</td><td align=\"right\">305</td><td align=\"right\">206</td><td align=\"left\">(68)</td><td align=\"right\">199</td><td align=\"left\">(65)</td><td align=\"right\">124</td><td align=\"left\">(41)</td></tr><tr><td align=\"left\">Prescription medicines in</td><td align=\"left\">Yes</td><td align=\"right\">222</td><td align=\"right\">136</td><td align=\"left\">(61)</td><td align=\"right\">127</td><td align=\"left\">(57)</td><td align=\"right\">105</td><td align=\"left\">(47)</td></tr><tr><td align=\"left\">regular use</td><td align=\"left\">No</td><td align=\"right\">403</td><td align=\"right\">288</td><td align=\"left\">(72)</td><td align=\"right\">272</td><td align=\"left\">(68)</td><td align=\"right\">165</td><td align=\"left\">(41)</td></tr><tr><td align=\"left\">Age, years</td><td align=\"left\">&lt; 60</td><td align=\"right\">425</td><td align=\"right\">308</td><td align=\"left\">(73)</td><td align=\"right\">274</td><td align=\"left\">(65)</td><td align=\"right\">188</td><td align=\"left\">(44)</td></tr><tr><td/><td align=\"left\">&#8805; 60</td><td align=\"right\">194</td><td align=\"right\">113</td><td align=\"left\">(58)</td><td align=\"right\">122</td><td align=\"left\">(63)</td><td align=\"right\">75</td><td align=\"left\">(39)</td></tr></tbody></table></body></html>", "text": "Pmid= 3262749:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of women included in the study cohort by type of progestin oral contraceptive used (n = 1,148,183)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\"><italic>Desogestrel</italic></th><th align=\"left\"><italic>Drospirenone</italic></th><th align=\"left\">Ethynodiol Diacetate</th><th align=\"left\"><italic>Levonorgestrel</italic></th><th align=\"left\"><italic>Norethindrone Acetate</italic></th><th align=\"left\"><italic>Norethindrone </italic></th><th align=\"left\"><italic>Norgestimate</italic></th><th align=\"left\"><italic>Norgestrel</italic></th></tr></thead><tbody><tr><td align=\"left\">Number of patients</td><td align=\"left\">139,871</td><td align=\"left\">224,408</td><td align=\"left\">17,295</td><td align=\"left\">180,720</td><td align=\"left\">93,818</td><td align=\"left\">234,105</td><td align=\"left\">228,276</td><td align=\"left\">29,690</td></tr><tr><td align=\"left\">Age</td><td align=\"left\">28.7</td><td align=\"left\">29.0</td><td align=\"left\">28.8</td><td align=\"left\">29.0</td><td align=\"left\">30.5</td><td align=\"left\">29.7</td><td align=\"left\">26.9</td><td align=\"left\">29.7</td></tr><tr><td align=\"left\">Mean follow up (days)</td><td align=\"left\">327</td><td align=\"left\">272</td><td align=\"left\">327</td><td align=\"left\">304</td><td align=\"left\">240</td><td align=\"left\">230</td><td align=\"left\">307</td><td align=\"left\">249</td></tr><tr><td align=\"left\">Number of cases</td><td align=\"left\">267</td><td align=\"left\">488</td><td align=\"left\">33</td><td align=\"left\">349</td><td align=\"left\">200</td><td align=\"left\">433</td><td align=\"left\">499</td><td align=\"left\">56</td></tr><tr><td align=\"left\"><bold>Covariates (%)</bold></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\">&#8195;CKD &#8224;</td><td align=\"left\">0.15</td><td align=\"left\">0.09</td><td align=\"left\">0.08</td><td align=\"left\">0.09</td><td align=\"left\">0.12</td><td align=\"left\">0.15</td><td align=\"left\">0.08</td><td align=\"left\">0.19</td></tr><tr><td align=\"left\">&#8195;Diabetes</td><td align=\"left\">4.10</td><td align=\"left\">4.10</td><td align=\"left\">4.41</td><td align=\"left\">3.93</td><td align=\"left\">4.13</td><td align=\"left\">4.12</td><td align=\"left\">3.37</td><td align=\"left\">5.43</td></tr><tr><td align=\"left\">&#8195;Hypertension</td><td align=\"left\">8.34</td><td align=\"left\">8.47</td><td align=\"left\">8.53</td><td align=\"left\">8.62</td><td align=\"left\">9.78</td><td align=\"left\">8.89</td><td align=\"left\">6.55</td><td align=\"left\">10.82</td></tr><tr><td align=\"left\">&#8195;IBD*</td><td align=\"left\">0.94</td><td align=\"left\">1.03</td><td align=\"left\">1.22</td><td align=\"left\">1.00</td><td align=\"left\">1.03</td><td align=\"left\">0.85</td><td align=\"left\">0.75</td><td align=\"left\">0.98</td></tr><tr><td align=\"left\">&#8195;Obesity</td><td align=\"left\">11.59</td><td align=\"left\">12.53</td><td align=\"left\">12.44</td><td align=\"left\">11.22</td><td align=\"left\">10.75</td><td align=\"left\">10.08</td><td align=\"left\">9.50</td><td align=\"left\">13.60</td></tr><tr><td align=\"left\">&#8195;PCOS &#7563;</td><td align=\"left\">4.47</td><td align=\"left\">5.78</td><td align=\"left\">5.00</td><td align=\"left\">2.11</td><td align=\"left\">2.80</td><td align=\"left\">2.81</td><td align=\"left\">2.21</td><td align=\"left\">3.48</td></tr><tr><td align=\"left\">&#8195;PTS (PMS/PMDD) &#8225;</td><td align=\"left\">3.63</td><td align=\"left\">5.53</td><td align=\"left\">3.04</td><td align=\"left\">3.01</td><td align=\"left\">3.26</td><td align=\"left\">1.95</td><td align=\"left\">1.69</td><td align=\"left\">2.73</td></tr><tr><td align=\"left\">&#8195;Smoking</td><td align=\"left\">6.62</td><td align=\"left\">5.94</td><td align=\"left\">8.48</td><td align=\"left\">7.36</td><td align=\"left\">6.43</td><td align=\"left\">6.49</td><td align=\"left\">6.97</td><td align=\"left\">9.00</td></tr><tr><td align=\"left\">&#8195;ACEI/ARB &#167;</td><td align=\"left\">0.50</td><td align=\"left\">0.47</td><td align=\"left\">0.56</td><td align=\"left\">0.60</td><td align=\"left\">0.75</td><td align=\"left\">0.67</td><td align=\"left\">0.42</td><td align=\"left\">0.80</td></tr><tr><td align=\"left\">&#8195;NSAIDS &#663;</td><td align=\"left\">5.67</td><td align=\"left\">4.84</td><td align=\"left\">5.79</td><td align=\"left\">5.56</td><td align=\"left\">5.13</td><td align=\"left\">5.90</td><td align=\"left\">4.77</td><td align=\"left\">6.09</td></tr><tr><td align=\"left\">&#8195;Spironolactone</td><td align=\"left\">0.43</td><td align=\"left\">0.74</td><td align=\"left\">0.84</td><td align=\"left\">0.28</td><td align=\"left\">0.32</td><td align=\"left\">0.19</td><td align=\"left\">0.32</td><td align=\"left\">0.29</td></tr><tr><td align=\"left\">&#8195;Other Medications &#658;</td><td align=\"left\">0.46</td><td align=\"left\">0.36</td><td align=\"left\">0.56</td><td align=\"left\">0.46</td><td align=\"left\">0.37</td><td align=\"left\">0.35</td><td align=\"left\">0.27</td><td align=\"left\">0.44</td></tr></tbody></table></body></html>", "text": "Pmid= 3265420:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Risk for hyperkalemia* with use of commonly used oral contraceptives</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Crude HR (95% CI)</th><th align=\"center\">Adjusted HR&#8224; (95%CI)</th></tr></thead><tbody><tr><td align=\"left\">Levonorgestrel</td><td align=\"center\">1.0 (reference)</td><td align=\"center\">1.0</td></tr><tr><td align=\"left\">Desogestrel</td><td align=\"center\">0.93 (0.79-1.09)</td><td align=\"center\">1.00 (0.85-1.17)</td></tr><tr><td align=\"left\">Drospirenone</td><td align=\"center\">1.26 (1.10-1.44)</td><td align=\"center\">1.10 (0.95-1.26)</td></tr><tr><td align=\"left\">Ethynodiol diacetate</td><td align=\"center\">0.96 (0.67-1.38)</td><td align=\"center\">0.71 (0.49-1.02)</td></tr><tr><td align=\"left\">Norethindrone acetate</td><td align=\"center\">1.41 (1.18-1.68)</td><td align=\"center\">1.08 (0.91-1.29)</td></tr><tr><td align=\"left\">Norethindrone</td><td align=\"center\">1.27 (1.11-1.47)</td><td align=\"center\">1.15 (1.00-1.33)</td></tr><tr><td align=\"left\">Norgestimate</td><td align=\"center\">1.13 (0.98-1.29)</td><td align=\"center\">1.27 (1.11-1.46)</td></tr><tr><td align=\"left\">Norgestrel</td><td align=\"center\">1.13 (0.85-1.49)</td><td align=\"center\">1.00 (0.76-1.33)</td></tr></tbody></table></body></html>", "text": "Pmid= 3265420:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of Withdrawal Reason</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Time</th><th align=\"center\">Overall<break/>(N = 480)</th><th align=\"center\">ITT<break/>(N = 426)</th></tr></thead><tbody><tr><td align=\"center\">Total</td><td align=\"center\">130 (27.1%)</td><td align=\"center\">76 (17.8%)</td></tr><tr><td align=\"center\">Death</td><td align=\"center\">1 (0.2%)</td><td align=\"center\">1 (0.2%)</td></tr><tr><td align=\"center\">Adverse Event</td><td align=\"center\">23 (4.8%)</td><td align=\"center\">17 (4.0%)</td></tr><tr><td align=\"center\">Insufficient Response</td><td align=\"center\">18 (3.8%)</td><td align=\"center\">16 (3.8%)</td></tr><tr><td align=\"center\">Ineligible to Continue</td><td align=\"center\">15 (3.1%)</td><td align=\"center\">0 (0.0%)</td></tr><tr><td align=\"center\">Lost to Follow-up</td><td align=\"center\">28 (5.8%)</td><td align=\"center\">16 (3.8%)</td></tr><tr><td align=\"center\">Withdrew Consent</td><td align=\"center\">35 (7.3%)</td><td align=\"center\">19 (4.5%)</td></tr><tr><td align=\"center\">Non-Compliant</td><td align=\"center\">8 (1.7%)</td><td align=\"center\">5 (1.2%)</td></tr><tr><td align=\"center\">Other</td><td align=\"center\">2 (0.4%)</td><td align=\"center\">2 (0.5%)</td></tr></tbody></table></body></html>", "text": "Pmid= 3282633:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of Demographics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Characteristics</th><th/><th align=\"center\">Overall<break/>(N = 480)</th><th align=\"center\">ITT<break/>(N = 426)</th></tr></thead><tbody><tr><td align=\"left\">Sex</td><td align=\"left\">Male</td><td align=\"center\">262 (54.6%)</td><td align=\"center\">238 (55.87%)</td></tr><tr><td/><td align=\"left\">Female</td><td align=\"center\">218 (45.4%)</td><td align=\"center\">188 (44.13%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Age (years)</td><td align=\"left\">N</td><td align=\"center\">&lt; 480 &gt;</td><td align=\"center\">&lt; 426 &gt;</td></tr><tr><td/><td align=\"left\">Mean (SD)</td><td align=\"center\">40.3 (10.6)</td><td align=\"center\">40.4 (10.6)</td></tr><tr><td/><td align=\"left\">Median</td><td align=\"center\">39.5</td><td align=\"center\">40.0</td></tr><tr><td/><td align=\"left\">Min. ~ Max.</td><td align=\"center\">16.0 ~ 72.0</td><td align=\"center\">17.0 ~ 72.0</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Diagnosis</td><td align=\"left\">Paranoid</td><td align=\"center\">300 (62.5%)</td><td align=\"center\">263 (61.74%)</td></tr><tr><td/><td align=\"left\">Disorganized</td><td align=\"center\">46 (9.6%)</td><td align=\"center\">46 (10.80%)</td></tr><tr><td/><td align=\"left\">Catatonic</td><td align=\"center\">6 (1.3%)</td><td align=\"center\">5 (1.17%)</td></tr><tr><td/><td align=\"left\">Undifferentiated</td><td align=\"center\">88 (18.3%)</td><td align=\"center\">80 (18.78%)</td></tr><tr><td/><td align=\"left\">Residual</td><td align=\"center\">37 (7.7%)</td><td align=\"center\">31 (7.28%)</td></tr><tr><td/><td align=\"left\">Other</td><td align=\"center\">3 (0.6%)</td><td align=\"center\">1 (0.23%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">In/Out Patient</td><td align=\"left\">In-patient</td><td align=\"center\">218 (45.4%)</td><td align=\"center\">207 (48.6%)</td></tr><tr><td/><td align=\"left\">Out-Patient</td><td align=\"center\">262 (54.6%)</td><td align=\"center\">219 (51.4%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Symptom onset (years)</td><td align=\"left\">Unspecified</td><td align=\"center\">46 (9.6%)</td><td align=\"center\">41 (9.62%)</td></tr><tr><td/><td align=\"left\">&lt; = 5</td><td align=\"center\">95 (19.8%)</td><td align=\"center\">78 (18.31%)</td></tr><tr><td/><td align=\"left\">&gt; 5~ &lt; = 10</td><td align=\"center\">83 (17.3%)</td><td align=\"center\">74 (17.37%)</td></tr><tr><td/><td align=\"left\">&gt; 10~ &lt; = 20</td><td align=\"center\">153 (31.9%)</td><td align=\"center\">142 (33.33%)</td></tr><tr><td/><td align=\"left\">&gt; 20~ &lt; = 30</td><td align=\"center\">78 (16.2%)</td><td align=\"center\">67 (15.73%)</td></tr><tr><td/><td align=\"left\">&gt; 30</td><td align=\"center\">25 (5.2%)</td><td align=\"center\">41 (9.62%)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Drug abuse</td><td align=\"left\">No</td><td align=\"center\">437 (91.0%)</td><td align=\"center\">386 (90.61%)</td></tr><tr><td/><td align=\"left\">Yes</td><td align=\"center\">23 (4.8%)</td><td align=\"center\">21 (4.93%)</td></tr><tr><td/><td align=\"left\">Unspecified</td><td align=\"center\">20 (4.2%)</td><td align=\"center\">19 (4.46%)</td></tr></tbody></table></body></html>", "text": "Pmid= 3282633:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of Previous Antipsychotics Treatment Received for Consecutive 3 Months</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Antipsychotic Treatments</th><th align=\"center\">Overall<break/>(N = 480)</th><th align=\"center\">ITT<break/>(N = 426)</th></tr></thead><tbody><tr><td align=\"left\">Oral Risperidone</td><td align=\"center\">224 (46.67%)</td><td align=\"center\">207 (48.59%)</td></tr><tr><td align=\"left\">Olanzapine</td><td align=\"center\">52 (10.83%)</td><td align=\"center\">49 (11.50%)</td></tr><tr><td align=\"left\">Quetiapine</td><td align=\"center\">35 (7.29%)</td><td align=\"center\">32 (7.51%)</td></tr><tr><td align=\"left\">Aripiprazole</td><td align=\"center\">30 (6.25%)</td><td align=\"center\">28 (6.57%)</td></tr><tr><td align=\"left\">Clozapine</td><td align=\"center\">14 (2.92%)</td><td align=\"center\">10 (2.35%)</td></tr><tr><td align=\"left\">Risperdal CONSTA</td><td align=\"center\">3 (0.63%)</td><td align=\"center\">1 (0.23%)</td></tr><tr><td align=\"left\">Other</td><td align=\"center\">125 (26.04%)</td><td align=\"center\">110 (25.82%)</td></tr></tbody></table></body></html>", "text": "Pmid= 3282633:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of Concurrent Disease with Incidence  5%</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">System</th><th align=\"center\">Overall<break/>(N = 480)</th><th align=\"center\">ITT<break/>(N = 426)</th></tr></thead><tbody><tr><td align=\"left\">Psychiatric</td><td align=\"center\">364 (75.83%)</td><td align=\"center\">329 (77.23%)</td></tr><tr><td align=\"left\">Gastrointestinal</td><td align=\"center\">156 (32.50%)</td><td align=\"center\">145 (34.04%)</td></tr><tr><td align=\"left\">Neurological</td><td align=\"center\">114 (23.75%)</td><td align=\"center\">104 (24.41%)</td></tr><tr><td align=\"left\">Cardiovascular</td><td align=\"center\">77 (16.04%)</td><td align=\"center\">74 (17.37%)</td></tr><tr><td align=\"left\">Endocrine</td><td align=\"center\">71 (14.79%)</td><td align=\"center\">62 (14.55%)</td></tr><tr><td align=\"left\">Respiratory</td><td align=\"center\">34 (7.08%)</td><td align=\"center\">31 (7.28%)</td></tr><tr><td align=\"left\">Ears, Nose, Throat</td><td align=\"center\">29 (6.04%)</td><td align=\"center\">28 (6.57%)</td></tr><tr><td align=\"left\">Musculoskeletal</td><td align=\"center\">32 (6.67%)</td><td align=\"center\">31 (7.28%)</td></tr></tbody></table></body></html>", "text": "Pmid= 3282633:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of Dose Disposition of ITT Population</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\" colspan=\"2\">ITT Population</th><th align=\"center\" colspan=\"4\">Initial Dose</th></tr><tr><th/><th/><th colspan=\"4\"><hr/></th></tr><tr><th/><th/><th align=\"center\">3 mg/day</th><th align=\"center\">6 mg/day</th><th align=\"center\">9 mg/day</th><th align=\"center\">12 mg/day</th></tr></thead><tbody><tr><td align=\"center\">Dose at the End of Study</td><td align=\"center\">3 mg/day</td><td align=\"center\">50</td><td align=\"center\">7</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td/><td align=\"center\">6 mg/day</td><td align=\"center\">69</td><td align=\"center\">152</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td/><td align=\"center\">9 mg/day</td><td align=\"center\">17</td><td align=\"center\">43</td><td align=\"center\">18</td><td align=\"center\">0</td></tr><tr><td/><td align=\"center\">12 mg/day</td><td align=\"center\">18</td><td align=\"center\">30</td><td align=\"center\">11</td><td align=\"center\">11</td></tr></tbody></table></body></html>", "text": "Pmid= 3282633:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of Dose Disposition of Complete Study Subjects</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\" colspan=\"2\">Complete Study Subjects</th><th align=\"center\" colspan=\"4\">Initial Dose</th></tr><tr><th/><th/><th colspan=\"4\"><hr/></th></tr><tr><th/><th/><th align=\"center\">3 mg/day</th><th align=\"center\">6 mg/day</th><th align=\"center\">9 mg/day</th><th align=\"center\">12 mg/day</th></tr></thead><tbody><tr><td align=\"center\">Dose at the End of Study</td><td align=\"center\">3 mg/day</td><td align=\"center\">40</td><td align=\"center\">5</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td/><td align=\"center\">6 mg/day</td><td align=\"center\">61</td><td align=\"center\">122</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td/><td align=\"center\">9 mg/day</td><td align=\"center\">11</td><td align=\"center\">42</td><td align=\"center\">11</td><td align=\"center\">0</td></tr><tr><td/><td align=\"center\">12 mg/day</td><td align=\"center\">15</td><td align=\"center\">26</td><td align=\"center\">8</td><td align=\"center\">9</td></tr></tbody></table></body></html>", "text": "Pmid= 3282633:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Adverse Events with Incidence  2%</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Preferred Term</th><th align=\"center\">N = 426<break/>N (%)</th></tr></thead><tbody><tr><td align=\"center\">Patients with any Adverse Event</td><td align=\"center\">213 (50.0%)</td></tr><tr><td align=\"center\">Disease progression</td><td align=\"center\">33 (7.7%)*</td></tr><tr><td align=\"center\">Upper respiratory tract infection</td><td align=\"center\">30 (7.0%)</td></tr><tr><td align=\"center\">Extrapyramidal disorder</td><td align=\"center\">22 (5.2%)</td></tr><tr><td align=\"center\">Insomnia</td><td align=\"center\">17 (4.0%)</td></tr><tr><td align=\"center\">Constipation</td><td align=\"center\">14 (3.3%)</td></tr><tr><td align=\"center\">Anxiety</td><td align=\"center\">11 (2.6%)</td></tr><tr><td align=\"center\">Nasopharyngitis</td><td align=\"center\">11 (2.6%)</td></tr><tr><td align=\"center\">Diarrhoea</td><td align=\"center\">9 (2.1%)</td></tr><tr><td align=\"center\">Headache</td><td align=\"center\">9 (2.1%)</td></tr><tr><td align=\"center\">Somnolence</td><td align=\"center\">9 (2.1%)</td></tr><tr><td align=\"center\">Tachycardia</td><td align=\"center\">9 (2.1%)</td></tr></tbody></table></body></html>", "text": "Pmid= 3282633:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Features of patients eligible for the study</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Parameter</th><th align=\"left\">n</th><th align=\"left\">%</th></tr></thead><tbody><tr><td align=\"left\">Men</td><td align=\"left\">362</td><td align=\"left\">40.58</td></tr><tr><td align=\"left\">Women</td><td align=\"left\">530</td><td align=\"left\">59.42</td></tr><tr><td align=\"left\"><bold>Age group</bold></td><td/><td/></tr><tr><td align=\"left\">10-20</td><td align=\"left\">8</td><td align=\"left\">0.93</td></tr><tr><td align=\"left\">21-30</td><td align=\"left\">50</td><td align=\"left\">5.61</td></tr><tr><td align=\"left\">31-40</td><td align=\"left\">124</td><td align=\"left\">13.90</td></tr><tr><td align=\"left\">41-50</td><td align=\"left\">190</td><td align=\"left\">21.30</td></tr><tr><td align=\"left\">51-60</td><td align=\"left\">167</td><td align=\"left\">18.72</td></tr><tr><td align=\"left\">61-70</td><td align=\"left\">154</td><td align=\"left\">17.26</td></tr><tr><td align=\"left\">71-80</td><td align=\"left\">133</td><td align=\"left\">14.91</td></tr><tr><td align=\"left\">81-90</td><td align=\"left\">61</td><td align=\"left\">6.84</td></tr><tr><td align=\"left\">91-100</td><td align=\"left\">5</td><td align=\"left\">0.56</td></tr><tr><td align=\"left\">Mean age, years</td><td align=\"left\">56 &#177; 10.09</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3293025:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Diagnosis reported in therapeutic programs and coded with the ICD-9 system</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">ICD-9</th><th align=\"left\">Correspondence</th><th align=\"left\">%</th></tr></thead><tbody><tr><td align=\"left\"><bold>296</bold></td><td align=\"left\">Mood disorders</td><td align=\"left\"><bold>36.4</bold></td></tr><tr><td align=\"left\"><bold>295</bold></td><td align=\"left\">Schizophrenia</td><td align=\"left\"><bold>35.4</bold></td></tr><tr><td align=\"left\"><bold>298</bold></td><td align=\"left\">Non-organic psychosis</td><td align=\"left\"><bold>5.6</bold></td></tr><tr><td align=\"left\"><bold>299</bold></td><td align=\"left\">Pervasive developmental disorders</td><td align=\"left\"><bold>4.7</bold></td></tr><tr><td align=\"left\"><bold>297</bold></td><td align=\"left\">Delusional disorders</td><td align=\"left\"><bold>4</bold></td></tr><tr><td align=\"left\"><bold>290</bold></td><td align=\"left\">Dementia</td><td align=\"left\"><bold>3.9</bold></td></tr><tr><td align=\"left\"><bold>294</bold></td><td align=\"left\">Persistent mental illnesses caused by pathologic conditions</td><td align=\"left\"><bold>3</bold></td></tr><tr><td align=\"left\"><bold>292</bold></td><td align=\"left\">Mental disorder caused by substances</td><td align=\"left\"><bold>2.4</bold></td></tr><tr><td align=\"left\"><bold>293</bold></td><td align=\"left\">Temporary mental illnesses caused by pathologic conditions</td><td align=\"left\"><bold>2</bold></td></tr><tr><td align=\"left\"><bold>300</bold></td><td align=\"left\">Anxiety disorders</td><td align=\"left\"><bold>1.42</bold></td></tr><tr><td align=\"left\"><bold>309</bold></td><td align=\"left\">Adaptation reactions</td><td align=\"left\"><bold>0.85</bold></td></tr><tr><td align=\"left\"><bold>318.1</bold></td><td align=\"left\">Severe mental retardation</td><td align=\"left\"><bold>0.28</bold></td></tr><tr><td align=\"left\"><bold>307.1</bold></td><td align=\"left\">Anorexia nervosa</td><td align=\"left\"><bold>0.14</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 3293025:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Patients treated with antipsychotics and treatment adherence</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Drug</th><th align=\"center\">n</th><th align=\"center\">% patients</th><th align=\"center\" colspan=\"3\">Adherence</th><th align=\"center\">CI 95%</th><th align=\"center\">P-value</th></tr><tr><th/><th/><th/><th align=\"center\">Minimum</th><th align=\"center\">Mean</th><th align=\"center\">Maximum</th><th/><th/></tr></thead><tbody><tr><td/><td align=\"center\" colspan=\"7\"><bold>SGAs</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"center\">Aripiprazole</td><td align=\"center\">43</td><td align=\"center\">7.6</td><td align=\"center\">7.78</td><td align=\"center\">62.07</td><td align=\"center\">100</td><td align=\"center\">22.6 - 80.1</td><td align=\"center\">0.01</td></tr><tr><td align=\"center\">Olanzapine</td><td align=\"center\">193</td><td align=\"center\">34.2</td><td align=\"center\">7.78</td><td align=\"center\">59.15</td><td align=\"center\">100</td><td align=\"center\">25.9 - 81.2</td><td align=\"center\">0.01</td></tr><tr><td align=\"center\">Quetiapine</td><td align=\"center\">156</td><td align=\"center\">27.7</td><td align=\"center\">8.33</td><td align=\"center\">66.68</td><td align=\"center\">100</td><td align=\"center\">27.9 - 88.5</td><td align=\"center\">0.01</td></tr><tr><td align=\"center\">Risperidone</td><td align=\"center\">109</td><td align=\"center\">19.3</td><td align=\"center\">8.33</td><td align=\"center\">59.75</td><td align=\"center\">100</td><td align=\"center\">29.3 -84.3</td><td align=\"center\">0.01</td></tr><tr><td align=\"center\">Clozapine</td><td align=\"center\">19</td><td align=\"center\">3.4</td><td align=\"center\">7.8</td><td align=\"center\">51.80</td><td align=\"center\">100</td><td align=\"center\">29.7 - 85.2</td><td align=\"center\">0.01</td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td/><td align=\"center\" colspan=\"7\"><bold>FGAs</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"center\">Haloperidol</td><td align=\"center\">26</td><td align=\"center\">4.6</td><td align=\"center\">8.33</td><td align=\"center\">63.99</td><td align=\"center\">100</td><td align=\"center\">17.4 - 59.2</td><td align=\"center\">0.01</td></tr><tr><td align=\"center\">Clotiapine</td><td align=\"center\">8</td><td align=\"center\">1.4</td><td align=\"center\">16</td><td align=\"center\">66.38</td><td align=\"center\">100</td><td align=\"center\">24.3 - 96.5</td><td align=\"center\">0.01</td></tr><tr><td align=\"center\">Levomepromazine</td><td align=\"center\">6</td><td align=\"center\">1.1</td><td align=\"center\">33.33</td><td align=\"center\">68.06</td><td align=\"center\">100</td><td align=\"center\">32.8 - 87.9</td><td align=\"center\">0.01</td></tr><tr><td align=\"center\">Clorpromazine</td><td align=\"center\">4</td><td align=\"center\">0.7</td><td align=\"center\">22.22</td><td align=\"center\">69.44</td><td align=\"center\">100</td><td align=\"center\">20.4 - 80.0</td><td align=\"center\">0.01</td></tr></tbody></table></body></html>", "text": "Pmid= 3293025:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Antipsychotic dosages in milligrams used in therapy</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Drug</th><th align=\"center\">DDD</th><th align=\"center\" colspan=\"3\">Dosage</th><th align=\"center\">SPC</th><th align=\"center\">Most commonly prescribed dosage, mg</th><th align=\"center\">% Patients with add-on anticholinergic</th></tr><tr><th/><th/><th colspan=\"3\"><hr/></th><th/><th/><th/></tr><tr><th/><th/><th align=\"center\">Minimum</th><th align=\"center\">Mean</th><th align=\"center\">Maximum</th><th/><th/><th/></tr></thead><tbody><tr><td align=\"center\" colspan=\"8\"><bold>SGAs</bold></td></tr><tr><td colspan=\"8\"><hr/></td></tr><tr><td align=\"center\">Aripiprazole</td><td align=\"center\">15</td><td align=\"center\">2.5</td><td align=\"center\">13.16</td><td align=\"center\">30</td><td align=\"center\">10-30</td><td align=\"center\">10</td><td align=\"center\">2.3</td></tr><tr><td align=\"center\">Olanzapine</td><td align=\"center\">10</td><td align=\"center\">1.3</td><td align=\"center\">8.6</td><td align=\"center\">20</td><td align=\"center\">5-20</td><td align=\"center\">5</td><td align=\"center\">6.7</td></tr><tr><td align=\"center\">Quetiapine</td><td align=\"center\">400</td><td align=\"center\">12.5</td><td align=\"center\">230.6</td><td align=\"center\">1200</td><td align=\"center\">200-800</td><td align=\"center\">200</td><td align=\"center\">2.6</td></tr><tr><td align=\"center\">Risperidone</td><td align=\"center\">5</td><td align=\"center\">0.5</td><td align=\"center\">3.7</td><td align=\"center\">9</td><td align=\"center\">2-16</td><td align=\"center\">2</td><td align=\"center\">11</td></tr><tr><td align=\"center\">Clozapine</td><td align=\"center\">300</td><td align=\"center\">25</td><td align=\"center\">179.5</td><td align=\"center\">450</td><td align=\"center\">200-450</td><td align=\"center\">100</td><td align=\"center\">10.5</td></tr><tr><td align=\"center\" colspan=\"8\"><bold>FGAs</bold></td></tr><tr><td align=\"center\">Haloperidol</td><td align=\"center\">8</td><td align=\"center\">1</td><td align=\"center\">3.71</td><td align=\"center\">8</td><td align=\"center\">60</td><td align=\"center\">2</td><td align=\"center\">27</td></tr><tr><td align=\"center\">Clotiapine</td><td align=\"center\">80</td><td align=\"center\">14</td><td align=\"center\">38.6</td><td align=\"center\">100</td><td align=\"center\">100-120</td><td align=\"center\">50</td><td align=\"center\">87.6</td></tr><tr><td align=\"center\">Levomepromazine</td><td align=\"center\">300</td><td align=\"center\">12.5</td><td align=\"center\">25</td><td align=\"center\">50</td><td align=\"center\">75-300</td><td align=\"center\">25</td><td align=\"center\">0</td></tr><tr><td align=\"center\">Chlorpromazine</td><td align=\"center\">300</td><td align=\"center\">62.5</td><td align=\"center\">62.5</td><td align=\"center\">100</td><td align=\"center\">30-75</td><td align=\"center\">50</td><td align=\"center\">50.4</td></tr></tbody></table></body></html>", "text": "Pmid= 3293025:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Patients treated with antidepressants and treatment adherence</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Drug</th><th align=\"center\">n</th><th align=\"center\">% patients</th><th align=\"center\" colspan=\"3\">Adherence</th><th align=\"center\">CI 95%</th><th align=\"center\">P-value</th></tr><tr><th/><th/><th/><th align=\"center\">Minimum</th><th align=\"center\">Mean</th><th align=\"center\">Maximum</th><th/><th/></tr></thead><tbody><tr><td align=\"center\">Paroxetine</td><td align=\"center\">75</td><td align=\"center\">20.83</td><td align=\"center\">7.78</td><td align=\"center\">57.7</td><td align=\"center\">100</td><td align=\"center\">23.8 - 76.5</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Citalopram</td><td align=\"center\">83</td><td align=\"center\">23.06</td><td align=\"center\">7.78</td><td align=\"center\">77.2</td><td align=\"center\">100</td><td align=\"center\">26.0 - 83.6</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Venlafaxine</td><td align=\"center\">87</td><td align=\"center\">24.17</td><td align=\"center\">8.33</td><td align=\"center\">61.65</td><td align=\"center\">100</td><td align=\"center\">24.1 - 81.2</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Sertraline</td><td align=\"center\">29</td><td align=\"center\">8.06</td><td align=\"center\">8.33</td><td align=\"center\">62.80</td><td align=\"center\">100</td><td align=\"center\">23.7 - 85.3</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Mirtazapine</td><td align=\"center\">32</td><td align=\"center\">8.89</td><td align=\"center\">59.14</td><td align=\"center\">59.14</td><td align=\"center\">100</td><td align=\"center\">25.8 - 82.2</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Trazodone</td><td align=\"center\">25</td><td align=\"center\">6.94</td><td align=\"center\">11.11</td><td align=\"center\">75.94</td><td align=\"center\">100</td><td align=\"center\">24.5 - 83.5</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Fluoxetine</td><td align=\"center\">10</td><td align=\"center\">2.78</td><td align=\"center\">13.33</td><td align=\"center\">52.18</td><td align=\"center\">93.33</td><td align=\"center\">18.9 - 73.1</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Amitriptiline</td><td align=\"center\">4</td><td align=\"center\">1.11</td><td align=\"center\">35.71</td><td align=\"center\">43.42</td><td align=\"center\">50</td><td align=\"center\">37.2 - 49.5</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Clomipramine</td><td align=\"center\">6</td><td align=\"center\">1.67</td><td align=\"center\">14.81</td><td align=\"center\">67.72</td><td align=\"center\">100</td><td align=\"center\">23.1 - 84.3</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\">Reboxetine</td><td align=\"center\">10</td><td align=\"center\">2.78</td><td align=\"center\">33.33</td><td align=\"center\">81.07</td><td align=\"center\">100</td><td align=\"center\">38.6 - 92.5</td><td align=\"center\">0.03</td></tr><tr><td align=\"center\"><bold>Total</bold></td><td align=\"center\"><bold>361</bold></td><td/><td/><td/><td/><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 3293025:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Antidepressants dosages in milligrams used in therapy</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Drug</th><th align=\"center\">DDD</th><th align=\"center\" colspan=\"3\">Dosage</th><th align=\"center\">Most commonly prescribed dosage, mg</th><th align=\"center\">SPC</th></tr><tr><th/><th/><th colspan=\"3\"><hr/></th><th/><th/></tr><tr><th/><th/><th align=\"center\">Minimum</th><th align=\"center\">Mean</th><th align=\"center\">Maximum</th><th/><th/></tr></thead><tbody><tr><td align=\"center\">Citalopram</td><td align=\"center\">20</td><td align=\"center\">10</td><td align=\"center\">44.25</td><td align=\"center\">60</td><td align=\"center\">20</td><td align=\"center\">20-60</td></tr><tr><td align=\"center\">Mirtazapine</td><td align=\"center\">30</td><td align=\"center\">15</td><td align=\"center\">44.23</td><td align=\"center\">45</td><td align=\"center\">30</td><td align=\"center\">15-45</td></tr><tr><td align=\"center\">Paroxetine</td><td align=\"center\">20</td><td align=\"center\">5</td><td align=\"center\">29.54</td><td align=\"center\">60</td><td align=\"center\">40</td><td align=\"center\">20-60</td></tr><tr><td align=\"center\">Sertraline</td><td align=\"center\">50</td><td align=\"center\">30</td><td align=\"center\">73.82</td><td align=\"center\">180</td><td align=\"center\">100</td><td align=\"center\">50-200</td></tr><tr><td align=\"center\">Venlafaxine</td><td align=\"center\">100</td><td align=\"center\">37.5</td><td align=\"center\">129.2</td><td align=\"center\">300</td><td align=\"center\">150</td><td align=\"center\">75-375</td></tr></tbody></table></body></html>", "text": "Pmid= 3293025:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Demographics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Age (years)</th><th align=\"left\">29 (10)</th></tr></thead><tbody><tr><td align=\"left\">Weight (kg)</td><td align=\"left\">87 (20)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Gender</td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&#8195;Female</td><td align=\"left\">64%</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&#8195;Male</td><td align=\"left\">36%</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Race</td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&#8195;White</td><td align=\"left\">79%</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&#8195;Black</td><td align=\"left\">21%</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Ethnicity</td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&#8195;Hispanic</td><td align=\"left\">36%</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&#8195;Non-Hispanic</td><td align=\"left\">64%</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Hemoglobin (g/dL)</td><td align=\"left\">15 (4)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Sodium (mmol/L)</td><td align=\"left\">139 (2)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Potassium (mmol/L)</td><td align=\"left\">4.1 (0.3)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Chloride (mmol/L)</td><td align=\"left\">102 (2)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Bicarbonate (mmol/L)</td><td align=\"left\">27 (2)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Glucose (mg/dL)</td><td align=\"left\">92 (9)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">BUN (mg/dL)</td><td align=\"left\">13 (3)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Creatinine (mg/dL)</td><td align=\"left\">0.8 (0.2)</td></tr></tbody></table></body></html>", "text": "Pmid= 3293077:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Pharmacokinetic Values</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">PARAMETER</th><th align=\"center\" colspan=\"3\">THIAMINE DOSE</th></tr></thead><tbody><tr><td/><td align=\"left\"><bold>100 mg</bold></td><td align=\"left\"><bold>500 mg</bold></td><td align=\"left\"><bold>1500 mg</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">AUC<sub>0-10 hr </sub>(nmol/Liter &#215; hours)</td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;whole blood</td><td align=\"left\">214 &#177; 69</td><td align=\"left\">623 &#177; 178</td><td align=\"left\">2046 &#177; 1222</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;plasma</td><td align=\"left\">177 &#177; 62</td><td align=\"left\">612 &#177; 257</td><td align=\"left\">2059 &#177; 1415</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">C<sub>max </sub>(nmol/Liter)</td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;whole blood</td><td align=\"left\">40 &#177; 11</td><td align=\"left\">95 &#177; 27</td><td align=\"left\">385 &#177; 188</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;plasma</td><td align=\"left\">39 &#177; 13</td><td align=\"left\">113 &#177; 42</td><td align=\"left\">397 &#177; 250</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">T<sub>max </sub>(hours)</td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;whole blood</td><td align=\"left\">3.43 &#177; 1.69</td><td align=\"left\">4.14 &#177; 1.57</td><td align=\"left\">4.14 &#177; 0.90</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">&#8195;plasma</td><td align=\"left\">3.14 &#177; 1.05</td><td align=\"left\">3.18 &#177; 0.98</td><td align=\"left\">4.27 &#177; 1.01</td></tr></tbody></table></body></html>", "text": "Pmid= 3293077:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Comparison of Slopes for 0 to 10 Hour AUC vs Thiamine Dose</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">AUC<sub>0-10 hr</sub></th><th align=\"center\" colspan=\"2\">C<sub>max</sub></th></tr></thead><tbody><tr><td align=\"left\"><bold>Segment</bold></td><td align=\"left\"><bold>Slope</bold></td><td align=\"left\"><bold><italic>p</italic>-value*</bold></td><td align=\"left\"><bold>Slope</bold></td><td align=\"left\"><bold><italic>p</italic>-value*</bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">0 to 100 mg</td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">&#8195;whole blood</td><td align=\"left\">2.14</td><td/><td align=\"left\">0.40</td><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">&#8195;plasma</td><td align=\"left\">1.76</td><td/><td align=\"left\">0.39</td><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">100 mg to 500 mg</td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">&#8195;whole blood</td><td align=\"left\">1.02</td><td align=\"left\">&lt; 0.01</td><td align=\"left\">0.14</td><td align=\"left\">&lt; 0.01</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">&#8195;plasma</td><td align=\"left\">1.09</td><td align=\"left\">0.06</td><td align=\"left\">0.18</td><td align=\"left\">&lt; 0.01</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">500 mg to 1500 mg</td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">&#8195;whole blood</td><td align=\"left\">1.42</td><td align=\"left\">0.06</td><td align=\"left\">0.29</td><td align=\"left\">0.03</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">&#8195;plasma</td><td align=\"left\">1.45</td><td align=\"left\">0.40</td><td align=\"left\">0.29</td><td align=\"left\">0.08</td></tr></tbody></table></body></html>", "text": "Pmid= 3293077:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Etomidate</th><th align=\"center\">Control</th><th align=\"center\">P-Value</th></tr><tr><th/><th align=\"center\">N = 23</th><th align=\"center\">N = 39</th><th/></tr></thead><tbody><tr><td align=\"left\"><bold>Age (years), mean &#177; SD</bold></td><td align=\"center\">64.0 &#177; 10.0</td><td align=\"center\">58.0 &#177; 13.0</td><td align=\"center\">0.10</td></tr><tr><td align=\"left\"><bold>Sex, female, No. (%)</bold></td><td align=\"center\">9 (39)</td><td align=\"center\">16 (41)</td><td align=\"center\">0.88</td></tr><tr><td align=\"left\"><bold>APACHE II, mean &#177; SD</bold></td><td align=\"center\">32.6 &#177; 6.6</td><td align=\"center\">30.2 &#177; 7.6</td><td align=\"center\">0.20</td></tr><tr><td align=\"left\"><bold>Child-Pugh, mean &#177; SD</bold></td><td align=\"center\">10.8 &#177; 1.8</td><td align=\"center\">11.5 &#177; 1.9</td><td align=\"center\">0.16</td></tr><tr><td align=\"left\"><bold>SOFA, mean &#177; SD</bold></td><td align=\"center\">15.0 &#177; 2.9</td><td align=\"center\">15.3 &#177; 3.7</td><td align=\"center\">0.79</td></tr><tr><td align=\"left\"><bold>Baseline cortisol (nmol/L), mean &#177; SD<sup>a</sup></bold></td><td align=\"center\">446.6 &#177; 283.5</td><td align=\"center\">671.9 &#177; 623.4</td><td align=\"center\">0.05</td></tr><tr><td align=\"left\"><bold>Delta cortisol post ACTH, mean &#177; SD</bold></td><td align=\"center\">99.9 &#177; 186.5</td><td align=\"center\">160.2 &#177; 343.3</td><td align=\"center\">0.40</td></tr><tr><td align=\"left\"><bold>Mean arterial pressure (mmHg), mean &#177; SD</bold></td><td align=\"center\">58.9 &#177; 9.1</td><td align=\"center\">60.0 &#177; 7.4</td><td align=\"center\">0.58</td></tr><tr><td align=\"left\"><bold>Bilirubin (&#956;mol/L), mean &#177; SD<sup>a</sup></bold></td><td align=\"center\">359.2 &#177; 337.7</td><td align=\"center\">331.9 &#177; 266.3</td><td align=\"center\">0.73</td></tr><tr><td align=\"left\"><bold>Lactic acid (mmol/L), mean &#177; SD<sup>a </sup></bold></td><td align=\"center\">3.7 &#177; 2.7</td><td align=\"center\">4.9 &#177; 4.9</td><td align=\"center\">0.21</td></tr><tr><td align=\"left\"><bold>INR, mean &#177; SD</bold></td><td align=\"center\">2.6 &#177; 1.5</td><td align=\"center\">2.7 &#177; 1.4</td><td align=\"center\">0.84</td></tr><tr><td align=\"left\"><bold>Ammonia (&#956;mol/L), mean &#177; SD<sup>a</sup></bold></td><td align=\"center\">122.2 &#177; 147.9</td><td align=\"center\">110.4 &#177; 66</td><td align=\"center\">0.72</td></tr><tr><td align=\"left\"><bold>AST (U/L), mean &#177; SD</bold></td><td align=\"center\">93.0 &#177; 94.0</td><td align=\"center\">273.7 &#177; 627.7</td><td align=\"center\">0.08</td></tr><tr><td align=\"left\"><bold>ALT (U/L), mean &#177; SD</bold></td><td align=\"center\">43.0 &#177; 33.3</td><td align=\"center\">74.1 &#177; 108.9</td><td align=\"center\">0.10</td></tr><tr><td align=\"left\"><bold>ALK (U/L), mean &#177; SD</bold></td><td align=\"center\">150.6 &#177; 131.3</td><td align=\"center\">132.5 &#177; 81.6</td><td align=\"center\">0.56</td></tr><tr><td align=\"left\"><bold>Albumin in (G/L), mean &#177; SD</bold></td><td align=\"center\">31.5 &#177; 7.3</td><td align=\"center\">32.2 &#177; 6.4</td><td align=\"center\">0.70</td></tr><tr><td align=\"left\"><bold>Platelets (10^9 g/L), mean &#177; SD</bold></td><td align=\"center\">87.2 &#177; 59.2</td><td align=\"center\">111.7 &#177; 84.2</td><td align=\"center\">0.22</td></tr><tr><td align=\"left\"><bold>Hemoglobin (g/L), mean &#177; SD</bold></td><td align=\"center\">81.7 &#177; 23.3</td><td align=\"center\">85.9 &#177; 15.4</td><td align=\"center\">0.45</td></tr><tr><td align=\"left\"><bold>WBC (10^9/L), mean &#177; SD</bold></td><td align=\"center\">13.6 &#177; 8</td><td align=\"center\">13.1 &#177; 8.5</td><td align=\"center\">0.82</td></tr><tr><td align=\"left\"><bold>PaO2/FiO2, mean &#177; SD</bold></td><td align=\"center\">225.9 &#177; 121.1</td><td align=\"center\">230.5 &#177; 144</td><td align=\"center\">0.90</td></tr><tr><td align=\"left\"><bold>Duration of shock before inclusion (Hours), mean &#177; SD</bold></td><td align=\"center\">18.2 &#177; 15</td><td align=\"center\">12.5 &#177; 16.1</td><td align=\"center\">0.17</td></tr><tr><td align=\"left\"><bold>Norepinephrine dose at inclusion (&#956;cg/kg/min), mean &#177; SD</bold></td><td align=\"center\">0.4 &#177; 0.4</td><td align=\"center\">0.36 &#177; 0.4</td><td align=\"center\">0.54</td></tr><tr><td align=\"left\"><bold>Dopamine dose at inclusion (&#956;cg/kg/min), mean &#177; SD</bold></td><td align=\"center\">4.1 &#177; 6.3</td><td align=\"center\">3.3 &#177; 6</td><td align=\"center\">0.60</td></tr><tr><td align=\"left\" colspan=\"4\"><bold>Source of Infection, No. (%)*</bold></td></tr><tr><td align=\"left\">&#8195;<bold>Pulmonary</bold></td><td align=\"center\">9 (39.1)</td><td align=\"center\">15 (38.5)</td><td align=\"center\">0.96</td></tr><tr><td align=\"left\">&#8195;<bold>UTI</bold></td><td align=\"center\">6 (26.1)</td><td align=\"center\">6 (15.4)</td><td align=\"center\">0.33</td></tr><tr><td align=\"left\">&#8195;<bold>Skin</bold></td><td align=\"center\">2 (8.7)</td><td align=\"center\">1 (2.6)</td><td align=\"center\">0.55</td></tr><tr><td align=\"left\">&#8195;<bold>SBP</bold></td><td align=\"center\">7 (30.4)</td><td align=\"center\">13 (33.3)</td><td align=\"center\">0.81</td></tr><tr><td align=\"left\">&#8195;<bold>No clear source</bold></td><td align=\"center\">6 (26.1)</td><td align=\"center\">9 (23.1)</td><td align=\"center\">0.79</td></tr><tr><td align=\"left\">&#8195;<bold>Other abdominal</bold></td><td align=\"center\">1 (4.3)</td><td align=\"center\">6 (15.4)</td><td align=\"center\">0.24</td></tr><tr><td align=\"left\" colspan=\"4\"><bold>Etiology of liver disease, No. (%)</bold></td></tr><tr><td align=\"left\">&#8195;<bold>HEP C</bold></td><td align=\"center\">11 (47.8)</td><td align=\"center\">21 (53.9)</td><td align=\"center\">0.68</td></tr><tr><td align=\"left\">&#8195;<bold>HEP B</bold></td><td align=\"center\">7 (30.4)</td><td align=\"center\">8 (20.5)</td><td/></tr><tr><td align=\"left\">&#8195;<bold>Others (Schistomiasis, auto-immune hepatitis, etc)</bold></td><td align=\"center\">5 (21.7)</td><td align=\"center\">10 (25.6)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3295685:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Outcomes of etomidate vs. control groups</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Etomidate</th><th align=\"center\">Control</th><th align=\"center\">P-Value</th></tr><tr><th/><th align=\"center\">N = 23</th><th align=\"center\">N = 39</th><th/></tr></thead><tbody><tr><td align=\"left\"><bold>ICU mortality, No. (%)</bold></td><td align=\"center\">21 (91)</td><td align=\"center\">25 (64)</td><td align=\"center\">0.02</td></tr><tr><td align=\"left\"><bold>Hospital mortality, No. (%)</bold></td><td align=\"center\">23 (100)</td><td align=\"center\">37 (95)</td><td align=\"center\">0.23</td></tr><tr><td align=\"left\"><bold>28-day mortality, No. (%)</bold></td><td align=\"center\">21 (91)</td><td align=\"center\">33 (84)</td><td align=\"center\">0.45</td></tr><tr><td align=\"left\"><bold>Delta norepinephrine (D2-1)</bold><break/><bold>(&#956;/kg/min), mean &#177; SD</bold></td><td align=\"center\">0.03 &#177; 0.30</td><td align=\"center\">-0.01 &#177; 0.26</td><td align=\"center\">0.61</td></tr><tr><td align=\"left\"><bold>Delta norepinephrine (D3-1)</bold><break/><bold>(&#956;/kg/min), mean &#177; SD</bold></td><td align=\"center\">0.07 &#177; 0.37</td><td align=\"center\">-0.06 &#177; 0.33</td><td align=\"center\">0.15</td></tr><tr><td align=\"left\"><bold>ICU length of stay (days), mean &#177; SD</bold></td><td align=\"center\">12.6 &#177; 7.8</td><td align=\"center\">9.4 &#177; 5.8</td><td align=\"center\">0.06</td></tr><tr><td align=\"left\"><bold>Ventilation-free days, mean &#177; SD</bold></td><td align=\"center\">2.3 &#177; 4.6</td><td align=\"center\">6.0 &#177; 7.5</td><td align=\"center\">0.02</td></tr><tr><td align=\"left\"><bold>Vasopressor-free days, mean &#177; SD</bold></td><td align=\"center\">3.2 &#177; 6</td><td align=\"center\">5.5 &#177; 7.8</td><td align=\"center\">0.23</td></tr></tbody></table></body></html>", "text": "Pmid= 3295685:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Outcomes of etomidate vs. control stratified by hydrocortisone use</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"3\">Etomidate (n = 23)</th><th align=\"center\" colspan=\"3\">Control (n = 39)</th></tr><tr><th/><th align=\"center\">Hydrocortisone</th><th align=\"center\">Placebo</th><th align=\"center\">P-Value</th><th align=\"center\">Hydrocortisone</th><th align=\"center\">Placebo</th><th align=\"center\">P-value</th></tr><tr><th/><th align=\"center\">N = 14</th><th align=\"center\">N = 9</th><th/><th align=\"center\">N = 20</th><th align=\"center\">N = 19</th><th/></tr></thead><tbody><tr><td align=\"left\"><bold>ICU mortality, No.%</bold></td><td align=\"center\">12 (85.7)</td><td align=\"center\">9 (100)</td><td align=\"center\">0.50</td><td align=\"center\">12 (60)</td><td align=\"center\">13 (68.4)</td><td align=\"center\">0.74</td></tr><tr><td align=\"left\"><bold>Hospital mortality, No.%</bold></td><td align=\"center\">14 (100)</td><td align=\"center\">9 (100)</td><td/><td align=\"center\">18 (90)</td><td align=\"center\">19 (100)</td><td align=\"center\">0.49</td></tr><tr><td align=\"left\"><bold>28-day mortality, No.%</bold></td><td align=\"center\">13 (92.9)</td><td align=\"center\">8 (88.9)</td><td align=\"center\">1.0</td><td align=\"center\">18 (90)</td><td align=\"center\">15 (79)</td><td align=\"center\">0.41</td></tr><tr><td align=\"left\"><bold>Delta norepinephrine (d2-1) (&#956;/kg/min)</bold></td><td align=\"center\">-0.05 &#177; 0.23</td><td align=\"center\">0.15 &#177; 0.36</td><td align=\"center\">0.05</td><td align=\"center\">-0.10 &#177; 0.24</td><td align=\"center\">0.08 &#177; 0.25</td><td align=\"center\">0.02</td></tr><tr><td align=\"left\"><bold>Delta norepinephrine (d3-1) (&#956;/kg/min)</bold></td><td align=\"center\">-0.10 &#177; 0.26</td><td align=\"center\">0.31 &#177; 0.36</td><td align=\"center\">0.01</td><td align=\"center\">-0.20 &#177; 0.33</td><td align=\"center\">0.06 &#177; 0.28</td><td align=\"center\">0.02</td></tr><tr><td align=\"left\"><bold>ICU length of stay (days), mean &#177; SD</bold></td><td align=\"center\">13.7 &#177; 7.2</td><td align=\"center\">10.9 &#177; 8.5</td><td align=\"center\">0.23</td><td align=\"center\">9.4 &#177; 5.9</td><td align=\"center\">9.3 &#177; 5.6</td><td align=\"center\">0.93</td></tr><tr><td align=\"left\"><bold>Ventilation-free days, mean &#177; SD</bold></td><td align=\"center\">3.6 &#177; 5.6</td><td align=\"center\">0.2 &#177; 0.4</td><td align=\"center\">0.04</td><td align=\"center\">6.2 &#177; 6.6</td><td align=\"center\">5.8 &#177; 8.5</td><td align=\"center\">0.6</td></tr><tr><td align=\"left\"><bold>Vasopressor-free days, mean &#177; SD</bold></td><td align=\"center\">4.6 &#177; 6.9</td><td align=\"center\">1.1 &#177; 3.3</td><td align=\"center\">0.05</td><td align=\"center\">7.1 &#177; 8.0</td><td align=\"center\">3.8 &#177; 7.5</td><td align=\"center\">0.20</td></tr></tbody></table></body></html>", "text": "Pmid= 3295685:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Definitions of rating categories used in the modified RAM study [</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Rating category</th><th align=\"left\">Definition</th></tr></thead><tbody><tr><td align=\"left\">\\'Appropriate\\'</td><td align=\"left\">In an average patient, the expected health benefit usually exceeds the expected negative consequences by a sufficiently wide margin that prescribing is worthwhile, irrespective of cost</td></tr><tr><td align=\"left\">\\'Inappropriate\\'</td><td align=\"left\">In an average patient, the expected negative consequences usually exceed the expected health benefits by a sufficiently wide margin that prescribing is not worthwhile, irrespective of cost</td></tr><tr><td align=\"left\">\\'Necessary to do\\'</td><td align=\"left\">In an average patient, it would be considered improper care NOT to prescribe as stated, because<break/>(1) there is sufficient evidence, that the patient is likely to benefit AND<break/>(2) the likely benefit to the patient is large enough to be clinically significant</td></tr><tr><td align=\"left\">\\'Necessary to avoid\\'</td><td align=\"left\">In an average patient, it would be considered improper care to prescribe as stated, because<break/>(1) there is sufficient evidence, that the patient is likely to be harmed AND<break/>(2) the likely harm to the patient is large enough to be clinically significant</td></tr></tbody></table></body></html>", "text": "Pmid= 3296596:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of final quality assessment criteria designed from candidates accepted in the modified RAM study as appropriate (App) or necessary to do (NecDo)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Condition targeted</th><th align=\"left\" colspan=\"5\">Final quality assessment criteria</th></tr><tr><th/><th colspan=\"5\"><hr/></th></tr><tr><th/><th align=\"left\">Medication quality category (MQ):<break/>Targeted prescribing</th><th align=\"left\">Associated PDRM event</th><th align=\"center\" colspan=\"3\">Count</th></tr><tr><th/><th/><th/><th colspan=\"3\"><hr/></th></tr><tr><th/><th/><th/><th align=\"center\">App</th><th align=\"center\">NecDo</th><th align=\"center\">Total</th></tr></thead><tbody><tr><td align=\"left\">HYPERTENSION</td><td align=\"left\">MQ2: Selection of first line antihypertensives</td><td align=\"left\">CV events</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">13 (25%)</td></tr><tr><td/><td align=\"left\">MQ3: Blood pressure control</td><td align=\"left\">CV events</td><td align=\"center\">5</td><td align=\"center\">7</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">DIABETES</td><td align=\"left\">MQ1: Use of ACEI/ARB if micro-albuminuria</td><td align=\"left\">DM complications</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">6 (12%)</td></tr><tr><td/><td align=\"left\">MQ2: Selection of metformin if overweight</td><td align=\"left\">DM complications</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td/><td align=\"left\">MQ3: HbA1c control</td><td align=\"left\">DM complications</td><td align=\"center\">2</td><td align=\"center\">2</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">AT RISK OF PRIMARY/SECONDARY<break/>VASCULAR EVENTS</td><td align=\"left\">MQ1: Use of antiplatelet or anticoagulant</td><td align=\"left\">CV events</td><td align=\"center\">1</td><td align=\"center\">4</td><td align=\"center\">17 (33%)</td></tr><tr><td/><td align=\"left\">Use of statin</td><td align=\"left\">CV events</td><td align=\"center\">1</td><td align=\"center\">3</td><td/></tr><tr><td/><td align=\"left\">Use of ACEI or ARB in CHD</td><td align=\"left\">CV events</td><td align=\"center\">1</td><td align=\"center\">1</td><td/></tr><tr><td/><td align=\"left\">Use of beta blockers in CHD</td><td align=\"left\">CV events</td><td align=\"center\">-</td><td align=\"center\">2</td><td/></tr><tr><td/><td align=\"left\">MQ4: Achievement of target statin dose</td><td align=\"left\">CV events</td><td align=\"center\">-</td><td align=\"center\">4</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">CHRONIC HEART<break/>FAILURE</td><td align=\"left\">MQ1: Use of ACEI or ARB</td><td align=\"left\">CHF progression</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">5(10%)</td></tr><tr><td/><td align=\"left\">Use of beta blocker</td><td align=\"left\">CHF progression</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td/><td align=\"left\">MQ2: Selection of beta blocker licensed for CHF</td><td align=\"left\">CHF progression</td><td align=\"center\">1</td><td align=\"center\">-</td><td/></tr><tr><td/><td align=\"left\">MQ4: Achievement of target ACEI/ARB dose</td><td align=\"left\">CHF progression</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td/><td align=\"left\">Achievement of target BB dose</td><td align=\"left\">CHF progression</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">ATRIAL FIBRILLATION</td><td align=\"left\">MQ1: Use of antiplatelet or anticoagulant</td><td align=\"left\">Stroke/Embolism</td><td align=\"center\">-</td><td align=\"center\">3</td><td align=\"center\">4(8%)</td></tr><tr><td/><td align=\"left\">MQ2: Selection of warfarin in high risk of stroke</td><td align=\"left\">Stroke/Embolism</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">ASTHMA</td><td align=\"left\">MQ1: Use of inhaled corticosteroid</td><td align=\"left\">Asthma exacerbation</td><td align=\"center\">1</td><td align=\"center\">3</td><td align=\"center\">4 (8%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">OSTEOPOROSIS</td><td align=\"left\">MQ1: Use of bone protecting agent</td><td align=\"left\">Fractures</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">3(6%)</td></tr><tr><td/><td align=\"left\">Use of calcium/vitamin D supplement</td><td align=\"left\">Fractures</td><td align=\"center\">-</td><td align=\"center\">2</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td/><td/><td align=\"center\"><bold>12</bold></td><td align=\"center\"><bold>40</bold></td><td align=\"center\"><bold>52 (100%)</bold></td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\" colspan=\"5\"><bold>Medication Quality categories</bold></td><td/></tr><tr><td align=\"left\">1. INDICATION</td><td align=\"left\" colspan=\"2\">MQ1: Need for treatment to control condition</td><td align=\"center\">4</td><td align=\"center\">22</td><td align=\"center\">26 (52%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">2. SELECTION</td><td align=\"left\" colspan=\"2\">MQ2: Selection of first line option within drug class</td><td align=\"center\">1</td><td align=\"center\">3</td><td align=\"center\">4 (8%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">3. INTENSITY</td><td align=\"left\" colspan=\"2\">MQ3: Achievement of intermediate outcome target</td><td align=\"center\">7</td><td align=\"center\">9</td><td align=\"center\">16 (31%)</td></tr><tr><td/><td align=\"left\" colspan=\"2\">MQ4: Achievement of target dose</td><td align=\"center\">-</td><td align=\"center\">6</td><td align=\"center\">6 (12%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\" colspan=\"6\"><bold>Criteria restricted to the elderly</bold></td></tr><tr><td align=\"left\">Aged &#8805; 75</td><td/><td/><td align=\"center\">4</td><td align=\"center\">4</td><td align=\"center\">8 (15%)</td></tr><tr><td align=\"left\">Aged &#8805; 80</td><td/><td/><td align=\"center\">-</td><td align=\"center\">2</td><td align=\"center\">2 (4%)</td></tr></tbody></table></body></html>", "text": "Pmid= 3296596:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Summary of final safety assessment criteria designed from candidates accepted in the modified RAM study as inappropriate (InApp) or necessary to avoid (NecAv)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">High-risk drug/patient group</th><th align=\"left\" colspan=\"5\">Final safety assessment criteria</th></tr><tr><th/><th colspan=\"5\"><hr/></th></tr><tr><th/><th align=\"left\" colspan=\"1\">Medication safety category (MS):<break/>Targeted prescribing/monitoring</th><th align=\"left\">Associated PDRM event</th><th align=\"center\" colspan=\"3\">Count</th></tr><tr><th/><th/><th/><th align=\"center\">InApp</th><th align=\"center\">NecAv</th><th align=\"center\">Total</th></tr></thead><tbody><tr><td align=\"left\" colspan=\"6\"><bold>Drugs frequently implicated in PDRM hospital admissions</bold></td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">ANTIPLATELET</td><td align=\"left\">MS1: Use without gastroprotection</td><td align=\"left\">GI toxicity/bleeding</td><td align=\"center\">1</td><td align=\"center\">4</td><td align=\"center\">5 (4%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">DIURETIC</td><td align=\"left\">MS1: Unmet need for allopurinol in thiazide users</td><td align=\"left\">Gout</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">11 (9%)</td></tr><tr><td/><td align=\"left\">MS3: Use of thiazides in CKD</td><td align=\"left\">Renal toxicity</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td/><td align=\"left\">Use of aldosterone antagonist in CKD</td><td align=\"left\">Hyperkalaemia</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td/><td align=\"left\">MS6: Excess duration of potassium supplement</td><td align=\"left\">Hyperkalaemia</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td/><td align=\"left\">MS8: Inconsistent monitoring of U&amp;E\\'s</td><td align=\"left\">Electrolyte disturbances</td><td align=\"center\">2</td><td align=\"center\">5</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">NSAID</td><td align=\"left\">MS1: Unmet need for gastroprotection</td><td align=\"left\">GI toxicity/bleeding</td><td align=\"center\">1</td><td align=\"center\">4</td><td align=\"center\">18 (15%)</td></tr><tr><td/><td align=\"left\">MS2: Use of COX II selective agents in aspirin users</td><td align=\"left\">CV events</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td/><td align=\"left\">Paracetamol not tried first</td><td align=\"left\">General NSAID toxicity</td><td align=\"center\">1</td><td align=\"center\">2</td><td/></tr><tr><td/><td align=\"left\">MS3: Use in CKD</td><td align=\"left\">Renal toxicity</td><td align=\"center\">-</td><td align=\"center\">2</td><td/></tr><tr><td/><td align=\"left\">Use of COX II selective agents in high CV risk</td><td align=\"left\">CV events</td><td align=\"center\">-</td><td align=\"center\">2</td><td/></tr><tr><td/><td align=\"left\">MS4: Co-prescription with diuretic and/or ACEI or ARB</td><td align=\"left\">Renal toxicity</td><td align=\"center\">2</td><td align=\"center\">3</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">ANTICOAGULANT</td><td align=\"left\">MS2: Use of warfarin in AF and low risk of stroke</td><td align=\"left\">Bleeding</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">11 (9%)</td></tr><tr><td/><td align=\"left\">MS4: Co-prescription of high-risk anti-infectives</td><td align=\"left\">Bleeding</td><td align=\"center\">1</td><td align=\"center\">9</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">OPIOID</td><td align=\"left\">MS1: No laxative co-prescribed in strong opioid users</td><td align=\"left\">Constipation</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">2 (2%</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">BETA BLOCKER</td><td align=\"left\">MS3: Use in asthma</td><td align=\"left\">Asthma exacerbation</td><td align=\"center\">1</td><td align=\"center\">2</td><td align=\"center\">4 (3%)</td></tr><tr><td/><td align=\"left\">MS4: Co-prescription with verapamil/diltiazem</td><td align=\"left\">Bradycardia</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">ACEI/ARB</td><td align=\"left\">MS8: Inconsistent monitoring of U&amp;E\\'s</td><td align=\"left\">Hyperkalaemia</td><td align=\"center\">-</td><td align=\"center\">2</td><td align=\"center\">2 (2%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">ANTIDIABETIC</td><td align=\"left\">MS3: Use of long acting sulphonylureas in CKD</td><td align=\"left\">Hypoglycaemia</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">2 (2%)</td></tr><tr><td/><td align=\"left\">Use of metformin in CKD</td><td align=\"left\">Lactic acidosis</td><td align=\"center\">-</td><td align=\"center\">1</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">DIGOXIN</td><td align=\"left\">MS5: Excessive dose in CKD or the elderly</td><td align=\"left\">Digoxin toxicity</td><td align=\"center\">-</td><td align=\"center\">2</td><td align=\"center\">10 (8%)</td></tr><tr><td/><td align=\"left\">Excessive dose in patients on interacting drugs</td><td/><td align=\"center\">-</td><td align=\"center\">6</td><td/></tr><tr><td/><td align=\"left\">MS8: Inconsistent monitoring of U&amp;E\\'s</td><td/><td align=\"center\">-</td><td align=\"center\">2</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">ORAL STEROID</td><td align=\"left\">MS1: Unmet need for bone protecting agents</td><td align=\"left\">Bone fracture</td><td align=\"center\">-</td><td align=\"center\">2</td><td align=\"center\">2 (2%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><bold>Other drugs implicated in severe adverse drug events</bold></td><td/><td/><td/></tr><tr><td align=\"left\">DMARD</td><td align=\"left\">MS7: Lack of dose instructions/Use of 2 strengths</td><td align=\"left\">Miscellaneous</td><td align=\"center\">-</td><td align=\"center\">2</td><td align=\"center\">10 (8%)</td></tr><tr><td/><td align=\"left\">MS8: Inconsistent monitoring of FBC</td><td align=\"left\">Blood dyscrasias</td><td align=\"center\">2</td><td align=\"center\">6</td><td/></tr><tr><td align=\"left\">FEMALE</td><td align=\"left\">MS3: Use of estrogens in women w/o hysterectomy</td><td align=\"left\">Gynaecological cancer</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">7 (6%)</td></tr><tr><td align=\"left\">STEROIDS</td><td align=\"left\">MS3: Use in women with CVD or CVD risk &gt; 20%</td><td align=\"left\">Vascular events</td><td align=\"center\">2</td><td align=\"center\">2</td><td/></tr><tr><td/><td align=\"left\">MS6: Excess duration in postmenopausal women</td><td/><td align=\"center\">1</td><td align=\"center\">1</td><td/></tr><tr><td align=\"left\">AMIODARONE</td><td align=\"left\">MS8: Inconsistent monitoring of thyroid function</td><td align=\"left\">Thyroid disturbances</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">1 (1%)</td></tr><tr><td align=\"left\">THEOPHYLLIN</td><td align=\"left\">MS2: Use without inhaled anticholinergics/steroids</td><td align=\"left\">Theophylline toxicity</td><td align=\"center\">-</td><td align=\"center\">1</td><td align=\"center\">1 (1%)</td></tr><tr><td align=\"left\">STATIN</td><td align=\"left\">MS5: Excessive dose in patients on interacting drugs</td><td align=\"left\">Rhabdomyolysis</td><td align=\"center\">-</td><td align=\"center\">5</td><td align=\"center\">5 (4%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\" colspan=\"6\"><bold>Particularly vulnerable patient groups</bold></td></tr><tr><td align=\"left\">ELDERLY</td><td align=\"left\">MS3: Miscellaneous drugs to be avoided</td><td align=\"left\">Miscellaneous</td><td align=\"center\">1</td><td align=\"center\">10</td><td align=\"center\">18 (15%)</td></tr><tr><td/><td align=\"left\">MS6: Miscellaneous drugs for excessive duration</td><td align=\"left\">Miscellaneous</td><td align=\"center\">-</td><td align=\"center\">7</td><td/></tr><tr><td align=\"left\">HEART FAILURE</td><td align=\"left\">MS3: Miscellaneous drugs to be generally avoided</td><td align=\"left\">HF exacerbation</td><td align=\"center\">-</td><td align=\"center\">10</td><td align=\"center\">10 (8%)</td></tr><tr><td align=\"left\">CHILDREN</td><td align=\"left\">MS3: Miscellaneous drugs to be generally avoided</td><td align=\"left\">Miscellaneous</td><td align=\"center\">1</td><td align=\"center\">4</td><td align=\"center\">5 (4%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td/><td/><td align=\"center\"><bold>17</bold></td><td align=\"center\"><bold>107</bold></td><td align=\"center\"><bold>124 (100%)</bold></td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\" colspan=\"5\"><bold>Medication Safety (MS) categories</bold></td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">1. INDICATION</td><td align=\"left\" colspan=\"2\">MS1: Unmet need for risk mitigating drug</td><td align=\"center\">3</td><td align=\"center\">12</td><td align=\"center\">15 (12%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">2. SELECTION</td><td align=\"left\" colspan=\"2\">MS2: High risk drug without compelling indication</td><td align=\"center\">1</td><td align=\"center\">5</td><td align=\"center\">64 (52%)</td></tr><tr><td/><td align=\"left\" colspan=\"2\">MS3: Drug-disease or Drug-age interaction</td><td align=\"center\">5</td><td align=\"center\">37</td><td/></tr><tr><td/><td align=\"left\" colspan=\"2\">MS4: Drug-Drug interaction (DDI)</td><td align=\"center\">3</td><td align=\"center\">13</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">3. INTENSITY</td><td align=\"left\" colspan=\"2\">MS5: Excessive dose</td><td align=\"center\">-</td><td align=\"center\">13</td><td align=\"center\">23 (19%)</td></tr><tr><td/><td align=\"left\" colspan=\"2\">MS6: Excessive duration</td><td align=\"center\">1</td><td align=\"center\">9</td><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">4. COMPLIANCE</td><td align=\"left\" colspan=\"2\">MS7: Issues related to patient compliance</td><td align=\"center\">-</td><td align=\"center\">2</td><td align=\"center\">2 (2%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">5. MONITORING</td><td align=\"left\" colspan=\"2\">MS8: Inconsistent laboratory monitoring</td><td align=\"center\">4</td><td align=\"center\">16</td><td align=\"center\">20 (16%)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\" colspan=\"6\"><bold>Criteria restricted to the elderly</bold></td></tr><tr><td align=\"left\">&#8195;Aged &#8805; 65</td><td/><td/><td align=\"center\">3</td><td align=\"center\">21</td><td align=\"center\">24 (19%)</td></tr><tr><td align=\"left\">&#8195;Aged &#8805; 75</td><td/><td/><td align=\"center\">2</td><td align=\"center\">9</td><td align=\"center\">11 (9%)</td></tr><tr><td align=\"left\">&#8195;Aged &#8805; 85</td><td/><td/><td align=\"center\">1</td><td align=\"center\">-</td><td align=\"center\">1 (1%)</td></tr></tbody></table></body></html>", "text": "Pmid= 3296596:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Quality assessment criteria generated from candidates that the RAM panel classified as 'appropriate but not necessary to do' (A) and 'appropriate and necessary to do' (N)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Topic No.</th><th align=\"left\">Treatment targeted - Associated PDRM event (Medication quality category)</th></tr></thead><tbody><tr><td align=\"left\" colspan=\"2\">HYPERTENSION</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Q1</bold></td><td align=\"left\"><bold>Selection of first line antihypertensives - Hypertension complications (MQ2)</bold></td></tr><tr><td/><td align=\"left\">1. (N) Patient with HTN and without CHD - is started on antihypertensive treatment with a first-line antihypertensive</td></tr><tr><td align=\"left\"><bold>Q2</bold></td><td align=\"left\"><bold>Treatment to blood pressure (BP) target - Hypertension complications (MQ3)</bold></td></tr><tr><td/><td align=\"left\">Patient aged &lt; 75 years, who has a history of hypertension WITHOUT complications</td></tr><tr><td/><td align=\"left\">2. (N) and BP is &gt; 150/90 mmHg on &lt; 3 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">3. (N) and BP is &gt; 140/85 mmHg on &lt; 2 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">4. (A) and BP is &gt; 140/85 mmHg on &lt; 3 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">Patient aged &#8805; 75 years, who has a history of hypertension WITHOUT complications</td></tr><tr><td/><td align=\"left\">5. (N) and BP is &gt; 150/90 mmHg on &lt; 2 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">6. (N) and BP is &gt; 140/85 mmHg without antihypertensive treatment - has antihypertensive treatment started</td></tr><tr><td/><td align=\"left\">7. (A) and BP is &gt; 150/90 mmHg on &lt; 3 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">8. (A) and BP is &gt; 140/85 mmHg on &lt; 2 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">Patient aged &lt; 75 years, who has a history of hypertension WITH complications</td></tr><tr><td/><td align=\"left\">9. (N) and BP is &gt; 130/80 mmHg on &lt; 2 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">Patient aged &#8805; 75 years, who has a history of hypertension WITH complications</td></tr><tr><td/><td align=\"left\">10. (N) and BP is &gt; 140/85 mmHg on &lt; 2 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">11. (N) and BP is &gt; 130/80 mmHg without antihypertensive treatment - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">12. (A) and BP is &gt; 140/85 mmHg on &lt; 3 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td/><td align=\"left\">13. (A) and BP is &gt; 130/80 mmHg on &lt; 2 antihypertensive drugs - has antihypertensive treatment intensified</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">DIABETES MELLITUS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Q3</bold></td><td align=\"left\"><bold>Treatment to HbA1c target - Diabetes complications (MQ3)</bold></td></tr><tr><td/><td align=\"left\">Patient with diabetes mellitus type 2,</td></tr><tr><td/><td align=\"left\">14. (N) who has HbA1c of &gt; 7% on &lt; 2 oral antidiabetic drugs - has antidiabetic treatment intensified</td></tr><tr><td/><td align=\"left\">15. (N) who has HbA1c of &gt; 9% on &lt; 3 oral antidiabetic drugs - has antidiabetic treatment intensified</td></tr><tr><td/><td align=\"left\">16. (A) who has HbA1c of 6.6 to 7% without antidiabetic treatment - has antidiabetic treatment intensified</td></tr><tr><td/><td align=\"left\">17. (A) who has HbA1c of 7.6 to 9% on &lt; 3 oral antidiabetic drugs - has antidiabetic treatment intensified</td></tr><tr><td align=\"left\"><bold>Q4</bold></td><td align=\"left\"><bold>Selection of first line oral antidiabetic - Diabetes complications (MQ2)</bold></td></tr><tr><td/><td align=\"left\">18. (N) Patient with diabetes mellitus type 2, who is overweight - is started on metformin</td></tr><tr><td align=\"left\"><bold>Q5</bold></td><td align=\"left\"><bold>Indication for ACEI or ARB in patients with renal complications - Diabetes complications (MQ1)</bold></td></tr><tr><td/><td align=\"left\">19. (N) Patient with diabetes mellitus and micro-albuminuria - is prescribed an ACEI or ARB</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">AT RISK OF/MANIFEST VASCULAR DISEASE</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Q6</bold></td><td align=\"left\"><bold>Indication for statin in patients with manifest vascular disease or risk factors - Vascular events (MQ1)</bold></td></tr><tr><td/><td align=\"left\">20. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed a statin</td></tr><tr><td/><td align=\"left\">21. (N) Patient with peripheral vascular disease - is prescribed a statin</td></tr><tr><td/><td align=\"left\">22. (N) Patient aged &gt; 40 with DM without established vascular disease - is prescribed a statin</td></tr><tr><td/><td align=\"left\">23. (A) Patient with 10 year CVD risk &gt; 20% without diabetes - is prescribed a statin</td></tr><tr><td align=\"left\"><bold>Q7</bold></td><td align=\"left\"><bold>Treatment to target statin dose in patients with manifest vascular disease or risk factors - Vascular events (MQ4)</bold></td></tr><tr><td/><td align=\"left\">24. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed simvastatin &#8805; 40 mg/d (or equivalent)</td></tr><tr><td/><td align=\"left\">25. (N) Patient with peripheral vascular disease - is prescribed simvastatin &#8805; 40 mg/d (or equivalent)</td></tr><tr><td/><td align=\"left\">26. (N) Patient aged &gt; 40 with DM without established vascular disease - is prescribed simvastatin &#8805; 40 mg/d (or equiv.)</td></tr><tr><td/><td align=\"left\">27. (N) Patient with 10 year CVD risk &gt; 20% without diabetes - is prescribed simvastatin &#8805; 40 mg/d (or equivalent)</td></tr><tr><td align=\"left\"><bold>Q8</bold></td><td align=\"left\"><bold>Indication for thrombo-embolic prophylaxis in patients with CHD - Vascular events (MQ1)</bold></td></tr><tr><td/><td align=\"left\">28. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed any thrombo-embolic prophylaxis</td></tr><tr><td/><td align=\"left\">29. (N) Patient with a history of peripheral vascular disease - is prescribed any thrombo-embolic prophylaxis</td></tr><tr><td/><td align=\"left\">Indication for dual antiplatelets in CHD with a history of ACS - Vascular events (MQ1)</td></tr><tr><td/><td align=\"left\">30. (N) Patient with previous stroke/TIA - is co-prescribed aspirin and dipyridamole (unless on warfarin or clopidogrel)</td></tr><tr><td/><td align=\"left\">31. (N) Patient with ACS 0 to 3 months ago - is co-prescribed aspirin and clopidogrel (unless on warfarin)</td></tr><tr><td/><td align=\"left\">32. (A) Patient with ACS 4 to 9 months ago - is co-prescribed aspirin and clopidogrel (unless on warfarin)</td></tr><tr><td align=\"left\"><bold>Q9</bold></td><td align=\"left\"><bold>Indication for beta blockers in CHD - Vascular events (MQ1)</bold></td></tr><tr><td/><td align=\"left\">33. (N) Patient with a history of acute coronary syndrome - is prescribed a beta blocker</td></tr><tr><td/><td align=\"left\">34. (N) Patient with stable angina without a history of acute coronary syndrome - is prescribed a beta blocker</td></tr><tr><td align=\"left\"><bold>Q10</bold></td><td align=\"left\"><bold>Indication for ACEI or ARB in CHD - Vascular events (MQ1)</bold></td></tr><tr><td/><td align=\"left\">35. (N) Patient with a history of acute coronary syndrome - is prescribed an ACEI or ARB</td></tr><tr><td/><td align=\"left\">36. (A) Patient with stable angina without a history of acute coronary syndrome - is prescribed an ACEI or ARB</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">CHRONIC HEART FAILURE</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Q11</bold></td><td align=\"left\"><bold>Indication for ACEI or ARB in CHF - Heart failure progression (MQ1)</bold></td></tr><tr><td/><td align=\"left\">37. (N) Patient with CHF - is prescribed an ACE or ARB</td></tr><tr><td align=\"left\"><bold>Q12</bold></td><td align=\"left\"><bold>Indication for Beta blocker in CHF - Heart failure progression (MQ1)</bold></td></tr><tr><td/><td align=\"left\">38. (N) Patient with CHF - is prescribed a beta blocker</td></tr><tr><td/><td align=\"left\"><bold>Selection of licensed beta blocker in CHF - Heart failure progression (MQ2)</bold></td></tr><tr><td/><td align=\"left\">39. (A) Patient with CHF and treated with a BB - is prescribed a BB licensed for CHF</td></tr><tr><td align=\"left\"><bold>Q13</bold></td><td align=\"left\"><bold>Treatment to target dose (ACEI and ARB) in CHF - Heart failure progression (MQ4)</bold></td></tr><tr><td/><td align=\"left\">40. (N) Patient with CHF and treated with an ACEI or ARB - has achieved the recommended target dose</td></tr><tr><td align=\"left\"><bold>Q13</bold></td><td align=\"left\"><bold>Treatment to target dose (beta blocker) - CHF- Prevention of heart failure progression (MQ4)</bold></td></tr><tr><td/><td align=\"left\">41. (N) Patient with CHF and treated with a beta blocker - has achieved the recommended target dose</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">ATRIAL FIBRILLATION</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Q14</bold></td><td align=\"left\"><bold>Indication for thrombo-embolic prophylaxis in AF - Thrombo-embolism (MQ1)</bold></td></tr><tr><td/><td align=\"left\">42. (N) Patient with atrial fibrillation and a CHADS2 score of 0 or 1 - is prescribed thrombo-embolic prophylaxis</td></tr><tr><td/><td align=\"left\">43. (N) Patient with atrial fibrillation and a CHADS2 score of 2 - is prescribed thrombo-embolic prophylaxis</td></tr><tr><td/><td align=\"left\">44. (N) Patient with atrial fibrillation and a CHADS2 score &#8805; 3 - is prescribed thrombo-embolic prophylaxis</td></tr><tr><td align=\"left\"><bold>Q15</bold></td><td align=\"left\"><bold>Selection of thrombo-embolic prophylaxis in AF - Thrombo-embolism (MQ2)</bold></td></tr><tr><td/><td align=\"left\">45. (N) Patient with AF and a CHADS<sub>2 </sub>score &#8805; 3 treated with an antithrombotic - is prescribed an oral anticoagulant</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">ASTHMA</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Q16</bold></td><td align=\"left\"><bold>Indication for inhaled corticosteroids in asthma - Asthma exacerbation (MQ1)</bold></td></tr><tr><td/><td align=\"left\">Patient aged &gt; 4 with asthma but without COPD and</td></tr><tr><td/><td align=\"left\">46. (N) is treated with a step 3 drug* - is also prescribed an inhaled corticosteroid</td></tr><tr><td/><td align=\"left\">47. (N) has received oral prednisolone in last 12 weeks - is also prescribed an inhaled corticosteroid</td></tr><tr><td/><td align=\"left\">48. (N) has received &#8805; 3 prescriptions of SABAs in last 12 weeks - is also prescribed an inhaled corticosteroid</td></tr><tr><td/><td align=\"left\">49. (A) has received 2 prescriptions of SABAs in last 12 weeks - is also prescribed an inhaled corticosteroid</td></tr><tr><td/><td align=\"left\">* long acting beta agonist, leukotriene receptor antagonist or theophylline</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">OSTEOPOROSIS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Q17</bold></td><td align=\"left\"><bold>Indication for bone protecting agents in patients with osteoporosis - Fractures (MQ1)</bold></td></tr><tr><td/><td align=\"left\">50. (N) Female patient with osteoporosis who had a vertebral fracture - is prescribed a bone protecting agent*</td></tr><tr><td/><td align=\"left\">* a bisphosphonate, strontium ranelate, raloxifene or teriparatide</td></tr><tr><td align=\"left\"><bold>Q18</bold></td><td align=\"left\"><bold>Indication for Calcium/vitamin D in patients at risk of osteoporosis - Fractures (MQ1)</bold></td></tr><tr><td/><td align=\"left\">51. (N) Female patient aged &#8805; 80 who is housebound - is prescribed calcium and vitamin D</td></tr><tr><td/><td align=\"left\">52. (N) Female patient aged &#8805; 80 who lives in a nursing home/residential care - is prescribed calcium and vitamin D</td></tr></tbody></table></body></html>", "text": "Pmid= 3296596:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Safety assessment criteria generated from candidates that the RAM panel classified as 'inappropriate' (I) or 'necessary to avoid' (N)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\"><bold>Topic No</bold>.</th><th align=\"left\">Treatment targeted - Associated PDRM event (Medication safety category)</th></tr></thead><tbody><tr><td align=\"left\" colspan=\"2\"><bold>A. DRUGS FREQUENTLY IMPLICATED IN PDRM HOSPITAL ADMISSIONS</bold></td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">ANTIPLATELETS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S1</bold></td><td align=\"left\"><bold>High-risk use without gastro-intestinal protection (GIP) - GI toxicity/bleeding (MS1)</bold></td></tr><tr><td/><td align=\"left\">1. (N) Patient with previous peptic ulcer (PU) treated with low dose aspirin - is not prescribed GIP</td></tr><tr><td/><td align=\"left\">2. (N) Patient aged &#8805; 65 treated with warfarin AND low dose aspirin - is not prescribed GIP</td></tr><tr><td/><td align=\"left\">3. (N) Patient aged &#8805; 65 treated with warfarin AND clopidogrel - is not prescribed GIP</td></tr><tr><td/><td align=\"left\">4. (N) Patient aged &#8805; 65 treated with low dose aspirin AND clopidogrel - is not prescribed GIP</td></tr><tr><td/><td align=\"left\">5. (I) Patient aged &#8805; 75 years treated with low dose aspirin - is not prescribed GIP</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">NSAIDS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S1</bold></td><td align=\"left\"><bold>High-risk use without gastroprotection (GIP) - GI toxicity/bleeding (MS1)</bold></td></tr><tr><td/><td align=\"left\">6. (N) Patient with previous PU treated with an oral NS NSAID for &gt; 12 weeks - is not prescribed GIP</td></tr><tr><td/><td align=\"left\">7. (N) Patient is aged &#8805; 75 years treated with an oral NS NSAID for &gt; 12 weeks - is not prescribed GIP</td></tr><tr><td/><td align=\"left\">8. (I) Patient is aged 65 to 74 treated with an oral NS NSAID for &gt; 12 weeks - is not prescribed GIP</td></tr><tr><td align=\"left\"><bold>S1</bold></td><td align=\"left\"><bold>High-risk use without gastroprotection - GI toxicity/bleeding (MS1)</bold></td></tr><tr><td/><td align=\"left\">9. (N) Patient aged &#8805; 65 treated with warfarin AND an oral NS NSAID - is not prescribed GIP</td></tr><tr><td/><td align=\"left\">10. (N) Patient aged &#8805; 65 treated with low dose aspirin AND an oral NS NSAID for &gt; 12 weeks - is not prescribed GIP</td></tr><tr><td align=\"left\"><bold>S2</bold></td><td align=\"left\"><bold>High risk drug without compelling indication - General drug specific toxicity (MS2)</bold></td></tr><tr><td/><td align=\"left\">11. (N) Patient aged &#8805; 65 - is prescribed an oral NSAID for osteoarthritis without previous trial of full dose paracetamol</td></tr><tr><td/><td align=\"left\">12. (N) Patient aged &#8805; 75 - is prescribed an oral NSAID for minor trauma without previous trial of full dose paracetamol</td></tr><tr><td/><td align=\"left\">13. (I) Patient aged 65 to 74 - is prescribed an oral NSAID for minor trauma without previous trial of full dose paracetamol</td></tr><tr><td align=\"left\"><bold>S3</bold></td><td align=\"left\"><bold>High-risk selection in renal impairment - Renal toxicity (MS3)</bold></td></tr><tr><td/><td align=\"left\">14. (N) Patient with CKD stage 3 - is prescribed an oral NSAID</td></tr><tr><td/><td align=\"left\">15. (N) Patient with CKD stage 4 or 5 - is prescribed an oral NSAID</td></tr><tr><td align=\"left\"><bold>S3</bold></td><td align=\"left\"><bold>Drug-Drug interaction (additive toxicity) - Renal toxicity (MS4)</bold></td></tr><tr><td/><td align=\"left\">16. (N) Patient aged &#8805; 65 treated with an ACEI or ARB but no diuretic - is co-prescribed an oral NSAID</td></tr><tr><td/><td align=\"left\">17. (N) Patient aged &#8805; 75 treated with a diuretic but no ACEI or ARB - is co-prescribed an oral NSAID</td></tr><tr><td/><td align=\"left\">18. (N) Patient treated with an ACEI or ARB AND a diuretic - is co-prescribed an oral NSAID</td></tr><tr><td/><td align=\"left\">19. (I) Patient aged &#8804; 65 treated with an ACEI or ARB but no diuretic - is co-prescribed an oral NSAID</td></tr><tr><td/><td align=\"left\">20. (I) Patient aged 65 to 74 treated with a diuretic but no ACEI or ARB - is co-prescribed an oral NSAID</td></tr><tr><td align=\"left\"><bold>S4</bold></td><td align=\"left\"><bold>High-risk drug without compelling indication - CV events (MS2)</bold></td></tr><tr><td/><td align=\"left\">21. (N) Patient treated with low-dose aspirin - is prescribed an oral COX II selective NSAID</td></tr><tr><td align=\"left\"><bold>S5</bold></td><td align=\"left\"><bold>High-risk selection in patients at high vascular risk- Vascular events (MS3)</bold></td></tr><tr><td/><td align=\"left\">22. (N) Patient aged &gt; 40 and CVD risk &gt; 20% - is prescribed a COX II selective NSAID</td></tr><tr><td/><td align=\"left\">23. (N) Patient with a history of vascular events - is prescribed a COX II selective NSAID</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">DIURETICS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S6</bold></td><td align=\"left\"><bold>Monitoring of U&amp;E\\'s - Electrolyte imbalance (MS8)</bold></td></tr><tr><td/><td align=\"left\">24. (N) Patient treated with a potassium sparing diuretic -had no U&amp;Es check before treatment start</td></tr><tr><td/><td align=\"left\">25. (N) Patient treated with a potassium sparing diuretic - had no U&amp;Es check in the last 48 weeks</td></tr><tr><td/><td align=\"left\">26. (N) Patient treated with a loop diuretic - had no U&amp;Es check before treatment start</td></tr><tr><td/><td align=\"left\">27. (N) Patient treated with a loop AND a thiazide diuretic or metolazone - had no U&amp;Es check in the last 24 weeks</td></tr><tr><td/><td align=\"left\">28. (N) Patient treated with a potassium sparing diuretic AND an ACEI or ARB - had no U&amp;Es check in the last 48 weeks</td></tr><tr><td/><td align=\"left\">29. (I) Patient treated with a potassium wasting diuretic - had no U&amp;Es check in the last 48 weeks</td></tr><tr><td/><td align=\"left\">30. (I) Patient treated with a potassium sparing diuretic AND an ACEI or ARB - had no U&amp;Es check in the last 24 weeks</td></tr><tr><td align=\"left\"><bold>S7</bold></td><td align=\"left\"><bold>High-risk selection in renal impairment - Renal toxicity/Treatment failure (MS3)</bold></td></tr><tr><td/><td align=\"left\">31. (N) Patient with chronic kidney disease stage 4 or 5 - is prescribed a thiazide diuretic</td></tr><tr><td align=\"left\"><bold>S8</bold></td><td align=\"left\"><bold>High-risk use without allopurinol - Gout (MS1)</bold></td></tr><tr><td/><td align=\"left\">32. (N) Patient with a history of gout and treated with a thiazide diuretic - is not prescribed allopurinol</td></tr><tr><td align=\"left\"><bold>S9</bold></td><td align=\"left\"><bold>High-risk selection in renal impairment - Electrolyte imbalance (MS3)</bold></td></tr><tr><td/><td align=\"left\">33. (N) Patient with CKD stage 4 or 5 - is prescribed an aldosterone antagonist</td></tr><tr><td align=\"left\"><bold>S10</bold></td><td align=\"left\"><bold>Excess duration - Electrolyte imbalance (MS6)</bold></td></tr><tr><td/><td align=\"left\">34. (N) Patient treated with a potassium (KI) sparing diuretic - is prescribed a K+ supplement for &#8805; 4 weeks</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">ANTICOAGULANTS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S11</bold></td><td align=\"left\"><bold>Drug-Drug interaction (pharmacokinetic) - Bleeding (MS4)</bold></td></tr><tr><td/><td align=\"left\">35. (N) Patient treated with warfarin - is co-presribed a macrolide</td></tr><tr><td/><td align=\"left\">36. (N) Patient treated with warfarin - is co-prescribed a sulfonamide</td></tr><tr><td/><td align=\"left\">37. (N) Patient treated with warfarin - is co-prescribed an azole antifungal</td></tr><tr><td/><td align=\"left\">38. (N) Patient treated with warfarin - is co-prescribed metronidazole</td></tr><tr><td/><td align=\"left\">39. (N) Patient treated with warfarin - is co-prescribed chloramphenicol</td></tr><tr><td/><td align=\"left\">40. (N) Patient treated with warfarin- is co-prescribed isoniazid</td></tr><tr><td/><td align=\"left\">41. (N) Patient treated with warfarin - is co-prescribed rifampin</td></tr><tr><td/><td align=\"left\">42. (N) Patient treated with warfarin - is co-prescribed griseofulvin</td></tr><tr><td/><td align=\"left\">43. (N) Patient treated with warfarin - is co-prescribed ribavirin</td></tr><tr><td/><td align=\"left\">44. (I) Patient treated with warfarin - is co-prescribed tetracyclines</td></tr><tr><td align=\"left\"><bold>S12</bold></td><td align=\"left\"><bold>High risk drug without compelling indication- Bleeding (MS2)</bold></td></tr><tr><td/><td align=\"left\">45. (N) Patient with atrial fibrillation - is prescribed warfarin despite CHADS2 score = 0</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">OPIOIDS - CONSTIPATION</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S13</bold></td><td align=\"left\"><bold>High-risk use without laxative - Constipation (MS1)</bold></td></tr><tr><td/><td align=\"left\">46. (N) Patient treated with a strong opioid (morphine &gt; 10 mg or equivalent) for &gt; 4 weeks - is not prescribed a laxative</td></tr><tr><td/><td align=\"left\">47. (I) Patient aged &#8805; 65 treated with a strong opioid (morphine &gt; 10 mg or equivalent) - is not prescribed a laxative</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">BETA BLOCKERS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S14</bold></td><td align=\"left\"><bold>Drug-drug interaction (additive toxicity) - Bradycardia (MS4)</bold></td></tr><tr><td/><td align=\"left\">48. (N) Patient treated with a beta-blocker - is co-prescribed verapamil or diltiazem</td></tr><tr><td align=\"left\"><bold>S15</bold></td><td align=\"left\"><bold>High-risk selection in asthma - Asthma exacerbation (MS3)</bold></td></tr><tr><td/><td align=\"left\">49. (N) Patient with active asthma (prescribed beta agonist inhaler in last year) without COPD - is prescribed any oral BB</td></tr><tr><td/><td align=\"left\">50. (N) Patient with active asthma without COPD - is prescribed a non-cardio-selective oral BB</td></tr><tr><td/><td align=\"left\">51. (I) Patient with active asthma without COPD - is prescribed beta-blocker eye drops</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">ACE INHIBITORS (ACEIs) AND ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S6</bold></td><td align=\"left\"><bold>Monitoring of U&amp;E\\'s - Electrolyte imbalance (MS8)</bold></td></tr><tr><td/><td align=\"left\">52. (N) Patient co-prescribed an ACEI AND ARB - has not had a U&amp;Es check &gt; 24 weeks ago</td></tr><tr><td/><td align=\"left\">Monitoring of U&amp;E\\'s - Electrolyte imbalance (MS8)</td></tr><tr><td/><td align=\"left\">53. (N) Patient prescribed an ACEI or ARB - has not had a U&amp;Es check before treatment start</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">ANTIDIABETICS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S16</bold></td><td align=\"left\"><bold>High-risk selection in renal impairment- Lactic acidosis (MS3)</bold></td></tr><tr><td/><td align=\"left\">54. (N) Patient with chronic kidney disease (CKD) stage 4 or 5 - is prescribed metformin</td></tr><tr><td align=\"left\"><bold>S17</bold></td><td align=\"left\"><bold>High-risk selection in renal impairment - Hypoglycaemia (MS3)</bold></td></tr><tr><td/><td align=\"left\">55. (N) Patient with CKD stage 4 or 5 - is prescribed a sulphonylurea other than gliclazide or tolbutamide</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">DIGOXIN</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S18</bold></td><td align=\"left\"><bold>Excessive dose (Elderly) - General digoxin toxicity (MS5)</bold></td></tr><tr><td/><td align=\"left\">56. (N) Patient aged &#8805; 65 years - is prescribed digoxin &#8805; 250 mcg/day</td></tr><tr><td/><td align=\"left\">57. (N) Patient with CKD stage 3, 4 or 5 (eGFR &lt; 60) - is prescribed digoxin &#8805; 250 mcg/day</td></tr><tr><td align=\"left\"><bold>S18</bold></td><td align=\"left\"><bold>Excessive dose (DDI without dose adjustment) - General digoxin toxicity (MS5)</bold></td></tr><tr><td/><td align=\"left\">58. (N) Patient treated with digoxin and amiodarone - is prescribed digoxin &#8805; 250 mcg/day</td></tr><tr><td/><td align=\"left\">59. (N) Patient treated with digoxin and propafenone - is prescribed digoxin &#8805; 250 mcg/day</td></tr><tr><td/><td align=\"left\">60. (N) Patient treated with digoxin and chloroquine or hydroxychloroquine - is prescribed digoxin &#8805; 250 mcg/day</td></tr><tr><td/><td align=\"left\">61. (N) Patient treated with digoxin and quinine - is prescribed digoxin &#8805; 250 mcg/day</td></tr><tr><td/><td align=\"left\">62. (N) Patient treated with digoxin and a calcium channel blocker * - is prescribed digoxin &#8805; 250 mcg/day</td></tr><tr><td/><td align=\"left\">63. (N) Patient treated with digoxin and ciclosporin - is prescribed digoxin &#8805; 250 mcg/day</td></tr><tr><td/><td align=\"left\"><italic>* lercanidipine, nicardipine, nifedipine, diltiazem, verapamil) </italic></td></tr><tr><td align=\"left\"><bold>S8</bold></td><td align=\"left\"><bold>Monitoring of U&amp;E\\'s - General digoxin toxicity (MS8)</bold></td></tr><tr><td/><td align=\"left\">64. (N) Patient is co-prescribed a potassium wasting diuretic AND digoxin with last U&amp;Es check before treatment start</td></tr><tr><td/><td align=\"left\">65. (N) Patient is co-prescribed a potassium wasting diuretic AND digoxin with last U&amp;Es check &gt; 48 weeks ago</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">CORTICOSTEROIDS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S19</bold></td><td align=\"left\"><bold>High-risk use without bone protecting agent - Bone fracture (MS1)</bold></td></tr><tr><td/><td align=\"left\">66. (N) Patient aged &#8805; 65 years treated with an oral corticosteroid for &#8805; 12 weeks - is not prescribed bone protection *</td></tr><tr><td/><td align=\"left\">67. (N) Patient with low trauma fracture and treated with an oral corticosteroid for &#8805; 12 weeks - is not prescribed bone protection*</td></tr><tr><td/><td align=\"left\"><italic>*a bisphosphonate, calcitriol or hormone replacement therapy</italic></td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\"><bold>B. OTHER HIGH RISK DRUGS</bold></td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">DMARDS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S20</bold></td><td align=\"left\"><bold>High-risk drug without taking action to ensure patient compliance - General toxicity (MS7)</bold></td></tr><tr><td/><td align=\"left\">68. (N) Patient treated with methotrexate - has not been given explicit dose instructions of weekly dosing</td></tr><tr><td/><td align=\"left\">69. (N) Patient treated with methotrexate - is prescribed &gt; 1 strength of methotrexate tablets</td></tr><tr><td align=\"left\"><bold>S21</bold></td><td align=\"left\"><bold>Monitoring of full blood count (FBC) - Blood dyscrasias (MS8)</bold></td></tr><tr><td/><td align=\"left\">70. (N) Patient treated with auranofin - had no FBC check in the last 8 weeks</td></tr><tr><td/><td align=\"left\">71. (N) Patient treated with aurothiomalate - had no FBC check in the last 8 weeks</td></tr><tr><td/><td align=\"left\">72. (N) Patient treated with penicillamine - had no FBC check in the last 8 weeks</td></tr><tr><td/><td align=\"left\">73. (N) Patient treated with leflunomide - had no FBC check in the last 12 weeks</td></tr><tr><td/><td align=\"left\">74. (N) Patient treated with methotrexate - had no FBC check in the last 12 weeks</td></tr><tr><td/><td align=\"left\">75. (N) Patient treated with azathioprine - had no FBC check in the last 12 weeks</td></tr><tr><td/><td align=\"left\">76. (I) Patient treated with cyclophosphamide - had no FBC check in the last 24 weeks</td></tr><tr><td/><td align=\"left\">77. (I) Patient treated with sulfasalazine - had no FBC check in the last 24 weeks</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">FEMALE HORMONES</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S22</bold></td><td align=\"left\"><bold>Selection in patients at high vascular risk - Vascular events (MS3)</bold></td></tr><tr><td/><td align=\"left\">78. (N) Patient with previous vascular disease/events - is prescribed any hormone replacement therapy (HRT)</td></tr><tr><td/><td align=\"left\">79. (N) Patient with an estimated 10 year CVD risk &#8805; 20% - is prescribed combined contraceptives</td></tr><tr><td/><td align=\"left\">80. (I) Patient with an estimated 10 year CVD risk &#8805; 20% and aged 50 to 59 - is prescribed combined HRT</td></tr><tr><td/><td align=\"left\">81. (I) Patient with an estimated 10 year CVD risk &#8805; 20% and aged &#8805; 60 - is prescribed (any) HRT</td></tr><tr><td align=\"left\"><bold>S23</bold></td><td align=\"left\"><bold>Excess duration - Gynaecological cancer (MS6)</bold></td></tr><tr><td/><td align=\"left\">82. (N) Patient aged &#8805; 50 - is prescribed combined HRT for &#8805; 5 years</td></tr><tr><td/><td align=\"left\">83. (N) Patient aged &#8805; 50 without hysterectomy - is prescribed estrogens without cyclical progestogen</td></tr><tr><td/><td align=\"left\">84. (I) Patient aged &#8805; 50 - is prescribed estrogens only HRT for &#8805; 5 years</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">AMIODARONE</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S24</bold></td><td align=\"left\"><bold>Monitoring of thyroid function - Hypo-/Hyperthyroidism (MS8)</bold></td></tr><tr><td/><td align=\"left\">85. (N) Patient prescribed amiodarone - had no thyroid function test in last 9 months</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">THEOPHYLLINE</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S25</bold></td><td align=\"left\"><bold>High-risk drug without compelling indication - General theophylline toxicity (MS2)</bold></td></tr><tr><td/><td align=\"left\">86. (N) Patient aged &#8805; 65 with COPD - is prescribed theophylline without use of a long acting beta2 - agonist or antimuscarinic</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">STATINS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S26</bold></td><td align=\"left\"><bold>Excessive dose (DDI without dose adjustment) - Rhabdomyolysis (MS5)</bold></td></tr><tr><td/><td align=\"left\">87. (N) Patient treated with simvastatin and an HIV protease inhibitor - is prescribed simvastatin &gt; 10 mg/day</td></tr><tr><td/><td align=\"left\">88. (N) Patient treated with simvastatin and ciclosporin - is prescribed simvastatin &gt; 10 mg/day</td></tr><tr><td/><td align=\"left\">89. (N) Patient treated with simvastatin and verapamil - is prescribed simvastatin &gt; 10 mg/day</td></tr><tr><td/><td align=\"left\">90. (N) Patient treated with simvastatin and a fibrate (except fenofibrate) - is prescribed simvastatin &gt; 10 mg/day</td></tr><tr><td/><td align=\"left\">91. (N) Patient treated with simvastatin and amiodarone - is prescribed simvastatin &gt; 20 mg/day</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\"><bold>C. PATIENT GROUPS PARTICULARLY VULNERABLE TO ADVERSE DRUG EVENTS</bold></td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">ELDERLY PATIENTS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S27</bold></td><td align=\"left\"><bold>High-risk drug selection in the elderly - Miscellaneous (MS3)</bold></td></tr><tr><td/><td align=\"left\">92. (N) Patient aged &#8805; 65 with dementia - is prescribed a TCA</td></tr><tr><td/><td align=\"left\">93. (N) Patient aged &#8805; 65 with dementia but no psychosis - is prescribed an antipsychotic</td></tr><tr><td/><td align=\"left\">94. (N) Patient aged &#8805; 65 with dementia and psychosis - is prescribed antipsychotic other than risperidone</td></tr><tr><td/><td align=\"left\">95. (N) Patient aged &#8805; 65 - is prescribed a long acting benzodiazepine</td></tr><tr><td/><td align=\"left\">96. (N) Patient aged &#8805; 65 with Parkinson\\'s disease - is prescribed an antipsychotic other than quetiapine or clozapine</td></tr><tr><td/><td align=\"left\">97. (N) Patient aged &#8805; 65 with Parkinson\\'s disease - is prescribed a phenothiazine antiemetic</td></tr><tr><td/><td align=\"left\">98. (N) Patient aged &#8805; 75 - is prescribed a TCA</td></tr><tr><td/><td align=\"left\">99. (N) Patient aged &#8805; 75 - is prescribed a short acting benzodiazepine</td></tr><tr><td/><td align=\"left\">100. (N) Patient aged &#8805; 75 - is prescribed a Z-drug</td></tr><tr><td/><td align=\"left\">101. (N) Patient aged &#8805; 75 - is prescribed an antihistamine with antimuscarinic properties</td></tr><tr><td/><td align=\"left\">102. (A) Patient aged &#8805; 85 - is prescribed an antispasmodic with antimuscarinic properties</td></tr><tr><td align=\"left\"><bold>S27</bold></td><td align=\"left\"><bold>Excess duration - Miscellaneous (MS6)</bold></td></tr><tr><td/><td align=\"left\">103. (N) Patient aged &#8805; 65 - is prescribed a TCA for &#8805; 4 weeks</td></tr><tr><td/><td align=\"left\">104. (N) Patient aged &#8805; 65 - is prescribed a short acting benzodiazepine for &#8805; 4 weeks</td></tr><tr><td/><td align=\"left\">105. (N) Patient aged &#8805; 65 - is prescribed a Z-drug for &#8805; 4 weeks</td></tr><tr><td/><td align=\"left\">106. (N) Patient aged &#8805; 65 - is prescribed an antispasmodic with antimuscarinic properties for &#8805; 4 weeks</td></tr><tr><td/><td align=\"left\">107. (N) Patient aged &#8805; 65 with dementia and psychosis - is prescribed risperidone for &#8805; 12 weeks</td></tr><tr><td/><td align=\"left\">108. (N) Patient aged 66 to 75 - is prescribed an antihistamine with antimuscarinic properties for &#8805; 4 weeks</td></tr><tr><td/><td align=\"left\">109. (N) Patient aged &#8805; 75 - is prescribed urologicals with antimuscarinic properties for &#8805; 4 weeks</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">PATIENTS WITH HEART FAILURE</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S28</bold></td><td align=\"left\"><bold>Use in heart failure - Heart failure exacerbation (MS3)</bold></td></tr><tr><td/><td align=\"left\">110. (N) Patient with chronic heart failure - is prescribed a class 1 or 3 antiarrhythmics except amiodarone</td></tr><tr><td/><td align=\"left\">111. (N) Patient with chronic heart failure - is prescribed verapamil or diltiazem</td></tr><tr><td/><td align=\"left\">112. (N) Patient with chronic heart failure - is prescribed minoxidil</td></tr><tr><td/><td align=\"left\">113. (N) Patient with chronic heart failure - is prescribed any oral NSAID</td></tr><tr><td/><td align=\"left\">114. (N) Patient with chronic heart failure - is prescribed a glitazone</td></tr><tr><td/><td align=\"left\">115. (N) Patient with chronic heart failure - is prescribed a tricyclic antidepressant</td></tr><tr><td/><td align=\"left\">116. (N) Patient with chronic heart failure - is prescribed itraconazole</td></tr><tr><td/><td align=\"left\">117. (N) Patient with chronic heart failure - is prescribed other antifungals (e.g. ketoconazole, fluconazole)</td></tr><tr><td/><td align=\"left\">118. (N) Patient with chronic heart failure - is prescribed tadalafil</td></tr><tr><td/><td align=\"left\">119. (N) Patient with chronic heart failure - is prescribed disulfiram</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\" colspan=\"2\">CHILDREN AND YOUNG ADULTS</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>S29</bold></td><td align=\"left\"><bold>Use in children - Miscellaneous (MS3)</bold></td></tr><tr><td/><td align=\"left\">120. (N) Patient aged &#8804; 20 - is prescribed a phenothiazine anti-emetic</td></tr><tr><td/><td align=\"left\">121. (N) Patient aged &#8804; 16 who has no record of Kawasaki disease - is prescribed aspirin</td></tr><tr><td/><td align=\"left\">122. (N) Patient aged &#8804; 12 - is prescribed a tetracycline</td></tr><tr><td/><td align=\"left\">123. (N) Patient aged &#8804; 18 - is prescribed an antidepressant other than fluoxetine</td></tr><tr><td/><td align=\"left\">124. (I) Patient aged &#8804; 18 - is prescribed fluoxetine</td></tr></tbody></table></body></html>", "text": "Pmid= 3296596:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Delphi study: Demographics of the 26 panellists, who completed both rounds of ratings</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"left\" colspan=\"2\">Pharmacists<break/>n = 9 (35%)</th><th align=\"left\" colspan=\"2\">General practitioners<break/>n = 17 (65%)</th><th align=\"left\">Total</th></tr><tr><th/><th colspan=\"5\"><hr/></th></tr><tr><th/><th align=\"left\"><italic>Currently</italic></th><th align=\"left\"><italic>Previously</italic></th><th align=\"left\"><italic>Currently</italic></th><th align=\"left\"><italic>Previously</italic></th><th/></tr></thead><tbody><tr><td align=\"left\">Works in primary care</td><td align=\"left\">7</td><td align=\"left\">2</td><td align=\"left\">17</td><td align=\"left\">-</td><td align=\"left\">26 (100%)</td></tr><tr><td align=\"left\">Has a prescribing role</td><td align=\"left\">2</td><td align=\"left\">1</td><td align=\"left\">17</td><td align=\"left\">-</td><td align=\"left\">20 (77%)</td></tr><tr><td align=\"left\">Has a strategic role</td><td align=\"left\">2</td><td align=\"left\">-</td><td align=\"left\">1</td><td align=\"left\">1</td><td align=\"left\">4 (15%)</td></tr><tr><td align=\"left\">Mean age in years (SD)</td><td align=\"left\">47 (9)</td><td/><td align=\"left\">47 (9)</td><td/><td align=\"left\">47 (9)</td></tr><tr><td align=\"left\">Mean years since training completed (SD)</td><td align=\"left\">22 (11)</td><td/><td align=\"left\">22 (9)</td><td/><td align=\"left\">23 (10)</td></tr><tr><td align=\"left\">Mean years of experience of working in primary care (SD)</td><td align=\"left\">11 (11)</td><td/><td align=\"left\">19 (8)</td><td/><td align=\"left\">15 (8)</td></tr></tbody></table></body></html>", "text": "Pmid= 3296596:Table= Table 6"}
{"html": "<!DOCTYPE html><html><body><h1>Delphi study priority ratings by the 26 panellists</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" colspan=\"2\">Topic</th><th align=\"left\"><italic>Median</italic></th><th align=\"left\"><italic>Mean</italic></th><th align=\"left\"><italic>Priority </italic></th></tr></thead><tbody><tr><td/><td align=\"left\"><bold>Accepted as priorities</bold></td><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\"><bold><italic>Quality</italic></bold></td><td/><td/><td/></tr><tr><td align=\"left\">Q 16</td><td align=\"left\">Not using inhaled corticosteroids in patients with uncontrolled asthma</td><td align=\"left\">8</td><td align=\"left\">8.0</td><td align=\"left\">++</td></tr><tr><td align=\"left\">Q 15</td><td align=\"left\">Not using oral anticoagulants in patients with AF and high risk of stroke</td><td align=\"left\">8</td><td align=\"left\">7.9</td><td align=\"left\">++</td></tr><tr><td align=\"left\">Q 11</td><td align=\"left\">Not using ACEIs or ARBs in patients with a history of chronic heart failure</td><td align=\"left\">8</td><td align=\"left\">7.9</td><td align=\"left\">++</td></tr><tr><td align=\"left\">Q 14</td><td align=\"left\">Not using thrombo-embolic prophylaxis in AF patients at low/moderate risk of stroke</td><td align=\"left\">8</td><td align=\"left\">7.7</td><td align=\"left\">++</td></tr><tr><td align=\"left\">Q 5</td><td align=\"left\">Not using ACEIs or ARBs in patients with DM and renal complications</td><td align=\"left\">8</td><td align=\"left\">7.7</td><td align=\"left\">++</td></tr><tr><td align=\"left\">Q 12</td><td align=\"left\">Not using beta blockers in patients with a history of chronic heart failure</td><td align=\"left\">8</td><td align=\"left\">7.7</td><td align=\"left\">++</td></tr><tr><td align=\"left\">Q 4</td><td align=\"left\">Not using metformin as first line antidiabetic in overweight type 2 diabetics</td><td align=\"left\">8</td><td align=\"left\">7.6</td><td align=\"left\">++</td></tr><tr><td align=\"left\">Q 8</td><td align=\"left\">Not using antiplatelets in patients at risk of vascular events</td><td align=\"left\">7</td><td align=\"left\">7.5</td><td align=\"left\">+</td></tr><tr><td align=\"left\">Q 6</td><td align=\"left\">Not using statins in patients at high risk of cardiovascular events</td><td align=\"left\">7</td><td align=\"left\">7.4</td><td align=\"left\">+</td></tr><tr><td align=\"left\">Q 17</td><td align=\"left\">Not using bone sparing agents in female patients at high risk of fractures</td><td align=\"left\">7</td><td align=\"left\">7.3</td><td align=\"left\">+</td></tr><tr><td align=\"left\">Q 3</td><td align=\"left\">Low intensity antidiabetic treatment despite suboptimal HbA1c control</td><td align=\"left\">7</td><td align=\"left\">7.2</td><td align=\"left\">+</td></tr><tr><td align=\"left\">Q 10</td><td align=\"left\">Not using ACEIs or ARBs in patients with a history of ACS</td><td align=\"left\">7</td><td align=\"left\">7.0</td><td align=\"left\">+</td></tr><tr><td align=\"left\">Q 2</td><td align=\"left\">Low intensity antihypertensive treatment despite suboptimal BP control</td><td align=\"left\">7</td><td align=\"left\">6.9</td><td align=\"left\">+</td></tr><tr><td align=\"left\">Q 9</td><td align=\"left\">Not using beta blockers in coronary heart disease</td><td align=\"left\">7</td><td align=\"left\">6.8</td><td align=\"left\">+</td></tr><tr><td align=\"left\">Q 7</td><td align=\"left\">Underdosing of statins in patients at high risk of cardiovascular events</td><td align=\"left\">7</td><td align=\"left\">6.7</td><td align=\"left\">+</td></tr><tr><td/><td align=\"left\"><bold><italic>Safety</italic></bold></td><td/><td/><td/></tr><tr><td align=\"left\">S 20</td><td align=\"left\">Using MTX without taking precautionary action to prevent patient overdosing</td><td align=\"left\">9</td><td align=\"left\">8.4</td><td align=\"left\">++</td></tr><tr><td align=\"left\">S 1</td><td align=\"left\">Not using gastro-protection in oral NSAIDs/antiplatelets users at high risk of bleeding</td><td align=\"left\">8</td><td align=\"left\">8.2</td><td align=\"left\">++</td></tr><tr><td align=\"left\">S 3</td><td align=\"left\">Using oral NSAIDs in patients at increased risk of renal failure</td><td align=\"left\">8</td><td align=\"left\">7.9</td><td align=\"left\">++</td></tr><tr><td align=\"left\">S 21</td><td align=\"left\">Inconsistent monitoring of FBC in patients on DMARDs</td><td align=\"left\">8</td><td align=\"left\">7.8</td><td align=\"left\">++</td></tr><tr><td align=\"left\">S 27</td><td align=\"left\">Using sedatives, antipsychotics, anticholinergics in elderly patients</td><td align=\"left\">7</td><td align=\"left\">7.3</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 19</td><td align=\"left\">Using bone protection in users of long term oral corticosteroids</td><td align=\"left\">7</td><td align=\"left\">7.3</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 23</td><td align=\"left\">Excess duration of female hormones in patients at risk of gynaecological cancer</td><td align=\"left\">7</td><td align=\"left\">7.3</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 10</td><td align=\"left\">Excess duration of potassium supplements <italic>and </italic>potassium sparing diuretics</td><td align=\"left\">7</td><td align=\"left\">7.2</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 28</td><td align=\"left\">Using drugs to avoid in patients with heart failure</td><td align=\"left\">7</td><td align=\"left\">7.1</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 18</td><td align=\"left\">Excessive dosing of digoxin in patients susceptible to digoxin toxicity</td><td align=\"left\">7</td><td align=\"left\">7.1</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 24</td><td align=\"left\">Inconsistent monitoring of thyroid function in patients prescribed amiodarone</td><td align=\"left\">7</td><td align=\"left\">7.0</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 6</td><td align=\"left\">Inconsistent monitoring of U&amp;Es in patients at risk of electrolyte imbalance</td><td align=\"left\">7</td><td align=\"left\">7.0</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 14</td><td align=\"left\">Co-prescribing beta blockers and rate-limiting calcium channel blockers</td><td align=\"left\">7</td><td align=\"left\">6.9</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 25</td><td align=\"left\">Using theophylline in elderly COPD patients without a compelling indication</td><td align=\"left\">7</td><td align=\"left\">6.9</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 15</td><td align=\"left\">Using beta blockers in patients with active asthma</td><td align=\"left\">7</td><td align=\"left\">6.8</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 13</td><td align=\"left\">Not using of laxatives in strong opioid users</td><td align=\"left\">7</td><td align=\"left\">6.8</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 29</td><td align=\"left\">Using drugs to avoid in children and young adults</td><td align=\"left\">7</td><td align=\"left\">6.7</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 5</td><td align=\"left\">Using COX II inhibitors in patients at high risk of cardiovascular events</td><td align=\"left\">7</td><td align=\"left\">6.6</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 7</td><td align=\"left\">Using thiazide diuretics in patients with a history of CKD</td><td align=\"left\">7</td><td align=\"left\">6.6</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 17</td><td align=\"left\">Using long acting sulphonylureas in patients at risk of hypoglycaemia</td><td align=\"left\">7</td><td align=\"left\">6.6</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 4</td><td align=\"left\">Using COX II inhibitors without compelling indication (low dose aspirin users)</td><td align=\"left\">7</td><td align=\"left\">6.4</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 16</td><td align=\"left\">Using metformin in patients with CKD</td><td align=\"left\">7</td><td align=\"left\">6.4</td><td align=\"left\">+</td></tr><tr><td align=\"left\">S 26</td><td align=\"left\">Excessive dosing of statins in patients on interacting drugs</td><td align=\"left\">7</td><td align=\"left\">6.3</td><td align=\"left\">+</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\"><bold>Not scored as priorities for medication improvement</bold></td><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td/><td align=\"left\"><bold><italic>Quality</italic></bold></td><td/><td/><td/></tr><tr><td align=\"left\">Q 13</td><td align=\"left\">Inadequate dose titration of ACEI, ARBs and BBs in chronic heart failure</td><td align=\"left\">6</td><td align=\"left\">6.2</td><td/></tr><tr><td align=\"left\">Q 1</td><td align=\"left\">Not using first line antihypertensives when initiating treatment for high blood pressure</td><td align=\"left\">6</td><td align=\"left\">6.4</td><td/></tr><tr><td align=\"left\">Q 18</td><td align=\"left\">Not using calcium/vitamin D supplementation in female elderly patients</td><td align=\"left\">6</td><td align=\"left\">6.4</td><td/></tr><tr><td/><td align=\"left\"><bold><italic>Safety</italic></bold></td><td/><td/><td/></tr><tr><td align=\"left\">S 2</td><td align=\"left\">Using oral NSAIDs in the elderly without compelling indication (no previous trial of full dose paracetamol)</td><td align=\"left\">6</td><td align=\"left\">6.6</td><td/></tr><tr><td align=\"left\">S 9</td><td align=\"left\">Using of aldosterone antagonists in patients with a history of CKD</td><td align=\"left\">6</td><td align=\"left\">6.5</td><td/></tr><tr><td align=\"left\">S 11</td><td align=\"left\">Co-prescribing anti-infectives with high risk of affecting INR in patients on warfarin</td><td align=\"left\">6</td><td align=\"left\">6.4</td><td/></tr><tr><td align=\"left\">S 12</td><td align=\"left\">Using warfarin without a compelling indication in AF with low risk of stroke</td><td align=\"left\">6</td><td align=\"left\">6.3</td><td/></tr><tr><td align=\"left\">S 22</td><td align=\"left\">Using HRT in female patients at high risk of cardiovascular events</td><td align=\"left\">6</td><td align=\"left\">6.2</td><td/></tr><tr><td align=\"left\">S 8</td><td align=\"left\">Not using allopurinol in thiazide users with a history of gout</td><td align=\"left\">6</td><td align=\"left\">5.8</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3296596:Table= Table 7"}
{"html": "<!DOCTYPE html><html><body><h1>Baseline Characteristics of Study Population</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Variable</th><th align=\"left\">% (n)</th></tr></thead><tbody><tr><td align=\"left\"><bold>Sex</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Female</td><td align=\"left\">64.38 (1,706)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Male</td><td align=\"left\">35.62 (944)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Age (years)</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&lt; 15</td><td align=\"left\">6.26 (144)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">16-45</td><td align=\"left\">80.0 (2120)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&gt; 45</td><td align=\"left\">13.74 (364)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Baseline CD4</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&lt; = 200</td><td align=\"left\">58.72 (1556)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">200 - 350</td><td align=\"left\">26.68 (707)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&gt; 350</td><td align=\"left\">14.60 (387)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Median baseline CD4 (IQR)</td><td align=\"left\">172 (85-275)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>Baseline WHO Staging*</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Stage I</td><td align=\"left\">27.36 (725)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Stage II</td><td align=\"left\">26.60 (705)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Stage III</td><td align=\"left\">40.23 (1066)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Stage IV</td><td align=\"left\">4.08 (108)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>ART Regimen</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>NRTI Backbone</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Zidovudine based</td><td align=\"left\">51.85 (1374)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Stavudine based</td><td align=\"left\">46.15 (1223)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Tenofovir based</td><td align=\"left\">1.74 (46)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Others</td><td align=\"left\">0.26 (7)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>NNRTI Backbone</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Nevirapine_based</td><td align=\"left\">80.04 (2121)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Efavirenze_based</td><td align=\"left\">19.96 (529)</td></tr></tbody></table></body></html>", "text": "Pmid= 3317861:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Onset and Distribution of ADR</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" colspan=\"2\">Onset of Adverse Drug Reaction From ART Initiation* (n = 102)</th></tr></thead><tbody><tr><td align=\"left\"><bold>Onset of ADR</bold></td><td align=\"left\"><bold>n (%)</bold></td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">0-3 months</td><td align=\"left\">8 (7.84)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">3-6 months</td><td align=\"left\">14 (13.73)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">6-12 months</td><td align=\"left\">22 (21.57)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">12-24 months</td><td align=\"left\">46 (45.10)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">24-36 months</td><td align=\"left\">10 (9.80)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&gt; 36 months</td><td align=\"left\">2 (1.96)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>ADR distribution by age (n = 114)</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&lt; 15 years</td><td align=\"left\">0</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">16-45 years</td><td align=\"left\">97 (85.09)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">&gt; 45 years</td><td align=\"left\">17 (14.91)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\"><bold>ADR distribution by gender (n = 114)</bold></td><td/></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Male</td><td align=\"left\">41 (35.96)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Female</td><td align=\"left\">73 (64.04)</td></tr></tbody></table></body></html>", "text": "Pmid= 3317861:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Incidence Rates of ADR by Regimen per 100 person-years of Treatment</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Specific ADR by Organ System</th><th align=\"center\">AZT_based (n)</th><th align=\"center\">d4T_based (n)</th><th align=\"center\">TDF_based (n)</th><th align=\"center\">Total (%)</th></tr></thead><tbody><tr><td align=\"left\"><bold>Gastrointestinal</bold></td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Abdominal pain</td><td align=\"center\">-</td><td align=\"center\">0.09 (1)</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Diarrhea</td><td align=\"center\">0.32 (4)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">4 (4.82)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Dyspepsia</td><td align=\"center\">0.08 (1)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Nausea &amp; Vomiting</td><td align=\"center\">0.24 (3)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">3 (3.61)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Cardiovascular/Respiratory System</bold></td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Chest pain</td><td align=\"center\">-</td><td align=\"center\">0.09 (1)</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Cough</td><td align=\"center\">-</td><td align=\"center\">0.09 (1)</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Skin and Appendages</bold></td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Pruritus</td><td align=\"center\">0.24 (3)</td><td align=\"center\">0.61 (7)</td><td align=\"center\">-</td><td align=\"center\">10 (12.05)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Steven Johnson syndrome</td><td align=\"center\">0.08 (1)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Skin rash</td><td align=\"center\">0.64 (8)</td><td align=\"center\">0.52 (6)</td><td align=\"center\">2.56 (1)</td><td align=\"center\">15 (18.07)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Central and Peripheral Nervous System</bold></td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Headache</td><td align=\"center\">0.08 (1)</td><td align=\"center\">0.09 (1)</td><td align=\"center\">-</td><td align=\"center\">2 (2.41)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Dizziness</td><td align=\"center\">0.08 (1)</td><td align=\"center\">0.44 (5)</td><td align=\"center\">-</td><td align=\"center\">6 (7.23)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Insomnia</td><td align=\"center\">0.16 (2)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">2 (2.41)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Nightmare</td><td align=\"center\">0.08 (1)</td><td align=\"center\">0.09 (1)</td><td align=\"center\">-</td><td align=\"center\">2 (2.41)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Pain/Tingling/Numbness</td><td align=\"center\">0.08 (1)</td><td align=\"center\">2.09 (24)</td><td align=\"center\">-</td><td align=\"center\">25 (30.12)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Musculoskeletal System</bold></td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Myalgia</td><td align=\"center\">0.08 (1)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Systemic Signs/Symptoms</bold></td><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Rigor</td><td align=\"center\">0.08 (1)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Fatigue</td><td align=\"center\">0.08 (1)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Fever</td><td align=\"center\">0.08 (1)</td><td align=\"center\">-</td><td align=\"center\">-</td><td align=\"center\">1 (1.20)</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td align=\"center\"><bold>34</bold></td><td align=\"center\"><bold>48</bold></td><td align=\"center\"><bold>1</bold></td><td align=\"center\"><bold>83</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 3317861:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Generalized Estimating Equation Analysis for Risk Factors Associated with ADR</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Variables</th><th align=\"left\">N (%)</th><th align=\"center\">Unadjusted OR</th><th align=\"center\"><italic>p</italic></th><th align=\"center\">Adjusted OR</th><th align=\"center\"><italic>p</italic></th></tr></thead><tbody><tr><td align=\"left\"><bold>Gender</bold></td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">&#8195;Female</td><td align=\"left\">1706 (64.4)</td><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">&#8195;Male</td><td align=\"left\">944 (35.6)</td><td align=\"center\">1.11(0.71-1.73)</td><td align=\"center\">0.663</td><td align=\"center\">0.83 (0.43-1.57)</td><td align=\"center\">0.562</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>Age (years)</bold></td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">&#8195;15-45</td><td align=\"left\">2120 (85.3)</td><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">&#8195;&gt; 45</td><td align=\"left\">364 (14.7)</td><td align=\"center\">0.81(0.48-1.36)</td><td align=\"center\">0.422</td><td align=\"center\">1.27 (0.59-2.77)</td><td align=\"center\">0.544</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>Regimen</bold></td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">TDF_based</td><td align=\"left\">46 (1.7)</td><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">AZT_based</td><td align=\"left\">1374 (52.0)</td><td align=\"center\">0.56 (0.18-1.75)</td><td align=\"center\">0.319</td><td align=\"center\">0.24 (0.07-0.90)</td><td align=\"center\">0.034</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">D4T_based</td><td align=\"left\">1223 (46.3)</td><td align=\"center\">0.33 (0.10-1.03)</td><td align=\"center\">0.057</td><td align=\"center\">0.18 (0.05-0.64)</td><td align=\"center\">0.009</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>Duration on treatment (months)</bold></td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">0-6</td><td align=\"left\">21 (0.79)</td><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">6-12</td><td align=\"left\">79 (2.98)</td><td align=\"center\">0.54 (0.33-0.89)</td><td align=\"center\">0.02</td><td align=\"center\">0.38 (0.16-0.91)</td><td align=\"center\">0.03</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">12-24</td><td align=\"left\">259 (47.5)</td><td align=\"center\">0.25 (0.15-0.41)</td><td align=\"center\">&lt; 0.001</td><td align=\"center\">0.35 (0.16-0.73)</td><td align=\"center\">0.005</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">24-36</td><td align=\"left\">952 (35.9)</td><td align=\"center\">0.16 (0.08-0.34)</td><td align=\"center\">&lt; 0.001</td><td align=\"center\">0.37 (0.14-0.96)</td><td align=\"center\">0.042</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\"><bold>CD4 cell count cells/&#956;L</bold></td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">&lt; 350</td><td align=\"left\">950 (44.8)</td><td/><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"left\">&gt; 350</td><td align=\"left\">1180 (55.2)</td><td align=\"center\">1.08 (0.6-2.0)</td><td align=\"center\">0.791</td><td align=\"center\">0.93 (0.51-1.70)</td><td align=\"center\">0.816</td></tr></tbody></table></body></html>", "text": "Pmid= 3317861:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Probability for hepatotoxicity and death, when antidotes are administered within 0-10 and 10-24 hours from the acute ingestion</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\">Probability for<break/>AST/ALT &gt; 1000 IU/l (n/N)<break/>[<xref ref-type=\"bibr\" rid=\"B6\">6</xref>,<xref ref-type=\"bibr\" rid=\"B7\">7</xref>]</th><th align=\"center\">Probability for death (n/N)</th><th align=\"center\">Note</th></tr></thead><tbody><tr><td align=\"left\" colspan=\"4\"><bold>IV NAC 300 mg/kg over 20.25 hours</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Within 10 hours</td><td align=\"center\">4% (13/315)</td><td align=\"center\">0<sup>&#8224;</sup>(0/13)</td><td align=\"center\">*</td></tr><tr><td/><td align=\"center\">(95% CI 2.5 to 7.0)</td><td align=\"center\">(95% CI 0 to 24)</td><td/></tr><tr><td align=\"left\">Within 10-24 hours</td><td align=\"center\">20% (67/322)</td><td align=\"center\">9%<sup>&#8225; </sup>(6/67)</td><td align=\"center\">*</td></tr><tr><td/><td align=\"center\">(95% CI 17 to 26)</td><td align=\"center\">(95% CI 3.8 to 18)</td><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\" colspan=\"4\"><bold>Methionine 1 g 4 hourly 4 doses</bold></td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Within 10 hours</td><td align=\"center\">9% (13/143)</td><td align=\"center\">0<sup>&#8224;</sup></td><td align=\"center\">#</td></tr><tr><td/><td align=\"center\">(95% CI 4.5 to 15)</td><td align=\"center\">(95% CI 0 to 24)</td><td/></tr><tr><td align=\"left\">Within 10-24 hours</td><td align=\"center\">38%(17/41)</td><td align=\"center\">12%<sup>&#928;</sup>(2/17)</td><td align=\"center\">#</td></tr><tr><td/><td align=\"center\">(95% CI 26.3 to 57.9)</td><td align=\"center\">(95% CI 2 to 36)</td><td/></tr></tbody></table></body></html>", "text": "Pmid= 3350452:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Incremental cost per life saved for baseline data and following one way sensitivity analysis (Number of lives saved as the final outcome measure)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th align=\"center\" colspan=\"2\">Incremental cost per life saved(LKR/Life saved)</th></tr><tr><th/><th colspan=\"2\"><hr/></th></tr><tr><th/><th align=\"center\">0-10 hrs</th><th align=\"center\">10-24 hrs</th></tr></thead><tbody><tr><td align=\"left\"><bold>Baseline results</bold></td><td align=\"center\">Not applicable<sup>&#8225;</sup></td><td align=\"center\">316,182</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><bold>One way sensitivity analysis results</bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><bold><italic>Increasing by 50%</italic></bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">NAC deaths</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">469,173</td></tr><tr><td align=\"left\">NAC cost</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">565,805</td></tr><tr><td align=\"left\">Methionine deaths</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">173,147</td></tr><tr><td align=\"left\">Methionine cost</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">265,107</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><bold><italic>Decreasing by 50%</italic></bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">NAC deaths</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">238,432</td></tr><tr><td align=\"left\">NAC cost</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">55,312</td></tr><tr><td align=\"left\">Methionine deaths</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">1,818,046</td></tr><tr><td align=\"left\">Methionine cost</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">366,486</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><bold><italic>Upper confidence interval(CI)</italic></bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">NAC deaths</td><td align=\"center\"><underline>Dominance for methionine </underline><sup>&#8224; </sup></td><td align=\"center\">909,023</td></tr><tr><td align=\"left\">NAC hepatotoxicity</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">445,229</td></tr><tr><td align=\"left\">Methionine deaths</td><td align=\"center\">5,365,130</td><td align=\"center\">73,456</td></tr><tr><td align=\"left\">Methionine hepatotoxicity</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">94,349</td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\" colspan=\"3\"><bold><italic>Lower confidence interval(CI)</italic></bold></td></tr><tr><td colspan=\"3\"><hr/></td></tr><tr><td align=\"left\">NAC deaths</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\">229,648</td></tr><tr><td align=\"left\">NAC hepatotoxicity</td><td align=\"center\">Not applicable<sup>&#8225;</sup></td><td align=\"center\">268,907</td></tr><tr><td align=\"left\">Methionine deaths</td><td align=\"center\">Not applicable<sup>&#8225; </sup></td><td align=\"center\"><underline>Dominance for methionine </underline><sup>&#8224; </sup></td></tr><tr><td align=\"left\">Methionine hepatotoxicity</td><td align=\"center\">Not applicable</td><td align=\"center\">836,480</td></tr></tbody></table></body></html>", "text": "Pmid= 3350452:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Characteristics of the study participants (n = 670)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Age, mean, in years (SD)</th><th align=\"left\">81 (10)</th></tr></thead><tbody><tr><td align=\"left\">Sex, % female</td><td align=\"left\">53%</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Number of drugs at admission, median (IQR)</td><td/></tr><tr><td align=\"left\">Regular use</td><td align=\"left\">7 (5-11)</td></tr><tr><td align=\"left\">As needed</td><td align=\"left\">1 (0-2)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Patients using a multi-dose system (ApoDos<sup>&#174;</sup>), % of patients</td><td align=\"left\">21%</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Length of stay in the ward, median days (IQR)</td><td align=\"left\">8 (4-12)</td></tr><tr><td colspan=\"2\"><hr/></td></tr><tr><td align=\"left\">Number of drugs at discharge, median (IQR)</td><td/></tr><tr><td align=\"left\">Regular use</td><td align=\"left\">8 (5-11)</td></tr><tr><td align=\"left\">As needed</td><td align=\"left\">1 (1-3)</td></tr></tbody></table></body></html>", "text": "Pmid= 3353244:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Number of medication errors by type, and most frequent ATC codes for each type of error.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Type of error</th><th align=\"center\">Medication errors; numbers (%)</th><th align=\"center\" colspan=\"6\">The three most frequent ATC codes by type of error; number of errors</th></tr></thead><tbody><tr><td/><td/><td align=\"left\"><bold>B03</bold></td><td align=\"left\"><bold>C07</bold></td><td align=\"left\"><bold>N02</bold></td><td align=\"left\"><bold>N05</bold></td><td align=\"left\"><bold>N06</bold></td><td align=\"left\"><bold>R03</bold></td></tr><tr><td/><td/><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Omission of drug</td><td align=\"center\">417 (62)</td><td/><td/><td align=\"left\">37</td><td align=\"left\">37</td><td/><td align=\"left\">47</td></tr><tr><td align=\"center\">Dose too high</td><td align=\"center\">86 (13)</td><td align=\"left\">8</td><td/><td align=\"left\">9</td><td align=\"left\">11</td><td/><td/></tr><tr><td align=\"center\">Dose too low</td><td align=\"center\">82 (12)</td><td/><td/><td align=\"left\">11</td><td align=\"left\">12</td><td align=\"left\">7</td><td/></tr><tr><td align=\"center\">Additional drug</td><td align=\"center\">79 (12)</td><td/><td/><td align=\"left\">7</td><td align=\"left\">8</td><td/><td align=\"left\">8</td></tr><tr><td align=\"center\">Wrong dosage form</td><td align=\"center\">8 (1)</td><td/><td align=\"left\">3</td><td align=\"left\">3</td><td/><td/><td align=\"left\">2</td></tr><tr><td align=\"center\"><bold>Total</bold></td><td align=\"center\"><bold>672 (100)</bold></td><td/><td/><td align=\"left\"><bold>67</bold></td><td align=\"left\"><bold>68</bold></td><td/><td align=\"left\"><bold>57</bold></td></tr></tbody></table></body></html>", "text": "Pmid= 3353244:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Predictors of errors in the medication history at admission to hospital.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Potential predictors</th><th/><th align=\"left\">Number of patients with an error (%)</th><th align=\"center\">Odds ratio (95% CI)</th></tr></thead><tbody><tr><td align=\"left\">Number of drugs at admission</td><td align=\"left\">For each 1-drug increase</td><td align=\"left\">313 (47)</td><td align=\"left\">1.10 (1.06-1.14)*</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Age</td><td align=\"left\">For each 10-yr increase</td><td align=\"left\">313 (47)</td><td align=\"left\">1.08 (0.92-1.27)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Ward</td><td align=\"left\">A</td><td align=\"left\">250 (48)</td><td align=\"left\">Reference</td></tr><tr><td/><td colspan=\"3\"><hr/></td></tr><tr><td/><td align=\"left\">B</td><td align=\"left\">63 (43)</td><td align=\"left\">0.82 (0.56-1.21)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Sex</td><td align=\"left\">Male</td><td align=\"left\">135 (43)</td><td align=\"left\">Reference</td></tr><tr><td/><td colspan=\"3\"><hr/></td></tr><tr><td/><td align=\"left\">Female</td><td align=\"left\">178 (50)</td><td align=\"left\">1.33 (0.96-1.83)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Type of care service before admission</td><td align=\"left\">Care home</td><td align=\"left\">63 (47)</td><td align=\"left\">Reference</td></tr><tr><td/><td colspan=\"3\"><hr/></td></tr><tr><td/><td align=\"left\">Own home with community care services</td><td align=\"left\">74 (45)</td><td align=\"left\">1.08 (0.67-1.75)</td></tr><tr><td/><td colspan=\"3\"><hr/></td></tr><tr><td/><td align=\"left\">Own home, no care service</td><td align=\"left\">176 (48)</td><td align=\"left\">1.58 (1.02-2.45)*</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Directly admitted to study ward <bold><sup>a</sup></bold></td><td align=\"left\">Yes</td><td align=\"left\">155 (47)</td><td align=\"left\">Reference</td></tr><tr><td/><td colspan=\"3\"><hr/></td></tr><tr><td/><td align=\"left\">No; transferred from another ward</td><td align=\"left\">131 (49)</td><td align=\"left\">1.12 (0.80-1.57)</td></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\"><bold>Days until medication reconciliation</bold></td><td/><td/><td/></tr><tr><td colspan=\"4\"><hr/></td></tr><tr><td align=\"left\">Number of days until the pharmacist\\'s medication reconciliation <bold><sup>a</sup></bold></td><td align=\"left\">0-1 days</td><td align=\"left\">168 (51)</td><td align=\"left\">Reference</td></tr><tr><td/><td colspan=\"3\"><hr/></td></tr><tr><td/><td align=\"left\">2-3 days</td><td align=\"left\">101 (49)</td><td align=\"left\">0.85 (0.59-1.23)</td></tr><tr><td/><td colspan=\"3\"><hr/></td></tr><tr><td/><td align=\"left\">4-11 days</td><td align=\"left\">24 (38)</td><td align=\"left\">0.52 (0.30-0.91)*</td></tr></tbody></table></body></html>", "text": "Pmid= 3353244:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Ethinyl Estradiol Single- and Multiple-dose Pharmacokinetics: Comparison of Mean Pharmacokinetic Parameters Across Treatments</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\" colspan=\"2\">Single Dose</th><th align=\"center\" colspan=\"2\">Multiple Dose</th></tr></thead><tbody><tr><td/><td/><td align=\"center\"><bold>LS Geometric Mean</bold></td><td align=\"center\"><bold>Comparison to OC alone: Ratio (90% CI)</bold></td><td align=\"center\"><bold>LS Geometric Mean</bold></td><td align=\"center\"><bold>Comparison to OC alone: Ratio (90% CI)</bold></td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>AUC (pg&#183;h/mL)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">718.89</td><td align=\"center\">-</td><td align=\"center\">761.06</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">691.69</td><td align=\"center\">0.96 (0.91, 1.02)</td><td align=\"center\">716.70</td><td align=\"center\">0.94 (0.88, 1.01)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">692.56</td><td align=\"center\">0.96 (0.91, 1.02)</td><td align=\"center\">734.01</td><td align=\"center\">0.96 (0.90, 1.04)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>C<sub>max </sub>(pg/mL)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">72.18</td><td align=\"center\">-</td><td align=\"center\">102.15</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">65.49</td><td align=\"center\">0.91 (0.83, 0.99)</td><td align=\"center\">87.09</td><td align=\"center\">0.85 (0.78, 0.93)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">38.64</td><td align=\"center\">0.54 (0.49, 0.58)</td><td align=\"center\">56.32</td><td align=\"center\">0.55 (0.50, 0.60)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>24-h concentration (pg/mL)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">8.27</td><td align=\"center\">-</td><td align=\"center\">14.64</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">8.13</td><td align=\"center\">0.98 (0.92, 1.05)</td><td align=\"center\">15.03</td><td align=\"center\">1.03 (0.95, 1.11)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">10.25</td><td align=\"center\">1.24 (1.16, 1.33)</td><td align=\"center\">17.52</td><td align=\"center\">1.20 (1.10, 1.30)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>T<sub>max </sub>median (range) (h)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">-</td><td align=\"center\">1.50 (0.50-2.50)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">-</td><td align=\"center\">1.50 (0.50-2.00)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">-</td><td align=\"center\">6.00 (2.00-6.13)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>t<sub>1/2 </sub>geometric mean (range) (h)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">-</td><td align=\"center\">19.5 (13.8-32.1)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">-</td><td align=\"center\">18.9 (14.0-30.1)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">-</td><td align=\"center\">17.4 (8.78-31.9)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr></tbody></table></body></html>", "text": "Pmid= 3378442:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Levonorgestrel Single- and Multiple-dose Pharmacokinetics: Comparison of Mean Pharmacokinetic Parameters Across Treatments</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th/><th/><th align=\"center\" colspan=\"2\">Single Dose</th><th align=\"center\" colspan=\"2\">Multiple Dose</th></tr></thead><tbody><tr><td/><td/><td align=\"center\"><bold>LS Geometric Mean</bold></td><td align=\"center\"><bold>Comparison to OC alone: Ratio (90% CI)</bold></td><td align=\"center\"><bold>LS Geometric Mean</bold></td><td align=\"center\"><bold>Comparison to OC alone: Ratio (90% CI)</bold></td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>AUC (pg&#183;h/mL)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">55698.79</td><td align=\"center\">-</td><td align=\"center\">72974.62</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">53530.64</td><td align=\"center\">0.96 (0.90, 1.03)</td><td align=\"center\">72952.67</td><td align=\"center\">1.00 (0.92, 1.09)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">60591.89</td><td align=\"center\">1.09 (1.01, 1.17)</td><td align=\"center\">76344.29</td><td align=\"center\">1.05 (0.96, 1.14)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>C<sub>max </sub>(pg/mL)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">3882.56</td><td align=\"center\">-</td><td align=\"center\">6598.95</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">4061.86</td><td align=\"center\">1.05 (0.94, 1.16)</td><td align=\"center\">6657.22</td><td align=\"center\">1.01 (0.92, 1.10)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">2284.25</td><td align=\"center\">0.59 (0.53, 0.65)</td><td align=\"center\">4800.68</td><td align=\"center\">0.73 (0.67, 0.79)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>24-h concentration (pg/mL)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">600.88</td><td align=\"center\">-</td><td align=\"center\">2136.51</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">571.47</td><td align=\"center\">0.95 (0.89, 1.02)</td><td align=\"center\">2173.05</td><td align=\"center\">1.02 (0.93, 1.11)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">691.10</td><td align=\"center\">1.15 (1.07, 1.23)</td><td align=\"center\">2367.68</td><td align=\"center\">1.11 (1.01, 1.21)</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>T<sub>max </sub>median (range) (h)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">-</td><td align=\"center\">1.00 (0.50-2.07)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">-</td><td align=\"center\">0.92 (0.50-1.50)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">-</td><td align=\"center\">4.75 (3.00-6.02)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td><bold>t<sub>1/2 </sub>geometric mean (range) (h)</bold></td><td align=\"center\">OC alone</td><td align=\"center\">-</td><td align=\"center\">33.6 (20.0-78.5)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"/><td align=\"center\">1 h before exenatide</td><td align=\"center\">-</td><td align=\"center\">32.1 (19.8-55.7)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td/><td align=\"center\">0.5 h after exenatide</td><td align=\"center\">-</td><td align=\"center\">32.6 (17.9-72.4)</td><td align=\"center\">-</td><td align=\"center\">-</td></tr></tbody></table></body></html>", "text": "Pmid= 3378442:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Mass transitions of analytes and internal standards</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Internal Standard<break/>Quantifier</th><th align=\"center\">Q1</th><th align=\"center\">Q3</th><th align=\"center\">Analyte<break/>Quantifier</th><th align=\"center\">Q1</th><th align=\"center\">Q3</th></tr></thead><tbody><tr><td align=\"center\">Cyclosporine A-d<sub>4</sub></td><td align=\"center\">1224.0</td><td align=\"center\">1206.9</td><td align=\"center\">Cyclosporine A</td><td align=\"center\">1219.9</td><td align=\"center\">1203.0</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Tacrolimus<sup>13</sup>C-d<sub>2</sub></td><td align=\"center\">824.6</td><td align=\"center\">771.6</td><td align=\"center\">Tacrolimus</td><td align=\"center\">821.5</td><td align=\"center\">768.4</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Sirolimus-<sup>13</sup>C-d<sub>3</sub></td><td align=\"center\">935.6</td><td align=\"center\">864.6</td><td align=\"center\">Sirolimus</td><td align=\"center\">931.6</td><td align=\"center\">864.7</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Everolimus-d<sub>4</sub></td><td align=\"center\">979.6</td><td align=\"center\">912.6</td><td align=\"center\">Everolimus</td><td align=\"center\">975.6</td><td align=\"center\">908.5</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Mycophenolic acid-d<sub>3</sub></td><td align=\"center\">341.2</td><td align=\"center\">210.1</td><td align=\"center\">Mycophenolic acid</td><td align=\"center\">338.2</td><td align=\"center\">207.1</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Mycophenolic acid glucuronide</td><td align=\"center\">513.6</td><td align=\"center\">207.2</td><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Carboxy butoxy ether of mycophenolic acid</td><td align=\"center\">438.2</td><td align=\"center\">303.0</td><td/><td/><td/></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\"><bold>Internal Standard</bold><break/><bold>Qualifier</bold></td><td align=\"center\"><bold>Q1</bold></td><td align=\"center\"><bold>Q3</bold></td><td align=\"center\"><bold>Analyte</bold><break/><bold>Qualifier</bold></td><td align=\"center\"><bold>Q1</bold></td><td align=\"center\"><bold>Q3</bold></td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Cyclosporine A-d<sub>4</sub></td><td align=\"center\">1224.0</td><td align=\"center\">1188.8</td><td align=\"center\">Cyclosporine A</td><td align=\"center\">1219.9</td><td align=\"center\">1185.0</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Tacrolimus<sup>13</sup>C-d<sub>2</sub></td><td align=\"center\">824.6</td><td align=\"center\">789.4</td><td align=\"center\">Tacrolimus</td><td align=\"center\">821.5</td><td align=\"center\">786.5</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Sirolimus-<sup>13</sup>C-d<sub>3</sub></td><td align=\"center\">935.6</td><td align=\"center\">882.4</td><td align=\"center\">Sirolimus</td><td align=\"center\">931.6</td><td align=\"center\">882.4</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Everolimus-d<sub>4</sub></td><td align=\"center\">979.6</td><td align=\"center\">930.5</td><td align=\"center\">Everolimus</td><td align=\"center\">975.6</td><td align=\"center\">926.6</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Mycophenolic acid-d<sub>3</sub></td><td align=\"center\">341.2</td><td align=\"center\">306.3</td><td align=\"center\">Mycophenolic acid</td><td align=\"center\">338.2</td><td align=\"center\">210.1</td></tr><tr><td colspan=\"6\"><hr/></td></tr><tr><td align=\"center\">Carboxy butoxy ether of mycophenolic acid</td><td align=\"center\">438.2</td><td align=\"center\">195.0</td><td/><td/><td/></tr></tbody></table></body></html>", "text": "Pmid= 3398287:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Validation results</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Analyte</th><th align=\"center\">Measuring Range (ng/ml)<break/>MPA: &#956;g/ml<break/>n = 3</th><th align=\"center\">LOQ, CV (%)<break/>Accuracy<break/>(%)<break/>n = 5</th><th align=\"center\"><bold>Sample Conc</bold>.<break/>(ng/ml)<break/>MPA: &#956;g/ml</th><th align=\"center\">Intra Assay Precision<break/>(%)<break/>n = 5</th><th align=\"center\">Inter Assay Precision (%)<break/>n = 20</th><th align=\"center\">Accuracy (%)<break/>Intra/Inter<break/>Assay</th></tr></thead><tbody><tr><td align=\"left\">Cyclosporine A</td><td align=\"center\">2 - 1250</td><td align=\"center\">3.7</td><td align=\"center\">2</td><td align=\"center\">7.4</td><td align=\"center\">7.1</td><td align=\"center\">125/113</td></tr><tr><td/><td align=\"center\">r<sup>2</sup>= 0.997</td><td align=\"center\">104</td><td align=\"center\">100</td><td align=\"center\">2.3</td><td align=\"center\">2.9</td><td align=\"center\">104/106</td></tr><tr><td/><td/><td/><td align=\"center\">500</td><td align=\"center\">0.9</td><td align=\"center\">2.5</td><td align=\"center\">106/105</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">Tacrolimus</td><td align=\"center\">0.5 - 42.2</td><td align=\"center\">7.5</td><td align=\"center\">0.5</td><td align=\"center\">12.3</td><td align=\"center\">9.1</td><td align=\"center\">138/100</td></tr><tr><td/><td align=\"center\">r<sup>2</sup>= 0.998</td><td align=\"center\">108</td><td align=\"center\">10</td><td align=\"center\">3.7</td><td align=\"center\">4.9</td><td align=\"center\">116/99</td></tr><tr><td/><td/><td/><td align=\"center\">20</td><td align=\"center\">3.8</td><td align=\"center\">4.5</td><td align=\"center\">111/98</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">Sirolimus</td><td align=\"center\">0.62 - 49.2</td><td align=\"center\">4.6</td><td align=\"center\">1</td><td align=\"center\">12.0</td><td align=\"center\">11.5</td><td align=\"center\">125/107</td></tr><tr><td/><td align=\"center\">r<sup>2</sup>= 0.999</td><td align=\"center\">106</td><td align=\"center\">10</td><td align=\"center\">5.1</td><td align=\"center\">5.0</td><td align=\"center\">100/102</td></tr><tr><td/><td/><td/><td align=\"center\">20</td><td align=\"center\">5.0</td><td align=\"center\">4.9</td><td align=\"center\">108/102</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">Everolimus</td><td align=\"center\">0.53 - 40.8</td><td align=\"center\">6.4</td><td align=\"center\">1</td><td align=\"center\">14.7</td><td align=\"center\">12.5</td><td align=\"center\">89/90</td></tr><tr><td/><td align=\"center\">r<sup>2</sup>= 0.999</td><td align=\"center\">118</td><td align=\"center\">10</td><td align=\"center\">2.9</td><td align=\"center\">6.9</td><td align=\"center\">97/96</td></tr><tr><td/><td/><td/><td align=\"center\">20</td><td align=\"center\">5.1</td><td align=\"center\">5.7</td><td align=\"center\">102/97</td></tr><tr><td colspan=\"7\"><hr/></td></tr><tr><td align=\"left\">MPA</td><td align=\"center\">0.01 - 7.5</td><td align=\"center\">7.0</td><td align=\"center\">0.02</td><td align=\"center\">11.0</td><td align=\"center\">9.8</td><td align=\"center\">97/102</td></tr><tr><td/><td align=\"center\">r<sup>2</sup>= 0.999</td><td align=\"center\">105</td><td align=\"center\">0.2</td><td align=\"center\">1.3</td><td align=\"center\">3.2</td><td align=\"center\">97/97</td></tr><tr><td/><td/><td/><td align=\"center\">5</td><td align=\"center\">1.6</td><td align=\"center\">3.0</td><td align=\"center\">102/99</td></tr></tbody></table></body></html>", "text": "Pmid= 3398287:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Calibration results (Intra Assay Precision)</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\">Analyte</th><th align=\"center\">Target Value<break/>(ng/ml)<break/>MPA<break/>(&#956;g/ml)</th><th align=\"center\">Measured Value<break/>(ng/ml)<break/>MPA<break/>(&#956;g/ml)</th><th align=\"center\">Accuracy (%)</th><th align=\"center\">Linear Regression<break/>(1/x weighting)</th></tr></thead><tbody><tr><td align=\"center\">Cyclosporine A</td><td align=\"center\">0</td><td align=\"center\">&lt; 0</td><td align=\"center\">N/A</td><td align=\"center\">y = 0.00419 &#215; + 0.000559</td></tr><tr><td/><td align=\"center\">23.5</td><td align=\"center\">24.5</td><td align=\"center\">104</td><td align=\"center\">r = 0.9996</td></tr><tr><td/><td align=\"center\">127</td><td align=\"center\">121</td><td align=\"center\">94.9</td><td/></tr><tr><td/><td align=\"center\">299</td><td align=\"center\">291</td><td align=\"center\">97.3</td><td/></tr><tr><td/><td align=\"center\">484</td><td align=\"center\">506</td><td align=\"center\">105</td><td/></tr><tr><td/><td align=\"center\">703</td><td align=\"center\">714</td><td align=\"center\">102</td><td/></tr><tr><td/><td align=\"center\">896</td><td align=\"center\">877</td><td align=\"center\">97.8</td><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Tacrolimus</td><td align=\"center\">0</td><td align=\"center\">&lt; 0</td><td align=\"center\">N/A</td><td align=\"center\">y = 0.145 &#215; + 0.00678</td></tr><tr><td/><td align=\"center\">2.1</td><td align=\"center\">2.45</td><td align=\"center\">117</td><td align=\"center\">r = 0.9994</td></tr><tr><td/><td align=\"center\">5.8</td><td align=\"center\">6.06</td><td align=\"center\">105</td><td/></tr><tr><td/><td align=\"center\">12.1</td><td align=\"center\">12.3</td><td align=\"center\">102</td><td/></tr><tr><td/><td align=\"center\">18.1</td><td align=\"center\">18.7</td><td align=\"center\">103</td><td/></tr><tr><td/><td align=\"center\">24.4</td><td align=\"center\">24.2</td><td align=\"center\">99.3</td><td/></tr><tr><td/><td align=\"center\">42.4</td><td align=\"center\">41.1</td><td align=\"center\">97.0</td><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Sirolimus</td><td align=\"center\">0</td><td align=\"center\">&lt; 0</td><td align=\"center\">N/A</td><td align=\"center\">y = 0.104 &#215; + 0.0171</td></tr><tr><td/><td align=\"center\">2.6</td><td align=\"center\">2.25</td><td align=\"center\">86.7</td><td align=\"center\">r = 0.9996</td></tr><tr><td/><td align=\"center\">6.6</td><td align=\"center\">6.21</td><td align=\"center\">94.2</td><td/></tr><tr><td/><td align=\"center\">12.8</td><td align=\"center\">13.0</td><td align=\"center\">102</td><td/></tr><tr><td/><td align=\"center\">20.0</td><td align=\"center\">20.8</td><td align=\"center\">104</td><td/></tr><tr><td/><td align=\"center\">29.0</td><td align=\"center\">28.9</td><td align=\"center\">99.5</td><td/></tr><tr><td/><td align=\"center\">49.2</td><td align=\"center\">49.1</td><td align=\"center\">99.7</td><td/></tr><tr><td/><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Everolimus</td><td align=\"center\">0</td><td align=\"center\">&lt; 0</td><td align=\"center\">N/A</td><td align=\"center\">y = 0.112 &#215; + 9.76e-0.09</td></tr><tr><td/><td align=\"center\">2.2</td><td align=\"center\">2.25</td><td align=\"center\">102</td><td align=\"center\">r = 0.9992</td></tr><tr><td/><td align=\"center\">5.9</td><td align=\"center\">5.66</td><td align=\"center\">95.8</td><td/></tr><tr><td/><td align=\"center\">11.6</td><td align=\"center\">11.2</td><td align=\"center\">96.3</td><td/></tr><tr><td/><td align=\"center\">17.0</td><td align=\"center\">18.0</td><td align=\"center\">106</td><td/></tr><tr><td/><td align=\"center\">23.2</td><td align=\"center\">24.0</td><td align=\"center\">103</td><td/></tr><tr><td/><td align=\"center\">40.8</td><td align=\"center\">39.6</td><td align=\"center\">97</td><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">MPA</td><td align=\"center\">4.27</td><td align=\"center\" colspan=\"2\">1-point calibration<break/>linear through zero</td><td align=\"center\">y = 0.00494 x<break/>r = 1.0</td></tr></tbody></table></body></html>", "text": "Pmid= 3398287:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Patient characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th rowspan=\"2\" align=\"left\"><bold>Chains</bold></th><th rowspan=\"2\" align=\"left\"><bold>Number of Patients</bold></th><th colspan=\"2\" align=\"left\" valign=\"bottom\"><bold>Age of dispensing</bold><hr/></th><th rowspan=\"2\" align=\"left\"><bold>Female</bold></th><th rowspan=\"2\" align=\"left\"><bold>White</bold></th></tr><tr><th colspan=\"2\" align=\"left\"><bold>(Mean</bold>&#177;<bold>SD)</bold></th></tr></thead><tbody valign=\"top\"><tr><td align=\"left\" valign=\"bottom\"><bold>Chain1</bold>&#8224;<hr/></td><td align=\"left\" valign=\"bottom\">424<hr/></td><td align=\"left\" valign=\"bottom\">63.9<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 12.0<hr/></td><td align=\"left\" valign=\"bottom\">50.70%<hr/></td><td align=\"left\" valign=\"bottom\">83.20%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain2</bold><hr/></td><td align=\"left\" valign=\"bottom\">489<hr/></td><td align=\"left\" valign=\"bottom\">61.2<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 13.0<hr/></td><td align=\"left\" valign=\"bottom\">43.90%<hr/></td><td align=\"left\" valign=\"bottom\">87.50%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain3</bold><hr/></td><td align=\"left\" valign=\"bottom\">693<hr/></td><td align=\"left\" valign=\"bottom\">66.4<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 10.4<hr/></td><td align=\"left\" valign=\"bottom\">51.50%<hr/></td><td align=\"left\" valign=\"bottom\">81.70%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain4</bold>&#8224;<hr/></td><td align=\"left\" valign=\"bottom\">727<hr/></td><td align=\"left\" valign=\"bottom\">60.7<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 13.1<hr/></td><td align=\"left\" valign=\"bottom\">45.20%<hr/></td><td align=\"left\" valign=\"bottom\">91.20%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain5</bold>&#8224;<hr/></td><td align=\"left\" valign=\"bottom\">810<hr/></td><td align=\"left\" valign=\"bottom\">53.5<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 12.3<hr/></td><td align=\"left\" valign=\"bottom\">52.30%<hr/></td><td align=\"left\" valign=\"bottom\">84.20%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain6</bold>&#8225;<hr/></td><td align=\"left\" valign=\"bottom\">966<hr/></td><td align=\"left\" valign=\"bottom\">57.3<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 12.6<hr/></td><td align=\"left\" valign=\"bottom\">45.60%<hr/></td><td align=\"left\" valign=\"bottom\">83.60%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain7</bold><hr/></td><td align=\"left\" valign=\"bottom\">1,708<hr/></td><td align=\"left\" valign=\"bottom\">60.8<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 11.0<hr/></td><td align=\"left\" valign=\"bottom\">40.10%<hr/></td><td align=\"left\" valign=\"bottom\">89.60%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain8</bold><hr/></td><td align=\"left\" valign=\"bottom\">2,892<hr/></td><td align=\"left\" valign=\"bottom\">60.8<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 10.2<hr/></td><td align=\"left\" valign=\"bottom\">40.80%<hr/></td><td align=\"left\" valign=\"bottom\">91.80%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain9</bold><hr/></td><td align=\"left\" valign=\"bottom\">3,461<hr/></td><td align=\"left\" valign=\"bottom\">64.0<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 11.0<hr/></td><td align=\"left\" valign=\"bottom\">43.10%<hr/></td><td align=\"left\" valign=\"bottom\">87.80%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain10</bold>&#8224;<hr/></td><td align=\"left\" valign=\"bottom\">3,932<hr/></td><td align=\"left\" valign=\"bottom\">59.1<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 12.8<hr/></td><td align=\"left\" valign=\"bottom\">51.00%<hr/></td><td align=\"left\" valign=\"bottom\">87.70%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain11</bold>&#8224;<hr/></td><td align=\"left\" valign=\"bottom\">5,623<hr/></td><td align=\"left\" valign=\"bottom\">57.6<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 12.3<hr/></td><td align=\"left\" valign=\"bottom\">50.80%<hr/></td><td align=\"left\" valign=\"bottom\">82.40%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain12</bold><hr/></td><td align=\"left\" valign=\"bottom\">7,971<hr/></td><td align=\"left\" valign=\"bottom\">58.2<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 12.8<hr/></td><td align=\"left\" valign=\"bottom\">51.70%<hr/></td><td align=\"left\" valign=\"bottom\">75.10%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain13</bold><hr/></td><td align=\"left\" valign=\"bottom\">9,882<hr/></td><td align=\"left\" valign=\"bottom\">66.6<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 10.6<hr/></td><td align=\"left\" valign=\"bottom\">43.10%<hr/></td><td align=\"left\" valign=\"bottom\">85.10%<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><bold>Chain14</bold>&#8224;<hr/></td><td align=\"left\" valign=\"bottom\">16,788<hr/></td><td align=\"left\" valign=\"bottom\">59.1<hr/></td><td align=\"left\" valign=\"bottom\">&#177; 12.9<hr/></td><td align=\"left\" valign=\"bottom\">49.00%<hr/></td><td align=\"left\" valign=\"bottom\">79.00%<hr/></td></tr><tr><td align=\"left\"><bold>MEPS</bold></td><td align=\"left\">13.7million</td><td align=\"left\">60.7</td><td align=\"left\">&#177; 12.8</td><td align=\"left\">44.2%</td><td align=\"left\">66.8%</td></tr></tbody></table></body></html>", "text": "Pmid= 3416643:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Proportion of patients using selected oral hypoglycemic agent (OHA) by chain</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th align=\"left\"><bold>Ingredient</bold></th><th align=\"left\"><bold>MEPS</bold></th><th align=\"left\"><bold>Chain14</bold></th><th align=\"left\"><bold>Chain11</bold></th><th align=\"left\"><bold>Chain1</bold></th><th align=\"left\"><bold>Chain10</bold></th><th align=\"left\"><bold>Chain4</bold></th><th align=\"left\"><bold>Chain2</bold></th><th align=\"left\"><bold>Chain5</bold></th><th align=\"left\"><bold>Chain13</bold></th></tr></thead><tbody valign=\"top\"><tr><td align=\"left\" valign=\"bottom\">Chlorpropamide *<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.04<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.01<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.02<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.03<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Glimepiride *<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">9.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">17.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">19.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">18.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">18.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">17.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">22.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">16.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">19.9<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Glipizide *<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">14.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">17.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">20.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">23.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">20.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">20.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">18.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">12.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">19.6<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Glyburide *<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">10.7<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">5.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.7<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.6<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Metformin *<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">51.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">69.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">72.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">53.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">72.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">62.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">66.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">80.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">59.9<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Acarbose<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.4<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Glimepiride/Pioglitazone<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.26<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Glimepiride/Rosiglitazone<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.17<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Glipizide/Metformin<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.56<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.7<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Glyburide/Metformin<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">6.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.1<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Pioglitazone<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">11.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">17.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">15.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">27.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">15.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">19.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">22.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">14.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">25.8<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Pioglitazone/Metformin<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.6<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Repaglinde<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.0<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Rosiglitazone<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">6.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">3.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">5.6<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Rosiglitazone/Metformin<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.6<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.0<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Sitagliptin<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">10.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">9.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">12.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">9.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">12.7<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">12.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">8.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">14.3<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Sitagliptin/Metformin<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">1.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.9<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">2.8<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">6.7<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">6.1<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">4.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">5.3<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Low-cost OHA<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">85.3<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">89.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">78.5<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">89.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">83.2<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">83.4<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">90.0<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">79.0<hr/></td></tr><tr><td align=\"left\">Non-low-cost OHA</td><td align=\"left\">&#160;</td><td align=\"char\" char=\".\">55.3</td><td align=\"char\" char=\".\">33.8</td><td align=\"char\" char=\".\">52.1</td><td align=\"char\" char=\".\">34.4</td><td align=\"char\" char=\".\">43.4</td><td align=\"char\" char=\".\">43.7</td><td align=\"char\" char=\".\">29.3</td><td align=\"char\" char=\".\">52.2</td></tr></tbody></table></body></html>", "text": "Pmid= 3416643:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1></h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th align=\"left\">&#160;</th><th align=\"left\">&#160;</th><th align=\"left\">Individuals who filled at least one prescription</th><th align=\"left\">Average prescriptions per individual<sup>1</sup></th><th align=\"left\">&gt; 3.25 g/day(%)</th><th align=\"left\">&gt; 4.0 g/day(%)</th></tr></thead><tbody valign=\"top\"><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">Male<hr/></td><td align=\"left\" valign=\"bottom\">27,384<hr/></td><td align=\"left\" valign=\"bottom\">2.53<hr/></td><td align=\"left\" valign=\"bottom\">4,939 (18 %)<hr/></td><td align=\"left\" valign=\"bottom\">2,145(7.8%)<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Sex<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">Female<hr/></td><td align=\"left\" valign=\"bottom\">31,813<hr/></td><td align=\"left\" valign=\"bottom\">2.80<hr/></td><td align=\"left\" valign=\"bottom\">6,069 (19.0%)<hr/></td><td align=\"left\" valign=\"bottom\">1,641 (5.1%)<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&lt;65<hr/></td><td align=\"left\" valign=\"bottom\">44,443<hr/></td><td align=\"left\" valign=\"bottom\">2.62<hr/></td><td align=\"left\" valign=\"bottom\">8,216 (18.4%)<hr/></td><td align=\"left\" valign=\"bottom\">3,062 (6.8%)<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Age<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">65+<hr/></td><td align=\"left\" valign=\"bottom\">14,754<hr/></td><td align=\"left\" valign=\"bottom\">2.75<hr/></td><td align=\"left\" valign=\"bottom\">2,792 (18.9%)<hr/></td><td align=\"left\" valign=\"bottom\">724 (4.9%)<hr/></td></tr><tr><td align=\"left\">Total</td><td align=\"left\">&#160;</td><td align=\"left\">59,197</td><td align=\"left\">2.68</td><td align=\"left\">11,008 (18.6 %)</td><td align=\"left\">3,786 (6.4 %)</td></tr></tbody></table></body></html>", "text": "Pmid= 3416683:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Socio demographic characteristics of study participants</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th align=\"left\"><bold>S.No.</bold></th><th align=\"left\"><bold>Socio-demographic</bold></th><th align=\"left\"><bold>Characteristics</bold></th><th align=\"left\"><bold>Frequency</bold></th><th align=\"left\"><bold>Percent</bold></th></tr></thead><tbody valign=\"top\"><tr><td rowspan=\"2\" align=\"left\" valign=\"bottom\">1<hr/></td><td rowspan=\"2\" align=\"left\" valign=\"bottom\">Gender<hr/></td><td align=\"left\" valign=\"bottom\">Male<hr/></td><td align=\"left\" valign=\"bottom\">185<hr/></td><td align=\"left\" valign=\"bottom\">54.8<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Female<hr/></td><td align=\"left\" valign=\"bottom\">151<hr/></td><td align=\"left\" valign=\"bottom\">45.5<hr/></td></tr><tr><td rowspan=\"5\" align=\"left\" valign=\"bottom\">2<hr/></td><td rowspan=\"5\" align=\"left\" valign=\"bottom\">Age (in years)<hr/></td><td align=\"left\" valign=\"bottom\">10-20<hr/></td><td align=\"left\" valign=\"bottom\">57<hr/></td><td align=\"left\" valign=\"bottom\">17.5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">21-30<hr/></td><td align=\"left\" valign=\"bottom\">109<hr/></td><td align=\"left\" valign=\"bottom\">33,6<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">31-40<hr/></td><td align=\"left\" valign=\"bottom\">74<hr/></td><td align=\"left\" valign=\"bottom\">22.7<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">41-50<hr/></td><td align=\"left\" valign=\"bottom\">58<hr/></td><td align=\"left\" valign=\"bottom\">18.0<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">50+<hr/></td><td align=\"left\" valign=\"bottom\">37<hr/></td><td align=\"left\" valign=\"bottom\">8.1<hr/></td></tr><tr><td rowspan=\"4\" align=\"left\" valign=\"bottom\">3<hr/></td><td rowspan=\"4\" align=\"left\" valign=\"bottom\">Marital status<hr/></td><td align=\"left\" valign=\"bottom\">Never married<hr/></td><td align=\"left\" valign=\"bottom\">151<hr/></td><td align=\"left\" valign=\"bottom\">44.9<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Married<hr/></td><td align=\"left\" valign=\"bottom\">137<hr/></td><td align=\"left\" valign=\"bottom\">40.7<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Divorced<hr/></td><td align=\"left\" valign=\"bottom\">24<hr/></td><td align=\"left\" valign=\"bottom\">7.2<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Widowed<hr/></td><td align=\"left\" valign=\"bottom\">24<hr/></td><td align=\"left\" valign=\"bottom\">7.2<hr/></td></tr><tr><td rowspan=\"3\" align=\"left\" valign=\"bottom\">4<hr/></td><td rowspan=\"3\" align=\"left\" valign=\"bottom\">Living Condition<hr/></td><td align=\"left\" valign=\"bottom\">With family<hr/></td><td align=\"left\" valign=\"bottom\">300<hr/></td><td align=\"left\" valign=\"bottom\">89.9<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Living alone<hr/></td><td align=\"left\" valign=\"bottom\">19<hr/></td><td align=\"left\" valign=\"bottom\">5.5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Others<hr/></td><td align=\"left\" valign=\"bottom\">17<hr/></td><td align=\"left\" valign=\"bottom\">4.5<hr/></td></tr><tr><td rowspan=\"5\" align=\"left\" valign=\"bottom\">5<hr/></td><td rowspan=\"5\" align=\"left\" valign=\"bottom\">Educational status<hr/></td><td align=\"left\" valign=\"bottom\">Diploma &amp;above<hr/></td><td align=\"left\" valign=\"bottom\">62<hr/></td><td align=\"left\" valign=\"bottom\">18.3<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">10-12 grade<hr/></td><td align=\"left\" valign=\"bottom\">117<hr/></td><td align=\"left\" valign=\"bottom\">34.7<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">7-10 grade<hr/></td><td align=\"left\" valign=\"bottom\">71<hr/></td><td align=\"left\" valign=\"bottom\">21<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">1-6 grade<hr/></td><td align=\"left\" valign=\"bottom\">33<hr/></td><td align=\"left\" valign=\"bottom\">9.6<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">No formal schooling<hr/></td><td align=\"left\" valign=\"bottom\">53<hr/></td><td align=\"left\" valign=\"bottom\">13.2<hr/></td></tr><tr><td rowspan=\"7\" align=\"left\" valign=\"bottom\">6<hr/></td><td rowspan=\"7\" align=\"left\" valign=\"bottom\">Occupational status<hr/></td><td align=\"left\" valign=\"bottom\">Unemployed<hr/></td><td align=\"left\" valign=\"bottom\">89<hr/></td><td align=\"left\" valign=\"bottom\">26.5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Private NGO<hr/></td><td align=\"left\" valign=\"bottom\">63<hr/></td><td align=\"left\" valign=\"bottom\">18.9<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Government<hr/></td><td align=\"left\" valign=\"bottom\">52<hr/></td><td align=\"left\" valign=\"bottom\">15.5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Farmer<hr/></td><td align=\"left\" valign=\"bottom\">39<hr/></td><td align=\"left\" valign=\"bottom\">11.4<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Student<hr/></td><td align=\"left\" valign=\"bottom\">28<hr/></td><td align=\"left\" valign=\"bottom\">8.2<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Merchant<hr/></td><td align=\"left\" valign=\"bottom\">19<hr/></td><td align=\"left\" valign=\"bottom\">5.5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Others<hr/></td><td align=\"left\" valign=\"bottom\">46<hr/></td><td align=\"left\" valign=\"bottom\">13.2<hr/></td></tr><tr><td rowspan=\"5\" align=\"left\" valign=\"bottom\">7<hr/></td><td rowspan=\"5\" align=\"left\" valign=\"bottom\">Religion<hr/></td><td align=\"left\" valign=\"bottom\">Orthodox<hr/></td><td align=\"left\" valign=\"bottom\">145<hr/></td><td align=\"left\" valign=\"bottom\">42.9<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Muslim<hr/></td><td align=\"left\" valign=\"bottom\">83<hr/></td><td align=\"left\" valign=\"bottom\">24.7<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Protestant<hr/></td><td align=\"left\" valign=\"bottom\">81<hr/></td><td align=\"left\" valign=\"bottom\">24. 2<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Catholic<hr/></td><td align=\"left\" valign=\"bottom\">13<hr/></td><td align=\"left\" valign=\"bottom\">3.7<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Others<hr/></td><td align=\"left\" valign=\"bottom\">14<hr/></td><td align=\"left\" valign=\"bottom\">4.6<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">8<hr/></td><td align=\"left\" valign=\"bottom\">Monthly income (In birr)<hr/></td><td align=\"left\" valign=\"bottom\">300+<hr/></td><td align=\"left\" valign=\"bottom\">108<hr/></td><td align=\"left\" valign=\"bottom\">32.1<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">200-300<hr/></td><td align=\"left\" valign=\"bottom\">81<hr/></td><td align=\"left\" valign=\"bottom\">24.1<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">100-200<hr/></td><td align=\"left\" valign=\"bottom\">72<hr/></td><td align=\"left\" valign=\"bottom\">21.5<hr/></td></tr><tr><td align=\"left\">&#160;</td><td align=\"left\">&#160;</td><td align=\"left\">&lt; 100</td><td align=\"left\">75</td><td align=\"left\">22.3</td></tr></tbody></table></body></html>", "text": "Pmid= 3416691:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Patients reason for missing their anti-psychotic medication using self-report</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th align=\"left\"><bold>Reasons</bold></th><th align=\"left\"><bold>Frequency</bold></th><th align=\"left\"><bold>Percent</bold></th></tr></thead><tbody valign=\"top\"><tr><td align=\"left\" valign=\"bottom\">Forgetfulness<hr/></td><td align=\"left\" valign=\"bottom\">59<hr/></td><td align=\"left\" valign=\"bottom\">36.2<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Lack of information<hr/></td><td align=\"left\" valign=\"bottom\">17<hr/></td><td align=\"left\" valign=\"bottom\">10.5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Being busy<hr/></td><td align=\"left\" valign=\"bottom\">34<hr/></td><td align=\"left\" valign=\"bottom\">21.0<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Decision to omit<hr/></td><td align=\"left\" valign=\"bottom\">20<hr/></td><td align=\"left\" valign=\"bottom\">12.4<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Others<hr/></td><td align=\"left\" valign=\"bottom\">27<hr/></td><td align=\"left\" valign=\"bottom\">12.4<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Both forgetfulness and being busy<hr/></td><td align=\"left\" valign=\"bottom\">7<hr/></td><td align=\"left\" valign=\"bottom\">3.8<hr/></td></tr><tr><td align=\"left\">Total</td><td align=\"left\">164</td><td align=\"left\">100.0</td></tr></tbody></table></body></html>", "text": "Pmid= 3416691:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Number of adherence of patients defined by socio- demographic characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th rowspan=\"2\" align=\"left\"><bold>Socio-demographic Characteristic</bold></th><th rowspan=\"2\" align=\"left\"><bold>Description</bold></th><th colspan=\"4\" align=\"left\" valign=\"bottom\"><bold>Compliant Fill Rate (CFR)</bold><hr/></th></tr><tr><th align=\"left\"><bold>25%</bold></th><th align=\"left\"><bold>50%</bold></th><th align=\"left\"><bold>75%</bold></th><th align=\"left\"><bold>100%</bold></th></tr></thead><tbody valign=\"top\"><tr><td rowspan=\"2\" align=\"left\" valign=\"bottom\">Gender<hr/></td><td align=\"left\" valign=\"bottom\">Male<hr/></td><td align=\"left\" valign=\"bottom\">61<hr/></td><td align=\"left\" valign=\"bottom\">57<hr/></td><td align=\"left\" valign=\"bottom\">35<hr/></td><td align=\"left\" valign=\"bottom\">31<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Female<hr/></td><td align=\"left\" valign=\"bottom\">37<hr/></td><td align=\"left\" valign=\"bottom\">48<hr/></td><td align=\"left\" valign=\"bottom\">32<hr/></td><td align=\"left\" valign=\"bottom\">35<hr/></td></tr><tr><td rowspan=\"4\" align=\"left\" valign=\"bottom\">Age (in years)<hr/></td><td align=\"left\" valign=\"bottom\">10-20<hr/></td><td align=\"left\" valign=\"bottom\">20<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">21-30<hr/></td><td align=\"left\" valign=\"bottom\">26<hr/></td><td align=\"left\" valign=\"bottom\">37<hr/></td><td align=\"left\" valign=\"bottom\">22<hr/></td><td align=\"left\" valign=\"bottom\">25<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">31-40<hr/></td><td align=\"left\" valign=\"bottom\">20<hr/></td><td align=\"left\" valign=\"bottom\">25<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td><td align=\"left\" valign=\"bottom\">17<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">41-50<hr/></td><td align=\"left\" valign=\"bottom\">11<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td></tr><tr><td rowspan=\"4\" align=\"left\" valign=\"bottom\">Marital status<hr/></td><td align=\"left\" valign=\"bottom\">Never married<hr/></td><td align=\"left\" valign=\"bottom\">38<hr/></td><td align=\"left\" valign=\"bottom\">48<hr/></td><td align=\"left\" valign=\"bottom\">29<hr/></td><td align=\"left\" valign=\"bottom\">35<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Married<hr/></td><td align=\"left\" valign=\"bottom\">38<hr/></td><td align=\"left\" valign=\"bottom\">48<hr/></td><td align=\"left\" valign=\"bottom\">28<hr/></td><td align=\"left\" valign=\"bottom\">23<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Divorced<hr/></td><td align=\"left\" valign=\"bottom\">11<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Widowed<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td><td align=\"left\" valign=\"bottom\">5<hr/></td></tr><tr><td rowspan=\"5\" align=\"left\" valign=\"bottom\">Educational status<hr/></td><td align=\"left\" valign=\"bottom\">Diploma &amp;above<hr/></td><td align=\"left\" valign=\"bottom\">23<hr/></td><td align=\"left\" valign=\"bottom\">23<hr/></td><td align=\"left\" valign=\"bottom\">9<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">10-12 grade<hr/></td><td align=\"left\" valign=\"bottom\">28<hr/></td><td align=\"left\" valign=\"bottom\">37<hr/></td><td align=\"left\" valign=\"bottom\">29<hr/></td><td align=\"left\" valign=\"bottom\">23<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">7-10 grade<hr/></td><td align=\"left\" valign=\"bottom\">23<hr/></td><td align=\"left\" valign=\"bottom\">18<hr/></td><td align=\"left\" valign=\"bottom\">14<hr/></td><td align=\"left\" valign=\"bottom\">15<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">1-6 grade<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td><td align=\"left\" valign=\"bottom\">11<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">No formal schooling<hr/></td><td align=\"left\" valign=\"bottom\">17<hr/></td><td align=\"left\" valign=\"bottom\">11<hr/></td><td align=\"left\" valign=\"bottom\">8<hr/></td><td align=\"left\" valign=\"bottom\">9<hr/></td></tr><tr><td rowspan=\"7\" align=\"left\" valign=\"bottom\">Occupational status<hr/></td><td align=\"left\" valign=\"bottom\">Unemployed<hr/></td><td align=\"left\" valign=\"bottom\">20<hr/></td><td align=\"left\" valign=\"bottom\">291<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td><td align=\"left\" valign=\"bottom\">28<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Private NGO<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td><td align=\"left\" valign=\"bottom\">17<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td><td align=\"left\" valign=\"bottom\">11<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Government<hr/></td><td align=\"left\" valign=\"bottom\">26<hr/></td><td align=\"left\" valign=\"bottom\">20<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td><td align=\"left\" valign=\"bottom\">5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Farmer<hr/></td><td align=\"left\" valign=\"bottom\">18<hr/></td><td align=\"left\" valign=\"bottom\">8<hr/></td><td align=\"left\" valign=\"bottom\">8<hr/></td><td align=\"left\" valign=\"bottom\">5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Student<hr/></td><td align=\"left\" valign=\"bottom\">11<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td><td align=\"left\" valign=\"bottom\">5<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Merchant<hr/></td><td align=\"left\" valign=\"bottom\">5<hr/></td><td align=\"left\" valign=\"bottom\">9<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td><td align=\"left\" valign=\"bottom\">2<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Others<hr/></td><td align=\"left\" valign=\"bottom\">5<hr/></td><td align=\"left\" valign=\"bottom\">15<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td><td align=\"left\" valign=\"bottom\">12<hr/></td></tr><tr><td rowspan=\"5\" align=\"left\" valign=\"bottom\">Religion<hr/></td><td align=\"left\" valign=\"bottom\">Orthodox<hr/></td><td align=\"left\" valign=\"bottom\">46<hr/></td><td align=\"left\" valign=\"bottom\">43<hr/></td><td align=\"left\" valign=\"bottom\">29<hr/></td><td align=\"left\" valign=\"bottom\">26<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Muslim<hr/></td><td align=\"left\" valign=\"bottom\">20<hr/></td><td align=\"left\" valign=\"bottom\">26<hr/></td><td align=\"left\" valign=\"bottom\">14<hr/></td><td align=\"left\" valign=\"bottom\">20<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Protestant<hr/></td><td align=\"left\" valign=\"bottom\">23<hr/></td><td align=\"left\" valign=\"bottom\">28<hr/></td><td align=\"left\" valign=\"bottom\">18<hr/></td><td align=\"left\" valign=\"bottom\">15<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Catholic<hr/></td><td align=\"left\" valign=\"bottom\">6<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td><td align=\"left\" valign=\"bottom\">2<hr/></td><td align=\"left\" valign=\"bottom\">2<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Others<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td><td align=\"left\" valign=\"bottom\">5<hr/></td><td align=\"left\" valign=\"bottom\">5<hr/></td><td align=\"left\" valign=\"bottom\">3<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Monthly income (In Ethiopian Birr)<hr/></td><td align=\"left\" valign=\"bottom\">&gt;300<hr/></td><td align=\"left\" valign=\"bottom\">18<hr/></td><td align=\"left\" valign=\"bottom\">22<hr/></td><td align=\"left\" valign=\"bottom\">15<hr/></td><td align=\"left\" valign=\"bottom\">15<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">200-300<hr/></td><td align=\"left\" valign=\"bottom\">23<hr/></td><td align=\"left\" valign=\"bottom\">20<hr/></td><td align=\"left\" valign=\"bottom\">14<hr/></td><td align=\"left\" valign=\"bottom\">11<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">100-200<hr/></td><td align=\"left\" valign=\"bottom\">26<hr/></td><td align=\"left\" valign=\"bottom\">22<hr/></td><td align=\"left\" valign=\"bottom\">14<hr/></td><td align=\"left\" valign=\"bottom\">9<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">&#160;<hr/></td><td align=\"left\" valign=\"bottom\">&lt; 100<hr/></td><td align=\"left\" valign=\"bottom\">22<hr/></td><td align=\"left\" valign=\"bottom\">28<hr/></td><td align=\"left\" valign=\"bottom\">18<hr/></td><td align=\"left\" valign=\"bottom\">17<hr/></td></tr><tr><td align=\"left\">&#160;</td><td align=\"left\">&#160;</td><td align=\"left\">9</td><td align=\"left\">12</td><td align=\"left\">6</td><td align=\"left\">14</td></tr></tbody></table></body></html>", "text": "Pmid= 3416691:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Association between rate of adherence and different variables</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th align=\"left\"><bold>Variables</bold></th><th align=\"left\"><bold>P- value</bold></th><th align=\"left\"><bold>Pearson correlation coefficient (r)</bold></th></tr></thead><tbody valign=\"top\"><tr><td align=\"left\" valign=\"bottom\">Duration of medication<hr/></td><td align=\"left\" valign=\"bottom\">0.04<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">0.54<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Side effect of medications<hr/></td><td align=\"left\" valign=\"bottom\">0.03<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">&#8722;0.19<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">Exposure to social drugs<hr/></td><td align=\"left\" valign=\"bottom\">0.05<hr/></td><td align=\"char\" valign=\"bottom\" char=\".\">&#8722;0.13<hr/></td></tr><tr><td align=\"left\">Number of different types of medication</td><td align=\"left\">0.01</td><td align=\"char\" char=\".\">&#8722;0.12</td></tr></tbody></table></body></html>", "text": "Pmid= 3416691:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Cut offs for biochemical tests below which the respondents would enrol patients into the proposed trial</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th rowspan=\"2\" align=\"left\" valign=\"top\"><bold>THRESHOLD</bold></th><th colspan=\"3\" align=\"left\" valign=\"bottom\"><bold>OVERALL (%)</bold><hr/></th><th colspan=\"3\" align=\"left\" valign=\"bottom\"><bold>UK (%)</bold><hr/></th><th colspan=\"3\" align=\"left\" valign=\"bottom\"><bold>ANZ (%)</bold><hr/></th></tr><tr><th align=\"left\"><bold>ALT/AST</bold></th><th align=\"left\"><bold>CK</bold></th><th align=\"left\"><bold>BILIRUBIN</bold></th><th align=\"left\"><bold>ALT/AST</bold></th><th align=\"left\"><bold>CK</bold></th><th align=\"left\"><bold>BILIRUBIN</bold></th><th align=\"left\"><bold>ALT/AST</bold></th><th align=\"left\"><bold>CK</bold></th><th align=\"left\"><bold>BILIRUBIN</bold></th></tr></thead><tbody valign=\"top\"><tr><td align=\"left\" valign=\"bottom\"><sc>uln</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>27.6</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>34.7</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>33.9</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>31.6</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>41.8</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>38.4</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>16.1</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>14.5</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>21.0</sc><hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><sc>3 uln</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>42.3</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>33.9</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>37.7</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>36.7</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>26.0</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>32.2</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>58.1</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>56.5</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>53.2</sc><hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><sc>5 uln</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>13.8</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>13.4</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>12.1</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>11.3</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>10.7</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>8.5</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>21.0</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>21.0</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>22.6</sc><hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><sc>10 uln</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>2.5</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>2.9</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>1.7</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>2.3</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>2.8</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>1.7</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>3.2</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>3.2</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>1.6</sc><hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><sc>&gt;10 uln</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>0.4</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>1.7</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>1.3</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>0</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>0.6</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>1.1</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>1.6</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>4.8</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>1.6</sc><hr/></td></tr><tr><td align=\"left\" valign=\"bottom\"><sc>missing/no response</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>13.4</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>13.4</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>13.4</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>18.1</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>18.1</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>18.1</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>0</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>0</sc><hr/></td><td align=\"left\" valign=\"bottom\"><sc>0</sc><hr/></td></tr><tr><td align=\"left\"><sc>total</sc></td><td align=\"left\"><sc>100</sc></td><td align=\"left\"><sc>100</sc></td><td align=\"left\"><sc>100</sc></td><td align=\"left\"><sc>100</sc></td><td align=\"left\"><sc>100</sc></td><td align=\"left\"><sc>100</sc></td><td align=\"left\"><sc>100</sc></td><td align=\"left\"><sc>100</sc></td><td align=\"left\"><sc>100</sc></td></tr></tbody></table></body></html>", "text": "Pmid= 3416708:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Preferred follow up duration for the proposed statin interventional trial</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" frame=\"hsides\" rules=\"groups\" border=\"1\"><colgroup><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/><col align=\"left\"/></colgroup><thead valign=\"top\"><tr><th align=\"left\"><bold>follow up duration</bold></th><th align=\"left\"><bold>overall - %</bold></th><th align=\"left\"><bold>uk - %</bold></th><th align=\"left\"><bold>anz - %</bold></th><th align=\"left\"><bold>p*</bold></th></tr></thead><tbody valign=\"top\"><tr><td align=\"left\" valign=\"bottom\">1-7&#8201;days<hr/></td><td align=\"left\" valign=\"bottom\">1.9<hr/></td><td align=\"left\" valign=\"bottom\">1.4<hr/></td><td align=\"left\" valign=\"bottom\">3.2<hr/></td><td align=\"left\" valign=\"bottom\">0.585<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">8-14&#8201;days<hr/></td><td align=\"left\" valign=\"bottom\">3.4<hr/></td><td align=\"left\" valign=\"bottom\">4.1<hr/></td><td align=\"left\" valign=\"bottom\">1.6<hr/></td><td align=\"left\" valign=\"bottom\">0.677<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">15-21&#8201;days<hr/></td><td align=\"left\" valign=\"bottom\">2.4<hr/></td><td align=\"left\" valign=\"bottom\">2.8<hr/></td><td align=\"left\" valign=\"bottom\">1.6<hr/></td><td align=\"left\" valign=\"bottom\">1.000<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">21-28&#8201;days<hr/></td><td align=\"left\" valign=\"bottom\">33.3<hr/></td><td align=\"left\" valign=\"bottom\">37.9<hr/></td><td align=\"left\" valign=\"bottom\">22.6<hr/></td><td align=\"left\" valign=\"bottom\">0.032<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">3&#8201;months<hr/></td><td align=\"left\" valign=\"bottom\">29.0<hr/></td><td align=\"left\" valign=\"bottom\">22.8<hr/></td><td align=\"left\" valign=\"bottom\">43.6<hr/></td><td align=\"left\" valign=\"bottom\">0.003<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">6&#8201;months<hr/></td><td align=\"left\" valign=\"bottom\">26.1<hr/></td><td align=\"left\" valign=\"bottom\">28.3<hr/></td><td align=\"left\" valign=\"bottom\">21.0<hr/></td><td align=\"left\" valign=\"bottom\">0.304<hr/></td></tr><tr><td align=\"left\" valign=\"bottom\">other<hr/></td><td align=\"left\" valign=\"bottom\">3.9<hr/></td><td align=\"left\" valign=\"bottom\">2.8<hr/></td><td align=\"left\" valign=\"bottom\">6.5<hr/></td><td align=\"left\" valign=\"bottom\">0.244<hr/></td></tr><tr><td align=\"left\">total</td><td align=\"left\">100</td><td align=\"left\">100</td><td align=\"left\">100</td><td align=\"left\">&#160;</td></tr></tbody></table></body></html>", "text": "Pmid= 3416708:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Patient characteristics</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><tbody><tr><td align=\"left\">Karnofsky performance status (median (range))</td><td align=\"left\">60 (40&#8211;80)</td></tr><tr><td align=\"left\">Cancer Diagnoses</td><td/></tr><tr><td align=\"left\">&#8195;Prostate</td><td align=\"left\">11</td></tr><tr><td align=\"left\">&#8195;Colorectal</td><td align=\"left\">5</td></tr><tr><td align=\"left\">&#8195;Kidney</td><td align=\"left\">3</td></tr><tr><td align=\"left\">&#8195;Breast</td><td align=\"left\">3</td></tr><tr><td align=\"left\">&#8195;Pancreatic</td><td align=\"left\">2</td></tr><tr><td align=\"left\">&#8195;Lung</td><td align=\"left\">2</td></tr><tr><td align=\"left\">&#8195;Gastric</td><td align=\"left\">1</td></tr><tr><td align=\"left\">&#8195;Malignant melanoma</td><td align=\"left\">1</td></tr><tr><td align=\"left\">&#8195;Leiomyosarcoma</td><td align=\"left\">1</td></tr><tr><td align=\"left\">Metastases</td><td/></tr><tr><td align=\"left\">&#8195;Liver</td><td align=\"left\">7</td></tr><tr><td align=\"left\">&#8195;Bone</td><td align=\"left\">16</td></tr><tr><td align=\"left\">&#8195;Other</td><td align=\"left\">16</td></tr><tr><td align=\"left\">Antidepressants</td><td align=\"left\">4</td></tr><tr><td align=\"left\">Neuroleptics</td><td align=\"left\">1</td></tr><tr><td align=\"left\">Benzodiazepines</td><td align=\"left\">6</td></tr><tr><td align=\"left\">Corticosteroids</td><td align=\"left\">13</td></tr><tr><td align=\"left\">Antiemetics</td><td align=\"left\">7</td></tr></tbody></table></body></html>", "text": "Pmid= 526195:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Symptom scores All scores were obtained using a 5 category verbal rating scale score (scores; 15). All results are given as mean (SD). No significant differences in scores were observed between trial days.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">Trial day 2</td><td align=\"left\">Trial day 3</td><td align=\"left\">Trial day 4</td></tr></thead><tbody><tr><td align=\"left\">Pain</td><td align=\"left\">2.8 (0.7)</td><td align=\"left\">2.2 (1.1)</td><td align=\"left\">2.2 (1,1)</td></tr><tr><td align=\"left\">Nausea</td><td align=\"left\">1.7 (1.0)</td><td align=\"left\">1.7 (1.1)</td><td align=\"left\">1.8 (0.9)</td></tr><tr><td align=\"left\">Sedation</td><td align=\"left\">3.4 (1.2)</td><td align=\"left\">3.4 (1.0)</td><td align=\"left\">3.2 (1.1)</td></tr></tbody></table></body></html>", "text": "Pmid= 526195:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Serum concentrations for morphine and metabolites for the oral route The morphine doses (mg/24 h) vary because of variable doses of rescue morphine. A total of 23 trial periods in 19 patients were studied. All data are given as median and range.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">Day 1</td><td align=\"left\">Day 2</td><td align=\"left\">Day 3</td><td align=\"left\">Day 4</td></tr></thead><tbody><tr><td align=\"left\">Morphine dose (mg/24 h)</td><td align=\"left\">90 (20&#8211;1460)</td><td align=\"left\">80 (20 &#8211; 1700)</td><td align=\"left\">95 (30 &#8211; 1520)</td><td align=\"left\">90 (20 &#8211; 1580)</td></tr><tr><td align=\"left\">Serum morphine (nmol/l)</td><td align=\"left\">255 (46&#8211;2520)</td><td align=\"left\">59 (17&#8211;1437)</td><td align=\"left\">94 (12&#8211;1429)</td><td align=\"left\">77 (9&#8211;2296)</td></tr><tr><td align=\"left\">Serum M6G (nmol/l)</td><td align=\"left\">1156 (149&#8211;7874)</td><td align=\"left\">568 (66&#8211;7874)</td><td align=\"left\">516 (66&#8211;9678)</td><td align=\"left\">620 (80&#8211;8026)</td></tr><tr><td align=\"left\">Serum M3G (nmol/l)</td><td align=\"left\">6341 (1734&#8211;31997)</td><td align=\"left\">3696 (404&#8211;36887)</td><td align=\"left\">3226 (595&#8211;41452)</td><td align=\"left\">3778 (526&#8211;43043)</td></tr></tbody></table></body></html>", "text": "Pmid= 526195:Table= Table 3"}
{"html": "<!DOCTYPE html><html><body><h1>Serum concentrations for morphine and metabolites for the subcutaneous route The morphine doses (mg/24 h) vary because of variable doses of rescue morphine. A total of 17 trial periods in 10 patients were studied. All data are given as median and range.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\">Day 1</td><td align=\"left\">Day 2</td><td align=\"left\">Day 3</td><td align=\"left\">Day 4</td></tr></thead><tbody><tr><td align=\"left\">Morphine dose (mg/24 h)</td><td align=\"left\">135 (30&#8211;340)</td><td align=\"left\">163 (30 &#8211; 335)</td><td align=\"left\">164 (50 &#8211; 440)</td><td align=\"left\">150 (84 &#8211; 440)</td></tr><tr><td align=\"left\">Serum morphine (nmol/l)</td><td align=\"left\">240 (42&#8211;741)</td><td align=\"left\">254 (62&#8211;1297)</td><td align=\"left\">305 (106&#8211;1045)</td><td align=\"left\">373 (103&#8211;1222)</td></tr><tr><td align=\"left\">Serum M6G (nmol/l)</td><td align=\"left\">723 (78&#8211;1811)</td><td align=\"left\">674 (88&#8211;2867)</td><td align=\"left\">1009 (374&#8211;2023)</td><td align=\"left\">1225 (400&#8211;2339)</td></tr><tr><td align=\"left\">Serum M3G (nmol/l)</td><td align=\"left\">5350 (578&#8211;11784)</td><td align=\"left\">4490 (779&#8211;16312)</td><td align=\"left\">5631 (3028&#8211;8342)</td><td align=\"left\">6119 (2777&#8211;13715)</td></tr></tbody></table></body></html>", "text": "Pmid= 526195:Table= Table 4"}
{"html": "<!DOCTYPE html><html><body><h1>Biological coefficients of variation (CV) of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) serum concentrations during four consecutive days of oral or subcutaneous morphine treatment. All values are given as median and range.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\" colspan=\"2\">Biological coefficient of variation %</td></tr><tr><td/><td colspan=\"2\"><hr/></td></tr><tr><td/><td align=\"left\">Oral morphine</td><td align=\"left\">Subcutaneous morphine</td></tr></thead><tbody><tr><td align=\"left\">Morphine</td><td align=\"left\">46 (13&#8211;103)</td><td align=\"left\">10 (0&#8211;36)</td></tr><tr><td align=\"left\">M6G</td><td align=\"left\">25 (1&#8211;72)</td><td align=\"left\">13 (2&#8211;40)</td></tr><tr><td align=\"left\">M3G</td><td align=\"left\">18 (0&#8211;57)</td><td align=\"left\">9 (0&#8211;34)</td></tr></tbody></table></body></html>", "text": "Pmid= 526195:Table= Table 5"}
{"html": "<!DOCTYPE html><html><body><h1>Definitions of prescribed daily doses (PDD) and WHO/ATC defined daily doses (DDD) for systemic antifungal drugs.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\">PDD</td><td align=\"center\">DDD</td></tr></thead><tbody><tr><td align=\"left\">amphotericin B deoxycholate*</td><td align=\"center\">50 mg</td><td align=\"center\">35 mg</td></tr><tr><td align=\"left\">liposomal amphotericin B</td><td align=\"center\">250 mg</td><td align=\"center\">nd<sup>#</sup></td></tr><tr><td align=\"left\">flucytosin</td><td align=\"center\">10 g</td><td align=\"center\">10 g</td></tr><tr><td align=\"left\">ketoconazole</td><td align=\"center\">400 mg</td><td align=\"center\">400 mg</td></tr><tr><td align=\"left\">fluconazole</td><td align=\"center\">400 mg</td><td align=\"center\">200 mg</td></tr><tr><td align=\"left\">itraconazole</td><td align=\"center\">400 mg</td><td align=\"center\">200 mg</td></tr><tr><td align=\"left\">voriconazole</td><td align=\"center\">400 mg</td><td align=\"center\">400 mg</td></tr><tr><td align=\"left\">caspofungin</td><td align=\"center\">50 mg</td><td align=\"center\">50 mg</td></tr></tbody></table></body></html>", "text": "Pmid= 549558:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Isoflavone contents in soy preparations used in this study.</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"center\">Daidzin</td><td align=\"center\">Genistin</td><td align=\"center\">Total<sup>1</sup></td></tr></thead><tbody><tr><td align=\"left\">Soy flour</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mg/g</td><td align=\"center\">0.62 &#177; 0.005</td><td align=\"center\">0.70 &#177; 0.01</td><td align=\"center\">1.32 &#177; 0.01</td></tr><tr><td align=\"left\">&#8195;%</td><td align=\"center\">47</td><td align=\"center\">53</td><td align=\"center\">100</td></tr><tr><td align=\"left\">Soy extract capsule</td><td/><td/><td/></tr><tr><td align=\"left\">&#8195;Mg/capsule</td><td align=\"center\">3.90 &#177; 0.04</td><td align=\"center\">11.29 &#177; 0.17</td><td align=\"center\">15.18 &#177; 0.21</td></tr><tr><td align=\"left\">&#8195;%</td><td align=\"center\">26</td><td align=\"center\">74</td><td align=\"center\">100</td></tr></tbody></table></body></html>", "text": "Pmid= 555741:Table= Table 1"}
{"html": "<!DOCTYPE html><html><body><h1>Individual and mean pharmacokinetic parameters of daidzein following a single dose of orally administered soy beverage (B) and soy extract capsules (C).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Subj No.</td><td align=\"center\" colspan=\"2\">C<sub>max </sub>(ng/ml)</td><td align=\"center\" colspan=\"2\">C<sub>max</sub>/Dose<sup>1</sup></td><td align=\"center\" colspan=\"2\">AUC<sub>0&#8211;32 </sub>(ng.h/ml)</td><td align=\"center\" colspan=\"2\">AUC<sub>0&#8211;32</sub>/Dose<sup>1</sup></td><td align=\"center\" colspan=\"2\">AUC<sub>0-&#8733; </sub>(ng.h/ml)</td><td align=\"center\" colspan=\"2\">AUC<sub>0-&#8733;</sub>/Dose<sup>1</sup></td><td align=\"center\" colspan=\"2\">T<sub>max </sub>(h)</td><td align=\"center\" colspan=\"2\">t<sub>1/2 </sub>(h)</td></tr><tr><td/><td colspan=\"16\"><hr/></td></tr><tr><td/><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td></tr></thead><tbody><tr><td align=\"center\">1</td><td align=\"center\">67.42</td><td align=\"center\">60.73</td><td align=\"center\">7.27</td><td align=\"center\">7.80</td><td align=\"center\">354.62</td><td align=\"center\">650.40</td><td align=\"center\">38.25</td><td align=\"center\">83.49</td><td align=\"center\">496.21</td><td align=\"center\">722.51</td><td align=\"center\">53.53</td><td align=\"center\">92.75</td><td align=\"center\">6</td><td align=\"center\">6</td><td align=\"center\">6.06</td><td align=\"center\">8.04</td></tr><tr><td align=\"center\">2</td><td align=\"center\">142.17</td><td align=\"center\">56.33</td><td align=\"center\">15.34</td><td align=\"center\">7.23</td><td align=\"center\">1142.38</td><td align=\"center\">931.84</td><td align=\"center\">123.23</td><td align=\"center\">119.62</td><td align=\"center\">1206.09</td><td align=\"center\">1024.24</td><td align=\"center\">130.11</td><td align=\"center\">131.48</td><td align=\"center\">6</td><td align=\"center\">1</td><td align=\"center\">6.74</td><td align=\"center\">6.02</td></tr><tr><td align=\"center\">3</td><td align=\"center\">64.95</td><td align=\"center\">76.70</td><td align=\"center\">7.01</td><td align=\"center\">9.85</td><td align=\"center\">1118.40</td><td align=\"center\">1117.20</td><td align=\"center\">120.65</td><td align=\"center\">143.41</td><td align=\"center\">1704.60</td><td align=\"center\">1171.78</td><td align=\"center\">183.88</td><td align=\"center\">150.42</td><td align=\"center\">8</td><td align=\"center\">6</td><td align=\"center\">19.80</td><td align=\"center\">6.85</td></tr><tr><td align=\"center\">4</td><td align=\"center\">132.30</td><td align=\"center\">124.43</td><td align=\"center\">14.27</td><td align=\"center\">15.97</td><td align=\"center\">1336.29</td><td align=\"center\">1356.49</td><td align=\"center\">144.15</td><td align=\"center\">174.13</td><td align=\"center\">1402.26</td><td align=\"center\">1427.11</td><td align=\"center\">151.27</td><td align=\"center\">183.20</td><td align=\"center\">6</td><td align=\"center\">6</td><td align=\"center\">6.70</td><td align=\"center\">6.91</td></tr><tr><td align=\"center\">5</td><td align=\"center\">77.66</td><td align=\"center\">93.20</td><td align=\"center\">8.38</td><td align=\"center\">11.96</td><td align=\"center\">1293.52</td><td align=\"center\">1251.35</td><td align=\"center\">139.54</td><td align=\"center\">160.64</td><td align=\"center\">1483.69</td><td align=\"center\">1561.72</td><td align=\"center\">160.05</td><td align=\"center\">200.48</td><td align=\"center\">8</td><td align=\"center\">10</td><td align=\"center\">9.94</td><td align=\"center\">10.50</td></tr><tr><td align=\"center\">6</td><td align=\"center\">105.65</td><td align=\"center\">142.82</td><td align=\"center\">11.40</td><td align=\"center\">18.33</td><td align=\"center\">1409.24</td><td align=\"center\">1378.43</td><td align=\"center\">152.02</td><td align=\"center\">176.95</td><td align=\"center\">1533.26</td><td align=\"center\">1450.55</td><td align=\"center\">165.40</td><td align=\"center\">186.21</td><td align=\"center\">10</td><td align=\"center\">6</td><td align=\"center\">6.21</td><td align=\"center\">6.86</td></tr><tr><td align=\"center\">7</td><td align=\"center\">160.86</td><td align=\"center\">125.37</td><td align=\"center\">17.35</td><td align=\"center\">16.09</td><td align=\"center\">1576.65</td><td align=\"center\">1669.28</td><td align=\"center\">170.08</td><td align=\"center\">214.28</td><td align=\"center\">1761.36</td><td align=\"center\">1721.18</td><td align=\"center\">190.01</td><td align=\"center\">220.95</td><td align=\"center\">4</td><td align=\"center\">6</td><td align=\"center\">8.48</td><td align=\"center\">5.97</td></tr><tr><td align=\"center\">8</td><td align=\"center\">102.77</td><td align=\"center\">74.08</td><td align=\"center\">11.09</td><td align=\"center\">9.51</td><td align=\"center\">1158.07</td><td align=\"center\">1090.36</td><td align=\"center\">124.93</td><td align=\"center\">139.97</td><td align=\"center\">1227.07</td><td align=\"center\">1149.04</td><td align=\"center\">132.37</td><td align=\"center\">147.50</td><td align=\"center\">6</td><td align=\"center\">6</td><td align=\"center\">6.85</td><td align=\"center\">6.76</td></tr><tr><td align=\"center\">9</td><td align=\"center\">45.34</td><td align=\"center\">105.77</td><td align=\"center\">4.89</td><td align=\"center\">13.58</td><td align=\"center\">300.89</td><td align=\"center\">849.39</td><td align=\"center\">32.46</td><td align=\"center\">109.04</td><td align=\"center\">340.35</td><td align=\"center\">876.40</td><td align=\"center\">36.72</td><td align=\"center\">112.50</td><td align=\"center\">4</td><td align=\"center\">6</td><td align=\"center\">3.46</td><td align=\"center\">4.40</td></tr><tr><td align=\"center\">10</td><td align=\"center\">52.98</td><td align=\"center\">84.74</td><td align=\"center\">5.72</td><td align=\"center\">10.88</td><td align=\"center\">401.82</td><td align=\"center\">579.95</td><td align=\"center\">43.35</td><td align=\"center\">74.45</td><td align=\"center\">533.03</td><td align=\"center\">761.42</td><td align=\"center\">57.50</td><td align=\"center\">97.74</td><td align=\"center\">1</td><td align=\"center\">6</td><td align=\"center\">4.82</td><td align=\"center\">4.38</td></tr><tr><td align=\"center\">11</td><td align=\"center\">99.98</td><td align=\"center\">87.38</td><td align=\"center\">10.79</td><td align=\"center\">11.22</td><td align=\"center\">1291.80</td><td align=\"center\">1546.66</td><td align=\"center\">139.35</td><td align=\"center\">198.54</td><td align=\"center\">1455.80</td><td align=\"center\">1705.46</td><td align=\"center\">157.04</td><td align=\"center\">218.93</td><td align=\"center\">8</td><td align=\"center\">10</td><td align=\"center\">6.59</td><td align=\"center\">7.63</td></tr><tr><td align=\"center\">12</td><td align=\"center\">103.60</td><td align=\"center\">120.64</td><td align=\"center\">11.18</td><td align=\"center\">15.49</td><td align=\"center\">578.60</td><td align=\"center\">909.87</td><td align=\"center\">62.42</td><td align=\"center\">116.80</td><td align=\"center\">665.06</td><td align=\"center\">971.69</td><td align=\"center\">71.74</td><td align=\"center\">124.74</td><td align=\"center\">4</td><td align=\"center\">6</td><td align=\"center\">6.49</td><td align=\"center\">5.71</td></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"center\"><bold>Mean</bold></td><td align=\"center\">96.31</td><td align=\"center\">96.02<sup>ND</sup></td><td align=\"center\">10.39</td><td align=\"center\">12.33</td><td align=\"center\">996.86</td><td align=\"center\">1110.94<sup>ND</sup></td><td align=\"center\">107.54</td><td align=\"center\">142.61*</td><td align=\"center\">1150.73</td><td align=\"center\">1211.93<sup>ND</sup></td><td align=\"center\">124.14</td><td align=\"center\">155.57*</td><td align=\"center\">5.92</td><td align=\"center\">6.25</td><td align=\"center\">7.68</td><td align=\"center\">6.67</td></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"center\"><bold>SD</bold></td><td align=\"center\">36.18</td><td align=\"center\">27.71</td><td align=\"center\">3.90</td><td align=\"center\">3.56</td><td align=\"center\">455.69</td><td align=\"center\">342.26</td><td align=\"center\">49.16</td><td align=\"center\">43.94</td><td align=\"center\">504.94</td><td align=\"center\">354.46</td><td align=\"center\">54.47</td><td align=\"center\">45.50</td><td align=\"center\">2.43</td><td align=\"center\">2.26</td><td align=\"center\">4.14</td><td align=\"center\">1.65</td></tr></tbody></table></body></html>", "text": "Pmid= 555741:Table= Table 2"}
{"html": "<!DOCTYPE html><html><body><h1>Individual and mean pharmacokinetic parameters of genistein following a single dose of orally administered soy beverage (B) and soy extract capsules (C).</h1><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\">Subj No.</td><td align=\"center\" colspan=\"2\">C<sub>max </sub>(ng/ml)</td><td align=\"center\" colspan=\"2\">C<sub>max</sub>/Dose<sup>1</sup></td><td align=\"center\" colspan=\"2\">AUC<sub>0&#8211;32 </sub>(ng.h/ml)</td><td align=\"center\" colspan=\"2\">AUC<sub>0&#8211;32</sub>/Dose<sup>1</sup></td><td align=\"center\" colspan=\"2\">AUC<sub>0-&#8733; </sub>(ng.h/ml)</td><td align=\"center\" colspan=\"2\">AUC<sub>0-&#8733;</sub>/Dose<sup>1</sup></td><td align=\"center\" colspan=\"2\">T<sub>max </sub>(h)</td><td align=\"center\" colspan=\"2\">t<sub>1/2 </sub>(h)</td></tr><tr><td/><td colspan=\"16\"><hr/></td></tr><tr><td/><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td><td align=\"center\">B</td><td align=\"center\">C</td></tr></thead><tbody><tr><td align=\"center\">1</td><td align=\"center\">90.41</td><td align=\"center\">151.49</td><td align=\"center\">8.60</td><td align=\"center\">6.71</td><td align=\"center\">954.82</td><td align=\"center\">1950.40</td><td align=\"center\">90.85</td><td align=\"center\">86.42</td><td align=\"center\">1040.69</td><td align=\"center\">2248.09</td><td align=\"center\">99.02</td><td align=\"center\">99.61</td><td align=\"center\">6</td><td align=\"center\">6</td><td align=\"center\">8.46</td><td align=\"center\">9.92</td></tr><tr><td align=\"center\">2</td><td align=\"center\">68.08</td><td align=\"center\">124.90</td><td align=\"center\">6.48</td><td align=\"center\">5.53</td><td align=\"center\">693.31</td><td align=\"center\">1821.17</td><td align=\"center\">65.97</td><td align=\"center\">80.69</td><td align=\"center\">739.89</td><td align=\"center\">1941.50</td><td align=\"center\">70.40</td><td align=\"center\">86.02</td><td align=\"center\">1</td><td align=\"center\">8</td><td align=\"center\">7.62</td><td align=\"center\">7.42</td></tr><tr><td align=\"center\">3</td><td align=\"center\">149.53</td><td align=\"center\">301.34</td><td align=\"center\">14.23</td><td align=\"center\">13.35</td><td align=\"center\">1801.34</td><td align=\"center\">4392.34</td><td align=\"center\">171.39</td><td align=\"center\">194.61</td><td align=\"center\">1989.66</td><td align=\"center\">5048.92</td><td align=\"center\">189.31</td><td align=\"center\">223.70</td><td align=\"center\">8</td><td align=\"center\">8</td><td align=\"center\">8.25</td><td align=\"center\">9.37</td></tr><tr><td align=\"center\">4</td><td align=\"center\">212.94</td><td align=\"center\">516.77</td><td align=\"center\">20.26</td><td align=\"center\">22.90</td><td align=\"center\">1979.53</td><td align=\"center\">5541.88</td><td align=\"center\">188.35</td><td align=\"center\">245.54</td><td align=\"center\">2140.25</td><td align=\"center\">6175.55</td><td align=\"center\">203.64</td><td align=\"center\">273.62</td><td align=\"center\">6</td><td align=\"center\">6</td><td align=\"center\">8.10</td><td align=\"center\">8.93</td></tr><tr><td align=\"center\">5</td><td align=\"center\">96.95</td><td align=\"center\">220.38</td><td align=\"center\">9.22</td><td align=\"center\">9.76</td><td align=\"center\">1281.58</td><td align=\"center\">2478.42</td><td align=\"center\">121.94</td><td align=\"center\">109.81</td><td align=\"center\">1423.11</td><td align=\"center\">3072.33</td><td align=\"center\">135.41</td><td align=\"center\">136.12</td><td align=\"center\">8</td><td align=\"center\">10</td><td align=\"center\">9.73</td><td align=\"center\">12.40</td></tr><tr><td align=\"center\">6</td><td align=\"center\">96.57</td><td align=\"center\">301.62</td><td align=\"center\">9.19</td><td align=\"center\">13.36</td><td align=\"center\">1277.75</td><td align=\"center\">2776.28</td><td align=\"center\">121.57</td><td align=\"center\">123.01</td><td align=\"center\">1483.87</td><td align=\"center\">2972.50</td><td align=\"center\">141.19</td><td align=\"center\">131.70</td><td align=\"center\">10</td><td align=\"center\">6</td><td align=\"center\">10.10</td><td align=\"center\">7.74</td></tr><tr><td align=\"center\">7</td><td align=\"center\">223.77</td><td align=\"center\">371.31</td><td align=\"center\">21.29</td><td align=\"center\">16.45</td><td align=\"center\">3184.25</td><td align=\"center\">5260.83</td><td align=\"center\">302.97</td><td align=\"center\">233.09</td><td align=\"center\">4022.02</td><td align=\"center\">6003.94</td><td align=\"center\">382.69</td><td align=\"center\">266.01</td><td align=\"center\">4</td><td align=\"center\">8</td><td align=\"center\">12.60</td><td align=\"center\">9.58</td></tr><tr><td align=\"center\">8</td><td align=\"center\">110.60</td><td align=\"center\">193.01</td><td align=\"center\">10.52</td><td align=\"center\">8.55</td><td align=\"center\">948.75</td><td align=\"center\">2217.44</td><td align=\"center\">90.27</td><td align=\"center\">98.25</td><td align=\"center\">998.31</td><td align=\"center\">2370.24</td><td align=\"center\">94.99</td><td align=\"center\">105.02</td><td align=\"center\">6</td><td align=\"center\">6</td><td align=\"center\">5.07</td><td align=\"center\">8.41</td></tr><tr><td align=\"center\">9</td><td align=\"center\">54.86</td><td align=\"center\">183.88</td><td align=\"center\">5.22</td><td align=\"center\">8.15</td><td align=\"center\">425.80</td><td align=\"center\">1481.47</td><td align=\"center\">40.51</td><td align=\"center\">65.64</td><td align=\"center\">527.69</td><td align=\"center\">1500.60</td><td align=\"center\">50.21</td><td align=\"center\">66.49</td><td align=\"center\">4</td><td align=\"center\">6</td><td align=\"center\">4.41</td><td align=\"center\">4.80</td></tr><tr><td align=\"center\">10</td><td align=\"center\">69.95</td><td align=\"center\">214.54</td><td align=\"center\">6.66</td><td align=\"center\">9.51</td><td align=\"center\">773.90</td><td align=\"center\">1856.73</td><td align=\"center\">73.63</td><td align=\"center\">82.27</td><td align=\"center\">789.07</td><td align=\"center\">1940.05</td><td align=\"center\">75.08</td><td align=\"center\">85.96</td><td align=\"center\">6</td><td align=\"center\">6</td><td align=\"center\">5.34</td><td align=\"center\">6.63</td></tr><tr><td align=\"center\">11</td><td align=\"center\">105.13</td><td align=\"center\">217.57</td><td align=\"center\">10.00</td><td align=\"center\">9.64</td><td align=\"center\">1128.81</td><td align=\"center\">3121.71</td><td align=\"center\">107.40</td><td align=\"center\">138.31</td><td align=\"center\">1177.74</td><td align=\"center\">3208.73</td><td align=\"center\">112.06</td><td align=\"center\">142.17</td><td align=\"center\">6</td><td align=\"center\">8</td><td align=\"center\">6.32</td><td align=\"center\">5.27</td></tr><tr><td align=\"center\">12</td><td align=\"center\">117.61</td><td align=\"center\">345.31</td><td align=\"center\">11.19</td><td align=\"center\">15.30</td><td align=\"center\">871.60</td><td align=\"center\">2591.36</td><td align=\"center\">82.93</td><td align=\"center\">114.81</td><td align=\"center\">914.46</td><td align=\"center\">2631.99</td><td align=\"center\">87.01</td><td align=\"center\">116.61</td><td align=\"center\">4</td><td align=\"center\">6</td><td align=\"center\">5.35</td><td align=\"center\">5.05</td></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"center\"><bold>Mean</bold></td><td align=\"center\">116.37</td><td align=\"center\">261.84<sup>ND</sup></td><td align=\"center\">11.07</td><td align=\"center\">11.60</td><td align=\"center\">1276.79</td><td align=\"center\">2957.50<sup>ND</sup></td><td align=\"center\">121.48</td><td align=\"center\">131.04</td><td align=\"center\">1437.23</td><td align=\"center\">3259.54<sup>ND</sup></td><td align=\"center\">136.75</td><td align=\"center\">144.42</td><td align=\"center\">5.75</td><td align=\"center\">7.00</td><td align=\"center\">7.61</td><td align=\"center\">7.96</td></tr><tr><td colspan=\"17\"><hr/></td></tr><tr><td align=\"center\"><bold>SD</bold></td><td align=\"center\">53.80</td><td align=\"center\">110.68</td><td align=\"center\">5.12</td><td align=\"center\">4.90</td><td align=\"center\">746.04</td><td align=\"center\">1372.13</td><td align=\"center\">70.98</td><td align=\"center\">60.79</td><td align=\"center\">949.02</td><td align=\"center\">1599.34</td><td align=\"center\">90.30</td><td align=\"center\">70.86</td><td align=\"center\">2.34</td><td align=\"center\">1.35</td><td align=\"center\">2.44</td><td align=\"center\">2.28</td></tr></tbody></table></body></html>", "text": "Pmid= 555741:Table= Table 3"}
